<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:currency="http://xbrl.sec.gov/currency/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rdy="http://www.drreddys.com/20220331"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rdy-20220331.xsd" xlink:type="simple"/>
    <context id="P04_01_2021To03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="P01_17_2022To01_17_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <startDate>2022-01-17</startDate>
            <endDate>2022-01-17</endDate>
        </period>
    </context>
    <context id="P10_28_2021To10_28_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <startDate>2021-10-28</startDate>
            <endDate>2021-10-28</endDate>
        </period>
    </context>
    <context id="P10_27_2020To10_27_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="P04_01_2006To03_31_2009">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <startDate>2006-04-01</startDate>
            <endDate>2009-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2009To03_31_2011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <startDate>2009-04-01</startDate>
            <endDate>2011-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2011To03_31_2014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <startDate>2011-04-01</startDate>
            <endDate>2014-03-31</endDate>
        </period>
    </context>
    <context id="P05_19_2022To05_19_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <startDate>2022-05-19</startDate>
            <endDate>2022-05-19</endDate>
        </period>
    </context>
    <context id="P02_28_2022To02_28_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="PAsOn02_12_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <instant>2020-02-12</instant>
        </period>
    </context>
    <context id="PAsOn01_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="P01_31_2020To01_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <startDate>2020-01-31</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="PAsOn06_23_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <instant>2022-06-23</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OrdinarySharesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_PreshipmentCreditMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:PreshipmentCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OtherWorkingCapitalBorrowingsMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingCapitalBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_KeyManagementPersonnelOfEntityOrParentMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OtherRelatedPartiesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AssetTypeMemberRDYAssetTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AssetTypeAxis">rdy:AssetTypeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">rdy:KunshanRotamReddyPharmaceuticalsCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FundsManagedByInsurersMemberRDYAssetCategoryAxis_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AssetCategoryAxis">rdy:FundsManagedByInsurersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OthersMemberRDYAssetCategoryAxis_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AssetCategoryAxis">rdy:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_IndiaCountryMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:IndiaCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_SwitzerlandCountryMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:SwitzerlandCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GermanyCountryMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:GermanyCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OtherCountriesMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LaterThanOneYearButNotLaterThanTwoYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">rdy:LaterThanOneYearButNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LaterThanFourYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">rdy:LaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">rdy:EmployeeBenefitObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OtherEnvironmentRelatedProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:OtherEnvironmentRelatedProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis_NeitherPastDueNorImpairedMemberRDYImpairedAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ImpairedAxis">rdy:NeitherPastDueNorImpairedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ifrs-full:FinancialAssetsPastDueButNotImpairedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ifrs-full:FinancialAssetsPastDueButNotImpairedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis_LaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ifrs-full:FinancialAssetsPastDueButNotImpairedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ifrs-full:FinancialAssetsPastDueButNotImpairedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FundsManagedByInsurersMemberRDYAssetCategoryAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AssetCategoryAxis">rdy:FundsManagedByInsurersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis_OthersMemberRDYAssetCategoryAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AssetCategoryAxis">rdy:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GlobalGenericsComplexInjectablesMemberRDYTypeOfCashgeneratingUnitsAxis_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCashgeneratingUnitsAxis">rdy:GlobalGenericsComplexInjectablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GlobalGenericsNorthAmericaOperationsMemberRDYTypeOfCashgeneratingUnitsAxis_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCashgeneratingUnitsAxis">rdy:GlobalGenericsNorthAmericaOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GlobalGenericsBrandedFormulationsMemberRDYTypeOfCashgeneratingUnitsAxis_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCashgeneratingUnitsAxis">rdy:GlobalGenericsBrandedFormulationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_OtherCashgeneratingUnitsMemberRDYTypeOfCashgeneratingUnitsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCashgeneratingUnitsAxis">rdy:OtherCashgeneratingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_PsaiActivePharmaceuticalOperationsMemberRDYTypeOfCashgeneratingUnitsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCashgeneratingUnitsAxis">rdy:PsaiActivePharmaceuticalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AurigenePharmaceuticalServicesLimitedMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">rdy:AurigenePharmaceuticalServicesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InventoryTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">rdy:InventoryTemporaryDifferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_MinimumAlternateTaxTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">rdy:MinimumAlternateTaxTemporaryDifferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_TradeAndOtherReceivablesTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">rdy:TradeAndOtherReceivablesTemporaryDifferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OperatingAndOtherTaxLossCarryforwardMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">rdy:OperatingAndOtherTaxLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OtherCurrentAssetsAndOtherCurrentLiabilitiesNetTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">rdy:OtherCurrentAssetsAndOtherCurrentLiabilitiesNetTemporaryDifferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_PropertyPlantAndEquipmentTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">rdy:PropertyPlantAndEquipmentTemporaryDifferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OtherIntangibleAssetsTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">rdy:OtherIntangibleAssetsTemporaryDifferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_NoncurrentAssetsMemberRDYAssetTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AssetTypeAxis">rdy:NoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">rdy:ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:OtherCurrencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">rdy:NonderivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:RussianRoublesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">rdy:NonderivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:EurosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">rdy:NonderivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:UsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">rdy:NonderivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">rdy:GratuityBenefitsOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_IndustriasQuimicaFalconDeMexicoMemberifrsfullDefinedBenefitPlansAxis_YearZeroMemberRDYTimeTakensAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TimeTakensAxis">rdy:YearZeroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicaFalconDeMexicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_DiscountRateMemberifrsfullMeasurementAxis_FiftyBasisPointsDecreaseMemberifrsfullActuarialAssumptionsAxis_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">rdy:FiftyBasisPointsDecreaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:DiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_DiscountRateMemberifrsfullMeasurementAxis_FiftyBasisPointsIncreaseMemberifrsfullActuarialAssumptionsAxis_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">rdy:FiftyBasisPointsIncreaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:DiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FiftyBasisPointsIncreaseMemberifrsfullActuarialAssumptionsAxis_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis_SalaryGrowthMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">rdy:FiftyBasisPointsIncreaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:SalaryGrowthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FiftyBasisPointsDecreaseMemberifrsfullActuarialAssumptionsAxis_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis_SalaryGrowthMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">rdy:FiftyBasisPointsDecreaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:SalaryGrowthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">rdy:EmployeeBenefitObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_DiscountRateMemberifrsfullMeasurementAxis_FiftyBasisPointsDecreaseMemberifrsfullActuarialAssumptionsAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">rdy:FiftyBasisPointsDecreaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:DiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_DiscountRateMemberifrsfullMeasurementAxis_FiftyBasisPointsIncreaseMemberifrsfullActuarialAssumptionsAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">rdy:FiftyBasisPointsIncreaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:DiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FiftyBasisPointsIncreaseMemberifrsfullActuarialAssumptionsAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis_SalaryGrowthMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">rdy:FiftyBasisPointsIncreaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:SalaryGrowthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FiftyBasisPointsDecreaseMemberifrsfullActuarialAssumptionsAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis_SalaryGrowthMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">rdy:FiftyBasisPointsDecreaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:SalaryGrowthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_INRsrtCurrencyAxis_NonConvertibleDebenturesMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:INR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:NonConvertibleDebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_IndustriasQuimicaFalconDeMexicoMemberifrsfullDefinedBenefitPlansAxis_YearOneMemberRDYTimeTakensAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TimeTakensAxis">rdy:YearOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicaFalconDeMexicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_IndustriasQuimicaFalconDeMexicoMemberifrsfullDefinedBenefitPlansAxis_YearTwoMemberRDYTimeTakensAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TimeTakensAxis">rdy:YearTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicaFalconDeMexicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_IndustriasQuimicaFalconDeMexicoMemberifrsfullDefinedBenefitPlansAxis_YearThreeMemberRDYTimeTakensAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TimeTakensAxis">rdy:YearThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicaFalconDeMexicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_IndustriasQuimicaFalconDeMexicoMemberifrsfullDefinedBenefitPlansAxis_YearFourMemberRDYTimeTakensAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TimeTakensAxis">rdy:YearFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicaFalconDeMexicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_IndustriasQuimicaFalconDeMexicoMemberifrsfullDefinedBenefitPlansAxis_YearFiveMemberRDYTimeTakensAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TimeTakensAxis">rdy:YearFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicaFalconDeMexicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AfterYearFiveMemberRDYTimeTakensAxis_IndustriasQuimicaFalconDeMexicoMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TimeTakensAxis">rdy:AfterYearFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicaFalconDeMexicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_Drl2002PlanMemberRDYDrl2002PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2002PlanAxis">rdy:Drl2002PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CategoriesAMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:CategoryAxis">rdy:CategoriesAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CategoriesBMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:CategoryAxis">rdy:CategoriesBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardAxis">rdy:EquitySettledShareBasedPaymentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GlobalGenericsComplexInjectablesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">rdy:GlobalGenericsComplexInjectablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis_InvestmentFundsMemberifrsfullUnconsolidatedStructuredEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnconsolidatedStructuredEntitiesAxis">ifrs-full:InvestmentFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InvestmentFundsMemberifrsfullUnconsolidatedStructuredEntitiesAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:RecognisedDirectlyInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnconsolidatedStructuredEntitiesAxis">ifrs-full:InvestmentFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentFundsMemberifrsfullUnconsolidatedStructuredEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:AtFairValueOrAmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnconsolidatedStructuredEntitiesAxis">ifrs-full:InvestmentFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis_BondMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:BondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_BondMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:BondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:RecognisedDirectlyInEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_BondMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:BondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:AtFairValueOrAmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis_InvestmentInCommercialPaperMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InvestmentInCommercialPaperMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:RecognisedDirectlyInEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentInCommercialPaperMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:AtFairValueOrAmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:TermDepositsWithBanksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:TermDepositsWithBanksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:RecognisedDirectlyInEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:TermDepositsWithBanksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:AtFairValueOrAmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:RecognisedDirectlyInEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:AtFairValueOrAmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:RecognisedDirectlyInEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:AtFairValueOrAmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis_InvestmentInLimitedLiabilityPartnershipMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInLimitedLiabilityPartnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InvestmentInLimitedLiabilityPartnershipMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInLimitedLiabilityPartnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:RecognisedDirectlyInEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentInLimitedLiabilityPartnershipMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInLimitedLiabilityPartnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:AtFairValueOrAmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis_OthersInvestmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:OthersInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OthersInvestmentMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:OthersInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:RecognisedDirectlyInEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_OthersInvestmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:OthersInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:AtFairValueOrAmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ValueTypeOfFinancialInstrumentAxis">rdy:TotalFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ValueTypeOfFinancialInstrumentAxis">rdy:TotalCarryingValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InterestRateSwapContractMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_BottomOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AfterTaxMemberifrsfullBusinessCombinationsAxis_BottomOfRangeMemberifrsfullRangeAxis_IntangiblesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">rdy:AfterTaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:IntangiblesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AfterTaxMemberifrsfullBusinessCombinationsAxis_IntangiblesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">rdy:AfterTaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:IntangiblesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_BeforeTaxMemberifrsfullBusinessCombinationsAxis_BottomOfRangeMemberifrsfullRangeAxis_IntangiblesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">rdy:BeforeTaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:IntangiblesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_BeforeTaxMemberifrsfullBusinessCombinationsAxis_IntangiblesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">rdy:BeforeTaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:IntangiblesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CardiovascularMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CompensatedAbsencesMemberRDYContributionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ContributionTypeAxis">rdy:CompensatedAbsencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2002PlanAxis">rdy:Drl2002PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryBParValueOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">rdy:ExercisepricesRs5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryBParValueOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">rdy:ExercisepricesRs5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CategoriesAMemberRDYCategoryAxis_Drl2002PlanMemberRDYDrl2002PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:CategoryAxis">rdy:CategoriesAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:Drl2002PlanAxis">rdy:Drl2002PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CategoriesBMemberRDYCategoryAxis_Drl2002PlanMemberRDYDrl2002PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:CategoryAxis">rdy:CategoriesBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:Drl2002PlanAxis">rdy:Drl2002PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_Drl2007PlansMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractOneMemberifrsfullHedgingInstrumentsAxis_ForwardContractAudInrSellsMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractAudInrSellsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractTwoMemberifrsfullHedgingInstrumentsAxis_ForwardContractGbpinrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractGbpinrSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractThreeMemberifrsfullHedgingInstrumentsAxis_ForwardContractRubInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractRubInrSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractFourMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsInrSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractFiveMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsMxnBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsMxnBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractSixMemberifrsfullHedgingInstrumentsAxis_ForwardContractZarInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractZarInrSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractSevenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsRubBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsRubBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractEightMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsRonBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsRonBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractNineMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsAudBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsAudBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractTenMemberifrsfullHedgingInstrumentsAxis_ForwardContractGbpUsBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractGbpUsBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractTenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractElevenMemberifrsfullHedgingInstrumentsAxis_ForwardContractEurUsBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractEurUsBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractElevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractTwelveMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsKztBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsKztBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractThirteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsClpBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsClpBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractFourteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsCopBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsCopBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractFifteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsBrlBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsBrlBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractSixteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractEurInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractEurInrSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractSeventeenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsThbBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsThbBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractSeventeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractEighteenMemberifrsfullHedgingInstrumentsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis_OptionContractUsInrSellMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:OptionContractUsInrSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractNineteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractAudInrSellsMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractAudInrSellsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfHighlyProbableForecastedTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractTwentyMemberifrsfullHedgingInstrumentsAxis_ForwardContractRubInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractRubInrSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfHighlyProbableForecastedTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractTwentyOneMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsInrSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfHighlyProbableForecastedTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractTwentyTwoMemberifrsfullHedgingInstrumentsAxis_ForwardContractZarInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractZarInrSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfHighlyProbableForecastedTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ContractTwentyThreeMemberifrsfullHedgingInstrumentsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis_OptionContractUsInrSellMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:OptionContractUsInrSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfHighlyProbableForecastedTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_UnutilizedCreditLimitsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">rdy:UnutilizedCreditLimitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanOneMemberRDYLoanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LoanAxis">rdy:LoanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanTwoMemberRDYLoanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LoanAxis">rdy:LoanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanThreeMemberRDYLoanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LoanAxis">rdy:LoanThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanFourMemberRDYLoanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LoanAxis">rdy:LoanFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanFiveMemberRDYLoanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LoanAxis">rdy:LoanFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanSixMemberRDYLoanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LoanAxis">rdy:LoanSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_WockhardtLimitedMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:WockhardtLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_UcbIndiaPrivateLimitedAndAffiliatesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:UcbIndiaPrivateLimitedAndAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_TevaAndAnAffiliateOfAllerganMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:TevaAndAnAffiliateOfAllerganMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GlenmarkPharmaceuticalsLimitedMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:GlenmarkPharmaceuticalsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_NovartisConsumerHealthIncMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:NovartisConsumerHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_DresEnergyPrivateLimitedMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">rdy:DresEnergyPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InvestmentInMfMemberRDYTransactionTypesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInMfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InvestmentInMfMemberRDYTransactionTypesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInMfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InvestmentInMfMemberRDYTransactionTypesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInMfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InvestmentInMfMemberRDYTransactionTypesAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInMfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InvestmentInLimitedLiabilityPartnershipFirmMemberRDYTransactionTypesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInLimitedLiabilityPartnershipFirmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InvestmentInLimitedLiabilityPartnershipFirmMemberRDYTransactionTypesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInLimitedLiabilityPartnershipFirmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InvestmentInLimitedLiabilityPartnershipFirmMemberRDYTransactionTypesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInLimitedLiabilityPartnershipFirmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InvestmentInLimitedLiabilityPartnershipFirmMemberRDYTransactionTypesAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInLimitedLiabilityPartnershipFirmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InvestmentInEquityMemberRDYTransactionTypesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InvestmentInEquityMemberRDYTransactionTypesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InvestmentInEquityMemberRDYTransactionTypesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InvestmentInEquityMemberRDYTransactionTypesAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RefundLiabilityMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:RefundLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GlobalGenericsNorthAmericaOperationsMemberRDYTypeOfCashgeneratingUnitsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCashgeneratingUnitsAxis">rdy:GlobalGenericsNorthAmericaOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardAxis">rdy:EquitySettledShareBasedPaymentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CashSettledSharebasedPaymentMemberRDYAwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardAxis">rdy:CashSettledSharebasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LegalProceedingsProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:LegalProceedingsProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RefundsProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_Year1MemberRDYTimeBandAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TimeBandAxis">rdy:Year1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_Year2MemberRDYTimeBandAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TimeBandAxis">rdy:Year2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_Year3MemberRDYTimeBandAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TimeBandAxis">rdy:Year3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_Year4MemberRDYTimeBandAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TimeBandAxis">rdy:Year4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_Year5MemberRDYTimeBandAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TimeBandAxis">rdy:Year5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AfterYear5MemberRDYTimeBandAxis_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TimeBandAxis">rdy:AfterYear5Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ObligationsUnderLeasesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">rdy:ObligationsUnderLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_DrReddysEmployeesStockOptionScheme2018MemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">rdy:DrReddysEmployeesStockOptionScheme2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FactoringOfReceivablesMemberifrsfullContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfTransferAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfTransferAxis">ifrs-full:FactoringOfReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">rdy:NimbusHealthGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ProfitTaxImpactMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">rdy:ProfitTaxImpactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CollaborationAgreementMemberRDYAgreementAxis_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AgreementAxis">rdy:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:NamePartyInvolvedInTransactionAxis">rdy:CurisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AmendmentToCollaborationAgreementMemberRDYAgreementAxis_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AgreementAxis">rdy:AmendmentToCollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:NamePartyInvolvedInTransactionAxis">rdy:CurisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:NamePartyInvolvedInTransactionAxis">rdy:CurisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AssociatedTaxImpactMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">rdy:AssociatedTaxImpactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_TermDepositsWithBanksAndBondsMemberRDYAssetCategoryAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AssetCategoryAxis">rdy:TermDepositsWithBanksAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_BioDeliverySciencesInternationalIncMemberifrsfullCounterpartiesAxis_OneYearFromClosingMemberRDYConsiderationReceivablePeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ConsiderationReceivablePeriodAxis">rdy:OneYearFromClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">rdy:BioDeliverySciencesInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_BioDeliverySciencesInternationalIncMemberifrsfullCounterpartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">rdy:BioDeliverySciencesInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AliumJscMemberifrsfullCounterpartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">rdy:AliumJscMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OtherWorkingsCapitalBorrowingsRubMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingsCapitalBorrowingsRubMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OtherWorkingsCapitalBorrowingssInrMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingsCapitalBorrowingssInrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OtherWorkingsCapitalBorrowingsUahMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingsCapitalBorrowingsUahMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OrdinarySharesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_PreshipmentCreditMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:PreshipmentCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OtherWorkingCapitalBorrowingsMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingCapitalBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_KeyManagementPersonnelOfEntityOrParentMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OtherRelatedPartiesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:OtherRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AssetTypeMemberRDYAssetTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AssetTypeAxis">rdy:AssetTypeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">rdy:KunshanRotamReddyPharmaceuticalsCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FundsManagedByInsurersMemberRDYAssetCategoryAxis_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AssetCategoryAxis">rdy:FundsManagedByInsurersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OthersMemberRDYAssetCategoryAxis_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AssetCategoryAxis">rdy:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_IndiaCountryMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:IndiaCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SwitzerlandCountryMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:SwitzerlandCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_USifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GermanyCountryMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:GermanyCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OtherCountriesMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_LaterThanOneYearButNotLaterThanTwoYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">rdy:LaterThanOneYearButNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_LaterThanFourYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">rdy:LaterThanFourYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">rdy:EmployeeBenefitObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis_NeitherPastDueNorImpairedMemberRDYImpairedAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ImpairedAxis">rdy:NeitherPastDueNorImpairedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ifrs-full:FinancialAssetsPastDueButNotImpairedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ifrs-full:FinancialAssetsPastDueButNotImpairedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis_LaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ifrs-full:FinancialAssetsPastDueButNotImpairedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ImpairmentOfFinancialAssetsAxis">ifrs-full:FinancialAssetsPastDueButNotImpairedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FundsManagedByInsurersMemberRDYAssetCategoryAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AssetCategoryAxis">rdy:FundsManagedByInsurersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis_OthersMemberRDYAssetCategoryAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AssetCategoryAxis">rdy:OthersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GlobalGenericsComplexInjectablesMemberRDYTypeOfCashgeneratingUnitsAxis_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCashgeneratingUnitsAxis">rdy:GlobalGenericsComplexInjectablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GlobalGenericsNorthAmericaOperationsMemberRDYTypeOfCashgeneratingUnitsAxis_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCashgeneratingUnitsAxis">rdy:GlobalGenericsNorthAmericaOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GlobalGenericsBrandedFormulationsMemberRDYTypeOfCashgeneratingUnitsAxis_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCashgeneratingUnitsAxis">rdy:GlobalGenericsBrandedFormulationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_OtherCashgeneratingUnitsMemberRDYTypeOfCashgeneratingUnitsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCashgeneratingUnitsAxis">rdy:OtherCashgeneratingUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_PsaiActivePharmaceuticalOperationsMemberRDYTypeOfCashgeneratingUnitsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCashgeneratingUnitsAxis">rdy:PsaiActivePharmaceuticalOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AurigenePharmaceuticalServicesLimitedMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">rdy:AurigenePharmaceuticalServicesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InventoryTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">rdy:InventoryTemporaryDifferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_MinimumAlternateTaxTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">rdy:MinimumAlternateTaxTemporaryDifferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_TradeAndOtherReceivablesTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">rdy:TradeAndOtherReceivablesTemporaryDifferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OperatingAndOtherTaxLossCarryforwardMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">rdy:OperatingAndOtherTaxLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OtherCurrentAssetsAndOtherCurrentLiabilitiesNetTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">rdy:OtherCurrentAssetsAndOtherCurrentLiabilitiesNetTemporaryDifferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_PropertyPlantAndEquipmentTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">rdy:PropertyPlantAndEquipmentTemporaryDifferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OtherIntangibleAssetsTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">rdy:OtherIntangibleAssetsTemporaryDifferenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:OtherTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_NoncurrentAssetsMemberRDYAssetTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AssetTypeAxis">rdy:NoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:UsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">rdy:NonderivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:EurosMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">rdy:NonderivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:RussianRoublesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">rdy:NonderivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:OtherCurrencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">rdy:NonderivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">rdy:ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">rdy:GratuityBenefitsOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">rdy:EmployeeBenefitObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_INRsrtCurrencyAxis_NonConvertibleDebenturesMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:INR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:NonConvertibleDebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_Drl2002PlanMemberRDYDrl2002PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2002PlanAxis">rdy:Drl2002PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CategoriesAMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:CategoryAxis">rdy:CategoriesAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CategoriesBMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:CategoryAxis">rdy:CategoriesBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardAxis">rdy:EquitySettledShareBasedPaymentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GlobalGenericsComplexInjectablesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">rdy:GlobalGenericsComplexInjectablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis_InvestmentFundsMemberifrsfullUnconsolidatedStructuredEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnconsolidatedStructuredEntitiesAxis">ifrs-full:InvestmentFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InvestmentFundsMemberifrsfullUnconsolidatedStructuredEntitiesAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:RecognisedDirectlyInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnconsolidatedStructuredEntitiesAxis">ifrs-full:InvestmentFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentFundsMemberifrsfullUnconsolidatedStructuredEntitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:AtFairValueOrAmortizedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnconsolidatedStructuredEntitiesAxis">ifrs-full:InvestmentFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis_BondMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:BondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_BondMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:BondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:RecognisedDirectlyInEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_BondMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:BondMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:AtFairValueOrAmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis_InvestmentInCommercialPaperMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InvestmentInCommercialPaperMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:RecognisedDirectlyInEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentInCommercialPaperMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInCommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:AtFairValueOrAmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:TermDepositsWithBanksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:TermDepositsWithBanksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:RecognisedDirectlyInEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:TermDepositsWithBanksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:AtFairValueOrAmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:RecognisedDirectlyInEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:AtFairValueOrAmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:RecognisedDirectlyInEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:AtFairValueOrAmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis_InvestmentInLimitedLiabilityPartnershipMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInLimitedLiabilityPartnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InvestmentInLimitedLiabilityPartnershipMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInLimitedLiabilityPartnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:RecognisedDirectlyInEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentInLimitedLiabilityPartnershipMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:InvestmentInLimitedLiabilityPartnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:AtFairValueOrAmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis_OthersInvestmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:OthersInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OthersInvestmentMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:OthersInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:RecognisedDirectlyInEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_OthersInvestmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:OthersInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">rdy:AtFairValueOrAmortizedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ValueTypeOfFinancialInstrumentAxis">rdy:TotalFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ValueTypeOfFinancialInstrumentAxis">rdy:TotalCarryingValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InterestRateSwapContractMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CompensatedAbsencesMemberRDYContributionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ContributionTypeAxis">rdy:CompensatedAbsencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2002PlanAxis">rdy:Drl2002PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryBParValueOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">rdy:ExercisepricesRs5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryBParValueOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">rdy:ExercisepricesRs5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractOneMemberifrsfullHedgingInstrumentsAxis_ForwardContractAudInrSellsMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractAudInrSellsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractTwoMemberifrsfullHedgingInstrumentsAxis_ForwardContractChfInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractChfInrSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractThreeMemberifrsfullHedgingInstrumentsAxis_ForwardContractGbpinrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractGbpinrSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractFourMemberifrsfullHedgingInstrumentsAxis_ForwardContractRubInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractRubInrSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractFiveMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsInrSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractSixMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsMxnBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsMxnBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractSevenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsUahBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsUahBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractEightMemberifrsfullHedgingInstrumentsAxis_ForwardContractZarInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractZarInrSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractNineMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsRubBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsRubBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractNineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractTenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsRonBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsRonBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractTenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractElevenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsAudBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsAudBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractElevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractTwelveMemberifrsfullHedgingInstrumentsAxis_ForwardContractGbpUsBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractGbpUsBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractTwelveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractThirteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractEurGbpSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractEurGbpSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractThirteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractFourteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractEurUsBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractEurUsBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractFifteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractChfUsBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractChfUsBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractSixteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsKztBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsKztBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractSixteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractSeventeenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsClpBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsClpBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractSeventeenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractEighteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsCopBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsCopBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractNineteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsBrlBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsBrlBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractTwentyMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsKztBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractUsKztBuyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractTwentyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfRecognisedAssetsAndLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractTwentyOneMemberifrsfullHedgingInstrumentsAxis_ForwardContractAudInrSellsMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractAudInrSellsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractTwentyOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfHighlyProbableForecastedTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractTwentyTwoMemberifrsfullHedgingInstrumentsAxis_ForwardContractRubInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractRubInrSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractTwentyTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfHighlyProbableForecastedTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractTwentyThreeMemberifrsfullHedgingInstrumentsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis_OptionContractUsInrSellRiskReversalMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:OptionContractUsInrSellRiskReversalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfHighlyProbableForecastedTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContractTwentyFourMemberifrsfullHedgingInstrumentsAxis_ForwardContractZarInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">rdy:ForwardContractZarInrSellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">rdy:ContractTwentyFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">rdy:HedgesOfHighlyProbableForecastedTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_UnutilizedCreditLimitsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">rdy:UnutilizedCreditLimitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanSevenMemberRDYLoanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LoanAxis">rdy:LoanSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanEightMemberRDYLoanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LoanAxis">rdy:LoanEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfHedgesAxis">ifrs-full:CashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_DresEnergyPrivateLimitedMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">rdy:DresEnergyPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InvestmentInMfMemberRDYTransactionTypesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInMfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InvestmentInMfMemberRDYTransactionTypesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInMfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InvestmentInMfMemberRDYTransactionTypesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInMfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InvestmentInMfMemberRDYTransactionTypesAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInMfMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InvestmentInLimitedLiabilityPartnershipFirmMemberRDYTransactionTypesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInLimitedLiabilityPartnershipFirmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InvestmentInLimitedLiabilityPartnershipFirmMemberRDYTransactionTypesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInLimitedLiabilityPartnershipFirmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InvestmentInLimitedLiabilityPartnershipFirmMemberRDYTransactionTypesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInLimitedLiabilityPartnershipFirmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InvestmentInLimitedLiabilityPartnershipFirmMemberRDYTransactionTypesAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInLimitedLiabilityPartnershipFirmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InvestmentInEquityMemberRDYTransactionTypesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InvestmentInEquityMemberRDYTransactionTypesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InvestmentInEquityMemberRDYTransactionTypesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InvestmentInEquityMemberRDYTransactionTypesAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:InvestmentInEquityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RefundLiabilityMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:RefundLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GlobalGenericsNorthAmericaOperationsMemberRDYTypeOfCashgeneratingUnitsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCashgeneratingUnitsAxis">rdy:GlobalGenericsNorthAmericaOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardAxis">rdy:EquitySettledShareBasedPaymentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CashSettledSharebasedPaymentMemberRDYAwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardAxis">rdy:CashSettledSharebasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_BottomOfRangeMemberifrsfullRangeAxis_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ObligationsUnderLeasesMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">rdy:ObligationsUnderLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_BottomOfRangeMemberifrsfullRangeAxis_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_DrReddysEmployeesStockOptionScheme2018MemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">rdy:DrReddysEmployeesStockOptionScheme2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FactoringOfReceivablesMemberifrsfullContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfTransferAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfTransferAxis">ifrs-full:FactoringOfReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">rdy:WockhardtLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">rdy:WockhardtLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AurigenePharmaceuticalServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NonConvertibleDebenturesMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:NonConvertibleDebenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:AurigenePharmaceuticalServicesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_TermDepositsWithBanksAndBondsMemberRDYAssetCategoryAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AssetCategoryAxis">rdy:TermDepositsWithBanksAndBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContingentConsiderationpursuantToTheBusinessTransferAgreementMemberRDYTransactionTypesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:ContingentConsiderationpursuantToTheBusinessTransferAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContingentConsiderationpursuantToTheBusinessTransferAgreementMemberRDYTransactionTypesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:ContingentConsiderationpursuantToTheBusinessTransferAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContingentConsiderationpursuantToTheBusinessTransferAgreementMemberRDYTransactionTypesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:ContingentConsiderationpursuantToTheBusinessTransferAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ContingentConsiderationpursuantToTheBusinessTransferAgreementMemberRDYTransactionTypesAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TransactionTypesAxis">rdy:ContingentConsiderationpursuantToTheBusinessTransferAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:RecurringFairValueMeasurementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_PackingCreditBorrowingsInrOneMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:PackingCreditBorrowingsInrOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OtherWorkingsCapitalBorrowingssInrMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingsCapitalBorrowingssInrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OtherWorkingsCapitalBorrowingsBrlMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingsCapitalBorrowingsBrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OtherWorkingsCapitalBorrowingsUahMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingsCapitalBorrowingsUahMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DerivativesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ReportableSegmentsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">ifrs-full:ReportableSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">rdy:KeyManagementPersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:KunshanRotamReddyPharmaceuticalsCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OrdinarySharesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MajorCustomer1MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rdy:MajorCustomer1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MajorCustomer2MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rdy:MajorCustomer2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_EquitySharedPaymentSettledMemberRDYAwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardAxis">rdy:EquitySharedPaymentSettledMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ForeignCountriesMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CashSettledSharebasedPaymentMemberRDYAwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardAxis">rdy:CashSettledSharebasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">rdy:KunshanRotamReddyPharmaceuticalsCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:CostOfRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_SellingGeneralAndAdministrativeExpensesOneMemberRDYTypeOfExpensesByNatureAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:SellingGeneralAndAdministrativeExpensesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ResearchAndDevelopmentExpensesMemberRDYTypeOfExpensesByNatureAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_IndiaCountryMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:IndiaCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_SwitzerlandCountryMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:SwitzerlandCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OncologyMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OtherCountriesMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OtherSegmentMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_PharmaceuticalServicesAndActiveIngredientsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ProprietaryProductMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:ProprietaryProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RussiaCountryMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:RussiaCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OthersCountriesCountryMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:OthersCountriesCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">rdy:GratuityBenefitsOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RefundsProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OtherEnvironmentRelatedProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:OtherEnvironmentRelatedProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LegalProceedingsProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:LegalProceedingsProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrlAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DrlAxis">rdy:Drl2002PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CategoryBMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrlAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DrlAxis">rdy:Drl2002PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_Drl2002PlanMemberRDYDrlAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DrlAxis">rdy:Drl2002PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_Drl2002PlanMemberRDYDrl2002PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2002PlanAxis">rdy:Drl2002PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OrdinarySharesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_Drl2007PlansMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DRL2018PlanMemberRDYDRLPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DRLPlanNameAxis">rdy:DRL2018PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_Drl2007PlansMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_PackingCreditBorrowingsInrMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:PackingCreditBorrowingsInrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_PackingCreditBorrowingsInrOneMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:PackingCreditBorrowingsInrOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_PreshipmentCreditBorrowingsUsdMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:PreshipmentCreditBorrowingsUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OtherWorkingsCapitalBorrowingsRubMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingsCapitalBorrowingsRubMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OtherWorkingsCapitalBorrowingsMxnMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingsCapitalBorrowingsMxnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OtherWorkingsCapitalBorrowingssInrMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingsCapitalBorrowingssInrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OtherWorkingsCapitalBorrowingsBrlMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingsCapitalBorrowingsBrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OtherWorkingsCapitalBorrowingsUahMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingsCapitalBorrowingsUahMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OtherWorkingCapitalBorrowingsUsdMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingCapitalBorrowingsUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:SouthAfricanRandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LaterThanSixMonthsAndNotLaterThanOneYearMemberifrsfullMaturityAxis_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:SouthAfricanRandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrsfullMaturityAxis_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:SouthAfricanRandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LaterThanOneMonthAndNotLaterThanThreeMonthsMemberifrsfullMaturityAxis_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:SouthAfricanRandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_NotLaterThanOneMonthMemberifrsfullMaturityAxis_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:SouthAfricanRandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AustralianDollarsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:AustralianDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AustralianDollarsMemberRDYTypeOfCurrencyAxis_LaterThanSixMonthsAndNotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:AustralianDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AustralianDollarsMemberRDYTypeOfCurrencyAxis_LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:AustralianDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AustralianDollarsMemberRDYTypeOfCurrencyAxis_LaterThanOneMonthAndNotLaterThanThreeMonthsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:AustralianDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AustralianDollarsMemberRDYTypeOfCurrencyAxis_NotLaterThanOneMonthMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:AustralianDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RussianRoublesMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:RussianRoublesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LaterThanSixMonthsAndNotLaterThanOneYearMemberifrsfullMaturityAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:RussianRoublesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrsfullMaturityAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:RussianRoublesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LaterThanOneMonthAndNotLaterThanThreeMonthsMemberifrsfullMaturityAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:RussianRoublesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_NotLaterThanOneMonthMemberifrsfullMaturityAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:RussianRoublesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LaterThanSixMonthsAndNotLaterThanOneYearMemberifrsfullMaturityAxis_UsDollarsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:UsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrsfullMaturityAxis_UsDollarsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:UsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LaterThanOneMonthAndNotLaterThanThreeMonthsMemberifrsfullMaturityAxis_UsDollarsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:UsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_NotLaterThanOneMonthMemberifrsfullMaturityAxis_UsDollarsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:UsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_UsDollarsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:UsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:CostOfRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:CostOfRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_ProprietaryProductsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:CostOfRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:ProprietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_OthersSegmentsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:CostOfRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:OthersSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_InventorydeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:InventorydeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MinimumAlternateTaxdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:MinimumAlternateTaxdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_TradeAndOtherReceivablesdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:TradeAndOtherReceivablesdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OperatingAndOtherTaxLossCarryforwardMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:OperatingAndOtherTaxLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_IntangibleAssetsdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:IntangibleAssetsdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OthersdeferredTaxLiabilityAssetMemberMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:OthersdeferredTaxLiabilityAssetMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CentralNervousSystemMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:CentralNervousSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GastrointestinalMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:GastrointestinalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlobalGenericMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlobalGenericMemberifrsfullSegmentsAxis_OtherGlobalGenericsMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OtherGlobalGenericsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AntiinfectiveMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:AntiinfectiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlobalGenericMemberifrsfullSegmentsAxis_PainManagementMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:PainManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlobalGenericMemberifrsfullSegmentsAxis_NutraceuticalMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:NutraceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlobalGenericMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:RespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CardiovascularMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlobalGenericMemberifrsfullSegmentsAxis_HematologyMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DermatologyMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:DermatologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OtherPsaiMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OtherPsaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OncologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CentralNervousSystemMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:CentralNervousSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_PainManagementMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:PainManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AntiInfectiveOneMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:AntiInfectiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CardiovascularMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GastrointestinalMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:GastrointestinalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GenitourinaryMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:GenitourinaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:RespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DiabetologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:DiabetologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DermatologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:DermatologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_PropertyPlantAndEquipmentMemberRDYInterestCapitalizationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:InterestCapitalizationAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:FairValueReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalRedemptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:SpecialEconomicZoneReinvestmentReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:DebentureRedemptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:ActuarialGainsLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_InterestRateSwapContractMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ProvidentFundBenefitsMemberRDYContributionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ContributionTypeAxis">rdy:ProvidentFundBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_SuperannuationBenefitsMemberRDYContributionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ContributionTypeAxis">rdy:SuperannuationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LandPollutionMemberRDYLegalProceedingsContingentLiabilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LegalProceedingsContingentLiabilityAxis">rdy:LandPollutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2002PlanAxis">rdy:Drl2002PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryBParValueOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">rdy:ExercisepricesRs5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryBParValueOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">rdy:ExercisepricesRs5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_Us401kretirementSavingsPlanMemberRDYContributionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ContributionTypeAxis">rdy:Us401kretirementSavingsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_UkSocialSecuriyPlanMemberRDYContributionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ContributionTypeAxis">rdy:UkSocialSecuriyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CategoriesBMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:CategoryAxis">rdy:CategoriesBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CategoriesAMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:CategoryAxis">rdy:CategoriesAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardAxis">rdy:EquitySettledShareBasedPaymentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardAxis">rdy:EquitySettledShareBasedPaymentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_NorfloxacinIndiaLitigationMemberRDYLegalProceedingsContingentLiabilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LegalProceedingsContingentLiabilityAxis">rdy:NorfloxacinIndiaLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanOneMemberRDYLoanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LoanAxis">rdy:LoanOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanTwoMemberRDYLoanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LoanAxis">rdy:LoanTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanThreeMemberRDYLoanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LoanAxis">rdy:LoanThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanFourMemberRDYLoanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LoanAxis">rdy:LoanFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanFiveMemberRDYLoanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LoanAxis">rdy:LoanFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanSixMemberRDYLoanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LoanAxis">rdy:LoanSixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AurigeneDiscoveryTechnologiesMalaysiaSdnBhdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:AurigeneDiscoveryTechnologiesMalaysiaSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AurigeneDiscoveryTechnologiesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:AurigeneDiscoveryTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AurigenePharmaceuticalServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:AurigenePharmaceuticalServicesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_BetaInstitutGemeinnutzigeGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:BetaInstitutGemeinnutzigeGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_BetapharmArzneimittelGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:BetapharmArzneimittelGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CheminorInvestmentsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:CheminorInvestmentsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CheminorEmployeesWelfareTrustsMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:CheminorEmployeesWelfareTrustsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ChirotechTechnologyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:ChirotechTechnologyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrreddysResearchFoundationMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrreddysResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrReddysLaboratoriesEsosTrustMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrReddysLaboratoriesEsosTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrreddysFarmaceuticaDoBrasilLtdaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrreddysFarmaceuticaDoBrasilLtdaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrreddysLaboratoriesEuLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrreddysLaboratoriesEuLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrreddysLaboratoriesProprietaryLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrreddysLaboratoriesProprietaryLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrreddysLaboratoriesUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrreddysLaboratoriesUkLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrreddysLaboratoriesCanadaIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrreddysLaboratoriesCanadaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrReddysLaboratoriesChileSpaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrReddysLaboratoriesChileSpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrreddysLaboratoriesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrreddysLaboratoriesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrReddysLaboratoriesJapanKkMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrReddysLaboratoriesJapanKkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrReddysLaboratoriesKazakhstanLlpMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrReddysLaboratoriesKazakhstanLlpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrreddysLaboratoriesLouisianaLlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrreddysLaboratoriesLouisianaLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrReddysLaboratoriesMalaysiaSdnBhdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrReddysLaboratoriesMalaysiaSdnBhdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrreddysLaboratoriesNewYorkIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrreddysLaboratoriesNewYorkIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrreddysLaboratoriesRomaniaSrlMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrreddysLaboratoriesRomaniaSrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrreddysLaboratoriesSaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrreddysLaboratoriesSaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrreddysLaboratoriesLlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrreddysLaboratoriesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrreddysNewZealandLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrreddysNewZealandLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrReddysSrlMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrReddysSrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrReddyswuxiPharmaceuticalCompanyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrReddyswuxiPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrReddysBeijingPharmaceuticalCoLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrReddysBeijingPharmaceuticalCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DresEnergyPrivateLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DresEnergyPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrlImpexLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrlImpexLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrReddysFormulationsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrReddysFormulationsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_Idea2enterprisesIndiaPvtLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:Idea2enterprisesIndiaPvtLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ImperialCreditPrivateLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:ImperialCreditPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoSaDeCvMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:IndustriasQuimicasFalconDeMexicoSaDeCvMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_KunshanRotamReddyPharmaceuticalComanyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:KunshanRotamReddyPharmaceuticalComanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_LacockHoldingsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:LacockHoldingsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrReddysLaboratoriesPhilippinesMemberMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrReddysLaboratoriesPhilippinesMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrReddysLaboratoriesTaiwanLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrReddysLaboratoriesTaiwanLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrReddysLaboratoriesThailandMemberMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrReddysLaboratoriesThailandMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrreddysBiosciencesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrreddysBiosciencesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrreddysLaboratoriesAustraliaPtyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrreddysLaboratoriesAustraliaPtyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrReddysLaboratoriesSasMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrReddysLaboratoriesSasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrreddysResearchAndDevelopmentBvFormerlyOctoplusBvMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrreddysResearchAndDevelopmentBvFormerlyOctoplusBvMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrreddysVenezuelaCaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrreddysVenezuelaCaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrReddysLaboratoriesBvFormerlyEuobridgeConsultingBvMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrReddysLaboratoriesBvFormerlyEuobridgeConsultingBvMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_NimbusHealthGmbhFromFebruary242022MemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:NimbusHealthGmbhFromFebruary242022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_Dr.ReddysLaboratoriesLlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:Dr.ReddysLaboratoriesLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrsLlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DrsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_PromiusPharmaLlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:PromiusPharmaLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ReddyHoldingGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:ReddyHoldingGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ReddyNetherlandsBvMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:ReddyNetherlandsBvMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ReddyPharmaIberiaSauMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:ReddyPharmaIberiaSauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ReddyPharmaItaliaSrlMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:ReddyPharmaItaliaSrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ReddyPharmasSasMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:ReddyPharmasSasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_SvaasWellnessLimitedFormerlyRegkineticsServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:SvaasWellnessLimitedFormerlyRegkineticsServicesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AurigeneDiscoveryTechnologiesInc.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:AurigeneDiscoveryTechnologiesInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DRANULLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:DRANULLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AurigeneDiscoveryTechnologiesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:AurigeneDiscoveryTechnologiesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_WockhardtLimitedMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:WockhardtLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_UcbIndiaPrivateLimitedAndAffiliatesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:UcbIndiaPrivateLimitedAndAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_TevaAndAnAffiliateOfAllerganMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:TevaAndAnAffiliateOfAllerganMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlenmarkPharmaceuticalsLimitedMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:GlenmarkPharmaceuticalsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_NovartisConsumerHealthIncMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:NovartisConsumerHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DresEnergyPrivateLimitedMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">rdy:DresEnergyPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DRL2018PlanMemberRDYPlanAxis_SecuritiesAcquiredFromSecondaryMarketMemberRDYSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:PlanAxis">rdy:DRL2018PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:SecuritiesAxis">rdy:SecuritiesAcquiredFromSecondaryMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DRL2018PlanMemberRDYPlanAxis_SecuritiesIssuedByTheCompanyMemberRDYSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:PlanAxis">rdy:DRL2018PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:SecuritiesAxis">rdy:SecuritiesIssuedByTheCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DRL2018PlanMemberRDYPlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:PlanAxis">rdy:DRL2018PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_PPC06TepilamideFumarateExtendedReleaseTabletsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ProprietaryProductsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:PPC06TepilamideFumarateExtendedReleaseTabletsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:ProprietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OtherIPRDandotherintangibleassetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ProprietaryProductsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:OtherIPRDandotherintangibleassetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:ProprietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ProprietaryProductsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:ProprietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OthersSegmentsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:OthersSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ChargebacksMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RebatesMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MedicaidMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RefundLiabilityMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:RefundLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis_NervousSystemMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:NervousSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GastrointestinalMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:GastrointestinalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AntiinfectiveMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:AntiinfectiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis_PainManagementMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:PainManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:RespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CardiovascularMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis_OtherGlobalGenericsMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OtherGlobalGenericsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis_NutraceuticalMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:NutraceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DermatologyMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:DermatologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis_HematologyMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AntiinfectiveMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:AntiinfectiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_OtherPsaiSegmentMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OtherPsaiSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MajorCustomerOneMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rdy:MajorCustomerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MajorCustomerTwoMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rdy:MajorCustomerTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_MankindPharmaLimitedMemberifrsfullCounterpartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">rdy:MankindPharmaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AliumJscMemberifrsfullCounterpartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">rdy:AliumJscMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AdrMemberdeiDocumentInformationDocumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:DocumentInformationDocumentAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_ProprietaryProductsMemberifrsfullSegmentsAxis_UpsherSmithLaboratoriesLLCMemberifrsfullCounterpartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">rdy:UpsherSmithLaboratoriesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:ProprietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_BioDeliverySciencesInternationalIncMemberifrsfullCounterpartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">rdy:BioDeliverySciencesInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_DrReddysEmployeesStockOptionScheme2018MemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">rdy:DrReddysEmployeesStockOptionScheme2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_TopOfRangeMemberifrsfullRangeAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_FixturesAndFittingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_FixturesAndFittingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:FixturesAndFittingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AncillaryStructuresMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:AncillaryStructuresMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_AncillaryStructuresMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_BottomOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:AncillaryStructuresMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_FactoryAndAdministrativeBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:FactoryAndAdministrativeBuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_FactoryAndAdministrativeBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:FactoryAndAdministrativeBuildingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlobalgenericscomplexinjectablesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">rdy:GlobalgenericscomplexinjectablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">rdy:NimbusHealthGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis_USsrtStatementGeographicalAxis_WarehousingAgreementMemberRDYAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:AgreementAxis">rdy:WarehousingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">rdy:WockhardtLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:NamePartyInvolvedInTransactionAxis">rdy:CurisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis_HatchtechPtyLimitedMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LegalProceedingsContingentLiabilityAxis">rdy:CivilLitigationAndArbitrationWithHatchtechPtyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rdy:HatchtechPtyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis_HatchtechPtyLimitedMemberdeiLegalEntityAxis_ImpairmentOfNoncurrentAssetsMemberRDYIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:IncomeStatementLocationAxis">rdy:ImpairmentOfNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:LegalProceedingsContingentLiabilityAxis">rdy:CivilLitigationAndArbitrationWithHatchtechPtyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rdy:HatchtechPtyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis_HatchtechPtyLimitedMemberdeiLegalEntityAxis_SellingGeneralAndAdministrativeExpenseMemberRDYIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:IncomeStatementLocationAxis">ifrs-full:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:LegalProceedingsContingentLiabilityAxis">rdy:CivilLitigationAndArbitrationWithHatchtechPtyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rdy:HatchtechPtyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_CitiusPharmaceuticalsMemberRDYAcquirerOfIntangibleAssetsAxis_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ProprietaryProductsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AcquirerOfIntangibleAssetsAxis">rdy:CitiusPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:ProprietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_GlobalGenericsComplexInjectablesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis">rdy:GlobalGenericsComplexInjectablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_HatchtechPtyLimitedMemberdeiLegalEntityAxis_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rdy:HatchtechPtyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To03_31_2022_INRsrtCurrencyAxis_NonConvertibleDebenturesMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:INR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:NonConvertibleDebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_DerivativesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">rdy:KeyManagementPersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OrdinarySharesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_MajorCustomer1MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rdy:MajorCustomer1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_MajorCustomer2MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rdy:MajorCustomer2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_EquitySharedPaymentSettledMemberRDYAwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardAxis">rdy:EquitySharedPaymentSettledMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CountryOfDomicileMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ForeignCountriesMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CashSettledSharebasedPaymentMemberRDYAwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardAxis">rdy:CashSettledSharebasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">rdy:KunshanRotamReddyPharmaceuticalsCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:CostOfRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SellingGeneralAndAdministrativeExpensesOneMemberRDYTypeOfExpensesByNatureAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:SellingGeneralAndAdministrativeExpensesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ResearchAndDevelopmentExpensesMemberRDYTypeOfExpensesByNatureAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_IndiaCountryMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:IndiaCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SwitzerlandCountryMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:SwitzerlandCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OncologyMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OtherCountriesMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OtherSegmentMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_PharmaceuticalServicesAndActiveIngredientsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ProprietaryProductMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:ProprietaryProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_RussiaCountryMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:RussiaCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OthersCountriesCountryMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:OthersCountriesCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">rdy:GratuityBenefitsOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OrdinarySharesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_PackingCreditBorrowingsInrMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:PackingCreditBorrowingsInrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_PackingCreditBorrowingsInrOneMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:PackingCreditBorrowingsInrOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_PreshipmentCreditBorrowingsUsdMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:PreshipmentCreditBorrowingsUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OtherWorkingsCapitalBorrowingsRubMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingsCapitalBorrowingsRubMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OtherWorkingsCapitalBorrowingsMxnMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingsCapitalBorrowingsMxnMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OtherWorkingsCapitalBorrowingssInrMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingsCapitalBorrowingssInrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OtherWorkingsCapitalBorrowingsBrlMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingsCapitalBorrowingsBrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OtherWorkingsCapitalBorrowingsUahMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingsCapitalBorrowingsUahMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OtherWorkingCapitalBorrowingsUsdMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:OtherWorkingCapitalBorrowingsUsdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:SouthAfricanRandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_LaterThanSixMonthsAndNotLaterThanOneYearMemberifrsfullMaturityAxis_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:SouthAfricanRandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrsfullMaturityAxis_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:SouthAfricanRandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_LaterThanOneMonthAndNotLaterThanThreeMonthsMemberifrsfullMaturityAxis_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:SouthAfricanRandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_NotLaterThanOneMonthMemberifrsfullMaturityAxis_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:SouthAfricanRandsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AustralianDollarsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:AustralianDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AustralianDollarsMemberRDYTypeOfCurrencyAxis_LaterThanSixMonthsAndNotLaterThanOneYearMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:AustralianDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AustralianDollarsMemberRDYTypeOfCurrencyAxis_LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:AustralianDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AustralianDollarsMemberRDYTypeOfCurrencyAxis_LaterThanOneMonthAndNotLaterThanThreeMonthsMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:AustralianDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AustralianDollarsMemberRDYTypeOfCurrencyAxis_NotLaterThanOneMonthMemberifrsfullMaturityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:AustralianDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_RussianRoublesMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:RussianRoublesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_LaterThanSixMonthsAndNotLaterThanOneYearMemberifrsfullMaturityAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:RussianRoublesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrsfullMaturityAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:RussianRoublesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_LaterThanOneMonthAndNotLaterThanThreeMonthsMemberifrsfullMaturityAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:RussianRoublesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_NotLaterThanOneMonthMemberifrsfullMaturityAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:RussianRoublesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_LaterThanSixMonthsAndNotLaterThanOneYearMemberifrsfullMaturityAxis_UsDollarsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:UsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrsfullMaturityAxis_UsDollarsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:UsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_LaterThanOneMonthAndNotLaterThanThreeMonthsMemberifrsfullMaturityAxis_UsDollarsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:UsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_NotLaterThanOneMonthMemberifrsfullMaturityAxis_UsDollarsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:UsDollarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneMonthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_UsDollarsMemberRDYTypeOfCurrencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfCurrencyAxis">rdy:UsDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:CostOfRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:CostOfRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_ProprietaryProductsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:CostOfRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:ProprietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_OthersSegmentsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:CostOfRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:OthersSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_InventorydeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:InventorydeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_MinimumAlternateTaxdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:MinimumAlternateTaxdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_TradeAndOtherReceivablesdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:TradeAndOtherReceivablesdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OperatingAndOtherTaxLossCarryforwardMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:OperatingAndOtherTaxLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_IntangibleAssetsdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:IntangibleAssetsdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OthersdeferredTaxLiabilityAssetMemberMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:OthersdeferredTaxLiabilityAssetMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CentralNervousSystemMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:CentralNervousSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GastrointestinalMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:GastrointestinalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericMemberifrsfullSegmentsAxis_OtherGlobalGenericsMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OtherGlobalGenericsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AntiinfectiveMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:AntiinfectiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericMemberifrsfullSegmentsAxis_PainManagementMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:PainManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericMemberifrsfullSegmentsAxis_NutraceuticalMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:NutraceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:RespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CardiovascularMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericMemberifrsfullSegmentsAxis_HematologyMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_DermatologyMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:DermatologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OtherPsaiMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OtherPsaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OncologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CentralNervousSystemMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:CentralNervousSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_PainManagementMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:PainManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AntiInfectiveOneMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:AntiInfectiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CardiovascularMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GenitourinaryMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:GenitourinaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:RespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_DiabetologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:DiabetologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GastrointestinalMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:GastrointestinalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_DermatologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:DermatologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_PropertyPlantAndEquipmentMemberRDYInterestCapitalizationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:InterestCapitalizationAxis">ifrs-full:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:FairValueReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalRedemptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:SpecialEconomicZoneReinvestmentReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:ActuarialGainsLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:DebentureRedemptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_InterestRateSwapContractMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ProvidentFundBenefitsMemberRDYContributionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ContributionTypeAxis">rdy:ProvidentFundBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SuperannuationBenefitsMemberRDYContributionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ContributionTypeAxis">rdy:SuperannuationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2002PlanAxis">rdy:Drl2002PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryBParValueOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">rdy:ExercisepricesRs5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryBParValueOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">rdy:ExercisepricesRs5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_Us401kretirementSavingsPlanMemberRDYContributionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ContributionTypeAxis">rdy:Us401kretirementSavingsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_UkSocialSecuriyPlanMemberRDYContributionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ContributionTypeAxis">rdy:UkSocialSecuriyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_BottomOfRangeMemberifrsfullRangeAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_Drl2002PlanMemberRDYDrl2002PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2002PlanAxis">rdy:Drl2002PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CategoriesBMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:CategoryAxis">rdy:CategoriesBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardAxis">rdy:EquitySettledShareBasedPaymentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CategoriesAMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:CategoryAxis">rdy:CategoriesAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardAxis">rdy:EquitySettledShareBasedPaymentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanSevenMemberRDYLoanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LoanAxis">rdy:LoanSevenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanEightMemberRDYLoanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LoanAxis">rdy:LoanEightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FloatingInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_DresEnergyPrivateLimitedMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">rdy:DresEnergyPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ProprietaryProductsMemberifrsfullSegmentsAxis_XeglyzeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:XeglyzeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:ProprietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis_GnuvaringMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:GnuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_XeglyzeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:XeglyzeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericsAndProperietaryProductsMemberifrsfullSegmentsAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsAndProperietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericsOneMemberifrsfullSegmentsAxis_SaxagliptinMetforminPhentermineAndTopiramateMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:SaxagliptinMetforminPhentermineAndTopiramateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericsAndProperietaryProductsMemberifrsfullSegmentsAxis_HigherThanExpectedPriceErosionAndIncreasedCompetitionMemberRDYTriggeringEventAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TriggeringEventAxis">rdy:HigherThanExpectedPriceErosionAndIncreasedCompetitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsAndProperietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ProprietaryProductsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:ProprietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OthersSegmentsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:OthersSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ChargebacksMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_RebatesMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_MedicaidMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_RefundLiabilityMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:RefundLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis_NervousSystemMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:NervousSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GastrointestinalMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:GastrointestinalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AntiinfectiveMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:AntiinfectiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis_PainManagementMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:PainManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:RespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CardiovascularMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis_OtherGlobalGenericsMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OtherGlobalGenericsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis_NutraceuticalMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:NutraceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_DermatologyMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:DermatologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis_HematologyMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AntiinfectiveMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:AntiinfectiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OtherPsaiSegmentMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OtherPsaiSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_MajorCustomerOneMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rdy:MajorCustomerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_MajorCustomerTwoMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rdy:MajorCustomerTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_BottomOfRangeMemberifrsfullRangeAxis_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_BottomOfRangeMemberifrsfullRangeAxis_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_DrReddysEmployeesStockOptionScheme2018MemberifrsfullTypesOfSharebasedPaymentArrangementsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">rdy:DrReddysEmployeesStockOptionScheme2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_BuildingsMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">rdy:WockhardtLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AurigenePharmaceuticalServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NonConvertibleDebenturesMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:NonConvertibleDebenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SignificantInvestmentsInSubsidiariesAxis">rdy:AurigenePharmaceuticalServicesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_INRsrtCurrencyAxis_NonConvertibleDebenturesMemberifrsfullBorrowingsByNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:INR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">rdy:NonConvertibleDebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_DerivativesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">rdy:KeyManagementPersonnelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_OrdinarySharesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_MajorCustomer1MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rdy:MajorCustomer1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_MajorCustomer2MembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rdy:MajorCustomer2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_EquitySharedPaymentSettledMemberRDYAwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardAxis">rdy:EquitySharedPaymentSettledMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_CountryOfDomicileMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:CountryOfDomicileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_ForeignCountriesMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">ifrs-full:ForeignCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_CashSettledSharebasedPaymentMemberRDYAwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardAxis">rdy:CashSettledSharebasedPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">rdy:KunshanRotamReddyPharmaceuticalsCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:CostOfRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_SellingGeneralAndAdministrativeExpensesOneMemberRDYTypeOfExpensesByNatureAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:SellingGeneralAndAdministrativeExpensesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_ResearchAndDevelopmentExpensesMemberRDYTypeOfExpensesByNatureAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_OtherSegmentMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:OtherSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_PharmaceuticalServicesAndActiveIngredientsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_ProprietaryProductMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:ProprietaryProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_IndiaCountryMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:IndiaCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_OncologyMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_RussiaCountryMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:RussiaCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_OthersCountriesCountryMemberifrsfullGeographicalAreasAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">rdy:OthersCountriesCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:CostOfRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:CostOfRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_ProprietaryProductsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:CostOfRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:ProprietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_OthersSegmentsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TypeOfExpensesByNatureAxis">rdy:CostOfRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:OthersSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_CentralNervousSystemMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:CentralNervousSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GastrointestinalMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:GastrointestinalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericMemberifrsfullSegmentsAxis_OtherGlobalGenericsMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OtherGlobalGenericsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_AntiinfectiveMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:AntiinfectiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericMemberifrsfullSegmentsAxis_PainManagementMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:PainManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericMemberifrsfullSegmentsAxis_NutraceuticalMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:NutraceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:RespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_CardiovascularMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericMemberifrsfullSegmentsAxis_HematologyMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_DermatologyMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:DermatologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_OtherPsaiMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OtherPsaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_OncologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_CentralNervousSystemMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:CentralNervousSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_PainManagementMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:PainManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_AntiInfectiveOneMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:AntiInfectiveOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_CardiovascularMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GastrointestinalMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:GastrointestinalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GenitourinaryMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:GenitourinaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:RespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_DiabetologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:DiabetologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_DermatologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:DermatologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_TreasurySharesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:FairValueReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalRedemptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:SpecialEconomicZoneReinvestmentReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:DebentureRedemptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:ActuarialGainsLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_InterestRateSwapContractMemberifrsfullClassesOfFinancialAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:InterestRateSwapContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_ProvidentFundBenefitsMemberRDYContributionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ContributionTypeAxis">rdy:ProvidentFundBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_SuperannuationBenefitsMemberRDYContributionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ContributionTypeAxis">rdy:SuperannuationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_Us401kretirementSavingsPlanMemberRDYContributionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ContributionTypeAxis">rdy:Us401kretirementSavingsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_UkSocialSecuriyPlanMemberRDYContributionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ContributionTypeAxis">rdy:UkSocialSecuriyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_DresEnergyPrivateLimitedMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">rdy:DresEnergyPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_TobramycinInhalationSolutionRamelteonAndImiquimodCreamProductMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:TobramycinInhalationSolutionRamelteonAndImiquimodCreamProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericsAndProperietaryProductsMemberifrsfullSegmentsAxis_HigherThanExpectedPriceErosionAndIncreasedCompetitionMemberRDYTriggeringEventAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:TriggeringEventAxis">rdy:HigherThanExpectedPriceErosionAndIncreasedCompetitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsAndProperietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_GnuvaringMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:GnuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericsAndProperietaryProductsMemberifrsfullSegmentsAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsAndProperietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_ProprietaryProductsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:ProprietaryProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_OthersSegmentsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:OthersSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_ChargebacksMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_RebatesMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_MedicaidMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_RefundLiabilityMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:RefundLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_NervousSystemMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:NervousSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GastrointestinalMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:GastrointestinalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_AntiinfectiveMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:AntiinfectiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_PainManagementMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:PainManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:RespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_CardiovascularMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:CardiovascularMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_OtherGlobalGenericsMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OtherGlobalGenericsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_NutraceuticalMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:NutraceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_DermatologyMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:DermatologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_HematologyMemberifrsfullProductsAndServicesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:HematologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_AntiinfectiveMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:AntiinfectiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_OtherPsaiSegmentMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdy:OtherPsaiSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:PharmaceuticalServicesAndActiveIngredientMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_MajorCustomerOneMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rdy:MajorCustomerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_MajorCustomerTwoMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">rdy:MajorCustomerTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn02_12_2020_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">rdy:WockhardtLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-12</instant>
        </period>
    </context>
    <context id="PAsOn02_12_2020_MajorBusinessCombinationMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">rdy:WockhardtLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-12</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">rdy:KunshanRotamReddyPharmaceuticalsCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">rdy:EmployeeBenefitObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ActuarialAssumptionsAxis">rdy:EmployeeBenefitObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_DresEnergyPrivateLimitedMemberifrsfullJointVenturesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:JointVenturesAxis">rdy:DresEnergyPrivateLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_GnuvaringMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">rdy:GnuvaringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:GlobalGenericsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="P10_28_2021To10_28_2021_OptionOneOnTwentyEightOctoberTwoThousandTwentyOneMemberRDYAwardDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardDateAxis">rdy:OptionOneOnTwentyEightOctoberTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-28</startDate>
            <endDate>2021-10-28</endDate>
        </period>
    </context>
    <context id="P10_28_2021To10_28_2021_OptionTwoOnTwentyEightOctoberTwoThousandTwentyOneMemberRDYAwardDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardDateAxis">rdy:OptionTwoOnTwentyEightOctoberTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-28</startDate>
            <endDate>2021-10-28</endDate>
        </period>
    </context>
    <context id="P05_13_2021To05_13_2021_OptionOneOnThirteenMayTwoThousandTwentyOneMemberRDYAwardDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardDateAxis">rdy:OptionOneOnThirteenMayTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="P05_13_2021To05_13_2021_OptionTwoOnThirteenMayTwoThousandTwentyOneMemberRDYAwardDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardDateAxis">rdy:OptionTwoOnThirteenMayTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="P05_19_2020To05_19_2020_OptionOneOnNineteenMayTwoThousandTwentyMemberRDYAwardDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardDateAxis">rdy:OptionOneOnNineteenMayTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-19</startDate>
            <endDate>2020-05-19</endDate>
        </period>
    </context>
    <context id="P05_19_2020To05_19_2020_OptionTwoOnNineteenMayTwoThousandTwentyMemberRDYAwardDateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AwardDateAxis">rdy:OptionTwoOnNineteenMayTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-19</startDate>
            <endDate>2020-05-19</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2006_NorfloxacinIndiaLitigationMemberRDYLegalProceedingsContingentLiabilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LegalProceedingsContingentLiabilityAxis">rdy:NorfloxacinIndiaLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2006-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2008_NorfloxacinIndiaLitigationMemberRDYLegalProceedingsContingentLiabilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LegalProceedingsContingentLiabilityAxis">rdy:NorfloxacinIndiaLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2008-03-31</instant>
        </period>
    </context>
    <context id="PAsOn07_27_2017_CardiovascularMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-27</instant>
        </period>
    </context>
    <context id="PAsOn08_08_2017_CardiovascularMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-08</instant>
        </period>
    </context>
    <context id="PAsOn09_13_2017_CardiovascularMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-13</instant>
        </period>
    </context>
    <context id="PAsOn09_15_2017_CardiovascularMemberifrsfullSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:SegmentsAxis">rdy:CardiovascularMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-15</instant>
        </period>
    </context>
    <context id="PAsOn01_18_2018_ConsumerProductSafetyCommissionMemberRDYLegalProceedingsContingentLiabilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LegalProceedingsContingentLiabilityAxis">rdy:ConsumerProductSafetyCommissionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-18</instant>
        </period>
    </context>
    <context id="PAsOn08_23_2020_NamendaLitigationMemberRDYLegalProceedingsContingentLiabilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LegalProceedingsContingentLiabilityAxis">rdy:NamendaLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-23</instant>
        </period>
    </context>
    <context id="P09_07_2015To09_07_2015_AssetPurchaseAgreementMemberRDYAgreementAxis_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis_HatchtechPtyLimitedMemberdeiLegalEntityAxis_NdaApprovedMemberRDYMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AgreementAxis">rdy:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:LegalProceedingsContingentLiabilityAxis">rdy:CivilLitigationAndArbitrationWithHatchtechPtyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:MilestoneAxis">rdy:NdaApprovedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rdy:HatchtechPtyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-07</startDate>
            <endDate>2015-09-07</endDate>
        </period>
    </context>
    <context id="P09_07_2015To09_07_2015_AssetPurchaseAgreementMemberRDYAgreementAxis_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis_HatchtechPtyLimitedMemberdeiLegalEntityAxis_OvicidalLabelApprovedMemberRDYMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AgreementAxis">rdy:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:LegalProceedingsContingentLiabilityAxis">rdy:CivilLitigationAndArbitrationWithHatchtechPtyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:MilestoneAxis">rdy:OvicidalLabelApprovedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rdy:HatchtechPtyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-07</startDate>
            <endDate>2015-09-07</endDate>
        </period>
    </context>
    <context id="PAsOn10_08_2020_AssetPurchaseAgreementMemberRDYAgreementAxis_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis_HatchtechPtyLimitedMemberdeiLegalEntityAxis_NdaApprovedMemberRDYMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AgreementAxis">rdy:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:LegalProceedingsContingentLiabilityAxis">rdy:CivilLitigationAndArbitrationWithHatchtechPtyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:MilestoneAxis">rdy:NdaApprovedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rdy:HatchtechPtyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-08</instant>
        </period>
    </context>
    <context id="PAsOn10_08_2020_AssetPurchaseAgreementMemberRDYAgreementAxis_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis_HatchtechPtyLimitedMemberdeiLegalEntityAxis_OvicidalLabelApprovedMemberRDYMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AgreementAxis">rdy:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:LegalProceedingsContingentLiabilityAxis">rdy:CivilLitigationAndArbitrationWithHatchtechPtyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:MilestoneAxis">rdy:OvicidalLabelApprovedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rdy:HatchtechPtyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-08</instant>
        </period>
    </context>
    <context id="PAsOn01_25_2021_AaaicdrArbitrationMemberRDYAssociationAndDisputeResolutionAxis_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AssociationAndDisputeResolutionAxis">rdy:AaaicdrArbitrationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:LegalProceedingsContingentLiabilityAxis">rdy:CivilLitigationAndArbitrationWithHatchtechPtyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-25</instant>
        </period>
    </context>
    <context id="PAsOn05_15_2020_SecuritiesClassActionLitigationMemberRDYLegalProceedingsContingentLiabilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:LegalProceedingsContingentLiabilityAxis">rdy:SecuritiesClassActionLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-15</instant>
        </period>
    </context>
    <context id="P04_01_2008To03_31_2013_FuelSurchargeAdjustmentsMemberRDYDisallowanceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DisallowanceAxis">rdy:FuelSurchargeAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-04-01</startDate>
            <endDate>2013-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2016To06_30_2016_FuelSurchargeAdjustmentsMemberRDYDisallowanceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DisallowanceAxis">rdy:FuelSurchargeAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn01_18_2015_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:NamePartyInvolvedInTransactionAxis">rdy:CurisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-01-18</instant>
        </period>
    </context>
    <context id="PAsOn09_07_2016_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:NamePartyInvolvedInTransactionAxis">rdy:CurisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-07</instant>
        </period>
    </context>
    <context id="PAsOn05_31_2019_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:NamePartyInvolvedInTransactionAxis">rdy:CurisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="P07_29_2019To07_29_2019_DrReddysHoldingsLimitedMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">rdy:DrReddysHoldingsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-29</startDate>
            <endDate>2019-07-29</endDate>
        </period>
    </context>
    <context id="PAsOn04_08_2022_EventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdy:EventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-08</instant>
        </period>
    </context>
    <context id="P04_08_2022To04_08_2022_EventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdy:EventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-08</startDate>
            <endDate>2022-04-08</endDate>
        </period>
    </context>
    <context id="P05_01_2018To05_31_2018_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:NamePartyInvolvedInTransactionAxis">rdy:CurisIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="PAsOn02_03_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">rdy:NimbusHealthGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-03</instant>
        </period>
    </context>
    <context id="P02_03_2022To02_03_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">rdy:NimbusHealthGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-03</startDate>
            <endDate>2022-02-03</endDate>
        </period>
    </context>
    <context id="P02_12_2020To02_12_2020_MajorBusinessCombinationMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">rdy:WockhardtLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorBusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-12</startDate>
            <endDate>2020-02-12</endDate>
        </period>
    </context>
    <context id="P02_12_2020To02_12_2020_BottomOfRangeMemberifrsfullRangeAxis_MajorBusinessCombinationMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_ScenarioForecastOneMembersrtStatementScenarioAxis_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">rdy:ScenarioForecastOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:BusinessCombinationsAxis">rdy:WockhardtLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorBusinessCombinationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-12</startDate>
            <endDate>2020-02-12</endDate>
        </period>
    </context>
    <context id="PAsOn06_14_2021_NonadjustingEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdy:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-14</instant>
        </period>
    </context>
    <context id="P02_15_2022To02_15_2022_SettlementAndTransferAgreementDated2February2022MemberRDYAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AgreementAxis">rdy:SettlementAndTransferAgreementDated2February2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-15</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="P04_01_2017To04_01_2017_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-01</endDate>
        </period>
    </context>
    <context id="P04_01_2017To04_01_2017_BottomOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-04-01</endDate>
        </period>
    </context>
    <context id="P04_01_2020To04_01_2020_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="P04_01_2020To04_01_2020_BottomOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-01</endDate>
        </period>
    </context>
    <context id="P04_01_2012To03_31_2013_FuelSurchargeAdjustmentsMemberRDYDisallowanceAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DisallowanceAxis">rdy:FuelSurchargeAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-04-01</startDate>
            <endDate>2013-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn04_01_2022_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_NovartisAGMemberRDYAcquireeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AcquireeAxis">rdy:NovartisAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdy:NonadjustongEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-01</instant>
        </period>
    </context>
    <context id="PAsOn06_01_2022_NonadjustingEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_TexasAgAndTexasHealthAndHumanServicesCommissionMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rdy:TexasAgAndTexasHealthAndHumanServicesCommissionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdy:NonadjustingEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="PAsOn06_23_2022_Drl2007PlansMemberRDYPlanNameAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:PlanNameAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdy:NonadjustongEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-23</instant>
        </period>
    </context>
    <context id="PAsOn06_23_2022_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdy:NonadjustongEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-23</instant>
        </period>
    </context>
    <context id="PAsOn06_23_2022_Drl2002PlanMemberRDYPlanNameAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:PlanNameAxis">rdy:Drl2002PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdy:NonadjustongEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-23</instant>
        </period>
    </context>
    <context id="PAsOn06_23_2022_AdrMemberRDYClassOfStockAxis_Drl2007PlansMemberRDYPlanNameAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:PlanNameAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdy:NonadjustongEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-23</instant>
        </period>
    </context>
    <context id="PAsOn06_23_2022_Drl2007PlansMemberRDYPlanNameAxis_ExercisePriceOfTwoEightOneFourPerShareMemberRDYExercisePriceAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ExercisePriceAxis">rdy:ExercisePriceOfTwoEightOneFourPerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:PlanNameAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdy:NonadjustongEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-23</instant>
        </period>
    </context>
    <context id="PAsOn06_23_2022_Drl2007PlansMemberRDYPlanNameAxis_ExercisePriceOfThreeSixSevenNinePerShareMemberRDYExercisePriceAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ExercisePriceAxis">rdy:ExercisePriceOfThreeSixSevenNinePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:PlanNameAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdy:NonadjustongEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-23</instant>
        </period>
    </context>
    <context id="PAsOn06_23_2022_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_SettlementAgreementMemberRDYAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:AgreementAxis">rdy:SettlementAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdy:NonadjustongEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-23</instant>
        </period>
    </context>
    <context id="P06_23_2022To06_23_2022_Drl2007PlansMemberRDYPlanNameAxis_ExercisePriceOfThreeSixSevenNinePerShareMemberRDYExercisePriceAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ExercisePriceAxis">rdy:ExercisePriceOfThreeSixSevenNinePerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:PlanNameAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdy:NonadjustongEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-23</startDate>
            <endDate>2022-06-23</endDate>
        </period>
    </context>
    <context id="P06_23_2022To06_23_2022_Drl2007PlansMemberRDYPlanNameAxis_ExercisePriceOfTwoEightOneFourPerShareMemberRDYExercisePriceAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ExercisePriceAxis">rdy:ExercisePriceOfTwoEightOneFourPerShareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:PlanNameAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdy:NonadjustongEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-23</startDate>
            <endDate>2022-06-23</endDate>
        </period>
    </context>
    <context id="P06_23_2022To06_23_2022_Drl2007PlansMemberRDYPlanNameAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:PlanNameAxis">rdy:Drl2007PlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdy:NonadjustongEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-23</startDate>
            <endDate>2022-06-23</endDate>
        </period>
    </context>
    <context id="P06_23_2022To06_23_2022_Drl2002PlanMemberRDYPlanNameAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:PlanNameAxis">rdy:Drl2002PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdy:NonadjustongEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-23</startDate>
            <endDate>2022-06-23</endDate>
        </period>
    </context>
    <context id="PAsOn06_24_2022_BrandedAndGenericInjectableProductsMemberRDYProductOrServicesAxis_EtonPharmaceuticalsIncMemberRDYSupplierAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProductOrServicesAxis">rdy:BrandedAndGenericInjectableProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="rdy:SupplierAxis">rdy:EtonPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdy:NonadjustongEventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-24</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:RefundsProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OtherEnvironmentRelatedProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:OtherEnvironmentRelatedProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_LegalProceedingsProvisionMemberifrsfullClassesOfProvisionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">ifrs-full:LegalProceedingsProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_InventorydeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:InventorydeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_MinimumAlternateTaxdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:MinimumAlternateTaxdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_TradeAndOtherReceivablesdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:TradeAndOtherReceivablesdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OperatingAndOtherTaxLossCarryforwardMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:OperatingAndOtherTaxLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_IntangibleAssetsdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:IntangibleAssetsdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OthersdeferredTaxLiabilityAssetMemberMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:OthersdeferredTaxLiabilityAssetMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:FairValueReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalRedemptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:SpecialEconomicZoneReinvestmentReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:DebentureRedemptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:ActuarialGainsLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_InventorydeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:InventorydeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_MinimumAlternateTaxdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:MinimumAlternateTaxdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_TradeAndOtherReceivablesdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:TradeAndOtherReceivablesdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OperatingAndOtherTaxLossCarryforwardMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:OperatingAndOtherTaxLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_IntangibleAssetsdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:IntangibleAssetsdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OthersdeferredTaxLiabilityAssetMemberMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:OthersdeferredTaxLiabilityAssetMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ChargebacksMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RebatesMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_MedicaidMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ChargebacksMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RebatesMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_MedicaidMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_BuildingsMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LandMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:ActuarialGainsLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:DebentureRedemptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:SpecialEconomicZoneReinvestmentReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalRedemptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:FairValueReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:IntangibleAssetsUnderDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:IndustriasQuimicasFalconDeMexicoPensionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NetDefinedBenefitLiabilityAssetAxis">rdy:GratuityBenefitsOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_OrdinarySharesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:LongtermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LiabilitiesArisingFromFinancingActivitiesAxis">ifrs-full:ShorttermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:DefinedBenefitPlansAxis">rdy:ParentCompanyGratuityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_InventorydeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:InventorydeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_MinimumAlternateTaxdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:MinimumAlternateTaxdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_TradeAndOtherReceivablesdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:TradeAndOtherReceivablesdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_OperatingAndOtherTaxLossCarryforwardMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:OperatingAndOtherTaxLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_IntangibleAssetsdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:IntangibleAssetsdeferredTaxLiabilityAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_OthersdeferredTaxLiabilityAssetMemberMemberRDYDeferredTaxAssetsAndLiabilitiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:DeferredTaxAssetsAndLiabilitiesAxis">rdy:OthersdeferredTaxLiabilityAssetMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_TreasurySharesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:FairValueReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalRedemptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:SpecialEconomicZoneReinvestmentReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:ActuarialGainsLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:DebentureRedemptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationAndImpairmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2002PlanAxis">rdy:Drl2002PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryBParValueOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">rdy:ExercisepricesRs5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryBParValueOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">rdy:ExercisepricesRs5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ChargebacksMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_RebatesMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_MedicaidMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_RefundLiabilityMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:RefundLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_BottomOfRangeMemberifrsfullRangeAxis_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2007PlanAxis">rdy:DrlTwoThousandSevenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">rdy:CategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_BottomOfRangeMemberifrsfullRangeAxis_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_TopOfRangeMemberifrsfullRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:Drl2018PlanNameAxis">rdy:DrlTwoThousandEighteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:AccumulatedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_BuildingsMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_LandMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_BuildingsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">rdy:ExcludingCapitalworkinprogressMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_SharePremiumMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_TreasurySharesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_FairValueReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:FairValueReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfCashFlowHedgesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalRedemptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:SpecialEconomicZoneReinvestmentReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:DebentureRedemptionReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdy:ActuarialGainsLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_ChargebacksMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_RebatesMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:RebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_MedicaidMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_RefundLiabilityMemberRDYProvisionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rdy:ProvisionAxis">rdy:RefundLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_LandMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_BuildingsMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:PlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">rdy:FurnitureFixturesAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_VehiclesMemberifrsfullClassesOfAssetsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:RecipesFormulaeModelsDesignsAndPrototypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001135951</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsOtherThanGoodwillAxis">ifrs-full:CustomerrelatedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <unit id="Unit_INR">
        <measure>iso4217:INR</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_AUD">
        <measure>iso4217:AUD</measure>
    </unit>
    <unit id="Unit_GBP">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="Unit_RUB">
        <measure>iso4217:RUB</measure>
    </unit>
    <unit id="Unit_ZAR">
        <measure>iso4217:ZAR</measure>
    </unit>
    <unit id="Unit_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_CHF">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="Unit_MXN">
        <measure>iso4217:MXN</measure>
    </unit>
    <unit id="Unit_INR_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:INR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_INRPerUSD">
        <measure>rdy:INRPerUSD</measure>
    </unit>
    <unit id="Unit_Number">
        <measure>rdy:Number</measure>
    </unit>
    <unit id="Unit_INR_acre">
        <divide>
            <unitNumerator>
                <measure>iso4217:INR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>utr:acre</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_acre">
        <measure>utr:acre</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Brand">
        <measure>rdy:Brand</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_Employees">
        <measure>rdy:Employees</measure>
    </unit>
    <unit id="Unit_M">
        <measure>utr:M</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P04_01_2021To03_31_2022">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="P04_01_2021To03_31_2022">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityRegistrantName contextRef="P04_01_2021To03_31_2022" id="hidden50539544">DR REDDYS LABORATORIES LTD</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="P04_01_2021To03_31_2022">0001135951</dei:EntityCentralIndexKey>
    <dei:EntityIncorporationStateCountryCode contextRef="P04_01_2021To03_31_2022" id="hidden50540306">K7</dei:EntityIncorporationStateCountryCode>
    <dei:DocumentType contextRef="P04_01_2021To03_31_2022">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="P04_01_2021To03_31_2022">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="P04_01_2021To03_31_2022">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="P04_01_2021To03_31_2022">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="P04_01_2021To03_31_2022">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P04_01_2021To03_31_2022">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="P04_01_2021To03_31_2022">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="P04_01_2021To03_31_2022">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="P04_01_2021To03_31_2022">1-15182</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="P04_01_2021To03_31_2022">8-2-337</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="P04_01_2021To03_31_2022">Road No. 3</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="P04_01_2021To03_31_2022">Banjara Hills</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="P04_01_2021To03_31_2022">Hyderabad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P04_01_2021To03_31_2022">500 034</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="P04_01_2021To03_31_2022">IN</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="P04_01_2021To03_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Parag Agarwal</dei:ContactPersonnelName>
    <dei:CountryRegion contextRef="P04_01_2021To03_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">91</dei:CountryRegion>
    <dei:CityAreaCode contextRef="P04_01_2021To03_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">40</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P04_01_2021To03_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">49002931</dei:LocalPhoneNumber>
    <dei:ContactPersonnelEmailAddress contextRef="P04_01_2021To03_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">parag.agarwal@drreddys.com</dei:ContactPersonnelEmailAddress>
    <dei:EntityAddressAddressLine1 contextRef="P04_01_2021To03_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">8-2-337</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="P04_01_2021To03_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Road No. 3</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="P04_01_2021To03_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Banjara Hills</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="P04_01_2021To03_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">Hyderabad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P04_01_2021To03_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">500 034</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="P04_01_2021To03_31_2022_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">IN</dei:EntityAddressCountry>
    <dei:Security12bTitle contextRef="P04_01_2021To03_31_2022_AdrMemberdeiDocumentInformationDocumentAxis">American depositary shares, each representing one equity share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P04_01_2021To03_31_2022_AdrMemberdeiDocumentInformationDocumentAxis">RDY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P04_01_2021To03_31_2022_AdrMemberdeiDocumentInformationDocumentAxis">NYSE</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn03_31_2022"
      decimals="0"
      unitRef="Unit_shares">166425849</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="P04_01_2021To03_31_2022">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="P04_01_2021To03_31_2022">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="P04_01_2021To03_31_2022">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P04_01_2021To03_31_2022">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P04_01_2021To03_31_2022">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="P04_01_2021To03_31_2022">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="P04_01_2021To03_31_2022">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard contextRef="P04_01_2021To03_31_2022">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="P04_01_2021To03_31_2022">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="P04_01_2021To03_31_2022">1712</dei:AuditorFirmId>
    <dei:AuditorName contextRef="P04_01_2021To03_31_2022">Ernst &amp; Young Associates LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="P04_01_2021To03_31_2022">Hyderabad, India</dei:AuditorLocation>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">196000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">14852000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">14829000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">389000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">29513000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">19744000000</ifrs-full:CurrentInvestments>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">880000000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">66764000000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">49641000000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:Inventories
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">671000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">50884000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">45412000000</ifrs-full:Inventories>
    <ifrs-full:CurrentDerivativeFinancialAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">25000000</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentDerivativeFinancialAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1906000000</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentDerivativeFinancialAssets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1218000000</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">53000000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4035000000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2745000000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:OtherCurrentAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">183000000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">13902000000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">14509000000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2397000000</ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">181856000000</ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">148098000000</ifrs-full:CurrentAssetsOtherThanAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">0</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">151000000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2397000000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">181856000000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">148249000000</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">819000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">62169000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">57111000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:Goodwill
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">58000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4418000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">4568000000</ifrs-full:Goodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">359000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">27246000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">35648000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:NoncurrentReceivables
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1000000</ifrs-full:NoncurrentReceivables>
    <ifrs-full:NoncurrentReceivables
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">54000000</ifrs-full:NoncurrentReceivables>
    <ifrs-full:NoncurrentReceivables
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">118000000</ifrs-full:NoncurrentReceivables>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">57000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4318000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">3375000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">48000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">3668000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">4958000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">108000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">8204000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:DeferredTaxAssets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">10630000000</ifrs-full:DeferredTaxAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">12000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">894000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">834000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1463000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">110971000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">117242000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">3860000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">292827000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">265491000000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">337000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">25572000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">23744000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">357000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">27082000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">23136000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:CurrentPortionOfLongtermBorrowings
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">13000000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:CurrentPortionOfLongtermBorrowings
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1017000000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:CurrentPortionOfLongtermBorrowings
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">864000000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">56000000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4258000000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">3435000000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">21000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1615000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1389000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">6000000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">479000000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">326000000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">9000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">448000000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">33992000000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">30488000000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1239000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">94015000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">83391000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">76000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">5746000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">6299000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">60000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">338000000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:OtherLongtermProvisions
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1000000</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:OtherLongtermProvisions
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">57000000</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:OtherLongtermProvisions
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">58000000</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">32000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2422000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2343000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">109000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">8285000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">9038000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1348000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">102300000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">92429000000</ifrs-full:Liabilities>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">11000000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">832000000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">832000000</ifrs-full:IssuedCapital>
    <ifrs-full:TreasuryShares
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">21000000</ifrs-full:TreasuryShares>
    <ifrs-full:TreasuryShares
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1601000000</ifrs-full:TreasuryShares>
    <ifrs-full:TreasuryShares
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1967000000</ifrs-full:TreasuryShares>
    <ifrs-full:SharePremium
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">122000000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">9280000000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">8887000000</ifrs-full:SharePremium>
    <ifrs-full:ReserveOfSharebasedPayments
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">21000000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1628000000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:ReserveOfSharebasedPayments
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1461000000</ifrs-full:ReserveOfSharebasedPayments>
    <ifrs-full:CapitalRedemptionReserve
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2000000</ifrs-full:CapitalRedemptionReserve>
    <ifrs-full:CapitalRedemptionReserve
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">173000000</ifrs-full:CapitalRedemptionReserve>
    <ifrs-full:CapitalRedemptionReserve
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">173000000</ifrs-full:CapitalRedemptionReserve>
    <rdy:DebentureRedemptionReserve
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">4000000</rdy:DebentureRedemptionReserve>
    <rdy:DebentureRedemptionReserve
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">304000000</rdy:DebentureRedemptionReserve>
    <rdy:DebentureRedemptionReserve
      contextRef="PAsOn03_31_2021"
      unitRef="Unit_INR"
      xsi:nil="true"/>
    <rdy:SpecialEconomicZoneReinvestmentReserve
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">10000000</rdy:SpecialEconomicZoneReinvestmentReserve>
    <rdy:SpecialEconomicZoneReinvestmentReserve
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">755000000</rdy:SpecialEconomicZoneReinvestmentReserve>
    <rdy:SpecialEconomicZoneReinvestmentReserve
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1326000000</rdy:SpecialEconomicZoneReinvestmentReserve>
    <ifrs-full:RetainedEarnings
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2316000000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">175712000000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">156023000000</ifrs-full:RetainedEarnings>
    <ifrs-full:OtherReserves
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">45000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">3444000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">6327000000</ifrs-full:OtherReserves>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2511000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">190527000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">173062000000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">3860000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">292827000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">265491000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2826000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">214391000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">189722000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">174600000000</ifrs-full:Revenue>
    <ifrs-full:CostOfSales
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1325000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">100551000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">86645000000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">80591000000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1500000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">113840000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">103077000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">94009000000</ifrs-full:GrossProfit>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">818000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">62081000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">54650000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">50129000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">230000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">17482000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">16541000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">15410000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">100000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">7562000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">8588000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">16767000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">36000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2761000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">982000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">4290000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OperatingExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1112000000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">84364000000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">78797000000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">78016000000</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">389000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">29476000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">24280000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">15993000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">41000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">3077000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2623000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">2461000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">13000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">958000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">970000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">983000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncomeCost
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">28000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2119000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1653000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">1478000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">9000000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">703000000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">480000000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">561000000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">426000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">32298000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">26413000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">18032000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">115000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">8730000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">9175000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-1466000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">311000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">23568000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">17238000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">19498000000</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P04_01_2021To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.87</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P04_01_2021To03_31_2022"
      decimals="2"
      unitRef="Unit_INR_per_Share">142.08</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P04_01_2020To03_31_2021"
      decimals="2"
      unitRef="Unit_INR_per_Share">103.94</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P04_01_2019To03_31_2020"
      decimals="2"
      unitRef="Unit_INR_per_Share">117.63</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P04_01_2021To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.87</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P04_01_2021To03_31_2022"
      decimals="2"
      unitRef="Unit_INR_per_Share">141.69</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P04_01_2020To03_31_2021"
      decimals="2"
      unitRef="Unit_INR_per_Share">103.65</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P04_01_2019To03_31_2020"
      decimals="2"
      unitRef="Unit_INR_per_Share">117.4</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">311000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">23568000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">17238000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">19498000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-47000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-3534000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">4242000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-469000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">0</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-34000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-216000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">57000000</ifrs-full:OtherComprehensiveIncomeBeforeTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-4000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-305000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">220000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">22000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-43000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-3263000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">3806000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-434000000</ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">7000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-7000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-3000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-214000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">706000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">311000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">12000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">882000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1123000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-951000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">4000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">288000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">319000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss>
    <ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-232000000</ifrs-full:IncomeTaxRelatingToComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">5000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">380000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1517000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-415000000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-38000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-2883000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">5323000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-849000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">273000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">20685000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">22561000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">18649000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">832000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">8887000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-1967000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">1461000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537832"
      unitRef="Unit_INR">1540000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">5049000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">241000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">173000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537836"
      unitRef="Unit_INR">1326000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537837"
      unitRef="Unit_INR">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-503000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">156023000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">173062000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537845"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537849"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537954"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">23568000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">23568000000</ifrs-full:ProfitLoss>
    <rdy:IncomeTaxRelatingToInvestmentsInEquityInstrumentsAndFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIncludedInOtherComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">293000000</rdy:IncomeTaxRelatingToInvestmentsInEquityInstrumentsAndFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIncludedInOtherComprehensiveIncome>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2021To03_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2021To03_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2021To03_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2021To03_31_2022_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2021To03_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539963"
      unitRef="Unit_INR">-3241000000</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2021To03_31_2022_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2021To03_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2021To03_31_2022_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2021To03_31_2022_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539967"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2021To03_31_2022_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539968"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2021To03_31_2022_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2021To03_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-3241000000</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2021To03_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2021To03_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2021To03_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2021To03_31_2022_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2021To03_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538252"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2021To03_31_2022_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-214000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2021To03_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2021To03_31_2022_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2021To03_31_2022_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538256"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2021To03_31_2022_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538257"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2021To03_31_2022_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2021To03_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-214000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-288000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2021To03_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2021To03_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2021To03_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2021To03_31_2022_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2021To03_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538265"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2021To03_31_2022_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2021To03_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">594000000</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2021To03_31_2022_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2021To03_31_2022_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538269"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2021To03_31_2022_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538270"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2021To03_31_2022_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2021To03_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">594000000</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">12000000</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2021To03_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2021To03_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2021To03_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2021To03_31_2022_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2021To03_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538278"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2021To03_31_2022_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2021To03_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2021To03_31_2022_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2021To03_31_2022_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538282"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2021To03_31_2022_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538283"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2021To03_31_2022_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-22000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2021To03_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-22000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538291"
      unitRef="Unit_INR">-3241000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-214000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">594000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538295"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538296"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-22000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">23568000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">20685000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538300"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">393000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">366000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-425000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538304"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538308"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538309"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">334000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2021To03_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2021To03_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2021To03_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2021To03_31_2022_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">592000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2021To03_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538317"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2021To03_31_2022_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2021To03_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2021To03_31_2022_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2021To03_31_2022_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538321"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2021To03_31_2022_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538322"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2021To03_31_2022_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2021To03_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">592000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2021To03_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2021To03_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2021To03_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2021To03_31_2022_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2021To03_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538330"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2021To03_31_2022_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2021To03_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2021To03_31_2022_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2021To03_31_2022_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538334"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2021To03_31_2022_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538335"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2021To03_31_2022_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2021To03_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">4146000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4146000000</ifrs-full:DividendsPaid>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2021To03_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538509"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2021To03_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">393000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2021To03_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">366000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2021To03_31_2022_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">167000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2021To03_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538513"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2021To03_31_2022_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2021To03_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2021To03_31_2022_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2021To03_31_2022_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538517"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2021To03_31_2022_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538518"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2021To03_31_2022_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2021To03_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-4146000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-3220000000</ifrs-full:ChangesInEquity>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2021To03_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2021To03_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2021To03_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2021To03_31_2022_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2021To03_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539976"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2021To03_31_2022_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2021To03_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2021To03_31_2022_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2021To03_31_2022_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539980"
      unitRef="Unit_INR">-571000000</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2021To03_31_2022_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539981"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2021To03_31_2022_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2021To03_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">571000000</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:TransferFromGeneralReserveToDebentureRedemptionReserve
      contextRef="P04_01_2021To03_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromGeneralReserveToDebentureRedemptionReserve>
    <rdy:TransferFromGeneralReserveToDebentureRedemptionReserve
      contextRef="P04_01_2021To03_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromGeneralReserveToDebentureRedemptionReserve>
    <rdy:TransferFromGeneralReserveToDebentureRedemptionReserve
      contextRef="P04_01_2021To03_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromGeneralReserveToDebentureRedemptionReserve>
    <rdy:TransferFromGeneralReserveToDebentureRedemptionReserve
      contextRef="P04_01_2021To03_31_2022_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromGeneralReserveToDebentureRedemptionReserve>
    <rdy:TransferFromGeneralReserveToDebentureRedemptionReserve
      contextRef="P04_01_2021To03_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539989"
      unitRef="Unit_INR">0</rdy:TransferFromGeneralReserveToDebentureRedemptionReserve>
    <rdy:TransferFromGeneralReserveToDebentureRedemptionReserve
      contextRef="P04_01_2021To03_31_2022_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromGeneralReserveToDebentureRedemptionReserve>
    <rdy:TransferFromGeneralReserveToDebentureRedemptionReserve
      contextRef="P04_01_2021To03_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromGeneralReserveToDebentureRedemptionReserve>
    <rdy:TransferFromGeneralReserveToDebentureRedemptionReserve
      contextRef="P04_01_2021To03_31_2022_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromGeneralReserveToDebentureRedemptionReserve>
    <rdy:TransferFromGeneralReserveToDebentureRedemptionReserve
      contextRef="P04_01_2021To03_31_2022_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539993"
      unitRef="Unit_INR">0</rdy:TransferFromGeneralReserveToDebentureRedemptionReserve>
    <rdy:TransferFromGeneralReserveToDebentureRedemptionReserve
      contextRef="P04_01_2021To03_31_2022_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539994"
      unitRef="Unit_INR">304000000</rdy:TransferFromGeneralReserveToDebentureRedemptionReserve>
    <rdy:TransferFromGeneralReserveToDebentureRedemptionReserve
      contextRef="P04_01_2021To03_31_2022_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromGeneralReserveToDebentureRedemptionReserve>
    <rdy:TransferFromGeneralReserveToDebentureRedemptionReserve
      contextRef="P04_01_2021To03_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-304000000</rdy:TransferFromGeneralReserveToDebentureRedemptionReserve>
    <rdy:TransferFromGeneralReserveToDebentureRedemptionReserve
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromGeneralReserveToDebentureRedemptionReserve>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2021To03_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2021To03_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2021To03_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2021To03_31_2022_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2021To03_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50540097"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2021To03_31_2022_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2021To03_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2021To03_31_2022_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2021To03_31_2022_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50540093"
      unitRef="Unit_INR">-571000000</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2021To03_31_2022_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50540092"
      unitRef="Unit_INR">304000000</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2021To03_31_2022_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2021To03_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">267000000</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">832000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">9280000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-1601000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2022_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">1628000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538564"
      unitRef="Unit_INR">-1701000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2022_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">4835000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">835000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2022_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">173000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2022_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538560"
      unitRef="Unit_INR">755000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2022_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538559"
      unitRef="Unit_INR">304000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2022_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-525000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">175712000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">190527000000</ifrs-full:Equity>
    <rdy:ConvenienceTranslationRates
      contextRef="P04_01_2021To03_31_2022_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_USD">11000000</rdy:ConvenienceTranslationRates>
    <rdy:ConvenienceTranslationRates
      contextRef="P04_01_2021To03_31_2022_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_USD">122000000</rdy:ConvenienceTranslationRates>
    <rdy:ConvenienceTranslationRates
      contextRef="P04_01_2021To03_31_2022_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_USD">-21000000</rdy:ConvenienceTranslationRates>
    <rdy:ConvenienceTranslationRates
      contextRef="P04_01_2021To03_31_2022_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_USD">22000000</rdy:ConvenienceTranslationRates>
    <rdy:ConvenienceTranslationRates
      contextRef="P04_01_2021To03_31_2022_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539371"
      unitRef="Unit_USD">-22000000</rdy:ConvenienceTranslationRates>
    <rdy:ConvenienceTranslationRates
      contextRef="P04_01_2021To03_31_2022_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_USD">64000000</rdy:ConvenienceTranslationRates>
    <rdy:ConvenienceTranslationRates
      contextRef="P04_01_2021To03_31_2022_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_USD">11000000</rdy:ConvenienceTranslationRates>
    <rdy:ConvenienceTranslationRates
      contextRef="P04_01_2021To03_31_2022_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</rdy:ConvenienceTranslationRates>
    <rdy:ConvenienceTranslationRates
      contextRef="P04_01_2021To03_31_2022_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539368"
      unitRef="Unit_USD">10000000</rdy:ConvenienceTranslationRates>
    <rdy:ConvenienceTranslationRates
      contextRef="P04_01_2021To03_31_2022_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539367"
      unitRef="Unit_USD">4000000</rdy:ConvenienceTranslationRates>
    <rdy:ConvenienceTranslationRates
      contextRef="P04_01_2021To03_31_2022_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_USD">-7000000</rdy:ConvenienceTranslationRates>
    <rdy:ConvenienceTranslationRates
      contextRef="P04_01_2021To03_31_2022_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_USD">2316000000</rdy:ConvenienceTranslationRates>
    <rdy:ConvenienceTranslationRates
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">2511000000</rdy:ConvenienceTranslationRates>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">831000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">8495000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-1006000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">1233000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537728"
      unitRef="Unit_INR">-2405000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">4343000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-563000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">173000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537732"
      unitRef="Unit_INR">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537818"
      unitRef="Unit_INR">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-360000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">144247000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">154988000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537740"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537744"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537819"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">17238000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">17238000000</ifrs-full:ProfitLoss>
    <rdy:IncomeTaxRelatingToInvestmentsInEquityInstrumentsAndFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIncludedInOtherComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">293000000</rdy:IncomeTaxRelatingToInvestmentsInEquityInstrumentsAndFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIncludedInOtherComprehensiveIncome>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2020To03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2020To03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2020To03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2020To03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2020To03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539636"
      unitRef="Unit_INR">3945000000</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2020To03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2020To03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2020To03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2020To03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539640"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2020To03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539951"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2020To03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539642"
      unitRef="Unit_INR">11000000</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">3956000000</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2020To03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2020To03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2020To03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2020To03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2020To03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538131"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2020To03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">706000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2020To03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2020To03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2020To03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538135"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2020To03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538211"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2020To03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">706000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-319000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2020To03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2020To03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2020To03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2020To03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2020To03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538143"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2020To03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2020To03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">804000000</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2020To03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2020To03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538147"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2020To03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538212"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2020To03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">804000000</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">73000000</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2020To03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2020To03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2020To03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2020To03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2020To03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538155"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2020To03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2020To03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2020To03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2020To03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538159"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2020To03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538213"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2020To03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-143000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-143000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538167"
      unitRef="Unit_INR">3945000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">706000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">804000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538171"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538214"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-143000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">17249000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">22561000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2020To03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">1000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2020To03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">392000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2020To03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">232000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2020To03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-356000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2020To03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538179"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2020To03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2020To03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2020To03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2020To03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538183"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2020To03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538215"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2020To03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">269000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2020To03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2020To03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2020To03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2020To03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">584000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2020To03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538191"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2020To03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2020To03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2020To03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2020To03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538195"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2020To03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538216"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2020To03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">584000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2020To03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2020To03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2020To03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-1193000000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2020To03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2020To03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538693"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2020To03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2020To03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2020To03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2020To03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538689"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2020To03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539328"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2020To03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-1193000000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2020To03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2020To03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2020To03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2020To03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2020To03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538203"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2020To03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2020To03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2020To03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2020To03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538207"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2020To03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538217"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2020To03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">4147000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">4147000000</ifrs-full:DividendsPaid>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2020To03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">1000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2020To03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">392000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2020To03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-961000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2020To03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">228000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2020To03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538389"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2020To03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2020To03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2020To03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2020To03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538393"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2020To03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538499"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2020To03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-4147000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-4487000000</ifrs-full:ChangesInEquity>
    <rdy:ReversalFromSpecialEconomicZoneReinvestmentReserve
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">127000000</rdy:ReversalFromSpecialEconomicZoneReinvestmentReserve>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2020To03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2020To03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2020To03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2020To03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2020To03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539677"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2020To03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2020To03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2020To03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2020To03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539673"
      unitRef="Unit_INR">1402000000</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2020To03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539952"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2020To03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-1402000000</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughTransferToSpecialEconomicZoneReserveNetOfReversal>
    <rdy:TransferFromSpecialEconomicZoneReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromSpecialEconomicZoneReserveOnUtilization>
    <rdy:TransferFromSpecialEconomicZoneReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromSpecialEconomicZoneReserveOnUtilization>
    <rdy:TransferFromSpecialEconomicZoneReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromSpecialEconomicZoneReserveOnUtilization>
    <rdy:TransferFromSpecialEconomicZoneReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromSpecialEconomicZoneReserveOnUtilization>
    <rdy:TransferFromSpecialEconomicZoneReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539665"
      unitRef="Unit_INR">0</rdy:TransferFromSpecialEconomicZoneReserveOnUtilization>
    <rdy:TransferFromSpecialEconomicZoneReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromSpecialEconomicZoneReserveOnUtilization>
    <rdy:TransferFromSpecialEconomicZoneReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromSpecialEconomicZoneReserveOnUtilization>
    <rdy:TransferFromSpecialEconomicZoneReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromSpecialEconomicZoneReserveOnUtilization>
    <rdy:TransferFromSpecialEconomicZoneReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539661"
      unitRef="Unit_INR">-76000000</rdy:TransferFromSpecialEconomicZoneReserveOnUtilization>
    <rdy:TransferFromSpecialEconomicZoneReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539953"
      unitRef="Unit_INR">0</rdy:TransferFromSpecialEconomicZoneReserveOnUtilization>
    <rdy:TransferFromSpecialEconomicZoneReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromSpecialEconomicZoneReserveOnUtilization>
    <rdy:TransferFromSpecialEconomicZoneReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">76000000</rdy:TransferFromSpecialEconomicZoneReserveOnUtilization>
    <rdy:TransferFromSpecialEconomicZoneReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TransferFromSpecialEconomicZoneReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539653"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539649"
      unitRef="Unit_INR">1326000000</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539954"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-1326000000</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TotalTransferThroughTofromSpecialEconomicZoneReinvestmentReserveOnUtilization>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">832000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">8887000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-1967000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">1461000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538426"
      unitRef="Unit_INR">1540000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">5049000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">241000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">173000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538422"
      unitRef="Unit_INR">1326000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538500"
      unitRef="Unit_INR">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-503000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">156023000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">173062000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2019_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">830000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2019_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">8210000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2019_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-535000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2019_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">990000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2019_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537704"
      unitRef="Unit_INR">-1910000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2019_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">4032000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2019_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">156000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2019_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">173000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2019_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537708"
      unitRef="Unit_INR">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2019_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537820"
      unitRef="Unit_INR">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2019_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-395000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2019_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">128646000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2019"
      decimals="-6"
      unitRef="Unit_INR">140197000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537716"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537720"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50537824"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">19498000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">19498000000</ifrs-full:ProfitLoss>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2019To03_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2019To03_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2019To03_31_2020_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2019To03_31_2020_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2019To03_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539624"
      unitRef="Unit_INR">-495000000</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2019To03_31_2020_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2019To03_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2019To03_31_2020_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2019To03_31_2020_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539628"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2019To03_31_2020_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539955"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2019To03_31_2020_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2019To03_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539957"
      unitRef="Unit_INR">19000000</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-476000000</rdy:NetChangeInFairValueOfEquityAndDebtInstrumentsNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2019To03_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2019To03_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2019To03_31_2020_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2019To03_31_2020_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2019To03_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538047"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2019To03_31_2020_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">311000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2019To03_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2019To03_31_2020_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2019To03_31_2020_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538051"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2019To03_31_2020_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538218"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2019To03_31_2020_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2019To03_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">311000000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-232000000</ifrs-full:IncomeTaxRelatingToCashFlowHedgesOfOtherComprehensiveIncome>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2019To03_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2019To03_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2019To03_31_2020_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2019To03_31_2020_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2019To03_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538059"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2019To03_31_2020_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2019To03_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-719000000</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2019To03_31_2020_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2019To03_31_2020_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538063"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2019To03_31_2020_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538222"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2019To03_31_2020_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2019To03_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-719000000</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-22000000</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2019To03_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2019To03_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2019To03_31_2020_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2019To03_31_2020_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2019To03_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538071"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2019To03_31_2020_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2019To03_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2019To03_31_2020_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2019To03_31_2020_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538075"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2019To03_31_2020_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538226"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2019To03_31_2020_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">35000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2019To03_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">35000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538083"
      unitRef="Unit_INR">-495000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-311000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-719000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538087"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538230"
      unitRef="Unit_INR">0</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">35000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">19517000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">18649000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2019To03_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">1000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2019To03_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">285000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2019To03_31_2020_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">3000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2019To03_31_2020_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-278000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2019To03_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538095"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2019To03_31_2020_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2019To03_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2019To03_31_2020_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2019To03_31_2020_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538099"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2019To03_31_2020_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538234"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2019To03_31_2020_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2019To03_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">11000000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2019To03_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2019To03_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2019To03_31_2020_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      unitRef="Unit_INR"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2019To03_31_2020_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">521000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2019To03_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538107"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2019To03_31_2020_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2019To03_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2019To03_31_2020_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2019To03_31_2020_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538111"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2019To03_31_2020_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538238"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2019To03_31_2020_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2019To03_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">521000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2019To03_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2019To03_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2019To03_31_2020_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-474000000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2019To03_31_2020_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2019To03_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538671"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2019To03_31_2020_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2019To03_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2019To03_31_2020_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2019To03_31_2020_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538675"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2019To03_31_2020_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539329"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2019To03_31_2020_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2019To03_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-474000000</ifrs-full:IncreaseDecreaseThroughTreasuryShareTransactions>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2019To03_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2019To03_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2019To03_31_2020_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2019To03_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538119"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2019To03_31_2020_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2019To03_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2019To03_31_2020_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2019To03_31_2020_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538123"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2019To03_31_2020_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538242"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2019To03_31_2020_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2019To03_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">3916000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">3916000000</ifrs-full:DividendsPaid>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2019To03_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">1000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2019To03_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">285000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2019To03_31_2020_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-471000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2019To03_31_2020_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">243000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2019To03_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538365"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2019To03_31_2020_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2019To03_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2019To03_31_2020_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2019To03_31_2020_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538369"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2019To03_31_2020_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538501"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2019To03_31_2020_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2019To03_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-3916000000</ifrs-full:ChangesInEquity>
    <ifrs-full:ChangesInEquity
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-3858000000</ifrs-full:ChangesInEquity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_IssuedCapitalMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">831000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_SharePremiumMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">8495000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_TreasurySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-1006000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_ReserveOfSharebasedPaymentsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">1233000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_FairValueReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538377"
      unitRef="Unit_INR">-2405000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_ReserveOfChangeInValueOfForeignCurrencyBasisSpreadsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">4343000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_ReserveOfCashFlowHedgesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-563000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_CapitalRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">173000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_SpecialEconomicZoneReinvestmentReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538381"
      unitRef="Unit_INR">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_DebentureRedemptionReserveMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538505"
      unitRef="Unit_INR">0</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_ActuarialGainsLossesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">-360000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_RetainedEarningsMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">144247000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">154988000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">311000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">23568000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">17238000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">19498000000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">115000000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">8730000000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">9175000000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-1466000000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">4000000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">277000000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">557000000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForFairValueGainsLosses
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">929000000</ifrs-full:AdjustmentsForFairValueGainsLosses>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">156000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">11824000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">12796000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">12472000000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">100000000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">7562000000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">8588000000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">16767000000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:AdditionalAllowanceRecognisedInProfitOrLossAllowanceAccountForCreditLossesOfFinancialAssets
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1000000</ifrs-full:AdditionalAllowanceRecognisedInProfitOrLossAllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:AdditionalAllowanceRecognisedInProfitOrLossAllowanceAccountForCreditLossesOfFinancialAssets
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">55000000</ifrs-full:AdditionalAllowanceRecognisedInProfitOrLossAllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:AdditionalAllowanceRecognisedInProfitOrLossAllowanceAccountForCreditLossesOfFinancialAssets
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">230000000</ifrs-full:AdditionalAllowanceRecognisedInProfitOrLossAllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:AdditionalAllowanceRecognisedInProfitOrLossAllowanceAccountForCreditLossesOfFinancialAssets
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">190000000</ifrs-full:AdditionalAllowanceRecognisedInProfitOrLossAllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-15000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-1119000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">42000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">68000000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">9000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">703000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">480000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">561000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-10000000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-766000000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1856000000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-2168000000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:InterestRevenueExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      id="Fact_50538409"
      unitRef="Unit_USD">0</ifrs-full:InterestRevenueExpense>
    <ifrs-full:InterestRevenueExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">7000000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:InterestRevenueExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-144000000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:InterestRevenueExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-95000000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">8000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">592000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">584000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">521000000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForDividendIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">0</ifrs-full:AdjustmentsForDividendIncome>
    <ifrs-full:AdjustmentsForDividendIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:AdjustmentsForDividendIncome>
    <ifrs-full:AdjustmentsForDividendIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      id="Fact_50538804"
      unitRef="Unit_INR">0</ifrs-full:AdjustmentsForDividendIncome>
    <ifrs-full:AdjustmentsForDividendIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">5000000</ifrs-full:AdjustmentsForDividendIncome>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-224000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-17012000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2081000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-12446000000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-70000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-5328000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-9881000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-1487000000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">58000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4412000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2861000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">1576000000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <rdy:AdjustmentsForDecreaseIncreaseInOtherAssetsAndLiabilities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">53000000</rdy:AdjustmentsForDecreaseIncreaseInOtherAssetsAndLiabilities>
    <rdy:AdjustmentsForDecreaseIncreaseInOtherAssetsAndLiabilities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4014000000</rdy:AdjustmentsForDecreaseIncreaseInOtherAssetsAndLiabilities>
    <rdy:AdjustmentsForDecreaseIncreaseInOtherAssetsAndLiabilities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-3258000000</rdy:AdjustmentsForDecreaseIncreaseInOtherAssetsAndLiabilities>
    <rdy:AdjustmentsForDecreaseIncreaseInOtherAssetsAndLiabilities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">4821000000</rdy:AdjustmentsForDecreaseIncreaseInOtherAssetsAndLiabilities>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">468000000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">35545000000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">41419000000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">36946000000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">98000000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">7437000000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">5716000000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">7105000000</ifrs-full:IncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">370000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">28108000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">35703000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">29841000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">193000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">14660000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">9741000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">4846000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">5000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">370000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">85000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">131000000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">58000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4389000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2820000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">1269000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">39000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2946000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P04_01_2020To03_31_2021"
      unitRef="Unit_INR"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">259000000</ifrs-full:ProceedsFromSalesOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">4000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">326000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">15514000000</ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
      contextRef="P04_01_2019To03_31_2020"
      unitRef="Unit_INR"
      xsi:nil="true"/>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1173000000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">88972000000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">75418000000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">111918000000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">1025000000</ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">77771000000</ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">79528000000</ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">111704000000</ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:DividendsReceivedFromInvestmentsAccountedForUsingEquityMethodClassifiedAsInvestingActivities
      contextRef="P04_01_2021To03_31_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <ifrs-full:DividendsReceivedFromInvestmentsAccountedForUsingEquityMethodClassifiedAsInvestingActivities
      contextRef="P04_01_2021To03_31_2022"
      unitRef="Unit_INR"
      xsi:nil="true"/>
    <ifrs-full:DividendsReceivedFromInvestmentsAccountedForUsingEquityMethodClassifiedAsInvestingActivities
      contextRef="P04_01_2020To03_31_2021"
      unitRef="Unit_INR"
      xsi:nil="true"/>
    <ifrs-full:DividendsReceivedFromInvestmentsAccountedForUsingEquityMethodClassifiedAsInvestingActivities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">392000000</ifrs-full:DividendsReceivedFromInvestmentsAccountedForUsingEquityMethodClassifiedAsInvestingActivities>
    <rdy:InterestAndDividendReceived
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">12000000</rdy:InterestAndDividendReceived>
    <rdy:InterestAndDividendReceived
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">873000000</rdy:InterestAndDividendReceived>
    <rdy:InterestAndDividendReceived
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1220000000</rdy:InterestAndDividendReceived>
    <rdy:InterestAndDividendReceived
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">624000000</rdy:InterestAndDividendReceived>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-348000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-26387000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-22660000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-4923000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">4000000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">334000000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">269000000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">4000000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">0</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1193000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">474000000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <ifrs-full:ProceedsFromCurrentBorrowings
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">46000000</ifrs-full:ProceedsFromCurrentBorrowings>
    <ifrs-full:ProceedsFromCurrentBorrowings
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">3520000000</ifrs-full:ProceedsFromCurrentBorrowings>
    <ifrs-full:ProceedsFromCurrentBorrowings
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">6791000000</ifrs-full:ProceedsFromCurrentBorrowings>
    <ifrs-full:ProceedsFromCurrentBorrowings
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">4235000000</ifrs-full:ProceedsFromCurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="P04_01_2021To03_31_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="P04_01_2021To03_31_2022"
      unitRef="Unit_INR"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">3800000000</ifrs-full:ProceedsFromNoncurrentBorrowings>
    <ifrs-full:ProceedsFromNoncurrentBorrowings
      contextRef="P04_01_2019To03_31_2020"
      unitRef="Unit_INR"
      xsi:nil="true"/>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings
      contextRef="P04_01_2021To03_31_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings
      contextRef="P04_01_2021To03_31_2022"
      unitRef="Unit_INR"
      xsi:nil="true"/>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">3743000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <ifrs-full:RepaymentsOfNoncurrentBorrowings
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">22918000000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
    <rdy:PaymentsOfLeaseLiabilities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">10000000</rdy:PaymentsOfLeaseLiabilities>
    <rdy:PaymentsOfLeaseLiabilities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">785000000</rdy:PaymentsOfLeaseLiabilities>
    <rdy:PaymentsOfLeaseLiabilities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">754000000</rdy:PaymentsOfLeaseLiabilities>
    <rdy:PaymentsOfLeaseLiabilities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">482000000</rdy:PaymentsOfLeaseLiabilities>
    <ifrs-full:DividendsPaidClassifiedAsFinancingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">55000000</ifrs-full:DividendsPaidClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidClassifiedAsFinancingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4146000000</ifrs-full:DividendsPaidClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidClassifiedAsFinancingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">4147000000</ifrs-full:DividendsPaidClassifiedAsFinancingActivities>
    <ifrs-full:DividendsPaidClassifiedAsFinancingActivities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">3916000000</ifrs-full:DividendsPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">18000000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1345000000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1321000000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:InterestPaidClassifiedAsFinancingActivities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">1608000000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-32000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-2422000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-298000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-25159000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">-9000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-701000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">12745000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-241000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">10000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">733000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">113000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-25000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_USD">195000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">14820000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">1962000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn03_31_2019"
      decimals="-6"
      unitRef="Unit_INR">2228000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">196000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">14852000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">14820000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">1962000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <rdy:DisclosureOfNatureOfBusinessExplanatoryTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.&#160;Reporting entity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Limited (the &#x201c;parent company&#x201d;), together with its subsidiaries and joint ventures (collectively, the &#x201c;Company&#x201d;), is a leading India-based pharmaceutical company headquartered and having its registered office in Hyderabad, Telangana, India. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products &#x2013; the Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients (&#x201c;APIs&#x201d;), Custom Pharmaceutical Services (&#x201c;CPS&#x201d;), generics, biosimilars and differentiated formulations.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s principal research and development facilities are located in the states of Telangana and Andhra Pradesh in India, Cambridge in the United Kingdom and Leiden in the Netherlands; its principal manufacturing facilities are located in the states of Telangana, Andhra Pradesh and Himachal Pradesh in India, Cuernavaca-Cuautla in Mexico, Mirfield in the United Kingdom, and Louisiana in the United States; and its principal markets are in India, Russia, the United States, and Germany. The Company&#x2019;s shares trade on the Bombay Stock Exchange, the National Stock Exchange, the NSE IFSC Limited in India and on the New York Stock Exchange in the United States.&lt;/div&gt;&lt;/div&gt;</rdy:DisclosureOfNatureOfBusinessExplanatoryTextBlock>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2. Basis of preparation of financial statements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;a. Statement of compliance &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These consolidated financial statements as of and for the year ended March 31, 2022 comply in all material aspects with the International Financial Reporting Standards and its interpretations (&#x201c;IFRS&#x201d;) as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;).&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These consolidated financial statements have been prepared by the Company as a going concern on the basis of relevant IFRS that are effective or elected for early adoption at the Company&#x2019;s annual reporting date, March 31, 2022. These consolidated financial statements were authorized for issuance by the Company&#x2019;s Board of Directors on &lt;/div&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;June 27, 2022.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;    &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;b. Basis of measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These consolidated financial statements have been prepared on the historical cost convention and on an accrual basis, except for the following material items in the statement of financial position:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;derivative financial instruments are measured at fair value;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;financial assets are measured either at fair value or at amortized cost, depending on the classification;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;employee defined benefit assets/(liabilities) are recognized as the net total of the fair value of plan assets, adjusted for actuarial gains/(losses) and the present value of the defined benefit obligation;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;long-term borrowings are measured at amortized cost using the effective interest rate method;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;share-based payments are measured at fair value;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;investments in joint ventures are accounted for using the equity method;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;assets held for sale are measured at fair value;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;assets acquired and liabilities assumed as part of business combinations are measured at fair value;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;contingent consideration arising out of business combination are measured at fair value; and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use the assets are recognized at the present value of lease payments that are not paid at that date. This amount is adjusted for any lease payments made at or before the commencement date, lease incentives received and initial direct costs, incurred, if any.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 27pt; text-align: justify; text-indent: -14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px;;font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;                                         &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;c. Convenience translation (unaudited) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These consolidated financial statements have been prepared in Indian rupees. Solely for the convenience of the reader, these consolidated financial statements as of and for the year ended March&#160;31,&#160;202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&#160;have been translated into U.S. dollars at the certified foreign exchange rate of U.S.$1.00 = Rs.75.87, as published by the Federal Reserve Board of Governors on March&#160;31,&#160;2022. No representation is made that the Indian rupee amounts have been, could have been or could be converted into U.S. dollars at such a rate or any other rate. Such convenience translation is not subject to audit by the Company&#x2019;s Independent Registered Public Accounting Firm.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;                   &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-align: justify; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;  &lt;div style="margin-bottom: 6pt; margin-top: 0px; font-family: Calibri, sans-serif; font-size: 10pt; line-height: 10pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;d. Use of estimates and judgments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In particular, information about significant areas of estimation uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following notes:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3(a) and 15 &#x2014; Evaluation of joint arrangements;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;     &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;                    &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 3(b) &#x2014; Assessment of functional currency;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;     &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;   &lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3(c), 3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0&lt;/div&gt; and 3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt; &#x2014; Financial instruments;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;     &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3(d) and 6 &#x2014; Business combinations; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;       &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3(e) and (f) &#x2014; Useful lives of property, plant and equipment and intangible assets;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3(g) &#x2013; Determination of cost for right-of-use assets and lease term;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3(h) and 10&#x2014; Valuation of inventories;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3(i), 12, 13 and 14&#x2014; Measurement of recoverable amounts of cash-generating units;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3 (j) and 2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt; &#x2014; Assets and obligations relating to employee benefits;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3 (&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;k&lt;/div&gt;) and 2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;&#x2014; Share-based payments;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 3(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;l&lt;/div&gt;) and 18 &#x2014; Provisions and other accruals;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 3(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;m&lt;/div&gt;) &#x2014; Measurement of transaction price in a revenue transaction (sales returns, rebates and chargeback provisions);&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 3(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;p&lt;/div&gt;) and 25 &#x2014; Evaluation of recoverability of deferred tax assets, and estimation of income tax payable and income tax expense in relation to uncertain tax positions; and&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt; &#x2014; Contingencies.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                      &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;e. Current and non-current classification&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company presents assets and liabilities in the balance sheet based on current/ non-current classification.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All assets and liabilities have been classified as current or non-current as per the Company&#x2019;s normal operating cycle and other criteria set out in IAS 1, &lt;div style="font-style:italic;display:inline;"&gt;&#x201c;Presentation of financial statements&#x201d;&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An asset is classified as current when it satisfies any of the following criteria:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;a)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;it is expected to be realized in, or is intended for sale or consumption in, the Company&#x2019;s normal operating cycle;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;b)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;it is held primarily for the purpose of being traded;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;c)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;it is expected to be realized within twelve months after the reporting date; or&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;d)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;it is cash or a cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A liability is classified as current when it satisfies any of the following criteria:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;a)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;it is expected to be settled in the Company&#x2019;s normal operating cycle;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;b)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;it is held primarily for the purpose of being traded;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;c)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;it is due to be settled within twelve months after the reporting date; or&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;d)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;the Company does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current assets and liabilities include the current portion of non-current assets and liabilities respectively. All other assets and liabilities are classified as non-current. Deferred tax assets and liabilities are always classified as non-current. The operating cycle is the time between the acquisition of assets for processing and their reali&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;z&lt;/div&gt;ation in cash and cash equivalents. The Company has identified twelve months as its operating cycle.&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px;;font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  </ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:StatementOfIFRSCompliance contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;a. Statement of compliance &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These consolidated financial statements as of and for the year ended March 31, 2022 comply in all material aspects with the International Financial Reporting Standards and its interpretations (&#x201c;IFRS&#x201d;) as issued by the International Accounting Standards Board (&#x201c;IASB&#x201d;).&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These consolidated financial statements have been prepared by the Company as a going concern on the basis of relevant IFRS that are effective or elected for early adoption at the Company&#x2019;s annual reporting date, March 31, 2022. These consolidated financial statements were authorized for issuance by the Company&#x2019;s Board of Directors on &lt;/div&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;June 27, 2022.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;</ifrs-full:StatementOfIFRSCompliance>
    <ifrs-full:ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;b. Basis of measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These consolidated financial statements have been prepared on the historical cost convention and on an accrual basis, except for the following material items in the statement of financial position:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;derivative financial instruments are measured at fair value;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;financial assets are measured either at fair value or at amortized cost, depending on the classification;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;employee defined benefit assets/(liabilities) are recognized as the net total of the fair value of plan assets, adjusted for actuarial gains/(losses) and the present value of the defined benefit obligation;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;long-term borrowings are measured at amortized cost using the effective interest rate method;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;share-based payments are measured at fair value;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;investments in joint ventures are accounted for using the equity method;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;assets held for sale are measured at fair value;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;assets acquired and liabilities assumed as part of business combinations are measured at fair value;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;contingent consideration arising out of business combination are measured at fair value; and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use the assets are recognized at the present value of lease payments that are not paid at that date. This amount is adjusted for any lease payments made at or before the commencement date, lease incentives received and initial direct costs, incurred, if any.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 27pt; text-align: justify; text-indent: -14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px;;font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;                   </ifrs-full:ExplanationOfMeasurementBasesUsedInPreparingFinancialStatements>
    <rdy:DescriptionOfConvenienceTranslationIntoUsDollarsTextBlockTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;c. Convenience translation (unaudited) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These consolidated financial statements have been prepared in Indian rupees. Solely for the convenience of the reader, these consolidated financial statements as of and for the year ended March&#160;31,&#160;202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&#160;have been translated into U.S. dollars at the certified foreign exchange rate of U.S.$1.00 = Rs.75.87, as published by the Federal Reserve Board of Governors on March&#160;31,&#160;2022. No representation is made that the Indian rupee amounts have been, could have been or could be converted into U.S. dollars at such a rate or any other rate. Such convenience translation is not subject to audit by the Company&#x2019;s Independent Registered Public Accounting Firm.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</rdy:DescriptionOfConvenienceTranslationIntoUsDollarsTextBlockTextBlock>
    <rdy:ConvenienceTranslationRate
      contextRef="PAsOn03_31_2022"
      decimals="2"
      unitRef="Unit_INRPerUSD">75.87</rdy:ConvenienceTranslationRate>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="margin-bottom: 6pt; margin-top: 0px; font-family: Calibri, sans-serif; font-size: 10pt; line-height: 10pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;d. Use of estimates and judgments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In particular, information about significant areas of estimation uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following notes:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3(a) and 15 &#x2014; Evaluation of joint arrangements;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;     &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;                    &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 10pt; font-family: 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 3(b) &#x2014; Assessment of functional currency;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;     &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;   &lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3(c), 3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0&lt;/div&gt; and 3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt; &#x2014; Financial instruments;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;     &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3(d) and 6 &#x2014; Business combinations; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;       &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3(e) and (f) &#x2014; Useful lives of property, plant and equipment and intangible assets;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3(g) &#x2013; Determination of cost for right-of-use assets and lease term;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3(h) and 10&#x2014; Valuation of inventories;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3(i), 12, 13 and 14&#x2014; Measurement of recoverable amounts of cash-generating units;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3 (j) and 2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt; &#x2014; Assets and obligations relating to employee benefits;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notes 3 (&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;k&lt;/div&gt;) and 2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;&#x2014; Share-based payments;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 3(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;l&lt;/div&gt;) and 18 &#x2014; Provisions and other accruals;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 3(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;m&lt;/div&gt;) &#x2014; Measurement of transaction price in a revenue transaction (sales returns, rebates and chargeback provisions);&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 3(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;p&lt;/div&gt;) and 25 &#x2014; Evaluation of recoverability of deferred tax assets, and estimation of income tax payable and income tax expense in relation to uncertain tax positions; and&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt; &#x2014; Contingencies.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <rdy:CurrentAndNonCurrentClassificationPolicyTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;e. Current and non-current classification&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company presents assets and liabilities in the balance sheet based on current/ non-current classification.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All assets and liabilities have been classified as current or non-current as per the Company&#x2019;s normal operating cycle and other criteria set out in IAS 1, &lt;div style="font-style:italic;display:inline;"&gt;&#x201c;Presentation of financial statements&#x201d;&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An asset is classified as current when it satisfies any of the following criteria:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;a)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;it is expected to be realized in, or is intended for sale or consumption in, the Company&#x2019;s normal operating cycle;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;b)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;it is held primarily for the purpose of being traded;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;c)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;it is expected to be realized within twelve months after the reporting date; or&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;d)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;it is cash or a cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A liability is classified as current when it satisfies any of the following criteria:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;a)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;it is expected to be settled in the Company&#x2019;s normal operating cycle;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;b)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;it is held primarily for the purpose of being traded;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;c)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;it is due to be settled within twelve months after the reporting date; or&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.25in;"&gt;d)&lt;/td&gt;&lt;td style="text-align: justify;"&gt;the Company does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current assets and liabilities include the current portion of non-current assets and liabilities respectively. All other assets and liabilities are classified as non-current. Deferred tax assets and liabilities are always classified as non-current. The operating cycle is the time between the acquisition of assets for processing and their reali&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;z&lt;/div&gt;ation in cash and cash equivalents. The Company has identified twelve months as its operating cycle.&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px;;font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</rdy:CurrentAndNonCurrentClassificationPolicyTextBlock>
    <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3. Significant accounting policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;New Standards adopted by the Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="text-indent: 0px;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;

&lt;div style="margin-bottom: 6pt; text-align: justify; text-indent: 0.25in; margin-top: 0px; font-family: Calibri, sans-serif; font-size: 10pt; line-height: 10pt; margin-left: 0in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; text-indent: 0px; line-height: 10pt;;display:inline;"&gt;Amendments to IFRS 16, &#x201c;&lt;div style="line-height: 10pt; font-size: 10pt;;font-style:italic;display:inline;"&gt;Leases&lt;/div&gt;&#x201d; regarding Covid-19-Related Rent Concessions beyond &#160;June 30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="text-indent: 0px;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-size: 9pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-stretch: normal;"&gt;On 28 May 2020, the IASB issued &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; text-indent: 0px; line-height: 10pt;;font-style:italic;display:inline;"&gt;Covid-19-Related Rent Concessions - amendment to IFRS 16 Leases&lt;/div&gt;. The amendments provide relief to lessees from applying IFRS 16 guidance on lease modification accounting for rent concessions arising as a direct consequence of the Covid-19 pandemic. As a practical expedient, a lessee may elect not to assess whether a Covid-19 related rent concession from a lessor is a lease modification. The amendment was intended to apply until June 30, 2021, but as the impact of the Covid-19 pandemic is continuing, on March 31, 2021, the IASB extended the period of application of the practical expedient to June 30, 2022.The amendment applies to annual reporting periods beginning on or after April 1, 2021.&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0in;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.26in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt;The aforesaid amendment&#160;had no impact on the consolidated financial statements.&lt;/div&gt; &lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0in;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"/&gt;Standard issued but not effective&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amendments to IAS 1, &#x201c;&lt;div style="font-style:italic;display:inline;"&gt;Presentation of Financial Statements&lt;/div&gt;&#x201d; regarding classification of liabilities as current or non-current&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; white-space:pre-line; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January 23, 2020, the IASB issued amendments to paragraphs 69 to 76 of &lt;div style="font-style:italic;display:inline;"&gt;IAS 1 Presentation of Financial Statements&lt;/div&gt; to specify the requirements for classifying liabilities as current or non-current. The amendments clarify what is meant by a right to defer settlement, that a right to defer must exist at the end of the reporting period, that the classification is unaffected by the likelihood that an entity will exercise its deferral right, and that only if the conversion option itself is classified as an equity instrument would settlement by way of own equity instruments be disregarded when determining whether the liability is current or non-current. In July 2021, the IASB decided to defer the effective date of the 2020 amendments to no earlier than January 1, 2024.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amendments to IAS 12, &#x201c;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&#x201d; regarding Assets and Liabilities arising from a Single Transaction&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2021, the IASB issued amendments to IAS 12, which narrow the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The proposed amendments will typically apply to transactions such as leases for the lessee and decommissioning obligations.&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paragraphs 15 and 24 of IAS 12 were amended to include an additional condition where the initial recognition exemption is not applied. According to the amended guidance, a temporary difference that arises on initial recognition of an asset or liability is not subject to the initial recognition exemption if that transaction gave rise to equal taxable and deductible temporary differences.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These amendments should be applied for annual periods beginning on or after January 1, 2023.&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amendments to IAS 1 and IFRS Practice Statement (&#x201c;PS&#x201d;), &#x201c;&lt;div style="font-style:italic;display:inline;"&gt;Presentation of Financial Statements&lt;/div&gt;&#x201d; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2021, the IASB issued amendments to IAS 1 and IFRS Practice Statement 2, Making Materiality Judgments (the PS), in which it provides guidance and examples to help entities apply materiality judgments to accounting policy disclosures. The proposed amendments are effective for annual periods beginning on or after January 1, 2023. &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amendments to IAS 8, &#x201c;&lt;div style="font-style:italic;display:inline;"&gt;Accounting Policies, Changes in Accounting Estimates and Errors&lt;/div&gt;&#x201d; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2021, the IASB issued amendments to IAS 8, in which it introduces a new definition of &#x2018;accounting estimates&#x2019;. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, they clarify how entities use measurement techniques and inputs to develop accounting estimates. The proposed amendments are effective for annual periods beginning on or after January 1, 2023.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IFRS 17, &#x201c;&lt;div style="font-style:italic;display:inline;"&gt;Insurance Contracts&lt;/div&gt;&#x201d; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2017, the IASB issued IFRS 17 Insurance Contracts, a comprehensive new accounting standard for insurance contracts covering recognition and measurement, presentation and disclosure. This standard is effective for annual periods beginning on or after January 1, 2023.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Narrow-scope amendments to certain other Standards&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The IASB, on May 14, 2020, issued several small amendments to IFRS Standards.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The package of amendments includes narrow-scope amendments to&#160; Standards as well as the IASB&#x2019;s Annual Improvements, which are changes that clarify the wording or correct minor consequences, oversights or conflicts between requirements in the Standards.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amendments to IFRS 3 Business Combinations&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt; update a reference in IFRS 3 to the Conceptual Framework for Financial Reporting without changing the accounting requirements for business combinations.&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin-bottom: 6pt; text-align: justify; text-indent: 0.25in; margin-top: 0px; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;br/&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;a. Basis of consolidation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsidiaries&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements comprise the financial statements of the Company and its subsidiaries as at March 31, 2022. Subsidiaries are all entities (including special purpose entities) that are controlled by the Company. Control exists when the Company is exposed to, or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through power over the entity. In assessing control, potential voting rights are considered only if the rights are substantive. The financial statements of subsidiaries are included in these consolidated financial statements from the date that control commences until the date that control ceases.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated income statement, consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidate&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt;&#160;statement of financial position, respectively.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidated financial statements are prepared using uniform accounting policies for like transactions and other events in similar circumstances. If a subsidiary of the Company uses accounting policies other than those adopted in the consolidated financial statements for like transactions and events in similar circumstances, appropriate adjustments are made to that subsidiary&#x2019;s financial statements in preparing the consolidated financial statements to ensure conformity with the Company&#x2019;s accounting policies.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Joint arrangements (equity accounted investees)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Joint arrangements are those arrangements over which the parties have joint control, established by contractual agreement and requiring unanimous consent for strategic financial and operating decisions. The considerations made in determining whether significant influence or joint control are similar to those necessary to determine control over the subsidiaries.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;A joint arrangement is either a joint operation or a joint venture. A joint operation is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the assets, and obligations for the liabilities, relating to the arrangement. A joint venture is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the arrangement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;With respect to joint operations, the Company recognizes its direct right to the assets, liabilities, revenues and expenses of joint operations and its share of any jointly held or incurred assets, liabilities, revenues and expenses.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments in joint ventures are accounted for using the equity method and are initially recognized at cost. The carrying value of the Company&#x2019;s investment includes goodwill identified on acquisition, net of any accumulated impairment losses. The Company does not consolidate entities where the non-controlling interest (&#x201c;NCI&#x201d;) holders have certain significant participating rights that provide for effective involvement in significant decisions in the ordinary course of business of such entities. Investments in such entities are accounted by the equity method of accounting. When the Company&#x2019;s share of losses exceeds its interest in an equity accounted investee, the carrying amount of that interest (including any long-term investments) is reduced to zero and the recognition of further losses is discontinued except to the extent that the Company has an obligation or has made payments on behalf of the investee.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the purpose of preparing these consolidated financial statements, the accounting policies of joint ventures have been changed where necessary to align them with the policies adopted by the Company. Furthermore, the financial statements of the joint ventures are prepared for the same reporting period as of the Company.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;div style="margin: 0in 0in 0.0001pt 20.15pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; color: black; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; color: black; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;a. Basis of consolidation (continued)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0in; text-align: justify; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0in; text-align: justify; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidation procedure &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the purpose of preparing these consolidated financial statements, intra-group transactions are consolidated using the following procedures:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;a.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Combine like items of assets, liabilities, equity, income, expenses and cash flows of the parent with those of its subsidiaries. For this purpose, income and expenses of the subsidiary are based on the amounts of the assets and liabilities recognized in the consolidated financial statements at the acquisition date.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Offset (eliminate) the carrying amount of the parent&#x2019;s investment in each subsidiary and the parent&#x2019;s portion of equity of each subsidiary.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;c.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Eliminate in full intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between entities of the group (profits or losses resulting from intragroup transactions that are recognized in assets, such as inventory and&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;property, plant and equipment,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;are eliminated in full). Intragroup losses may indicate an impairment that requires recognition in the consolidated financial statements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Changes in ownership interests&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;Acquisition of some or all of the NCI is accounted for as a transaction with equity holders in their capacity as equity holders. Consequently, the difference arising between the fair value of the purchase consideration paid and the carrying value of the NCI is recorded as an adjustment to retained earnings that is attributable to the parent company. The associated cash flows are classified as financing activities. No goodwill is recognized as a result of such transactions.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Loss of Control&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0.26in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At the time of loss of control, the Company&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;derecognizes the assets (including goodwill) and liabilities of the subsidiary at their carrying amounts at the date when control is lost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;derecognizes the carrying amount of any non-controlling interests&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;derecognizes the cumulative translation differences recorded in equity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognizes the fair value of the consideration received&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognizes the fair value of any investment retained&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognizes any surplus or deficit in income statement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;reclassifies the parent&#x2019;s share of components previously recognized in OCI to income statement or transferred directly to retained earnings, if required by other IFRSs as would be required if the Company had directly disposed of the related assets or liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;
  &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;b. Foreign currency&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Functional and presentation currency &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;These consolidated financial statements are presented in Indian rupees, which is the functional currency of the parent company. All financial information presented in Indian rupees has been rounded to the nearest million.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In respect of certain non-Indian subsidiaries that operate as marketing arms of the parent company in their respective countries/regions, the functional currency has been determined to be the functional currency of the parent company (i.e., the Indian rupee). The operations of these entities are largely restricted to importing of finished goods from the parent company in India, sales of these products in the foreign country and making of import payments to the parent company. The cash flows realized from sales of goods are available for making import payments to the parent company and cash is paid to the parent company on a regular basis. The costs incurred by these entities are primarily the cost of goods imported from the parent company. The financing of these subsidiaries is done directly or indirectly by the parent company.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In respect of subsidiaries whose operations are self-contained and integrated within their respective countries/regions, the functional currency has been generally determined to be the local currency of those countries/regions, unless use of a different currency is considered appropriate.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency transactions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transactions in foreign currencies are translated to the respective functional currencies of entities within the Company at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated into the functional currency at the exchange rate at that date. Non-monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition during the period or in previous financial statements are recognized in the consolidated income statement in the period in which they arise.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;However, foreign currency differences arising from the translation of the following items are recognized in OCI:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 42.55pt; text-align: justify; text-indent: -14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;certain debt instruments classified as measured at FVTOCI;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;certain equity instruments where the Company had made an irrevocable election to present in OCI subsequent changes in the fair value;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;a financial liability designated as a hedge of the net investment in a foreign operation, to the extent that the hedge is effective; and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;qualifying cash flow hedges, to the extent that the hedges are effective.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 42.55pt; text-align: justify; text-indent: -14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;When several exchange rates are available, the rate used is that at which the future cash flows represented by the transaction or balance could have been settled if those cash flows had occurred at the measurement date.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-align: justify;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign operations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign exchange gains and losses arising from a monetary item receivable from a foreign operation, the settlement of which is neither planned nor likely in the foreseeable future, are considered to form part of the net investment in the foreign operation and are recognized in OCI and presented within equity as foreign currency translation reserve (&#x201c;FCTR&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;In case of foreign operations whose functional currency is different from the parent company&#x2019;s functional currency, the assets and liabilities of such foreign operations, including goodwill and fair value adjustments arising upon acquisition, are translated to the reporting currency at exchange rates at the reporting date. The income and expenses of such foreign operations are translated to the reporting currency at the monthly average exchange rates prevailing during the year. Resulting foreign currency differences are recognized in OCI and presented within equity as part of FCTR. When a foreign operation is disposed of, in part or in full, such that control, significant influence or joint control is lost, the relevant amount in the FCTR is reclassified to the consolidated income statement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;br/&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;c. Financial instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Initial recognition and measurement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All financial assets are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (e.g., regular way trades) are recognized on the trade date, i.e., the date that the Company commits to purchase or sell the asset.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade receivables are recognized initially at the amount of consideration that is unconditional unless they contain significant financing components, in which case they are recognized at fair value. The Company&#x2019;s trade receivables do not contain any significant financing component and hence are measured at the transaction price measured under IFRS 15, &lt;div style="font-style:italic;display:inline;"&gt;&#x201c;Revenue from Contracts with Customers&#x201d;&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subsequent measurement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For purposes of subsequent measurement, financial assets are classified in four categories:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt instruments at amortized cost;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;










































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt instruments at FVTOCI;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;










































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt instruments, derivatives and equity instruments at FVTPL; and &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;










































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity instruments measured at FVTOCI.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;










































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Debt instruments at amortized cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A &#x201c;debt instrument&#x201d; is measured at the amortized cost if both the following conditions are met:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;a)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;the asset is held within a business model whose objective is to hold assets for collecting contractual cash flows; and&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;










































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;b)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (&#x201c;SPPI&#x201d;) on the principal amount outstanding.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;










































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;After initial measurement, such financial assets are subsequently measured at amortized cost using the effective interest rate method and are subject to impairment. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on de-recognition is recognized directly in the consolidated income statement and presented in other income/(losses),net. The losses arising from impairment are recognized in the consolidated income statement. This category generally applies to trade and other receivables.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt instrument at FVTOCI&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 14.2pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A &#x201c;debt instrument&#x201d; is classified as at the FVTOCI if both of the following criteria are met:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt 0.5in; text-align: justify; text-indent: -0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-spacing: 0px;"&gt;

		&lt;tr&gt;
			&lt;td style="width:.25in; padding:0in 0in 0in 0in;vertical-align:top;"/&gt;
			&lt;td style="width: 0.25in; padding: 0in; font-size: 10pt;;vertical-align:top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;a)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in; font-size: 10pt;;vertical-align:top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets; and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;























&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 12pt;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-spacing: 0px;"&gt;

		&lt;tr&gt;
			&lt;td style="width:.25in; padding:0in 0in 0in 0in;vertical-align:top;"/&gt;
			&lt;td style="width: 0.25in; padding: 0in; font-size: 10pt;;vertical-align:top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;b)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in; font-size: 10pt;;vertical-align:top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the asset&#x2019;s contractual cash flows represent SPPI.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;























&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt instruments included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in the OCI. However, the Company recognizes interest income, impairment losses and reversals and foreign exchange gain or loss in the consolidated income statement. On de-recognition of the asset, cumulative gain or loss previously recognized in OCI is reclassified to the consolidated income statement. Interest earned while holding a FVTOCI debt instrument is reported as interest income using the effective interest rate method.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt instrument at FVTPL&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 14.2pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as at FVTPL.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 14.2pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, the Company may elect to designate a debt instrument, which otherwise meets amortized cost or FVTOCI criteria, as FVTPL. However, such election is allowed only if doing so reduces or eliminates a measurement or recognition inconsistency (referred to as an &#x201c;accounting mismatch&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 14.2pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;Debt instruments included within the FVTPL category are measured at fair value with all changes recognized in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Equity investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All equity investments within the scope of IFRS 9 are measured at fair value. Equity instruments which are held for trading and contingent consideration recognized by an acquirer in a business combination to which IFRS 3 applies, are classified as at FVTPL. For all other equity instruments, the Company may make an irrevocable election to present in OCI subsequent changes in the fair value. The Company makes such election on an instrument-by-instrument basis. The classification is made upon initial recognition and is irrevocable.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the Company decides to classify an equity instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to the consolidated income statement, even on sale of investment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;However, on sale the Company may transfer the cumulative gain or loss within equity. Equity investments designated as FVTOCI are not subject to impairment assessment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;De-recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Company&#x2019;s consolidated statement of financial position) when:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the rights to receive cash flows from the asset have expired; or&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Both (1) the Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a &#x201c;pass-through&#x201d; arrangement&#x37e; and (2) either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognize the transferred asset to the extent of the Company&#x2019;s continuing involvement. In that case, the Company also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Impairment of trade receivables and other financial assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with IFRS 9, the Company applies the expected credit loss (&#x201c;ECL&#x201d;) model for measurement and recognition of impairment loss on trade receivables or any contractual right to receive cash or another financial asset.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For this purpose, the Company follows a &#x201c;simplified approach&#x201d; for recognition of impairment loss allowance on the trade receivable balances. The application of this simplified approach does not require the Company to track changes in credit risk. Rather, it recognizes impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As a practical expedient, the Company uses a provision matrix to determine impairment loss allowance on portfolio of its trade receivables. The provision matrix is based on its historically observed default rates over the expected life of the trade receivables and is adjusted for forward-looking estimates. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analyzed.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Initial recognition and measurement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liabilities are classified, at initial recognition, as financial liabilities at FVTPL, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s financial liabilities include trade and other payables, loans and borrowings including bank overdrafts and derivative financial instruments.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subsequent measurement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;The measurement of financial liabilities depends on their classification, as described below:&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Financial liabilities at FVTPL&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liabilities at FVTPL include financial liabilities held for trading and financial liabilities designated upon initial recognition as at FVTPL. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by IFRS 9. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gains or losses on liabilities held for trading are recognized in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liabilities designated upon initial recognition at FVTPL are designated as such at the initial date of recognition, and only if the criteria in IFRS 9 are satisfied. For liabilities designated as FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI. These gains or losses are not subsequently transferred to the consolidated income statement.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;However, the Company may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognized in the consolidated income statement. The Company has not designated any financial liability as FVTPL.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Loans and borrowings&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Borrowings are initially recognized at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognized in the consolidated income statement over the period of the borrowings using the effective interest method.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortized cost using the effective interest rate method. Gains and losses are recognized in the consolidated income statement when the liabilities are derecognized as well as through the effective interest rate amortization process.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortization is included as finance costs in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;De-recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;

&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative financial instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 14.2pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is exposed to exchange rate risk which arises from its foreign exchange revenues and expenses, primarily in U.S. dollars, U.K. pounds sterling, Russian roubles, Brazilian reals, Swiss francs, South African rands, Kazakhstan tenges, Romanian new leus, Australian dollars and Euros, and foreign currency debt in U.S. dollars, Russian roubles, South African rands, Mexican pesos, Ukrainian hryvnias and Brazilian reals.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company uses derivative financial instruments such as foreign exchange forward contracts, option contracts and swap contracts to mitigate its risk of changes in foreign currency exchange rates. The Company also uses non-derivative financial instruments as part of its foreign currency exposure risk mitigation strategy. Derivatives are classified as financial assets when the fair value is positive and as financial liabilities when the fair value is negative.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hedges of highly probable forecasted transactions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 14.2pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company classifies its derivative financial instruments that hedge foreign currency risk associated with highly probable forecasted transactions as cash flow hedges and measures them at fair value. The effective portion of such cash flow hedges is recorded in the Company&#x2019;s hedging reserve as a component of equity and re-classified to the consolidated income statement as part of the hedged item in the period corresponding to the occurrence of the forecasted transactions. The ineffective portion of such cash flow hedges is recorded in the consolidated income statement as finance costs immediately.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 14.2pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;The Company also designates certain non-derivative financial liabilities, such as foreign currency borrowings from banks, as hedging instruments for hedge of foreign currency risk associated with highly probable forecasted transactions. Accordingly, the Company applies cash flow hedge accounting to such relationships. Re-measurement gain or loss on such non-derivative financial liabilities is recorded in the Company&#x2019;s hedging reserve as a component of equity and reclassified to the consolidated income statement as part of the hedged item in the period corresponding to the occurrence of the forecasted transactions.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the hedging instrument no longer meets the criteria for hedge accounting, expires or is sold, terminated or exercised, then hedge accounting is discontinued prospectively. The cumulative gain or loss previously recognized in OCI, remains there until the forecasted transaction occurs. If the forecasted transaction is no longer expected to occur, then the balance in OCI is recognized immediately in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Hedges of recognized assets and liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in the fair value of derivative contracts that economically hedge monetary assets and liabilities in foreign currencies, and for which no hedge accounting is applied, are recognized in the consolidated income statement. The changes in fair value of such derivative contracts, as well as the foreign exchange gains and losses relating to the monetary items, are recognized in the consolidated income statement. If the hedged item is derecognized, the unamortized fair value is recognized immediately in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Hedges of changes in the interest rates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consistent with its risk management policy, the Company uses interest rate swaps to mitigate the risk of changes in interest rates. The Company does not use them for trading or speculative purposes.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents consist of cash on hand, demand deposits and short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value. For this purpose, &#x201c;short-term&#x201d; means investments having original maturities of three months or less from the date of investment. Bank overdrafts that are repayable on demand form an integral part of the Company&#x2019;s cash management and are included as a component of cash and cash equivalents for the purpose of the consolidated statement of cash flows.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;d. Business combinations and goodwill&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Business combinations are accounted for using the acquisition method, regardless of whether equity instruments or other assets are acquired. The acquisition date is the date on which control is transferred to the acquirer. Judgment is applied in determining the acquisition date and determining whether control is transferred from one party to another. Control exists when the Company is exposed to, or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through power over the entity. In assessing control, potential voting rights are considered only if the rights are substantive.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company determines that it has acquired a business when the acquired set of activities and assets include an input and a substantive process that together significantly contribute to the ability to create outputs. The acquired process is considered substantive if it is critical to the ability to continue producing outputs, and the inputs acquired include an organized workforce with the necessary skills, knowledge, or experience to perform that process or it significantly contributes to the ability to continue producing outputs and is considered unique or scarce or cannot be replaced without significant cost, effort, or delay in the ability to continue producing outputs.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At the acquisition date, identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially at their fair values. For each business combination, the Company elects whether to measure the non-controlling interests in the acquiree at fair value or at the proportionate share of the acquiree&#x2019;s identifiable net assets.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisition related costs are expensed as incurred.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the business combination is achieved in stages, the acquisition date carrying value of the acquirer&#x2019;s previously held equity interest in the acquiree is re-measured to fair value at the acquisition date. Any gains or losses arising from such re-measurement are recognized in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Where settlement of any part of cash consideration is deferred, the amounts payable in the future are discounted to their present value as at the date of exchange. The discount rate used is the entity&#x2019;s incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions. &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration is classified either as equity or a financial liability. Contingent consideration classified as equity is not re-measured and its subsequent settlement is accounted for within equity. Amounts classified as a financial liability are subsequently re-measured to fair value, with changes in fair value recognized in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill is initially measured at cost, being the excess of the aggregate of:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 17.85pt; font-size: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 17.85pt;"&gt;&#x2022;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;the consideration transferred,&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&#x2022;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;the amount of any non-controlling interest in the acquired entity, and&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 17.85pt; font-size: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 17.85pt;"&gt;&#x2022;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;the acquisition date fair value of any previous equity interest in the acquired entity,&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;over the fair value of the net identifiable assets acquired is recorded as goodwill.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If those amounts are less than the fair value of the net identifiable assets of the business acquired, the difference is recognized directly in the consolidated income statement as a bargain purchase.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Company&#x2019;s cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;
 &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;e. Property, plant and equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recognition and measurement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses, if any. Cost includes expenditures that are directly attributable to the acquisition of the asset. The cost of self-constructed assets includes the cost of materials and other costs directly attributable to bringing the asset to a working condition for its intended use.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitali&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;z&lt;/div&gt;ed as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Capital work in progress is stated at cost, net of accumulated impairment loss, if any.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An item of property, plant and equipment and any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Gains and losses upon disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognized net within &#x201c;Other (income)/expense, net&#x201d; in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The costs of repairs and maintenance are recognized in the consolidated income statement as incurred.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Items of property, plant and equipment acquired through exchange of non-monetary assets are measured at fair value, unless the exchange transaction lacks commercial substance or the fair value of either the asset received or asset given up is not reliably measurable, in which case the asset exchanged is recorded at the carrying amount of the asset given up.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Depreciation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation is recognized in the consolidated income statement on a straight line basis over the estimated useful lives of property, plant and equipment. The depreciation expense is included in the costs of the functions using the asset. Land is not depreciated but subject to impairment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation methods, useful lives and residual values are reviewed at each reporting date and any changes are considered prospectively. The estimated useful lives are as follows:&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 80%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;"&gt;

		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 80%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buildings&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 20%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Factory and administrative buildings&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&#160;-&#160;50&#160;years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Ancillary structures&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 - 15 years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plant and equipment&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 - 15 years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture, fixtures and office equipment&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 - 10 years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vehicles&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4 - 5 years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;




























































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software for internal use, which is primarily acquired from third-party vendors and which is an integral part of a tangible asset, including consultancy charges for implementing the software, is capitalized as part of the related tangible asset. Subsequent costs associated with maintaining such software are recognized as expense as incurred. The capitalized costs are amortized over the estimated useful life of the software or the remaining useful life of the tangible fixed asset, whichever is lower.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Advances paid towards the acquisition of property, plant and equipment outstanding at each reporting date and the cost of property, plant and equipment not ready to use before such date are disclosed under capital work-in-progress. Assets not ready for use are not depreciated but are tested for impairment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;f. Goodwill and other intangible assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recognition and measurement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 15%; border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: justify; border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 84%; border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill represents the excess of consideration transferred, together with the amount of non-controlling interest in the acquiree, over the fair value of the Company&#x2019;s share of identifiable net assets acquired.&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill is measured at cost less accumulated impairment losses. In respect of equity accounted investees, the carrying amount of goodwill is included in the carrying amount of the investment, and any impairment loss on such an investment is not allocated to any asset, including goodwill, that forms part of the carrying value of the equity accounted investee.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other intangible assets that are acquired by the Company and that have finite useful lives are measured at cost less accumulated amortization and accumulated impairment losses. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expenditures on research activities undertaken with the prospect of gaining new scientific or technical knowledge and understanding are recognized in the consolidated income statement when incurred.&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures are capitalized only if:&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;development costs can be measured reliably; &lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;the product or process is technically and commercially feasible; &lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;future economic benefits are probable; and &lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;the Company intends to, and has sufficient resources, to complete development and to use or sell the asset.&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The expenditures to be capitalized include the cost of materials and other costs directly attributable to preparing the asset for its intended use. Other development expenditures are recognized in the consolidated income statement as incurred. As of March 31, 2022, none of the development expenditure amounts has met the aforesaid recognition criteria.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;








&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 15%; border-top: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Separate acquisition of intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: justify; border-top: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 84%; text-align: justify; border-top: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments to third parties that generally take the form of up-front payments and milestones for in-licensed products, compounds and intellectual property are capitalized. The Company&#x2019;s criteria for capitalization of such assets are consistent with the guidance given in paragraph 25 of IAS 38, &#x201c;&lt;div style="font-style:italic;display:inline;"&gt;Intangible Assets&#x201d;&lt;/div&gt;. (i.e., the receipt of economic benefits embodied in each intangible asset separately purchased or licensed in the transaction is considered to be probable).&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td style="border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;In-Process Research and Development assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired research and development intangible assets that are under development are recognized as In-Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) assets. IPR&amp;amp;D assets are not amortized, but evaluated for potential impairment on an annual basis or when there are indications that the carrying value may not be recoverable. Any impairment charge on such IPR&amp;amp;D assets is recorded in the consolidated income statement under &#x201c;Impairment of non-current assets&#x201d;.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subsequent expenditure&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: justify; border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures, including expenditures on internally generated goodwill and brands, is recognized in the consolidated income statement as incurred. &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td style="text-align: justify; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;IPR&amp;amp;D assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent expenditure on an IPR&amp;amp;D project acquired separately or in a business combination and recognized as an intangible asset is:&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 15%; text-align: justify; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 2%; text-align: justify; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 3%; text-align: justify; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: Symbol; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 80%; text-align: justify; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognized as an expense when incurred, if it is a research expenditure; &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="text-align: justify; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: Symbol; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognized as an expense when incurred, if it is a development expenditure that does not satisfy the criteria for recognition as an intangible asset in paragraph 57 of IAS 38; and&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: Symbol; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;added to the carrying amount of the acquired IPR&amp;amp;D project, if it is a development expenditure that satisfies the recognition criteria in paragraph 57 of IAS 38.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Amortization&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization is recognized in the consolidated income statement on a straight-line basis over the estimated useful lives of intangible assets. The amortization expense is recognized in the income statement in the expense category that is consistent with the function of the intangible asset. Intangible assets that are not available for use are amortized from the date they are available for use.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The estimated useful lives are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 80%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;"&gt;

		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 77%; text-align: justify; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product related intangibles&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: justify; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 18%; text-align: justify; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 &#x2013; 20&#160;years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="text-align: justify; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other intangibles&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 - 15&#160;years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

















































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amortization period and the amortization method for intangible assets with a finite useful life are reviewed at each reporting date. Changes in the expected useful lives or expected pattern of consumption of future economic benefits embodied in the assets are considered to modify the amortization period or method, as appropriate and are treated as change in accounting estimate.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill, intangible assets relating to products in development, other intangible assets not available for use and intangible assets having indefinite useful life are subject to impairment testing at each reporting date. All other intangible assets are tested for impairment when there are indications that the carrying value may not be recoverable. All impairment losses are recognized immediately in the consolidated income statement under &#x201c;Impairment of non-current assets&#x201d;.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;De-recognition of intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets are de-recognized either on their disposal or where no future economic benefits are expected from their use. Losses arising on such de-recognition are recorded in the consolidated income statement, and are measured as the difference between the net disposal proceeds, if any, and the carrying amount of respective intangible assets as at the date of de-recognition.&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0.25in; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;g. Leases&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;The Company assesses at contract inception whether a contract is or contains a lease, which applies if the contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration. The Company recognizes a right-of-use asset at the commencement date of the lease - i.e., the date the underlying asset is available for use. Assets and liabilities arising from a lease are initially measured on a present value basis.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities include the net present value of the following lease payments to be made over the lease term:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;fixed payments (including in-substance fixed payments), less any lease incentives receivable; &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;variable lease payment that are based on an index or a rate, initially measured using the index or rate as at the commencement date;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;amounts expected to be payable by the Company under residual value guarantees;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the exercise price of a purchase option if the Company is reasonably certain to exercise that option; and&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;payments of penalties for terminating the lease, if the lease term reflects the Company exercising that option.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Company, then the lessee&#x2019;s incremental borrowing rate is used. Such borrowing rate is calculated as the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions. The Company&#x2019;s lease liabilities are included in borrowings.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease payments are allocated between principal and interest cost. The interest cost is charged to consolidated income statement over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use assets are measured at cost less accumulated depreciation and accumulated impairment, comprised of the following:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the amount of the initial measurement of lease liability;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;any lease payments made at or before the commencement date less any lease incentives received; &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;any initial direct costs; and&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;restoration costs.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use assets are generally depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments associated with short-term leases of equipment and vehicles and all leases of low-value assets are recognized on a straight-line basis as an expense in the consolidated income statement. Short-term leases are leases with a lease term of 12 months or less. Low-value assets comprise IT equipment and small items of office furniture.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The right-of-use assets are initially recognized on the statement of financial position at cost, which is calculated as the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received and any initial direct costs incurred by the Company.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;h. Inventories&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories are valued at the lower of cost and net realizable value.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories consist of raw materials, stores and spares, work in progress and finished goods. The cost of all categories of inventories is based on the weighted average method. Cost includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. In the case of finished goods and work in progress, cost includes an appropriate share of overheads based on normal operating capacity. Stores and spares consists of packing materials, engineering spares (such as machinery spare parts) and consumables (such as lubricants, cotton waste and oils), which are used in operating machines or consumed as indirect materials in the manufacturing process.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The factors that the Company considers in determining the provision for slow moving, obsolete and other non-saleable inventory include estimated shelf life, planned product discontinuances, price changes, aging of inventory and introduction of competitive new products, to the extent each of these factors impact the Company&#x2019;s business and markets. The Company considers all these factors and adjusts the inventory provision to reflect its actual experience on a periodic basis.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;i. Impairment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Non-financial assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts of the Company&#x2019;s non-financial assets, other than inventories and deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset&#x2019;s recoverable amount is estimated. For goodwill and intangible assets that have indefinite lives or that are not yet available for use, an impairment test is performed each year at March&#160;31.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or the cash-generating unit. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generate cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the &#x201c;cash-generating unit&#x201d;).&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The goodwill acquired in a business combination is, for the purpose of impairment testing, allocated to cash-generating units that are expected to benefit from the synergies of the combination.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An impairment loss is recognized in the consolidated income statement if the estimated recoverable amount of an asset or its cash-generating unit is lower than its carrying amount. Impairment losses recognized in respect of cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to the units and then to reduce the carrying amount of the other assets in the unit on a pro-rata basis.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset&#x2019;s carrying amount does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. Goodwill that forms part of the carrying amount of an investment in a joint venture is not recognized separately, and therefore is not tested for impairment separately. Instead, the entire amount of the investment in a joint venture is tested for impairment as a single asset when there is objective evidence that the investment in a joint venture may be impaired.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An impairment loss in respect of equity accounted investee is measured by comparing the recoverable amount of investment with its carrying amount. An impairment loss is recognized in the consolidated income statement, and reversed if there has been a favorable change in the estimates used to determine the recoverable amount.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;j. Employee benefits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Short-term employee benefits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Defined contribution plans&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s contributions to defined contribution plans are charged to the consolidated income statement as and when the services are received from the employees.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Defined benefit plans&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The liability in respect of defined benefit plans and other post-employment benefits is calculated using the projected unit credit method consistent with the advice of qualified actuaries. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating to the terms of the related defined benefit obligation. In countries where there is no deep market in such bonds, the market interest rates on government bonds are used. The current service cost of the defined benefit plan, recognized in the consolidated income statement, reflects the increase in the defined benefit obligation resulting from employee service in the current year, benefit changes, curtailments and settlements. Past service costs are recognized immediately in the consolidated income statement. The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in the consolidated income statement. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions for defined benefit obligation and plan assets are recognized in OCI in the period in which they arise.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;When the benefits under a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service or the gain or loss on curtailment is recognized immediately in the consolidated income statement. The Company recognizes gains or losses on the settlement of a defined benefit plan obligation when the settlement occurs.&lt;/div&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Termination benefits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Termination benefits are recognized as an expense in the consolidated income statement when the Company is demonstrably committed, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. Termination benefits for voluntary redundancies are recognized as an expense in the consolidated income statement if the Company has made an offer encouraging voluntary redundancy, it is probable that the offer will be accepted, and the number of acceptances can be estimated reliably.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other long-term employee benefits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s net obligation in respect of other long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and previous periods. That benefit is discounted to determine its present value. Re-measurements are recognized in the consolidated income statement in the period in which they arise.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensated absences&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s current policies permit certain categories of its employees to accumulate and carry forward a portion of their unutilized compensated absences and utilize them in future periods or receive cash in lieu thereof in accordance with the terms of such policies. The Company measures the expected cost of accumulating compensated absences as the additional amount that the Company incurs as a result of the unused entitlement that has accumulated at the reporting date. Such measurement is based on actuarial valuation as at the reporting date carried out by a qualified actuary.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;k. Share based payments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Equity settled share-based payment transactions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The grant date fair value of options granted to employees is recognized as an expense in the consolidated income statement, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the options. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet the related service and performance conditions at the vesting date. The expense is recorded for each separately vesting portion of the award as if the award was, in substance, multiple awards. The increase in equity recognized in connection with share-based payment transaction is presented as a separate component in equity under &#x201c;share-based payment reserve&#x201d;. The amount recognized as an expense is adjusted to reflect the actual number of stock options that vest.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash settled share-based payment transactions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the amount payable to employees in respect of share-based payment transactions which are settled in cash is recognized as an expense, with a corresponding increase in liabilities, over the period during which the employees become unconditionally entitled to payment. The liability is re-measured at each reporting date and at the settlement date based on the fair value of the share-based payment transaction. Any changes in the liability are recognized in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;l. Provisions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A provision is recognized in the consolidated income statement if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restructuring&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A provision for restructuring is recognized in the consolidated income statement when the Company has approved a detailed and formal restructuring plan, and the restructuring either has commenced or has been announced publicly. Future operating costs are not provided.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Onerous contracts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A provision for onerous contracts is recognized in the consolidated income statement when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Company recognizes any impairment loss on the assets associated with that contract.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Reimbursement rights&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected reimbursements for expenditures required to settle a provision are recognized in the consolidated income statement only when receipt of such reimbursements is virtually certain. Such reimbursements are recognized as a separate asset in the statement of financial position, with a corresponding credit to the specific expense for which the provision has been made.&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;br/&gt;&lt;/div&gt;






&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingent liabilities and contingent assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent assets are not recognized in the financial statements. A contingent asset is disclosed where an inflow of economic benefits is probable. Contingent assets are assessed continually and, if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognized in the period in which the change occurs.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;m. Revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s revenue is derived from sales of goods, service income and income from licensing arrangements. Most of such revenue is generated from the sale of goods. The Company has generally concluded that it is the principal in its revenue arrangements.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue is recognized when the control of the goods has been transferred to a third party. This is usually when the title passes to the customer, either upon shipment or upon receipt of goods by the customer. At that point, the customer has full discretion over the channel and price to sell the products, and there are no unfulfilled obligations that could affect the customer&#x2019;s acceptance of the product.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from the sale of goods is measured at the transaction price which is the consideration received or receivable, net of returns, taxes and applicable trade discounts and allowances. Revenue includes shipping and handling costs billed to the customer.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In arriving at the transaction price, the Company considers the terms of the contract with the customers and its customary business practices. The transaction price is the amount of consideration the Company is entitled to receive in exchange for transferring promised goods or services, excluding amounts collected on behalf of third parties. The amount of consideration varies because of estimated rebates, returns and chargebacks, which are considered to be key estimates. Any amount of variable consideration is recognized as revenue only to the extent that it is highly probable that a significant reversal will not occur. The Company estimates the amount of variable consideration using the expected value method.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Presented below are the points of recognition of revenue with respect to the Company&#x2019;s sale of goods:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 25%; text-align: justify; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: justify; padding-bottom: 0.5pt;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 74%; text-align: justify; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;Point of recognition of revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sales of generic products in India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon delivery of products to distributors by clearing and forwarding agents of the Company. Control over the generic products is transferred by the Company when the goods are delivered to distributors from clearing and forwarding agents. &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sales of active pharmaceutical ingredients and intermediates in India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon delivery of products to customers (generally formulation manufacturers), from the factories of the Company.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Export sales and other sales outside of India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon delivery of the products to the customers unless the terms of the applicable contract provide for specific revenue generating activities to be completed, in which case revenue is recognized once all such activities are completed.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Profit share revenues&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company from time to time enters into marketing arrangements with certain business partners for the sale of its products in certain markets. Under such arrangements, the Company sells its products to the business partners at a non-refundable base purchase price agreed upon in the arrangement and is also entitled to a profit share which is over and above the base purchase price. The profit share is typically dependent on the business partner&#x2019;s ultimate net sale proceeds or net profits, subject to any reductions or adjustments that are required by the terms of the arrangement. Such arrangements typically require the business partner to provide confirmation of units sold and net sales or net profit computations for the products covered under the arrangement.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue in an amount equal to the base sale price is recognized in these transactions upon delivery of products to the business partners. An additional amount representing the profit share component is recognized as revenue only to the extent that it is highly probable that a significant reversal will not occur.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At the end of each reporting period, the Company updates the estimated transaction price (including updating its assessment of whether an estimate of variable consideration is constrained) to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.&lt;/div&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Out licensing arrangements, milestone payments and royalties&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues include amounts derived from product out-licensing agreements. These arrangements typically consist of an initial up-front payment &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;received&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;on inception of the license and subsequent payments dependent on achieving certain milestones in accordance with the terms prescribed in the agreement. In cases where the transaction has two or more &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;performance obligations,&lt;/div&gt; the Company accounts for the &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;completed obligation&lt;/div&gt; (for example&#160;the transfer of title) as a separate unit of accounting and record revenue upon delivery of that component, provided that the Company can make a reasonable estimate of the fair value of the undelivered component. Otherwise, non-refundable up-front license fees received in connection with product out-licensing agreements are deferred and recognized over the balance period in which the Company has pending performance obligations. Milestone payments which are contingent on achieving certain clinical milestones are recognized as revenues either on achievement of such milestones, over the performance period depending on the terms of the contract. If milestone payments are creditable against future royalty payments, the milestones are deferred and released over the period in which the royalties are anticipated to be paid.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Royalty income earned through a license is recognized when the underlying sales have occurred.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Provision for chargeback, rebates and discounts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions for chargeback, rebates, discounts and Medicaid payments are estimated and provided for in the year of sales and recorded as reduction of revenue. A chargeback claim is a claim made by the wholesaler for the difference between the price at which the product is initially invoiced to the wholesaler and the net price at which it is agreed to be procured from the Company. Provisions for such chargebacks are accrued and estimated based on historical average chargeback rate actually claimed over a period of time, current contract prices with wholesalers/other customers and estimated inventory holding by the wholesaler.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Shelf stock adjustments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shelf stock adjustments are credits issued to customers to reflect decreases in the selling price of products sold by the Company, and are accrued when the prices of certain products decline as a result of increased competition or otherwise. These credits are customary in the pharmaceutical industry, and are intended to reduce the customer inventory cost to better reflect the current market prices. The determination to grant a shelf stock adjustment to a customer is based on the terms of the applicable contract, which may or may not specifically limit the age of the stock on which a credit would be offered.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Refund Liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for sales returns accrual by recording refund liability concurrent with the recognition of revenue at the time of a product sale. This liability is based on the Company&#x2019;s estimate of expected sales returns. The Company deals in various products and operates in various markets. Accordingly, the estimate of sales returns is determined primarily by the Company&#x2019;s historical experience in the markets in which the Company operates. With respect to established products, the Company considers its historical experience of actual sales returns, levels of inventory in the distribution channel, estimated shelf life, any revision in the shelf life of the product, product discontinuances, price changes of competitive products, and the introduction of competitive new products, to the extent each of these factors impact the Company&#x2019;s business and markets. With respect to new products introduced by the Company, such products have historically been either extensions of an existing line of product where the Company has historical experience or in therapeutic categories where established products exist and are sold either by the Company or the Company&#x2019;s competitors. At the time of recognizing the refund liability, the Company also recognizes an asset, (i.e., the right to the returned goods) which is included in inventories for the products expected to be returned. The Company initially measures this asset at the former carrying amount of the inventory, less any expected costs to recover the goods, including any potential decreases in the value of the returned goods.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Along with re-measuring the refund liability at the end of each reporting period, the Company updates the measurement of the asset recorded for any revisions to its expected level of returns, as well as any additional decreases in the value of the returned products.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Services&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from services rendered, which primarily relate to contract research, is recognized in the consolidated income statement as the underlying services are performed. Upfront non-refundable payments received under these arrangements are deferred and recognized as revenue over the expected period over which the related services are expected to be performed.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;License fees&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License fees primarily consist of income from the out-licensing of intellectual property, and other licensing and supply arrangements with various parties. Revenue from license fees is recognized when control transfers to the third party and the Company&#x2019;s performance obligations are satisfied. Some of these arrangements include certain performance obligations by the Company. Revenue from such arrangements is recognized in the period in which the Company completes all its performance obligations.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;n. Shipping and handling costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shipping and handling costs incurred to transport products to customers, and internal transfer costs incurred to transport the products from the Company&#x2019;s factories to its various points of sale, are included in selling, general and administrative expenses.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;o. Finance income and expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance income consists of interest income on funds invested, dividend income and gains on the disposal of financial assets. Interest income is recognized in the consolidated income statement as it accrues, using the effective interest method. Dividend income is recognized in the consolidated income statement on the date that the Company&#x2019;s right to receive payment is established. The associated cash flows are classified as investing activities in the statement of cash flows. Finance expenses consist of interest expense on loans and borrowings.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Borrowing costs are recognized in the consolidated income statement using the effective interest method. The associated cash flows are classified as financing activities in the statement of cash flows.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency gains and losses are reported on a net basis within finance income and expense. These primarily include: exchange differences arising on the settlement or translation of monetary items; changes in the fair value of derivative contracts that economically hedge monetary assets and liabilities in foreign currencies and for which no hedge accounting is applied; and the ineffective portion of cash flow hedges.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;p. Income tax&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax expense consists of current and deferred tax. Income tax expense is recognized in the consolidated income statement except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax is recognized using the balance sheet method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities are recogni&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;z&lt;/div&gt;ed for all taxable temporary differences, except:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 17.45pt; font-size: 0px;"/&gt;
			&lt;td style="width: 18pt;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit; &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 17.45pt; font-size: 0px;"/&gt;
			&lt;td style="width: 18pt;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;temporary differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future; and &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 17.45pt; font-size: 0px;"/&gt;
			&lt;td style="width: 18pt;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;taxable temporary differences arising upon the initial recognition of goodwill. &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets are recogni&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;z&lt;/div&gt;ed for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recogni&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;z&lt;/div&gt;ed to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utili&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;z&lt;/div&gt;ed, except:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&#x2022;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;When the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;and&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&#x2022;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;In respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, deferred tax assets are recogni&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;z&lt;/div&gt;ed only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Any deferred tax asset or liability arising from deductible or taxable temporary differences in respect of unrealized inter-company profit or loss on inventories held by the Company in different tax jurisdictions is recognized using the tax rate of the jurisdiction in which such inventories are held. Withholding tax arising out of payment of dividends to shareholders under the Indian Income tax regulations is not considered a&#160;tax expense for the Company and all such taxes are recognized in the statement of changes in equity as part of the associated dividend payment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax is measured at the tax rates that are expected to be applied to the temporary differences when they reverse, based on the laws that have been enacted or substantively enacted at the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously.&lt;/div&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current and deferred tax is recognized in the consolidated income statement, except to the extent that it relates to items recognized in OCI or directly in equity. In this case, the tax is also recognized in OCI or directly in equity, respectively.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accruals for uncertain tax positions require management to make judgments of potential exposures. Accruals for uncertain tax positions are measured using either the most likely amount or the expected value amount, depending on which method the entity expects to better predict the resolution of the uncertainty. Tax benefits are not recognized unless the tax positions will probably be accepted by the tax authorities. This is based upon management&#x2019;s interpretation of applicable laws and regulations and the expectation of how the tax authority will resolve the matter. Once considered probable of not being accepted, management reviews each material tax benefit and reflects the effect of the uncertainty in determining the related taxable amounts.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;q. Earnings per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company presents basic and diluted earnings per share (&#x201c;EPS&#x201d;) data for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding for the effects of all dilutive potential ordinary shares, which includes all stock options granted to employees.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;r. Government grants and incentives&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes government grants only when there is reasonable assurance that the conditions attached to them will be complied with, and the grants will be received. Government grants received in relation to assets are presented as a reduction to the carrying amount of the related asset. Grants related to income are deducted in reporting the related expense in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Export entitlements from government authorities are recognized in the consolidated income statement as a reduction from &#x201c;Cost of Revenues&#x201d; when the right to receive credit as per the terms of the scheme is established in respect of the exports made by the Company, and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;s. Segment reporting&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The Chief Executive Officer of the Company is responsible for allocating resources and assessing performance of the operating segments and accordingly is identified as the chief operating decision maker.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;t. Treasury shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Own equity instruments that are reacquired (treasury shares) are recognized at cost and deducted from equity. No gain or loss is recognized in the consolidated income statement on the purchase, sale, issue or cancellation of the Company&#x2019;s own equity instruments. Any difference between the carrying amount and the consideration, if reissued, is recognized in the share premium.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 21.3pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;u. Non-currents assets held for sale&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company classifies non-current assets and disposal groups as held for sale if their carrying amounts will be recovered principally through a sale transaction rather than through continuing use. Non-current assets classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell. Costs to sell are the incremental costs directly attributable to the disposal of an asset, excluding finance costs and income tax expense. The criteria for held for sale classification is regarded as met only when the sale is highly probable, and the asset or disposal group is available for immediate sale in its present condition. Property, plant and equipment are not depreciated or amortized once classified as held for sale. Assets classified as held for sale are presented separately as current items in the statement of financial position.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;v. Rounding of amounts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All amounts disclosed in the consolidated financial statements and notes have been rounded off to the nearest million currency units unless otherwise stated.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consideration transferred for the acquisition of a subsidiary is comprised of:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;fair values of the assets transferred;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;liabilities incurred to the former owners of the acquired business;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;equity interests issued by the Company;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;fair value of any asset or liability resulting from a contingent consideration arrangement; and&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;fair value of any pre-existing equity interest in the subsidiary.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
    <rdy:DescriptionOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;New Standards adopted by the Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="text-indent: 0px;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;

&lt;div style="margin-bottom: 6pt; text-align: justify; text-indent: 0.25in; margin-top: 0px; font-family: Calibri, sans-serif; font-size: 10pt; line-height: 10pt; margin-left: 0in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; text-indent: 0px; line-height: 10pt;;display:inline;"&gt;Amendments to IFRS 16, &#x201c;&lt;div style="line-height: 10pt; font-size: 10pt;;font-style:italic;display:inline;"&gt;Leases&lt;/div&gt;&#x201d; regarding Covid-19-Related Rent Concessions beyond &#160;June 30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="text-indent: 0px;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-size: 9pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-stretch: normal;"&gt;On 28 May 2020, the IASB issued &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; text-indent: 0px; line-height: 10pt;;font-style:italic;display:inline;"&gt;Covid-19-Related Rent Concessions - amendment to IFRS 16 Leases&lt;/div&gt;. The amendments provide relief to lessees from applying IFRS 16 guidance on lease modification accounting for rent concessions arising as a direct consequence of the Covid-19 pandemic. As a practical expedient, a lessee may elect not to assess whether a Covid-19 related rent concession from a lessor is a lease modification. The amendment was intended to apply until June 30, 2021, but as the impact of the Covid-19 pandemic is continuing, on March 31, 2021, the IASB extended the period of application of the practical expedient to June 30, 2022.The amendment applies to annual reporting periods beginning on or after April 1, 2021.&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0in;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.26in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt;The aforesaid amendment&#160;had no impact on the consolidated financial statements.&lt;/div&gt; &lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0in;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"/&gt;Standard issued but not effective&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amendments to IAS 1, &#x201c;&lt;div style="font-style:italic;display:inline;"&gt;Presentation of Financial Statements&lt;/div&gt;&#x201d; regarding classification of liabilities as current or non-current&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; white-space:pre-line; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January 23, 2020, the IASB issued amendments to paragraphs 69 to 76 of &lt;div style="font-style:italic;display:inline;"&gt;IAS 1 Presentation of Financial Statements&lt;/div&gt; to specify the requirements for classifying liabilities as current or non-current. The amendments clarify what is meant by a right to defer settlement, that a right to defer must exist at the end of the reporting period, that the classification is unaffected by the likelihood that an entity will exercise its deferral right, and that only if the conversion option itself is classified as an equity instrument would settlement by way of own equity instruments be disregarded when determining whether the liability is current or non-current. In July 2021, the IASB decided to defer the effective date of the 2020 amendments to no earlier than January 1, 2024.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amendments to IAS 12, &#x201c;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&#x201d; regarding Assets and Liabilities arising from a Single Transaction&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2021, the IASB issued amendments to IAS 12, which narrow the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The proposed amendments will typically apply to transactions such as leases for the lessee and decommissioning obligations.&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paragraphs 15 and 24 of IAS 12 were amended to include an additional condition where the initial recognition exemption is not applied. According to the amended guidance, a temporary difference that arises on initial recognition of an asset or liability is not subject to the initial recognition exemption if that transaction gave rise to equal taxable and deductible temporary differences.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These amendments should be applied for annual periods beginning on or after January 1, 2023.&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amendments to IAS 1 and IFRS Practice Statement (&#x201c;PS&#x201d;), &#x201c;&lt;div style="font-style:italic;display:inline;"&gt;Presentation of Financial Statements&lt;/div&gt;&#x201d; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2021, the IASB issued amendments to IAS 1 and IFRS Practice Statement 2, Making Materiality Judgments (the PS), in which it provides guidance and examples to help entities apply materiality judgments to accounting policy disclosures. The proposed amendments are effective for annual periods beginning on or after January 1, 2023. &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amendments to IAS 8, &#x201c;&lt;div style="font-style:italic;display:inline;"&gt;Accounting Policies, Changes in Accounting Estimates and Errors&lt;/div&gt;&#x201d; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2021, the IASB issued amendments to IAS 8, in which it introduces a new definition of &#x2018;accounting estimates&#x2019;. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, they clarify how entities use measurement techniques and inputs to develop accounting estimates. The proposed amendments are effective for annual periods beginning on or after January 1, 2023.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;IFRS 17, &#x201c;&lt;div style="font-style:italic;display:inline;"&gt;Insurance Contracts&lt;/div&gt;&#x201d; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2017, the IASB issued IFRS 17 Insurance Contracts, a comprehensive new accounting standard for insurance contracts covering recognition and measurement, presentation and disclosure. This standard is effective for annual periods beginning on or after January 1, 2023.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Narrow-scope amendments to certain other Standards&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The IASB, on May 14, 2020, issued several small amendments to IFRS Standards.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The package of amendments includes narrow-scope amendments to&#160; Standards as well as the IASB&#x2019;s Annual Improvements, which are changes that clarify the wording or correct minor consequences, oversights or conflicts between requirements in the Standards.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; text-indent:0.25in; line-height:normal; font-family:Calibri,'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amendments to IFRS 3 Business Combinations&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt; update a reference in IFRS 3 to the Conceptual Framework for Financial Reporting without changing the accounting requirements for business combinations.&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin-bottom: 6pt; text-align: justify; text-indent: 0.25in; margin-top: 0px; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;br/&gt;&lt;/div&gt;</rdy:DescriptionOfAccountingPolicyForInitialApplicationOfStandardsOrInterpretationsExplanatoryPolicyTextBlock>
    <rdy:DisclosureOfBasisOfConsolidationExplanatoryPolicyTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;a. Basis of consolidation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsidiaries&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consolidated financial statements comprise the financial statements of the Company and its subsidiaries as at March 31, 2022. Subsidiaries are all entities (including special purpose entities) that are controlled by the Company. Control exists when the Company is exposed to, or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through power over the entity. In assessing control, potential voting rights are considered only if the rights are substantive. The financial statements of subsidiaries are included in these consolidated financial statements from the date that control commences until the date that control ceases.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated income statement, consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidate&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt;&#160;statement of financial position, respectively.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidated financial statements are prepared using uniform accounting policies for like transactions and other events in similar circumstances. If a subsidiary of the Company uses accounting policies other than those adopted in the consolidated financial statements for like transactions and events in similar circumstances, appropriate adjustments are made to that subsidiary&#x2019;s financial statements in preparing the consolidated financial statements to ensure conformity with the Company&#x2019;s accounting policies.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Joint arrangements (equity accounted investees)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Joint arrangements are those arrangements over which the parties have joint control, established by contractual agreement and requiring unanimous consent for strategic financial and operating decisions. The considerations made in determining whether significant influence or joint control are similar to those necessary to determine control over the subsidiaries.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;A joint arrangement is either a joint operation or a joint venture. A joint operation is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the assets, and obligations for the liabilities, relating to the arrangement. A joint venture is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the arrangement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;With respect to joint operations, the Company recognizes its direct right to the assets, liabilities, revenues and expenses of joint operations and its share of any jointly held or incurred assets, liabilities, revenues and expenses.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments in joint ventures are accounted for using the equity method and are initially recognized at cost. The carrying value of the Company&#x2019;s investment includes goodwill identified on acquisition, net of any accumulated impairment losses. The Company does not consolidate entities where the non-controlling interest (&#x201c;NCI&#x201d;) holders have certain significant participating rights that provide for effective involvement in significant decisions in the ordinary course of business of such entities. Investments in such entities are accounted by the equity method of accounting. When the Company&#x2019;s share of losses exceeds its interest in an equity accounted investee, the carrying amount of that interest (including any long-term investments) is reduced to zero and the recognition of further losses is discontinued except to the extent that the Company has an obligation or has made payments on behalf of the investee.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the purpose of preparing these consolidated financial statements, the accounting policies of joint ventures have been changed where necessary to align them with the policies adopted by the Company. Furthermore, the financial statements of the joint ventures are prepared for the same reporting period as of the Company.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;div style="margin: 0in 0in 0.0001pt 20.15pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; color: black; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; color: black; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;a. Basis of consolidation (continued)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0in; text-align: justify; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0in; text-align: justify; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consolidation procedure &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the purpose of preparing these consolidated financial statements, intra-group transactions are consolidated using the following procedures:&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;a.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Combine like items of assets, liabilities, equity, income, expenses and cash flows of the parent with those of its subsidiaries. For this purpose, income and expenses of the subsidiary are based on the amounts of the assets and liabilities recognized in the consolidated financial statements at the acquisition date.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Offset (eliminate) the carrying amount of the parent&#x2019;s investment in each subsidiary and the parent&#x2019;s portion of equity of each subsidiary.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;c.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Eliminate in full intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between entities of the group (profits or losses resulting from intragroup transactions that are recognized in assets, such as inventory and&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;property, plant and equipment,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;are eliminated in full). Intragroup losses may indicate an impairment that requires recognition in the consolidated financial statements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Changes in ownership interests&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;Acquisition of some or all of the NCI is accounted for as a transaction with equity holders in their capacity as equity holders. Consequently, the difference arising between the fair value of the purchase consideration paid and the carrying value of the NCI is recorded as an adjustment to retained earnings that is attributable to the parent company. The associated cash flows are classified as financing activities. No goodwill is recognized as a result of such transactions.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Loss of Control&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0.26in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At the time of loss of control, the Company&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;derecognizes the assets (including goodwill) and liabilities of the subsidiary at their carrying amounts at the date when control is lost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;derecognizes the carrying amount of any non-controlling interests&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;derecognizes the cumulative translation differences recorded in equity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognizes the fair value of the consideration received&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognizes the fair value of any investment retained&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognizes any surplus or deficit in income statement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;reclassifies the parent&#x2019;s share of components previously recognized in OCI to income statement or transferred directly to retained earnings, if required by other IFRSs as would be required if the Company had directly disposed of the related assets or liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;
</rdy:DisclosureOfBasisOfConsolidationExplanatoryPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;b. Foreign currency&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Functional and presentation currency &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;These consolidated financial statements are presented in Indian rupees, which is the functional currency of the parent company. All financial information presented in Indian rupees has been rounded to the nearest million.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In respect of certain non-Indian subsidiaries that operate as marketing arms of the parent company in their respective countries/regions, the functional currency has been determined to be the functional currency of the parent company (i.e., the Indian rupee). The operations of these entities are largely restricted to importing of finished goods from the parent company in India, sales of these products in the foreign country and making of import payments to the parent company. The cash flows realized from sales of goods are available for making import payments to the parent company and cash is paid to the parent company on a regular basis. The costs incurred by these entities are primarily the cost of goods imported from the parent company. The financing of these subsidiaries is done directly or indirectly by the parent company.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;In respect of subsidiaries whose operations are self-contained and integrated within their respective countries/regions, the functional currency has been generally determined to be the local currency of those countries/regions, unless use of a different currency is considered appropriate.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency transactions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transactions in foreign currencies are translated to the respective functional currencies of entities within the Company at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated into the functional currency at the exchange rate at that date. Non-monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition during the period or in previous financial statements are recognized in the consolidated income statement in the period in which they arise.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;However, foreign currency differences arising from the translation of the following items are recognized in OCI:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 42.55pt; text-align: justify; text-indent: -14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;certain debt instruments classified as measured at FVTOCI;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;certain equity instruments where the Company had made an irrevocable election to present in OCI subsequent changes in the fair value;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;a financial liability designated as a hedge of the net investment in a foreign operation, to the extent that the hedge is effective; and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;qualifying cash flow hedges, to the extent that the hedges are effective.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 42.55pt; text-align: justify; text-indent: -14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;When several exchange rates are available, the rate used is that at which the future cash flows represented by the transaction or balance could have been settled if those cash flows had occurred at the measurement date.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-align: justify;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign operations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign exchange gains and losses arising from a monetary item receivable from a foreign operation, the settlement of which is neither planned nor likely in the foreseeable future, are considered to form part of the net investment in the foreign operation and are recognized in OCI and presented within equity as foreign currency translation reserve (&#x201c;FCTR&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;In case of foreign operations whose functional currency is different from the parent company&#x2019;s functional currency, the assets and liabilities of such foreign operations, including goodwill and fair value adjustments arising upon acquisition, are translated to the reporting currency at exchange rates at the reporting date. The income and expenses of such foreign operations are translated to the reporting currency at the monthly average exchange rates prevailing during the year. Resulting foreign currency differences are recognized in OCI and presented within equity as part of FCTR. When a foreign operation is disposed of, in part or in full, such that control, significant influence or joint control is lost, the relevant amount in the FCTR is reclassified to the consolidated income statement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;c. Financial instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Initial recognition and measurement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All financial assets are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (e.g., regular way trades) are recognized on the trade date, i.e., the date that the Company commits to purchase or sell the asset.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade receivables are recognized initially at the amount of consideration that is unconditional unless they contain significant financing components, in which case they are recognized at fair value. The Company&#x2019;s trade receivables do not contain any significant financing component and hence are measured at the transaction price measured under IFRS 15, &lt;div style="font-style:italic;display:inline;"&gt;&#x201c;Revenue from Contracts with Customers&#x201d;&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subsequent measurement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For purposes of subsequent measurement, financial assets are classified in four categories:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt instruments at amortized cost;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;










































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt instruments at FVTOCI;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;










































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt instruments, derivatives and equity instruments at FVTPL; and &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;










































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity instruments measured at FVTOCI.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;










































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Debt instruments at amortized cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A &#x201c;debt instrument&#x201d; is measured at the amortized cost if both the following conditions are met:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;a)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;the asset is held within a business model whose objective is to hold assets for collecting contractual cash flows; and&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;










































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;b)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (&#x201c;SPPI&#x201d;) on the principal amount outstanding.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;










































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;After initial measurement, such financial assets are subsequently measured at amortized cost using the effective interest rate method and are subject to impairment. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on de-recognition is recognized directly in the consolidated income statement and presented in other income/(losses),net. The losses arising from impairment are recognized in the consolidated income statement. This category generally applies to trade and other receivables.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&#160;&lt;/div&gt;

&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt instrument at FVTOCI&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 14.2pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A &#x201c;debt instrument&#x201d; is classified as at the FVTOCI if both of the following criteria are met:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt 0.5in; text-align: justify; text-indent: -0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-spacing: 0px;"&gt;

		&lt;tr&gt;
			&lt;td style="width:.25in; padding:0in 0in 0in 0in;vertical-align:top;"/&gt;
			&lt;td style="width: 0.25in; padding: 0in; font-size: 10pt;;vertical-align:top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;a)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in; font-size: 10pt;;vertical-align:top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets; and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;























&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 12pt;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-spacing: 0px;"&gt;

		&lt;tr&gt;
			&lt;td style="width:.25in; padding:0in 0in 0in 0in;vertical-align:top;"/&gt;
			&lt;td style="width: 0.25in; padding: 0in; font-size: 10pt;;vertical-align:top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;b)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in; font-size: 10pt;;vertical-align:top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the asset&#x2019;s contractual cash flows represent SPPI.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;























&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt instruments included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in the OCI. However, the Company recognizes interest income, impairment losses and reversals and foreign exchange gain or loss in the consolidated income statement. On de-recognition of the asset, cumulative gain or loss previously recognized in OCI is reclassified to the consolidated income statement. Interest earned while holding a FVTOCI debt instrument is reported as interest income using the effective interest rate method.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt instrument at FVTPL&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 14.2pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as at FVTPL.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 14.2pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, the Company may elect to designate a debt instrument, which otherwise meets amortized cost or FVTOCI criteria, as FVTPL. However, such election is allowed only if doing so reduces or eliminates a measurement or recognition inconsistency (referred to as an &#x201c;accounting mismatch&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 14.2pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;Debt instruments included within the FVTPL category are measured at fair value with all changes recognized in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Equity investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All equity investments within the scope of IFRS 9 are measured at fair value. Equity instruments which are held for trading and contingent consideration recognized by an acquirer in a business combination to which IFRS 3 applies, are classified as at FVTPL. For all other equity instruments, the Company may make an irrevocable election to present in OCI subsequent changes in the fair value. The Company makes such election on an instrument-by-instrument basis. The classification is made upon initial recognition and is irrevocable.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the Company decides to classify an equity instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to the consolidated income statement, even on sale of investment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;However, on sale the Company may transfer the cumulative gain or loss within equity. Equity investments designated as FVTOCI are not subject to impairment assessment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;De-recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Company&#x2019;s consolidated statement of financial position) when:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the rights to receive cash flows from the asset have expired; or&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Both (1) the Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a &#x201c;pass-through&#x201d; arrangement&#x37e; and (2) either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognize the transferred asset to the extent of the Company&#x2019;s continuing involvement. In that case, the Company also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Impairment of trade receivables and other financial assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with IFRS 9, the Company applies the expected credit loss (&#x201c;ECL&#x201d;) model for measurement and recognition of impairment loss on trade receivables or any contractual right to receive cash or another financial asset.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For this purpose, the Company follows a &#x201c;simplified approach&#x201d; for recognition of impairment loss allowance on the trade receivable balances. The application of this simplified approach does not require the Company to track changes in credit risk. Rather, it recognizes impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As a practical expedient, the Company uses a provision matrix to determine impairment loss allowance on portfolio of its trade receivables. The provision matrix is based on its historically observed default rates over the expected life of the trade receivables and is adjusted for forward-looking estimates. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analyzed.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Financial liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Initial recognition and measurement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liabilities are classified, at initial recognition, as financial liabilities at FVTPL, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s financial liabilities include trade and other payables, loans and borrowings including bank overdrafts and derivative financial instruments.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subsequent measurement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;The measurement of financial liabilities depends on their classification, as described below:&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Financial liabilities at FVTPL&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liabilities at FVTPL include financial liabilities held for trading and financial liabilities designated upon initial recognition as at FVTPL. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by IFRS 9. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gains or losses on liabilities held for trading are recognized in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial liabilities designated upon initial recognition at FVTPL are designated as such at the initial date of recognition, and only if the criteria in IFRS 9 are satisfied. For liabilities designated as FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI. These gains or losses are not subsequently transferred to the consolidated income statement.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;However, the Company may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognized in the consolidated income statement. The Company has not designated any financial liability as FVTPL.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Loans and borrowings&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Borrowings are initially recognized at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognized in the consolidated income statement over the period of the borrowings using the effective interest method.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortized cost using the effective interest rate method. Gains and losses are recognized in the consolidated income statement when the liabilities are derecognized as well as through the effective interest rate amortization process.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortization is included as finance costs in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;De-recognition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;

&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative financial instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 14.2pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is exposed to exchange rate risk which arises from its foreign exchange revenues and expenses, primarily in U.S. dollars, U.K. pounds sterling, Russian roubles, Brazilian reals, Swiss francs, South African rands, Kazakhstan tenges, Romanian new leus, Australian dollars and Euros, and foreign currency debt in U.S. dollars, Russian roubles, South African rands, Mexican pesos, Ukrainian hryvnias and Brazilian reals.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company uses derivative financial instruments such as foreign exchange forward contracts, option contracts and swap contracts to mitigate its risk of changes in foreign currency exchange rates. The Company also uses non-derivative financial instruments as part of its foreign currency exposure risk mitigation strategy. Derivatives are classified as financial assets when the fair value is positive and as financial liabilities when the fair value is negative.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin:0in 0in 0.0001pt; text-align:justify; line-height:normal; font-family:Calibri,sans-serif"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hedges of highly probable forecasted transactions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 14.2pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company classifies its derivative financial instruments that hedge foreign currency risk associated with highly probable forecasted transactions as cash flow hedges and measures them at fair value. The effective portion of such cash flow hedges is recorded in the Company&#x2019;s hedging reserve as a component of equity and re-classified to the consolidated income statement as part of the hedged item in the period corresponding to the occurrence of the forecasted transactions. The ineffective portion of such cash flow hedges is recorded in the consolidated income statement as finance costs immediately.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 14.2pt; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, sans-serif; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;The Company also designates certain non-derivative financial liabilities, such as foreign currency borrowings from banks, as hedging instruments for hedge of foreign currency risk associated with highly probable forecasted transactions. Accordingly, the Company applies cash flow hedge accounting to such relationships. Re-measurement gain or loss on such non-derivative financial liabilities is recorded in the Company&#x2019;s hedging reserve as a component of equity and reclassified to the consolidated income statement as part of the hedged item in the period corresponding to the occurrence of the forecasted transactions.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the hedging instrument no longer meets the criteria for hedge accounting, expires or is sold, terminated or exercised, then hedge accounting is discontinued prospectively. The cumulative gain or loss previously recognized in OCI, remains there until the forecasted transaction occurs. If the forecasted transaction is no longer expected to occur, then the balance in OCI is recognized immediately in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Hedges of recognized assets and liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in the fair value of derivative contracts that economically hedge monetary assets and liabilities in foreign currencies, and for which no hedge accounting is applied, are recognized in the consolidated income statement. The changes in fair value of such derivative contracts, as well as the foreign exchange gains and losses relating to the monetary items, are recognized in the consolidated income statement. If the hedged item is derecognized, the unamortized fair value is recognized immediately in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Hedges of changes in the interest rates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consistent with its risk management policy, the Company uses interest rate swaps to mitigate the risk of changes in interest rates. The Company does not use them for trading or speculative purposes.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents consist of cash on hand, demand deposits and short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value. For this purpose, &#x201c;short-term&#x201d; means investments having original maturities of three months or less from the date of investment. Bank overdrafts that are repayable on demand form an integral part of the Company&#x2019;s cash management and are included as a component of cash and cash equivalents for the purpose of the consolidated statement of cash flows.&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;d. Business combinations and goodwill&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Business combinations are accounted for using the acquisition method, regardless of whether equity instruments or other assets are acquired. The acquisition date is the date on which control is transferred to the acquirer. Judgment is applied in determining the acquisition date and determining whether control is transferred from one party to another. Control exists when the Company is exposed to, or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through power over the entity. In assessing control, potential voting rights are considered only if the rights are substantive.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company determines that it has acquired a business when the acquired set of activities and assets include an input and a substantive process that together significantly contribute to the ability to create outputs. The acquired process is considered substantive if it is critical to the ability to continue producing outputs, and the inputs acquired include an organized workforce with the necessary skills, knowledge, or experience to perform that process or it significantly contributes to the ability to continue producing outputs and is considered unique or scarce or cannot be replaced without significant cost, effort, or delay in the ability to continue producing outputs.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consideration transferred for the acquisition of a subsidiary is comprised of:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;fair values of the assets transferred;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;liabilities incurred to the former owners of the acquired business;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;equity interests issued by the Company;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;fair value of any asset or liability resulting from a contingent consideration arrangement; and&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;fair value of any pre-existing equity interest in the subsidiary.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At the acquisition date, identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially at their fair values. For each business combination, the Company elects whether to measure the non-controlling interests in the acquiree at fair value or at the proportionate share of the acquiree&#x2019;s identifiable net assets.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisition related costs are expensed as incurred.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the business combination is achieved in stages, the acquisition date carrying value of the acquirer&#x2019;s previously held equity interest in the acquiree is re-measured to fair value at the acquisition date. Any gains or losses arising from such re-measurement are recognized in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Where settlement of any part of cash consideration is deferred, the amounts payable in the future are discounted to their present value as at the date of exchange. The discount rate used is the entity&#x2019;s incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions. &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent consideration is classified either as equity or a financial liability. Contingent consideration classified as equity is not re-measured and its subsequent settlement is accounted for within equity. Amounts classified as a financial liability are subsequently re-measured to fair value, with changes in fair value recognized in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill is initially measured at cost, being the excess of the aggregate of:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 17.85pt; font-size: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 17.85pt;"&gt;&#x2022;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;the consideration transferred,&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&#x2022;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;the amount of any non-controlling interest in the acquired entity, and&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 17.85pt; font-size: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 17.85pt;"&gt;&#x2022;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;the acquisition date fair value of any previous equity interest in the acquired entity,&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;over the fair value of the net identifiable assets acquired is recorded as goodwill.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If those amounts are less than the fair value of the net identifiable assets of the business acquired, the difference is recognized directly in the consolidated income statement as a bargain purchase.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of the Company&#x2019;s cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;e. Property, plant and equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recognition and measurement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses, if any. Cost includes expenditures that are directly attributable to the acquisition of the asset. The cost of self-constructed assets includes the cost of materials and other costs directly attributable to bringing the asset to a working condition for its intended use.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitali&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;z&lt;/div&gt;ed as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Capital work in progress is stated at cost, net of accumulated impairment loss, if any.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An item of property, plant and equipment and any significant part initially recognized is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Gains and losses upon disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognized net within &#x201c;Other (income)/expense, net&#x201d; in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The costs of repairs and maintenance are recognized in the consolidated income statement as incurred.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Items of property, plant and equipment acquired through exchange of non-monetary assets are measured at fair value, unless the exchange transaction lacks commercial substance or the fair value of either the asset received or asset given up is not reliably measurable, in which case the asset exchanged is recorded at the carrying amount of the asset given up.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Depreciation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation is recognized in the consolidated income statement on a straight line basis over the estimated useful lives of property, plant and equipment. The depreciation expense is included in the costs of the functions using the asset. Land is not depreciated but subject to impairment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation methods, useful lives and residual values are reviewed at each reporting date and any changes are considered prospectively. The estimated useful lives are as follows:&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 80%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;"&gt;

		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 80%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buildings&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 20%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Factory and administrative buildings&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&#160;-&#160;50&#160;years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Ancillary structures&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 - 15 years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plant and equipment&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 - 15 years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture, fixtures and office equipment&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 - 10 years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vehicles&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4 - 5 years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;




























































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software for internal use, which is primarily acquired from third-party vendors and which is an integral part of a tangible asset, including consultancy charges for implementing the software, is capitalized as part of the related tangible asset. Subsequent costs associated with maintaining such software are recognized as expense as incurred. The capitalized costs are amortized over the estimated useful life of the software or the remaining useful life of the tangible fixed asset, whichever is lower.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Advances paid towards the acquisition of property, plant and equipment outstanding at each reporting date and the cost of property, plant and equipment not ready to use before such date are disclosed under capital work-in-progress. Assets not ready for use are not depreciated but are tested for impairment.&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <rdy:DisclosureOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation methods, useful lives and residual values are reviewed at each reporting date and any changes are considered prospectively. The estimated useful lives are as follows:&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 80%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;"&gt;

		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 80%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buildings&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 20%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Factory and administrative buildings&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&#160;-&#160;50&#160;years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Ancillary structures&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 - 15 years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plant and equipment&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 - 15 years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture, fixtures and office equipment&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 - 10 years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vehicles&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4 - 5 years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































</rdy:DisclosureOfUsefulLivesOrDepreciationRatesPropertyPlantAndEquipmentTableTextBlock>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_FactoryAndAdministrativeBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">P20Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="P04_01_2021To03_31_2022_FactoryAndAdministrativeBuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis">P50Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="P04_01_2021To03_31_2022_AncillaryStructuresMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_BottomOfRangeMemberifrsfullRangeAxis">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="P04_01_2021To03_31_2022_AncillaryStructuresMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis">P15Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="P04_01_2021To03_31_2022_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis">P15Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_FixturesAndFittingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="P04_01_2021To03_31_2022_FixturesAndFittingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis">P10Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">P4Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment contextRef="P04_01_2021To03_31_2022_TopOfRangeMemberifrsfullRangeAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis">P5Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment>
    <ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;f. Goodwill and other intangible assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recognition and measurement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 15%; border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: justify; border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 84%; border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill represents the excess of consideration transferred, together with the amount of non-controlling interest in the acquiree, over the fair value of the Company&#x2019;s share of identifiable net assets acquired.&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill is measured at cost less accumulated impairment losses. In respect of equity accounted investees, the carrying amount of goodwill is included in the carrying amount of the investment, and any impairment loss on such an investment is not allocated to any asset, including goodwill, that forms part of the carrying value of the equity accounted investee.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other intangible assets that are acquired by the Company and that have finite useful lives are measured at cost less accumulated amortization and accumulated impairment losses. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expenditures on research activities undertaken with the prospect of gaining new scientific or technical knowledge and understanding are recognized in the consolidated income statement when incurred.&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures are capitalized only if:&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;development costs can be measured reliably; &lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;the product or process is technically and commercially feasible; &lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;future economic benefits are probable; and &lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;the Company intends to, and has sufficient resources, to complete development and to use or sell the asset.&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The expenditures to be capitalized include the cost of materials and other costs directly attributable to preparing the asset for its intended use. Other development expenditures are recognized in the consolidated income statement as incurred. As of March 31, 2022, none of the development expenditure amounts has met the aforesaid recognition criteria.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;








&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 15%; border-top: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Separate acquisition of intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: justify; border-top: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 84%; text-align: justify; border-top: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments to third parties that generally take the form of up-front payments and milestones for in-licensed products, compounds and intellectual property are capitalized. The Company&#x2019;s criteria for capitalization of such assets are consistent with the guidance given in paragraph 25 of IAS 38, &#x201c;&lt;div style="font-style:italic;display:inline;"&gt;Intangible Assets&#x201d;&lt;/div&gt;. (i.e., the receipt of economic benefits embodied in each intangible asset separately purchased or licensed in the transaction is considered to be probable).&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td style="border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;In-Process Research and Development assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired research and development intangible assets that are under development are recognized as In-Process Research and Development (&#x201c;IPR&amp;amp;D&#x201d;) assets. IPR&amp;amp;D assets are not amortized, but evaluated for potential impairment on an annual basis or when there are indications that the carrying value may not be recoverable. Any impairment charge on such IPR&amp;amp;D assets is recorded in the consolidated income statement under &#x201c;Impairment of non-current assets&#x201d;.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subsequent expenditure&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: justify; border-bottom: 1pt solid black; border-top: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures, including expenditures on internally generated goodwill and brands, is recognized in the consolidated income statement as incurred. &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td style="text-align: justify; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;IPR&amp;amp;D assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent expenditure on an IPR&amp;amp;D project acquired separately or in a business combination and recognized as an intangible asset is:&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 15%; text-align: justify; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 2%; text-align: justify; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 3%; text-align: justify; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: Symbol; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 80%; text-align: justify; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognized as an expense when incurred, if it is a research expenditure; &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="text-align: justify; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify; background-color: rgba(255, 255, 255, 0); padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: Symbol; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;recognized as an expense when incurred, if it is a development expenditure that does not satisfy the criteria for recognition as an intangible asset in paragraph 57 of IAS 38; and&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: Symbol; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom: 1pt solid black; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;added to the carrying amount of the acquired IPR&amp;amp;D project, if it is a development expenditure that satisfies the recognition criteria in paragraph 57 of IAS 38.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Amortization&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization is recognized in the consolidated income statement on a straight-line basis over the estimated useful lives of intangible assets. The amortization expense is recognized in the income statement in the expense category that is consistent with the function of the intangible asset. Intangible assets that are not available for use are amortized from the date they are available for use.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The estimated useful lives are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 80%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;"&gt;

		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 77%; text-align: justify; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product related intangibles&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: justify; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 18%; text-align: justify; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 &#x2013; 20&#160;years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="text-align: justify; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other intangibles&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 - 15&#160;years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

















































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amortization period and the amortization method for intangible assets with a finite useful life are reviewed at each reporting date. Changes in the expected useful lives or expected pattern of consumption of future economic benefits embodied in the assets are considered to modify the amortization period or method, as appropriate and are treated as change in accounting estimate.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill, intangible assets relating to products in development, other intangible assets not available for use and intangible assets having indefinite useful life are subject to impairment testing at each reporting date. All other intangible assets are tested for impairment when there are indications that the carrying value may not be recoverable. All impairment losses are recognized immediately in the consolidated income statement under &#x201c;Impairment of non-current assets&#x201d;.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;De-recognition of intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets are de-recognized either on their disposal or where no future economic benefits are expected from their use. Losses arising on such de-recognition are recorded in the consolidated income statement, and are measured as the difference between the net disposal proceeds, if any, and the carrying amount of respective intangible assets as at the date of de-recognition.&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0.25in; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DescriptionOfAccountingPolicyForIntangibleAssetsAndGoodwillExplanatory>
    <rdy:DisclosureOfUsefulLivesOrAmortisationRatesIntangibleAssetsOtherThanGoodwillTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The estimated useful lives are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 80%; border-collapse: collapse; border-spacing: 0px;;margin : 0px auto;;margin-left : auto;margin-right : auto;"&gt;

		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 77%; text-align: justify; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Product related intangibles&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 5%; text-align: justify; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 18%; text-align: justify; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 &#x2013; 20&#160;years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="text-align: justify; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other intangibles&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3 - 15&#160;years&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































</rdy:DisclosureOfUsefulLivesOrAmortisationRatesIntangibleAssetsOtherThanGoodwillTableTextBlock>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="P04_01_2021To03_31_2022_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">P20Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">P3Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill contextRef="P04_01_2021To03_31_2022_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis">P15Y</ifrs-full:UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;g. Leases&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;The Company assesses at contract inception whether a contract is or contains a lease, which applies if the contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration. The Company recognizes a right-of-use asset at the commencement date of the lease - i.e., the date the underlying asset is available for use. Assets and liabilities arising from a lease are initially measured on a present value basis.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities include the net present value of the following lease payments to be made over the lease term:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;fixed payments (including in-substance fixed payments), less any lease incentives receivable; &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;variable lease payment that are based on an index or a rate, initially measured using the index or rate as at the commencement date;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;amounts expected to be payable by the Company under residual value guarantees;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the exercise price of a purchase option if the Company is reasonably certain to exercise that option; and&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;payments of penalties for terminating the lease, if the lease term reflects the Company exercising that option.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Company, then the lessee&#x2019;s incremental borrowing rate is used. Such borrowing rate is calculated as the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions. The Company&#x2019;s lease liabilities are included in borrowings.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease payments are allocated between principal and interest cost. The interest cost is charged to consolidated income statement over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use assets are measured at cost less accumulated depreciation and accumulated impairment, comprised of the following:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the amount of the initial measurement of lease liability;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;any lease payments made at or before the commencement date less any lease incentives received; &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;any initial direct costs; and&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;restoration costs.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use assets are generally depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payments associated with short-term leases of equipment and vehicles and all leases of low-value assets are recognized on a straight-line basis as an expense in the consolidated income statement. Short-term leases are leases with a lease term of 12 months or less. Low-value assets comprise IT equipment and small items of office furniture.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The right-of-use assets are initially recognized on the statement of financial position at cost, which is calculated as the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received and any initial direct costs incurred by the Company.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;h. Inventories&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories are valued at the lower of cost and net realizable value.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories consist of raw materials, stores and spares, work in progress and finished goods. The cost of all categories of inventories is based on the weighted average method. Cost includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. In the case of finished goods and work in progress, cost includes an appropriate share of overheads based on normal operating capacity. Stores and spares consists of packing materials, engineering spares (such as machinery spare parts) and consumables (such as lubricants, cotton waste and oils), which are used in operating machines or consumed as indirect materials in the manufacturing process.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The factors that the Company considers in determining the provision for slow moving, obsolete and other non-saleable inventory include estimated shelf life, planned product discontinuances, price changes, aging of inventory and introduction of competitive new products, to the extent each of these factors impact the Company&#x2019;s business and markets. The Company considers all these factors and adjusts the inventory provision to reflect its actual experience on a periodic basis.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForMeasuringInventories>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;i. Impairment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Non-financial assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts of the Company&#x2019;s non-financial assets, other than inventories and deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset&#x2019;s recoverable amount is estimated. For goodwill and intangible assets that have indefinite lives or that are not yet available for use, an impairment test is performed each year at March&#160;31.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or the cash-generating unit. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generate cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the &#x201c;cash-generating unit&#x201d;).&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The goodwill acquired in a business combination is, for the purpose of impairment testing, allocated to cash-generating units that are expected to benefit from the synergies of the combination.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An impairment loss is recognized in the consolidated income statement if the estimated recoverable amount of an asset or its cash-generating unit is lower than its carrying amount. Impairment losses recognized in respect of cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to the units and then to reduce the carrying amount of the other assets in the unit on a pro-rata basis.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset&#x2019;s carrying amount does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. Goodwill that forms part of the carrying amount of an investment in a joint venture is not recognized separately, and therefore is not tested for impairment separately. Instead, the entire amount of the investment in a joint venture is tested for impairment as a single asset when there is objective evidence that the investment in a joint venture may be impaired.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An impairment loss in respect of equity accounted investee is measured by comparing the recoverable amount of investment with its carrying amount. An impairment loss is recognized in the consolidated income statement, and reversed if there has been a favorable change in the estimates used to determine the recoverable amount.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;j. Employee benefits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Short-term employee benefits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Defined contribution plans&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; background-color: white; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s contributions to defined contribution plans are charged to the consolidated income statement as and when the services are received from the employees.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Defined benefit plans&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The liability in respect of defined benefit plans and other post-employment benefits is calculated using the projected unit credit method consistent with the advice of qualified actuaries. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating to the terms of the related defined benefit obligation. In countries where there is no deep market in such bonds, the market interest rates on government bonds are used. The current service cost of the defined benefit plan, recognized in the consolidated income statement, reflects the increase in the defined benefit obligation resulting from employee service in the current year, benefit changes, curtailments and settlements. Past service costs are recognized immediately in the consolidated income statement. The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in the consolidated income statement. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions for defined benefit obligation and plan assets are recognized in OCI in the period in which they arise.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;When the benefits under a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service or the gain or loss on curtailment is recognized immediately in the consolidated income statement. The Company recognizes gains or losses on the settlement of a defined benefit plan obligation when the settlement occurs.&lt;/div&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Termination benefits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Termination benefits are recognized as an expense in the consolidated income statement when the Company is demonstrably committed, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. Termination benefits for voluntary redundancies are recognized as an expense in the consolidated income statement if the Company has made an offer encouraging voluntary redundancy, it is probable that the offer will be accepted, and the number of acceptances can be estimated reliably.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other long-term employee benefits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s net obligation in respect of other long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and previous periods. That benefit is discounted to determine its present value. Re-measurements are recognized in the consolidated income statement in the period in which they arise.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensated absences&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s current policies permit certain categories of its employees to accumulate and carry forward a portion of their unutilized compensated absences and utilize them in future periods or receive cash in lieu thereof in accordance with the terms of such policies. The Company measures the expected cost of accumulating compensated absences as the additional amount that the Company incurs as a result of the unused entitlement that has accumulated at the reporting date. Such measurement is based on actuarial valuation as at the reporting date carried out by a qualified actuary.&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;k. Share based payments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Equity settled share-based payment transactions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The grant date fair value of options granted to employees is recognized as an expense in the consolidated income statement, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the options. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet the related service and performance conditions at the vesting date. The expense is recorded for each separately vesting portion of the award as if the award was, in substance, multiple awards. The increase in equity recognized in connection with share-based payment transaction is presented as a separate component in equity under &#x201c;share-based payment reserve&#x201d;. The amount recognized as an expense is adjusted to reflect the actual number of stock options that vest.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash settled share-based payment transactions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the amount payable to employees in respect of share-based payment transactions which are settled in cash is recognized as an expense, with a corresponding increase in liabilities, over the period during which the employees become unconditionally entitled to payment. The liability is re-measured at each reporting date and at the settlement date based on the fair value of the share-based payment transaction. Any changes in the liability are recognized in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;l. Provisions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A provision is recognized in the consolidated income statement if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restructuring&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A provision for restructuring is recognized in the consolidated income statement when the Company has approved a detailed and formal restructuring plan, and the restructuring either has commenced or has been announced publicly. Future operating costs are not provided.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Onerous contracts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A provision for onerous contracts is recognized in the consolidated income statement when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Company recognizes any impairment loss on the assets associated with that contract.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Reimbursement rights&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected reimbursements for expenditures required to settle a provision are recognized in the consolidated income statement only when receipt of such reimbursements is virtually certain. Such reimbursements are recognized as a separate asset in the statement of financial position, with a corresponding credit to the specific expense for which the provision has been made.&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;br/&gt;&lt;/div&gt;






&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Contingent liabilities and contingent assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent assets are not recognized in the financial statements. A contingent asset is disclosed where an inflow of economic benefits is probable. Contingent assets are assessed continually and, if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognized in the period in which the change occurs.&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DescriptionOfAccountingPolicyForProvisionsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;m. Revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s revenue is derived from sales of goods, service income and income from licensing arrangements. Most of such revenue is generated from the sale of goods. The Company has generally concluded that it is the principal in its revenue arrangements.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue is recognized when the control of the goods has been transferred to a third party. This is usually when the title passes to the customer, either upon shipment or upon receipt of goods by the customer. At that point, the customer has full discretion over the channel and price to sell the products, and there are no unfulfilled obligations that could affect the customer&#x2019;s acceptance of the product.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from the sale of goods is measured at the transaction price which is the consideration received or receivable, net of returns, taxes and applicable trade discounts and allowances. Revenue includes shipping and handling costs billed to the customer.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In arriving at the transaction price, the Company considers the terms of the contract with the customers and its customary business practices. The transaction price is the amount of consideration the Company is entitled to receive in exchange for transferring promised goods or services, excluding amounts collected on behalf of third parties. The amount of consideration varies because of estimated rebates, returns and chargebacks, which are considered to be key estimates. Any amount of variable consideration is recognized as revenue only to the extent that it is highly probable that a significant reversal will not occur. The Company estimates the amount of variable consideration using the expected value method.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Presented below are the points of recognition of revenue with respect to the Company&#x2019;s sale of goods:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 25%; text-align: justify; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: justify; padding-bottom: 0.5pt;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 74%; text-align: justify; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;Point of recognition of revenue&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sales of generic products in India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon delivery of products to distributors by clearing and forwarding agents of the Company. Control over the generic products is transferred by the Company when the goods are delivered to distributors from clearing and forwarding agents. &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sales of active pharmaceutical ingredients and intermediates in India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon delivery of products to customers (generally formulation manufacturers), from the factories of the Company.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Export sales and other sales outside of India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon delivery of the products to the customers unless the terms of the applicable contract provide for specific revenue generating activities to be completed, in which case revenue is recognized once all such activities are completed.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Profit share revenues&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company from time to time enters into marketing arrangements with certain business partners for the sale of its products in certain markets. Under such arrangements, the Company sells its products to the business partners at a non-refundable base purchase price agreed upon in the arrangement and is also entitled to a profit share which is over and above the base purchase price. The profit share is typically dependent on the business partner&#x2019;s ultimate net sale proceeds or net profits, subject to any reductions or adjustments that are required by the terms of the arrangement. Such arrangements typically require the business partner to provide confirmation of units sold and net sales or net profit computations for the products covered under the arrangement.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue in an amount equal to the base sale price is recognized in these transactions upon delivery of products to the business partners. An additional amount representing the profit share component is recognized as revenue only to the extent that it is highly probable that a significant reversal will not occur.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At the end of each reporting period, the Company updates the estimated transaction price (including updating its assessment of whether an estimate of variable consideration is constrained) to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period.&lt;/div&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Out licensing arrangements, milestone payments and royalties&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues include amounts derived from product out-licensing agreements. These arrangements typically consist of an initial up-front payment &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;received&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;on inception of the license and subsequent payments dependent on achieving certain milestones in accordance with the terms prescribed in the agreement. In cases where the transaction has two or more &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;performance obligations,&lt;/div&gt; the Company accounts for the &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;completed obligation&lt;/div&gt; (for example&#160;the transfer of title) as a separate unit of accounting and record revenue upon delivery of that component, provided that the Company can make a reasonable estimate of the fair value of the undelivered component. Otherwise, non-refundable up-front license fees received in connection with product out-licensing agreements are deferred and recognized over the balance period in which the Company has pending performance obligations. Milestone payments which are contingent on achieving certain clinical milestones are recognized as revenues either on achievement of such milestones, over the performance period depending on the terms of the contract. If milestone payments are creditable against future royalty payments, the milestones are deferred and released over the period in which the royalties are anticipated to be paid.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Royalty income earned through a license is recognized when the underlying sales have occurred.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Provision for chargeback, rebates and discounts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provisions for chargeback, rebates, discounts and Medicaid payments are estimated and provided for in the year of sales and recorded as reduction of revenue. A chargeback claim is a claim made by the wholesaler for the difference between the price at which the product is initially invoiced to the wholesaler and the net price at which it is agreed to be procured from the Company. Provisions for such chargebacks are accrued and estimated based on historical average chargeback rate actually claimed over a period of time, current contract prices with wholesalers/other customers and estimated inventory holding by the wholesaler.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Shelf stock adjustments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shelf stock adjustments are credits issued to customers to reflect decreases in the selling price of products sold by the Company, and are accrued when the prices of certain products decline as a result of increased competition or otherwise. These credits are customary in the pharmaceutical industry, and are intended to reduce the customer inventory cost to better reflect the current market prices. The determination to grant a shelf stock adjustment to a customer is based on the terms of the applicable contract, which may or may not specifically limit the age of the stock on which a credit would be offered.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Refund Liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for sales returns accrual by recording refund liability concurrent with the recognition of revenue at the time of a product sale. This liability is based on the Company&#x2019;s estimate of expected sales returns. The Company deals in various products and operates in various markets. Accordingly, the estimate of sales returns is determined primarily by the Company&#x2019;s historical experience in the markets in which the Company operates. With respect to established products, the Company considers its historical experience of actual sales returns, levels of inventory in the distribution channel, estimated shelf life, any revision in the shelf life of the product, product discontinuances, price changes of competitive products, and the introduction of competitive new products, to the extent each of these factors impact the Company&#x2019;s business and markets. With respect to new products introduced by the Company, such products have historically been either extensions of an existing line of product where the Company has historical experience or in therapeutic categories where established products exist and are sold either by the Company or the Company&#x2019;s competitors. At the time of recognizing the refund liability, the Company also recognizes an asset, (i.e., the right to the returned goods) which is included in inventories for the products expected to be returned. The Company initially measures this asset at the former carrying amount of the inventory, less any expected costs to recover the goods, including any potential decreases in the value of the returned goods.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Along with re-measuring the refund liability at the end of each reporting period, the Company updates the measurement of the asset recorded for any revisions to its expected level of returns, as well as any additional decreases in the value of the returned products.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Services&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from services rendered, which primarily relate to contract research, is recognized in the consolidated income statement as the underlying services are performed. Upfront non-refundable payments received under these arrangements are deferred and recognized as revenue over the expected period over which the related services are expected to be performed.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;License fees&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License fees primarily consist of income from the out-licensing of intellectual property, and other licensing and supply arrangements with various parties. Revenue from license fees is recognized when control transfers to the third party and the Company&#x2019;s performance obligations are satisfied. Some of these arrangements include certain performance obligations by the Company. Revenue from such arrangements is recognized in the period in which the Company completes all its performance obligations.&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <rdy:DescriptionOfAccountingPolicyForShippingAndHandlingCostTextBlockTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;n. Shipping and handling costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shipping and handling costs incurred to transport products to customers, and internal transfer costs incurred to transport the products from the Company&#x2019;s factories to its various points of sale, are included in selling, general and administrative expenses.&lt;/div&gt;&lt;/div&gt;</rdy:DescriptionOfAccountingPolicyForShippingAndHandlingCostTextBlockTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;o. Finance income and expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance income consists of interest income on funds invested, dividend income and gains on the disposal of financial assets. Interest income is recognized in the consolidated income statement as it accrues, using the effective interest method. Dividend income is recognized in the consolidated income statement on the date that the Company&#x2019;s right to receive payment is established. The associated cash flows are classified as investing activities in the statement of cash flows. Finance expenses consist of interest expense on loans and borrowings.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Borrowing costs are recognized in the consolidated income statement using the effective interest method. The associated cash flows are classified as financing activities in the statement of cash flows.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign currency gains and losses are reported on a net basis within finance income and expense. These primarily include: exchange differences arising on the settlement or translation of monetary items; changes in the fair value of derivative contracts that economically hedge monetary assets and liabilities in foreign currencies and for which no hedge accounting is applied; and the ineffective portion of cash flow hedges.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;p. Income tax&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax expense consists of current and deferred tax. Income tax expense is recognized in the consolidated income statement except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax is recognized using the balance sheet method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities are recogni&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;z&lt;/div&gt;ed for all taxable temporary differences, except:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 17.45pt; font-size: 0px;"/&gt;
			&lt;td style="width: 18pt;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit; &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 17.45pt; font-size: 0px;"/&gt;
			&lt;td style="width: 18pt;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;temporary differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future; and &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 17.45pt; font-size: 0px;"/&gt;
			&lt;td style="width: 18pt;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;taxable temporary differences arising upon the initial recognition of goodwill. &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets are recogni&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;z&lt;/div&gt;ed for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recogni&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;z&lt;/div&gt;ed to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utili&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;z&lt;/div&gt;ed, except:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&#x2022;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;When the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;and&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&#x2022;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;In respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, deferred tax assets are recogni&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;z&lt;/div&gt;ed only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Any deferred tax asset or liability arising from deductible or taxable temporary differences in respect of unrealized inter-company profit or loss on inventories held by the Company in different tax jurisdictions is recognized using the tax rate of the jurisdiction in which such inventories are held. Withholding tax arising out of payment of dividends to shareholders under the Indian Income tax regulations is not considered a&#160;tax expense for the Company and all such taxes are recognized in the statement of changes in equity as part of the associated dividend payment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax is measured at the tax rates that are expected to be applied to the temporary differences when they reverse, based on the laws that have been enacted or substantively enacted at the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously.&lt;/div&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current and deferred tax is recognized in the consolidated income statement, except to the extent that it relates to items recognized in OCI or directly in equity. In this case, the tax is also recognized in OCI or directly in equity, respectively.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accruals for uncertain tax positions require management to make judgments of potential exposures. Accruals for uncertain tax positions are measured using either the most likely amount or the expected value amount, depending on which method the entity expects to better predict the resolution of the uncertainty. Tax benefits are not recognized unless the tax positions will probably be accepted by the tax authorities. This is based upon management&#x2019;s interpretation of applicable laws and regulations and the expectation of how the tax authority will resolve the matter. Once considered probable of not being accepted, management reviews each material tax benefit and reflects the effect of the uncertainty in determining the related taxable amounts.&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;q. Earnings per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company presents basic and diluted earnings per share (&#x201c;EPS&#x201d;) data for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding for the effects of all dilutive potential ordinary shares, which includes all stock options granted to employees.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;r. Government grants and incentives&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes government grants only when there is reasonable assurance that the conditions attached to them will be complied with, and the grants will be received. Government grants received in relation to assets are presented as a reduction to the carrying amount of the related asset. Grants related to income are deducted in reporting the related expense in the consolidated income statement.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Export entitlements from government authorities are recognized in the consolidated income statement as a reduction from &#x201c;Cost of Revenues&#x201d; when the right to receive credit as per the terms of the scheme is established in respect of the exports made by the Company, and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;s. Segment reporting&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The Chief Executive Officer of the Company is responsible for allocating resources and assessing performance of the operating segments and accordingly is identified as the chief operating decision maker.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;t. Treasury shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Own equity instruments that are reacquired (treasury shares) are recognized at cost and deducted from equity. No gain or loss is recognized in the consolidated income statement on the purchase, sale, issue or cancellation of the Company&#x2019;s own equity instruments. Any difference between the carrying amount and the consideration, if reissued, is recognized in the share premium.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForTreasurySharesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;u. Non-currents assets held for sale&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company classifies non-current assets and disposal groups as held for sale if their carrying amounts will be recovered principally through a sale transaction rather than through continuing use. Non-current assets classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell. Costs to sell are the incremental costs directly attributable to the disposal of an asset, excluding finance costs and income tax expense. The criteria for held for sale classification is regarded as met only when the sale is highly probable, and the asset or disposal group is available for immediate sale in its present condition. Property, plant and equipment are not depreciated or amortized once classified as held for sale. Assets classified as held for sale are presented separately as current items in the statement of financial position.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleExplanatory>
    <rdy:RoundingOfAmountsPolicyTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;v. Rounding of amounts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 14.2pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All amounts disclosed in the consolidated financial statements and notes have been rounded off to the nearest million currency units unless otherwise stated.&lt;/div&gt;&lt;/div&gt;</rdy:RoundingOfAmountsPolicyTextBlock>
    <ifrs-full:DisclosureOfFairValueMeasurementExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Determination of fair values &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s accounting policies and disclosures require the determination of fair value, for certain financial and non-financial assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following methods. When applicable, further information about the assumptions made in determining fair values is disclosed in the notes specific to that asset or liability.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability or in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Company.&lt;/div&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 1 &#x2014; Quoted (unadjusted) market prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 2 &#x2014; Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable. &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 3 &#x2014; Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable. &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;External valuers are involved for valuation of significant assets, such as assets acquired in a business combination and significant liabilities, such as contingent consideration. Involvement of external valuers is determined by the Management, based on market knowledge, reputation, independence and whether professional standards are maintained.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(i) Property, plant and equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, plant and equipment, if acquired in a business combination or through an exchange of non-monetary assets, is measured at fair value on the acquisition date. For this purpose, fair value is based on appraised market values and replacement cost.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(ii) Intangible assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of brands, technology related intangibles, and patents and trademarks acquired in a business combination is based on the discounted estimated royalty payments that have been avoided as a result of these brands, technology related intangibles, patents or trademarks being owned (the &#x201c;relief of royalty method&#x201d;). The fair value of customer related, product related and other intangibles acquired in a business combination has been determined using the multi-period excess earnings method. Under this method, value is estimated as the present value of the benefits anticipated from ownership of the intangible assets in excess of the returns required or the investment in the contributory assets necessary to realize those benefits.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(iii) Inventories &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of inventories acquired in a business combination is determined based on its estimated selling price in the ordinary course of business less the estimated costs of completion and sale, and a reasonable profit margin based on the effort required to complete and sell the inventories.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(iv) Investment&#160;in equity and debt securities and units of mutual funds &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of marketable equity and debt securities is determined by reference to their quoted market price at the reporting date. For debt securities where quoted market prices are not available, fair value is determined using pricing techniques such as discounted cash flow analysis.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In respect of investments in mutual funds, the fair values represent net asset value as stated by the issuers of these mutual fund units in the published statements. Net asset values represent the price at which the issuer will issue further units in the mutual fund and the price at which issuers will redeem such units from the investors.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accordingly, such net asset values are analogous to fair market value with respect to these investments, as transactions of these mutual funds are carried out at such prices between investors and the issuers of these units of mutual funds.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(v) Derivatives &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of foreign exchange forward contracts is estimated by discounting the difference between the contractual forward price and the current forward price for the residual maturity of the contract using a risk-free interest rate (based on government bonds). The fair value of foreign currency option and swap contracts and interest rate swap contracts is determined based on the appropriate valuation techniques, considering the terms of the contract.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(vi) Non-derivative financial liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value, which is determined for disclosure purposes, is calculated based on the present value of future principal and interest cash flows, discounted at the market rate of interest at the reporting date. For finance leases the market rate of interest is determined by reference to similar lease agreements. In respect of the Company&#x2019;s borrowings that have floating rates of interest, their fair value approximates carrying value.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(vii) Share-based payment transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of employee stock options is measured using the Black-Scholes-Merton valuation model. Measurement inputs include share price on grant date, exercise price of the instrument, expected volatility (based on weighted average historical volatility), expected life of the instrument (based on historical experience), expected dividends, and the risk free interest rate (based on government bonds).&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(viii) Contingent consideration&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the contingent consideration arising out of business combination is estimated by applying the income approach. The fair value measurement is based on significant inputs that are not observable in the market, which IFRS 13, &lt;div style="font-style:italic;display:inline;"&gt;&#x201c;Fair Value Measurement&#x201d;&lt;/div&gt; refers to as Level 3 inputs.&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DisclosureOfFairValueMeasurementExplanatory>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5. Segment reporting&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 27pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Chief Operating Decision Maker (&#x201c;CODM&#x201d;) evaluates the Company&#x2019;s performance and allocates resources based on an analysis of various performance indicators by operating segments. The CODM reviews revenue and gross profit as the performance indicator for all of the operating segments, and does not review the total assets and liabilities of an operating segment. &lt;/div&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Co-Chairman and Managing Director was previously the CODM of the Company. Pursuant to certain organizational changes, effective December 1, 2020, the office of Chief Executive Officer (&#x201c;CEO&#x201d;) assumed the authority and responsibility for making decisions about resources to be allocated to various segments and assessing their performance. Consequently, the CEO is currently the CODM of the Company.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s reportable operating segments are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Global Generics;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Pharmaceutical Services and Active Ingredients (&#x201c;PSAI&#x201d;);&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Proprietary Products; and&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&#x2022;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Others.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 27.35pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0in; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Global Generics.&lt;/div&gt;&lt;/div&gt; This segment consists of the Company&#x2019;s business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of the Company&#x2019;s biologics business.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0pt 0in; text-align: justify; text-indent: 0.25in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pharmaceutical Services and Active Ingredients&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;. This segment primarily consists of the Company&#x2019;s business of manufacturing and marketing active pharmaceutical ingredients and intermediates, also known as &#x201c;API&#x201d;, which are the principal ingredients for finished pharmaceutical products. Active pharmaceutical ingredients and intermediates become finished pharmaceutical products when the dosages are fixed in a form ready for human consumption such as a tablet, capsule or liquid using additional inactive ingredients. The Company also serves its customers with incremental value added products including semi-finished and finished formulations, which are included in this segment. This segment also includes the Company&#x2019;s contract research services business and its manufacture and sale of active pharmaceutical ingredients and steroids in accordance with the specific customer requirements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="margin: 0pt 0in; text-align: justify; text-indent: 0.25in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="margin: 0pt 0in; text-align: justify; text-indent: 0.25in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-style:italic;display:inline;"&gt;Proprietary Products.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0.5in; top: 0px;;display:inline;"&gt; This segment consists of the Company&#x2019;s business that focuses on the research and development of differentiated formulations. The segment is expected to earn revenues arising out of monetization of such assets and subsequent royalties, if any.&lt;/div&gt;&lt;/div&gt;
&lt;div style="margin: 0in -7pt 0pt 0in; text-align: justify; text-indent: 0.25in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Others. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;This segment consists of the Company&#x2019;s other business operations which includes its wholly-owned subsidiaries, Aurigene Discovery Technologies Limited (&#x201c;ADTL&#x201d;) and SVAAS Wellness Limited (&#x201c;SVAAS&#x201d;). ADTL is a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation. ADTL works with established pharmaceutical and biotechnology companies through customized models of drug-discovery collaborations. SVAAS is in the business of providing digital healthcare and information technology enabled business support services.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The measurement of each segment&#x2019;s revenues, expenses and assets is consistent with the accounting policies that are used in preparation of the Company&#x2019;s consolidated financial statements.&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="33" style="text-align: center; font-weight: normal; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Segment information:&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="9" style="text-align: center; font-weight: normal; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Global Generics&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="9" style="text-align: center; font-weight: normal; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PSAI&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="9" style="text-align: center; font-weight: normal; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Proprietary Products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reportable segments&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;179,170&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;154,404&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;138,123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30,740&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31,982&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; font-weight: normal;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25,747&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; font-weight: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,611&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;523&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,949&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;103,270&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;91,111&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;78,449&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,821&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,426&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,190&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,590&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;482&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,744&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Selling, general and administrative expenses&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Research and development expenses&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Impairment of &lt;br/&gt; non-current assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Other income, net&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Results from operating activities&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Finance income, net&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Share of profit of equity accounted investees, net of tax&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit before tax&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Tax expense/(benefit), net&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit for the year&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Segment information:&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="22" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reportable segments&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Others&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,870&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,813&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,781&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;214,391&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;189,722&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;174,600&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,159&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,058&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,626&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;113,840&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;103,077&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;94,009&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 22%; text-align: left;"&gt;Selling, general and administrative expenses&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;62,081&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;54,650&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;50,129&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Research and development expenses&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;17,482&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;16,541&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15,410&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Impairment of non-current assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,562&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;8,588&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;16,767&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;Other income, net&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 0.75pt solid black;"&gt;(2,761&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 0.75pt solid black;"&gt;(982&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 0.75pt solid black;"&gt;(4,290&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Results from operating activities&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,476&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,280&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,993&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Finance income, net&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,119&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,653&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,478&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Share of profit of equity accounted investees, net of tax&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;703&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;480&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;561&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit before tax&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;32,298&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;26,413&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;18,032&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Tax expense/(benefit), net&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;8,730&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;9,175&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,466&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit for the year&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;23,568&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17,238&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,498&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 13.7pt; text-align: justify; text-indent: -13.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Revenues for the year ended March 31, 2022 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,255 (as compared to Rs. 6,905 and Rs. 5,910 for the years ended March 31, 2021 and 2020, respectively).&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



















































 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues within the Global Generics segment:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues by therapeutic areas in the Company&#x2019;s Global Generics segment is given below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Nervous System&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;26,159&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,040&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;26,825&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 61%;"&gt;Gastrointestinal&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;23,386&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;21,132&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;19,394&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 61%; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Anti-Infective&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;22,526&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,906&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,402&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 61%; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pain Management&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;18,437&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,531&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13,808&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;Oncology&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;17,051&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;16,842&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;18,245&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-indent: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Respiratory&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;15,085&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;11,089&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;10,433&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; text-indent: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cardiovascular&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;14,856&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;15,460&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;14,729&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-indent: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hematology&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;11,737&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4,959&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4,725&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-indent: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dermatology&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;6,797&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;5,240&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;3,255&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nutraceutical&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,530&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,059&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="font-size: 9pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,441&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;18,606&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;18,146&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;13,866&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;179,170&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;154,404&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;138,123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;




















































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues within the PSAI segment:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues by therapeutic areas in the Company&#x2019;s PSAI segment is given below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;Cardiovascular&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font: 10pt 'Times New Roman', Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;7,729&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font: 10pt 'Times New Roman', Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;9,834&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font: 10pt 'Times New Roman', Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;8,567&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 61%; text-align: left; text-indent: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Anti-Infective&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;5,450&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4,126&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,264&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-indent: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pain Management&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;4,513&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;4,657&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;5,073&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Nervous System&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;3,017&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,704&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,797&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;Oncology&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;2,526&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;2,385&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;1,798&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="text-indent: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Gastrointestinal&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;982&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;1,098&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;705&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Genitourinary&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;705&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;825&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;441&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Respiratory&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;676&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;1,317&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;789&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="text-indent: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Diabetology&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;544&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;350&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;168&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dermatology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;498&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;768&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;1,370&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;4,100&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;3,918&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;1,775&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30,740&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31,982&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25,747&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;




















































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues by geography:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9.35pt; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows the distribution of the Company&#x2019;s revenues by country, based on the location of the customers:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9.35pt; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Country&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;India&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;43,986&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36,252&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;32,089&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 61%; text-align: left;"&gt;United States&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;80,564&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;76,702&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;76,028&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Russia&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;20,879&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15,816&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;16,900&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;68,962&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;60,952&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;49,583&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;214,391&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;189,722&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;174,600&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;
























































&lt;div style="clear: both; max-height: 0px;"/&gt;





&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Others include Germany, the United Kingdom, Ukraine, China, Canada and other countries across the world.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



















































&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: left; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;A&lt;/div&gt;ssets by geography:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.2in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows the distribution of the Company&#x2019;s non-current assets (other than financial instruments and deferred tax assets) by country, based on the location of assets:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Country&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%;"&gt;India&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;83,166&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;75,284&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Switzerland&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,748&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;11,661&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;United States&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,851&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,627&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Germany&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,263&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,087&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5,244&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5,109&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;98,272&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;100,768&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

























































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows the distribution of the Company&#x2019;s property, plant and equipment including capital work in progress and intangible assets acquired during the year (other than goodwill arising on business combination) by country, based on the location of assets:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Country&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%;"&gt;India&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;15,580&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;27,882&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Switzerland&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;195&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,760&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;United States&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;260&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,158&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,198&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,031&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17,233&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;34,831&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

























































&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 7.4pt; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;D&lt;/div&gt;epreciation and amortization, included in cost of revenues, by reportable segments:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%; text-align: left;"&gt;Global Generics&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,078&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,435&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,666&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;PSAI&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,507&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,578&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,804&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Proprietary Products&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;42&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;48&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;71&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,627&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,061&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,541&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

























































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.1in; text-align: justify; text-indent: -20.7pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Information about major customers&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 20.7pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;Revenues from two customers of the Company's Global Generics segment were Rs.20,596 and Rs.10,339&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; &lt;/div&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;representing approximately&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;&#160;10% and 5%, respectively, of the Company&#x2019;s total revenues for the year ended March 31, 2022.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues from two customers of the Company's Global Generics segment were Rs.19,341 and Rs.9,867, representing approximately 10% and 5%, respectively, of the Company&#x2019;s total revenues for the year ended March 31, 2021.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues from two customers of the Company's Global Generics segment were Rs.14,164 and Rs.9,267, representing approximately 8% and 5%, respectively, of the Company&#x2019;s total revenues for the year ended March 31, 2020.&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <rdy:DisclosureOfOperatingSegmentsTableTextBlock contextRef="P04_01_2021To03_31_2022">
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="33" style="text-align: center; font-weight: normal; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Segment information:&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="9" style="text-align: center; font-weight: normal; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Global Generics&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="9" style="text-align: center; font-weight: normal; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PSAI&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="9" style="text-align: center; font-weight: normal; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Proprietary Products&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reportable segments&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;179,170&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;154,404&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;138,123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30,740&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31,982&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; font-weight: normal;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25,747&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; font-weight: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,611&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;523&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,949&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;103,270&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;91,111&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;78,449&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,821&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,426&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,190&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,590&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;482&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,744&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Selling, general and administrative expenses&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Research and development expenses&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Impairment of &lt;br/&gt; non-current assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Other income, net&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Results from operating activities&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Finance income, net&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Share of profit of equity accounted investees, net of tax&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit before tax&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Tax expense/(benefit), net&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit for the year&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Segment information:&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="22" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reportable segments&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Others&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,870&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,813&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,781&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;214,391&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;189,722&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;174,600&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross profit&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,159&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,058&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,626&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;113,840&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;103,077&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;94,009&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 22%; text-align: left;"&gt;Selling, general and administrative expenses&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;62,081&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;54,650&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;50,129&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Research and development expenses&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;17,482&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;16,541&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15,410&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Impairment of non-current assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,562&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;8,588&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;16,767&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;Other income, net&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 0.75pt solid black;"&gt;(2,761&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 0.75pt solid black;"&gt;(982&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 0.75pt solid black;"&gt;(4,290&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Results from operating activities&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,476&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,280&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,993&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Finance income, net&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,119&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,653&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,478&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Share of profit of equity accounted investees, net of tax&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;703&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;480&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;561&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit before tax&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;32,298&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;26,413&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;18,032&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Tax expense/(benefit), net&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;8,730&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;9,175&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,466&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit for the year&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;23,568&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17,238&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;19,498&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 13.7pt; text-align: justify; text-indent: -13.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Revenues for the year ended March 31, 2022 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,255 (as compared to Rs. 6,905 and Rs. 5,910 for the years ended March 31, 2021 and 2020, respectively).&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



















































</rdy:DisclosureOfOperatingSegmentsTableTextBlock>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      id="Fact_50535376"
      unitRef="Unit_INR">179170000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      id="Fact_50535377"
      unitRef="Unit_INR">154404000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      id="Fact_50535378"
      unitRef="Unit_INR">138123000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_PharmaceuticalServicesAndActiveIngredientsMemberifrsfullSegmentsAxis"
      decimals="-6"
      id="Fact_50535385"
      unitRef="Unit_INR">30740000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_PharmaceuticalServicesAndActiveIngredientsMemberifrsfullSegmentsAxis"
      decimals="-6"
      id="Fact_50535386"
      unitRef="Unit_INR">31982000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_PharmaceuticalServicesAndActiveIngredientsMemberifrsfullSegmentsAxis"
      decimals="-6"
      id="Fact_50535387"
      unitRef="Unit_INR">25747000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_ProprietaryProductMemberifrsfullSegmentsAxis"
      decimals="-6"
      id="Fact_50535388"
      unitRef="Unit_INR">1611000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_ProprietaryProductMemberifrsfullSegmentsAxis"
      decimals="-6"
      id="Fact_50535389"
      unitRef="Unit_INR">523000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_ProprietaryProductMemberifrsfullSegmentsAxis"
      decimals="-6"
      id="Fact_50535390"
      unitRef="Unit_INR">7949000000</ifrs-full:Revenue>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">103270000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">91111000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">78449000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2021To03_31_2022_PharmaceuticalServicesAndActiveIngredientsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">6821000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2020To03_31_2021_PharmaceuticalServicesAndActiveIngredientsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">9426000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2019To03_31_2020_PharmaceuticalServicesAndActiveIngredientsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">6190000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2021To03_31_2022_ProprietaryProductMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">1590000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2020To03_31_2021_ProprietaryProductMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">482000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2019To03_31_2020_ProprietaryProductMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">7744000000</ifrs-full:GrossProfit>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_OtherSegmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      id="Fact_50535370"
      unitRef="Unit_INR">2870000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_OtherSegmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      id="Fact_50535371"
      unitRef="Unit_INR">2813000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_OtherSegmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      id="Fact_50535372"
      unitRef="Unit_INR">2781000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      id="Fact_50535373"
      unitRef="Unit_INR">214391000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      id="Fact_50535374"
      unitRef="Unit_INR">189722000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      id="Fact_50535375"
      unitRef="Unit_INR">174600000000</ifrs-full:Revenue>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2021To03_31_2022_OtherSegmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2159000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2020To03_31_2021_OtherSegmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2058000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2019To03_31_2020_OtherSegmentMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">1626000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">113840000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">103077000000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">94009000000</ifrs-full:GrossProfit>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">62081000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">54650000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">50129000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">17482000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">16541000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">15410000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">7562000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">8588000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">16767000000</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLoss>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2761000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">982000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">4290000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">29476000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">24280000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">15993000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncomeCost
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2119000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1653000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">1478000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">703000000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">480000000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">561000000</ifrs-full:ShareOfProfitLossOfJointVenturesAccountedForUsingEquityMethod>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">32298000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">26413000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">18032000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">8730000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">9175000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-1466000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">23568000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">17238000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">19498000000</ifrs-full:ProfitLoss>
    <rdy:IntersegmentRevenuesFromPsaiToGlobalGeneric
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">6255000000</rdy:IntersegmentRevenuesFromPsaiToGlobalGeneric>
    <rdy:IntersegmentRevenuesFromPsaiToGlobalGeneric
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">6905000000</rdy:IntersegmentRevenuesFromPsaiToGlobalGeneric>
    <rdy:IntersegmentRevenuesFromPsaiToGlobalGeneric
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">5910000000</rdy:IntersegmentRevenuesFromPsaiToGlobalGeneric>
    <rdy:DisclosureAndDetailsAboutRevenueWithInGlobalGenericSegmentsTableTextBlock contextRef="P04_01_2021To03_31_2022_ReportableSegmentsMemberifrsfullSegmentsAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues within the Global Generics segment:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues by therapeutic areas in the Company&#x2019;s Global Generics segment is given below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Nervous System&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;26,159&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,040&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;26,825&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 61%;"&gt;Gastrointestinal&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;23,386&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;21,132&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;19,394&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 61%; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Anti-Infective&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;22,526&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;12,906&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,402&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 61%; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pain Management&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;18,437&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;15,531&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13,808&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;Oncology&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;17,051&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;16,842&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;18,245&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-indent: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Respiratory&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;15,085&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;11,089&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;10,433&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; text-indent: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cardiovascular&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;14,856&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;15,460&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;14,729&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-indent: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hematology&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;11,737&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4,959&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4,725&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-indent: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dermatology&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;6,797&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;5,240&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;3,255&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nutraceutical&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,530&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,059&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="font-size: 9pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,441&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;18,606&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;18,146&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;13,866&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;179,170&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;154,404&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;138,123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































</rdy:DisclosureAndDetailsAboutRevenueWithInGlobalGenericSegmentsTableTextBlock>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_CentralNervousSystemMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">26159000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_CentralNervousSystemMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">29040000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_CentralNervousSystemMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">26825000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GastrointestinalMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">23386000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GastrointestinalMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">21132000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GastrointestinalMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">19394000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_AntiinfectiveMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">22526000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_AntiinfectiveMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">12906000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_AntiinfectiveMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">9402000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GlobalGenericMemberifrsfullSegmentsAxis_PainManagementMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">18437000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GlobalGenericMemberifrsfullSegmentsAxis_PainManagementMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">15531000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GlobalGenericMemberifrsfullSegmentsAxis_PainManagementMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">13808000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GlobalGenericMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">17051000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GlobalGenericMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">16842000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GlobalGenericMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">18245000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GlobalGenericMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">15085000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GlobalGenericMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">11089000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GlobalGenericMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">10433000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_CardiovascularMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">14856000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_CardiovascularMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">15460000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_CardiovascularMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">14729000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GlobalGenericMemberifrsfullSegmentsAxis_HematologyMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">11737000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GlobalGenericMemberifrsfullSegmentsAxis_HematologyMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">4959000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GlobalGenericMemberifrsfullSegmentsAxis_HematologyMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">4725000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_DermatologyMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">6797000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_DermatologyMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">5240000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_DermatologyMemberifrsfullProductsAndServicesAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">3255000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GlobalGenericMemberifrsfullSegmentsAxis_NutraceuticalMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">4530000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GlobalGenericMemberifrsfullSegmentsAxis_NutraceuticalMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">4059000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GlobalGenericMemberifrsfullSegmentsAxis_NutraceuticalMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">3441000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GlobalGenericMemberifrsfullSegmentsAxis_OtherGlobalGenericsMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">18606000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GlobalGenericMemberifrsfullSegmentsAxis_OtherGlobalGenericsMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">18146000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GlobalGenericMemberifrsfullSegmentsAxis_OtherGlobalGenericsMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">13866000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">179170000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">154404000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">138123000000</ifrs-full:Revenue>
    <rdy:DisclosureAndDetailsAboutRevenueFromTherapeuticsAreasTableTextBlock contextRef="P04_01_2021To03_31_2022_ReportableSegmentsMemberifrsfullSegmentsAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues within the PSAI segment:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues by therapeutic areas in the Company&#x2019;s PSAI segment is given below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;Cardiovascular&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font: 10pt 'Times New Roman', Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;7,729&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font: 10pt 'Times New Roman', Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;9,834&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font: 10pt 'Times New Roman', Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;8,567&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 61%; text-align: left; text-indent: 0px; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Anti-Infective&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;5,450&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4,126&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,264&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-indent: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pain Management&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;4,513&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;4,657&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;5,073&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Nervous System&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;3,017&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,704&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,797&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;Oncology&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;2,526&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;2,385&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;1,798&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="text-indent: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Gastrointestinal&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;982&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;1,098&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;705&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Genitourinary&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;705&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;825&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;441&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Respiratory&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;676&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;1,317&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;789&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="text-indent: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Diabetology&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;544&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;350&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;168&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dermatology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;498&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;768&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;1,370&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;4,100&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;3,918&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;1,775&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30,740&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31,982&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25,747&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































</rdy:DisclosureAndDetailsAboutRevenueFromTherapeuticsAreasTableTextBlock>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_CardiovascularMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">7729000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_CardiovascularMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">9834000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_CardiovascularMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">8567000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_AntiInfectiveOneMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">5450000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_AntiInfectiveOneMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">4126000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_AntiInfectiveOneMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2264000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_PainManagementMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">4513000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_PainManagementMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">4657000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_PainManagementMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">5073000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_CentralNervousSystemMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">3017000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_CentralNervousSystemMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2704000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_CentralNervousSystemMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2797000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_OncologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2526000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_OncologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2385000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_OncologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">1798000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GastrointestinalMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">982000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GastrointestinalMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">1098000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GastrointestinalMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">705000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GenitourinaryMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">705000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GenitourinaryMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">825000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GenitourinaryMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">441000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">676000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">1317000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">789000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_DiabetologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">544000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_DiabetologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">350000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_DiabetologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">168000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_DermatologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">498000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_DermatologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">768000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_DermatologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">1370000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_OtherPsaiMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">4100000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_OtherPsaiMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">3918000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_OtherPsaiMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">1775000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">30740000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">31982000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">25747000000</ifrs-full:Revenue>
    <rdy:DisaggregationOfRevenueByGeographicalAreasTableTextBlock contextRef="P04_01_2021To03_31_2022_ReportableSegmentsMemberifrsfullSegmentsAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues by geography:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9.35pt; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows the distribution of the Company&#x2019;s revenues by country, based on the location of the customers:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9.35pt; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Country&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;India&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;43,986&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36,252&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;32,089&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 61%; text-align: left;"&gt;United States&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;80,564&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;76,702&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;76,028&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Russia&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;20,879&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15,816&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;16,900&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;68,962&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;60,952&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;49,583&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;214,391&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;189,722&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;174,600&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;
























































&lt;div style="clear: both; max-height: 0px;"/&gt;





&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt 'Times New Roman', Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Others include Germany, the United Kingdom, Ukraine, China, Canada and other countries across the world.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































</rdy:DisaggregationOfRevenueByGeographicalAreasTableTextBlock>
    <rdy:Revenues
      contextRef="P04_01_2021To03_31_2022_IndiaCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">43986000000</rdy:Revenues>
    <rdy:Revenues
      contextRef="P04_01_2020To03_31_2021_IndiaCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">36252000000</rdy:Revenues>
    <rdy:Revenues
      contextRef="P04_01_2019To03_31_2020_IndiaCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">32089000000</rdy:Revenues>
    <rdy:Revenues
      contextRef="P04_01_2021To03_31_2022_OncologyMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">80564000000</rdy:Revenues>
    <rdy:Revenues
      contextRef="P04_01_2020To03_31_2021_OncologyMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">76702000000</rdy:Revenues>
    <rdy:Revenues
      contextRef="P04_01_2019To03_31_2020_OncologyMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">76028000000</rdy:Revenues>
    <rdy:Revenues
      contextRef="P04_01_2021To03_31_2022_RussiaCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">20879000000</rdy:Revenues>
    <rdy:Revenues
      contextRef="P04_01_2020To03_31_2021_RussiaCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">15816000000</rdy:Revenues>
    <rdy:Revenues
      contextRef="P04_01_2019To03_31_2020_RussiaCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">16900000000</rdy:Revenues>
    <rdy:Revenues
      contextRef="P04_01_2021To03_31_2022_OthersCountriesCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_50535436"
      unitRef="Unit_INR">68962000000</rdy:Revenues>
    <rdy:Revenues
      contextRef="P04_01_2020To03_31_2021_OthersCountriesCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_50535437"
      unitRef="Unit_INR">60952000000</rdy:Revenues>
    <rdy:Revenues
      contextRef="P04_01_2019To03_31_2020_OthersCountriesCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_50535438"
      unitRef="Unit_INR">49583000000</rdy:Revenues>
    <rdy:Revenues
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">214391000000</rdy:Revenues>
    <rdy:Revenues
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">189722000000</rdy:Revenues>
    <rdy:Revenues
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">174600000000</rdy:Revenues>
    <rdy:DisclosureOfAnalysisOfCompanysNoncurrentAssetsOtherThanFinancialInstrumentsAndDeferredTaxAssetsTableTextBlock contextRef="P04_01_2021To03_31_2022_ReportableSegmentsMemberifrsfullSegmentsAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.2in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows the distribution of the Company&#x2019;s non-current assets (other than financial instruments and deferred tax assets) by country, based on the location of assets:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Country&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%;"&gt;India&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;83,166&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;75,284&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Switzerland&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,748&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;11,661&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;United States&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,851&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,627&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Germany&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,263&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,087&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5,244&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5,109&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;98,272&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;100,768&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;























































</rdy:DisclosureOfAnalysisOfCompanysNoncurrentAssetsOtherThanFinancialInstrumentsAndDeferredTaxAssetsTableTextBlock>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn03_31_2022_IndiaCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">83166000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn03_31_2021_IndiaCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">75284000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn03_31_2022_SwitzerlandCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">4748000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn03_31_2021_SwitzerlandCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">11661000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn03_31_2022_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">3851000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn03_31_2021_USifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">7627000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn03_31_2022_GermanyCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">1263000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn03_31_2021_GermanyCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">1087000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn03_31_2022_OtherCountriesMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">5244000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn03_31_2021_OtherCountriesMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">5109000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">98272000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">100768000000</ifrs-full:NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts>
    <rdy:DisclosureOfDistributionOfCompanysPropertyPlantAndEquipmentAcquiredByCountryTableTextBlock contextRef="P04_01_2021To03_31_2022_ReportableSegmentsMemberifrsfullSegmentsAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows the distribution of the Company&#x2019;s property, plant and equipment including capital work in progress and intangible assets acquired during the year (other than goodwill arising on business combination) by country, based on the location of assets:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Country&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%;"&gt;India&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;15,580&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;27,882&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Switzerland&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;195&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,760&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;United States&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;260&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,158&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,198&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,031&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17,233&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;34,831&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;























































</rdy:DisclosureOfDistributionOfCompanysPropertyPlantAndEquipmentAcquiredByCountryTableTextBlock>
    <rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination
      contextRef="P04_01_2021To03_31_2022_IndiaCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">15580000000</rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination>
    <rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination
      contextRef="P04_01_2020To03_31_2021_IndiaCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">27882000000</rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination>
    <rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination
      contextRef="P04_01_2021To03_31_2022_SwitzerlandCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">195000000</rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination>
    <rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination
      contextRef="P04_01_2020To03_31_2021_SwitzerlandCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">3760000000</rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination>
    <rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination
      contextRef="P04_01_2021To03_31_2022_OncologyMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">260000000</rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination>
    <rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination
      contextRef="P04_01_2020To03_31_2021_OncologyMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">2158000000</rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination>
    <rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination
      contextRef="P04_01_2021To03_31_2022_OtherCountriesMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">1198000000</rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination>
    <rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination
      contextRef="P04_01_2020To03_31_2021_OtherCountriesMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">1031000000</rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination>
    <rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">17233000000</rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination>
    <rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">34831000000</rdy:PropertyPlantAndEquipmentsIncludingCapitalWorkInProgressAndIntangibleAssetsAcquiredOtherThanGoodwillArisingOnBusinessCombination>
    <rdy:DisclosureOfAnalysisOfDepreciationAndAmortizationIncludedInCostOfRevenuesTableTextBlock contextRef="P04_01_2021To03_31_2022_ReportableSegmentsMemberifrsfullSegmentsAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;D&lt;/div&gt;epreciation and amortization, included in cost of revenues, by reportable segments:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%; text-align: left;"&gt;Global Generics&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,078&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,435&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,666&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;PSAI&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,507&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,578&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,804&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Proprietary Products&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;42&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;48&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;71&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,627&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,061&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,541&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;























































</rdy:DisclosureOfAnalysisOfDepreciationAndAmortizationIncludedInCostOfRevenuesTableTextBlock>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P04_01_2021To03_31_2022_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">3078000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P04_01_2020To03_31_2021_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">3435000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P04_01_2019To03_31_2020_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_GlobalGenericMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">3666000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P04_01_2021To03_31_2022_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2507000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P04_01_2020To03_31_2021_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2578000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P04_01_2019To03_31_2020_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2804000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P04_01_2021To03_31_2022_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_ProprietaryProductsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P04_01_2020To03_31_2021_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_ProprietaryProductsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P04_01_2019To03_31_2020_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_ProprietaryProductsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P04_01_2021To03_31_2022_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_OthersSegmentsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">42000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P04_01_2020To03_31_2021_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_OthersSegmentsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">48000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P04_01_2019To03_31_2020_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis_OthersSegmentsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">71000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P04_01_2021To03_31_2022_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">5627000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P04_01_2020To03_31_2021_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">6061000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="P04_01_2019To03_31_2020_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">6541000000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_MajorCustomer1MembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_INR">20596000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_MajorCustomer2MembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_INR">10339000000</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="P04_01_2021To03_31_2022_MajorCustomer1MembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="P04_01_2021To03_31_2022_MajorCustomer2MembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_MajorCustomer1MembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_INR">19341000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_MajorCustomer2MembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_INR">9867000000</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="P04_01_2020To03_31_2021_MajorCustomer1MembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="P04_01_2020To03_31_2021_MajorCustomer2MembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_MajorCustomer1MembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_INR">14164000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_MajorCustomer2MembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_INR">9267000000</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="P04_01_2019To03_31_2020_MajorCustomer1MembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.08</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="P04_01_2019To03_31_2020_MajorCustomer2MembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:DisclosureOfBusinessCombinationsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6. Business Combinations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font-style: normal; font-variant: normal; font-size: 10pt; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; text-indent: -0.25in; font-stretch: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;A.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Acquisition of Nimbus Health, GmbH&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





























































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.4pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February 3, 2022&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; the Company entered into an agreement with Nimbus Health, GmbH (&#x201c;Nimbus Health&#x2019;&#x2019;) to acquire 100% &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the &lt;/div&gt;share capital of Nimbus Health along with the existing employees&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-weight: normal; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;The Company completed the acquisition effective as of February 24, 2022.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-size: 10pt; line-height: 115%; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consideration involved an upfront payment of&lt;/div&gt; &lt;div style="font-size: 10pt; line-height: 115%; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs. 337&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;and additional performance&lt;/div&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and milestone-based earn-outs over the next four years&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;pursuant to fulfillment of certain conditions.&lt;/div&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nimbus Health is a licensed pharmaceutical wholesaler in Germany focusing on medical &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cannabis based products.&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt; The acquisition will allow the Company to build on Nimbus Health strengths and introduce medical cannabis-based medicines as a promising treatment option for patients.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-weight: normal; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;The Company has accounted for the transaction under IFRS 3, &#x201c;Business Combinations&#x201d;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.4pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-size: 10pt; line-height: 115%; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As on &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;M&lt;/div&gt;arch 31, 2022, &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company, on a provisional basis estimated the purchase price allocation and recognized the following assets acquired, including goodwill, and liabilities assumed on the acquisition date:&lt;/div&gt; &lt;br/&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.4pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 85%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;337&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payment through Escrow account&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 0.75pt solid black;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 0.75pt solid black;"&gt;84&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total consideration&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;421&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets acquired&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;260&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;i&lt;/div&gt;&lt;/div&gt;ntangible&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;ass&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;et&lt;/div&gt;&lt;/div&gt;s&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;106&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;144&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade receivables&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;45&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="text-indent: 0px; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;2&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax asset&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255);"&gt;2&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; font-style: normal; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities assumed&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade payables&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255);"&gt;(141&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;(10&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total net assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;421&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

























































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.4pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total goodwill of Rs.260 consists largely of the synergies and economies of scale expected from the acquired business, together with the value of the workforce acquired.&#160;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;This goodwill has been assigned to the Company&#x2019;s Global Generics segment.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amount of revenue and loss&#160;pertaining to the acquired business&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;was not material for the year ended March 31, 2022.&lt;/div&gt; &lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;B.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Business Transfer Agreement with Wockhardt Limited&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





























































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2020, the Company entered into a Business Transfer Agreement (&#x201c;BTA&#x201d;) with Wockhardt Limited (&#x201c;Wockhardt&#x201d;) to acquire select divisions of its branded generics business in India and the territories of Nepal, Sri Lanka, Bhutan and Maldives for a consideration of Rs.18,500. &lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The business consists of a portfolio of 62 brands in multiple therapy areas, such as respiratory, neurology, venous malformations, dermatology, gastroenterology, pain and vaccines. This entire portfolio was to be transferred to the Company, along with related sales and marketing teams, the manufacturing plant located in Baddi, Himachal Pradesh and all plant employees (together the &#x201c;Business Undertaking&#x201d;). The transaction involved 2,051 employees engaged in operations of the acquired Business Undertaking.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March 31, 2020, the acquisition of this Business Undertaking was subject to certain closing conditions, such as approval from shareholders and lenders of Wockhardt and other requisite approvals under applicable statutes. Hence, the transaction was not accounted for in the year ended March 31, 2020. &lt;/div&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Due to the COVID-19 pandemic and the consequent government restrictions, there was a reduction in the revenue from the sales of the products forming part of the Business Undertaking during March and April 2020. Accordingly, through an amendment to the BTA, the Company and Wockhardt agreed that the consideration would be up to Rs.18,500, to be paid as per the following terms:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;a)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;an amount of Rs.14,830 to be paid on the date of closing;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;b)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;an amount of Rs.670 to be deposited in an escrow account which shall be released subject to adjustments for, inter alia, net working capital, employee liabilities and certain other contractual and statutory liabilities;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;c)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;an amount of Rs.3,000 (the &#x201c;Holdback Amount&#x201d;) which shall be released as follows:&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.5in;"/&gt;
			&lt;td style="width: 0.25in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the revenue from sales of the products forming part of the Business Undertaking during the twelve (12) months post-closing exceeds Rs.4,800, the Company will be required to pay to Wockhardt an amount equal to two (2) times the amount by which the revenue exceeds Rs.4,800, subject to the maximum of the Holdback Amount&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The acquisition is in line with the Company's strategic focus on India and has paved a path for accelerated growth and leadership in the domestic Indian market. The Company believes that the acquired Business Undertaking offers to strengthen the Company&#x2019;s pharmaceutical portfolio and products in the Indian market.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The transaction was completed on June 10, 2020. &lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has accounted for the transaction under IFRS 3.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of June 30, 2020, the purchase price allocation was preliminary. &lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the three months ended September 30, 2020, the Company completed the purchase price allocation. Tabulated below are the fair values of the assets acquired, including goodwill, and liabilities assumed on the acquisition date:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 85%;"&gt;Cash&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;14,990&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Payment through Escrow account&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;564&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Contingent consideration (Holdback Amount)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;561&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total consideration&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16,115&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets acquired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Goodwill&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;530&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Property, plant and equipment&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;373&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Product related intangibles&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14,888&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Inventories&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;466&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;245&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities assumed&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Employee benefits (Gratuity-Rs.70 and Compensated absences- Rs.75)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(145&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Refund liability&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(242&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total net assets&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16,115&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





























































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total goodwill of Rs.530 consists largely of the synergies and economies of scale expected from the acquired business, together with the value of the workforce acquired and has been assigned to the Company&#x2019;s Global Generics segment. The entire amount of goodwill is not deductible for tax purposes.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisition related costs amounted to Rs.60 and were excluded from the consideration transferred and were recognized as expense under &#x201c;Selling, general and administrative expenses&#x201d; in the consolidated income statements for the year ended March&#160;31,&#160;2021.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the contingent consideration of Rs.561 was estimated by applying the income approach. The fair value measurement is based on significant inputs that are not observable in the market, which IFRS 13 refers to as Level 3 inputs. The significant unobservable inputs in the valuation is the estimated sales forecast. During the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;year&lt;/div&gt; ended March 31, 2021, the Company, after taking into account the revenue of the products until twelve months post-closing (June 9, 2021), re-measured the contingent consideration to be Rs.420.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As on March 31, 2022 the outstanding amount of contingent consideration is Rs. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;194&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amount of revenue included in the consolidated income statements for the year ended March 31, 2021 pertaining to the acquired business since June&#160;10,&#160;2020 is Rs.3,887 and for the year ended March 31, 2022 is Rs.5,474. The acquired business has been integrated into the Company&#x2019;s existing activities and it is not practicable to identify the impact on the Company profit in the year.&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DisclosureOfBusinessCombinationsExplanatory>
    <ifrs-full:PercentageOfVotingEquityInterestsAcquired
      contextRef="PAsOn02_03_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:PercentageOfVotingEquityInterestsAcquired>
    <ifrs-full:CashTransferred
      contextRef="PAsOn02_03_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">337000000</ifrs-full:CashTransferred>
    <rdy:BusinessCombinationTimeLimitWithinWhichEarnoutShallBeSettled contextRef="P02_03_2022To02_03_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis">P4Y</rdy:BusinessCombinationTimeLimitWithinWhichEarnoutShallBeSettled>
    <ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory contextRef="P04_01_2021To03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.4pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 85%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;337&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Payment through Escrow account&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 0.75pt solid black;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 0.75pt solid black;"&gt;84&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total consideration&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;421&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets acquired&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;260&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property, plant and equipment&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;i&lt;/div&gt;&lt;/div&gt;ntangible&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;ass&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;et&lt;/div&gt;&lt;/div&gt;s&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;106&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;144&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade receivables&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;45&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="text-indent: 0px; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;2&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax asset&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255);"&gt;2&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; font-style: normal; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities assumed&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade payables&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255);"&gt;(141&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;"&gt;(10&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total net assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;421&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;























































</ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory>
    <ifrs-full:CashTransferred
      contextRef="PAsOn03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">337000000</ifrs-full:CashTransferred>
    <rdy:PaymentThroughEscrowAccount
      contextRef="P04_01_2021To03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">84000000</rdy:PaymentThroughEscrowAccount>
    <ifrs-full:EquityInterestsOfAcquirer
      contextRef="PAsOn03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">421000000</ifrs-full:EquityInterestsOfAcquirer>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">260000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">2000000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">106000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:InventoryRecognisedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">144000000</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
    <rdy:TradeReceivablesRecognizedAsOfAcquistionDate
      contextRef="PAsOn03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">45000000</rdy:TradeReceivablesRecognizedAsOfAcquistionDate>
    <ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">11000000</ifrs-full:CashAndCashEquivalentsRecognisedAsOfAcquisitionDate>
    <rdy:OtherAssetsRecognizedAsOfAcquistionDate
      contextRef="PAsOn03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">2000000</rdy:OtherAssetsRecognizedAsOfAcquistionDate>
    <ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">2000000</ifrs-full:DeferredTaxAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">141000000</ifrs-full:TradeAndOtherPayablesRecognisedAsOfAcquisitionDate>
    <rdy:OtherLiabilitiesRecognizedAsOfAcquistionDate
      contextRef="PAsOn03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">10000000</rdy:OtherLiabilitiesRecognizedAsOfAcquistionDate>
    <rdy:NetIdentifiableAssetsAcquiredIncludingGoodwill
      contextRef="PAsOn03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">421000000</rdy:NetIdentifiableAssetsAcquiredIncludingGoodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn02_03_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">260000000</ifrs-full:Goodwill>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="PAsOn02_12_2020_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">18500000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <rdy:NumberOfBrandsHeldUnderPortfolio
      contextRef="PAsOn02_12_2020_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="0"
      unitRef="Unit_Brand">62</rdy:NumberOfBrandsHeldUnderPortfolio>
    <ifrs-full:NumberOfEmployees
      contextRef="PAsOn02_12_2020_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="0"
      unitRef="Unit_Employees">2051</ifrs-full:NumberOfEmployees>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="PAsOn02_12_2020"
      decimals="-6"
      unitRef="Unit_INR">18500000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:ConsiderationPaidReceived
      contextRef="P02_12_2020To02_12_2020_MajorBusinessCombinationMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">14830000000</ifrs-full:ConsiderationPaidReceived>
    <rdy:BusinessCombinationConsiderationPayableForWorkingCapitalAdjustments
      contextRef="PAsOn02_12_2020_MajorBusinessCombinationMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">670000000</rdy:BusinessCombinationConsiderationPayableForWorkingCapitalAdjustments>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="PAsOn02_12_2020_MajorBusinessCombinationMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">3000000000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <rdy:EstimatedRevenueOfProductSalesOfTheAcquireePostBusinessCombination
      contextRef="P02_12_2020To02_12_2020_MajorBusinessCombinationMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">4800000000</rdy:EstimatedRevenueOfProductSalesOfTheAcquireePostBusinessCombination>
    <rdy:ProductOfTheNumberOfTimesAndTheExcessOfTheMinimumThresholdRevenueOfTheAcquiree
      contextRef="P02_12_2020To02_12_2020_MajorBusinessCombinationMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="0"
      unitRef="Unit_pure">2</rdy:ProductOfTheNumberOfTimesAndTheExcessOfTheMinimumThresholdRevenueOfTheAcquiree>
    <rdy:EstimatedRevenueOfProductSalesOfTheAcquireePostBusinessCombination
      contextRef="P02_12_2020To02_12_2020_BottomOfRangeMemberifrsfullRangeAxis_MajorBusinessCombinationMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_ScenarioForecastOneMembersrtStatementScenarioAxis_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">4800000000</rdy:EstimatedRevenueOfProductSalesOfTheAcquireePostBusinessCombination>
    <ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the three months ended September 30, 2020, the Company completed the purchase price allocation. Tabulated below are the fair values of the assets acquired, including goodwill, and liabilities assumed on the acquisition date:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 85%;"&gt;Cash&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;14,990&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Payment through Escrow account&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;564&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Contingent consideration (Holdback Amount)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;561&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total consideration&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16,115&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets acquired&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Goodwill&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;530&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Property, plant and equipment&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;373&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Product related intangibles&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14,888&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Inventories&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;466&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;245&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities assumed&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Employee benefits (Gratuity-Rs.70 and Compensated absences- Rs.75)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(145&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Refund liability&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(242&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total net assets&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16,115&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































</ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory>
    <ifrs-full:CashTransferred
      contextRef="PAsOn03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">14990000000</ifrs-full:CashTransferred>
    <rdy:PaymentThroughEscrowAccount
      contextRef="P04_01_2020To03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">564000000</rdy:PaymentThroughEscrowAccount>
    <rdy:BusinessCombinationHoldbackAmountTransferredOrTransferrable
      contextRef="P04_01_2020To03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">561000000</rdy:BusinessCombinationHoldbackAmountTransferredOrTransferrable>
    <ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred
      contextRef="PAsOn03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">16115000000</ifrs-full:AcquisitiondateFairValueOfTotalConsiderationTransferred>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">530000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">373000000</ifrs-full:PropertyPlantAndEquipmentRecognisedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">14888000000</ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate>
    <ifrs-full:InventoryRecognisedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">466000000</ifrs-full:InventoryRecognisedAsOfAcquisitionDate>
    <rdy:OtherAssetRecognizedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">245000000</rdy:OtherAssetRecognizedAsOfAcquisitionDate>
    <rdy:GratuityPayable
      contextRef="PAsOn03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">70000000</rdy:GratuityPayable>
    <rdy:CompensationAbsenceLiability
      contextRef="PAsOn03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">75000000</rdy:CompensationAbsenceLiability>
    <rdy:EmployeeBenefitsRecognizedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">-145000000</rdy:EmployeeBenefitsRecognizedAsOfAcquisitionDate>
    <rdy:SalesReturnLiabilityRecognizedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">-242000000</rdy:SalesReturnLiabilityRecognizedAsOfAcquisitionDate>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="PAsOn03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">16115000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:GoodwillRecognisedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">530000000</ifrs-full:GoodwillRecognisedAsOfAcquisitionDate>
    <ifrs-full:AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination
      contextRef="P04_01_2020To03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">60000000</ifrs-full:AcquisitionrelatedCostsRecognisedAsExpenseForTransactionRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombination>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">561000000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">420000000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">194000000</ifrs-full:ContingentConsiderationRecognisedAsOfAcquisitionDate>
    <ifrs-full:RevenueOfAcquiree
      contextRef="P04_01_2020To03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">3887000000</ifrs-full:RevenueOfAcquiree>
    <ifrs-full:RevenueOfAcquiree
      contextRef="P04_01_2021To03_31_2022_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">5474000000</ifrs-full:RevenueOfAcquiree>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7. Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents consist of the following:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Cash on hand&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Balances with banks&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14,494&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14,324&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Term deposits with banks (original maturities less than 3 months)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;357&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;504&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and cash equivalents in the statements of financial position&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,852&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,829&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Bank overdrafts used for cash management purposes&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;9&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and cash equivalents in the statements of cash flow&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,852&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,820&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restricted cash balances included above&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Balance in unclaimed dividend and debenture interest account&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;86&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;106&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balances in Escrow account pursuant to the Business Transfer Agreement with Wockhardt Limited &lt;div style="font-style:italic;display:inline;"&gt;(Refer to Note 6 for details)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;40&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;40&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balances in Escrow account pursuant to the Business Transfer Agreement with Nimbus Health GmbH &lt;div style="font-style:italic;display:inline;"&gt;(Refer to Note 6 for details)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;84&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Other restricted cash balances&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;72&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;82&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <rdy:CashAndCashEquivalentsTableTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents consist of the following:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Cash on hand&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Balances with banks&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14,494&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14,324&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Term deposits with banks (original maturities less than 3 months)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;357&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;504&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and cash equivalents in the statements of financial position&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,852&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,829&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Bank overdrafts used for cash management purposes&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;9&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash and cash equivalents in the statements of cash flow&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,852&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,820&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Restricted cash balances included above&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Balance in unclaimed dividend and debenture interest account&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;86&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;106&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balances in Escrow account pursuant to the Business Transfer Agreement with Wockhardt Limited &lt;div style="font-style:italic;display:inline;"&gt;(Refer to Note 6 for details)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;40&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;40&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balances in Escrow account pursuant to the Business Transfer Agreement with Nimbus Health GmbH &lt;div style="font-style:italic;display:inline;"&gt;(Refer to Note 6 for details)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;84&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Other restricted cash balances&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;72&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;82&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































</rdy:CashAndCashEquivalentsTableTableTextBlock>
    <ifrs-full:CashOnHand
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1000000</ifrs-full:CashOnHand>
    <ifrs-full:CashOnHand
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1000000</ifrs-full:CashOnHand>
    <ifrs-full:BalancesWithBanks
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">14494000000</ifrs-full:BalancesWithBanks>
    <ifrs-full:BalancesWithBanks
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">14324000000</ifrs-full:BalancesWithBanks>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">357000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">504000000</ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">14852000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">14829000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">9000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">14852000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">14820000000</ifrs-full:CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition>
    <rdy:BalanceInUnclaimedDividendAndDebentureInterestAccount
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">86000000</rdy:BalanceInUnclaimedDividendAndDebentureInterestAccount>
    <rdy:BalanceInUnclaimedDividendAndDebentureInterestAccount
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">106000000</rdy:BalanceInUnclaimedDividendAndDebentureInterestAccount>
    <rdy:EscrowDeposit
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">40000000</rdy:EscrowDeposit>
    <rdy:EscrowDeposit
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">40000000</rdy:EscrowDeposit>
    <rdy:EscrowDepositOne
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">84000000</rdy:EscrowDepositOne>
    <rdy:EscrowDepositOne
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:EscrowDepositOne>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">72000000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">82000000</ifrs-full:RestrictedCashAndCashEquivalents>
    <ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8. Other investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other investments consist of investments in units of mutual funds, equity securities, bonds, commercial paper, limited liability partnership firm and term deposits with banks (i.e., certificates of deposit having an original maturity period exceeding 3 months). The details of such investments as of March&#160;31,&#160;2022 and 2021 are as follows:&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;gain/(loss)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value/&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;a&lt;/div&gt;mortized&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;gain&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value/&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;a&lt;/div&gt;mortized&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current portion&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 34%; text-align: left;"&gt;In units of mutual funds&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;16,714&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;37&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;16,751&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;13,197&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;66&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;13,263&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;In term deposits with banks&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;9,340&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;9,340&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;5,959&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;5,959&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;In bonds&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,249&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,249&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;522&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;522&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;In commercial paper&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;973&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;973&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;In equity securities&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;214&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(14&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;200&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29,490&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;23&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29,513&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19,678&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;66&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19,744&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-current portion&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;In term deposits with banks&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,000&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,000&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In equity securities&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,701&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(1,701&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,000&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,701&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,832&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,533&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;In limited liability partnership firm&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;400&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(14&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;386&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;400&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;400&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="text-indent: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;In bonds&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;256&lt;/div&gt;&lt;div style="line-height: 10pt; background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;256&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; line-height: 10pt; font-size: 10pt;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; line-height: 10pt; font-size: 10pt;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;26&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;26&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;25&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;25&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,383&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,715&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,668&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,126&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,832&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,958&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Primarily represents the shares of Curis, Inc. Refer to Note 3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&#160;of these consolidated financial statements for further details.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px;"/&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the purpose of measurement, the aforesaid investments are classified as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 50%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments in units of mutual funds&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 49%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value through profit and loss&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments in bonds, commercial paper, term deposits and others&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortized cost&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments in equity securities&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value through other comprehensive income (on account of irrevocable option elected at time of transition) and fair value through profit and loss&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in limited liability partnership firm&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value through profit and loss&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






























































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;</ifrs-full:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodExplanatory>
    <rdy:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodTableTextBlock contextRef="P04_01_2021To03_31_2022">The details of such investments as of March&#160;31,&#160;2022 and 2021 are as follows:
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;gain/(loss)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value/&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;a&lt;/div&gt;mortized&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;gain&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value/&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;a&lt;/div&gt;mortized&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current portion&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 34%; text-align: left;"&gt;In units of mutual funds&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;16,714&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;37&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;16,751&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;13,197&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;66&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;13,263&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;In term deposits with banks&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;9,340&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;9,340&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;5,959&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;5,959&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;In bonds&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,249&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,249&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;522&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;522&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;In commercial paper&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;973&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;973&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;In equity securities&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;214&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(14&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;200&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29,490&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;23&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;29,513&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19,678&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;66&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19,744&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-current portion&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;In term deposits with banks&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,000&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,000&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In equity securities&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,701&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(1,701&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,000&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,701&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,832&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,533&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;In limited liability partnership firm&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;400&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(14&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;386&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;400&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;400&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="text-indent: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;In bonds&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;256&lt;/div&gt;&lt;div style="line-height: 10pt; background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;256&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; line-height: 10pt; font-size: 10pt;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; line-height: 10pt; font-size: 10pt;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; line-height: 10pt; font-size: 10pt;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;26&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;26&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;25&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;25&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,383&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,715&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,668&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,126&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,832&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,958&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Primarily represents the shares of Curis, Inc. Refer to Note 3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&#160;of these consolidated financial statements for further details.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px;"/&gt;



































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the purpose of measurement, the aforesaid investments are classified as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 50%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments in units of mutual funds&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 49%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value through profit and loss&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments in bonds, commercial paper, term deposits and others&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortized cost&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments in equity securities&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value through other comprehensive income (on account of irrevocable option elected at time of transition) and fair value through profit and loss&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in limited liability partnership firm&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value through profit and loss&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;




























































</rdy:DisclosureOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodTableTextBlock>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis_InvestmentFundsMemberifrsfullUnconsolidatedStructuredEntitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">16714000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_InvestmentFundsMemberifrsfullUnconsolidatedStructuredEntitiesAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">37000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentFundsMemberifrsfullUnconsolidatedStructuredEntitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">16751000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis_InvestmentFundsMemberifrsfullUnconsolidatedStructuredEntitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">13197000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_InvestmentFundsMemberifrsfullUnconsolidatedStructuredEntitiesAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">66000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentFundsMemberifrsfullUnconsolidatedStructuredEntitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">13263000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">9340000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">9340000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">5959000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">5959000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis_BondMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">2249000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_BondMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_BondMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">2249000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis_BondMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">522000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_BondMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_BondMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">522000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis_InvestmentInCommercialPaperMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">973000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_InvestmentInCommercialPaperMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentInCommercialPaperMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">973000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis_InvestmentInCommercialPaperMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_InvestmentInCommercialPaperMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentInCommercialPaperMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">214000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">-14000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">200000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">29490000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">23000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">29513000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">19678000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">66000000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments
      contextRef="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">19744000000</ifrs-full:CurrentInvestments>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">2000000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">2000000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_TermDepositsWithBanksMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      id="Fact_50535905"
      unitRef="Unit_INR">2701000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      id="Fact_50535906"
      unitRef="Unit_INR">-1701000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      id="Fact_50535907"
      unitRef="Unit_INR">1000000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      id="Fact_50535908"
      unitRef="Unit_INR">2701000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      id="Fact_50535909"
      unitRef="Unit_INR">-1832000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentInEquitySecuritiesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      id="Fact_50535910"
      unitRef="Unit_INR">4533000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis_InvestmentInLimitedLiabilityPartnershipMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">400000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_InvestmentInLimitedLiabilityPartnershipMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">-14000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentInLimitedLiabilityPartnershipMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">386000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis_InvestmentInLimitedLiabilityPartnershipMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">400000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_InvestmentInLimitedLiabilityPartnershipMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_InvestmentInLimitedLiabilityPartnershipMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">400000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis_BondMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">256000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_BondMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_BondMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">256000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis_BondMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_BondMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_BondMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis_OthersInvestmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">26000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_OthersInvestmentMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_OthersInvestmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">26000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis_OthersInvestmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">25000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_OthersInvestmentMemberifrsfullClassesOfAssetsAxis_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis_OthersInvestmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">25000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_AtCostMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">5383000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">-1715000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">3668000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_AtCostMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">3126000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_RecognisedDirectlyInEquityMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">1832000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_AtFairValueOrAmortizedCostMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">4958000000</ifrs-full:NoncurrentInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trade and other receivables&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Trade and other receivables, gross&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;67,958&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;50,937&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Less: Allowance for credit losses&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,194&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,296&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Trade and other receivables, net&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;66,764&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;49,641&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade and other receivables, gross&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;54&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;118&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Less: Allowance for credit losses&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Trade and other receivables, net&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;54&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;118&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 13.5pt; text-align: justify; text-indent: -13.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Represents amounts receivable pursuant to an out-licensing arrangement wit&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;h&lt;/div&gt; a customer. As these amounts are not expected to be realized within twelve months from the end of the reporting date, they are disclosed as non-current&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;




















































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-stretch: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="color: black; letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt;;display:inline;"&gt;During the year ended March 31, 2021, &lt;/div&gt;pursuant to an arrangement with a bank, the Company sold to the bank certain of its trade receivables forming part of its Global Generics segment, on a non-recourse basis. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; The receivables sold were mutually agreed upon with the bank after considering the creditworthiness and contractual terms with the customer, including any gross to net adjustments (due to rebates, discounts etc.) from the contracted amounts. As a result, the receivables sold are &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;were not more &lt;/div&gt; than the total net amount of trade receivables. The Company &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;had&lt;/div&gt; transferred substantially all the risks and rewards of ownership of such receivables sold to the bank, and accordingly, the same &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;were&lt;/div&gt; derecognized in the statements of financial position. As on March 31, 2022 and 2021, the amount of trade receivables de-recognized pursuant to the aforesaid arrangement was Rs.Nil and Rs.9,254, respectively.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with IFRS 9, the Company uses the expected credit loss (&#x201c;ECL&#x201d;) model for measurement and recognition of impairment loss on its trade receivables or any contractual right to receive cash or another financial asset that result from transactions that are within the scope of IFRS 15. For this purpose, the Company uses a provision matrix to compute the expected credit loss amount for trade receivables. The provision matrix takes into account external and internal credit risk factors and historical data of credit losses from various customers.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The details of changes in allowance for credit losses during the years ended March 31&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, 2022&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; and 2021&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, are as follows:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Balance at the beginning of the year&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;1,296&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;1,202&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Provision made during the year, net of reversals&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(3&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;176&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Trade and other receivables written off &amp;amp; exchange differences&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(99&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(82&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance at the end of the year&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,194&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,296&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
    <rdy:TradeAndOtherReceivablesTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Trade and other receivables, gross&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;67,958&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;50,937&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Less: Allowance for credit losses&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,194&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,296&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Trade and other receivables, net&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;66,764&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;49,641&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade and other receivables, gross&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;54&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;118&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Less: Allowance for credit losses&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Trade and other receivables, net&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;54&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;118&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 13.5pt; text-align: justify; text-indent: -13.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Represents amounts receivable pursuant to an out-licensing arrangement wit&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;h&lt;/div&gt; a customer. As these amounts are not expected to be realized within twelve months from the end of the reporting date, they are disclosed as non-current&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































</rdy:TradeAndOtherReceivablesTableTextBlock>
    <rdy:CurrentTradeAndOtherReceivableGross
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">67958000000</rdy:CurrentTradeAndOtherReceivableGross>
    <rdy:CurrentTradeAndOtherReceivableGross
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">50937000000</rdy:CurrentTradeAndOtherReceivableGross>
    <ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1194000000</ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1296000000</ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:CurrentTradeReceivables
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">66764000000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">49641000000</ifrs-full:CurrentTradeReceivables>
    <rdy:NonCurrentTradeAndOtherReceivableGross
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      id="Fact_50539712"
      unitRef="Unit_INR">54000000</rdy:NonCurrentTradeAndOtherReceivableGross>
    <rdy:NonCurrentTradeAndOtherReceivableGross
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      id="Fact_50539711"
      unitRef="Unit_INR">118000000</rdy:NonCurrentTradeAndOtherReceivableGross>
    <rdy:AllowanceAccountForCreditLossesOfFinancialNonCurrentAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:AllowanceAccountForCreditLossesOfFinancialNonCurrentAssets>
    <rdy:AllowanceAccountForCreditLossesOfFinancialNonCurrentAssets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:AllowanceAccountForCreditLossesOfFinancialNonCurrentAssets>
    <ifrs-full:NoncurrentTradeReceivables
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">54000000</ifrs-full:NoncurrentTradeReceivables>
    <ifrs-full:NoncurrentTradeReceivables
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">118000000</ifrs-full:NoncurrentTradeReceivables>
    <rdy:TradeReceivablesDerecognisedPursuantToSaleToTheBank
      contextRef="PAsOn03_31_2022_FactoringOfReceivablesMemberifrsfullContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfTransferAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TradeReceivablesDerecognisedPursuantToSaleToTheBank>
    <rdy:TradeReceivablesDerecognisedPursuantToSaleToTheBank
      contextRef="PAsOn03_31_2021_FactoringOfReceivablesMemberifrsfullContinuingInvolvementInDerecognisedFinancialAssetsByTypeOfTransferAxis"
      decimals="-6"
      unitRef="Unit_INR">9254000000</rdy:TradeReceivablesDerecognisedPursuantToSaleToTheBank>
    <rdy:AllowanceForCreditLossesTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The details of changes in allowance for credit losses during the years ended March 31&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, 2022&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; and 2021&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;, are as follows:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Balance at the beginning of the year&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;1,296&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;1,202&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Provision made during the year, net of reversals&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(3&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;176&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Trade and other receivables written off &amp;amp; exchange differences&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(99&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(82&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance at the end of the year&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,194&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,296&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































</rdy:AllowanceForCreditLossesTableTextBlock>
    <ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1296000000</ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets
      contextRef="PAsOn03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">1202000000</ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets>
    <rdy:AdditionalAllowanceRecognisedInProfitOrLossProvisionMadeDuringTheYearNetOfReversals
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-3000000</rdy:AdditionalAllowanceRecognisedInProfitOrLossProvisionMadeDuringTheYearNetOfReversals>
    <rdy:AdditionalAllowanceRecognisedInProfitOrLossProvisionMadeDuringTheYearNetOfReversals
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">176000000</rdy:AdditionalAllowanceRecognisedInProfitOrLossProvisionMadeDuringTheYearNetOfReversals>
    <ifrs-full:UtilisationAllowanceAccountForCreditLossesOfFinancialAssets
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">99000000</ifrs-full:UtilisationAllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:UtilisationAllowanceAccountForCreditLossesOfFinancialAssets
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">82000000</ifrs-full:UtilisationAllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1194000000</ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1296000000</ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10. Inventories&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 9pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories consist of the following:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Raw materials&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;13,707&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;12,287&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Work-in-progress&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;12,886&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;10,009&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Finished goods (includes stock-in-trade)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;20,491&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;19,829&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Packing materials, stores and spares&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3,800&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3,287&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;50,884&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;45,412&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of inventories recognized in the consolidated incom&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;e&lt;/div&gt;&#160;statement are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%; text-align: left;"&gt;Raw materials, consumables and changes in finished goods and work in progress&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;69,838&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;58,268&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;51,892&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventory write-downs&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,584&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,521&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,652&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;





























</ifrs-full:DisclosureOfInventoriesExplanatory>
    <rdy:DisclosureOfDetailedInformationAboutInventoriesTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventories consist of the following:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Raw materials&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;13,707&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;12,287&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Work-in-progress&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;12,886&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;10,009&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Finished goods (includes stock-in-trade)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;20,491&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;19,829&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Packing materials, stores and spares&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3,800&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3,287&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;50,884&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;45,412&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</rdy:DisclosureOfDetailedInformationAboutInventoriesTextBlock>
    <ifrs-full:RawMaterials
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">13707000000</ifrs-full:RawMaterials>
    <ifrs-full:RawMaterials
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">12287000000</ifrs-full:RawMaterials>
    <ifrs-full:WorkInProgress
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">12886000000</ifrs-full:WorkInProgress>
    <ifrs-full:WorkInProgress
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">10009000000</ifrs-full:WorkInProgress>
    <ifrs-full:FinishedGoods
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">20491000000</ifrs-full:FinishedGoods>
    <ifrs-full:FinishedGoods
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">19829000000</ifrs-full:FinishedGoods>
    <ifrs-full:CurrentPackagingAndStorageMaterials
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">3800000000</ifrs-full:CurrentPackagingAndStorageMaterials>
    <ifrs-full:CurrentPackagingAndStorageMaterials
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">3287000000</ifrs-full:CurrentPackagingAndStorageMaterials>
    <ifrs-full:Inventories
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">50884000000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">45412000000</ifrs-full:Inventories>
    <rdy:DisclosureOfDetailInformationAboutOfInventoriesRecognizedInConsolidatedIncomeStatementTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of inventories recognized in the consolidated incom&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;e&lt;/div&gt;&#160;statement are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%; text-align: left;"&gt;Raw materials, consumables and changes in finished goods and work in progress&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;69,838&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;58,268&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;51,892&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inventory write-downs&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,584&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,521&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,652&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;





























</rdy:DisclosureOfDetailInformationAboutOfInventoriesRecognizedInConsolidatedIncomeStatementTextBlock>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">69838000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">58268000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">51892000000</ifrs-full:CostOfInventoriesRecognisedAsExpenseDuringPeriod>
    <ifrs-full:InventoryWritedown2011
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4584000000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:InventoryWritedown2011
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2521000000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:InventoryWritedown2011
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">3652000000</ifrs-full:InventoryWritedown2011>
    <ifrs-full:DisclosureOfOtherAssetsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11. Other assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balances and receivables from statutory authorities&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;8,455&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;7,227&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Export benefits receivable&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,016&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,070&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Prepaid expenses&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,138&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,141&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3,293&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;4,071&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,902&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,509&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Security deposits&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;670&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;666&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;224&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;168&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;894&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;834&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.7pt; text-align: justify; text-indent: -13.7pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Balances and receivables from statutory authorities primarily consist of amounts recoverable towards the goods and service tax (&#x201c;GST&#x201d;), excise duty and value added tax, and from customs authorities of India.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Export benefits receivables primarily consist of amounts receivable from various government authorities of India towards incentives on export sales made by the Company.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Others primarily includes advances given to vendors and employees, security deposits, interest accrued but not due on investments, and claims receivable.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



















































</ifrs-full:DisclosureOfOtherAssetsExplanatory>
    <rdy:DisclosureOfDetailedInformationAboutOtherAssetsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balances and receivables from statutory authorities&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;8,455&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;7,227&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Export benefits receivable&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,016&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,070&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Prepaid expenses&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,138&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,141&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3,293&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;4,071&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13,902&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,509&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Security deposits&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;670&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;666&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;224&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;168&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;894&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;834&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.7pt; text-align: justify; text-indent: -13.7pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Balances and receivables from statutory authorities primarily consist of amounts recoverable towards the goods and service tax (&#x201c;GST&#x201d;), excise duty and value added tax, and from customs authorities of India.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Export benefits receivables primarily consist of amounts receivable from various government authorities of India towards incentives on export sales made by the Company.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Others primarily includes advances given to vendors and employees, security deposits, interest accrued but not due on investments, and claims receivable.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



















































</rdy:DisclosureOfDetailedInformationAboutOtherAssetsTableTextBlock>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax
      contextRef="PAsOn03_31_2022_AssetTypeMemberRDYAssetTypeAxis"
      decimals="-6"
      id="Fact_50535955"
      unitRef="Unit_INR">8455000000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax
      contextRef="PAsOn03_31_2021_AssetTypeMemberRDYAssetTypeAxis"
      decimals="-6"
      id="Fact_50535956"
      unitRef="Unit_INR">7227000000</ifrs-full:CurrentReceivablesFromTaxesOtherThanIncomeTax>
    <rdy:ExportBenefitReceivableCurrent
      contextRef="PAsOn03_31_2022_AssetTypeMemberRDYAssetTypeAxis"
      decimals="-6"
      id="Fact_50535957"
      unitRef="Unit_INR">1016000000</rdy:ExportBenefitReceivableCurrent>
    <rdy:ExportBenefitReceivableCurrent
      contextRef="PAsOn03_31_2021_AssetTypeMemberRDYAssetTypeAxis"
      decimals="-6"
      id="Fact_50535958"
      unitRef="Unit_INR">2070000000</rdy:ExportBenefitReceivableCurrent>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="PAsOn03_31_2022_AssetTypeMemberRDYAssetTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">1138000000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses
      contextRef="PAsOn03_31_2021_AssetTypeMemberRDYAssetTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">1141000000</ifrs-full:CurrentPrepaidExpenses>
    <rdy:OtherCurrentAssetsOther
      contextRef="PAsOn03_31_2022_AssetTypeMemberRDYAssetTypeAxis"
      decimals="-6"
      id="Fact_50535961"
      unitRef="Unit_INR">3293000000</rdy:OtherCurrentAssetsOther>
    <rdy:OtherCurrentAssetsOther
      contextRef="PAsOn03_31_2021_AssetTypeMemberRDYAssetTypeAxis"
      decimals="-6"
      id="Fact_50535962"
      unitRef="Unit_INR">4071000000</rdy:OtherCurrentAssetsOther>
    <ifrs-full:OtherCurrentAssets
      contextRef="PAsOn03_31_2022_AssetTypeMemberRDYAssetTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">13902000000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets
      contextRef="PAsOn03_31_2021_AssetTypeMemberRDYAssetTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">14509000000</ifrs-full:OtherCurrentAssets>
    <ifrs-full:LongtermDeposits
      contextRef="PAsOn03_31_2022_NoncurrentAssetsMemberRDYAssetTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">670000000</ifrs-full:LongtermDeposits>
    <ifrs-full:LongtermDeposits
      contextRef="PAsOn03_31_2021_NoncurrentAssetsMemberRDYAssetTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">666000000</ifrs-full:LongtermDeposits>
    <rdy:OtherNoncurrentAssetsOther
      contextRef="PAsOn03_31_2022_NoncurrentAssetsMemberRDYAssetTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">224000000</rdy:OtherNoncurrentAssetsOther>
    <rdy:OtherNoncurrentAssetsOther
      contextRef="PAsOn03_31_2021_NoncurrentAssetsMemberRDYAssetTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">168000000</rdy:OtherNoncurrentAssetsOther>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn03_31_2022_NoncurrentAssetsMemberRDYAssetTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">894000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="PAsOn03_31_2021_NoncurrentAssetsMemberRDYAssetTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">834000000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12. Property, plant and equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following is a summary of the changes in carrying value of property, plant and equipment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Land&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Buildings&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Plant and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Furniture,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;fixtures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;and office&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Vehicles&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross carrying value&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 34%; text-indent: 0px;"&gt;Balance as of April 1, 2020&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right; text-indent: 0px;"&gt;4,123&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right; text-indent: 0px;"&gt;24,956&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right; text-indent: 0px;"&gt;74,867&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right; text-indent: 0px;"&gt;5,965&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right; text-indent: 0px;"&gt;1,211&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right; text-indent: 0px;"&gt;111,122&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;Additions&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;13&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;2,720&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;4,544&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;437&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;220&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;7,934&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; width: 34%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets acquired through business combinations&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;84&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;113&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;165&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;11&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;373&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;Disposals&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(35&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(852&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(134&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(182&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(1,203&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; width: 34%;"&gt;Assets held for sale&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(18&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(245&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(334&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(58&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(655&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 34%;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; border-bottom: 1pt solid black;"&gt;26&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; border-bottom: 1pt solid black;"&gt;11&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; border-bottom: 1pt solid black;"&gt;244&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; border-bottom: 1pt solid black;"&gt;31&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; border-bottom: 1pt solid black;"&gt;8&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; border-bottom: 1pt solid black;"&gt;320&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 34%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,228&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,520&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;78,634&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,252&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,257&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;117,891&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-indent: 0px; width: 34%;"&gt;Balance as of April 1, 2021&lt;/td&gt;
			&lt;td style="text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%;"&gt;4,228&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%;"&gt;27,520&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%;"&gt;78,634&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%;"&gt;6,252&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%;"&gt;1,257&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%;"&gt;117,891&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;Additions&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;1,037&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;9,941&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;738&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;621&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;12,337&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; width: 34%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets acquired through business combinations&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;2&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;Disposals&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(221&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(1,219&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(186&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(391&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(2,017&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 34%; background-color: rgb(255, 255, 255);"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;5&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;85&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;313&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;9&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;(32&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;380&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 34%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,233&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;28,422&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;87,669&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,814&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,455&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;128,593&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 34%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; width: 34%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated Depreciation&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 34%; background-color: rgb(255, 255, 255);"&gt;Balance as of April 1, 2020&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,208&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;49,602&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;4,903&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;598&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;63,311&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; width: 34%; background-color: rgb(204, 238, 255);"&gt;Depreciation for the year&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;1,697&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;5,935&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;554&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;341&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;8,527&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 34%; background-color: rgb(255, 255, 255);"&gt;Impairment&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;4&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;32&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;9&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;46&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 34%; background-color: rgb(204, 238, 255);"&gt;Disposals&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(29&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(773&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(125&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(136&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(1,063&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; width: 34%; background-color: rgb(255, 255, 255);"&gt;Assets held for sale&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;(4&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;(140&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;(306&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;(54&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;(504&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 34%; background-color: rgb(204, 238, 255);"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;22&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;194&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;24&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;241&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 34%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,790&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;54,661&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,303&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;804&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;70,558&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 34%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 34%; background-color: rgb(255, 255, 255);"&gt;Balance as of April 1, 2021&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; width: 1%; background-color: rgb(255, 255, 255);"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,790&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;54,661&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,303&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;804&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;70,558&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; width: 34%; background-color: rgb(204, 238, 255);"&gt;Depreciation for the year&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;1,718&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;5,554&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;572&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;308&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;8,152&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 34%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;64&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;872&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;1,626&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;7&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;2,570&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 34%; background-color: rgb(204, 238, 255);"&gt;Disposals&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(118&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(1,092&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(182&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(342&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(1,734&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 34%; background-color: rgb(255, 255, 255);"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;20&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;167&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;7&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;(11&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;183&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 34%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;64&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12,282&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;60,916&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,707&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;760&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;79,729&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;




















































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Land&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Buildings&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Plant and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Furniture,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;fixtures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;and office&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Vehicles&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying value&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 34%;"&gt;As of April 1, 2020&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;4,123&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;16,748&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;25,265&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;1,062&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;613&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;47,811&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;As of March 31, 2021&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;4,228&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;17,730&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;23,973&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;949&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;453&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;47,333&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; width: 34%;"&gt;Add: Capital-work-in-progress&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;9,778&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;Total as of March 31, 2021&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;57,111&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 34%;"&gt;As of March 31, 2022&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;4,169&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;16,140&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;26,753&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;1,107&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;695&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;48,864&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; width: 34%;"&gt;Add: Capital-work-in-progress&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;13,394&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 34%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Impairment of Capital-work-in-progress&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; border-bottom: 1pt solid black;"&gt;(89&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 34%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total as of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;62,169&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;
























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Refer to Note 6 of these consolidated financial statements for further details.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;




















































&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in; text-indent: 0px;"/&gt;
			&lt;td style="width: 0.25in; text-align: left; text-indent: 0px;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; text-indent: 0px; vertical-align: bottom;"&gt;During the year ended March 31, 2022, the&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;re was&lt;/div&gt; a significant decline in the expected cash flows of the Company&#x2019;s subsidiary, Dr. Reddy&#x2019;s Laboratories Louisiana, LLC (Shreveport Cash Generating Unit (&#x201c;CGU&#x201d;)). Consequently, the Company tested the carrying amount of the CGU, being the smallest identifiable group of assets that generate cash inflows that are largely independent of the cash inflows from other assets or group of assets. This resulted in the recoverable amount of the CGU being lower than its carrying amount.&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Accordingly, the Company recognized an impairment loss of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the entire carrying value of&lt;/div&gt; &lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.2,570 &lt;/div&gt;&lt;/div&gt;&#160;for property, plant and equipment, Rs. 89 for capital-work-in-progress and Rs.392 for goodwill. This impairment loss pertains to the Company&#x2019;s Global Generics segment.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;
























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has lease contracts for various items of plant and equipment, vehicles and other equipment used in its operations. Below are the carrying amounts of right-of-use assets recognized and the movements during the year included in the above property, plant and equipment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Land&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Buildings&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Plant and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Furniture,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;fixtures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;and office&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Vehicles&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross carrying value&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 34%;"&gt;Balance as of April 1, 2020&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;78&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;1,688&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;18&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;45&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;530&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;2,359&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,212&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;194&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,413&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Disposals&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(120&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(121&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(14&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(11&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;81&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,886&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;51&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;604&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,640&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Balance as of April 1, 2021&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;81&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,886&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;18&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;51&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;604&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,640&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Additions&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;98&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;16&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;360&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;474&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Disposals&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(202&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(199&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(402&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(2&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(23&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(10&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(36&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;79&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,759&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;67&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;755&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,676&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated Depreciation&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Balance as of April 1, 2020&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;744&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;13&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;199&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;970&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Depreciation for the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;616&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;12&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;202&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;831&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Disposals&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(78&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(78&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(25&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(2&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(27&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,335&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;321&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,696&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Balance as of April 1, 2021&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,335&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;25&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;321&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,696&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Depreciation for the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;656&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;12&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;189&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;858&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Disposals&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(99&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(155&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(255&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(19&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(3&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(24&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,873&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;352&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,275&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying value&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;
			&lt;div style="line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of April 1, 2020&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;78&lt;/div&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;944&lt;/div&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;32&lt;/div&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;331&lt;/div&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,389&lt;/div&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;As of March 31, 2021&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;81&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;2,551&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;3&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;26&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;283&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;2,944&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;As of March 31, 2022&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;79&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;1,886&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;31&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;403&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,401&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































&#160;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; text-indent: 0px; vertical-align: bottom;"&gt;Additions for the year ended March 31, 2021 include recognition of a right-of-use asset of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt; 1,852 relating to a warehousing services agreement in the United States.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following are the amounts recognized in income statement:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Depreciation expense of right-of-use assets&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;858&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;831&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Interest expense on lease liabilities&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;221&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;227&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;




















































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company had total cash outflows for leases of Rs.1,341 and Rs.1,252 during the years ended March 31, 2022 and 2021, respectively. The maturity analysis of lease liabilities are disclosed in Note 17 of these consolidated financial statements.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Capital commitments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March 31, 2022 and 2021, the Company was committed to spend Rs.7,991 and Rs. 9,841, respectively, under agreements to purchase property, plant and equipment. This amount is net of capital advances paid in respect of such purchase commitments.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Interest capitalization&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the years ended March 31, 2022 and 2021, the Company capitalized interest cost of Rs.268 and Rs.149, respectively, with respect to qualifying assets. The rate for capitalization of interest cost for the years ended March 31, 2022 and 2021 was approximately 4.65% and 4.25%, respectively.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <rdy:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatoryTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following is a summary of the changes in carrying value of property, plant and equipment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Land&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Buildings&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Plant and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Furniture,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;fixtures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;and office&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Vehicles&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross carrying value&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 34%; text-indent: 0px;"&gt;Balance as of April 1, 2020&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right; text-indent: 0px;"&gt;4,123&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right; text-indent: 0px;"&gt;24,956&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right; text-indent: 0px;"&gt;74,867&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right; text-indent: 0px;"&gt;5,965&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right; text-indent: 0px;"&gt;1,211&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right; text-indent: 0px;"&gt;111,122&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;Additions&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;13&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;2,720&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;4,544&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;437&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;220&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;7,934&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; width: 34%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets acquired through business combinations&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;84&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;113&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;165&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;11&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;373&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;Disposals&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(35&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(852&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(134&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(182&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(1,203&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; width: 34%;"&gt;Assets held for sale&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(18&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(245&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(334&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(58&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(655&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 34%;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; border-bottom: 1pt solid black;"&gt;26&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; border-bottom: 1pt solid black;"&gt;11&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; border-bottom: 1pt solid black;"&gt;244&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; border-bottom: 1pt solid black;"&gt;31&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; border-bottom: 1pt solid black;"&gt;8&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; border-bottom: 1pt solid black;"&gt;320&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 34%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,228&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,520&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;78,634&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,252&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,257&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;117,891&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-indent: 0px; width: 34%;"&gt;Balance as of April 1, 2021&lt;/td&gt;
			&lt;td style="text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%;"&gt;4,228&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%;"&gt;27,520&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%;"&gt;78,634&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%;"&gt;6,252&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%;"&gt;1,257&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%;"&gt;117,891&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;Additions&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;1,037&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;9,941&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;738&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;621&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;12,337&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; width: 34%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets acquired through business combinations&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;2&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;Disposals&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(221&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(1,219&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(186&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(391&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;(2,017&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 34%; background-color: rgb(255, 255, 255);"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;5&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;85&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;313&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;9&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;(32&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;380&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 34%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,233&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;28,422&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;87,669&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,814&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,455&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;128,593&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 34%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; width: 34%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated Depreciation&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 34%; background-color: rgb(255, 255, 255);"&gt;Balance as of April 1, 2020&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,208&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;49,602&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;4,903&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;598&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;63,311&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; width: 34%; background-color: rgb(204, 238, 255);"&gt;Depreciation for the year&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;1,697&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;5,935&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;554&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;341&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;8,527&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 34%; background-color: rgb(255, 255, 255);"&gt;Impairment&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;4&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;32&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;9&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;46&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 34%; background-color: rgb(204, 238, 255);"&gt;Disposals&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(29&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(773&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(125&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(136&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(1,063&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; width: 34%; background-color: rgb(255, 255, 255);"&gt;Assets held for sale&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;(4&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;(140&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;(306&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;(54&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;(504&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 34%; background-color: rgb(204, 238, 255);"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;22&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;194&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;24&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;241&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 34%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,790&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;54,661&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,303&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;804&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;70,558&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 34%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 34%; background-color: rgb(255, 255, 255);"&gt;Balance as of April 1, 2021&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; width: 1%; background-color: rgb(255, 255, 255);"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,790&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;54,661&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,303&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;804&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;70,558&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; width: 34%; background-color: rgb(204, 238, 255);"&gt;Depreciation for the year&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;1,718&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;5,554&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;572&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;308&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;8,152&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 34%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;64&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;872&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;1,626&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;7&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255);"&gt;2,570&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 34%; background-color: rgb(204, 238, 255);"&gt;Disposals&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(118&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(1,092&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(182&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(342&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255);"&gt;(1,734&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 34%; background-color: rgb(255, 255, 255);"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;20&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;167&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;7&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;(11&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(255, 255, 255); border-bottom: 1pt solid black;"&gt;183&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 34%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;64&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12,282&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;60,916&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,707&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;760&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;79,729&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



















































&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Land&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Buildings&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Plant and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Furniture,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;fixtures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;and office&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Vehicles&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying value&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 34%;"&gt;As of April 1, 2020&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;4,123&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;16,748&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;25,265&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;1,062&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;613&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;47,811&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;As of March 31, 2021&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;4,228&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;17,730&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;23,973&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;949&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;453&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;47,333&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; width: 34%;"&gt;Add: Capital-work-in-progress&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;9,778&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%;"&gt;Total as of March 31, 2021&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;57,111&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 34%;"&gt;As of March 31, 2022&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;4,169&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;16,140&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;26,753&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;1,107&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;695&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;48,864&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; width: 34%;"&gt;Add: Capital-work-in-progress&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%;"&gt;13,394&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 34%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Impairment of Capital-work-in-progress&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; border-bottom: 1pt solid black;"&gt;(89&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 34%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total as of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; width: 8%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; width: 1%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; width: 8%; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;62,169&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; width: 1%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;
























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Refer to Note 6 of these consolidated financial statements for further details.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;




















































&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in; text-indent: 0px;"/&gt;
			&lt;td style="width: 0.25in; text-align: left; text-indent: 0px;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; text-indent: 0px; vertical-align: bottom;"&gt;During the year ended March 31, 2022, the&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;re was&lt;/div&gt; a significant decline in the expected cash flows of the Company&#x2019;s subsidiary, Dr. Reddy&#x2019;s Laboratories Louisiana, LLC (Shreveport Cash Generating Unit (&#x201c;CGU&#x201d;)). Consequently, the Company tested the carrying amount of the CGU, being the smallest identifiable group of assets that generate cash inflows that are largely independent of the cash inflows from other assets or group of assets. This resulted in the recoverable amount of the CGU being lower than its carrying amount.&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Accordingly, the Company recognized an impairment loss of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the entire carrying value of&lt;/div&gt; &lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.2,570 &lt;/div&gt;&lt;/div&gt;&#160;for property, plant and equipment, Rs. 89 for capital-work-in-progress and Rs.392 for goodwill. This impairment loss pertains to the Company&#x2019;s Global Generics segment.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;
























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
</rdy:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatoryTextBlock>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">4123000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">24956000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">74867000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">5965000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">1211000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">111122000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">13000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">2720000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">4544000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">437000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">220000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">7934000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      id="Fact_50539705"
      unitRef="Unit_INR">84000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      id="Fact_50539704"
      unitRef="Unit_INR">113000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      id="Fact_50539703"
      unitRef="Unit_INR">165000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      id="Fact_50539702"
      unitRef="Unit_INR">11000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      id="Fact_50539701"
      unitRef="Unit_INR">0</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      id="Fact_50539700"
      unitRef="Unit_INR">373000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">35000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">852000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">134000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">182000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">1203000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">18000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">245000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">334000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">58000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">655000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">26000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">11000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">244000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">31000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">8000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">320000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">4228000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">27520000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">78634000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">6252000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">1257000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">117891000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">4228000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">27520000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">78634000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">6252000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">1257000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">117891000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">1037000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">9941000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">738000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">621000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">12337000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      id="Fact_50539693"
      unitRef="Unit_INR">0</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      id="Fact_50539692"
      unitRef="Unit_INR">1000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      id="Fact_50539691"
      unitRef="Unit_INR">0</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      id="Fact_50539690"
      unitRef="Unit_INR">1000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      id="Fact_50539689"
      unitRef="Unit_INR">0</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      id="Fact_50539688"
      unitRef="Unit_INR">2000000</ifrs-full:AcquisitionsThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">221000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">1219000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">186000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">391000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">2017000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">5000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">85000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">313000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">9000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">-32000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">380000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">4233000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">28422000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">87669000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">6814000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">1455000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">128593000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">8208000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">49602000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">4903000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">598000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">63311000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">1697000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">5935000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">554000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">341000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">8527000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">4000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">32000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">9000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">1000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">46000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">29000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">773000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">125000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">136000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">1063000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">4000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">140000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">306000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">54000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">504000000</ifrs-full:DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">22000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">194000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">24000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">241000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">9790000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">54661000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">5303000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">804000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">70558000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">9790000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">54661000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">5303000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">804000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">70558000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">1718000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">5554000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">572000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">308000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">8152000000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      id="Fact_50535685"
      unitRef="Unit_INR">64000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      id="Fact_50535686"
      unitRef="Unit_INR">872000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      id="Fact_50535687"
      unitRef="Unit_INR">1626000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      id="Fact_50535714"
      unitRef="Unit_INR">7000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      id="Fact_50535715"
      unitRef="Unit_INR">1000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      id="Fact_50535716"
      unitRef="Unit_INR">2570000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">118000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">1092000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">182000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">342000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">1734000000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">20000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">167000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">7000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">-11000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">183000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">64000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">12282000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">60916000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">5707000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">760000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_AccumulatedDepreciationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">79729000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">4123000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">16748000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">25265000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">1062000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">613000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">47811000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">4228000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">17730000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">23973000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">949000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">453000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">47333000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2020_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">9778000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">57111000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">4169000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_BuildingsMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">16140000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">26753000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OfficeEquipmentMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">1107000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">695000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_ExcludingCapitalworkinprogressMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">48864000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022_ConstructionInProgressMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="-6"
      unitRef="Unit_INR">13394000000</ifrs-full:PropertyPlantAndEquipment>
    <rdy:ImpairmentOfCapitalWorkInProgress
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      id="Fact_50539553"
      unitRef="Unit_INR">-89000000</rdy:ImpairmentOfCapitalWorkInProgress>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">62169000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="P04_01_2021To03_31_2022_GlobalgenericscomplexinjectablesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"
      decimals="-6"
      unitRef="Unit_INR">2570000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <rdy:ImpairmentLossOfCapitalWorkInProgress
      contextRef="P04_01_2021To03_31_2022_GlobalgenericscomplexinjectablesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"
      decimals="-6"
      unitRef="Unit_INR">89000000</rdy:ImpairmentLossOfCapitalWorkInProgress>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill
      contextRef="P04_01_2021To03_31_2022_GlobalgenericscomplexinjectablesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"
      decimals="-6"
      unitRef="Unit_INR">392000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill>
    <rdy:SummaryOfDetailedInformationAboutRightofuseAssetsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has lease contracts for various items of plant and equipment, vehicles and other equipment used in its operations. Below are the carrying amounts of right-of-use assets recognized and the movements during the year included in the above property, plant and equipment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Land&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Buildings&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Plant and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Furniture,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;fixtures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;and office&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Vehicles&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross carrying value&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 34%;"&gt;Balance as of April 1, 2020&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;78&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;1,688&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;18&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;45&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;530&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;2,359&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,212&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;194&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,413&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Disposals&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(120&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(121&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(14&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(11&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;81&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,886&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;51&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;604&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,640&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Balance as of April 1, 2021&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;81&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,886&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;18&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;51&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;604&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,640&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Additions&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;98&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;16&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;360&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;474&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Disposals&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(202&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(199&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(402&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(2&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(23&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(10&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(36&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;79&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,759&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;67&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;755&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,676&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated Depreciation&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Balance as of April 1, 2020&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;744&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;13&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;199&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;970&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Depreciation for the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;616&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;12&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;202&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;831&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Disposals&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(78&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(78&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(25&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(2&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(27&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,335&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;321&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,696&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Balance as of April 1, 2021&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,335&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;25&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;321&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,696&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Depreciation for the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;656&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;12&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;189&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;858&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Disposals&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(99&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(155&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(255&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(19&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(3&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(24&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,873&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;352&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,275&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying value&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;
			&lt;div style="line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of April 1, 2020&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;78&lt;/div&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;944&lt;/div&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;32&lt;/div&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;331&lt;/div&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,389&lt;/div&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;As of March 31, 2021&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;81&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;2,551&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;3&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;26&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;283&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;2,944&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;As of March 31, 2022&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;79&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;1,886&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;31&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;403&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,401&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



















































&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; text-indent: 0px; vertical-align: bottom;"&gt;Additions for the year ended March 31, 2021 include recognition of a right-of-use asset of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt; 1,852 relating to a warehousing services agreement in the United States.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



















































</rdy:SummaryOfDetailedInformationAboutRightofuseAssetsTableTextBlock>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">78000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020_BuildingsMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">1688000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">18000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">45000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">530000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">2359000000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      id="Fact_50538840"
      unitRef="Unit_INR">0</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_BuildingsMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      id="Fact_50538839"
      unitRef="Unit_INR">2212000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      id="Fact_50538838"
      unitRef="Unit_INR">0</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      id="Fact_50538837"
      unitRef="Unit_INR">7000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      id="Fact_50538836"
      unitRef="Unit_INR">194000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      id="Fact_50538835"
      unitRef="Unit_INR">2413000000</ifrs-full:AdditionsToRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_BuildingsMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-1000000</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-120000000</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-121000000</rdy:DisposalsRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">3000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_BuildingsMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-14000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-11000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">81000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_BuildingsMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">3886000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">18000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">51000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">604000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">4640000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">81000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_BuildingsMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">3886000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">18000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">51000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">604000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">4640000000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">98000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">16000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">360000000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">474000000</ifrs-full:AdditionsToRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-202000000</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-1000000</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-199000000</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-402000000</rdy:DisposalsRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-2000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-23000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-1000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-10000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-36000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">79000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">3759000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">16000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">67000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">755000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">4676000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">744000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">14000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">13000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">199000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">970000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">616000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">1000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">12000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">202000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">831000000</ifrs-full:DepreciationRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-78000000</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-78000000</rdy:DisposalsRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-25000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-2000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-27000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">1335000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">15000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">25000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">321000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">1696000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">1335000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">15000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">25000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">321000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">1696000000</ifrs-full:RightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">656000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">1000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">12000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">189000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">858000000</ifrs-full:DepreciationRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-99000000</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-1000000</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-155000000</rdy:DisposalsRightofuseAssets>
    <rdy:DisposalsRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-255000000</rdy:DisposalsRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-19000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-1000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-1000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-3000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-24000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesRightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">1873000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">14000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">36000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">352000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022_AccumulatedDepreciationMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">2275000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">78000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">944000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">4000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">32000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">331000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">1389000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">81000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">2551000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">3000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">26000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">283000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2944000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022_LandMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">79000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">1886000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022_PlantAndEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">2000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022_FurnitureFixturesAndOfficeEquipmentMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">31000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022_VehiclesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">403000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2401000000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets
      contextRef="P04_01_2021To03_31_2022_BuildingsMemberifrsfullClassesOfAssetsAxis_USsrtStatementGeographicalAxis_WarehousingAgreementMemberRDYAgreementAxis"
      decimals="-6"
      unitRef="Unit_INR">1852000000</ifrs-full:AdditionsToRightofuseAssets>
    <rdy:SummaryOfDetailedInformationAboutAmountsRecognizedInIncomeStatementForRightofuseAssetsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following are the amounts recognized in income statement:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Depreciation expense of right-of-use assets&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;858&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;831&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Interest expense on lease liabilities&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;221&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;227&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































</rdy:SummaryOfDetailedInformationAboutAmountsRecognizedInIncomeStatementForRightofuseAssetsTableTextBlock>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">858000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">831000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">221000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">227000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:CashOutflowForLeases
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1341000000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1252000000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">7991000000</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
    <ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">9841000000</ifrs-full:ContractualCommitmentsForAcquisitionOfPropertyPlantAndEquipment>
    <ifrs-full:InterestCostsCapitalised
      contextRef="P04_01_2021To03_31_2022_PropertyPlantAndEquipmentMemberRDYInterestCapitalizationAxis"
      decimals="-6"
      unitRef="Unit_INR">268000000</ifrs-full:InterestCostsCapitalised>
    <ifrs-full:InterestCostsCapitalised
      contextRef="P04_01_2020To03_31_2021_PropertyPlantAndEquipmentMemberRDYInterestCapitalizationAxis"
      decimals="-6"
      unitRef="Unit_INR">149000000</ifrs-full:InterestCostsCapitalised>
    <ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation
      contextRef="P04_01_2021To03_31_2022_PropertyPlantAndEquipmentMemberRDYInterestCapitalizationAxis"
      decimals="4"
      unitRef="Unit_pure">0.0465</ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation>
    <ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation
      contextRef="P04_01_2020To03_31_2021_PropertyPlantAndEquipmentMemberRDYInterestCapitalizationAxis"
      decimals="4"
      unitRef="Unit_pure">0.0425</ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation>
    <ifrs-full:DisclosureOfGoodwillExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13. Goodwill&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill arising upon business combinations is not amortized but tested for impairment at least annually or more frequently if there is any indication that the cash generating unit to which goodwill is allocated is impaired.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the changes in goodwill during the years ended March 31, 2022 and 2021:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Opening balance, gross&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;20,852&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;20,278&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill arising on business combinations&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;260&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;530&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Effect of translation adjustments&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(18&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;44&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment loss&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(16,676&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(16,284&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Closing balance&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,418&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,568&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;
























































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 22.5pt; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin: 0in -4.3pt 0.0001pt -13.5pt; text-align: justify; text-indent: 0.25in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;The carrying amount of goodwill (other than those arising upon investment in a joint venture) was allocated to the cash generating units as follows:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="height:.15in"&gt;
			&lt;td style="width: 382.5pt; padding: 0in 5.4pt 0.5pt; height: 0.15in; font-size: 9pt;;vertical-align:top;"&gt;
			&lt;div style="font-size: 9pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td colspan="2" style="width: 2in; padding: 0in 5.4pt; height: 0.15in; border-bottom: 1pt solid windowtext;"&gt;
			&lt;div style="margin: 0in -7pt 0.0001pt -5.4pt; text-align: center; text-indent: -0.8pt; font-size: 9pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="height:.15in"&gt;
			&lt;td style="width: 382.5pt; padding: 0in 5.4pt 0.5pt; height: 0.15in; font-size: 9pt;;vertical-align:top;"&gt;
			&lt;div style="margin-left: 0.5in; font-size: 9pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1in; padding: 0in 5.4pt; height: 0.15in; border-bottom: 1pt solid windowtext;;vertical-align:bottom;"&gt;
			&lt;div style="margin: 0in 1.25pt 0.0001pt -0.9pt; text-align: right; text-indent: -5.3pt; font-size: 9pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1in; padding: 0in 5.4pt; height: 0.15in; border-bottom: 1pt solid windowtext; border-top: 1pt solid windowtext;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: -2.75pt; text-align: right; text-indent: -3.45pt; font-size: 9pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background: rgb(204, 237, 254); width: 382.5pt; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 2pt; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;PSAI-Active Pharmaceutical Operations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 237, 254); width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 0.5in; text-align: right; text-indent: -11.7pt; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Rs.997&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 237, 254); width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 1.05pt; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Rs.997&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 382.5pt; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 2pt; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Global Generics-Complex Injectables&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 0.5in; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;1,396&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 1.05pt; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;1,421&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background: rgb(204, 237, 255); width: 382.5pt; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 2pt; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Global Generics-North America Operations&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 237, 255); width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 0.5in; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;631&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 237, 255); width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 1.05pt; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;1,015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 382.5pt; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 2pt; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Global Generics-Branded Formulations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 0.5in; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;1,281&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 1.05pt; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;1,021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background: rgb(204, 237, 255); width: 382.5pt; padding: 0in 5.4pt 0.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 2pt; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Others&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 237, 255); width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt; border-bottom: 1pt solid windowtext;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 0.5in; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;113&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 237, 255); width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt; border-bottom: 1pt solid windowtext;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 1.05pt; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;114&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="height:.15in"&gt;
			&lt;td style="width: 382.5pt; padding: 0in 5.4pt 0.5pt; height: 0.15in; font-size: 9pt;;vertical-align:top;"&gt;
			&lt;div style="margin-left: 0.5in; font-size: 9pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1in; padding: 0in 5.4pt; height: 0.15in; font-size: 9pt; border-bottom: 1pt solid windowtext;;vertical-align:bottom;"&gt;
			&lt;div style="text-align: right; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.4,418&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1in; padding: 0in 5.4pt; height: 0.15in; font-size: 9pt; border-bottom: 1pt solid windowtext;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 1.05pt; text-align: right; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.4,568&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Refer to Note 6 of these consolidated financial statements for further details.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;




























&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the years ended March 31, 2022, the Company recorded impairment loss of Rs.392&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="text-indent: 0in; letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;pertaining to Shreveport CGU.&#160; Refer to Note 12 of these consolidated financial statements for further details. The said goodwill was included as part of &#x201c;Global Generics-North America Operations&#x201d;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

















&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The impairment loss of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.16,676 and &lt;/div&gt;16,284 includes Rs.16,003 pertaining to the Company&#x2019;s German subsidiary, betapharm Arzneimittel GmbH, which is part of the Company&#x2019;s Global Generics segment. This impairment loss was recorded for the years ended March 31, 2009 and 2010.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the purpose of impairment testing, goodwill is allocated to a cash generating unit, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;representing &lt;/div&gt;the lowest level within the Company at which goodwill is monitored for internal management purposes and which is not higher than the Company&#x2019;s operating segment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The recoverable amounts of the above cash generating units have been assessed using a value-in-use model. Value in use is generally calculated as the net present value of the projected post-tax cash flows plus a terminal value of the cash generating unit to which the goodwill is allocated. Initially, a post-tax discount rate is applied to calculate the net present value of the post-tax cash flows. Key assumptions upon which the Company has based its determinations of value-in-use include:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;a)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Estimated cash flows for five years, based on management&#x2019;s projections.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;b)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;A terminal value arrived at by extrapolating the last forecasted year cash flows to perpetuity, using a constant long-term growth rate of 0-2%. This long-term growth rate takes into consideration external macroeconomic sources of data. Such long-term growth rate considered does not exceed that of the relevant business and industry sector.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;c)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;The after tax discount rates used are based on the Company&#x2019;s weighted average cost of capital.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;d)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;The after tax discount rates used range from 11.7% to 14% for various cash generating units. The pre-tax discount rates range from 12.72% to 17.92%.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company believes that any reasonably possible change in the key assumptions on which a recoverable amount is based would not cause the aggregate carrying amount to exceed the aggregate recoverable amount of the cash-generating unit.&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DisclosureOfGoodwillExplanatory>
    <rdy:DisclosureOfReconciliationOfChangesInGoodwillTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the changes in goodwill during the years ended March 31, 2022 and 2021:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Opening balance, gross&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;20,852&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;20,278&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill arising on business combinations&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;260&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;530&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Effect of translation adjustments&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(18&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;44&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment loss&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(16,676&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(16,284&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Closing balance&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,418&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,568&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;
























































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 22.5pt; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Refer to Note 6 of these consolidated financial statements for further details.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;




























&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the years ended March 31, 2022, the Company recorded impairment loss of Rs.392&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="text-indent: 0in; letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;pertaining to Shreveport CGU.&#160; Refer to Note 12 of these consolidated financial statements for further details. The said goodwill was included as part of &#x201c;Global Generics-North America Operations&#x201d;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















</rdy:DisclosureOfReconciliationOfChangesInGoodwillTableTextBlock>
    <rdy:GoodwillGrossBalance
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">20852000000</rdy:GoodwillGrossBalance>
    <rdy:GoodwillGrossBalance
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">20278000000</rdy:GoodwillGrossBalance>
    <ifrs-full:AdditionalRecognitionGoodwill
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      id="Fact_50535770"
      unitRef="Unit_INR">260000000</ifrs-full:AdditionalRecognitionGoodwill>
    <ifrs-full:AdditionalRecognitionGoodwill
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      id="Fact_50535771"
      unitRef="Unit_INR">530000000</ifrs-full:AdditionalRecognitionGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-18000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">44000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesGoodwill>
    <rdy:ImpairmentLossRecordedInGoodwillTillDate
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      id="Fact_50539776"
      unitRef="Unit_INR">16676000000</rdy:ImpairmentLossRecordedInGoodwillTillDate>
    <rdy:ImpairmentLossRecordedInGoodwillTillDate
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      id="Fact_50539777"
      unitRef="Unit_INR">16284000000</rdy:ImpairmentLossRecordedInGoodwillTillDate>
    <ifrs-full:Goodwill
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4418000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">4568000000</ifrs-full:Goodwill>
    <rdy:DisclosureOfInformationForCashGeneratingUnitsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="margin: 0in -4.3pt 0.0001pt -13.5pt; text-align: justify; text-indent: 0.25in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;The carrying amount of goodwill (other than those arising upon investment in a joint venture) was allocated to the cash generating units as follows:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="height:.15in"&gt;
			&lt;td style="width: 382.5pt; padding: 0in 5.4pt 0.5pt; height: 0.15in; font-size: 9pt;;vertical-align:top;"&gt;
			&lt;div style="font-size: 9pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td colspan="2" style="width: 2in; padding: 0in 5.4pt; height: 0.15in; border-bottom: 1pt solid windowtext;"&gt;
			&lt;div style="margin: 0in -7pt 0.0001pt -5.4pt; text-align: center; text-indent: -0.8pt; font-size: 9pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="height:.15in"&gt;
			&lt;td style="width: 382.5pt; padding: 0in 5.4pt 0.5pt; height: 0.15in; font-size: 9pt;;vertical-align:top;"&gt;
			&lt;div style="margin-left: 0.5in; font-size: 9pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1in; padding: 0in 5.4pt; height: 0.15in; border-bottom: 1pt solid windowtext;;vertical-align:bottom;"&gt;
			&lt;div style="margin: 0in 1.25pt 0.0001pt -0.9pt; text-align: right; text-indent: -5.3pt; font-size: 9pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1in; padding: 0in 5.4pt; height: 0.15in; border-bottom: 1pt solid windowtext; border-top: 1pt solid windowtext;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: -2.75pt; text-align: right; text-indent: -3.45pt; font-size: 9pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background: rgb(204, 237, 254); width: 382.5pt; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 2pt; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;PSAI-Active Pharmaceutical Operations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 237, 254); width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 0.5in; text-align: right; text-indent: -11.7pt; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Rs.997&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 237, 254); width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 1.05pt; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Rs.997&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 382.5pt; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 2pt; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Global Generics-Complex Injectables&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 0.5in; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;1,396&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 1.05pt; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;1,421&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background: rgb(204, 237, 255); width: 382.5pt; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 2pt; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Global Generics-North America Operations&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 237, 255); width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 0.5in; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;631&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 237, 255); width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 1.05pt; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;1,015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 382.5pt; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 2pt; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Global Generics-Branded Formulations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 0.5in; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;1,281&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 1.05pt; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;1,021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background: rgb(204, 237, 255); width: 382.5pt; padding: 0in 5.4pt 0.5pt; font-size: 10pt; line-height: 10pt;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 2pt; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Others&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 237, 255); width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt; border-bottom: 1pt solid windowtext;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 0.5in; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;113&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 237, 255); width: 1in; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt; border-bottom: 1pt solid windowtext;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 1.05pt; text-align: right; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;114&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="height:.15in"&gt;
			&lt;td style="width: 382.5pt; padding: 0in 5.4pt 0.5pt; height: 0.15in; font-size: 9pt;;vertical-align:top;"&gt;
			&lt;div style="margin-left: 0.5in; font-size: 9pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1in; padding: 0in 5.4pt; height: 0.15in; font-size: 9pt; border-bottom: 1pt solid windowtext;;vertical-align:bottom;"&gt;
			&lt;div style="text-align: right; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.4,418&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1in; padding: 0in 5.4pt; height: 0.15in; font-size: 9pt; border-bottom: 1pt solid windowtext;;vertical-align:bottom;"&gt;
			&lt;div style="margin-left: 1.05pt; text-align: right; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.4,568&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the years ended March 31, 2022, the Company recorded impairment loss of Rs.392&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;div style="text-indent: 0in; letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;pertaining to Shreveport CGU.&#160; Refer to Note 12 of these consolidated financial statements for further details. The said goodwill was included as part of &#x201c;Global Generics-North America Operations&#x201d;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















</rdy:DisclosureOfInformationForCashGeneratingUnitsTableTextBlock>
    <ifrs-full:Goodwill
      contextRef="PAsOn03_31_2022_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_PsaiActivePharmaceuticalOperationsMemberRDYTypeOfCashgeneratingUnitsAxis"
      decimals="-6"
      unitRef="Unit_INR">997000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn03_31_2021_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_PsaiActivePharmaceuticalOperationsMemberRDYTypeOfCashgeneratingUnitsAxis"
      decimals="-6"
      unitRef="Unit_INR">997000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn03_31_2022_GlobalGenericsComplexInjectablesMemberRDYTypeOfCashgeneratingUnitsAxis_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"
      decimals="-6"
      unitRef="Unit_INR">1396000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn03_31_2021_GlobalGenericsComplexInjectablesMemberRDYTypeOfCashgeneratingUnitsAxis_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"
      decimals="-6"
      unitRef="Unit_INR">1421000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn03_31_2022_GlobalGenericsNorthAmericaOperationsMemberRDYTypeOfCashgeneratingUnitsAxis_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"
      decimals="-6"
      id="Fact_50536966"
      unitRef="Unit_INR">631000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn03_31_2021_GlobalGenericsNorthAmericaOperationsMemberRDYTypeOfCashgeneratingUnitsAxis_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"
      decimals="-6"
      id="Fact_50536967"
      unitRef="Unit_INR">1015000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn03_31_2022_GlobalGenericsBrandedFormulationsMemberRDYTypeOfCashgeneratingUnitsAxis_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"
      decimals="-6"
      unitRef="Unit_INR">1281000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn03_31_2021_GlobalGenericsBrandedFormulationsMemberRDYTypeOfCashgeneratingUnitsAxis_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"
      decimals="-6"
      unitRef="Unit_INR">1021000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn03_31_2022_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_OtherCashgeneratingUnitsMemberRDYTypeOfCashgeneratingUnitsAxis"
      decimals="-6"
      unitRef="Unit_INR">113000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn03_31_2021_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis_OtherCashgeneratingUnitsMemberRDYTypeOfCashgeneratingUnitsAxis"
      decimals="-6"
      unitRef="Unit_INR">114000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn03_31_2022_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"
      decimals="-6"
      unitRef="Unit_INR">4418000000</ifrs-full:Goodwill>
    <ifrs-full:Goodwill
      contextRef="PAsOn03_31_2021_IndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"
      decimals="-6"
      unitRef="Unit_INR">4568000000</ifrs-full:Goodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill
      contextRef="P04_01_2021To03_31_2022_GlobalGenericsComplexInjectablesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"
      decimals="-6"
      unitRef="Unit_INR">392000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossGoodwill>
    <rdy:ImpairmentLossRecordedInGoodwillTillDate
      contextRef="PAsOn03_31_2022_GlobalGenericsComplexInjectablesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"
      decimals="-6"
      unitRef="Unit_INR">16676000000</rdy:ImpairmentLossRecordedInGoodwillTillDate>
    <rdy:ImpairmentLossRecordedInGoodwillTillDate
      contextRef="PAsOn03_31_2021_GlobalGenericsComplexInjectablesMemberifrsfullIndividualAssetsOrCashgeneratingUnitsWithSignificantAmountOfGoodwillOrIntangibleAssetsWithIndefiniteUsefulLivesAxis"
      decimals="-6"
      unitRef="Unit_INR">-16284000000</rdy:ImpairmentLossRecordedInGoodwillTillDate>
    <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections
      contextRef="PAsOn03_31_2022_BottomOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
    <ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections
      contextRef="PAsOn03_31_2022_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.02</ifrs-full:DescriptionOfGrowthRateUsedToExtrapolateCashFlowProjections>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections
      contextRef="PAsOn03_31_2022_AfterTaxMemberifrsfullBusinessCombinationsAxis_BottomOfRangeMemberifrsfullRangeAxis_IntangiblesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="3"
      unitRef="Unit_pure">0.117</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections
      contextRef="PAsOn03_31_2022_AfterTaxMemberifrsfullBusinessCombinationsAxis_IntangiblesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.14</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections
      contextRef="PAsOn03_31_2022_BeforeTaxMemberifrsfullBusinessCombinationsAxis_BottomOfRangeMemberifrsfullRangeAxis_IntangiblesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis"
      decimals="4"
      unitRef="Unit_pure">0.1272</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections
      contextRef="PAsOn03_31_2022_BeforeTaxMemberifrsfullBusinessCombinationsAxis_IntangiblesMemberifrsfullClassesOfPropertyPlantAndEquipmentAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.1792</ifrs-full:DescriptionOfDiscountRatesAppliedToCashFlowProjections>
    <ifrs-full:DisclosureOfIntangibleAssetsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;. Other intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 9.35pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following is a summary of changes in the carrying value of intangible assets:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 9.35pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Product&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;related&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;intangibles&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Customer&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;related&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;intangibles&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Others&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross carrying value&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 40%;"&gt;Balance as of April 1, 2020&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;87,330&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,766&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;91,096&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,107&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;304&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,411&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets acquired through business combinations&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14,888&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14,888&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Disposals/De-recognitions&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(192&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(192&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(900&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(900&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;107,233&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,070&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;111,303&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Balance as of April 1, 2021&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;107,233&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,070&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;111,303&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Additions&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;816&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;379&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,195&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets acquired through business combinations&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;5&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;98&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;106&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Disposals/De-recognitions&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(6,398&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(5&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(6,403&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,254&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,255&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;102,910&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;98&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,448&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;107,456&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortization/impairment loss&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Balance as of April 1, 2020&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;61,531&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,906&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;63,437&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Amortization for the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,972&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;297&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,269&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Impairment loss&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;8,542&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;8,542&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Disposals/De-recognitions&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(192&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(192&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(401&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(401&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;73,452&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,203&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;75,655&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Balance as of April 1, 2021&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;73,452&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,203&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;75,655&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Amortization for the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,415&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;257&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,672&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Impairment loss&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,511&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,511&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Disposals/De-recognitions&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(4,519&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(2&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(4,521&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;892&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;893&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;77,751&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,459&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;80,210&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying value&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;As of April 1, 2020&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;25,799&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,860&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;27,659&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;As of March 31, 2021&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;33,781&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,867&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;35,648&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25,159&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;98&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,989&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,246&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

















&lt;div style="clear: both; max-height: 0px;"/&gt;












&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt; line-height: 10pt;"&gt;
			&lt;div style="font-size: 10pt; margin-top: 0pt; margin-right: 0in; margin-bottom: 0pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="font-size: 10pt; margin-top: 0pt; margin-right: 0in; margin-bottom: 0pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;;display:inline;"&gt;During the year ended March 31, 2021 the Company entered into a definitive agreement with Glenmark Pharmaceuticals Limited to acquire marketing authorizations and other rights of select brands in four &#x201c;Emerging Markets&#x201d; countries. The acquired brands represent two products, (a) a mometasone mono product and (b) a combination of mometasone with azelastine, and are indicated for the treatment of seasonal and perennial allergic rhinitis. The total consideration paid was Rs.1,516. Following the principles of IAS 38, the Company recognized the acquired brands at their acquisition cost. The acquisition pertains to the Company&#x2019;s Global Generics segment.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































&lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;





&lt;div style="clear: both; max-height: 0px; text-indent: 0px; font-size: 10pt;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 10pt; margin-top: 0pt; margin-right: 0in; margin-bottom: 0pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-bottom: 0pt; margin-top: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; line-height: 12pt;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="font-size: 10pt; margin-top: 0pt; margin-right: 0in; margin-bottom: 0pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-bottom: 0pt; margin-top: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; line-height: 12pt;;display:inline;"&gt;Refer to Note 6 of these consolidated financial statements for further details.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px; font-size: 10pt;"/&gt;


&lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 10pt; margin-top: 0pt; margin-right: 0in; margin-bottom: 0pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; line-height: 12pt;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="font-size: 10pt; margin-top: 0pt; margin-right: 0in; margin-bottom: 0pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; line-height: 12pt;;display:inline;"&gt;Disposals/de-recognitions for the year ended March 31, 2022 primarily include the following IPR&amp;amp;D assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































&lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;





&lt;div style="clear: both; max-height: 0px; text-indent: 0px; font-size: 10pt;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="margin: 0in 0in 8pt; line-height: 107%; font-family: Calibri, sans-serif; font-size: 10pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; line-height: 107%; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;div style="font-size: 10pt; line-height: 107%; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 10pt; text-align: justify; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; line-height: 12pt;;display:inline;"&gt;Rs.4,498 upon its settlement with Hatchtech Pty Limited regarding their civil litigation and arbitration, relating to the acquisition of the product Xeglyze&#xae;. Refer to Note 3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt; (Contingencies) of these consolidated financial statements under &#x201c;Civil Litigation and Arbitration with Hatchtech Pty Limited&#x201d; for further details.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px; font-size: 10pt;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="margin: 0in 0in 8pt; line-height: 107%; font-family: Calibri, sans-serif; font-size: 10pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; line-height: 107%; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;div style="font-size: 10pt; line-height: 107%; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 10pt; text-align: justify; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; line-height: 12pt;;display:inline;"&gt;Rs. 1,879 upon sale of all rights relating to anti-cancer agent E7777 (denileukin diftitox) to Citius Pharmaceuticals, Inc. (&#x201c;Citius&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px; font-size: 10pt;"/&gt;


&lt;div style="font-size: 10pt; margin: 0in 0in 6pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 10pt;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font-size: 10pt; margin: 0in 0in 6pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; text-indent: 0px; line-height: 10pt;;display:inline;"&gt;In-process research and development assets (&#x201c;IPR&amp;amp;D&#x201d;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;





&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; text-indent: -4.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tabulated below is the reconciliation of amounts relating to in-process research and development assets as at the beginning and at the end of the year:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Opening balance&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;6,113&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;10,987&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Add&lt;/div&gt;: Additions during the year&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;153&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,557&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Less&lt;/div&gt;: Disposals/De-recognitions&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(1,879&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Less: Impairments during the year&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(4,435&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(8,099&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;186&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(332&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Closing balance&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;138&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,113&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 14.2pt; text-align: justify; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;

















&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:10.1px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions during the year ended March 31, 2021 include Rs.3,291, representing the expenditure for purchase of intellectual property rights relating to&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; color: black; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Xeglyze&#xae;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt; forming part of the Company&#x2019;s Proprietary Products segment.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font-size:11pt; margin:0in 0in 0in 0.25in; text-align:justify; text-indent:-0.25in; font-family:Calibri, 'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:10.1px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2022, the Company entered into a definitive agreement with Citius Pharmaceuticals, Inc. (&#x201c;Citius&#x201d;) for the sale of all of its rights relating to its anti-cancer agent E7777 (denileukin diftitox) to Citius. The Company received Rs.2,951 (U.S.$40) as an upfront amount upon the closing of the transaction. Consequent to this definite agreement, the company de-recognised Rs. 1,879 representing the carrying cost of the said asset.&#160; Refer to Note 23 for the amount of gain on sale of such intangible asset.&#160; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































&lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; text-align: justify; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Interest capitalization&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 18.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the years ended March 31, 2022 and 2021, the Company capitalized interest cost of Rs.153 and Rs.266, respectively, with respect to certain qualifying assets. The rate for capitalization of interest cost for the years ended March 31, 2022 and 2021 ranged from 4.42% to 4.89% and from 3.95% to 4.74%&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 18.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; text-indent: -4.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment losses recorded for the year ended March 31, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="text-align: justify; margin-bottom: 0.0001pt; margin-top: 0px; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="text-align: justify; margin-bottom: 0.0001pt; margin-top: 0px; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; text-indent: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', 'serif'; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2022, there were significant changes to the market conditions for certain of the Company&#x2019;s products forming part of Company's Proprietary Products and Global Generics segments. The changes include, decrease in the market potential of products, increased competition leading to lower volumes, and revenues not being in line with projections. Due to these adverse market developments, the Company recorded an impairment loss of&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the complete carrying value for:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="text-align: justify; margin-bottom: 0.0001pt; margin-top: 0px; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="text-align: justify; margin-bottom: 0.0001pt; margin-top: 0px; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; margin-left: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', 'serif'; letter-spacing: 0px; top: 0px;;display:inline;"&gt;- Rs.4,337 relating to PPC-06 (Tepilamide Fumarate Extended Release Tablets), an IPR&amp;amp;D asset forming part of the Company's Proprietary Products segment; and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="text-align: justify; margin-bottom: 0.0001pt; margin-top: 0px; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="text-align: justify; margin-bottom: 0.0001pt; margin-top: 0px; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; margin-left: 0.25in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', 'serif'; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;- Rs.174 pertaining to other IPR&amp;amp;D and other intangible assets forming part of Company&#x2019;s Global Generics Segment.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 18.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; text-indent: -4.5pt;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 18.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company used the discounted cash flow approach to calculate the value-in-use which considered assumptions such as revenue projections, rate of generic penetration, estimated price erosion, the useful life of the asset and the net cash flows have been discounted based on post tax discount rate.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; text-indent: -4.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; text-indent: -4.5pt;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment losses recorded for the year ended March 31, 2021&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; text-indent: -4.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 18.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total impairment charges for the year ended March 31, 2021 were Rs.8,542 which were recorded in impairment of non-current assets in the consolidated income statement, of which Rs.3,180 was attributable to impairment of gNuvaring, Rs.3,291 was attributable to impairment of Xeglyze&#xae; and the balance of Rs.2,071 was attributable to other product related intangibles.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of gNuvaring&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 18.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2021, there were significant changes to the generics market for Ethinyl estradiol/Ethenogestral vaginal ring (a generic equivalent to Nuvaring&#xae;), one of the 8 ANDAs acquired from Teva in June 2016. The changes include the launch by a competitor of a generic version of the product in January 2021. Due to these adverse market developments, the Company tested the carrying value of this product at the product cash generating unit (&#x201c;CGU&#x201d;) level, being the smallest identifiable group of assets that generate cash inflows that are largely independent of the cash inflows from other assets or groups of assets. The recoverable amount was determined by reference to the product&#x2019;s value-in-use or fair value less costs to sell, whichever is higher. This resulted in the value-in-use being the recoverable value of the product. Accordingly, the Company recorded an impairment loss of Rs.3,180 for the year ended March 31, 2021. This impairment loss pertained to the Company&#x2019;s Global Generics segment. With this impairment, the carrying value of the asset has been reduced to Rs.Nil.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 18.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0.5pt; text-align: justify; text-indent: -0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of Xeglyze&#xae;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0.5pt; text-align: justify; text-indent: -0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin: 0pt -7pt 0pt 0.26in; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consequent to the decline in the market potential of the product Xeglyze&#xae; forming part of the Company's Proprietary Products segment, the Company recorded an amount of Rs.3,291 as impairment loss for the year ended March 31, 2021. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 20.8pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0.5pt; text-align: justify; text-indent: -0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0.5pt; text-align: justify; text-indent: -0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 18.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;With respect to the saxagliptin/metformin (generic version of Kombiglyze&#xae;-XR) and phentermine and topiramate (generic version of Qsymia&#xae;), two of the 8 ANDAs acquired from Teva in June 2016, there has been a significant decrease in the market potential of these products, primarily due to higher than expected value erosion. Accordingly, the Company assessed the recoverable amount by revisiting market volume, share and price assumptions for these two products and recorded an amount of Rs.1,587 as impairment loss for the year ended March 31, 2021. This impairment loss pertained to the Company&#x2019;s Global Generics segment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 18.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 18.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In view of the specific triggers occurring in the year with respect to some other product related intangible assets forming part of the Company's Global Generics segment, the Company determined that there was a decrease in the market potential of these products primarily due to higher than expected price erosion and increased competition leading to lower volumes. Consequently, the Company recorded an amount of Rs.484 as impairment loss for the year ended March 31, 2021.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 18.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 18.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company used the discounted cash flow approach to calculate the value-in-use which considered assumptions such as revenue projections, rate of generic penetration, estimated price erosion, the useful life of the asset and the net cash flows have been discounted based on post tax discount rate.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; text-indent: -4.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; text-indent: -4.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment losses recorded for the year ended March 31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; text-indent: -4.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 18.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total impairment charges for the year ended March 31, 2020 were Rs.16,757 which were recorded in impairment of non-current assets in the consolidated income statement, of which Rs.11,137 was attributable to impairment of gNuvaring and the balance of Rs.5,620 was attributable to other product related intangibles.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Impairment of gNuvaring&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2020, there were significant changes to the generics market for Ethinyl estradiol / Ethenogestral vaginal ring (a generic equivalent to Nuvaring&#xae;), one of the 8 ANDAs acquired from Teva in June 2016. The changes include the launches by competitors of both generic and authorized generic versions of the product in December 2019. Due to these adverse market developments, as at December 31, 2019, the Company tested the carrying value of this product at the product cash generating unit (&#x201c;CGU&#x201d;) level, being the smallest identifiable group of assets that generate cash inflows that are largely independent of the cash inflows from other assets or groups of assets. The recoverable amount was determined by reference to the product&#x2019;s value-in-use or fair value less costs to sell, whichever is higher. This resulted in the value-in-use being the recoverable value of the product. Accordingly, the Company recorded an impairment loss of Rs.11,137 for the year ended March 31, 2020. This impairment loss pertained to the Company&#x2019;s Global Generics segment. The carrying value of the asset after the impairment was Rs.3,269.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company used the discounted cash flow approach to calculate the value in use, with the assistance of independent appraisers. The key assumptions considered in the calculation are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;a.&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Weighted average of probability adjusted revenue projections, which take into consideration different scenarios such as the base case, the upside case and the downside case;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;b.&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Rate of generic penetration and estimated price erosion throughout the period;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;c.&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Estimate of useful life over which the product is expected to generate cash flows; and&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;d.&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;the net cash flows have been discounted based on a post-tax discounting tax rate of 8%.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 18.2pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2019, the Company launched tobramycin inhalation solution, USP, a therapeutic equivalent generic version of TOBI&#xae; (tobramycin) Inhalation Solution, and in July 2019 the Company launched ramelteon tablets, 8 mg, a therapeutically equivalent generic version of Rozerem&#xae; (ramelteon, 8 mg) Tablets. Subsequent to their respective launches, both products experienced adverse market conditions, such as increased competition and reduced selling prices by competitors. As a result, the performance of the products was significantly lower than the Company&#x2019;s prior estimates. Furthermore, the Company decided to drop the launch of its planned imiquimod cream product. Accordingly, the Company assessed the recoverable amount of intangible assets associated with these three products, and recognized an impairment loss of Rs.4,385 for the year ended March 31, 2020. These impairment losses pertained to the Company&#x2019;s Global Generics segment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In view of the specific triggers occurring in the year with respect to some other product related intangible assets forming part of the Company's Global Generics and Proprietary Products segments, the Company determined that there was a decrease in the market potential of these products primarily due to higher than expected price erosion and increased competition leading to lower volumes. Consequently, the Company recorded an amount of Rs.1,235 as impairment loss for the year ended March 31, 2020.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; text-indent: -4.5pt;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; text-indent: -4.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Significant separately acquired intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 7.1pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 7.1pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of significant separately acquired intangible assets as of March 31, 2022 are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 13.5pt; text-indent: -13.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr&gt;
			&lt;td style="width: 51%; vertical-align: bottom; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars of the asset&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; vertical-align: top; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 34%; vertical-align: bottom; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Acquired from&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; vertical-align: top; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; vertical-align: bottom; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Select portfolio of branded generics business&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Wockhardt Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.13,440&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;Select portfolio of dermatology, respiratory and pediatric assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;UCB India Private Limited and affiliates&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,064&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Various ANDAs&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva and an affiliate of Allergan&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,327&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;Select Anti-Allergy brands&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Glenmark Pharmaceuticals Limited&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,386&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Habitrol&#xae; brand&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Novartis Consumer Health Inc.&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,053&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIntangibleAssetsExplanatory>
    <rdy:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatoryTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following is a summary of changes in the carrying value of intangible assets:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 9.35pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Product&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;related&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;intangibles&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Customer&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;related&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;intangibles&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Others&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross carrying value&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 40%;"&gt;Balance as of April 1, 2020&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;87,330&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,766&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;91,096&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,107&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;304&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,411&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets acquired through business combinations&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14,888&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14,888&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Disposals/De-recognitions&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(192&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(192&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(900&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(900&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;107,233&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,070&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;111,303&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Balance as of April 1, 2021&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;107,233&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,070&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;111,303&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Additions&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;816&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;379&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,195&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets acquired through business combinations&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;5&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;98&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;106&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Disposals/De-recognitions&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(6,398&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(5&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(6,403&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,254&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,255&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;102,910&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;98&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,448&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;107,456&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortization/impairment loss&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Balance as of April 1, 2020&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;61,531&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,906&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;63,437&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Amortization for the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,972&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;297&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,269&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Impairment loss&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;8,542&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;8,542&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Disposals/De-recognitions&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(192&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(192&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(401&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(401&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;73,452&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,203&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;75,655&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Balance as of April 1, 2021&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;73,452&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,203&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;75,655&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Amortization for the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,415&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;257&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,672&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Impairment loss&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,511&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,511&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Disposals/De-recognitions&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(4,519&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(2&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(4,521&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;892&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;893&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;77,751&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,459&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;80,210&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net carrying value&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;As of April 1, 2020&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;25,799&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,860&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;27,659&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;As of March 31, 2021&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;33,781&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,867&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;35,648&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25,159&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;98&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,989&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,246&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

















&lt;div style="clear: both; max-height: 0px;"/&gt;












&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt; line-height: 10pt;"&gt;
			&lt;div style="font-size: 10pt; margin-top: 0pt; margin-right: 0in; margin-bottom: 0pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="font-size: 10pt; margin-top: 0pt; margin-right: 0in; margin-bottom: 0pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;;display:inline;"&gt;During the year ended March 31, 2021 the Company entered into a definitive agreement with Glenmark Pharmaceuticals Limited to acquire marketing authorizations and other rights of select brands in four &#x201c;Emerging Markets&#x201d; countries. The acquired brands represent two products, (a) a mometasone mono product and (b) a combination of mometasone with azelastine, and are indicated for the treatment of seasonal and perennial allergic rhinitis. The total consideration paid was Rs.1,516. Following the principles of IAS 38, the Company recognized the acquired brands at their acquisition cost. The acquisition pertains to the Company&#x2019;s Global Generics segment.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































&lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;





&lt;div style="clear: both; max-height: 0px; text-indent: 0px; font-size: 10pt;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 10pt; margin-top: 0pt; margin-right: 0in; margin-bottom: 0pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-bottom: 0pt; margin-top: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; line-height: 12pt;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="font-size: 10pt; margin-top: 0pt; margin-right: 0in; margin-bottom: 0pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-bottom: 0pt; margin-top: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; line-height: 12pt;;display:inline;"&gt;Refer to Note 6 of these consolidated financial statements for further details.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px; font-size: 10pt;"/&gt;


&lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 10pt; margin-top: 0pt; margin-right: 0in; margin-bottom: 0pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; line-height: 12pt;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="font-size: 10pt; margin-top: 0pt; margin-right: 0in; margin-bottom: 0pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; line-height: 12pt;;display:inline;"&gt;Disposals/de-recognitions for the year ended March 31, 2022 primarily include the following IPR&amp;amp;D assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































&lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;





&lt;div style="clear: both; max-height: 0px; text-indent: 0px; font-size: 10pt;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="margin: 0in 0in 8pt; line-height: 107%; font-family: Calibri, sans-serif; font-size: 10pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; line-height: 107%; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;div style="font-size: 10pt; line-height: 107%; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 10pt; text-align: justify; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; line-height: 12pt;;display:inline;"&gt;Rs.4,498 upon its settlement with Hatchtech Pty Limited regarding their civil litigation and arbitration, relating to the acquisition of the product Xeglyze&#xae;. Refer to Note 3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt; (Contingencies) of these consolidated financial statements under &#x201c;Civil Litigation and Arbitration with Hatchtech Pty Limited&#x201d; for further details.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px; font-size: 10pt;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="margin: 0in 0in 8pt; line-height: 107%; font-family: Calibri, sans-serif; font-size: 10pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; line-height: 107%; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;div style="font-size: 10pt; line-height: 107%; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 10pt; text-align: justify; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; line-height: 12pt;;display:inline;"&gt;Rs. 1,879 upon sale of all rights relating to anti-cancer agent E7777 (denileukin diftitox) to Citius Pharmaceuticals, Inc. (&#x201c;Citius&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px; font-size: 10pt;"/&gt;
</rdy:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatoryTextBlock>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">87330000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2020_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">3766000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2020_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">91096000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">6107000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">304000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">6411000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">14888000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">14888000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">192000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">192000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">-900000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-900000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">107233000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">4070000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">111303000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">107233000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">4070000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">111303000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">816000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">379000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">1195000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">5000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">98000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">3000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">106000000</ifrs-full:AcquisitionsThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">6398000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">5000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">6403000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">1254000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">1255000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">102910000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2022_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">98000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">4448000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2022_GrossCarryingAmountMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">107456000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2020_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">-61531000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2020_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2020_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">-1906000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2020_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-63437000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">3972000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">297000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">4269000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">8542000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">8542000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">-192000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-192000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">-401000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-401000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">-73452000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">-2203000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-75655000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">-73452000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">-2203000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-75655000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">3415000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">257000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">3672000000</ifrs-full:AmortisationIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">4511000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">4511000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">-4519000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">-2000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-4521000000</ifrs-full:DisposalsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">892000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">893000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">-77751000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">-2459000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2022_AccumulatedDepreciationAmortisationAndImpairmentMemberifrsfullCarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"
      decimals="-6"
      unitRef="Unit_INR">-80210000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2020_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">25799000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2020_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2020_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">1860000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">27659000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">33781000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">1867000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">35648000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2022_RecipesFormulaeModelsDesignsAndPrototypesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">25159000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2022_CustomerrelatedIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">98000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2022_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">1989000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">27246000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:CashTransferred
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1516000000</ifrs-full:CashTransferred>
    <rdy:DisposalsAndDerecognitionsIntangibleAssetsOtherThanGoodwillUponSettlementOfCivilLitigationAndArbitationRelatingToAcquisitionOfProduct
      contextRef="P04_01_2021To03_31_2022_HatchtechPtyLimitedMemberdeiLegalEntityAxis_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">4498000000</rdy:DisposalsAndDerecognitionsIntangibleAssetsOtherThanGoodwillUponSettlementOfCivilLitigationAndArbitationRelatingToAcquisitionOfProduct>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">1879000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <rdy:DisclosureOfDetailedInformationAboutIntangibleAssetsUnderDevelopmentTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tabulated below is the reconciliation of amounts relating to in-process research and development assets as at the beginning and at the end of the year:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Opening balance&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;6,113&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;10,987&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Add&lt;/div&gt;: Additions during the year&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;153&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,557&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Less&lt;/div&gt;: Disposals/De-recognitions&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(1,879&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Less: Impairments during the year&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(4,435&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(8,099&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;186&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(332&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Closing balance&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;138&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,113&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

































































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 14.2pt; text-align: justify; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;

















&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:10.1px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions during the year ended March 31, 2021 include Rs.3,291, representing the expenditure for purchase of intellectual property rights relating to&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; color: black; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Xeglyze&#xae;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt; forming part of the Company&#x2019;s Proprietary Products segment.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font-size:11pt; margin:0in 0in 0in 0.25in; text-align:justify; text-indent:-0.25in; font-family:Calibri, 'sans-serif'"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:10.1px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2022, the Company entered into a definitive agreement with Citius Pharmaceuticals, Inc. (&#x201c;Citius&#x201d;) for the sale of all of its rights relating to its anti-cancer agent E7777 (denileukin diftitox) to Citius. The Company received Rs.2,951 (U.S.$40) as an upfront amount upon the closing of the transaction. Consequent to this definite agreement, the company de-recognised Rs. 1,879 representing the carrying cost of the said asset.&#160; Refer to Note 23 for the amount of gain on sale of such intangible asset.&#160; &#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































&lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; text-align: justify; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;</rdy:DisclosureOfDetailedInformationAboutIntangibleAssetsUnderDevelopmentTextBlock>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">6113000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2020_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">10987000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">153000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">3557000000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">1879000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">4435000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">8099000000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">186000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2020To03_31_2021_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">-332000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2022_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">138000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="PAsOn03_31_2021_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">6113000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="P04_01_2020To03_31_2021_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">3291000000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <rdy:UpfrontPaymentReceived
      contextRef="P04_01_2021To03_31_2022_CitiusPharmaceuticalsMemberRDYAcquirerOfIntangibleAssetsAxis_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ProprietaryProductsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2951000000</rdy:UpfrontPaymentReceived>
    <rdy:UpfrontPaymentReceived
      contextRef="P04_01_2021To03_31_2022_CitiusPharmaceuticalsMemberRDYAcquirerOfIntangibleAssetsAxis_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ProprietaryProductsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_USD">40000000</rdy:UpfrontPaymentReceived>
    <ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill
      contextRef="P04_01_2021To03_31_2022_IntangibleAssetsUnderDevelopmentMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">1879000000</ifrs-full:DisposalsAndRetirementsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:InterestCostsCapitalised
      contextRef="P04_01_2021To03_31_2022_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">153000000</ifrs-full:InterestCostsCapitalised>
    <ifrs-full:InterestCostsCapitalised
      contextRef="P04_01_2020To03_31_2021_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">266000000</ifrs-full:InterestCostsCapitalised>
    <ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation
      contextRef="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="4"
      unitRef="Unit_pure">0.0442</ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation>
    <ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation
      contextRef="P04_01_2021To03_31_2022_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0489</ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation>
    <ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation
      contextRef="P04_01_2020To03_31_2021_BottomOfRangeMemberifrsfullRangeAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="4"
      unitRef="Unit_pure">0.0395</ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation>
    <ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation
      contextRef="P04_01_2020To03_31_2021_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0474</ifrs-full:CapitalisationRateOfBorrowingCostsEligibleForCapitalisation>
    <ifrs-full:ImpairmentLoss
      contextRef="P04_01_2021To03_31_2022_PPC06TepilamideFumarateExtendedReleaseTabletsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ProprietaryProductsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">4337000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="P04_01_2021To03_31_2022_OtherIPRDandotherintangibleassetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis_ProprietaryProductsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">174000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">8542000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis_GnuvaringMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">3180000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="P04_01_2020To03_31_2021_XeglyzeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">3291000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="P04_01_2020To03_31_2021_GlobalGenericsAndProperietaryProductsMemberifrsfullSegmentsAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">2071000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis_GnuvaringMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">3180000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="P04_01_2020To03_31_2021_ProprietaryProductsMemberifrsfullSegmentsAxis_XeglyzeMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">3291000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="P04_01_2020To03_31_2021_GlobalGenericsOneMemberifrsfullSegmentsAxis_SaxagliptinMetforminPhentermineAndTopiramateMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">1587000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="P04_01_2020To03_31_2021_GlobalGenericsAndProperietaryProductsMemberifrsfullSegmentsAxis_HigherThanExpectedPriceErosionAndIncreasedCompetitionMemberRDYTriggeringEventAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">484000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">16757000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_GnuvaringMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">11137000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="P04_01_2019To03_31_2020_GlobalGenericsAndProperietaryProductsMemberifrsfullSegmentsAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">5620000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_GnuvaringMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">11137000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:RecoverableAmountOfAssetOrCashgeneratingUnit
      contextRef="PAsOn03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_GnuvaringMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">3269000000</ifrs-full:RecoverableAmountOfAssetOrCashgeneratingUnit>
    <ifrs-full:ImpairmentLoss
      contextRef="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_TobramycinInhalationSolutionRamelteonAndImiquimodCreamProductMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">4385000000</ifrs-full:ImpairmentLoss>
    <ifrs-full:ImpairmentLoss
      contextRef="P04_01_2019To03_31_2020_GlobalGenericsAndProperietaryProductsMemberifrsfullSegmentsAxis_HigherThanExpectedPriceErosionAndIncreasedCompetitionMemberRDYTriggeringEventAxis_OtherIntangibleAssetsMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">1235000000</ifrs-full:ImpairmentLoss>
    <rdy:DescriptionOfSignificantSeparatelyAcquiredIntangibleAssetsTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 7.1pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of significant separately acquired intangible assets as of March 31, 2022 are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 13.5pt; text-indent: -13.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr&gt;
			&lt;td style="width: 51%; vertical-align: bottom; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars of the asset&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; vertical-align: top; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 34%; vertical-align: bottom; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Acquired from&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; vertical-align: top; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: right; vertical-align: bottom; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Carrying cost&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Select portfolio of branded generics business&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Wockhardt Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.13,440&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;Select portfolio of dermatology, respiratory and pediatric assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;UCB India Private Limited and affiliates&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,064&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Various ANDAs&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Teva and an affiliate of Allergan&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,327&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: white;"&gt;
			&lt;td&gt;Select Anti-Allergy brands&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Glenmark Pharmaceuticals Limited&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,386&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Habitrol&#xae; brand&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Novartis Consumer Health Inc.&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,053&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</rdy:DescriptionOfSignificantSeparatelyAcquiredIntangibleAssetsTextBlock>
    <ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsMaterialToEntity contextRef="P04_01_2021To03_31_2022_WockhardtLimitedMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">Select portfolio of branded generics business</ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsMaterialToEntity>
    <ifrs-full:IntangibleAssetsMaterialToEntity
      contextRef="PAsOn03_31_2022_WockhardtLimitedMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">13440000000</ifrs-full:IntangibleAssetsMaterialToEntity>
    <ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsMaterialToEntity contextRef="P04_01_2021To03_31_2022_UcbIndiaPrivateLimitedAndAffiliatesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">Select portfolio of dermatology, respiratory and pediatric assets</ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsMaterialToEntity>
    <ifrs-full:IntangibleAssetsMaterialToEntity
      contextRef="PAsOn03_31_2022_UcbIndiaPrivateLimitedAndAffiliatesMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">4064000000</ifrs-full:IntangibleAssetsMaterialToEntity>
    <ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsMaterialToEntity contextRef="P04_01_2021To03_31_2022_TevaAndAnAffiliateOfAllerganMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">Various ANDAs</ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsMaterialToEntity>
    <ifrs-full:IntangibleAssetsMaterialToEntity
      contextRef="PAsOn03_31_2022_TevaAndAnAffiliateOfAllerganMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">3327000000</ifrs-full:IntangibleAssetsMaterialToEntity>
    <ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsMaterialToEntity contextRef="P04_01_2021To03_31_2022_GlenmarkPharmaceuticalsLimitedMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">Select Anti-Allergy brands</ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsMaterialToEntity>
    <ifrs-full:IntangibleAssetsMaterialToEntity
      contextRef="PAsOn03_31_2022_GlenmarkPharmaceuticalsLimitedMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">1386000000</ifrs-full:IntangibleAssetsMaterialToEntity>
    <ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsMaterialToEntity contextRef="P04_01_2021To03_31_2022_NovartisConsumerHealthIncMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis">Habitrol&#xae; brand</ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsMaterialToEntity>
    <ifrs-full:IntangibleAssetsMaterialToEntity
      contextRef="PAsOn03_31_2022_NovartisConsumerHealthIncMemberifrsfullClassesOfIntangibleAssetsOtherThanGoodwillAxis"
      decimals="-6"
      unitRef="Unit_INR">1053000000</ifrs-full:IntangibleAssetsMaterialToEntity>
    <ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;. Investment in equity accounted investees&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Equity shares held in Kunshan Rotam Reddy Pharmaceutical Company Limited, China&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;4,259&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,307&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Equity shares held in DRES Energy Private Limited, India&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;59&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;68&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,318&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,375&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Details of the Company&#x2019;s investment in Kunshan Rotam Reddy Pharmaceuticals Company Limited:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kunshan Rotam Reddy Pharmaceuticals Company Limited (&#x201c;Reddy Kunshan&#x201d;) is engaged in manufacturing and marketing of finished dosages in China. The Company&#x2019;s interest in Reddy Kunshan was 51.3% as of March 31, 2022 and 2021. Four directors of the Company are on the board of Reddy Kunshan, which consists of eight directors. Under the terms of the joint venture agreement, all major decisions with respect to operating activities, significant financing and other activities are taken by the approval of at least five of the eight directors of Reddy Kunshan&#x2019;s board. As the Company does not control Reddy Kunshan&#x2019;s board and the other partners have significant participation rights, the Company&#x2019;s interest in Reddy Kunshan has been accounted for under the equity method of accounting.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Summary financial information of Reddy Kunshan, as translated into the reporting currency of the Company and not adjusted for the percentage ownership held by the Company, is as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of/for the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%;"&gt;Ownership&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;51.3&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;51.3&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;51.3&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Total current assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,569&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;8,778&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,925&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Total non-current assets&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,460&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;892&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;732&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,029&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,670&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,657&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Equity&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,944&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,088&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,931&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Total current liabilities&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,085&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3,582&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,726&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total equity and liabilities&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,029&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,670&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,657&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Revenues&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;9,867&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;9,017&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,679&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Expenses&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;8,480&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;8,117&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;6,554&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit for the year&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,387&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;900&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,125&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Company&#x2019;s share of profits for the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;712&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;461&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;577&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carrying value of the Company&#x2019;s investment&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,259&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,307&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,714&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Translation adjustment arising out of translation of foreign currency balances&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;678&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;438&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;306&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Includes Rs.181 representing the goodwill on acquisition of investment.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"/&gt;













&lt;div style="margin-top: 1em; margin-bottom: 1em"/&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31 2020, the Company recognized an amount of Rs.392, representing its &lt;div style="display:inline;"&gt;s&lt;/div&gt;hare of dividend declared by the equity accounted investee, Reddy Kunshan. The amount of dividend is adjusted against the carrying amount of investment in the consolidated statement of financial position.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Details of the Company&#x2019;s investment in DRES Energy Private Limited:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of/for the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 55%; text-align: left;"&gt;Carrying value of the Company&#x2019;s investment&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;59&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;68&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;49&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Company&#x2019;s share of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(l&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;oss)/&lt;/div&gt;&lt;/div&gt;profit for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(9&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;19&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(16&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                        &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory>
    <rdy:DisclosureOfEquitySharesHeldInEquityAccountedInvesteesTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Equity shares held in Kunshan Rotam Reddy Pharmaceutical Company Limited, China&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;4,259&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,307&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Equity shares held in DRES Energy Private Limited, India&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;59&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;68&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,318&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,375&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































</rdy:DisclosureOfEquitySharesHeldInEquityAccountedInvesteesTableTextBlock>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">4259000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">3307000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_DresEnergyPrivateLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">59000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_DresEnergyPrivateLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">68000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4318000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">3375000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture
      contextRef="P04_01_2021To03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="3"
      unitRef="Unit_pure">0.513</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture
      contextRef="P04_01_2020To03_31_2021_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="3"
      unitRef="Unit_pure">0.513</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <rdy:DisclosureOfDetailedInformationAboutJointVentureTableTextBlock contextRef="P04_01_2021To03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Summary financial information of Reddy Kunshan, as translated into the reporting currency of the Company and not adjusted for the percentage ownership held by the Company, is as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of/for the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%;"&gt;Ownership&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;51.3&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;51.3&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;51.3&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Total current assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,569&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;8,778&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,925&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Total non-current assets&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,460&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;892&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;732&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total assets&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,029&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,670&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,657&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Equity&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,944&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,088&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,931&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Total current liabilities&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,085&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3,582&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,726&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total equity and liabilities&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,029&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,670&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,657&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Revenues&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;9,867&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;9,017&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,679&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Expenses&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;8,480&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;8,117&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;6,554&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit for the year&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,387&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;900&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,125&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Company&#x2019;s share of profits for the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;712&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;461&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;577&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carrying value of the Company&#x2019;s investment&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,259&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,307&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,714&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Translation adjustment arising out of translation of foreign currency balances&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;678&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;438&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;306&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; margin-top: 0in; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt; padding-top:0in"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; vertical-align: top; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: bottom; overflow-wrap: break-word; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt;"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Includes Rs.181 representing the goodwill on acquisition of investment.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





&lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"/&gt;











</rdy:DisclosureOfDetailedInformationAboutJointVentureTableTextBlock>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture
      contextRef="P04_01_2021To03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="3"
      unitRef="Unit_pure">0.513</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture
      contextRef="P04_01_2020To03_31_2021_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="3"
      unitRef="Unit_pure">0.513</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:ProportionOfOwnershipInterestInJointVenture
      contextRef="P04_01_2019To03_31_2020_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="3"
      unitRef="Unit_pure">0.513</ifrs-full:ProportionOfOwnershipInterestInJointVenture>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">7569000000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn03_31_2021_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">8778000000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="PAsOn03_31_2020_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">6925000000</ifrs-full:CurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">2460000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn03_31_2021_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">892000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="PAsOn03_31_2020_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">732000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets
      contextRef="PAsOn03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">10029000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn03_31_2021_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">9670000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn03_31_2020_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">7657000000</ifrs-full:Assets>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">7944000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2021_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">6088000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="PAsOn03_31_2020_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">4931000000</ifrs-full:Equity>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">2085000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn03_31_2021_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">3582000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="PAsOn03_31_2020_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">2726000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="PAsOn03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">10029000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="PAsOn03_31_2021_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">9670000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="PAsOn03_31_2020_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">7657000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">9867000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">9017000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">7679000000</ifrs-full:Revenue>
    <ifrs-full:OtherExpenseByFunction
      contextRef="P04_01_2021To03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">8480000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="P04_01_2020To03_31_2021_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">8117000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:OtherExpenseByFunction
      contextRef="P04_01_2019To03_31_2020_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">6554000000</ifrs-full:OtherExpenseByFunction>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2021To03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">1387000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2020To03_31_2021_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">900000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="P04_01_2019To03_31_2020_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">1125000000</ifrs-full:ProfitLoss>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="P04_01_2021To03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">712000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="P04_01_2020To03_31_2021_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">461000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="P04_01_2019To03_31_2020_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">577000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      id="Fact_50536066"
      unitRef="Unit_INR">4259000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      id="Fact_50536067"
      unitRef="Unit_INR">3307000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2020_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      id="Fact_50536068"
      unitRef="Unit_INR">2714000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesInvestmentInJointVentures
      contextRef="P04_01_2021To03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">678000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesInvestmentInJointVentures>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesInvestmentInJointVentures
      contextRef="P04_01_2020To03_31_2021_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">438000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesInvestmentInJointVentures>
    <rdy:IncreaseDecreaseThroughNetExchangeDifferencesInvestmentInJointVentures
      contextRef="P04_01_2019To03_31_2020_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">306000000</rdy:IncreaseDecreaseThroughNetExchangeDifferencesInvestmentInJointVentures>
    <ifrs-full:DividendsReceivedFromInvestmentsAccountedForUsingEquityMethodClassifiedAsInvestingActivities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">392000000</ifrs-full:DividendsReceivedFromInvestmentsAccountedForUsingEquityMethodClassifiedAsInvestingActivities>
    <rdy:DisclosureOfDetailedInformationAboutJointVentureTableTextBlock contextRef="P04_01_2021To03_31_2022_DresEnergyPrivateLimitedMemberifrsfullJointVenturesAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Details of the Company&#x2019;s investment in DRES Energy Private Limited:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of/for the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 55%; text-align: left;"&gt;Carrying value of the Company&#x2019;s investment&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;59&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;68&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;49&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Company&#x2019;s share of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(l&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;oss)/&lt;/div&gt;&lt;/div&gt;profit for the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(9&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;19&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(16&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                        &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</rdy:DisclosureOfDetailedInformationAboutJointVentureTableTextBlock>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_DresEnergyPrivateLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">59000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_DresEnergyPrivateLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">68000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2020_DresEnergyPrivateLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">49000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="P04_01_2021To03_31_2022_DresEnergyPrivateLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">-9000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="P04_01_2020To03_31_2021_DresEnergyPrivateLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">19000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="P04_01_2019To03_31_2020_DresEnergyPrivateLimitedMemberifrsfullJointVenturesAxis"
      decimals="-6"
      unitRef="Unit_INR">-16000000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;. Trade and other payables&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade and other payables consist of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 70%; text-align: left;"&gt;Trade payables&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;15,971&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;12,696&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Due to creditors for expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;6,691&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,413&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Due to capital creditors&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,910&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5,635&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25,572&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;23,744&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                                              &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For details regarding the Company&#x2019;s exposure to currency and liquidity risks, see Note 3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&#160;of these consolidated financial statements under &#x201c;Liquidity risk&#x201d;.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <rdy:TradeAndOtherPayablesTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade and other payables consist of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 70%; text-align: left;"&gt;Trade payables&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;15,971&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;12,696&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Due to creditors for expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;6,691&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,413&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Due to capital creditors&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,910&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5,635&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25,572&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;23,744&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                      </rdy:TradeAndOtherPayablesTableTextBlock>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">15971000000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">12696000000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:OtherPayables
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">6691000000</ifrs-full:OtherPayables>
    <ifrs-full:OtherPayables
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">5413000000</ifrs-full:OtherPayables>
    <ifrs-full:PayablesForPurchaseOfNoncurrentAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2910000000</ifrs-full:PayablesForPurchaseOfNoncurrentAssets>
    <ifrs-full:PayablesForPurchaseOfNoncurrentAssets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">5635000000</ifrs-full:PayablesForPurchaseOfNoncurrentAssets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">25572000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">23744000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:DisclosureOfBorrowingsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;. Loans and borrowings&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Short-term borrowings&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term borrowings primarily consist of &#x201c;pre-shipment credit&#x201d; drawn by the parent company and other unsecured loans drawn by parent company and certain &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;of&lt;/div&gt; its subsidiaries in Russia, Brazil, Mexico, Ukraine and Switzerland which are repayable within&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;12 months from the date of drawdown.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term borrowings consist of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 70%; text-align: left;"&gt;Pre-shipment credit&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;18,211&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;10,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Other working capital borrowings&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;8,871&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;12,836&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,082&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;23,136&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                                              &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The interest rate profile of short-term borrowings from banks is given below:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &#160;&#160;&#160;&#160;&#160; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 5.4pt 0.5pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%; border-bottom: 1pt solid windowtext;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 5.4pt 0.5pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%; border-bottom: 1pt solid windowtext; border-top: 0px none;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%; border-bottom: 1pt solid windowtext; border-top: 0px solid windowtext;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="width: 48%; padding: 0px 5.4pt 0.375pt; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.375pt; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; height: 8.65pt; white-space: nowrap; vertical-align: bottom; width: 11%; border-top: 0px none; border-bottom: 0.75pt solid black;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Currency&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.375pt; height: 8.65pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.375pt; height: 8.65pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; height: 8.65pt; white-space: nowrap; vertical-align: bottom; width: 11%; border-top: 0px solid windowtext; border-bottom: 0.75pt solid black;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Interest Rate&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.375pt; height: 8.65pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.375pt; height: 8.65pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; height: 8.65pt; white-space: nowrap; vertical-align: bottom; width: 11%; border-top: 0px none; border-bottom: 0.75pt solid black;"&gt;&lt;div style="text-align: center; text-indent: -5.4pt; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 5.4pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Currency&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.375pt; height: 8.65pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.375pt; height: 8.65pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; height: 8.65pt; white-space: nowrap; vertical-align: bottom; width: 11%; border-top: 0px none; border-bottom: 0.75pt solid black;"&gt;&lt;div style="text-align: center; text-indent: -5.4pt; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 5.4pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Interest Rate&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.375pt; height: 8.65pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="background: rgb(204, 238, 255); width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-shipment credit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;INR&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;3 Months T-bill &#x2013; 5 bps&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;INR&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;3 Months T-bill + 30 bps&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;INR&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;3 Months T-bill&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;INR&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;5.75&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 0in; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="background: rgb(204, 238, 255); width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;INR&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;3 Months T-bill + 25 bps&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;INR&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other working capital borrowings&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-right: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.&lt;/div&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;1 Months LIBOR+ 80 bps&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-indent: -5.4pt; margin: 0px 0in 0.0001pt 5.4pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S&lt;/div&gt;.$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;(2.2)% to (1.8)%&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="background: rgb(204, 238, 255); width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;RUB&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;8.88&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;RUB&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;3.00% to 3.40% and 5.55%&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;MXN&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;TIIE + 1.15%&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;MXN&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;TIIE + 1.20%&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="background: rgb(204, 238, 255); width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;INR&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;4.00&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;INR&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;4.00&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 0in; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;BRL&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;CDI + 1.79%&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;BRL&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;4.00&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 0in; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="background: rgb(204, 238, 255); width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;UAH&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;13.00&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;UAH&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;4.75&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 0in; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;        &lt;div style="clear: both; max-height: 0px;"/&gt;  &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;                 &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 7.1pt; text-indent: -20.6pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0in;"/&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: bottom;"&gt;&#x201c;INR&#x201d; means Indian rupees, &#x201c;U.S.$&#x201d; means United States Dollars, &#x201c;RUB&#x201d; means Russian roubles, &#x201c;MXN&#x201d; means Mexican pesos, &#x201c;BRL&#x201d; means Brazilian reals and &#x201c;UAH&#x201d; means Ukrainian hryvnia.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                        &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0in;"/&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: bottom;"&gt;&#x201c;LIBOR&#x201d; means the London Inter-bank Offered Rate, &#x201c;TIIE&#x201d; means the Equilibrium Inter-banking Interest Rate (Tasa de Inter&#xe9;s Interbancaria de Equilibrio), &#x201c;T-bill&#x201d; means India Treasury bill and &#x201c;CDI&#x201d; means Brazilian interbank deposit rate (Certificado de Dep&#xf3;sito Interbanc&#xe1;rio).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Long-term borrowings&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term borrowings consist of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31, 2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 48%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-convertible debentures by the APSL subsidiary&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;3,800&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;3,800&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Obligations under leases&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,946&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,017&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,499&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;864&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,746&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,017&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,299&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;864&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                        &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0px;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom;"&gt;&#x201c;APSL subsidiary&#x201d; refers to Aurigene Pharmaceutical Services Limited.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                        &lt;div style="clear: both; max-height: 0px;"/&gt;                                          &lt;div style="font-style: normal; font-variant: normal; font-size: 10pt; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-stretch: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2021, the APSL subsidiary issued non-convertible debentures for Rs.3,800. The aforesaid non-convertible debentures are repayable at par after 3 years following the date of issue&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The interest rate profiles of long-term borrowings (other than obligations under leases) as of March 31, 2022 and 2021 were as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest Rate&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest Rate&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 48%; text-align: left;"&gt;Non-convertible debentures&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;6.77&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;6.77&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                        &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0in;"/&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: bottom;"&gt;&#x201c;INR&#x201d; means Indian rupees.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                                              &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate maturities of long-term loans and borrowings, based on contractual maturities, as of March 31, 2022 were as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturing in&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;convertible&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;debentures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Obligations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;under leases&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Less than 1 year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,017&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,017&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 61%;"&gt;1-2 years&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;3,800&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;868&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;4,668&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;2-3 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;809&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;809&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;3-4 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;155&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;155&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;4-5 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;65&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;65&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;49&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;49&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,800&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,963&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,763&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                        &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate maturities of long-term loans and borrowings, based on contractual maturities, as of March 31, 2021 were as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturing in&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;convertible&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;debentures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Obligations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;under leases&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Less than 1 year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;864&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;864&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 61%;"&gt;1-2 years&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;802&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;802&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;2-3 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,800&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;745&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,545&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;3-4 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;734&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;734&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;4-5 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;118&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;118&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;100&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;100&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,800&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,363&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,163&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                                              &lt;div style="font-style: normal; font-variant: normal; font-size: 10pt; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; font-stretch: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-style: normal; font-variant: normal; font-size: 10pt; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; font-stretch: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Uncommitted lines of credit from banks&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company had uncommitted lines of credit of Rs.39,989 and Rs.38,766 as of March 31, 2022 and 2021, respectively, from its banks for working capital requirements. The Company draw upon these lines of credit based on its working capital requirements.&lt;/div&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.7pt; text-indent: -13.7pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reconciliation of liabilities arising from financing activities during the year ended March 31, 2022:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.7pt; text-indent: -13.7pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Long-term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;borrowings&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Short-term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;borrowings&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Opening balance&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,163&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;23,136&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;30,299&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 61%; text-align: left;"&gt;Recognition of right-of-use liability during the year&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;327&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;327&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Payment of principal portion of lease liabilities&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(785&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(785&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Borrowings made during the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;51,518&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;51,518&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Borrowings repaid during the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(47,998&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(47,998&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;58&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;426&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;484&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Closing balance&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,763&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;27,082&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;33,845&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reconciliation of liabilities arising from financing activities during the year ended March 31, 2021:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Long-term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;borrowings&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Short-term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;borrowings&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 61%; text-align: left;"&gt;Opening balance&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;5,570&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;16,441&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;22,011&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Recognition of right-of-use liability during the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,393&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,393&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Payment of principal portion of lease liabilities&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(754&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(754&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Borrowings made during the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,800&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;44,469&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;48,269&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Borrowings repaid during the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(3,743&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(37,678&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(41,421&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(103&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(96&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(199&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Closing balance&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,163&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;23,136&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;30,299&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.7pt; text-indent: -13.7pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Includes current portion.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























</ifrs-full:DisclosureOfBorrowingsExplanatory>
    <rdy:DisclosureOfShortTermBorrowingsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term borrowings consist of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 70%; text-align: left;"&gt;Pre-shipment credit&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;18,211&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;10,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Other working capital borrowings&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;8,871&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;12,836&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,082&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;23,136&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                      </rdy:DisclosureOfShortTermBorrowingsTableTextBlock>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2022_PreshipmentCreditMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_INR">18211000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2021_PreshipmentCreditMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_INR">10300000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2022_OtherWorkingCapitalBorrowingsMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_INR">8871000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2021_OtherWorkingCapitalBorrowingsMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_INR">12836000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">27082000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">23136000000</ifrs-full:ShorttermBorrowings>
    <rdy:DisclosureOfInterestRateProfileOfShortTermBorrowingsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The interest rate profile of short-term borrowings from banks is given below:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &#160;&#160;&#160;&#160;&#160; &lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 5.4pt 0.5pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%; border-bottom: 1pt solid windowtext;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width: 48%; padding: 0px 5.4pt 0.5pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%; border-bottom: 1pt solid windowtext; border-top: 0px none;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="padding: 0in; white-space: nowrap; vertical-align: bottom; width: 11%; border-bottom: 1pt solid windowtext; border-top: 0px solid windowtext;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.5pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="width: 48%; padding: 0px 5.4pt 0.375pt; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.375pt; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; height: 8.65pt; white-space: nowrap; vertical-align: bottom; width: 11%; border-top: 0px none; border-bottom: 0.75pt solid black;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Currency&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.375pt; height: 8.65pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.375pt; height: 8.65pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; height: 8.65pt; white-space: nowrap; vertical-align: bottom; width: 11%; border-top: 0px solid windowtext; border-bottom: 0.75pt solid black;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Interest Rate&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.375pt; height: 8.65pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.375pt; height: 8.65pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; height: 8.65pt; white-space: nowrap; vertical-align: bottom; width: 11%; border-top: 0px none; border-bottom: 0.75pt solid black;"&gt;&lt;div style="text-align: center; text-indent: -5.4pt; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 5.4pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Currency&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.375pt; height: 8.65pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.375pt; height: 8.65pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding: 0in; height: 8.65pt; white-space: nowrap; vertical-align: bottom; width: 11%; border-top: 0px none; border-bottom: 0.75pt solid black;"&gt;&lt;div style="text-align: center; text-indent: -5.4pt; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 5.4pt;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;Interest Rate&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0in 0in 0.375pt; height: 8.65pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="background: rgb(204, 238, 255); width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-shipment credit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;INR&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;3 Months T-bill &#x2013; 5 bps&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;INR&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;3 Months T-bill + 30 bps&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;INR&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;3 Months T-bill&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;INR&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;5.75&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 0in; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="background: rgb(204, 238, 255); width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;INR&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;3 Months T-bill + 25 bps&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;INR&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other working capital borrowings&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-right: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.&lt;/div&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;1 Months LIBOR+ 80 bps&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom;"&gt;&lt;div style="text-indent: -5.4pt; margin: 0px 0in 0.0001pt 5.4pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S&lt;/div&gt;.$&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;(2.2)% to (1.8)%&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="background: rgb(204, 238, 255); width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;RUB&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;8.88&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;RUB&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;3.00% to 3.40% and 5.55%&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;MXN&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;TIIE + 1.15%&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;MXN&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;TIIE + 1.20%&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="background: rgb(204, 238, 255); width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;INR&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;4.00&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;INR&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;4.00&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 0in; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;BRL&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;CDI + 1.79%&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;BRL&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom; text-align: right;"&gt;4.00&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 0in; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.65pt"&gt;&lt;td style="background: rgb(204, 238, 255); width: 48%; padding: 0px 5.4pt; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; text-align: left; vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;UAH&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;13.00&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;UAH&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom;"&gt;&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; vertical-align: bottom; text-align: right;"&gt;4.75&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 8.65pt; font-size: 9pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;&lt;div style="text-align: left; text-indent: 0in; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in;"&gt;&lt;div style="white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;        &lt;div style="clear: both; max-height: 0px;"/&gt;  &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt;                 &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 7.1pt; text-indent: -20.6pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0in;"/&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: bottom;"&gt;&#x201c;INR&#x201d; means Indian rupees, &#x201c;U.S.$&#x201d; means United States Dollars, &#x201c;RUB&#x201d; means Russian roubles, &#x201c;MXN&#x201d; means Mexican pesos, &#x201c;BRL&#x201d; means Brazilian reals and &#x201c;UAH&#x201d; means Ukrainian hryvnia.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                        &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0in;"/&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: bottom;"&gt;&#x201c;LIBOR&#x201d; means the London Inter-bank Offered Rate, &#x201c;TIIE&#x201d; means the Equilibrium Inter-banking Interest Rate (Tasa de Inter&#xe9;s Interbancaria de Equilibrio), &#x201c;T-bill&#x201d; means India Treasury bill and &#x201c;CDI&#x201d; means Brazilian interbank deposit rate (Certificado de Dep&#xf3;sito Interbanc&#xe1;rio).&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                       &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</rdy:DisclosureOfInterestRateProfileOfShortTermBorrowingsTableTextBlock>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2021To03_31_2022_PackingCreditBorrowingsInrMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537014">INR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRateBasis
      contextRef="P04_01_2021To03_31_2022_PackingCreditBorrowingsInrMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537032">3 Months T-bill &#x2013; 5 bps</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2020To03_31_2021_PackingCreditBorrowingsInrMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537015">INR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRateBasis
      contextRef="P04_01_2020To03_31_2021_PackingCreditBorrowingsInrMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537033">3 Months T-bill + 30 bps</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2021To03_31_2022_PackingCreditBorrowingsInrOneMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537016">INR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRateBasis
      contextRef="P04_01_2021To03_31_2022_PackingCreditBorrowingsInrOneMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537034">3 Months T-bill</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2020To03_31_2021_PackingCreditBorrowingsInrOneMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537017">INR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRate
      contextRef="PAsOn03_31_2021_PackingCreditBorrowingsInrOneMemberifrsfullBorrowingsByNameAxis"
      decimals="4"
      id="Fact_50540737"
      unitRef="Unit_pure">0.0575</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2021To03_31_2022_PreshipmentCreditBorrowingsUsdMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537018">INR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRateBasis
      contextRef="P04_01_2021To03_31_2022_PreshipmentCreditBorrowingsUsdMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537036">3 Months T-bill + 25 bps</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2020To03_31_2021_PreshipmentCreditBorrowingsUsdMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537019">INR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRateBasis
      contextRef="P04_01_2020To03_31_2021_PreshipmentCreditBorrowingsUsdMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537037">0</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2021To03_31_2022_OtherWorkingCapitalBorrowingsUsdMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537030">U.S</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRateBasis
      contextRef="P04_01_2021To03_31_2022_OtherWorkingCapitalBorrowingsUsdMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537038">1 Months LIBOR+ 80 bps</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2020To03_31_2021_OtherWorkingCapitalBorrowingsUsdMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537031">U.S</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRateBasis
      contextRef="P04_01_2020To03_31_2021_OtherWorkingCapitalBorrowingsUsdMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537039">(2.2)% to (1.8)%</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2021To03_31_2022_OtherWorkingsCapitalBorrowingsRubMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537020">RUB</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRate
      contextRef="PAsOn03_31_2022_OtherWorkingsCapitalBorrowingsRubMemberifrsfullBorrowingsByNameAxis"
      decimals="4"
      id="Fact_50540738"
      unitRef="Unit_pure">0.0888</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2020To03_31_2021_OtherWorkingsCapitalBorrowingsRubMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537021">RUB</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRateBasis
      contextRef="P04_01_2020To03_31_2021_OtherWorkingsCapitalBorrowingsRubMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537041">3.00% to 3.40% and 5.55%</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2021To03_31_2022_OtherWorkingsCapitalBorrowingsMxnMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537022">MXN</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRateBasis
      contextRef="P04_01_2021To03_31_2022_OtherWorkingsCapitalBorrowingsMxnMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537042">TIIE + 1.15%</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2020To03_31_2021_OtherWorkingsCapitalBorrowingsMxnMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537023">MXN</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRateBasis
      contextRef="P04_01_2020To03_31_2021_OtherWorkingsCapitalBorrowingsMxnMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537043">TIIE + 1.20%</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2021To03_31_2022_OtherWorkingsCapitalBorrowingssInrMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537024">INR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRate
      contextRef="PAsOn03_31_2022_OtherWorkingsCapitalBorrowingssInrMemberifrsfullBorrowingsByNameAxis"
      decimals="4"
      id="Fact_50540739"
      unitRef="Unit_pure">0.04</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2020To03_31_2021_OtherWorkingsCapitalBorrowingssInrMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537025">INR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRate
      contextRef="PAsOn03_31_2021_OtherWorkingsCapitalBorrowingssInrMemberifrsfullBorrowingsByNameAxis"
      decimals="4"
      id="Fact_50540740"
      unitRef="Unit_pure">0.04</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2021To03_31_2022_OtherWorkingsCapitalBorrowingsBrlMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537026">BRL</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRateBasis
      contextRef="P04_01_2021To03_31_2022_OtherWorkingsCapitalBorrowingsBrlMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537046">CDI + 1.79%</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2020To03_31_2021_OtherWorkingsCapitalBorrowingsBrlMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537027">BRL</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRate
      contextRef="PAsOn03_31_2021_OtherWorkingsCapitalBorrowingsBrlMemberifrsfullBorrowingsByNameAxis"
      decimals="4"
      id="Fact_50540741"
      unitRef="Unit_pure">0.04</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2021To03_31_2022_OtherWorkingsCapitalBorrowingsUahMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537028">UAH</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRate
      contextRef="PAsOn03_31_2022_OtherWorkingsCapitalBorrowingsUahMemberifrsfullBorrowingsByNameAxis"
      decimals="4"
      id="Fact_50540742"
      unitRef="Unit_pure">0.13</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2020To03_31_2021_OtherWorkingsCapitalBorrowingsUahMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50537029">UAH</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRate
      contextRef="PAsOn03_31_2021_OtherWorkingsCapitalBorrowingsUahMemberifrsfullBorrowingsByNameAxis"
      decimals="4"
      id="Fact_50540743"
      unitRef="Unit_pure">0.0475</ifrs-full:BorrowingsInterestRate>
    <rdy:DisclosureOfLongTermBorrowingsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term borrowings consist of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31, 2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 48%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-convertible debentures by the APSL subsidiary&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;3,800&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;3,800&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Obligations under leases&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,946&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,017&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,499&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;864&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,746&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,017&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,299&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;864&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                        &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0px;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align: bottom;"&gt;&#x201c;APSL subsidiary&#x201d; refers to Aurigene Pharmaceutical Services Limited.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                        &lt;div style="clear: both; max-height: 0px;"/&gt;        </rdy:DisclosureOfLongTermBorrowingsTableTextBlock>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn03_31_2022_AurigenePharmaceuticalServicesLimitedMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      id="Fact_50535995"
      unitRef="Unit_INR">3800000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:CurrentPortionOfLongtermBorrowings
      contextRef="PAsOn03_31_2022_AurigenePharmaceuticalServicesLimitedMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      id="Fact_50535996"
      unitRef="Unit_INR">0</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn03_31_2021_AurigenePharmaceuticalServicesLimitedMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      id="Fact_50535997"
      unitRef="Unit_INR">3800000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:CurrentPortionOfLongtermBorrowings
      contextRef="PAsOn03_31_2021_AurigenePharmaceuticalServicesLimitedMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      id="Fact_50535998"
      unitRef="Unit_INR">0</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="PAsOn03_31_2022_ObligationsUnderLeasesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">1946000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="PAsOn03_31_2022_ObligationsUnderLeasesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">1017000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="PAsOn03_31_2021_ObligationsUnderLeasesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">2499000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="PAsOn03_31_2021_ObligationsUnderLeasesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">864000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">5746000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:CurrentPortionOfLongtermBorrowings
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1017000000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">6299000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:CurrentPortionOfLongtermBorrowings
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">864000000</ifrs-full:CurrentPortionOfLongtermBorrowings>
    <ifrs-full:NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued
      contextRef="PAsOn03_31_2021_AurigenePharmaceuticalServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NonConvertibleDebenturesMemberifrsfullBorrowingsByNameAxis"
      decimals="-6"
      unitRef="Unit_INR">3800000000</ifrs-full:NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued>
    <ifrs-full:BorrowingsMaturity contextRef="P04_01_2020To03_31_2021_AurigenePharmaceuticalServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis_NonConvertibleDebenturesMemberifrsfullBorrowingsByNameAxis">3 years</ifrs-full:BorrowingsMaturity>
    <rdy:DisclosureOfInterestRateProfileOfLongtermBorrowingsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The interest rate profiles of long-term borrowings (other than obligations under leases) as of March 31, 2022 and 2021 were as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest Rate&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Currency&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest Rate&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 48%; text-align: left;"&gt;Non-convertible debentures&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;6.77&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;6.77&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                        &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0in;"/&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: bottom;"&gt;&#x201c;INR&#x201d; means Indian rupees.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                      </rdy:DisclosureOfInterestRateProfileOfLongtermBorrowingsTableTextBlock>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2021To03_31_2022_INRsrtCurrencyAxis_NonConvertibleDebenturesMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50539785">INR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRate
      contextRef="PAsOn03_31_2022_INRsrtCurrencyAxis_NonConvertibleDebenturesMemberifrsfullBorrowingsByNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0677</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:BorrowingsOriginalCurrency
      contextRef="P04_01_2020To03_31_2021_INRsrtCurrencyAxis_NonConvertibleDebenturesMemberifrsfullBorrowingsByNameAxis"
      id="Fact_50540129">INR</ifrs-full:BorrowingsOriginalCurrency>
    <ifrs-full:BorrowingsInterestRate
      contextRef="PAsOn03_31_2021_INRsrtCurrencyAxis_NonConvertibleDebenturesMemberifrsfullBorrowingsByNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.0677</ifrs-full:BorrowingsInterestRate>
    <rdy:DisclosureOfContractualMaturitiesOfLongTermBorrowingsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate maturities of long-term loans and borrowings, based on contractual maturities, as of March 31, 2022 were as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturing in&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;convertible&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;debentures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Obligations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;under leases&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Less than 1 year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,017&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,017&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 61%;"&gt;1-2 years&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;3,800&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;868&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;4,668&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;2-3 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;809&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;809&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;3-4 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;155&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;155&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;4-5 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;65&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;65&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;49&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;49&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,800&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,963&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,763&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                        &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate maturities of long-term loans and borrowings, based on contractual maturities, as of March 31, 2021 were as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Maturing in&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;convertible&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;debentures&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Obligations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;under leases&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Less than 1 year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;864&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;864&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 61%;"&gt;1-2 years&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;802&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;802&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;2-3 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,800&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;745&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,545&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;3-4 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;734&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;734&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;4-5 years&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;118&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;118&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;100&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;100&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,800&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,363&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,163&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                      </rdy:DisclosureOfContractualMaturitiesOfLongTermBorrowingsTableTextBlock>
    <rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted
      contextRef="PAsOn03_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="PAsOn03_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">1017000000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">1017000000</ifrs-full:Borrowings>
    <rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted
      contextRef="PAsOn03_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">3800000000</rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="PAsOn03_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">868000000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2022_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">4668000000</ifrs-full:Borrowings>
    <rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted
      contextRef="PAsOn03_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="PAsOn03_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">809000000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">809000000</ifrs-full:Borrowings>
    <rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted
      contextRef="PAsOn03_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="PAsOn03_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">155000000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">155000000</ifrs-full:Borrowings>
    <rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted
      contextRef="PAsOn03_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="PAsOn03_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">65000000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2022_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">65000000</ifrs-full:Borrowings>
    <rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted
      contextRef="PAsOn03_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="PAsOn03_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">49000000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2022_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">49000000</ifrs-full:Borrowings>
    <rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">3800000000</rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2963000000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">6763000000</ifrs-full:Borrowings>
    <rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted
      contextRef="PAsOn03_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="PAsOn03_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">864000000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">864000000</ifrs-full:Borrowings>
    <rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted
      contextRef="PAsOn03_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="PAsOn03_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">802000000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2021_LaterThanOneYearAndNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">802000000</ifrs-full:Borrowings>
    <rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted
      contextRef="PAsOn03_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">3800000000</rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="PAsOn03_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">745000000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">4545000000</ifrs-full:Borrowings>
    <rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted
      contextRef="PAsOn03_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="PAsOn03_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">734000000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">734000000</ifrs-full:Borrowings>
    <rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted
      contextRef="PAsOn03_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="PAsOn03_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">118000000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2021_LaterThanFourYearsAndNotLaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">118000000</ifrs-full:Borrowings>
    <rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted
      contextRef="PAsOn03_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="PAsOn03_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">100000000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2021_LaterThanFiveYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">100000000</ifrs-full:Borrowings>
    <rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">3800000000</rdy:NonCurrentPortionOfNonCurrentDebenturesUndiscounted>
    <ifrs-full:GrossLeaseLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">3363000000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">7163000000</ifrs-full:Borrowings>
    <ifrs-full:UndrawnBorrowingFacilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">39989000000</ifrs-full:UndrawnBorrowingFacilities>
    <ifrs-full:UndrawnBorrowingFacilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">38766000000</ifrs-full:UndrawnBorrowingFacilities>
    <ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory contextRef="P04_01_2021To03_31_2022">
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.7pt; text-indent: -13.7pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reconciliation of liabilities arising from financing activities during the year ended March 31, 2022:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.7pt; text-indent: -13.7pt; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Long-term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;borrowings&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Short-term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;borrowings&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Opening balance&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,163&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;23,136&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;30,299&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 61%; text-align: left;"&gt;Recognition of right-of-use liability during the year&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;327&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;327&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Payment of principal portion of lease liabilities&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(785&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(785&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Borrowings made during the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;51,518&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;51,518&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Borrowings repaid during the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(47,998&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(47,998&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;58&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;426&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;484&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Closing balance&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,763&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;27,082&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;33,845&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reconciliation of liabilities arising from financing activities during the year ended March 31, 2021:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal; background-color: white;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Long-term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;borrowings&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Short-term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;borrowings&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 61%; text-align: left;"&gt;Opening balance&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;5,570&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;16,441&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;22,011&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Recognition of right-of-use liability during the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,393&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,393&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Payment of principal portion of lease liabilities&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(754&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(754&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Borrowings made during the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,800&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;44,469&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;48,269&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Borrowings repaid during the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(3,743&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(37,678&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(41,421&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(103&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(96&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(199&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Closing balance&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7,163&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;23,136&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;30,299&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 13.7pt; text-indent: -13.7pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Includes current portion.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























</ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn03_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">7163000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn03_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">23136000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">30299000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="P04_01_2021To03_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      id="Fact_50538940"
      unitRef="Unit_INR">327000000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="P04_01_2021To03_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">327000000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <rdy:PaymentsOfPrincipalPortionOfLeaseLiabilitiesClassifiedAsFinancingActivitiees
      contextRef="P04_01_2021To03_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      id="Fact_50538943"
      unitRef="Unit_INR">-785000000</rdy:PaymentsOfPrincipalPortionOfLeaseLiabilitiesClassifiedAsFinancingActivitiees>
    <rdy:PaymentsOfPrincipalPortionOfLeaseLiabilitiesClassifiedAsFinancingActivitiees
      contextRef="P04_01_2021To03_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:PaymentsOfPrincipalPortionOfLeaseLiabilitiesClassifiedAsFinancingActivitiees>
    <rdy:PaymentsOfPrincipalPortionOfLeaseLiabilitiesClassifiedAsFinancingActivitiees
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-785000000</rdy:PaymentsOfPrincipalPortionOfLeaseLiabilitiesClassifiedAsFinancingActivitiees>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="P04_01_2021To03_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      id="Fact_50536101"
      unitRef="Unit_INR">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="P04_01_2021To03_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">51518000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">51518000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="P04_01_2021To03_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      id="Fact_50536104"
      unitRef="Unit_INR">0</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="P04_01_2021To03_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">47998000000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">47998000000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P04_01_2021To03_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      id="Fact_50536107"
      unitRef="Unit_INR">58000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P04_01_2021To03_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">426000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">484000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn03_31_2022_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      id="Fact_50536110"
      unitRef="Unit_INR">6763000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn03_31_2022_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">27082000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">33845000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn03_31_2020_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">5570000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn03_31_2020_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">16441000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">22011000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="P04_01_2020To03_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      id="Fact_50538946"
      unitRef="Unit_INR">2393000000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="P04_01_2020To03_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2393000000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <rdy:PaymentsOfPrincipalPortionOfLeaseLiabilitiesClassifiedAsFinancingActivitiees
      contextRef="P04_01_2020To03_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      id="Fact_50538949"
      unitRef="Unit_INR">-754000000</rdy:PaymentsOfPrincipalPortionOfLeaseLiabilitiesClassifiedAsFinancingActivitiees>
    <rdy:PaymentsOfPrincipalPortionOfLeaseLiabilitiesClassifiedAsFinancingActivitiees
      contextRef="P04_01_2020To03_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:PaymentsOfPrincipalPortionOfLeaseLiabilitiesClassifiedAsFinancingActivitiees>
    <rdy:PaymentsOfPrincipalPortionOfLeaseLiabilitiesClassifiedAsFinancingActivitiees
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-754000000</rdy:PaymentsOfPrincipalPortionOfLeaseLiabilitiesClassifiedAsFinancingActivitiees>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="P04_01_2020To03_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      id="Fact_50536116"
      unitRef="Unit_INR">3800000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="P04_01_2020To03_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">44469000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">48269000000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="P04_01_2020To03_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      id="Fact_50536119"
      unitRef="Unit_INR">3743000000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="P04_01_2020To03_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">37678000000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">41421000000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P04_01_2020To03_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      id="Fact_50536122"
      unitRef="Unit_INR">-103000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P04_01_2020To03_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-96000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-199000000</ifrs-full:IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn03_31_2021_LongtermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      id="Fact_50536125"
      unitRef="Unit_INR">7163000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn03_31_2021_ShorttermBorrowingsMemberifrsfullLiabilitiesArisingFromFinancingActivitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">23136000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:LiabilitiesArisingFromFinancingActivities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">30299000000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
    <ifrs-full:DisclosureOfOtherProvisionsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;. Provisions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The details of changes in provisions during the year ended March 31, 2022 are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Refund&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liability&lt;/div&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Environmental&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;liability&lt;/div&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Legal and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;others&lt;/div&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as at beginning of the year&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,824&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;58&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;611&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,493&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 48%; text-align: left;"&gt;Provision made during the year, net of reversals&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;4,406&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;64&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;4,470&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Provision used during the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(3,699&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(3,699&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;52&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;51&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as at end of the year&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,583&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;57&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;675&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,315&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Current&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,583&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;675&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,258&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Non-current&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;57&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;57&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,583&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;57&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;675&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,315&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





































&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 13.5pt; text-align: justify; text-indent: -13.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px; text-indent: 0px;"/&gt;
			&lt;td style="width: 0.2in; text-indent: 0px;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; text-indent: 0px; font-size: 10pt; vertical-align: bottom;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; line-height: 10pt; font-size: 10pt;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;Refund liability is accounted for by recording a provision based on the Company&#x2019;s estimate of expected sales returns. See Note 3.m of these consolidated financial statements for the Company&#x2019;s accounting policy on refund liability.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; line-height: 10pt; font-size: 10pt;;display:inline;"/&gt;&lt;/div&gt; &lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; text-indent: -0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;As a result of the acquisition of a unit of The Dow Chemical Company in April 2008, the Company assumed a liability for contamination of the Mirfield site acquired of Rs.39 (carrying value Rs.57). The seller is required to indemnify the Company for this liability. Accordingly, a corresponding asset has also been recorded in the consolidated statements of financial position.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; text-indent: -0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Primarily consists of provision recorded towards the potential liability arising out of a litigation relating to cardiovascular and anti-diabetic formulations. Refer to Note 3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&#160;(Contingencies) of these consolidated financial statements under &#x201c;Product and patent related matters - Matters relating to National Pharmaceutical Pricing Authority &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;and&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;Litigation relating to Cardiovascular and Anti-diabetic formulations&#x201d; for further details.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


























</ifrs-full:DisclosureOfOtherProvisionsExplanatory>
    <rdy:DisclosureOfProvisionTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The details of changes in provisions during the year ended March 31, 2022 are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Refund&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liability&lt;/div&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Environmental&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;liability&lt;/div&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Legal and&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;others&lt;/div&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as at beginning of the year&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,824&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;58&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;611&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,493&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 48%; text-align: left;"&gt;Provision made during the year, net of reversals&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;4,406&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;64&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;4,470&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Provision used during the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(3,699&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(3,699&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;52&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;51&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as at end of the year&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,583&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;57&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;675&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,315&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Current&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,583&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;675&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,258&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Non-current&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;57&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;57&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,583&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;57&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;675&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,315&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































</rdy:DisclosureOfProvisionTableTextBlock>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2021_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536477"
      unitRef="Unit_INR">2824000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2021_OtherEnvironmentRelatedProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536478"
      unitRef="Unit_INR">58000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2021_LegalProceedingsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536479"
      unitRef="Unit_INR">611000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">3493000000</ifrs-full:OtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P04_01_2021To03_31_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536481"
      unitRef="Unit_INR">4406000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P04_01_2021To03_31_2022_OtherEnvironmentRelatedProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536482"
      unitRef="Unit_INR">0</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P04_01_2021To03_31_2022_LegalProceedingsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536483"
      unitRef="Unit_INR">64000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4470000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2021To03_31_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536485"
      unitRef="Unit_INR">3699000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2021To03_31_2022_OtherEnvironmentRelatedProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536486"
      unitRef="Unit_INR">0</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2021To03_31_2022_LegalProceedingsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536487"
      unitRef="Unit_INR">0</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">3699000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="P04_01_2021To03_31_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536489"
      unitRef="Unit_INR">52000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="P04_01_2021To03_31_2022_OtherEnvironmentRelatedProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536490"
      unitRef="Unit_INR">-1000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="P04_01_2021To03_31_2022_LegalProceedingsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536491"
      unitRef="Unit_INR">0</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">51000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536493"
      unitRef="Unit_INR">3583000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2022_OtherEnvironmentRelatedProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536494"
      unitRef="Unit_INR">57000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2022_LegalProceedingsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536495"
      unitRef="Unit_INR">675000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4315000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn03_31_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536497"
      unitRef="Unit_INR">3583000000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn03_31_2022_OtherEnvironmentRelatedProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536498"
      unitRef="Unit_INR">0</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn03_31_2022_LegalProceedingsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536499"
      unitRef="Unit_INR">675000000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherShorttermProvisions
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4258000000</ifrs-full:OtherShorttermProvisions>
    <ifrs-full:OtherLongtermProvisions
      contextRef="PAsOn03_31_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536501"
      unitRef="Unit_INR">0</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:OtherLongtermProvisions
      contextRef="PAsOn03_31_2022_OtherEnvironmentRelatedProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536502"
      unitRef="Unit_INR">57000000</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:OtherLongtermProvisions
      contextRef="PAsOn03_31_2022_LegalProceedingsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536503"
      unitRef="Unit_INR">0</ifrs-full:OtherLongtermProvisions>
    <ifrs-full:OtherLongtermProvisions
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">57000000</ifrs-full:OtherLongtermProvisions>
    <rdy:DueToCreditorsForExpenses
      contextRef="PAsOn03_31_2022_RefundsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50539349"
      unitRef="Unit_INR">3583000000</rdy:DueToCreditorsForExpenses>
    <rdy:DueToCreditorsForExpenses
      contextRef="PAsOn03_31_2022_OtherEnvironmentRelatedProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50539348"
      unitRef="Unit_INR">57000000</rdy:DueToCreditorsForExpenses>
    <rdy:DueToCreditorsForExpenses
      contextRef="PAsOn03_31_2022_LegalProceedingsProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50539347"
      unitRef="Unit_INR">675000000</rdy:DueToCreditorsForExpenses>
    <rdy:DueToCreditorsForExpenses
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4315000000</rdy:DueToCreditorsForExpenses>
    <rdy:InitialLiabilityAssumed
      contextRef="PAsOn03_31_2022_OtherEnvironmentRelatedProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      unitRef="Unit_INR">39000000</rdy:InitialLiabilityAssumed>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2022_OtherEnvironmentRelatedProvisionMemberifrsfullClassesOfProvisionsAxis"
      decimals="-6"
      id="Fact_50536931"
      unitRef="Unit_INR">57000000</ifrs-full:OtherProvisions>
    <ifrs-full:DisclosureOfOtherLiabilitiesExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&lt;/div&gt;. Other liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities consist of the following:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Accrued expenses&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;20,055&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,821&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 74%; text-align: left;"&gt;Employee benefits payable&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;5,662&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;5,607&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Statutory dues payable&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,675&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,968&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,235&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,052&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Advance from customers&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,341&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;981&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,024&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,059&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;33,992&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30,488&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,597&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,531&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;825&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;812&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,422&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,343&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 9pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Refer to Note 22 for details of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;deferred &lt;/div&gt;revenue.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































</ifrs-full:DisclosureOfOtherLiabilitiesExplanatory>
    <rdy:ScheduleOfOtherLiabilitiesTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities consist of the following:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Accrued expenses&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;20,055&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,821&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 74%; text-align: left;"&gt;Employee benefits payable&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;5,662&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;5,607&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Statutory dues payable&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,675&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,968&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,235&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,052&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Advance from customers&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,341&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;981&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,024&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,059&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;33,992&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30,488&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Non-current&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,597&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,531&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;825&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;812&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,422&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,343&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 9pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Refer to Note 22 for details of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;deferred &lt;/div&gt;revenue.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































</rdy:ScheduleOfOtherLiabilitiesTableTextBlock>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">20055000000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">17821000000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">5662000000</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:CurrentProvisionsForEmployeeBenefits
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">5607000000</ifrs-full:CurrentProvisionsForEmployeeBenefits>
    <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">3675000000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2968000000</ifrs-full:CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax>
    <ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      id="Fact_50536511"
      unitRef="Unit_INR">1235000000</ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      id="Fact_50536512"
      unitRef="Unit_INR">1052000000</ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities>
    <ifrs-full:CurrentAdvances
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1341000000</ifrs-full:CurrentAdvances>
    <ifrs-full:CurrentAdvances
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">981000000</ifrs-full:CurrentAdvances>
    <rdy:OthersClassifiedAsCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2024000000</rdy:OthersClassifiedAsCurrent>
    <rdy:OthersClassifiedAsCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2059000000</rdy:OthersClassifiedAsCurrent>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">33992000000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">30488000000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:NoncurrentDeferredIncomeOtherThanNoncurrentContractLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      id="Fact_50536933"
      unitRef="Unit_INR">1597000000</ifrs-full:NoncurrentDeferredIncomeOtherThanNoncurrentContractLiabilities>
    <ifrs-full:NoncurrentDeferredIncomeOtherThanNoncurrentContractLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      id="Fact_50536934"
      unitRef="Unit_INR">1531000000</ifrs-full:NoncurrentDeferredIncomeOtherThanNoncurrentContractLiabilities>
    <rdy:OthersClassifiedAsNoncurrent
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">825000000</rdy:OthersClassifiedAsNoncurrent>
    <rdy:OthersClassifiedAsNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">812000000</rdy:OthersClassifiedAsNoncurrent>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2422000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2343000000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20&lt;/div&gt;&lt;/div&gt;. Share Capital&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 48%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Authorized share capital&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;240,000,000&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;1,200&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;240,000,000&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;1,200&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fully paid up share capital&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Opening number of equity shares/share capital&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;166,301,231&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;832&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;166,172,082&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;831&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Add: Equity shares issued pursuant to employee stock option plan&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;124,618&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;129,149&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Closing number of equity shares/share capital&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;166,425,849&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;832&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;166,301,231&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;832&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Treasury shares&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;468,471&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,601&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;575,201&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,967&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width:0.25in; vertical-align:top; overflow-wrap:break-word; font-family:Calibri, 'sans-serif'"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align:justify; vertical-align:top; overflow-wrap:break-word; font-family:Calibri, 'sans-serif'"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; text-indent: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;Rounded to the nearest million.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





























&lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;





&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;During the years ended March 31, 2022 and 2021, equity shares were issued as a result of the exercise of vested options granted to employees pursuant to the Dr. Reddy&#x2019;s Employees Stock Option Scheme, 2002 and the Dr. Reddy&#x2019;s Employees Stock Option Scheme, 2007. The options exercised had an exercise price of Rs.5, Rs.2,607, Rs.2,814 or Rs. 3,679 per share. Upon the exercise of such options, the amount of compensation cost (computed using the grant date fair value) previously recognized in the &#x201c;share based payment reserve&#x201d; was transferred to&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&#x201c;share premium&#x201d; in the consolidated statements of changes in equity.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; text-indent: -0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Pursuant to the special resolution approved by the shareholders in the Annual General Meeting held on July 27, 2018, the Dr. Reddy&#x2019;s Employees ESOS Trust (the &#x201c;ESOS Trust&#x201d;) was formed to support the Dr. Reddy&#x2019;s Employees Stock Option Scheme, 2018 by acquiring, from the Company or through secondary market acquisitions, equity shares which are used for issuance to eligible employees (as defined therein) upon exercise of stock options thereunder. During the years ended March 31, 2022 and 2021, an aggregate of 106,730 and 85,250 equity shares, respectively were issued as a result of the exercise of vested options granted to employees pursuant to the Dr. Reddy&#x2019;s Employees Stock Option Scheme, 2018. The options exercised had an exercise price of Rs.2,607, Rs.2,814 or Rs. 3,679 per share. Upon the exercise of such options, the amount of compensation cost (computed using the grant date fair value) previously recognized in the &#x201c;share based payment reserve&#x201d; was transferred to &#x201c;share premium&#x201d; in the consolidated statements of changes in equity. In addition, any difference between the carrying amount of treasury shares and the consideration received was recognized in the &#x201c;share premium&#x201d;. As of March 31, 2022 and 2021, the ESOS Trust had outstanding 468,471 and 575,201 shares, respectively, which it purchased from the secondary market for an aggregate consideration of Rs.1,601 and Rs.1,967, respectively. Refer to Note 2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;&#160;of these consolidated financial statements for further details on the Dr. Reddy&#x2019;s Employees Stock Option Scheme, 2018.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


























  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has only one class of equity shares having a par value of Rs.5 per share. For all matters submitted to vote in a shareholders meeting of the Company, every holder of an equity share, as reflected in the records of the Company as on the record date set for the shareholders meeting, shall have one vote in respect of each share held.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Should the Company declare and pay any dividends, such dividends will be paid in Indian rupees to each holder of equity shares in proportion to the number of shares held to the total equity shares outstanding as on that date. Indian law on foreign exchange governs the remittance of dividends outside India.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the event of liquidation of the Company, all preferential amounts, if any, shall be discharged by the Company. The remaining assets of the Company shall be distributed to the holders of equity shares in proportion to the number of shares held to the total equity shares outstanding as on that date.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Final dividends on equity shares (including dividend tax on distribution of such dividends, if any) are recorded as a liability on the date of their approval by the shareholders and interim dividends are recorded as a liability on the date of declaration by the Company&#x2019;s Board of Directors. The details of dividends paid by the Company are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Dividend per share (in absolute Rs.)&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;20&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 61%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Dividend distribution tax on the dividend paid&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;602&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;Dividend paid during the year&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;4,146&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;4,147&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;3,314&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

















































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Proposed dividend&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At the Company&#x2019;s Board of Directors&#x2019; meeting held on May 19, 2022, the Board proposed a dividend of Rs.30 per share and&#160;aggregating to Rs.4,993, which is subject to the approval of the Company&#x2019;s shareholders.&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <rdy:DisclosureOfClassesOfShareCapitalTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 48%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Authorized share capital&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;240,000,000&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;1,200&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;240,000,000&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;1,200&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fully paid up share capital&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Opening number of equity shares/share capital&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;166,301,231&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;832&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;166,172,082&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;831&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Add: Equity shares issued pursuant to employee stock option plan&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;124,618&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;129,149&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Closing number of equity shares/share capital&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;166,425,849&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;832&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;166,301,231&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;832&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Treasury shares&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;468,471&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,601&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;575,201&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,967&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top; padding-bottom:0.0001pt"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width:0.25in; vertical-align:top; overflow-wrap:break-word; font-family:Calibri, 'sans-serif'"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align:justify; vertical-align:top; overflow-wrap:break-word; font-family:Calibri, 'sans-serif'"&gt;
			&lt;div style="font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; text-indent: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;Rounded to the nearest million.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





























&lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;





&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;During the years ended March 31, 2022 and 2021, equity shares were issued as a result of the exercise of vested options granted to employees pursuant to the Dr. Reddy&#x2019;s Employees Stock Option Scheme, 2002 and the Dr. Reddy&#x2019;s Employees Stock Option Scheme, 2007. The options exercised had an exercise price of Rs.5, Rs.2,607, Rs.2,814 or Rs. 3,679 per share. Upon the exercise of such options, the amount of compensation cost (computed using the grant date fair value) previously recognized in the &#x201c;share based payment reserve&#x201d; was transferred to&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&#x201c;share premium&#x201d; in the consolidated statements of changes in equity.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; text-indent: -0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Pursuant to the special resolution approved by the shareholders in the Annual General Meeting held on July 27, 2018, the Dr. Reddy&#x2019;s Employees ESOS Trust (the &#x201c;ESOS Trust&#x201d;) was formed to support the Dr. Reddy&#x2019;s Employees Stock Option Scheme, 2018 by acquiring, from the Company or through secondary market acquisitions, equity shares which are used for issuance to eligible employees (as defined therein) upon exercise of stock options thereunder. During the years ended March 31, 2022 and 2021, an aggregate of 106,730 and 85,250 equity shares, respectively were issued as a result of the exercise of vested options granted to employees pursuant to the Dr. Reddy&#x2019;s Employees Stock Option Scheme, 2018. The options exercised had an exercise price of Rs.2,607, Rs.2,814 or Rs. 3,679 per share. Upon the exercise of such options, the amount of compensation cost (computed using the grant date fair value) previously recognized in the &#x201c;share based payment reserve&#x201d; was transferred to &#x201c;share premium&#x201d; in the consolidated statements of changes in equity. In addition, any difference between the carrying amount of treasury shares and the consideration received was recognized in the &#x201c;share premium&#x201d;. As of March 31, 2022 and 2021, the ESOS Trust had outstanding 468,471 and 575,201 shares, respectively, which it purchased from the secondary market for an aggregate consideration of Rs.1,601 and Rs.1,967, respectively. Refer to Note 2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8&lt;/div&gt;&#160;of these consolidated financial statements for further details on the Dr. Reddy&#x2019;s Employees Stock Option Scheme, 2018.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


























</rdy:DisclosureOfClassesOfShareCapitalTableTextBlock>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="PAsOn03_31_2022_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_shares">240000000</ifrs-full:NumberOfSharesAuthorised>
    <rdy:AmountOfSharesAuthorised
      contextRef="PAsOn03_31_2022_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">1200000000</rdy:AmountOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="PAsOn03_31_2021_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_shares">240000000</ifrs-full:NumberOfSharesAuthorised>
    <rdy:AmountOfSharesAuthorised
      contextRef="PAsOn03_31_2021_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">1200000000</rdy:AmountOfSharesAuthorised>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="PAsOn03_31_2021_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_shares">166301231</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn03_31_2021_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">832000000</ifrs-full:IssuedCapital>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="PAsOn03_31_2020_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_shares">166172082</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn03_31_2020_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">831000000</ifrs-full:IssuedCapital>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="P04_01_2021To03_31_2022_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      id="Fact_50536136"
      unitRef="Unit_shares">124618</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <rdy:IncreaseDecreaseThroughExerciseOfOption
      contextRef="P04_01_2021To03_31_2022_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539786"
      unitRef="Unit_INR">0</rdy:IncreaseDecreaseThroughExerciseOfOption>
    <ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding
      contextRef="P04_01_2020To03_31_2021_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      id="Fact_50536137"
      unitRef="Unit_shares">129149</ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding>
    <rdy:IncreaseDecreaseThroughExerciseOfOption
      contextRef="P04_01_2020To03_31_2021_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50539787"
      unitRef="Unit_INR">1000000</rdy:IncreaseDecreaseThroughExerciseOfOption>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="PAsOn03_31_2022_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_shares">166425849</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn03_31_2022_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">832000000</ifrs-full:IssuedCapital>
    <ifrs-full:NumberOfSharesIssuedAndFullyPaid
      contextRef="PAsOn03_31_2021_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      unitRef="Unit_shares">166301231</ifrs-full:NumberOfSharesIssuedAndFullyPaid>
    <ifrs-full:IssuedCapital
      contextRef="PAsOn03_31_2021_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      unitRef="Unit_INR">832000000</ifrs-full:IssuedCapital>
    <rdy:NumberOfTreasurySharesIssued
      contextRef="P04_01_2021To03_31_2022_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      id="Fact_50538954"
      unitRef="Unit_shares">468471</rdy:NumberOfTreasurySharesIssued>
    <ifrs-full:TreasuryShares
      contextRef="PAsOn03_31_2022_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538955"
      unitRef="Unit_INR">1601000000</ifrs-full:TreasuryShares>
    <rdy:NumberOfTreasurySharesIssued
      contextRef="P04_01_2020To03_31_2021_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="0"
      id="Fact_50538956"
      unitRef="Unit_shares">575201</rdy:NumberOfTreasurySharesIssued>
    <ifrs-full:TreasuryShares
      contextRef="PAsOn03_31_2021_OrdinarySharesMemberifrsfullComponentsOfEquityAxis"
      decimals="-6"
      id="Fact_50538957"
      unitRef="Unit_INR">1967000000</ifrs-full:TreasuryShares>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_DrReddysEmployeesStockOptionScheme2018MemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">106730</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_DrReddysEmployeesStockOptionScheme2018MemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">85250</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2021To03_31_2022_DrReddysEmployeesStockOptionScheme2018MemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_INR_per_Share">2607</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2020To03_31_2021_DrReddysEmployeesStockOptionScheme2018MemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_INR_per_Share">2814</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="P04_01_2021To03_31_2022_DrReddysEmployeesStockOptionScheme2018MemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_INR_per_Share">3679</ifrs-full:WeightedAverageSharePrice2019>
    <rdy:NumberOfTreasurySharesOutstanding
      contextRef="PAsOn03_31_2022_DrReddysEmployeesStockOptionScheme2018MemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">468471</rdy:NumberOfTreasurySharesOutstanding>
    <rdy:NumberOfTreasurySharesOutstanding
      contextRef="PAsOn03_31_2021_DrReddysEmployeesStockOptionScheme2018MemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="0"
      unitRef="Unit_shares">575201</rdy:NumberOfTreasurySharesOutstanding>
    <ifrs-full:TreasuryShares
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1601000000</ifrs-full:TreasuryShares>
    <ifrs-full:TreasuryShares
      contextRef="PAsOn03_31_2022_DrReddysEmployeesStockOptionScheme2018MemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_INR">1601000000</ifrs-full:TreasuryShares>
    <ifrs-full:TreasuryShares
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1967000000</ifrs-full:TreasuryShares>
    <ifrs-full:TreasuryShares
      contextRef="PAsOn03_31_2021_DrReddysEmployeesStockOptionScheme2018MemberifrsfullTypesOfSharebasedPaymentArrangementsAxis"
      decimals="-6"
      unitRef="Unit_INR">1967000000</ifrs-full:TreasuryShares>
    <ifrs-full:RightsPreferencesAndRestrictionsAttachingToClassOfShareCapital contextRef="P04_01_2021To03_31_2022">&#160;


The Company has only one class of equity shares having a par value of Rs.5 per share. For all matters submitted to vote in a shareholders meeting of the Company, every holder of an equity share, as reflected in the records of the Company as on the record date set for the shareholders meeting, shall have one vote in respect of each share held.


&#160;


Should the Company declare and pay any dividends, such dividends will be paid in Indian rupees to each holder of equity shares in proportion to the number of shares held to the total equity shares outstanding as on that date. Indian law on foreign exchange governs the remittance of dividends outside India.


&#160;


In the event of liquidation of the Company, all preferential amounts, if any, shall be discharged by the Company. The remaining assets of the Company shall be distributed to the holders of equity shares in proportion to the number of shares held to the total equity shares outstanding as on that date.</ifrs-full:RightsPreferencesAndRestrictionsAttachingToClassOfShareCapital>
    <ifrs-full:ParValuePerShare
      contextRef="PAsOn03_31_2022"
      decimals="0"
      unitRef="Unit_INR_per_Share">5</ifrs-full:ParValuePerShare>
    <rdy:DisclosureOfDetailedInformationAboutDividendsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Final dividends on equity shares (including dividend tax on distribution of such dividends, if any) are recorded as a liability on the date of their approval by the shareholders and interim dividends are recorded as a liability on the date of declaration by the Company&#x2019;s Board of Directors. The details of dividends paid by the Company are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Dividend per share (in absolute Rs.)&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;20&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 61%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Dividend distribution tax on the dividend paid&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;602&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;Dividend paid during the year&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;4,146&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;4,147&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;3,314&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































</rdy:DisclosureOfDetailedInformationAboutDividendsTableTextBlock>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersPerShare
      contextRef="P04_01_2021To03_31_2022"
      decimals="0"
      unitRef="Unit_INR_per_Share">25</ifrs-full:DividendsRecognisedAsDistributionsToOwnersPerShare>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersPerShare
      contextRef="P04_01_2020To03_31_2021"
      decimals="0"
      unitRef="Unit_INR_per_Share">25</ifrs-full:DividendsRecognisedAsDistributionsToOwnersPerShare>
    <ifrs-full:DividendsRecognisedAsDistributionsToOwnersPerShare
      contextRef="P04_01_2019To03_31_2020"
      decimals="0"
      unitRef="Unit_INR_per_Share">20</ifrs-full:DividendsRecognisedAsDistributionsToOwnersPerShare>
    <rdy:DividendDistributionTaxOnDividendPaid
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:DividendDistributionTaxOnDividendPaid>
    <rdy:DividendDistributionTaxOnDividendPaid
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:DividendDistributionTaxOnDividendPaid>
    <rdy:DividendDistributionTaxOnDividendPaid
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">602000000</rdy:DividendDistributionTaxOnDividendPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2021To03_31_2022_OrdinarySharesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">4146000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2020To03_31_2021_OrdinarySharesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">4147000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsPaid
      contextRef="P04_01_2019To03_31_2020_OrdinarySharesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">3314000000</ifrs-full:DividendsPaid>
    <ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare
      contextRef="P05_19_2022To05_19_2022"
      decimals="0"
      unitRef="Unit_INR_per_Share">30</ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwnersPerShare>
    <ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners
      contextRef="P05_19_2022To05_19_2022"
      decimals="-6"
      unitRef="Unit_INR">4993000000</ifrs-full:DividendsProposedOrDeclaredBeforeFinancialStatementsAuthorisedForIssueButNotRecognisedAsDistributionToOwners>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;. Earnings per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculation of basic and diluted earnings per share for the years ended March 31, 2022, 2021 and 2020 was based on the profit attributable to equity shareholders of the Company, being Rs.23,568, Rs.17,238 and Rs. 19,498, respectively.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average number of equity shares outstanding, used for calculating the basic earnings per share, are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 61%; text-align: left;"&gt;Number of equity shares at the beginning of the year (excluding treasury shares)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;165,726,030&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;165,776,132&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;165,847,972&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Effect of treasury shares held during the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(56,014&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(154,020&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Effect of equity shares issued on exercise of stock options&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;156,667&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;124,222&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;64,432&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Weighted average number of equity shares &#x2013; Basic&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;165,882,697&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;165,844,340&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;165,758,384&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Earnings per share of par value Rs.5 &#x2013; Basic&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;142.08&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;103.94&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;117.63&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

















































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average number of equity shares outstanding, used for calculating the diluted earnings per share, are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 61%;"&gt;Weighted average number of equity shares &#x2013; Basic&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;165,882,697&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;165,844,340&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;165,758,384&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive effect of stock options outstanding&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;455,937&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;471,701&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;323,601&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Weighted average number of equity shares &#x2013; Diluted&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;166,338,634&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;166,316,041&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;166,081,985&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Earnings per share of par value Rs.5 &#x2013; Diluted&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;141.69&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;103.65&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;117.40&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;As of March 31, 2022, 2021 and 2020, 13,284, 235,460 and 475,575 options, respectively, were excluded from the diluted weighted average number of equity shares calculation because their effect would have been anti-dilutive. The average market value of the Company&#x2019;s shares for the purpose of calculating the dilutive effect of stock options was based on quoted market prices for the year during which the options were&#160;outstanding.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

















































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">23568000000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">17238000000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">19498000000</ifrs-full:ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntity>
    <rdy:BasicEarningsPerShareTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average number of equity shares outstanding, used for calculating the basic earnings per share, are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 61%; text-align: left;"&gt;Number of equity shares at the beginning of the year (excluding treasury shares)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;165,726,030&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;165,776,132&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;165,847,972&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Effect of treasury shares held during the year&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(56,014&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(154,020&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Effect of equity shares issued on exercise of stock options&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;156,667&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;124,222&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;64,432&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Weighted average number of equity shares &#x2013; Basic&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;165,882,697&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;165,844,340&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;165,758,384&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Earnings per share of par value Rs.5 &#x2013; Basic&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;142.08&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;103.94&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;117.63&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































</rdy:BasicEarningsPerShareTableTextBlock>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="PAsOn03_31_2022"
      decimals="0"
      unitRef="Unit_shares">165726030</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="PAsOn03_31_2021"
      decimals="0"
      unitRef="Unit_shares">165776132</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="PAsOn03_31_2020"
      decimals="0"
      unitRef="Unit_shares">165847972</ifrs-full:NumberOfSharesOutstanding>
    <rdy:IncreaseDecreaseInNumberOfTreasurySharesHeld
      contextRef="P04_01_2021To03_31_2022"
      decimals="0"
      unitRef="Unit_shares">0</rdy:IncreaseDecreaseInNumberOfTreasurySharesHeld>
    <rdy:IncreaseDecreaseInNumberOfTreasurySharesHeld
      contextRef="P04_01_2020To03_31_2021"
      decimals="0"
      unitRef="Unit_shares">56014</rdy:IncreaseDecreaseInNumberOfTreasurySharesHeld>
    <rdy:IncreaseDecreaseInNumberOfTreasurySharesHeld
      contextRef="P04_01_2019To03_31_2020"
      decimals="0"
      unitRef="Unit_shares">154020</rdy:IncreaseDecreaseInNumberOfTreasurySharesHeld>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="P04_01_2021To03_31_2022"
      decimals="0"
      unitRef="Unit_shares">156667</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="P04_01_2020To03_31_2021"
      decimals="0"
      unitRef="Unit_shares">124222</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="P04_01_2019To03_31_2020"
      decimals="0"
      unitRef="Unit_shares">64432</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <ifrs-full:WeightedAverageShares
      contextRef="P04_01_2021To03_31_2022"
      decimals="0"
      unitRef="Unit_shares">165882697</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="P04_01_2020To03_31_2021"
      decimals="0"
      unitRef="Unit_shares">165844340</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="P04_01_2019To03_31_2020"
      decimals="0"
      unitRef="Unit_shares">165758384</ifrs-full:WeightedAverageShares>
    <ifrs-full:ParValuePerShare
      contextRef="PAsOn03_31_2021"
      decimals="0"
      unitRef="Unit_INR_per_Share">5</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="PAsOn03_31_2020"
      decimals="0"
      unitRef="Unit_INR_per_Share">5</ifrs-full:ParValuePerShare>
    <ifrs-full:ParValuePerShare
      contextRef="PAsOn03_31_2022"
      decimals="0"
      unitRef="Unit_INR_per_Share">5</ifrs-full:ParValuePerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P04_01_2021To03_31_2022"
      decimals="2"
      unitRef="Unit_INR_per_Share">142.08</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P04_01_2020To03_31_2021"
      decimals="2"
      unitRef="Unit_INR_per_Share">103.94</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="P04_01_2019To03_31_2020"
      decimals="2"
      unitRef="Unit_INR_per_Share">117.63</ifrs-full:BasicEarningsLossPerShare>
    <rdy:DilutedEarningsPerShareTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average number of equity shares outstanding, used for calculating the diluted earnings per share, are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 61%;"&gt;Weighted average number of equity shares &#x2013; Basic&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;165,882,697&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;165,844,340&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;165,758,384&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive effect of stock options outstanding&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;455,937&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;471,701&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;323,601&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Weighted average number of equity shares &#x2013; Diluted&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;166,338,634&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;166,316,041&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;166,081,985&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Earnings per share of par value Rs.5 &#x2013; Diluted&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;141.69&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;103.65&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;117.40&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;As of March 31, 2022, 2021 and 2020, 13,284, 235,460 and 475,575 options, respectively, were excluded from the diluted weighted average number of equity shares calculation because their effect would have been anti-dilutive. The average market value of the Company&#x2019;s shares for the purpose of calculating the dilutive effect of stock options was based on quoted market prices for the year during which the options were&#160;outstanding.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































</rdy:DilutedEarningsPerShareTableTextBlock>
    <ifrs-full:WeightedAverageShares
      contextRef="P04_01_2021To03_31_2022"
      decimals="0"
      unitRef="Unit_shares">165882697</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="P04_01_2020To03_31_2021"
      decimals="0"
      unitRef="Unit_shares">165844340</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="P04_01_2019To03_31_2020"
      decimals="0"
      unitRef="Unit_shares">165758384</ifrs-full:WeightedAverageShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="P04_01_2021To03_31_2022"
      decimals="0"
      id="Fact_50536166"
      unitRef="Unit_shares">455937</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="P04_01_2020To03_31_2021"
      decimals="0"
      id="Fact_50536167"
      unitRef="Unit_shares">471701</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares
      contextRef="P04_01_2019To03_31_2020"
      decimals="0"
      id="Fact_50536168"
      unitRef="Unit_shares">323601</ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="P04_01_2021To03_31_2022"
      decimals="0"
      unitRef="Unit_shares">166338634</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="P04_01_2020To03_31_2021"
      decimals="0"
      unitRef="Unit_shares">166316041</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="P04_01_2019To03_31_2020"
      decimals="0"
      unitRef="Unit_shares">166081985</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P04_01_2021To03_31_2022"
      decimals="2"
      unitRef="Unit_INR_per_Share">141.69</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P04_01_2020To03_31_2021"
      decimals="2"
      unitRef="Unit_INR_per_Share">103.65</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="P04_01_2019To03_31_2020"
      decimals="2"
      unitRef="Unit_INR_per_Share">117.4</ifrs-full:DilutedEarningsLossPerShare>
    <rdy:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmounts
      contextRef="PAsOn03_31_2022"
      decimals="0"
      unitRef="Unit_shares">13284</rdy:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmounts>
    <rdy:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmounts
      contextRef="PAsOn03_31_2021"
      decimals="0"
      unitRef="Unit_shares">235460</rdy:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmounts>
    <rdy:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmounts
      contextRef="PAsOn03_31_2020"
      decimals="0"
      unitRef="Unit_shares">475575</rdy:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmounts>
    <ifrs-full:DisclosureOfRevenueExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;. Revenue from contracts with customers and trade receivables&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 13.5pt; text-indent: -13.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue from contracts with customers:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 13.5pt; text-indent: -13.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Sales&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;205,144&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;184,202&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;163,574&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 61%; text-align: left;"&gt;Service income&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;4,380&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;4,105&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;2,409&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License fees&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;4,867&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,415&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;8,617&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;214,391&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;189,722&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;174,600&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 10.9pt; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; text-indent: 0px; vertical-align: bottom;"&gt;During the year ended March 31, 2022, the Company entered into the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;following agreements&lt;/div&gt;:&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;





&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; text-align: justify; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; text-align: justify; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An agreement with Alium JSC for the sale of the Company&#x2019;s territorial rights relating to two of its anti-bacterial brands (Ciprolet&#xae; and Levolet&#xae;) in Russia and certain countries of the former Soviet Union. The consideration for the arrangement is Rs.1,971 and the Company recognized revenue of Rs.1,774 for the performance obligations relating to the milestones met. This transaction pertains to the Company&#x2019;s Global Generics segment.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; text-align: justify; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; text-align: justify; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An agreement with Mankind Pharma Limited towards the sale of two of the Company's brands (Daffy bar and Combihale) in India&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;which formed part of the Company&#x2019;s Global Generics segment. License fees includes an amount of&#160; Rs.390 towards the aforesaid sales transaction. &lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; text-align: justify; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; text-align: justify; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A definitive agreement with BioDelivery Sciences International, Inc. (&#x201c;BDSI&#x201d;), pursuant to which the Company sold its U.S. and Canada territory rights for ELYXYB (celecoxib oral solution) 25 mg/mL, to BDSI.&#160; Under the terms of agreement, the Company was entitled to receive U.S.$6 up front at the closing&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&#160;U.S.$9 one year from the closing&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; event based milestone payments upon achievement of certain regulatory approvals; sales-based milestone payments; and quarterly earn-out payments based on a percentage (which varies based on sales volumes) of net sales of the product in the territory.&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;T&lt;/div&gt;he Company recognized an amount of Rs.1,084 as a licensee fee from this transaction.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; white-space:pre-line; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt; &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;This transaction pertains to the Company&#x2019;s Proprietary Products segment.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;





&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 14.2pt; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0in; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2020, the Company entered into a definitive agreement with Upsher-Smith Laboratories, LLC for the sale of its U.S. and select territory rights for ZEMBRACE&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#xae;&lt;/div&gt; SYMTOUCH&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#xae;&lt;/div&gt; (sumatriptan injection) 3 mg and TOSYMRA&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#xae;&lt;/div&gt; (sumatriptan nasal spray) 10 mg (formerly referred to as &#x201c;DFN-02&#x201d;), which formed part of its Proprietary Products segment. License fees includes an amount of Rs.7,486 towards the aforesaid sale transaction.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 14.2pt; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues by segments:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.05in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Segment&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Global Generics&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;179,170&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;154,404&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;138,123&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 61%; background-color: rgba(255, 255, 255, 0);"&gt;PSAI&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;30,740&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;31,982&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;25,747&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Proprietary products&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;1,611&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;523&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;7,949&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;2,870&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;2,813&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;2,781&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;214,391&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;189,722&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;174,600&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

















































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px;;font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues within the Global Generics segment:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues by therapeutic areas in the Company&#x2019;s Global Generics segment is given below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Nervous System&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;26,159&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,040&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;26,825&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 61%;"&gt;Gastrointestinal&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;23,386&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;21,132&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;19,394&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Anti-Infective&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;22,526&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;12,906&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;9,402&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Pain Management&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;18,437&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15,531&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;13,808&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Oncology&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;17,051&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;16,842&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;18,245&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Respiratory&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15,085&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;11,089&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;10,433&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Cardiovascular&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14,856&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15,460&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14,729&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background: white; width: 310.3pt; padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; height: 0.15in;"&gt;
			&lt;div style="margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: -0.05pt; top: 0px;;display:inline;"&gt;Hematology&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: white; width: 9%; padding: 0pt; height: 0.15in;"&gt;
			&lt;div style="margin-left: -5.4pt; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,737&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: white; width: 9%; padding: 0pt; height: 0.15in;"&gt;
			&lt;div style="margin-left: -6.05pt; text-align: right; text-indent: 0.65pt; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,959&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 9%; padding: 0pt; height: 0.15in;"&gt;
			&lt;div style="margin: 0in -0.5pt 0.0001pt -5.3pt; text-align: right; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,725&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 310.3pt; padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; height: 0.15in;"&gt;
			&lt;div style="margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: -0.05pt; top: 0px;;display:inline;"&gt;Dermatology&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 9%; padding: 0pt; height: 0.15in;"&gt;
			&lt;div style="margin-left: -5.4pt; text-align: right; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,797&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 9%; padding: 0pt; height: 0.15in;"&gt;
			&lt;div style="margin-left: -6.05pt; text-align: right; text-indent: 0.65pt; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,240&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 9%; padding: 0pt; height: 0.15in; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin: 0in -0.5pt 0.0001pt -5.3pt; text-align: right; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,255&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background: rgba(255, 255, 255, 0); width: 310.3pt; padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; height: 0.15in;"&gt;
			&lt;div style="margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: -0.05pt; top: 0px;;display:inline;"&gt;Nutraceutical&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgba(255, 255, 255, 0); width: 9%; padding: 0pt; height: 0.15in;"&gt;
			&lt;div style="margin-left: -5.4pt; text-align: right; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,530&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgba(255, 255, 255, 0); width: 9%; padding: 0pt; height: 0.15in;"&gt;
			&lt;div style="margin-left: -6.05pt; text-align: right; text-indent: 0.65pt; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,059&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 9%; padding: 0pt; height: 0.15in; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin: 0in -0.5pt 0.0001pt -5.3pt; text-align: right; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,441&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;18,606&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;18,146&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;13,866&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;179,170&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;154,404&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;138,123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

















































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues within the PSAI segment:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues by therapeutic areas in the Company&#x2019;s PSAI segment is given below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;Cardiovascular&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,729&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;9,834&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,567&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 61%; background-color: rgba(255, 255, 255, 0);"&gt;Anti-Infective&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;5,450&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4,126&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,264&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Pain Management&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;4,513&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;4,657&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;5,073&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Nervous System&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;3,017&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,704&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,797&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;Oncology&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;2,526&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;2,385&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;1,798&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="text-indent: 0px; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gastrointestinal&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;982&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,098&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;705&lt;/div&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Genitourinary&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;705&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;825&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;441&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Respiratory&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;676&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,317&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;789&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diabetology&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;544&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;350&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;168&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;Dermatology&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;498&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;768&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;1,370&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;4,100&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;3,918&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;1,775&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30,740&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31,982&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25,747&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;























































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues by geography:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows the distribution of the Company&#x2019;s revenues by country, based on the location of the customers:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Country&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;India&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;43,986&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36,252&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;32,089&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 61%; text-align: left;"&gt;United States&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;80,564&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;76,702&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;76,028&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Russia&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;20,879&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15,816&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;16,900&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;68,962&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;60,952&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;49,583&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;214,391&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;189,722&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;174,600&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;























































&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 13.7pt; text-align: justify; text-indent: -13.7pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Others include Germany, the United Kingdom, Ukraine, China, Canada and other countries across the world.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 7.1pt; text-align: justify; text-indent: -20.6pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 20.9pt; text-align: justify; text-indent: -20.9pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Information about major customers&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues from two customers of the Company's Global Generics segment were Rs.20,596 and Rs.10,339, representing approximately 10% and 5%, respectively, of the Company&#x2019;s total revenues for the year ended March 31, 2022.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues from two customers of the Company's Global Generics segment were Rs.19,341 and Rs.9,867, representing approximately 10% and 5%, respectively, of the Company&#x2019;s total revenues for the year ended March 31, 2021.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues from two customers of the Company's Global Generics &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;segment &lt;/div&gt;were Rs.14,164 and Rs.9,267, representing approximately 8% and 5%, respectively, of the Company&#x2019;s total revenues for the year ended March 31, 2020.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;D&lt;/div&gt;eferred revenue:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tabulated below is the reconciliation of deferred revenue for the years &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ended &lt;/div&gt;March 31, 2022 and 2021.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="white-space: nowrap; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of April 1&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,583&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,198&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 74%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Revenue recognized during the year&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(1,961&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(1,089&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;Milestone payment received during the year&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;2,210&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;474&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,832&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,583&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;Current&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;1,235&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;1,052&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;Non-current&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;1,597&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;1,531&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;























































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0.55pt; text-align: justify; text-indent: -0.55pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;S&lt;/div&gt;ignificant gross to net adjustments relating to Company&#x2019;s North America Generics business (amounts in U.S.$ millions)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A roll-forward for each major accrual for the Company&#x2019;s North America Generics business for the fiscal years ended March 31, 2020, 2021 and 2022 is as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Chargebacks&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rebates&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Medicaid&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Refund Liability&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-style: normal; border-bottom: 1pt solid black;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(All &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;amounts&lt;/div&gt; in U.S.$ millions)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 48%;"&gt;Beginning Balance: April 1, 2019&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;128&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;92&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;11&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;30&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current provisions relating to sales during the year&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,468&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;319&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;20&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;21&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Provisions and adjustments relating to sales in prior years&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Credits and payments**&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,440&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(331&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(20&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(27&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ending Balance: March 31, 2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;156&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;80&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;24&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Beginning Balance: April 1, 2020&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;156&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;80&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;11&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current provisions relating to sales during the year &lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,702&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;245&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;21&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Provisions and adjustments relating to sales in prior years&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Credits and payments**&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,656&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(247&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(19&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(20&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ending Balance: March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;202&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;78&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Beginning Balance: April 1, 2021&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;202&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;78&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;13&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;19&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current provisions relating to sales during the year &lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,897&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;235&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;23&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;25&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Provisions and adjustments relating to sales in prior years&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Credits and payments**&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,836&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(219&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(23&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(20&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ending Balance: March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;263&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;94&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;24&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;




































&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.25in;"&gt;*&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Currently, the Company does not separately track provisions and adjustments, in each case to the extent relating to prior years for chargebacks. However, the adjustments are expected to be non-material. The volumes used to calculate the closing balance of chargebacks represent approximately 1.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1 t&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;o 1.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#160;months equivalent of sales, which corresponds to the pending chargeback claims yet to be processed.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;** Currently, the Company does not separately track the credits and payments, in each case to the extent relating to prior years for chargebacks, rebates, medicaid payments or refund liability.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;























&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;























&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;

















&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chargebacks&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;provisions and payments for the year ended March 31, 2021 were each higher as compared to the year ended March 31, 2020, primarily as a result of higher sales volumes and also due to higher pricing rates per unit for chargebacks, due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company&#x2019;s products. The rebates provisions and payments for the year ended March 31, 2021 were each lower as compared to the year ended March 31, 2020, primarily as a result of lower pricing rates per unit for rebates, due to a reduction in the invoice price to wholesalers for certain of the Company&#x2019;s products and also due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company&#x2019;s products, which were partially off-set by higher sales volumes during the year ended March 31, 2021 as compared to the year ended March 31, 2020.&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font-size:11pt; margin:0in 0in 0in 0.25in; text-align:justify; text-indent:-0.25in; font-family:Calibri, 'sans-serif'"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal; text-indent: 0px;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chargebacks provisions and payments for the year ended March 31, 2022 were each higher as compared to the year ended March 31, 2021, primarily as a result of higher sales volumes and also due to higher pricing rates per unit for chargebacks, due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company products, which were partially off-set due to a lower pricing rates per unit for chargebacks. Such lower pricing rates were primarily on account of a reduction in the invoice price to wholesalers for certain of the Company products The rebates provisions and payments for the year ended March 31, 2022 were each lower as compared to the year ended March 31, 2021, primarily as a result of lower pricing rates per unit for rebates, due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company products.&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;




















&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, 'sans-serif'; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: 'Times New Roman', 'serif'; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, 'sans-serif'; line-height: normal; text-indent: 0px;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s overall refund liability as of March 31, 2022 relating to the Company North America Generics business was U.S.$24&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&#160; as compared to a liability of U.S.$19&#160;as of March 31, 2021. This increase in liability was primarily attributable to certain product mix changes and recent trends in actual sales returns for the year ended March 31, 2022, as compared to the year ended March 31, 2021. &lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


























&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The estimates of &#x201c;gross-to-net&#x201d; adjustments for the Company&#x2019;s operations in India and other countries outside of the United States relate mainly to refund liability in all such operations, and certain rebates to healthcare insurance providers are specific to the Company&#x2019;s German operations. The pattern of such refund liability is generally consistent with the Company&#x2019;s gross sales. In Germany, the rebates to healthcare insurance providers mentioned above are contractually fixed in nature and do not involve significant estimations by the Company.&lt;/div&gt; &lt;br/&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;efund liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance at the beginning of the year&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,824&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,252&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 74%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Provision made during the year, net of reversals&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4,406&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,934&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Provision used during the year&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(3,699&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(3,309&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;52&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;(53&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance at the closing of the year&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,583&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,824&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;Current&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;3,583&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,824&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;Non-current&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                                        &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;ontract asset:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As mentioned in the accounting policies for refund liability set forth in Note 3.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;m&lt;/div&gt;. of these consolidated financial statements, the Company recognizes an asset (i.e., the right to the returned goods),&#160;for the products expected to be returned. The Company initially measures this asset at the former carrying amount of the inventory, less any expected costs to recover the goods, including any potential decreases in the value of the returned goods. Along with re-measuring the refund liability at the end of each reporting period, the Company updates the measurement of the asset recorded for any revisions to its expected level of returns, as well as any additional decreases in the value of the returned products.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March 31, 2022 and 2021, the Company had Rs.43 and Rs.37, respectively, as contract assets representing the right to returned goods.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;ontract liabilities&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;:&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 74%; text-align: left; padding-bottom: 0.5pt;"&gt;Advance from customers&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1pt solid black;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 10%; text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,341&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1pt solid black;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 10%; text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;981&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,341&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;981&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                                       </ifrs-full:DisclosureOfRevenueExplanatory>
    <rdy:ScheduleOfRevenueTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Revenue from contracts with customers:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 13.5pt; text-indent: -13.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Sales&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;205,144&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;184,202&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;163,574&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 61%; text-align: left;"&gt;Service income&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;4,380&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;4,105&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;2,409&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;License fees&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;4,867&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,415&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;8,617&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;214,391&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;189,722&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;174,600&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 10.9pt; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; text-indent: 0px; vertical-align: bottom;"&gt;During the year ended March 31, 2022, the Company entered into the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;following agreements&lt;/div&gt;:&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;





&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; text-align: justify; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; text-align: justify; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An agreement with Alium JSC for the sale of the Company&#x2019;s territorial rights relating to two of its anti-bacterial brands (Ciprolet&#xae; and Levolet&#xae;) in Russia and certain countries of the former Soviet Union. The consideration for the arrangement is Rs.1,971 and the Company recognized revenue of Rs.1,774 for the performance obligations relating to the milestones met. This transaction pertains to the Company&#x2019;s Global Generics segment.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; text-align: justify; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; text-align: justify; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;An agreement with Mankind Pharma Limited towards the sale of two of the Company's brands (Daffy bar and Combihale) in India&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;which formed part of the Company&#x2019;s Global Generics segment. License fees includes an amount of&#160; Rs.390 towards the aforesaid sales transaction. &lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0.25in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; text-align: justify; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; text-align: justify; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A definitive agreement with BioDelivery Sciences International, Inc. (&#x201c;BDSI&#x201d;), pursuant to which the Company sold its U.S. and Canada territory rights for ELYXYB (celecoxib oral solution) 25 mg/mL, to BDSI.&#160; Under the terms of agreement, the Company was entitled to receive U.S.$6 up front at the closing&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&#160;U.S.$9 one year from the closing&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; event based milestone payments upon achievement of certain regulatory approvals; sales-based milestone payments; and quarterly earn-out payments based on a percentage (which varies based on sales volumes) of net sales of the product in the territory.&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;T&lt;/div&gt;he Company recognized an amount of Rs.1,084 as a licensee fee from this transaction.&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; white-space:pre-line; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt; &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;This transaction pertains to the Company&#x2019;s Proprietary Products segment.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;





&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;</rdy:ScheduleOfRevenueTableTextBlock>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">205144000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">184202000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">163574000000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromRenderingOfServices
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4380000000</ifrs-full:RevenueFromRenderingOfServices>
    <ifrs-full:RevenueFromRenderingOfServices
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">4105000000</ifrs-full:RevenueFromRenderingOfServices>
    <ifrs-full:RevenueFromRenderingOfServices
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">2409000000</ifrs-full:RevenueFromRenderingOfServices>
    <ifrs-full:LicenceFeeIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      id="Fact_50536529"
      unitRef="Unit_INR">4867000000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:LicenceFeeIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      id="Fact_50536530"
      unitRef="Unit_INR">1415000000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:LicenceFeeIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      id="Fact_50536531"
      unitRef="Unit_INR">8617000000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">214391000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">189722000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">174600000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_AliumJscMemberifrsfullCounterpartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">1971000000</ifrs-full:Revenue>
    <rdy:ConsiderationReceivable
      contextRef="PAsOn03_31_2022_AliumJscMemberifrsfullCounterpartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">1774000000</rdy:ConsiderationReceivable>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_MankindPharmaLimitedMemberifrsfullCounterpartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">390000000</ifrs-full:Revenue>
    <rdy:ConsiderationReceivable
      contextRef="PAsOn03_31_2022_BioDeliverySciencesInternationalIncMemberifrsfullCounterpartiesAxis"
      decimals="-6"
      unitRef="Unit_USD">6000000</rdy:ConsiderationReceivable>
    <rdy:ConsiderationReceivable
      contextRef="PAsOn03_31_2022_BioDeliverySciencesInternationalIncMemberifrsfullCounterpartiesAxis_OneYearFromClosingMemberRDYConsiderationReceivablePeriodAxis"
      decimals="-6"
      unitRef="Unit_USD">9000000</rdy:ConsiderationReceivable>
    <ifrs-full:LicenceFeeIncome
      contextRef="P04_01_2021To03_31_2022_BioDeliverySciencesInternationalIncMemberifrsfullCounterpartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">1084000000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:LicenceFeeIncome
      contextRef="P04_01_2021To03_31_2022_ProprietaryProductsMemberifrsfullSegmentsAxis_UpsherSmithLaboratoriesLLCMemberifrsfullCounterpartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">7486000000</ifrs-full:LicenceFeeIncome>
    <rdy:DisclosureOfRevenueBySegmentsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues by segments:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.05in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Segment&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Global Generics&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;179,170&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;154,404&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;138,123&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 61%; background-color: rgba(255, 255, 255, 0);"&gt;PSAI&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;30,740&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;31,982&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;25,747&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Proprietary products&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;1,611&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;523&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;7,949&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;2,870&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;2,813&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;2,781&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;214,391&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;189,722&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;174,600&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































</rdy:DisclosureOfRevenueBySegmentsTableTextBlock>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">179170000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">154404000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">138123000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">30740000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">31982000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">25747000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_ProprietaryProductsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">1611000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_ProprietaryProductsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">523000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_ProprietaryProductsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">7949000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_OthersSegmentsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2870000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_OthersSegmentsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2813000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_OthersSegmentsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2781000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">214391000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">189722000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">174600000000</ifrs-full:Revenue>
    <rdy:DisclosureAndDetailsAboutRevenueWithInGlobalGenericSegmentsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues within the Global Generics segment:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues by therapeutic areas in the Company&#x2019;s Global Generics segment is given below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Nervous System&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;26,159&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,040&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;26,825&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 61%;"&gt;Gastrointestinal&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;23,386&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;21,132&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;19,394&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Anti-Infective&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;22,526&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;12,906&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;9,402&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Pain Management&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;18,437&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15,531&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;13,808&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Oncology&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;17,051&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;16,842&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;18,245&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Respiratory&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15,085&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;11,089&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;10,433&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Cardiovascular&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14,856&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15,460&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14,729&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background: white; width: 310.3pt; padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; height: 0.15in;"&gt;
			&lt;div style="margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: -0.05pt; top: 0px;;display:inline;"&gt;Hematology&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: white; width: 9%; padding: 0pt; height: 0.15in;"&gt;
			&lt;div style="margin-left: -5.4pt; font-size: 10pt; text-align: right; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11,737&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: white; width: 9%; padding: 0pt; height: 0.15in;"&gt;
			&lt;div style="margin-left: -6.05pt; text-align: right; text-indent: 0.65pt; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,959&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 9%; padding: 0pt; height: 0.15in;"&gt;
			&lt;div style="margin: 0in -0.5pt 0.0001pt -5.3pt; text-align: right; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,725&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 310.3pt; padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; height: 0.15in;"&gt;
			&lt;div style="margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: -0.05pt; top: 0px;;display:inline;"&gt;Dermatology&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 9%; padding: 0pt; height: 0.15in;"&gt;
			&lt;div style="margin-left: -5.4pt; text-align: right; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,797&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 9%; padding: 0pt; height: 0.15in;"&gt;
			&lt;div style="margin-left: -6.05pt; text-align: right; text-indent: 0.65pt; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,240&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 9%; padding: 0pt; height: 0.15in; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin: 0in -0.5pt 0.0001pt -5.3pt; text-align: right; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,255&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background: rgba(255, 255, 255, 0); width: 310.3pt; padding-top: 0in; padding-right: 5.4pt; padding-bottom: 0in; height: 0.15in;"&gt;
			&lt;div style="margin-left: 0in; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: -0.05pt; top: 0px;;display:inline;"&gt;Nutraceutical&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgba(255, 255, 255, 0); width: 9%; padding: 0pt; height: 0.15in;"&gt;
			&lt;div style="margin-left: -5.4pt; text-align: right; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,530&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgba(255, 255, 255, 0); width: 9%; padding: 0pt; height: 0.15in;"&gt;
			&lt;div style="margin-left: -6.05pt; text-align: right; text-indent: 0.65pt; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,059&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 9%; padding: 0pt; height: 0.15in; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin: 0in -0.5pt 0.0001pt -5.3pt; text-align: right; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,441&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;18,606&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;18,146&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;13,866&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;179,170&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;154,404&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;138,123&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































</rdy:DisclosureAndDetailsAboutRevenueWithInGlobalGenericSegmentsTableTextBlock>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis_NervousSystemMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">26159000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis_NervousSystemMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">29040000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_NervousSystemMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">26825000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GastrointestinalMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">23386000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GastrointestinalMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">21132000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GastrointestinalMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">19394000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_AntiinfectiveMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">22526000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_AntiinfectiveMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">12906000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_AntiinfectiveMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">9402000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis_PainManagementMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">18437000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis_PainManagementMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">15531000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_PainManagementMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">13808000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">17051000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">16842000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_OncologyMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">18245000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">15085000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">11089000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">10433000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_CardiovascularMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">14856000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_CardiovascularMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">15460000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_CardiovascularMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">14729000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis_HematologyMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">11737000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis_HematologyMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">4959000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_HematologyMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">4725000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_DermatologyMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">6797000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_DermatologyMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">5240000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_DermatologyMemberifrsfullProductsAndServicesAxis_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">3255000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis_NutraceuticalMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">4530000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis_NutraceuticalMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">4059000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_NutraceuticalMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">3441000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis_OtherGlobalGenericsMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">18606000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis_OtherGlobalGenericsMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">18146000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis_OtherGlobalGenericsMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">13866000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">179170000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">154404000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GlobalGenericsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">138123000000</ifrs-full:Revenue>
    <rdy:DisclosureAndDetailsAboutRevenueFromTherapeuticsAreasTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;evenues by therapeutic areas in the Company&#x2019;s PSAI segment is given below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;Cardiovascular&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7,729&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;9,834&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,567&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 61%; background-color: rgba(255, 255, 255, 0);"&gt;Anti-Infective&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;5,450&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4,126&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,264&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Pain Management&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;4,513&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;4,657&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;5,073&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Nervous System&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;3,017&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,704&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,797&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;Oncology&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;2,526&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;2,385&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;1,798&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="text-indent: 0px; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gastrointestinal&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;982&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,098&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;705&lt;/div&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Genitourinary&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;705&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;825&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;441&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Respiratory&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;676&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,317&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;789&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diabetology&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;544&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;350&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;168&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;Dermatology&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;498&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;768&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;1,370&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;4,100&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;3,918&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;1,775&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30,740&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31,982&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;25,747&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































</rdy:DisclosureAndDetailsAboutRevenueFromTherapeuticsAreasTableTextBlock>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_CardiovascularMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">7729000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_CardiovascularMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">9834000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_CardiovascularMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">8567000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_AntiinfectiveMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">5450000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_AntiinfectiveMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">4126000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_AntiinfectiveMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2264000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_PainManagementMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">4513000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_PainManagementMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">4657000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_PainManagementMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">5073000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_CentralNervousSystemMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">3017000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_CentralNervousSystemMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2704000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_CentralNervousSystemMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2797000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_OncologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2526000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_OncologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2385000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_OncologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">1798000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GastrointestinalMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">982000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GastrointestinalMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">1098000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GastrointestinalMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">705000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_GenitourinaryMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">705000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_GenitourinaryMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">825000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_GenitourinaryMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">441000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">676000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">1317000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis_RespiratoryMemberifrsfullProductsAndServicesAxis"
      decimals="-6"
      unitRef="Unit_INR">789000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_DiabetologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">544000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_DiabetologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">350000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_DiabetologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">168000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_DermatologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">498000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_DermatologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">768000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_DermatologyMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">1370000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_OtherPsaiSegmentMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">4100000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_OtherPsaiSegmentMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">3918000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_OtherPsaiSegmentMemberifrsfullProductsAndServicesAxis_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">1775000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">30740000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">31982000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_PharmaceuticalServicesAndActiveIngredientMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">25747000000</ifrs-full:Revenue>
    <rdy:DisaggregationOfRevenueByGeographicalAreasTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows the distribution of the Company&#x2019;s revenues by country, based on the location of the customers:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Country&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;India&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;43,986&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36,252&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;32,089&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 61%; text-align: left;"&gt;United States&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;80,564&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;76,702&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;76,028&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Russia&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;20,879&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15,816&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;16,900&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;68,962&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;60,952&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;49,583&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;214,391&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;189,722&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;174,600&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































</rdy:DisaggregationOfRevenueByGeographicalAreasTableTextBlock>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_IndiaCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">43986000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_IndiaCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">36252000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_IndiaCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">32089000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_OncologyMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">80564000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_OncologyMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">76702000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_OncologyMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">76028000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_RussiaCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">20879000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_RussiaCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">15816000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_RussiaCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">16900000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_OthersCountriesCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_50539037"
      unitRef="Unit_INR">68962000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_OthersCountriesCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_50539038"
      unitRef="Unit_INR">60952000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_OthersCountriesCountryMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      id="Fact_50539039"
      unitRef="Unit_INR">49583000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">214391000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">189722000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">174600000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_MajorCustomerOneMembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_INR">20596000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2021To03_31_2022_MajorCustomerTwoMembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_INR">10339000000</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="P04_01_2021To03_31_2022_MajorCustomerOneMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="P04_01_2021To03_31_2022_MajorCustomerTwoMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_MajorCustomerOneMembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_INR">19341000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2020To03_31_2021_MajorCustomerTwoMembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_INR">9867000000</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="P04_01_2020To03_31_2021_MajorCustomerOneMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="P04_01_2020To03_31_2021_MajorCustomerTwoMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_MajorCustomerOneMembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_INR">14164000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="P04_01_2019To03_31_2020_MajorCustomerTwoMembersrtMajorCustomersAxis"
      decimals="-6"
      unitRef="Unit_INR">9267000000</ifrs-full:Revenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="P04_01_2019To03_31_2020_MajorCustomerTwoMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.08</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="P04_01_2019To03_31_2020_MajorCustomerOneMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</ifrs-full:PercentageOfEntitysRevenue>
    <rdy:DisclosureOfReconciliationOfDeferredRevenueTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tabulated below is the reconciliation of deferred revenue for the years &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ended &lt;/div&gt;March 31, 2022 and 2021.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="white-space: nowrap; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; white-space: nowrap; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of April 1&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,583&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,198&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 74%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Revenue recognized during the year&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(1,961&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(1,089&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;Milestone payment received during the year&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;2,210&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;474&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as of March 31&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,832&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,583&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;Current&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;1,235&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;1,052&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;Non-current&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;1,597&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;1,531&lt;/td&gt;
			&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































</rdy:DisclosureOfReconciliationOfDeferredRevenueTableTextBlock>
    <ifrs-full:DeferredIncomeOtherThanContractLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2583000000</ifrs-full:DeferredIncomeOtherThanContractLiabilities>
    <ifrs-full:DeferredIncomeOtherThanContractLiabilities
      contextRef="PAsOn03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">3198000000</ifrs-full:DeferredIncomeOtherThanContractLiabilities>
    <rdy:RevenueRecognised
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1961000000</rdy:RevenueRecognised>
    <rdy:RevenueRecognised
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1089000000</rdy:RevenueRecognised>
    <rdy:MilestonePaymentDuringTheYear
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2210000000</rdy:MilestonePaymentDuringTheYear>
    <rdy:MilestonePaymentDuringTheYear
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">474000000</rdy:MilestonePaymentDuringTheYear>
    <ifrs-full:DeferredIncomeOtherThanContractLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2832000000</ifrs-full:DeferredIncomeOtherThanContractLiabilities>
    <ifrs-full:DeferredIncomeOtherThanContractLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2583000000</ifrs-full:DeferredIncomeOtherThanContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1235000000</ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities>
    <ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1052000000</ifrs-full:CurrentDeferredIncomeOtherThanCurrentContractLiabilities>
    <ifrs-full:NoncurrentDeferredIncomeOtherThanNoncurrentContractLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1597000000</ifrs-full:NoncurrentDeferredIncomeOtherThanNoncurrentContractLiabilities>
    <ifrs-full:NoncurrentDeferredIncomeOtherThanNoncurrentContractLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1531000000</ifrs-full:NoncurrentDeferredIncomeOtherThanNoncurrentContractLiabilities>
    <rdy:DisclosureOfAccrualForTheCompanysNorthAmericaOperationTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A roll-forward for each major accrual for the Company&#x2019;s North America Generics business for the fiscal years ended March 31, 2020, 2021 and 2022 is as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Chargebacks&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rebates&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Medicaid&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Refund Liability&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="14" style="text-align: center; font-style: normal; border-bottom: 1pt solid black;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;(All &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;amounts&lt;/div&gt; in U.S.$ millions)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 48%;"&gt;Beginning Balance: April 1, 2019&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;128&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;92&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;11&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 10%; text-align: right;"&gt;30&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current provisions relating to sales during the year&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,468&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;319&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;20&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;21&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Provisions and adjustments relating to sales in prior years&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Credits and payments**&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,440&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(331&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(20&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(27&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ending Balance: March 31, 2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;156&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;80&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;24&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Beginning Balance: April 1, 2020&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;156&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;80&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;11&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current provisions relating to sales during the year &lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,702&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;245&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;21&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Provisions and adjustments relating to sales in prior years&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Credits and payments**&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,656&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(247&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(19&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(20&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ending Balance: March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;202&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;78&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;19&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Beginning Balance: April 1, 2021&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;202&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;78&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;13&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;19&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current provisions relating to sales during the year &lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,897&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;235&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;23&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;25&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Provisions and adjustments relating to sales in prior years&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Credits and payments**&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,836&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(219&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(23&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(20&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ending Balance: March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;263&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;94&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;24&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;




































&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.25in;"&gt;*&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Currently, the Company does not separately track provisions and adjustments, in each case to the extent relating to prior years for chargebacks. However, the adjustments are expected to be non-material. The volumes used to calculate the closing balance of chargebacks represent approximately 1.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1 t&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;o 1.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#160;months equivalent of sales, which corresponds to the pending chargeback claims yet to be processed.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;** Currently, the Company does not separately track the credits and payments, in each case to the extent relating to prior years for chargebacks, rebates, medicaid payments or refund liability.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;























&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;























&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;

















&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chargebacks&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;provisions and payments for the year ended March 31, 2021 were each higher as compared to the year ended March 31, 2020, primarily as a result of higher sales volumes and also due to higher pricing rates per unit for chargebacks, due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company&#x2019;s products. The rebates provisions and payments for the year ended March 31, 2021 were each lower as compared to the year ended March 31, 2020, primarily as a result of lower pricing rates per unit for rebates, due to a reduction in the invoice price to wholesalers for certain of the Company&#x2019;s products and also due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company&#x2019;s products, which were partially off-set by higher sales volumes during the year ended March 31, 2021 as compared to the year ended March 31, 2020.&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font-size:11pt; margin:0in 0in 0in 0.25in; text-align:justify; text-indent:-0.25in; font-family:Calibri, 'sans-serif'"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 11pt; border-spacing: 0px; border-collapse: collapse; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align:top"&gt;
			&lt;td style="width:0in; overflow-wrap:break-word; vertical-align:top"/&gt;
			&lt;td style="width: 0.25in; font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="font-size: 10pt;"&gt;
			&lt;div style="font-size: 11pt; margin-top: 0in; margin-right: 0in; margin-bottom: 0in; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; line-height: normal; text-indent: 0px;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chargebacks provisions and payments for the year ended March 31, 2022 were each higher as compared to the year ended March 31, 2021, primarily as a result of higher sales volumes and also due to higher pricing rates per unit for chargebacks, due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company products, which were partially off-set due to a lower pricing rates per unit for chargebacks. Such lower pricing rates were primarily on account of a reduction in the invoice price to wholesalers for certain of the Company products The rebates provisions and payments for the year ended March 31, 2022 were each lower as compared to the year ended March 31, 2021, primarily as a result of lower pricing rates per unit for rebates, due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company products.&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


















</rdy:DisclosureOfAccrualForTheCompanysNorthAmericaOperationTableTextBlock>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2019_ChargebacksMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">128000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2019_RebatesMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">92000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2019_MedicaidMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">11000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2019_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539067"
      unitRef="Unit_USD">30000000</ifrs-full:OtherProvisions>
    <ifrs-full:NewProvisionsOtherProvisions
      contextRef="P04_01_2019To03_31_2020_ChargebacksMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">1468000000</ifrs-full:NewProvisionsOtherProvisions>
    <ifrs-full:NewProvisionsOtherProvisions
      contextRef="P04_01_2019To03_31_2020_RebatesMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">319000000</ifrs-full:NewProvisionsOtherProvisions>
    <ifrs-full:NewProvisionsOtherProvisions
      contextRef="P04_01_2019To03_31_2020_MedicaidMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</ifrs-full:NewProvisionsOtherProvisions>
    <ifrs-full:NewProvisionsOtherProvisions
      contextRef="P04_01_2019To03_31_2020_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539071"
      unitRef="Unit_USD">21000000</ifrs-full:NewProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="P04_01_2019To03_31_2020_ChargebacksMemberRDYProvisionAxis"
      id="Fact_50539072"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="P04_01_2019To03_31_2020_RebatesMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">0</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="P04_01_2019To03_31_2020_MedicaidMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">0</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="P04_01_2019To03_31_2020_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539075"
      unitRef="Unit_USD">0</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2019To03_31_2020_ChargebacksMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539076"
      unitRef="Unit_USD">1440000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2019To03_31_2020_RebatesMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539077"
      unitRef="Unit_USD">331000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2019To03_31_2020_MedicaidMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539078"
      unitRef="Unit_USD">20000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2019To03_31_2020_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539079"
      unitRef="Unit_USD">27000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2020_ChargebacksMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">156000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2020_RebatesMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">80000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2020_MedicaidMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">11000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2020_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539083"
      unitRef="Unit_USD">24000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2020_ChargebacksMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">156000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2020_RebatesMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">80000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2020_MedicaidMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">11000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2020_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539087"
      unitRef="Unit_USD">24000000</ifrs-full:OtherProvisions>
    <ifrs-full:NewProvisionsOtherProvisions
      contextRef="P04_01_2020To03_31_2021_ChargebacksMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539088"
      unitRef="Unit_USD">1702000000</ifrs-full:NewProvisionsOtherProvisions>
    <ifrs-full:NewProvisionsOtherProvisions
      contextRef="P04_01_2020To03_31_2021_RebatesMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539089"
      unitRef="Unit_USD">245000000</ifrs-full:NewProvisionsOtherProvisions>
    <ifrs-full:NewProvisionsOtherProvisions
      contextRef="P04_01_2020To03_31_2021_MedicaidMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539090"
      unitRef="Unit_USD">21000000</ifrs-full:NewProvisionsOtherProvisions>
    <ifrs-full:NewProvisionsOtherProvisions
      contextRef="P04_01_2020To03_31_2021_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539091"
      unitRef="Unit_USD">15000000</ifrs-full:NewProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="P04_01_2020To03_31_2021_ChargebacksMemberRDYProvisionAxis"
      id="Fact_50539092"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="P04_01_2020To03_31_2021_RebatesMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">0</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="P04_01_2020To03_31_2021_MedicaidMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">0</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="P04_01_2020To03_31_2021_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539095"
      unitRef="Unit_USD">0</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2020To03_31_2021_ChargebacksMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539096"
      unitRef="Unit_USD">1656000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2020To03_31_2021_RebatesMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539097"
      unitRef="Unit_USD">247000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2020To03_31_2021_MedicaidMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539098"
      unitRef="Unit_USD">19000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2020To03_31_2021_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539099"
      unitRef="Unit_USD">20000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2021_ChargebacksMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">202000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2021_RebatesMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">78000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2021_MedicaidMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">13000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2021_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539103"
      unitRef="Unit_USD">19000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2021_ChargebacksMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">202000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2021_RebatesMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">78000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2021_MedicaidMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">13000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2021_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539107"
      unitRef="Unit_USD">19000000</ifrs-full:OtherProvisions>
    <ifrs-full:NewProvisionsOtherProvisions
      contextRef="P04_01_2021To03_31_2022_ChargebacksMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539108"
      unitRef="Unit_USD">1897000000</ifrs-full:NewProvisionsOtherProvisions>
    <ifrs-full:NewProvisionsOtherProvisions
      contextRef="P04_01_2021To03_31_2022_RebatesMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539109"
      unitRef="Unit_USD">235000000</ifrs-full:NewProvisionsOtherProvisions>
    <ifrs-full:NewProvisionsOtherProvisions
      contextRef="P04_01_2021To03_31_2022_MedicaidMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539110"
      unitRef="Unit_USD">23000000</ifrs-full:NewProvisionsOtherProvisions>
    <ifrs-full:NewProvisionsOtherProvisions
      contextRef="P04_01_2021To03_31_2022_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539115"
      unitRef="Unit_USD">25000000</ifrs-full:NewProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="P04_01_2021To03_31_2022_ChargebacksMemberRDYProvisionAxis"
      id="Fact_50539116"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="P04_01_2021To03_31_2022_RebatesMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">0</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="P04_01_2021To03_31_2022_MedicaidMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">0</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="P04_01_2021To03_31_2022_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539119"
      unitRef="Unit_USD">0</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2021To03_31_2022_ChargebacksMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539120"
      unitRef="Unit_USD">1836000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2021To03_31_2022_RebatesMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539121"
      unitRef="Unit_USD">219000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2021To03_31_2022_MedicaidMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539122"
      unitRef="Unit_USD">23000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2021To03_31_2022_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539123"
      unitRef="Unit_USD">20000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2022_ChargebacksMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">263000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2022_RebatesMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">94000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2022_MedicaidMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_USD">13000000</ifrs-full:OtherProvisions>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2022_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      id="Fact_50539114"
      unitRef="Unit_USD">24000000</ifrs-full:OtherProvisions>
    <ifrs-full:RefundsProvision
      contextRef="PAsOn03_31_2022_GlobalGenericsNorthAmericaOperationsMemberRDYTypeOfCashgeneratingUnitsAxis"
      decimals="-6"
      unitRef="Unit_USD">24000000</ifrs-full:RefundsProvision>
    <ifrs-full:RefundsProvision
      contextRef="PAsOn03_31_2021_GlobalGenericsNorthAmericaOperationsMemberRDYTypeOfCashgeneratingUnitsAxis"
      decimals="-6"
      unitRef="Unit_USD">19000000</ifrs-full:RefundsProvision>
    <rdy:ScheduleOfMovementOfRefundLiabilitiesTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&lt;/div&gt;efund liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance at the beginning of the year&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,824&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,252&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 74%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Provision made during the year, net of reversals&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;4,406&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,934&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Provision used during the year&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(3,699&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(3,309&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;Effect of changes in foreign exchange rates&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;52&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;(53&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance at the closing of the year&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,583&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,824&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;Current&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;3,583&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;2,824&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;Non-current&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                   </rdy:ScheduleOfMovementOfRefundLiabilitiesTableTextBlock>
    <ifrs-full:RefundsProvision
      contextRef="PAsOn03_31_2021_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_INR">2824000000</ifrs-full:RefundsProvision>
    <ifrs-full:RefundsProvision
      contextRef="PAsOn03_31_2020_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_INR">3252000000</ifrs-full:RefundsProvision>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P04_01_2021To03_31_2022_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_INR">4406000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:AdditionalProvisionsOtherProvisions
      contextRef="P04_01_2020To03_31_2021_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_INR">2934000000</ifrs-full:AdditionalProvisionsOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2021To03_31_2022_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_INR">3699000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="P04_01_2020To03_31_2021_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_INR">3309000000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="P04_01_2021To03_31_2022_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_INR">52000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions
      contextRef="P04_01_2020To03_31_2021_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_INR">-53000000</ifrs-full:IncreaseDecreaseThroughNetExchangeDifferencesOtherProvisions>
    <ifrs-full:RefundsProvision
      contextRef="PAsOn03_31_2022_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_INR">3583000000</ifrs-full:RefundsProvision>
    <ifrs-full:RefundsProvision
      contextRef="PAsOn03_31_2021_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_INR">2824000000</ifrs-full:RefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="PAsOn03_31_2022_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_INR">3583000000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="PAsOn03_31_2021_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_INR">2824000000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:NoncurrentRefundsProvision
      contextRef="PAsOn03_31_2022_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:NoncurrentRefundsProvision>
    <ifrs-full:NoncurrentRefundsProvision
      contextRef="PAsOn03_31_2021_RefundLiabilityMemberRDYProvisionAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:NoncurrentRefundsProvision>
    <ifrs-full:ContractAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">43000000</ifrs-full:ContractAssets>
    <ifrs-full:ContractAssets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">37000000</ifrs-full:ContractAssets>
    <rdy:DisclosureOfContractLiabilitiesTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;ontract liabilities&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;:&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 74%; text-align: left; padding-bottom: 0.5pt;"&gt;Advance from customers&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1pt solid black;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 10%; text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,341&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1pt solid black;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 10%; text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;981&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,341&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;981&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                   </rdy:DisclosureOfContractLiabilitiesTableTextBlock>
    <ifrs-full:Advances
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1341000000</ifrs-full:Advances>
    <ifrs-full:Advances
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">981000000</ifrs-full:Advances>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1341000000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">981000000</ifrs-full:ContractLiabilities>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;. Other income, net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income, net consists of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss/(gain) on sale/disposal of non-current assets, net&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;(1,119&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;42&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 61%; text-align: left;"&gt;Sale of spent chemicals&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;(348&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;(270&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;(306&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Scrap sales&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(206&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(142&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(167&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Miscellaneous income, net&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,088&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(612&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(3,827&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,761)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(982)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4,290)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                     &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0px; text-indent: 0px;"/&gt;&lt;td style="width: 0.2in; text-indent: 0px;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2022, the Company entered into a definitive agreement with Citius Pharmaceuticals, Inc. ("Citius") for the sale of all of its rights relating to its anti-cancer agent E7777 (denileukin diftitox) to Citius. The Company received Rs. 2,951 (U.S.$40) as an up front amount upon the closing of the transaction. Further, the Company is entitled to additional payments on achievement of milestones of up to U.S.$40 upon the CTCL (cutaneous Tcell lymphoma) indication regulatory approval, up to U.S.$70 in milestone payments upon additional indication regulatory approvals, and certain sales-based milestones and tiered earn-out payments. &#160;Consequently, an amount of Rs.1,064, representing the excess of sale consideration over the carrying cost, has been recognized as gain on sale of intangible assets. &#160;The transaction pertains to the &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;Company&lt;/div&gt;&#x2019;s&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; Proprietary Products segment.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                     &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; text-indent: -0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0px;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Miscellaneous income, net for the year ended March 31, 2020 includes Rs.3,457 received from Celgene pursuant to a settlement agreement entered into in April 2019. The agreement effectively settles any claim the Company or its affiliates may have had for damages under section 8 of the Canadian Patented Medicines (Notice of Compliance) Regulations in regard to the Company&#x2019;s ANDS for a generic version of REVLIMID&#xae; brand capsules (Lenalidomide) pending before Health Canada.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                           </ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory>
    <rdy:OtherOperatingIncomeExpenseTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income, net consists of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss/(gain) on sale/disposal of non-current assets, net&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;(1,119&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;42&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 61%; text-align: left;"&gt;Sale of spent chemicals&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;(348&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;(270&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;(306&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Scrap sales&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(206&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(142&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(167&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Miscellaneous income, net&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,088&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(612&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(3,827&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,761)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(982)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4,290)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                     &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0px; text-indent: 0px;"/&gt;&lt;td style="width: 0.2in; text-indent: 0px;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2022, the Company entered into a definitive agreement with Citius Pharmaceuticals, Inc. ("Citius") for the sale of all of its rights relating to its anti-cancer agent E7777 (denileukin diftitox) to Citius. The Company received Rs. 2,951 (U.S.$40) as an up front amount upon the closing of the transaction. Further, the Company is entitled to additional payments on achievement of milestones of up to U.S.$40 upon the CTCL (cutaneous Tcell lymphoma) indication regulatory approval, up to U.S.$70 in milestone payments upon additional indication regulatory approvals, and certain sales-based milestones and tiered earn-out payments. &#160;Consequently, an amount of Rs.1,064, representing the excess of sale consideration over the carrying cost, has been recognized as gain on sale of intangible assets. &#160;The transaction pertains to the &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;Company&lt;/div&gt;&#x2019;s&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; Proprietary Products segment.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                     &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; text-indent: -0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0px;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;Miscellaneous income, net for the year ended March 31, 2020 includes Rs.3,457 received from Celgene pursuant to a settlement agreement entered into in April 2019. The agreement effectively settles any claim the Company or its affiliates may have had for damages under section 8 of the Canadian Patented Medicines (Notice of Compliance) Regulations in regard to the Company&#x2019;s ANDS for a generic version of REVLIMID&#xae; brand capsules (Lenalidomide) pending before Health Canada.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;             </rdy:OtherOperatingIncomeExpenseTableTextBlock>
    <ifrs-full:GainsLossesOnDisposalsOfNoncurrentAssets
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      id="Fact_50540722"
      unitRef="Unit_INR">1119000000</ifrs-full:GainsLossesOnDisposalsOfNoncurrentAssets>
    <ifrs-full:GainsLossesOnDisposalsOfNoncurrentAssets
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      id="Fact_50536536"
      unitRef="Unit_INR">-42000000</ifrs-full:GainsLossesOnDisposalsOfNoncurrentAssets>
    <ifrs-full:GainsLossesOnDisposalsOfNoncurrentAssets
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      id="Fact_50536537"
      unitRef="Unit_INR">-10000000</ifrs-full:GainsLossesOnDisposalsOfNoncurrentAssets>
    <rdy:SaleOfSpentChemical
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">348000000</rdy:SaleOfSpentChemical>
    <rdy:SaleOfSpentChemical
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">270000000</rdy:SaleOfSpentChemical>
    <rdy:SaleOfSpentChemical
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">306000000</rdy:SaleOfSpentChemical>
    <rdy:GainsLossesOnScrapSales
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">206000000</rdy:GainsLossesOnScrapSales>
    <rdy:GainsLossesOnScrapSales
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">142000000</rdy:GainsLossesOnScrapSales>
    <rdy:GainsLossesOnScrapSales
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">167000000</rdy:GainsLossesOnScrapSales>
    <rdy:MiscellaneousOthersOperatingIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      id="Fact_50539791"
      unitRef="Unit_INR">-1088000000</rdy:MiscellaneousOthersOperatingIncome>
    <rdy:MiscellaneousOthersOperatingIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      id="Fact_50539792"
      unitRef="Unit_INR">-612000000</rdy:MiscellaneousOthersOperatingIncome>
    <rdy:MiscellaneousOthersOperatingIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      id="Fact_50539793"
      unitRef="Unit_INR">-3827000000</rdy:MiscellaneousOthersOperatingIncome>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2761000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">982000000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">4290000000</ifrs-full:OtherOperatingIncomeExpense>
    <rdy:UpFrontPaymentReceived
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2951000000</rdy:UpFrontPaymentReceived>
    <rdy:UpFrontPaymentReceived
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">40000000</rdy:UpFrontPaymentReceived>
    <rdy:AdditionalPaymentsReceivableOnAchievementOfMilestones
      contextRef="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis"
      decimals="-6"
      unitRef="Unit_USD">40000000</rdy:AdditionalPaymentsReceivableOnAchievementOfMilestones>
    <rdy:AdditionalPaymentsReceivableOnAchievementOfMilestones
      contextRef="P04_01_2021To03_31_2022_TopOfRangeMemberifrsfullRangeAxis"
      decimals="-6"
      unitRef="Unit_USD">70000000</rdy:AdditionalPaymentsReceivableOnAchievementOfMilestones>
    <rdy:GainOnSaleOfIntangibleAssets
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1064000000</rdy:GainOnSaleOfIntangibleAssets>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="P04_01_2019To03_31_2020_ProprietaryProductsMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">3457000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-indent: -0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;. Finance income, net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance income, net consists of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Interest income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;965&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;826&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;888&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 61%; text-align: left;"&gt;Fair value changes and profit on sale of financial instruments measured at FVTPL, net&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;277&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;557&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;929&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Foreign exchange gain, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,835&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,240&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;639&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Miscellaneous income, net&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;*&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Finance income (A)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,077&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,623&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,461&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Interest expense&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(958)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(970)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(983)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Finance expense (B)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(958)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(970)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(983)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Finance income, net [(A)+(B)]&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,119&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,653&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,478&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                     &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;* Rounded to the nearest million.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <rdy:ScheduleOfFinanceExpenseIncomeTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance income, net consists of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Interest income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;965&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;826&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;888&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 61%; text-align: left;"&gt;Fair value changes and profit on sale of financial instruments measured at FVTPL, net&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;277&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;557&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;929&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Foreign exchange gain, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,835&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,240&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;639&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Miscellaneous income, net&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;*&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Finance income (A)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,077&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,623&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,461&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Interest expense&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(958)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(970)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(983)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Finance expense (B)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(958)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(970)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(983)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Finance income, net [(A)+(B)]&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,119&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,653&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,478&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                     &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;* Rounded to the nearest million.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</rdy:ScheduleOfFinanceExpenseIncomeTableTextBlock>
    <ifrs-full:InvestmentIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">965000000</ifrs-full:InvestmentIncome>
    <ifrs-full:InvestmentIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">826000000</ifrs-full:InvestmentIncome>
    <ifrs-full:InvestmentIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">888000000</ifrs-full:InvestmentIncome>
    <rdy:AdjustmentsForFairValueIncreaseDecreaseAndGainsLossesOnSaleOfFinancialInstrumentsMeasuredAtFairValueThroughProfitLossNet
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">277000000</rdy:AdjustmentsForFairValueIncreaseDecreaseAndGainsLossesOnSaleOfFinancialInstrumentsMeasuredAtFairValueThroughProfitLossNet>
    <rdy:AdjustmentsForFairValueIncreaseDecreaseAndGainsLossesOnSaleOfFinancialInstrumentsMeasuredAtFairValueThroughProfitLossNet
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">557000000</rdy:AdjustmentsForFairValueIncreaseDecreaseAndGainsLossesOnSaleOfFinancialInstrumentsMeasuredAtFairValueThroughProfitLossNet>
    <rdy:AdjustmentsForFairValueIncreaseDecreaseAndGainsLossesOnSaleOfFinancialInstrumentsMeasuredAtFairValueThroughProfitLossNet
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">929000000</rdy:AdjustmentsForFairValueIncreaseDecreaseAndGainsLossesOnSaleOfFinancialInstrumentsMeasuredAtFairValueThroughProfitLossNet>
    <ifrs-full:NetForeignExchangeGain
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1835000000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1240000000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">639000000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      id="Fact_50539145"
      unitRef="Unit_INR">0</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">5000000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:FinanceIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">3077000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2623000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">2461000000</ifrs-full:FinanceIncome>
    <ifrs-full:InterestExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">958000000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">970000000</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">983000000</ifrs-full:InterestExpense>
    <ifrs-full:FinanceCosts
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">958000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">970000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">983000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncomeCost
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2119000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1653000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">1478000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 13.5pt; text-indent: -13.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;. Income taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;a. Income tax expense/(benefit) recognized in the consolidated income statement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax expense/(benefit) recognized in the consolidated income statement consists of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current taxes&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Domestic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,180&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,849&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,157&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 61%; padding-bottom: 0.5pt;"&gt;Foreign&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; border-bottom: 1pt solid black;"&gt;2,231&lt;/td&gt;&lt;td style="width: 1%; text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; border-bottom: 1pt solid black;"&gt;2,323&lt;/td&gt;&lt;td style="width: 1%; text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; border-bottom: 1pt solid black;"&gt;1,459&lt;/td&gt;&lt;td style="width: 1%; text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,411&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,172&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,616&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred taxes&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Domestic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,165&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,736&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(6,580)&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;154&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,733&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,502&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,319&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,003&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8,082)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Tax expense/(benefit), net&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,730&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,175&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,466)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                                        &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 38.25pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;b. Income tax expense/(benefit) recognized directly in equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax expense/(benefit) recognized directly in equity consists of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 61%; text-align: left;"&gt;Tax effect on changes in fair value of other investments&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;(293&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;293&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Tax effect on effective portion of change in fair value of cash flow hedges&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;288&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;319&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(232&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Tax effect on actuarial gains/losses on defined benefit obligations&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(12&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(73&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;22&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;539&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(210&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                                        &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 38.25pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;c. Reconciliation of effective tax rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following is a reconciliation of the Company&#x2019;s effective tax rates for the years ended March 31, 2022, 2021 and 2020:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 61%; text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit before income taxes&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;32,298&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;26,413&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18,032&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Enacted tax rate in India&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;34.94&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;%&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;34.94&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;%&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;34.94&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Computed expected tax expense&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,285&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,229&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,301&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effect of:&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Differences between Indian and foreign tax rates&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(427&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;810&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;3,385&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Unrecognized deferred tax assets/(recognition of previously unrecognized deferred tax assets, net)&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;97&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;1,220&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(6,478&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Expenses not deductible for tax purposes&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;208&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;230&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;155&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Income exempt from income taxes&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(1,619&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(1,807&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(1,029&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Foreign exchange differences&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(55&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(18&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(64&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Incremental deduction allowed for research and development costs&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(1,241&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Tax expense on distributed/undistributed earnings of subsidiary outside India&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(220&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;254&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Income from sale of capital assets&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(305&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(2,620&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Effect of change in tax rate&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(333&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(37&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;(234&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;(156&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;(92&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income tax expense/(benefit)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,730&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,175&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,466&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effective tax rate&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;35&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(8&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                     &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 9pt; text-align: justify; text-indent: -9pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0px;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: bottom;"&gt;India&#x2019;s Finance Act, 2016 incorporated an amendment that reduces the weighted deduction on eligible research and development expenditure in a phased manner from 200% to 150% commencing from April 1, 2017 and from 150% to 100% effective April 1, 2020.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s effective tax rate for the year ended March 31, 2022 was lower as compared to the year ended March 31, 2021 primarily on account of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.5in; text-indent: 0px;"/&gt;
			&lt;td style="width: 0.25in; text-indent: 0px;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; text-indent: 0px; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;;display:inline;"&gt;lower profit base during the year ended March 31, 202&lt;div style="color: rgb(31, 73, 125); letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;;display:inline;"&gt;1 &lt;/div&gt;on account of impairment losses&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;a permanent difference resulting in a higher tax rate.&lt;/div&gt;&lt;div style="color: rgb(31, 73, 125); letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;After adjusting these impairment losses, the adjusted effective tax rate stands at 26.5% for the year ended March 31, 2021; and&lt;/div&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.75in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.5in; text-indent: 0px;"/&gt;
			&lt;td style="width: 0.25in; text-indent: 0px;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; text-indent: 0px; font-size: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;;display:inline;"&gt;inclusion of income from sale of capital assets, which is taxable at a rate lower than the enacted tax rate for the year ended March&#160;31,&#160;2022. Consequently, &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;;display:inline;"&gt;effective tax rate&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;;display:inline;"&gt; for the year ended March 31, 2022 was approximately lower by 1% on account of income from the sale of capital assets.&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.75in; text-align: justify; text-indent: -0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0in; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;;display:inline;"&gt;The balance impact is on account of changes in the Company&#x2019;s jurisdictional mix of earnings (i.e., decrease in the proportion of the Company profits from lower tax jurisdictions and increase in proportion of the Company profits from higher tax jurisdictions).&lt;/div&gt;&lt;/div&gt; &lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; text-indent: 0in;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;d. Unrecognized deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The details of unrecognized deferred tax assets are summarized below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Deductible temporary differences, net&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;538&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;738&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Operating tax loss carry-forward&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;4,590&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;4,742&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,128&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,480&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

















































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2022, the Company recognized deferred tax assets on &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;certain&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;operating tax losses &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;primaril&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;y&lt;/div&gt;&#160;&lt;/div&gt;pertaining&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;to Dr. Reddy&#x2019;s Laboratories SA, Switzerland&lt;div style="letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;,&lt;/div&gt; as the Company believes that it is probable that there will be available taxable profits against which such tax losses can be utilized.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income tax&#160;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;liability is&lt;/div&gt;&#160;not provided on undistributed earnings of Rs.18,471 and Rs. 19,543 as of March 31, 2022 and 2021, respectively of subsidiaries, where it is expected that earnings of the subsidiaries will not be distributed in the foreseeable future. Generally, the Company indefinitely reinvests all of the accumulated undistributed earnings of subsidiaries, and accordingly, has not recorded any deferred taxes in relation to such undistributed earnings of its subsidiaries.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;e. Deferred tax assets and liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The tax effects of significant temporary differences that resulted in deferred tax assets and liabilities and a description of the items that created these differences is given below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred tax assets/(liabilities):&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 70%;"&gt;Inventory&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,197&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,997&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Minimum Alternate Tax*&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,929&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,748&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other receivables**&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;710&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;569&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Operating/other tax loss carry-forward&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,053&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,593&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other current assets and other current liabilities, net&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,546&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,404&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Property, plant and equipment&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(3,300&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(2,547&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other intangible assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;34&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(283&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(25&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(189&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,144&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,292&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 7.1pt; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;*&lt;/div&gt;As per Indian tax laws, companies are liable for a Minimum Alternate Tax (&#x201c;MAT&#x201d;) when current tax, as computed under the provisions of the Income Tax Act, 1961 (&#x201c;Tax Act&#x201d;), is determined to be below the MAT computed under section 115JB of the Tax Act. If in any year the Company pays a MAT, then it is entitled to claim credit of the MAT paid over and above the normal tax liability in the subsequent years. The MAT credit is eligible to be carried forward and set-off in the future against the current tax liabilities over a period of 15 years starting from the succeeding fiscal year in which such credit was generated.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;**&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;The final regulations addressing changes in income recognition rules under Treas. Reg. sections 1.451-3 and 1.451-8 were published on January 6, 2021, and are effective for tax years beginning on or after January 1, 2021.&#160; The final regulations which are mandatory for tax years beginning after December 31, 2020, are consistent with the Internal Revenue Service&#x2019;s (IRS) position and therefore create the need for the Company to change its current accounting method used for chargebacks to align with the final regulations.&#160;&#160; As a consequence, of the new regulations, Dr. Reddy&#x2019;s Laboratories Inc. U.S.A. has created a deferred tax asset and deferred tax liability in the financial statements reported for the year ending March 31, 2022.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In assessing whether the deferred income tax assets will be realized, management considers whether some portion or all of the deferred income tax assets will not be realized. The ultimate realization of the deferred income tax assets and tax loss carry-forwards is dependent upon the generation of future taxable income during the periods in which the temporary differences become deductible. Management considers the scheduled reversals of deferred tax liabilities, projected future taxable income and tax planning strategy in making this assessment. Based on the level of historical taxable income and projections of future taxable income over the periods in which the deferred tax assets are deductible, management believes that the Company will realize the benefits of those recognized deductible differences and tax loss carry-forwards. Recoverability of deferred tax assets is based on estimates of future taxable income. Any changes in such future taxable income would impact the recoverability of deferred tax assets.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating loss carry-forward consists of business losses, unabsorbed depreciation and unabsorbed interest carry-forwards. A portion of this total loss can be carried indefinitely and the remaining amounts expire at various dates ranging from 2023 through 2040.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;f. Movement in deferred tax assets and liabilities during the years ended March 31, 2022 and 2021&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recognized in&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;income&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;statement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recognized in&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred tax assets/(liabilities):&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 40%;"&gt;Inventory&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,997&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;(800&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,197&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Minimum Alternate Tax&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,748&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(819&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,929&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other receivables&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;569&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;141&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;710&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Operating/other tax loss carry-forward&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,593&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(540&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,053&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other current assets and other current liabilities, net&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,404&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;142&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,546&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Property, plant and equipment&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(2,548&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(752&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(3,300&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other intangible assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(283&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;317&lt;/td&gt;
			&lt;td style="text-align: left;"/&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;34&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(188&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;146&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;17&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(25&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,292&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,165&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,144&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.3125in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The details of movement in deferred tax assets and liabilities are summarized below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recognized in&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;income&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;statement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recognized in&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred tax assets/(liabilities):&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 40%;"&gt;Inventory&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,216&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;781&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,997&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Minimum Alternate Tax&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,246&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(1,498&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,748&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other receivables&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;369&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;200&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;569&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Operating/other tax loss carry-forward&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,399&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(806&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,593&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other current assets and other current liabilities, net&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,448&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(44&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,404&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Property, plant and equipment&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(2,361&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(187&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(2,548&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other intangible assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(477&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;194&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(283&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;99&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;252&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(539&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(188&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,939&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,108&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(539&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,292&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

















































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amounts recognized in the consolidated income statement for the years ended March 31, 2022 and 2021 include Rs.154 and Rs. (105), respectively, which represent exchange differences arising due to foreign currency translations.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;g. Uncertain tax positions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is contesting various disallowances by the Indian Income Tax authorities. The associated tax impact for disallowances being more likely than not to be accepted by Tax authorities is Rs.2,726, and accordingly, no provision is made in these consolidated financial statements as of March&#160;31, 2022.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the years ended March 31, 2014, 2015 and 2016, Industrias Quimicas Falcon de Mexico, S.A. de CV, a wholly-owned subsidiary of the Company in Mexico, received a notice from Mexico's Tax Administration Service, Servicio de Administracion Tributaria (&#x201c;SAT&#x201d;), with respect to disallowance on account of transfer pricing adjustments pertaining to the calendar years ended December 31, 2006, December 31, 2007 and December 31, 2008. The associated tax impact is Rs.918 (MXN 241) and profit share impact is Rs.95 (MXN 25). The Company filed administrative appeals with the SAT by challenging these disallowances and, during February and March 2017, the Company received orders of the SAT confirming these disallowances by dismissing its administrative appeals. The Company disagrees with the SAT&#x2019;s disallowances and filed an appeal with the Tribunal Federal de Justicia Administrativa (Federal Tax and Administrative Court of Mexico) in March and April 2017. The Company believes that it is more likely than not that it would prevail over the SAT in this litigation. Accordingly, no provision has been made in these consolidated financial statements as of March 31, 2022.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <rdy:DisclosureOfIncomeTaxTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax expense/(benefit) recognized in the consolidated income statement consists of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Current taxes&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Domestic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,180&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,849&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,157&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 61%; padding-bottom: 0.5pt;"&gt;Foreign&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; border-bottom: 1pt solid black;"&gt;2,231&lt;/td&gt;&lt;td style="width: 1%; text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; border-bottom: 1pt solid black;"&gt;2,323&lt;/td&gt;&lt;td style="width: 1%; text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; border-bottom: 1pt solid black;"&gt;1,459&lt;/td&gt;&lt;td style="width: 1%; text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,411&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8,172&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6,616&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred taxes&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Domestic&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,165&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,736&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(6,580)&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;154&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,733&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,502&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,319&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,003&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(8,082)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Tax expense/(benefit), net&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,730&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9,175&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,466)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                   </rdy:DisclosureOfIncomeTaxTableTextBlock>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P04_01_2021To03_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">4180000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P04_01_2020To03_31_2021_CountryOfDomicileMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">5849000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P04_01_2019To03_31_2020_CountryOfDomicileMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">5157000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P04_01_2021To03_31_2022_ForeignCountriesMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">2231000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P04_01_2020To03_31_2021_ForeignCountriesMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">2323000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P04_01_2019To03_31_2020_ForeignCountriesMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">1459000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">6411000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">8172000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">6616000000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="P04_01_2021To03_31_2022_CountryOfDomicileMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">2165000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="P04_01_2020To03_31_2021_CountryOfDomicileMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">2736000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="P04_01_2019To03_31_2020_CountryOfDomicileMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">-6580000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="P04_01_2021To03_31_2022_ForeignCountriesMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">154000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="P04_01_2020To03_31_2021_ForeignCountriesMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">-1733000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="P04_01_2019To03_31_2020_ForeignCountriesMemberifrsfullGeographicalAreasAxis"
      decimals="-6"
      unitRef="Unit_INR">-1502000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2319000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1003000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:DeferredTaxExpenseIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-8082000000</ifrs-full:DeferredTaxExpenseIncome>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">8730000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">9175000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-1466000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <rdy:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax expense/(benefit) recognized directly in equity consists of the following:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 61%; text-align: left;"&gt;Tax effect on changes in fair value of other investments&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;(293&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;293&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Tax effect on effective portion of change in fair value of cash flow hedges&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;288&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;319&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(232&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Tax effect on actuarial gains/losses on defined benefit obligations&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(12&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(73&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;22&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(17&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;539&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(210&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                   </rdy:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquityTableTextBlock>
    <ifrs-full:IncomeTaxRelatingToAvailableforsaleFinancialAssetsOfOtherComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-293000000</ifrs-full:IncomeTaxRelatingToAvailableforsaleFinancialAssetsOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToAvailableforsaleFinancialAssetsOfOtherComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">293000000</ifrs-full:IncomeTaxRelatingToAvailableforsaleFinancialAssetsOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToAvailableforsaleFinancialAssetsOfOtherComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:IncomeTaxRelatingToAvailableforsaleFinancialAssetsOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">288000000</ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">319000000</ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-232000000</ifrs-full:IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">12000000</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">73000000</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-22000000</ifrs-full:IncomeTaxRelatingToRemeasurementsOfDefinedBenefitPlansOfOtherComprehensiveIncome>
    <ifrs-full:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-17000000</ifrs-full:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">539000000</ifrs-full:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-210000000</ifrs-full:CurrentAndDeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <rdy:ReconciliationBetweenEnactedAndEffectiveTaxRatesTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following is a reconciliation of the Company&#x2019;s effective tax rates for the years ended March 31, 2022, 2021 and 2020:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="width: 61%; text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Profit before income taxes&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;32,298&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;26,413&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18,032&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Enacted tax rate in India&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;34.94&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;%&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;34.94&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;%&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;34.94&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Computed expected tax expense&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,285&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,229&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,301&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effect of:&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Differences between Indian and foreign tax rates&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(427&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;810&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;3,385&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Unrecognized deferred tax assets/(recognition of previously unrecognized deferred tax assets, net)&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;97&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;1,220&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(6,478&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Expenses not deductible for tax purposes&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;208&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;230&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;155&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Income exempt from income taxes&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(1,619&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(1,807&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(1,029&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Foreign exchange differences&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(55&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(18&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(64&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Incremental deduction allowed for research and development costs&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(1,241&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Tax expense on distributed/undistributed earnings of subsidiary outside India&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(220&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;254&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;Income from sale of capital assets&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(305&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;-&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0);"&gt;(2,620&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;Effect of change in tax rate&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;-&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(333&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255);"&gt;(37&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;(234&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;(156&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;(92&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income tax expense/(benefit)&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,730&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9,175&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgb(204, 238, 255); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,466&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Effective tax rate&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;35&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;%&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; background-color: rgba(255, 255, 255, 0); border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(8&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                     &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 9pt; text-align: justify; text-indent: -9pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0px;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: bottom;"&gt;India&#x2019;s Finance Act, 2016 incorporated an amendment that reduces the weighted deduction on eligible research and development expenditure in a phased manner from 200% to 150% commencing from April 1, 2017 and from 150% to 100% effective April 1, 2020.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                   </rdy:ReconciliationBetweenEnactedAndEffectiveTaxRatesTableTextBlock>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">32298000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">26413000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">18032000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ApplicableTaxRate
      contextRef="P04_01_2021To03_31_2022"
      decimals="4"
      unitRef="Unit_pure">0.3494</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.3494</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate
      contextRef="P04_01_2019To03_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.3494</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-11285000000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-9229000000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-6301000000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-427000000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">810000000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">3385000000</ifrs-full:TaxEffectOfForeignTaxRates>
    <rdy:RecognitionOfPreviouslyUnrecognisedDeferredTaxAssetsOrUnrecognisedDeferredTaxAssets
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-97000000</rdy:RecognitionOfPreviouslyUnrecognisedDeferredTaxAssetsOrUnrecognisedDeferredTaxAssets>
    <rdy:RecognitionOfPreviouslyUnrecognisedDeferredTaxAssetsOrUnrecognisedDeferredTaxAssets
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-1220000000</rdy:RecognitionOfPreviouslyUnrecognisedDeferredTaxAssetsOrUnrecognisedDeferredTaxAssets>
    <rdy:RecognitionOfPreviouslyUnrecognisedDeferredTaxAssetsOrUnrecognisedDeferredTaxAssets
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">6478000000</rdy:RecognitionOfPreviouslyUnrecognisedDeferredTaxAssetsOrUnrecognisedDeferredTaxAssets>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">208000000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">230000000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">155000000</ifrs-full:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss>
    <ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1619000000</ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011>
    <ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1807000000</ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011>
    <ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">1029000000</ifrs-full:TaxEffectOfRevenuesExemptFromTaxation2011>
    <rdy:ForeignExchangeDifferencesOnIncomeTaxes
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-55000000</rdy:ForeignExchangeDifferencesOnIncomeTaxes>
    <rdy:ForeignExchangeDifferencesOnIncomeTaxes
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-18000000</rdy:ForeignExchangeDifferencesOnIncomeTaxes>
    <rdy:ForeignExchangeDifferencesOnIncomeTaxes
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-64000000</rdy:ForeignExchangeDifferencesOnIncomeTaxes>
    <rdy:IncrementalDeductionAllowedForResearchAndDevelopmentCosts
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncrementalDeductionAllowedForResearchAndDevelopmentCosts>
    <rdy:IncrementalDeductionAllowedForResearchAndDevelopmentCosts
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncrementalDeductionAllowedForResearchAndDevelopmentCosts>
    <rdy:IncrementalDeductionAllowedForResearchAndDevelopmentCosts
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-1241000000</rdy:IncrementalDeductionAllowedForResearchAndDevelopmentCosts>
    <rdy:TaxExpenseOnDistrubutionOfProfitsBySubsidiary
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">220000000</rdy:TaxExpenseOnDistrubutionOfProfitsBySubsidiary>
    <rdy:TaxExpenseOnDistrubutionOfProfitsBySubsidiary
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:TaxExpenseOnDistrubutionOfProfitsBySubsidiary>
    <rdy:TaxExpenseOnDistrubutionOfProfitsBySubsidiary
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-254000000</rdy:TaxExpenseOnDistrubutionOfProfitsBySubsidiary>
    <rdy:IncomeTaxReconcilationTaxEffectOfIncomeFromDisposalOfCapitalGains
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-305000000</rdy:IncomeTaxReconcilationTaxEffectOfIncomeFromDisposalOfCapitalGains>
    <rdy:IncomeTaxReconcilationTaxEffectOfIncomeFromDisposalOfCapitalGains
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:IncomeTaxReconcilationTaxEffectOfIncomeFromDisposalOfCapitalGains>
    <rdy:IncomeTaxReconcilationTaxEffectOfIncomeFromDisposalOfCapitalGains
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-2620000000</rdy:IncomeTaxReconcilationTaxEffectOfIncomeFromDisposalOfCapitalGains>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-333000000</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-37000000</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-234000000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-156000000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-92000000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">8730000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">9175000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">-1466000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:AverageEffectiveTaxRate
      contextRef="P04_01_2021To03_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.27</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate
      contextRef="P04_01_2020To03_31_2021"
      decimals="2"
      unitRef="Unit_pure">0.35</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate
      contextRef="P04_01_2019To03_31_2020"
      decimals="2"
      unitRef="Unit_pure">-0.08</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate
      contextRef="P04_01_2017To04_01_2017_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_pure">2</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate
      contextRef="P04_01_2017To04_01_2017_BottomOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_pure">1.50</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate
      contextRef="P04_01_2020To04_01_2020_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_pure">1.50</ifrs-full:AverageEffectiveTaxRate>
    <ifrs-full:AverageEffectiveTaxRate
      contextRef="P04_01_2020To04_01_2020_BottomOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:AverageEffectiveTaxRate>
    <rdy:AdjustedEffectiveTaxRate
      contextRef="P04_01_2020To03_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.265</rdy:AdjustedEffectiveTaxRate>
    <rdy:TaxableRateLowerThanEnactedTaxRate
      contextRef="P04_01_2021To03_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.01</rdy:TaxableRateLowerThanEnactedTaxRate>
    <rdy:DisclosureOfUnrecognisedDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The details of unrecognized deferred tax assets are summarized below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Deductible temporary differences, net&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;538&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;738&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Operating tax loss carry-forward&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;4,590&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;4,742&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,128&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,480&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































</rdy:DisclosureOfUnrecognisedDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">538000000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">738000000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">4590000000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">4742000000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <rdy:UnrecognizedDeferredTaxAssetsAndLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">5128000000</rdy:UnrecognizedDeferredTaxAssetsAndLiabilities>
    <rdy:UnrecognizedDeferredTaxAssetsAndLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">5480000000</rdy:UnrecognizedDeferredTaxAssetsAndLiabilities>
    <rdy:DeferredIncomeTaxesNotRecognizedOnUndistributedEarningsOfSubsidiaries
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">18471000000</rdy:DeferredIncomeTaxesNotRecognizedOnUndistributedEarningsOfSubsidiaries>
    <rdy:DeferredIncomeTaxesNotRecognizedOnUndistributedEarningsOfSubsidiaries
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">19543000000</rdy:DeferredIncomeTaxesNotRecognizedOnUndistributedEarningsOfSubsidiaries>
    <rdy:DisclosureOfTaxEffectsOfSignificantTemporaryDifferencesThatResultedInDeferredTaxTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The tax effects of significant temporary differences that resulted in deferred tax assets and liabilities and a description of the items that created these differences is given below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred tax assets/(liabilities):&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 70%;"&gt;Inventory&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,197&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,997&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Minimum Alternate Tax*&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,929&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,748&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other receivables**&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;710&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;569&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Operating/other tax loss carry-forward&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,053&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,593&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other current assets and other current liabilities, net&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,546&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,404&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Property, plant and equipment&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(3,300&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(2,547&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other intangible assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;34&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(283&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(25&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(189&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,144&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,292&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 7.1pt; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;*&lt;/div&gt;As per Indian tax laws, companies are liable for a Minimum Alternate Tax (&#x201c;MAT&#x201d;) when current tax, as computed under the provisions of the Income Tax Act, 1961 (&#x201c;Tax Act&#x201d;), is determined to be below the MAT computed under section 115JB of the Tax Act. If in any year the Company pays a MAT, then it is entitled to claim credit of the MAT paid over and above the normal tax liability in the subsequent years. The MAT credit is eligible to be carried forward and set-off in the future against the current tax liabilities over a period of 15 years starting from the succeeding fiscal year in which such credit was generated.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;**&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;The final regulations addressing changes in income recognition rules under Treas. Reg. sections 1.451-3 and 1.451-8 were published on January 6, 2021, and are effective for tax years beginning on or after January 1, 2021.&#160; The final regulations which are mandatory for tax years beginning after December 31, 2020, are consistent with the Internal Revenue Service&#x2019;s (IRS) position and therefore create the need for the Company to change its current accounting method used for chargebacks to align with the final regulations.&#160;&#160; As a consequence, of the new regulations, Dr. Reddy&#x2019;s Laboratories Inc. U.S.A. has created a deferred tax asset and deferred tax liability in the financial statements reported for the year ending March 31, 2022.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;</rdy:DisclosureOfTaxEffectsOfSignificantTemporaryDifferencesThatResultedInDeferredTaxTableTextBlock>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2022_InventoryTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">3197000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2021_InventoryTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">3997000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2022_MinimumAlternateTaxTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">3929000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2021_MinimumAlternateTaxTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">4748000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2022_TradeAndOtherReceivablesTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">710000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2021_TradeAndOtherReceivablesTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">569000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2022_OperatingAndOtherTaxLossCarryforwardMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">2053000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2021_OperatingAndOtherTaxLossCarryforwardMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">2593000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2022_OtherCurrentAssetsAndOtherCurrentLiabilitiesNetTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">1546000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2021_OtherCurrentAssetsAndOtherCurrentLiabilitiesNetTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">1404000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2022_PropertyPlantAndEquipmentTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">-3300000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2021_PropertyPlantAndEquipmentTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">-2547000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2022_OtherIntangibleAssetsTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">34000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2021_OtherIntangibleAssetsTemporaryDifferenceMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">-283000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2022_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">-25000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2021_OtherTemporaryDifferencesMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">-189000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">8144000000</ifrs-full:DeferredTaxLiabilityAsset>
    <ifrs-full:DeferredTaxLiabilityAsset
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">10292000000</ifrs-full:DeferredTaxLiabilityAsset>
    <rdy:DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recognized in&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;income&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;statement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recognized in&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred tax assets/(liabilities):&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 40%;"&gt;Inventory&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,997&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;(800&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,197&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Minimum Alternate Tax&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,748&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(819&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,929&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other receivables&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;569&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;141&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;710&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Operating/other tax loss carry-forward&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,593&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(540&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,053&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other current assets and other current liabilities, net&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,404&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;142&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,546&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Property, plant and equipment&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(2,548&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(752&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(3,300&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other intangible assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(283&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;317&lt;/td&gt;
			&lt;td style="text-align: left;"/&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;34&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(188&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;146&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;17&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(25&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,292&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,165&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;17&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,144&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.3125in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The details of movement in deferred tax assets and liabilities are summarized below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recognized in&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;income&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;statement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Recognized in&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;equity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Deferred tax assets/(liabilities):&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 40%;"&gt;Inventory&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,216&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;781&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,997&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Minimum Alternate Tax&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,246&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(1,498&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,748&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other receivables&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;369&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;200&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;569&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Operating/other tax loss carry-forward&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,399&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(806&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,593&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other current assets and other current liabilities, net&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,448&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(44&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,404&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Property, plant and equipment&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(2,361&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(187&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(2,548&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other intangible assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(477&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;194&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;-&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(283&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Others&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;99&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;252&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(539&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(188&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11,939&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(1,108&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(539&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10,292&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;















































</rdy:DisclosureOfMovementInDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021_InventorydeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">3997000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2021To03_31_2022_InventorydeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-800000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P04_01_2021To03_31_2022_InventorydeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2022_InventorydeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">3197000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021_MinimumAlternateTaxdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">4748000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2021To03_31_2022_MinimumAlternateTaxdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-819000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2022_MinimumAlternateTaxdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">3929000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021_TradeAndOtherReceivablesdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">569000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2021To03_31_2022_TradeAndOtherReceivablesdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">141000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2022_TradeAndOtherReceivablesdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">710000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021_OperatingAndOtherTaxLossCarryforwardMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">2593000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2021To03_31_2022_OperatingAndOtherTaxLossCarryforwardMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-540000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2022_OperatingAndOtherTaxLossCarryforwardMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">2053000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021_OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">1404000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2021To03_31_2022_OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">142000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2022_OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">1546000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021_PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-2548000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2021To03_31_2022_PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-752000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2022_PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-3300000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021_IntangibleAssetsdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-283000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2021To03_31_2022_IntangibleAssetsdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">317000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2022_IntangibleAssetsdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">34000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021_OthersdeferredTaxLiabilityAssetMemberMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-188000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2021To03_31_2022_OthersdeferredTaxLiabilityAssetMemberMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">146000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P04_01_2021To03_31_2022_OthersdeferredTaxLiabilityAssetMemberMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">17000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2022_OthersdeferredTaxLiabilityAssetMemberMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-25000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">10292000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">-2165000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">17000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">8144000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2020_InventorydeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">3216000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2020To03_31_2021_InventorydeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">781000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P04_01_2020To03_31_2021_InventorydeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021_InventorydeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">3997000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2020_MinimumAlternateTaxdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">6246000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2020To03_31_2021_MinimumAlternateTaxdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-1498000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021_MinimumAlternateTaxdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">4748000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2020_TradeAndOtherReceivablesdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">369000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2020To03_31_2021_TradeAndOtherReceivablesdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">200000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021_TradeAndOtherReceivablesdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">569000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2020_OperatingAndOtherTaxLossCarryforwardMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">3399000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2020To03_31_2021_OperatingAndOtherTaxLossCarryforwardMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-806000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021_OperatingAndOtherTaxLossCarryforwardMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">2593000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2020_OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">1448000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2020To03_31_2021_OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-44000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021_OtherCurrentAssetsAndOtherCurrentLiabilitiesNetdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">1404000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2020_PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-2361000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2020To03_31_2021_PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-187000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021_PropertyPlantAndEquipmentdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-2548000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2020_IntangibleAssetsdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-477000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2020To03_31_2021_IntangibleAssetsdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">194000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021_IntangibleAssetsdeferredTaxLiabilityAssetMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-283000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2020_OthersdeferredTaxLiabilityAssetMemberMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">99000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2020To03_31_2021_OthersdeferredTaxLiabilityAssetMemberMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">252000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P04_01_2020To03_31_2021_OthersdeferredTaxLiabilityAssetMemberMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-539000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021_OthersdeferredTaxLiabilityAssetMemberMemberRDYDeferredTaxAssetsAndLiabilitiesAxis"
      decimals="-6"
      unitRef="Unit_INR">-188000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">11939000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-1108000000</ifrs-full:DeferredTaxExpenseIncomeRecognisedInProfitOrLoss>
    <ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-539000000</ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">10292000000</ifrs-full:NetDeferredTaxAssets>
    <rdy:ExchangeDifferencesOnForeignCurrencyTranslationsRecognisedInIncomeStatementOnDeferredTax
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">154000000</rdy:ExchangeDifferencesOnForeignCurrencyTranslationsRecognisedInIncomeStatementOnDeferredTax>
    <rdy:ExchangeDifferencesOnForeignCurrencyTranslationsRecognisedInIncomeStatementOnDeferredTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-105000000</rdy:ExchangeDifferencesOnForeignCurrencyTranslationsRecognisedInIncomeStatementOnDeferredTax>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised
      contextRef="PAsOn03_31_2022_ProfitTaxImpactMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">2726000000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <rdy:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="PAsOn03_31_2022_AssociatedTaxImpactMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">918000000</rdy:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <rdy:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="PAsOn03_31_2022_AssociatedTaxImpactMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_MXN">241000000</rdy:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <rdy:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="PAsOn03_31_2022_ProfitTaxImpactMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_INR">95000000</rdy:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <rdy:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="PAsOn03_31_2022_ProfitTaxImpactMemberifrsfullTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"
      decimals="-6"
      unitRef="Unit_MXN">25000000</rdy:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&#160;Nature of Expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows supplemental information related to certain &#x201c;nature of expense&#x201d; items for the years ended March 31, 2022, 2021 and 2020:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding: 0px 0px 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%;"&gt;Cost of revenues&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;11,594&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;11,529&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;10,643&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Selling, general and administrative expenses&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;22,486&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;20,052&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;18,658&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Research and development expenses&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;4,778&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;4,718&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;4,501&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;38,858&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36,299&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;33,802&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Depreciation&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%;"&gt;Cost of revenues&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;5,627&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;6,061&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;6,366&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Selling, general and administrative expenses&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,476&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,491&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,294&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Research and development expenses&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,049&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;975&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;980&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,152&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,527&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,640&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; text-indent: -4.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortization&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%;"&gt;Cost of revenues&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;175&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Selling, general and administrative expenses&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,651&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,171&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,547&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Research and development expenses&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;21&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;98&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;110&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,672&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,269&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,832&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;








































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, for details relating to costs of material consumed, refer to Note 10 of these consolidated financial statements.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <rdy:SupplementalInformationAboutExpenseByNatureTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows supplemental information related to certain &#x201c;nature of expense&#x201d; items for the years ended March 31, 2022, 2021 and 2020:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding: 0px 0px 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Employee benefits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%;"&gt;Cost of revenues&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;11,594&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;11,529&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;10,643&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Selling, general and administrative expenses&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;22,486&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;20,052&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;18,658&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Research and development expenses&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;4,778&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;4,718&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;4,501&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;38,858&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;36,299&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;33,802&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Depreciation&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%;"&gt;Cost of revenues&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;5,627&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;6,061&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;6,366&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Selling, general and administrative expenses&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,476&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,491&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,294&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Research and development expenses&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,049&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;975&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;980&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,152&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,527&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,640&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; text-indent: -4.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortization&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%;"&gt;Cost of revenues&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;175&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Selling, general and administrative expenses&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,651&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,171&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,547&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Research and development expenses&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;21&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;98&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;110&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,672&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,269&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,832&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































</rdy:SupplementalInformationAboutExpenseByNatureTextBlock>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2021To03_31_2022_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">11594000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2020To03_31_2021_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">11529000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2019To03_31_2020_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">10643000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2021To03_31_2022_SellingGeneralAndAdministrativeExpensesOneMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">22486000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2020To03_31_2021_SellingGeneralAndAdministrativeExpensesOneMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">20052000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2019To03_31_2020_SellingGeneralAndAdministrativeExpensesOneMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">18658000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2021To03_31_2022_ResearchAndDevelopmentExpensesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">4778000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2020To03_31_2021_ResearchAndDevelopmentExpensesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">4718000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2019To03_31_2020_ResearchAndDevelopmentExpensesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">4501000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">38858000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">36299000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">33802000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DepreciationExpense
      contextRef="P04_01_2021To03_31_2022_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">5627000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="P04_01_2020To03_31_2021_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">6061000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="P04_01_2019To03_31_2020_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">6366000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="P04_01_2021To03_31_2022_SellingGeneralAndAdministrativeExpensesOneMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">1476000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="P04_01_2020To03_31_2021_SellingGeneralAndAdministrativeExpensesOneMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">1491000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="P04_01_2019To03_31_2020_SellingGeneralAndAdministrativeExpensesOneMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">1294000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="P04_01_2021To03_31_2022_ResearchAndDevelopmentExpensesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">1049000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="P04_01_2020To03_31_2021_ResearchAndDevelopmentExpensesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">975000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="P04_01_2019To03_31_2020_ResearchAndDevelopmentExpensesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">980000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">8152000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">8527000000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">8640000000</ifrs-full:DepreciationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="P04_01_2021To03_31_2022_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="P04_01_2020To03_31_2021_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="P04_01_2019To03_31_2020_CostOfRevenuesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">175000000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="P04_01_2021To03_31_2022_SellingGeneralAndAdministrativeExpensesOneMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">3651000000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="P04_01_2020To03_31_2021_SellingGeneralAndAdministrativeExpensesOneMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">4171000000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="P04_01_2019To03_31_2020_SellingGeneralAndAdministrativeExpensesOneMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">3547000000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="P04_01_2021To03_31_2022_ResearchAndDevelopmentExpensesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">21000000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="P04_01_2020To03_31_2021_ResearchAndDevelopmentExpensesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">98000000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="P04_01_2019To03_31_2020_ResearchAndDevelopmentExpensesMemberRDYTypeOfExpensesByNatureAxis"
      decimals="-6"
      unitRef="Unit_INR">110000000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">3672000000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">4269000000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">3832000000</ifrs-full:AmortisationExpense>
    <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;. Employee benefits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total employee benefit expenses, including share-based payments, incurred during the years ended March 31, 2022, 2021 and 2020 amounted to Rs.38,858, Rs. 36,299 and Rs. 33,802, respectively.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Gratuity benefits provided by the parent company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with applicable Indian laws, the Company has a defined benefit plan which provides for gratuity payments (the &#x201c;Gratuity Plan&#x201d;) and covers certain categories of employees in India. The Gratuity Plan provides a lump sum gratuity payment to eligible employees at retirement or termination of their employment. The amount of the payment is based on the respective employee&#x2019;s last drawn salary and the years of employment with the Company. Effective September 1, 1999, the Company established the Dr. Reddy&#x2019;s Laboratories Gratuity Fund (the &#x201c;Gratuity Fund&#x201d;) to fund the Gratuity Plan. Liabilities in respect of the Gratuity Plan are determined by an actuarial valuation, based upon which the Company makes contributions to the Gratuity Fund. Trustees administer the contributions made to the Gratuity Fund. Amounts contributed to the Gratuity Fund are invested in bonds issued by the Government of India and in debt securities and equity securities of Indian companies. &lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of gratuity cost recognized in the income statement for the years ended March 31, 2022, 2021 and 2020 consist of the following:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%; text-align: left;"&gt;Current service cost&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;328&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;281&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;276&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Interest on defined benefit liability&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;33&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;8&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(4&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gratuity cost recognized in income statement&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;361&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;289&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;272&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;








































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of the employee benefits obligations and plan assets are provided below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%;"&gt;Present value of funded obligations&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;2,894&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;2,628&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Fair value of plan assets&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(2,350&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,997&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net defined benefit liability recognized&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;544&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;631&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;







































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of changes in the present value of defined benefit obligations are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Defined benefit obligations at the beginning of the year&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;2,628&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;2,349&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Current service cost&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;328&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;281&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Interest on defined obligations&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;144&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;140&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Re-measurements due to:&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Actuarial loss/(gain) due to change in financial assumptions&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;153&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Actuarial loss/(gain) due to demographic assumptions&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(26&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Actuarial loss/(gain) due to experience changes&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;60&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;51&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Benefits paid&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(293&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(345&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities (transferred)&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;/&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;assumed&lt;/div&gt;&lt;div style="text-indent: 0px;;display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(4&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;25&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Defined benefit obligations at the end of the year&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,894&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,628&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Liabilities assumed/transferred&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;:&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2022&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; Rs.(4) represents &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the &lt;/div&gt;transfer of liabilities on account of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;the&lt;/div&gt; transfer &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;f&#160;employees between the parent company and its subsidiaries.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2021&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; Rs.25 is comprised of:&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.3in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;a)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Rs.70 increase in liabilities on account of the acquisition of employees pursuant to the Business Transfer Agreement with Wockhardt Limited. Refer to Note 6 of these consolidated financial statements for further details.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.3in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;b)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Rs.45 transfer of liabilities on account of a restructuring of the pharmaceutical services business between the parent company and its subsidiary.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of changes in the fair value of plan assets are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Fair value of plan assets at the beginning of the year&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;1,997&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;2,160&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Employer contributions&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;496&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;25&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Interest on plan assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;111&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;132&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Re-measurements due to:&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Return on plan assets excluding interest on plan assets&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;43&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Benefits paid&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(293&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(345&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(transferred)&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;/&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;acquired&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(4&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;26&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Plan assets at the end of the year&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,350&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,997&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Assets acquired/transferred&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;:&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2022&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&#160;Rs.(4) represents&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;the&lt;/div&gt; transfer of plan asset&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt; on account of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the &lt;/div&gt;transfer &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;f&#160;employees between the parent company and its subsidiaries.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2021 Rs. 26 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;is &lt;/div&gt;comprised of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.2in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;a)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Rs.70 increase in assets on account of the acquisition of employees pursuant to the Business Transfer Agreement with Wockhardt Limited. Refer to Note 6 of these consolidated financial statements for further details.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.2in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;b)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Rs.44 transfer of assets on account of a restructuring of the pharmaceutical services business between the parent company and its subsidiary.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;








































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sensitivity Analysis:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March 31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 85%; text-align: left; padding-left: 5.4pt;"&gt;Defined benefit obligation without effect of projected salary growth&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;1,904&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-left: 5.4pt;"&gt;Add: Effect of salary growth&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;990&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-left: 5.4pt;"&gt;Defined benefit obligation with projected salary growth&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,894&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-left: 5.4pt;"&gt;Defined benefit obligation, using discount rate minus 50 basis points&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,978&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-left: 5.4pt;"&gt;Defined benefit obligation, using discount rate plus 50 basis points&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,815&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-left: 5.4pt;"&gt;Defined benefit obligation, using salary growth rate plus 50 basis points&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,976&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-left: 5.4pt;"&gt;Defined benefit obligation, using salary growth rate minus 50 basis points&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,816&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;







































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Summary of the actuarial assumptions: &lt;/div&gt;The actuarial assumptions used in accounting for the Gratuity plan are as follows:&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The assumptions used to determine benefit obligations:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%; text-align: left;"&gt;Discount rate&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;6.45&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;6.00&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;6.65&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Rate of compensation increase&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;8.50&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;8.00&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7.50&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;














































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;





















  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Disaggregation of plan assets: &lt;/div&gt;The Gratuity Plan&#x2019;s weighted-average asset allocation as of March 31, 2022 and 2021, by asset category, was as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Funds managed by insurers&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;100&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;100&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Others&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





























































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The expected future cash flows in respect of gratuity as of March 31, 2022 were as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected contribution&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td&gt;During the year ended March 31, 2023 (estimated)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;Rs.229&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected future benefit payments&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 85%;"&gt;March 31, 2023&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;481&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;March 31, 2024&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;409&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;March 31, 2025&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;398&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;March 31, 2026&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;372&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;March 31, 2027&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;346&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Thereafter&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,437&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





























































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Pension plan of the Company&#x2019;s subsidiary, Industrias Quimicas Falcon de Mexico&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All employees of the Company&#x2019;s Mexican subsidiary, Industrias Quimicas Falcon de Mexico (&#x201c;Falcon&#x201d;), are entitled to a pension benefit in the form of a defined benefit pension plan. The Falcon pension plan provides for payment to vested employees at retirement or termination of employment. Liabilities in respect of the pension plan are determined by an actuarial valuation, based on which the Company makes contributions to the pension plan fund. This fund is administered by a third party, who is provided guidance by a technical committee formed by senior employees of Falcon.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of net pension cost recognized in the income statement for the years ended March 31, 2022, 2021 and 2020 consist of the following:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%; text-align: left;"&gt;Current service cost&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;16&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;13&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;11&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Interest on defined benefit liability&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;10&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;8&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;16&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total cost recognized in income statement&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;26&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of the employee benefits obligations and plan assets are provided below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%;"&gt;Present value of funded obligations&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;271&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;307&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Fair value of plan assets&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(215&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(169&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net defined benefit liability recognized&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;56&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;138&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





























































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of changes in the present value of defined benefit obligations are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Defined benefit obligations at the beginning of the year&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;307&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;234&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Current service cost&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;16&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;13&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Interest on defined obligations&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;21&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Re-measurements due to:&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Actuarial loss/(gain) due to change in financial assumptions&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(40&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Actuarial loss/(gain) due to experience changes&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;19&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Benefits paid&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(58&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(32&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Foreign exchanges differences&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;19&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;28&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Defined benefit obligations at the end of the year&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;271&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;307&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





























































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of changes in the fair value of plan assets are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Fair value of plan assets at the beginning of the year&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;169&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;128&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Employer contributions&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;84&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;32&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Interest on plan assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;13&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Re-measurements due to:&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Return on plan assets excluding interest on plan assets&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(6&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;12&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Benefits paid&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(58&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(32&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Foreign exchanges differences&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;11&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;16&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Plan assets at the end of the year&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;215&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;169&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





























































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sensitivity Analysis:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March 31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 85%; text-align: left;"&gt;Defined benefit obligation without effect of projected salary growth&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;185&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Add: Effect of salary growth&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;86&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Defined benefit obligation with projected salary growth&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;271&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Defined benefit obligation, using discount rate minus 50 basis points&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;283&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Defined benefit obligation, using discount rate plus 50 basis points&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;260&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Defined benefit obligation, using salary growth rate plus 50 basis points&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;284&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Defined benefit obligation, using salary growth rate minus 50 basis points&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;271&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





























































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Summary of the actuarial assumptions: &lt;/div&gt;The actuarial assumptions used in accounting for the Falcon defined benefit plans are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"/&gt;




























&lt;div style="margin-bottom: 3pt; margin-top: 0px; font-family: Calibri, sans-serif; font-size: 10pt; margin-left: 0.26in; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;The assumptions used to determine benefit obligations:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"&gt;

		&lt;tr style="height:.15in"&gt;
			&lt;td style="width: 61%; padding: 0px 5.4pt 0.5pt; height: 0.15in; font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in 0in 0.5pt; height: 0.15in; font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td colspan="10" style="padding: 0in; height: 0.15in; border-bottom: 1pt solid windowtext; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in 0in 0.5pt; height: 0.15in; white-space: nowrap; vertical-align: bottom; font-size: 10pt;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="height:.15in"&gt;
			&lt;td style="width: 61%; padding: 0px 5.4pt 0.5pt; height: 0.15in; font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in 0in 0.5pt; height: 0.15in; font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td colspan="2" style="padding: 0in; height: 0.15in; border-bottom: 1pt solid windowtext; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in 0in 0.5pt; height: 0.15in; white-space: nowrap; vertical-align: bottom; font-size: 10pt;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in 0in 0.5pt; height: 0.15in; white-space: nowrap; vertical-align: bottom; font-size: 10pt;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td colspan="2" style="padding: 0in; height: 0.15in; border-bottom: 1pt solid windowtext; border-top: 0px solid windowtext; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in 0in 0.5pt; height: 0.15in; white-space: nowrap; vertical-align: bottom; font-size: 10pt;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in 0in 0.5pt; height: 0.15in; white-space: nowrap; vertical-align: bottom; font-size: 10pt;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td colspan="2" style="padding: 0in; height: 0.15in; border-bottom: 1pt solid windowtext; border-top: 0px solid windowtext; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in 0in 0.5pt; height: 0.15in; white-space: nowrap; vertical-align: bottom; font-size: 10pt;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="height:11.5pt"&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 61%; padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px; height: 11.5pt; font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Discount rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; text-align: right; vertical-align: bottom;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-right: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;9.25&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; text-align: right; vertical-align: bottom;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-right: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;7.75&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; text-align: right; vertical-align: bottom;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-right: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;8.75&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="height:11.5pt"&gt;
			&lt;td style="width: 61%; padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0.375pt; height: 11.5pt; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rate of compensation increase&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in 0in 0.375pt; height: 11.5pt; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-right: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;4.50&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in 0in 0.375pt; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in 0in 0.375pt; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-right: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;4.50&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in 0in 0.375pt; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in 0in 0.375pt; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-right: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;4.50&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in 0in 0.375pt; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Disaggregation of plan assets: &lt;/div&gt;The Falcon pension plan&#x2019;s weighted-average asset allocation as of March 31, 2022 and 2021, by asset category, was as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 70%; text-align: left; padding-left: 5.4pt;"&gt;Funds managed by insurers&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;50&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;51&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 5.4pt;"&gt;Others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;50&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;49&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                                              &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The expected future cash flows in respect of post-employment benefit plans in Mexico as of March 31, 2022 were as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected contribution&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 85%;"&gt;During the year ended March 31, 2023 (estimated)&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;38&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected future benefit payments&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;March 31, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;March 31, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;March 31, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;March 31, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;14&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;March 31, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;23&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;639&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                                              &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Provident fund benefits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain categories of employees of the Company receive benefits from a provident fund, a defined contribution plan. Both the employee and employer each make monthly contributions to a government administered fund equal to 12% of the covered employee&#x2019;s qualifying salary. The Company has no further obligations under the plan beyond its monthly contributions. The Company contributed Rs.1,013, Rs.906 and Rs.812 to the provident fund plan during the years ended March 31, 2022, 2021 and 2020, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Superannuation benefits&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain categories of employees of the Company participate in superannuation, a defined contribution plan administered &lt;div style="display:inline;"&gt;by&lt;/div&gt; the Life Insurance Corporation of India. The Company makes monthly contributions based on a specified percentage of each covered employee&#x2019;s salary. The Company has no further obligations under the plan beyond its monthly contributions. The Company contributed Rs.83, Rs.84 and Rs.82 to the superannuation plan during the years ended March 31, 2022, 2021 and 2020, respectively.&lt;/div&gt;&lt;/div&gt;   &lt;div style="font-size:11pt; margin:0in -7.6pt 3pt 0in; font-family:Calibri, 'sans-serif'; color:#000000; font-style:normal; font-variant-ligatures:normal; font-variant-caps:normal; font-weight:400; letter-spacing:normal; orphans:2; text-indent:0px; text-transform:none; white-space:normal; widows:2; word-spacing:0px; -webkit-text-stroke-width:0px; text-decoration-thickness:initial; text-decoration-style:initial; text-decoration-color:initial; text-align:justify"&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other contribution plans&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the United States, the Company sponsors a defined contribution 401(k) retirement savings plan for all eligible employees who meet minimum age and service requirements. The Company contributed Rs.131, Rs.139 and Rs.177 to the 401(k) retirement savings plan during the years ended March 31, 2022, 2021 and 2020, respectively. The Company has no further obligations under the plan beyond its monthly matching contributions.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the United Kingdom, certain social security benefits (such as pension, unemployment and disability) are funded by employers and employees through mandatory National Insurance contributions. The contribution amounts are determined based upon the employee&#x2019;s salary. The Company has no further obligations under the plan beyond its monthly contributions. The Company contributed Rs.166, Rs.143 and Rs.135 to the National Insurance during the years ended March 31, 2022, 2021 and 2020, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensated absences&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company provides for accumulation of compensated absences by certain categories of its employees. These employees can carry forward a portion of the unutilized compensated absences and utilize them in future periods or receive cash in lieu thereof as per the Company&#x2019;s policy. The Company records a liability for compensated absences in the period in which the employee renders the services that increases this entitlement. The total liability recorded by the Company towards this obligation was Rs.1,061 and Rs.1,130 as of March 31, 2022 and 2021, respectively.&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">38858000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">36299000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">33802000000</ifrs-full:EmployeeBenefitsExpense>
    <rdy:CostRecognizedInIncomeStatementTextBlock contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of gratuity cost recognized in the income statement for the years ended March 31, 2022, 2021 and 2020 consist of the following:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%; text-align: left;"&gt;Current service cost&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;328&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;281&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;276&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Interest on defined benefit liability&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;33&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;8&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(4&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gratuity cost recognized in income statement&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;361&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;289&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;272&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































</rdy:CostRecognizedInIncomeStatementTextBlock>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">328000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">281000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2019To03_31_2020_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">276000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">33000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">8000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2019To03_31_2020_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">-4000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">361000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P04_01_2020To03_31_2021_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">289000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P04_01_2019To03_31_2020_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">272000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of the employee benefits obligations and plan assets are provided below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%;"&gt;Present value of funded obligations&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;2,894&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;2,628&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Fair value of plan assets&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(2,350&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,997&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net defined benefit liability recognized&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;544&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;631&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































</ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">2894000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn03_31_2021_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">2628000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">2350000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn03_31_2021_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">1997000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">-544000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn03_31_2021_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">-631000000</ifrs-full:SurplusDeficitInPlan>
    <rdy:DisclosureofChangesInPresentValueOfDefinedBenefitObligationsTableTextBlock contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of changes in the present value of defined benefit obligations are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Defined benefit obligations at the beginning of the year&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;2,628&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;2,349&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Current service cost&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;328&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;281&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Interest on defined obligations&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;144&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;140&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Re-measurements due to:&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Actuarial loss/(gain) due to change in financial assumptions&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;153&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Actuarial loss/(gain) due to demographic assumptions&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(26&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Actuarial loss/(gain) due to experience changes&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;60&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;51&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Benefits paid&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(293&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(345&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities (transferred)&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;/&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;assumed&lt;/div&gt;&lt;div style="text-indent: 0px;;display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(4&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;25&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Defined benefit obligations at the end of the year&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,894&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,628&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Liabilities assumed/transferred&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;:&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2022&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; Rs.(4) represents &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the &lt;/div&gt;transfer of liabilities on account of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;the&lt;/div&gt; transfer &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;f&#160;employees between the parent company and its subsidiaries.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2021&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; Rs.25 is comprised of:&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.3in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;a)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Rs.70 increase in liabilities on account of the acquisition of employees pursuant to the Business Transfer Agreement with Wockhardt Limited. Refer to Note 6 of these consolidated financial statements for further details.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.3in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;b)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Rs.45 transfer of liabilities on account of a restructuring of the pharmaceutical services business between the parent company and its subsidiary.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</rdy:DisclosureofChangesInPresentValueOfDefinedBenefitObligationsTableTextBlock>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn03_31_2021_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">2628000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn03_31_2020_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">2349000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">328000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">281000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <rdy:InterestExpenseIncomeDefinedBenefitObligation
      contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">144000000</rdy:InterestExpenseIncomeDefinedBenefitObligation>
    <rdy:InterestExpenseIncomeDefinedBenefitObligation
      contextRef="P04_01_2020To03_31_2021_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">140000000</rdy:InterestExpenseIncomeDefinedBenefitObligation>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">7000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">153000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">24000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">-26000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">60000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">51000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">293000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">345000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:LiabilitiesIncurred
      contextRef="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">-4000000</ifrs-full:LiabilitiesIncurred>
    <ifrs-full:LiabilitiesIncurred
      contextRef="PAsOn03_31_2021_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">25000000</ifrs-full:LiabilitiesIncurred>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">2894000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn03_31_2021_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">2628000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <rdy:TransferOfLiabilitiesOnRestructuringOfServices
      contextRef="P04_01_2021To03_31_2022_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">-4000000</rdy:TransferOfLiabilitiesOnRestructuringOfServices>
    <ifrs-full:LiabilitiesIncurred
      contextRef="PAsOn03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">25000000</ifrs-full:LiabilitiesIncurred>
    <rdy:IncreaseInLiabilitiesOnAcquisitionOfEmployeesRelatingToBusinessAcquisition
      contextRef="P04_01_2020To03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">70000000</rdy:IncreaseInLiabilitiesOnAcquisitionOfEmployeesRelatingToBusinessAcquisition>
    <rdy:TransferOfLiabilitiesOnRestructuringOfServices
      contextRef="P04_01_2020To03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">45000000</rdy:TransferOfLiabilitiesOnRestructuringOfServices>
    <ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of changes in the fair value of plan assets are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Fair value of plan assets at the beginning of the year&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;1,997&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;2,160&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Employer contributions&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;496&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;25&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Interest on plan assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;111&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;132&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Re-measurements due to:&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Return on plan assets excluding interest on plan assets&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;43&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Benefits paid&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(293&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(345&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(transferred)&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;/&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;acquired&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(4&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;26&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Plan assets at the end of the year&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,350&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,997&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;

		&lt;tr style="text-align: justify; vertical-align: top;"&gt;
			&lt;td style="width: 0in;"/&gt;
			&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Assets acquired/transferred&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;:&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2022&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&#160;Rs.(4) represents&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;the&lt;/div&gt; transfer of plan asset&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt; on account of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the &lt;/div&gt;transfer &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;f&#160;employees between the parent company and its subsidiaries.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2021 Rs. 26 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;is &lt;/div&gt;comprised of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.2in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;a)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Rs.70 increase in assets on account of the acquisition of employees pursuant to the Business Transfer Agreement with Wockhardt Limited. Refer to Note 6 of these consolidated financial statements for further details.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.2in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;b)&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;Rs.44 transfer of assets on account of a restructuring of the pharmaceutical services business between the parent company and its subsidiary.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































</ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn03_31_2021_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">1997000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn03_31_2020_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">2160000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">496000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">25000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <rdy:InterestExpenseIncomePlanAssets
      contextRef="P04_01_2021To03_31_2022_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">111000000</rdy:InterestExpenseIncomePlanAssets>
    <rdy:InterestExpenseIncomePlanAssets
      contextRef="P04_01_2020To03_31_2021_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">132000000</rdy:InterestExpenseIncomePlanAssets>
    <rdy:ReturnOtherThanInterestOnPlanAssets
      contextRef="P04_01_2021To03_31_2022_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">43000000</rdy:ReturnOtherThanInterestOnPlanAssets>
    <rdy:ReturnOtherThanInterestOnPlanAssets
      contextRef="P04_01_2020To03_31_2021_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">-1000000</rdy:ReturnOtherThanInterestOnPlanAssets>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">293000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">345000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="PAsOn03_31_2022_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">-4000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed
      contextRef="PAsOn03_31_2021_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">26000000</ifrs-full:IdentifiableAssetsAcquiredLiabilitiesAssumed>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn03_31_2022_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">2350000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn03_31_2021_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">1997000000</ifrs-full:PlanAssetsAtFairValue>
    <rdy:TransferOfPlanAssetsOnAccountOfTransferForEmployees
      contextRef="P04_01_2021To03_31_2022_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">-4000000</rdy:TransferOfPlanAssetsOnAccountOfTransferForEmployees>
    <ifrs-full:LiabilitiesIncurred
      contextRef="PAsOn03_31_2021_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">26000000</ifrs-full:LiabilitiesIncurred>
    <rdy:IncreaseInLiabilitiesOnAcquisitionOfEmployeesRelatingToBusinessAcquisition
      contextRef="P04_01_2020To03_31_2021_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">70000000</rdy:IncreaseInLiabilitiesOnAcquisitionOfEmployeesRelatingToBusinessAcquisition>
    <rdy:TransferOfLiabilitiesOnRestructuringOfServices
      contextRef="P04_01_2020To03_31_2021_GratuityBenefitsOfParentMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">44000000</rdy:TransferOfLiabilitiesOnRestructuringOfServices>
    <ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sensitivity Analysis:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March 31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 85%; text-align: left; padding-left: 5.4pt;"&gt;Defined benefit obligation without effect of projected salary growth&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;1,904&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-left: 5.4pt;"&gt;Add: Effect of salary growth&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;990&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-left: 5.4pt;"&gt;Defined benefit obligation with projected salary growth&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,894&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-left: 5.4pt;"&gt;Defined benefit obligation, using discount rate minus 50 basis points&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,978&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-left: 5.4pt;"&gt;Defined benefit obligation, using discount rate plus 50 basis points&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,815&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-left: 5.4pt;"&gt;Defined benefit obligation, using salary growth rate plus 50 basis points&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,976&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-left: 5.4pt;"&gt;Defined benefit obligation, using salary growth rate minus 50 basis points&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,816&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































</ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory>
    <rdy:DefinedBenefitObligationAtPresentValueWithoutEffectOfSalaryGrowth
      contextRef="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">1904000000</rdy:DefinedBenefitObligationAtPresentValueWithoutEffectOfSalaryGrowth>
    <rdy:ActuarialAssumptionOfExpectedSalaryIncreases
      contextRef="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">990000000</rdy:ActuarialAssumptionOfExpectedSalaryIncreases>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">2894000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <rdy:DefinedBenefitObligationDueToReasonablyPossibleChangeInActuarialAssumption
      contextRef="PAsOn03_31_2022_DiscountRateMemberifrsfullMeasurementAxis_FiftyBasisPointsDecreaseMemberifrsfullActuarialAssumptionsAxis_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">2978000000</rdy:DefinedBenefitObligationDueToReasonablyPossibleChangeInActuarialAssumption>
    <rdy:DefinedBenefitObligationDueToReasonablyPossibleChangeInActuarialAssumption
      contextRef="PAsOn03_31_2022_DiscountRateMemberifrsfullMeasurementAxis_FiftyBasisPointsIncreaseMemberifrsfullActuarialAssumptionsAxis_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">2815000000</rdy:DefinedBenefitObligationDueToReasonablyPossibleChangeInActuarialAssumption>
    <rdy:DefinedBenefitObligationDueToReasonablyPossibleChangeInActuarialAssumption
      contextRef="PAsOn03_31_2022_FiftyBasisPointsIncreaseMemberifrsfullActuarialAssumptionsAxis_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis_SalaryGrowthMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">2976000000</rdy:DefinedBenefitObligationDueToReasonablyPossibleChangeInActuarialAssumption>
    <rdy:DefinedBenefitObligationDueToReasonablyPossibleChangeInActuarialAssumption
      contextRef="PAsOn03_31_2022_FiftyBasisPointsDecreaseMemberifrsfullActuarialAssumptionsAxis_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis_SalaryGrowthMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">2816000000</rdy:DefinedBenefitObligationDueToReasonablyPossibleChangeInActuarialAssumption>
    <rdy:DisclosureOfAssumptionsUsedToDetermineBenefitObligationsTableTextBlock contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The assumptions used to determine benefit obligations:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%; text-align: left;"&gt;Discount rate&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;6.45&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;6.00&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;6.65&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Rate of compensation increase&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;8.50&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;8.00&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7.50&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;











</rdy:DisclosureOfAssumptionsUsedToDetermineBenefitObligationsTableTextBlock>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="PAsOn03_31_2022_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="4"
      unitRef="Unit_pure">0.0645</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="PAsOn03_31_2021_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="4"
      unitRef="Unit_pure">0.06</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="PAsOn03_31_2020_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="4"
      unitRef="Unit_pure">0.0665</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="PAsOn03_31_2022_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="4"
      unitRef="Unit_pure">0.085</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="PAsOn03_31_2021_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="4"
      unitRef="Unit_pure">0.08</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="PAsOn03_31_2020_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="4"
      unitRef="Unit_pure">0.075</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <rdy:DisclosureOfAssumptionsUsedToDetermineDefinedBenefitCostTableTextBlock contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">




















</rdy:DisclosureOfAssumptionsUsedToDetermineDefinedBenefitCostTableTextBlock>
    <rdy:DisclosureOfDisaggregationOfPlanAssetsTableTextBlock contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Disaggregation of plan assets: &lt;/div&gt;The Gratuity Plan&#x2019;s weighted-average asset allocation as of March 31, 2022 and 2021, by asset category, was as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Funds managed by insurers&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;100&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;100&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;Others&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































</rdy:DisclosureOfDisaggregationOfPlanAssetsTableTextBlock>
    <rdy:PercentageOfWeightedAverageAssetAllocation
      contextRef="PAsOn03_31_2022_FundsManagedByInsurersMemberRDYAssetCategoryAxis_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="2"
      unitRef="Unit_pure">1</rdy:PercentageOfWeightedAverageAssetAllocation>
    <rdy:PercentageOfWeightedAverageAssetAllocation
      contextRef="PAsOn03_31_2021_FundsManagedByInsurersMemberRDYAssetCategoryAxis_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="2"
      unitRef="Unit_pure">1</rdy:PercentageOfWeightedAverageAssetAllocation>
    <rdy:PercentageOfWeightedAverageAssetAllocation
      contextRef="PAsOn03_31_2022_OthersMemberRDYAssetCategoryAxis_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="0"
      unitRef="Unit_pure">0</rdy:PercentageOfWeightedAverageAssetAllocation>
    <rdy:PercentageOfWeightedAverageAssetAllocation
      contextRef="PAsOn03_31_2021_OthersMemberRDYAssetCategoryAxis_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="0"
      unitRef="Unit_pure">0</rdy:PercentageOfWeightedAverageAssetAllocation>
    <rdy:DisclosureOfExpectedFutureCashFlowsInRespectOfPostemploymentBenefitsTextBlock contextRef="P04_01_2021To03_31_2022_ParentCompanyGratuityPlanMemberifrsfullDefinedBenefitPlansAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The expected future cash flows in respect of gratuity as of March 31, 2022 were as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected contribution&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td&gt;During the year ended March 31, 2023 (estimated)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;Rs.229&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected future benefit payments&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 85%;"&gt;March 31, 2023&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;481&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;March 31, 2024&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;409&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;March 31, 2025&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;398&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;March 31, 2026&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;372&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;March 31, 2027&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;346&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Thereafter&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,437&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































</rdy:DisclosureOfExpectedFutureCashFlowsInRespectOfPostemploymentBenefitsTextBlock>
    <rdy:ExpectedContribution
      contextRef="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">229000000</rdy:ExpectedContribution>
    <rdy:ExpectedFutureBenefitPayments
      contextRef="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_Year1MemberRDYTimeBandAxis"
      decimals="-6"
      unitRef="Unit_INR">481000000</rdy:ExpectedFutureBenefitPayments>
    <rdy:ExpectedFutureBenefitPayments
      contextRef="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_Year2MemberRDYTimeBandAxis"
      decimals="-6"
      unitRef="Unit_INR">409000000</rdy:ExpectedFutureBenefitPayments>
    <rdy:ExpectedFutureBenefitPayments
      contextRef="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_Year3MemberRDYTimeBandAxis"
      decimals="-6"
      unitRef="Unit_INR">398000000</rdy:ExpectedFutureBenefitPayments>
    <rdy:ExpectedFutureBenefitPayments
      contextRef="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_Year4MemberRDYTimeBandAxis"
      decimals="-6"
      unitRef="Unit_INR">372000000</rdy:ExpectedFutureBenefitPayments>
    <rdy:ExpectedFutureBenefitPayments
      contextRef="PAsOn03_31_2022_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis_Year5MemberRDYTimeBandAxis"
      decimals="-6"
      unitRef="Unit_INR">346000000</rdy:ExpectedFutureBenefitPayments>
    <rdy:ExpectedFutureBenefitPayments
      contextRef="PAsOn03_31_2022_AfterYear5MemberRDYTimeBandAxis_ParentCompanyGratuityPlanMemberifrsfullNetDefinedBenefitLiabilityAssetAxis"
      decimals="-6"
      unitRef="Unit_INR">2437000000</rdy:ExpectedFutureBenefitPayments>
    <rdy:CostRecognizedInIncomeStatementTextBlock contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of net pension cost recognized in the income statement for the years ended March 31, 2022, 2021 and 2020 consist of the following:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%; text-align: left;"&gt;Current service cost&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;16&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;13&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;11&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Interest on defined benefit liability&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;10&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;8&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;16&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total cost recognized in income statement&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;26&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































</rdy:CostRecognizedInIncomeStatementTextBlock>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">16000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">13000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2019To03_31_2020_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">11000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">10000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">8000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2019To03_31_2020_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">16000000</ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">26000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P04_01_2020To03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">21000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans
      contextRef="P04_01_2019To03_31_2020_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">27000000</ifrs-full:PostemploymentBenefitExpenseDefinedBenefitPlans>
    <ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of the employee benefits obligations and plan assets are provided below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%;"&gt;Present value of funded obligations&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;271&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;307&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;Fair value of plan assets&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(215&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(169&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net defined benefit liability recognized&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;56&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;138&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































</ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">271000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">307000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">215000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">169000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">56000000</ifrs-full:SurplusDeficitInPlan>
    <ifrs-full:SurplusDeficitInPlan
      contextRef="PAsOn03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">138000000</ifrs-full:SurplusDeficitInPlan>
    <rdy:DisclosureofChangesInPresentValueOfDefinedBenefitObligationsTableTextBlock contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of changes in the present value of defined benefit obligations are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Defined benefit obligations at the beginning of the year&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;307&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;234&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Current service cost&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;16&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;13&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Interest on defined obligations&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;21&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Re-measurements due to:&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Actuarial loss/(gain) due to change in financial assumptions&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(40&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Actuarial loss/(gain) due to experience changes&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;19&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Benefits paid&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(58&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(32&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Foreign exchanges differences&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;19&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;28&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Defined benefit obligations at the end of the year&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;271&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;307&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































</rdy:DisclosureofChangesInPresentValueOfDefinedBenefitObligationsTableTextBlock>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">307000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn03_31_2020_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">234000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">16000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">13000000</ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset>
    <rdy:InterestExpenseIncomeDefinedBenefitObligation
      contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">24000000</rdy:InterestExpenseIncomeDefinedBenefitObligation>
    <rdy:InterestExpenseIncomeDefinedBenefitObligation
      contextRef="P04_01_2020To03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">21000000</rdy:InterestExpenseIncomeDefinedBenefitObligation>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">-40000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">24000000</ifrs-full:ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">3000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">19000000</ifrs-full:ActuarialGainsLossesArisingFromExperienceAdjustmentsNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">58000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">32000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <rdy:ForeignExchangeDifferences
      contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">19000000</rdy:ForeignExchangeDifferences>
    <rdy:ForeignExchangeDifferences
      contextRef="P04_01_2020To03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">28000000</rdy:ForeignExchangeDifferences>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">271000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DefinedBenefitObligationAtPresentValue
      contextRef="PAsOn03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">307000000</ifrs-full:DefinedBenefitObligationAtPresentValue>
    <ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of changes in the fair value of plan assets are as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Fair value of plan assets at the beginning of the year&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;169&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;128&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Employer contributions&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;84&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;32&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Interest on plan assets&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;13&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Re-measurements due to:&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Return on plan assets excluding interest on plan assets&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(6&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;12&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Benefits paid&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(58&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(32&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Foreign exchanges differences&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;11&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;16&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Plan assets at the end of the year&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;215&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;169&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































</ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">169000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn03_31_2020_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">128000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">84000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">32000000</ifrs-full:ContributionsToPlanByEmployerNetDefinedBenefitLiabilityAsset>
    <rdy:InterestExpenseIncomePlanAssets
      contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">15000000</rdy:InterestExpenseIncomePlanAssets>
    <rdy:InterestExpenseIncomePlanAssets
      contextRef="P04_01_2020To03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">13000000</rdy:InterestExpenseIncomePlanAssets>
    <rdy:ReturnOtherThanInterestOnPlanAssets
      contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">-6000000</rdy:ReturnOtherThanInterestOnPlanAssets>
    <rdy:ReturnOtherThanInterestOnPlanAssets
      contextRef="P04_01_2020To03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">12000000</rdy:ReturnOtherThanInterestOnPlanAssets>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">58000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">32000000</ifrs-full:PaymentsFromPlanNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">11000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset
      contextRef="P04_01_2020To03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">16000000</ifrs-full:IncreaseDecreaseThroughChangesInForeignExchangeRatesNetDefinedBenefitLiabilityAsset>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">215000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:PlanAssetsAtFairValue
      contextRef="PAsOn03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">169000000</ifrs-full:PlanAssetsAtFairValue>
    <ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sensitivity Analysis:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March 31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 85%; text-align: left;"&gt;Defined benefit obligation without effect of projected salary growth&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;185&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Add: Effect of salary growth&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;86&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Defined benefit obligation with projected salary growth&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;271&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Defined benefit obligation, using discount rate minus 50 basis points&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;283&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Defined benefit obligation, using discount rate plus 50 basis points&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;260&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Defined benefit obligation, using salary growth rate plus 50 basis points&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;284&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Defined benefit obligation, using salary growth rate minus 50 basis points&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;271&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



























































</ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory>
    <rdy:DefinedBenefitObligationAtPresentValueWithoutEffectOfSalaryGrowth
      contextRef="PAsOn03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">185000000</rdy:DefinedBenefitObligationAtPresentValueWithoutEffectOfSalaryGrowth>
    <rdy:ActuarialAssumptionOfExpectedSalaryIncreases
      contextRef="PAsOn03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">86000000</rdy:ActuarialAssumptionOfExpectedSalaryIncreases>
    <ifrs-full:LiabilityAssetOfDefinedBenefitPlans
      contextRef="PAsOn03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">271000000</ifrs-full:LiabilityAssetOfDefinedBenefitPlans>
    <rdy:DefinedBenefitObligationDueToReasonablyPossibleChangeInActuarialAssumption
      contextRef="PAsOn03_31_2022_DiscountRateMemberifrsfullMeasurementAxis_FiftyBasisPointsDecreaseMemberifrsfullActuarialAssumptionsAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">283000000</rdy:DefinedBenefitObligationDueToReasonablyPossibleChangeInActuarialAssumption>
    <rdy:DefinedBenefitObligationDueToReasonablyPossibleChangeInActuarialAssumption
      contextRef="PAsOn03_31_2022_DiscountRateMemberifrsfullMeasurementAxis_FiftyBasisPointsIncreaseMemberifrsfullActuarialAssumptionsAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">260000000</rdy:DefinedBenefitObligationDueToReasonablyPossibleChangeInActuarialAssumption>
    <rdy:DefinedBenefitObligationDueToReasonablyPossibleChangeInActuarialAssumption
      contextRef="PAsOn03_31_2022_FiftyBasisPointsIncreaseMemberifrsfullActuarialAssumptionsAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis_SalaryGrowthMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">284000000</rdy:DefinedBenefitObligationDueToReasonablyPossibleChangeInActuarialAssumption>
    <rdy:DefinedBenefitObligationDueToReasonablyPossibleChangeInActuarialAssumption
      contextRef="PAsOn03_31_2022_FiftyBasisPointsDecreaseMemberifrsfullActuarialAssumptionsAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis_SalaryGrowthMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">271000000</rdy:DefinedBenefitObligationDueToReasonablyPossibleChangeInActuarialAssumption>
    <rdy:DisclosureOfAssumptionsUsedToDetermineBenefitObligationsTableTextBlock contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">
&lt;div style="margin-bottom: 3pt; margin-top: 0px; font-family: Calibri, sans-serif; font-size: 10pt; margin-left: 0.26in; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;The assumptions used to determine benefit obligations:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;margin-right : auto;;margin-left : 0;margin-right : auto;"&gt;

		&lt;tr style="height:.15in"&gt;
			&lt;td style="width: 61%; padding: 0px 5.4pt 0.5pt; height: 0.15in; font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in 0in 0.5pt; height: 0.15in; font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td colspan="10" style="padding: 0in; height: 0.15in; border-bottom: 1pt solid windowtext; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in 0in 0.5pt; height: 0.15in; white-space: nowrap; vertical-align: bottom; font-size: 10pt;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="height:.15in"&gt;
			&lt;td style="width: 61%; padding: 0px 5.4pt 0.5pt; height: 0.15in; font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in 0in 0.5pt; height: 0.15in; font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td colspan="2" style="padding: 0in; height: 0.15in; border-bottom: 1pt solid windowtext; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in 0in 0.5pt; height: 0.15in; white-space: nowrap; vertical-align: bottom; font-size: 10pt;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in 0in 0.5pt; height: 0.15in; white-space: nowrap; vertical-align: bottom; font-size: 10pt;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td colspan="2" style="padding: 0in; height: 0.15in; border-bottom: 1pt solid windowtext; border-top: 0px solid windowtext; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in 0in 0.5pt; height: 0.15in; white-space: nowrap; vertical-align: bottom; font-size: 10pt;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in 0in 0.5pt; height: 0.15in; white-space: nowrap; vertical-align: bottom; font-size: 10pt;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td colspan="2" style="padding: 0in; height: 0.15in; border-bottom: 1pt solid windowtext; border-top: 0px solid windowtext; white-space: nowrap; vertical-align: bottom; width: 11%;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="white-space: nowrap;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0in 0in 0.5pt; height: 0.15in; white-space: nowrap; vertical-align: bottom; font-size: 10pt;"&gt;
			&lt;div style="text-align: center; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; line-height: normal; white-space: nowrap; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="height:11.5pt"&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 61%; padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0px; height: 11.5pt; font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Discount rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; text-align: right; vertical-align: bottom;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-right: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;9.25&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; text-align: right; vertical-align: bottom;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-right: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;7.75&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; vertical-align: bottom;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 10%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; text-align: right; vertical-align: bottom;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-right: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;8.75&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background: rgb(204, 238, 255); width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="height:11.5pt"&gt;
			&lt;td style="width: 61%; padding-top: 0px; padding-right: 5.4pt; padding-bottom: 0.375pt; height: 11.5pt; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rate of compensation increase&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in 0in 0.375pt; height: 11.5pt; font-size: 10pt; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;
			&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; margin-left: 0in; text-indent: 0in; text-align: left; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-right: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;4.50&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in 0in 0.375pt; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in 0in 0.375pt; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-right: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;4.50&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in 0in 0.375pt; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in 0in 0.375pt; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); vertical-align: bottom;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 10%; padding: 0in; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: right; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;
			&lt;div style="text-align: right; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-right: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;4.50&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding: 0in 0in 0.375pt; height: 11.5pt; font-size: 10pt; white-space: nowrap; background-color: rgba(255, 255, 255, 0); text-align: left; vertical-align: bottom;"&gt;
			&lt;div style="text-align: left; margin-bottom: 0.0001pt; margin-top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt; line-height: normal; white-space: nowrap; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"&gt;%&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;














&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="margin-top: 0px; margin-bottom: 0px; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;</rdy:DisclosureOfAssumptionsUsedToDetermineBenefitObligationsTableTextBlock>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="PAsOn03_31_2022_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="4"
      unitRef="Unit_pure">0.0925</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="PAsOn03_31_2021_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="4"
      unitRef="Unit_pure">0.0775</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfDiscountRates
      contextRef="PAsOn03_31_2020_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="4"
      unitRef="Unit_pure">0.0875</ifrs-full:ActuarialAssumptionOfDiscountRates>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="PAsOn03_31_2022_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="4"
      unitRef="Unit_pure">0.045</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="PAsOn03_31_2021_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="4"
      unitRef="Unit_pure">0.045</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases
      contextRef="PAsOn03_31_2020_EmployeeBenefitObligationsMemberifrsfullActuarialAssumptionsAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="4"
      unitRef="Unit_pure">0.045</ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreases>
    <rdy:DisclosureOfDisaggregationOfPlanAssetsTableTextBlock contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Disaggregation of plan assets: &lt;/div&gt;The Falcon pension plan&#x2019;s weighted-average asset allocation as of March 31, 2022 and 2021, by asset category, was as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 70%; text-align: left; padding-left: 5.4pt;"&gt;Funds managed by insurers&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;50&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;51&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 5.4pt;"&gt;Others&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;50&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;49&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                      </rdy:DisclosureOfDisaggregationOfPlanAssetsTableTextBlock>
    <rdy:PercentageOfWeightedAverageAssetAllocation
      contextRef="PAsOn03_31_2022_FundsManagedByInsurersMemberRDYAssetCategoryAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</rdy:PercentageOfWeightedAverageAssetAllocation>
    <rdy:PercentageOfWeightedAverageAssetAllocation
      contextRef="PAsOn03_31_2021_FundsManagedByInsurersMemberRDYAssetCategoryAxis_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis"
      decimals="2"
      unitRef="Unit_pure">0.51</rdy:PercentageOfWeightedAverageAssetAllocation>
    <rdy:PercentageOfWeightedAverageAssetAllocation
      contextRef="PAsOn03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis_OthersMemberRDYAssetCategoryAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</rdy:PercentageOfWeightedAverageAssetAllocation>
    <rdy:PercentageOfWeightedAverageAssetAllocation
      contextRef="PAsOn03_31_2021_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis_OthersMemberRDYAssetCategoryAxis"
      decimals="2"
      unitRef="Unit_pure">0.49</rdy:PercentageOfWeightedAverageAssetAllocation>
    <rdy:DisclosureOfExpectedFutureCashFlowsInRespectOfPostemploymentBenefitsTextBlock contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoPensionPlanMemberifrsfullDefinedBenefitPlansAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The expected future cash flows in respect of post-employment benefit plans in Mexico as of March 31, 2022 were as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected contribution&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 85%;"&gt;During the year ended March 31, 2023 (estimated)&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;38&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Expected future benefit payments&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.375pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;March 31, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;March 31, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;March 31, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;March 31, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;14&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;March 31, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;23&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Thereafter&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;639&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                      </rdy:DisclosureOfExpectedFutureCashFlowsInRespectOfPostemploymentBenefitsTextBlock>
    <rdy:ExpectedContribution
      contextRef="PAsOn03_31_2022_IndustriasQuimicaFalconDeMexicoMemberifrsfullDefinedBenefitPlansAxis_YearZeroMemberRDYTimeTakensAxis"
      decimals="-6"
      unitRef="Unit_INR">38000000</rdy:ExpectedContribution>
    <rdy:ExpectedFutureBenefitPayments
      contextRef="PAsOn03_31_2022_IndustriasQuimicaFalconDeMexicoMemberifrsfullDefinedBenefitPlansAxis_YearOneMemberRDYTimeTakensAxis"
      decimals="-6"
      unitRef="Unit_INR">3000000</rdy:ExpectedFutureBenefitPayments>
    <rdy:ExpectedFutureBenefitPayments
      contextRef="PAsOn03_31_2022_IndustriasQuimicaFalconDeMexicoMemberifrsfullDefinedBenefitPlansAxis_YearTwoMemberRDYTimeTakensAxis"
      decimals="-6"
      unitRef="Unit_INR">4000000</rdy:ExpectedFutureBenefitPayments>
    <rdy:ExpectedFutureBenefitPayments
      contextRef="PAsOn03_31_2022_IndustriasQuimicaFalconDeMexicoMemberifrsfullDefinedBenefitPlansAxis_YearThreeMemberRDYTimeTakensAxis"
      decimals="-6"
      unitRef="Unit_INR">8000000</rdy:ExpectedFutureBenefitPayments>
    <rdy:ExpectedFutureBenefitPayments
      contextRef="PAsOn03_31_2022_IndustriasQuimicaFalconDeMexicoMemberifrsfullDefinedBenefitPlansAxis_YearFourMemberRDYTimeTakensAxis"
      decimals="-6"
      unitRef="Unit_INR">14000000</rdy:ExpectedFutureBenefitPayments>
    <rdy:ExpectedFutureBenefitPayments
      contextRef="PAsOn03_31_2022_IndustriasQuimicaFalconDeMexicoMemberifrsfullDefinedBenefitPlansAxis_YearFiveMemberRDYTimeTakensAxis"
      decimals="-6"
      unitRef="Unit_INR">23000000</rdy:ExpectedFutureBenefitPayments>
    <rdy:ExpectedFutureBenefitPayments
      contextRef="PAsOn03_31_2022_AfterYearFiveMemberRDYTimeTakensAxis_IndustriasQuimicaFalconDeMexicoMemberifrsfullDefinedBenefitPlansAxis"
      decimals="-6"
      unitRef="Unit_INR">639000000</rdy:ExpectedFutureBenefitPayments>
    <rdy:ContributionsToPlanByPlanParticipantsDefinedContributionsPlan
      contextRef="P04_01_2021To03_31_2022_ProvidentFundBenefitsMemberRDYContributionTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.12</rdy:ContributionsToPlanByPlanParticipantsDefinedContributionsPlan>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="P04_01_2021To03_31_2022_ProvidentFundBenefitsMemberRDYContributionTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">1013000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="P04_01_2020To03_31_2021_ProvidentFundBenefitsMemberRDYContributionTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">906000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="P04_01_2019To03_31_2020_ProvidentFundBenefitsMemberRDYContributionTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">812000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="P04_01_2021To03_31_2022_SuperannuationBenefitsMemberRDYContributionTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">83000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="P04_01_2020To03_31_2021_SuperannuationBenefitsMemberRDYContributionTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">84000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans
      contextRef="P04_01_2019To03_31_2020_SuperannuationBenefitsMemberRDYContributionTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">82000000</ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans>
    <ifrs-full:SocialSecurityContributions
      contextRef="P04_01_2021To03_31_2022_Us401kretirementSavingsPlanMemberRDYContributionTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">131000000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="P04_01_2020To03_31_2021_Us401kretirementSavingsPlanMemberRDYContributionTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">139000000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="P04_01_2019To03_31_2020_Us401kretirementSavingsPlanMemberRDYContributionTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">177000000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="P04_01_2021To03_31_2022_UkSocialSecuriyPlanMemberRDYContributionTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">166000000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="P04_01_2020To03_31_2021_UkSocialSecuriyPlanMemberRDYContributionTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">143000000</ifrs-full:SocialSecurityContributions>
    <ifrs-full:SocialSecurityContributions
      contextRef="P04_01_2019To03_31_2020_UkSocialSecuriyPlanMemberRDYContributionTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">135000000</ifrs-full:SocialSecurityContributions>
    <rdy:LiabilitiesDefinedContributionPlan
      contextRef="PAsOn03_31_2022_CompensatedAbsencesMemberRDYContributionTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">1061000000</rdy:LiabilitiesDefinedContributionPlan>
    <rdy:LiabilitiesDefinedContributionPlan
      contextRef="PAsOn03_31_2021_CompensatedAbsencesMemberRDYContributionTypeAxis"
      decimals="-6"
      unitRef="Unit_INR">1130000000</rdy:LiabilitiesDefinedContributionPlan>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="background: white; margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;28. Employee stock incentive plans&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dr. Reddy&#x2019;s Employees Stock Option Scheme, 2002 (the &#x201c;DRL 2002 Plan&#x201d;):&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company instituted the DRL 2002 Plan for all eligible employees pursuant to the special resolution approved by the shareholders in the Annual General Meeting held on September 24, 2001. The DRL 2002 Plan covers all employees and directors (excluding promoter directors) of the parent company and its subsidiaries (collectively, &#x201c;eligible employees&#x201d;). The Nomination, Governance and Compensation Committee of the Board of the parent company (the &#x201c;Committee&#x201d;) administers the DRL 2002 Plan and grants stock options to eligible employees. The Committee determines which eligible employees will receive options, the number of options to be granted, the exercise price, the vesting period and the exercise period. The vesting period is determined for all options issued on the date of grant. The options issued under the DRL 2002 Plan vest in periods ranging between one and four years and generally have a maximum contractual term of five years.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The DRL 2002 Plan, as amended at annual general meetings of shareholders held on July 28, 2004 and on July 27, 2005, provides for stock option grants in two categories:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Category A&lt;/div&gt;: 300,000 stock options out of the total of 2,295,478 options reserved for grant having an exercise price equal to the fair market value of the underlying equity shares on the date of grant; and&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Category B&lt;/div&gt;: 1,995,478 stock options out of the total of 2,295,478 options reserved for grant having an exercise price equal to the par value of the underlying equity shares (i.e., Rs.5 per option).&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the DRL 2002 Plan, the exercise price of the fair market value options granted under Category A above is determined based on the average closing price for 30 days prior to the grant in the stock exchange where there is highest trading volume during that period. Notwithstanding the foregoing, the Committee may, after obtaining the approval of the shareholders in the annual general meeting, grant options with a per share exercise price other than fair market value and par value of the equity shares.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;After the stock split effected in the form of a stock dividend issued by the Company in August 2006, the DRL 2002 Plan provides for stock option grants in the above two categories as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;options reserved&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;under category A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;options reserved&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;under category B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 55%; text-align: left;"&gt;Options reserved under original Plan&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;1,995,478&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;2,295,478&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Options exercised prior to stock dividend date (A)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;94,061&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;147,793&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;241,854&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Balance of shares that can be allotted on exercise of options (B)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;205,939&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,847,685&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,053,624&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Options arising from stock dividend (C)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;205,939&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,847,685&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,053,624&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Options reserved after stock dividend (A+B+C)&lt;/td&gt;&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;505,939&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,843,163&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,349,102&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                          &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The term of the DRL 2002 plan was extended for a period of 10 years effective as of January 29, 2012 by the shareholders at the Company&#x2019;s Annual General Meeting held on July 20, 2012.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock option activity under the DRL 2002 Plan for the two categories of options during the years ended March 31, 2022 and 2021 is as follows:&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0px; text-align: justify;"&gt;&#160;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category A &#x2014; Fair Market Value Options:&lt;/div&gt; There was no stock activity under this category during the years ended March 31, 2022 and 2021, and there were no stock options outstanding under this category as of March&#160;31, 2022 and 2021.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category B &#x2014; Par Value Options:&lt;/div&gt; Stock options activity under this category during the years ended March 31, 2022 and 2021 was as set forth in the below table.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 1em; margin-bottom: 1em"/&gt; &lt;div style="margin-top: 1em; margin-bottom: 1em"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31, 2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category B &#x2014; Par Value Options&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares arising out&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining useful&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life (months)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 40%; text-align: left;"&gt;Outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;217,253&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;69&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;106,870&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;91&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expired/forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(30,322&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercised during the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(86,626&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;207,175&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;74&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21,235&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;43&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;           &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category B &#x2014; Par Value Options&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares arising out&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining useful&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life (months)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 40%; text-align: left;"&gt;Outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;232,837&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;69&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;92,092&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;93&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expired/forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(35,646&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercised during the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(72,030&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;217,253&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;69&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;46,130&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;44&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;          &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average grant date fair value of options granted during the years ended March 31, 2022 and 2021 was Rs.4,985 and Rs.3,677 per option, respectively. The weighted average share price on the date of exercise of options during the years ended March 31, 2022 and 2021 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;was Rs.4,948 and Rs.4,565 per share, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate intrinsic value of options exercised during the years ended March 31, 2022 and 2021 was Rs.428 and Rs.328, respectively. As of March 31, 2022, options outstanding had an aggregate intrinsic value of Rs.889 and options exercisable had an aggregate intrinsic value of Rs.91.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dr. Reddy&#x2019;s Employees ADR Stock Option Scheme, 2007 (the &#x201c;DRL 2007 Plan&#x201d;) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company instituted the DRL 2007 Plan for all eligible employees in pursuance of the special resolution approved by the shareholders in the Annual General Meeting held on July 27, 2005. The DRL 2007 Plan became effective upon its approval by the Board of Directors on January 22, 2007. The DRL 2007 Plan covers all employees and directors (excluding promoter directors) of DRL and its subsidiaries (collectively, &#x201c;eligible employees&#x201d;). The Committee administers the DRL 2007 Plan and grants stock options to eligible employees. The Committee determines which eligible employees will receive the options, the number of options to be granted, the exercise price, the vesting period and the exercise period. The vesting period is determined for all options issued on the date of grant. The options issued under the DRL 2007 Plan vest in periods ranging between one and four years and generally have a maximum contractual term of five years.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The DRL 2007 Plan provides for option grants in two categories:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Category A&lt;/div&gt;: 382,695 stock options out of the total of 1,530,779 stock options reserved for grant having an exercise price equal to the fair market value of the underlying equity shares on the date of grant; and&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.25in; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Category B&lt;/div&gt;: 1,148,084 stock options out of the total of 1,530,779 stock options reserved for grant having an exercise price equal to the par value of the underlying equity shares (i.e., Rs.5 per option).&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0.25in;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options activity under the DRL 2007 Plan for the above two categories of options during the years ended March 31, 2022 and 2021 was as follows:&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 1em; margin-bottom: 1em"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31, 2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category A &#x2014; Fair Market Value Options&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares arising out&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining useful&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life (months)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 40%; text-align: left;"&gt;Outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;270,340&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,982.00 to Rs. 3,679.00&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;2,791.65&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;67&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,144&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,301.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,301.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;90&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expired/forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(3,150&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,679.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,679.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercised during the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(6,120&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00 to 3,679.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3,078.55&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;Outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;266,214&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,982.00 to &lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&#160;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,301.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,823.04&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;56&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;Exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;132,845&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,982.00 to &lt;/div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&#160;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,679.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,457.33&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;41&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;           &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category A &#x2014; Fair Market Value Options&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares arising out&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining useful&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life (months)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 40%; text-align: left; text-indent: 0px;"&gt;Outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;202,760&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;1,982.00 to Rs. 2,814.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;2,353.62&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;72&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;96,080&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,679.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,679.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;90&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expired/forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(13,348&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00/ 2,814.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,678.03&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercised during the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(15,152&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00/ 2,814.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,643.48&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;Outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;270,340&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,982.00 to &lt;/div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&#160;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,679.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,791.65&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;67&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;Exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;69,530&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,982.00 to &lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&#160;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,814.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,182.21&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;45&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; text-align: justify; text-indent: 0.25in;;display:inline;"&gt;&#160;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; text-align: justify; text-indent: 0.25in;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average grant date fair value of options granted during the years ended March 31, 2022 and 2021 was Rs.1,841 and Rs.1,255 per option, respectively. The weighted average share price&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt; on the date of exercise of options during the year&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt; ended March 31, 2022 and 2021&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;was Rs.4,967 and Rs.4,506 per share&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectiv&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ely.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate intrinsic value of options exercised during the year ended March 31, 2022&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and 2021&lt;/div&gt; was Rs.12&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and Rs&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.28.&lt;/div&gt;&lt;/div&gt;&#160;As of March 31, 2022, options outstanding had an aggregate intrinsic value of Rs.392 and options exercisable had an aggregate intrinsic value of Rs.196.&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31, 2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category B &#x2014; Par Value Options&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares arising out&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining useful&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life (months)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 40%; text-align: left;"&gt;Outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;141,999&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;71&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;55,884&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;90&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expired/forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(18,996&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercised during the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(31,872&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;147,015&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;68&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,929&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;40&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;    &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category B &#x2014; Par Value Options&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares arising out&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining useful&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life (months)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 40%; text-align: left;"&gt;Outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;151,583&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;73&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;52,316&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;89&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expired/forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(19,933&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercised during the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(41,967&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;141,999&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;71&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15,393&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;41&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;       &lt;div style="margin-top: 1em; margin-bottom: 1em"/&gt;  &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"/&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average grant date fair value of options granted during the years ended March 31, 2022 and 2021 was Rs.5,235 and Rs. 3,631, respectively. The weighted average share price on the date of exercise of options during the years ended March 31, 2022 and 2021 was Rs.4,975 and Rs.4,334, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate intrinsic value of options exercised during the years ended March 31, 2022 and 2021 was Rs.158 and Rs.182, respectively. As of March 31, 2022, options outstanding had an aggregate intrinsic value of Rs.631 and options exercisable had an aggregate intrinsic value of Rs.120.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dr. Reddy&#x2019;s Employees Stock Option Scheme, 2018 (the &#x201c;DRL 2018 Plan&#x201d;) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company instituted the DRL 2018 Plan for all eligible employees pursuant to the special resolution approved by the shareholders at the Annual General Meeting held on July 27, 2018. The DRL 2018 Plan covers all employees and directors (excluding independent and promoter directors) of the parent company and its subsidiaries (collectively, &#x201c;eligible employees&#x201d;). Upon the exercise of options granted under the DRL 2018 Plan, the applicable equity shares may be issued directly by the Company to the eligible employee or may be transferred from the Dr. Reddy&#x2019;s Employees ESOS Trust (the &#x201c;ESOS Trust&#x201d;) to the eligible employee. The ESOS Trust may acquire such equity shares through primary issuances by the Company and/or by way of secondary market acquisitions funded through loans from the Company. The Nomination, Governance and Compensation Committee of the Board of the parent company (the &#x201c;Compensation Committee&#x201d;) administers the DRL 2018 Plan and grants stock options to eligible employees, but may delegate functions and powers relating to the administration of the DRL 2018 Plan to the ESOS Trust. The Compensation Committee determines which eligible employees will receive the options, the number of options to be granted, the exercise price, the vesting period and the exercise period. The vesting period is determined for all options issued on the date of grant. The options issued under the DRL 2018 Plan vest in periods ranging between the end of one and five years, and generally have a maximum contractual term of five years.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The DRL 2018 Plan provides for option grants having an exercise price equal to the fair market value of the underlying equity shares on the date of grant as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;to be acquired from&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;secondary market&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;to be issued by the&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 55%; text-align: left;"&gt;Options reserved against equity shares&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;2,500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;1,500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;4,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Options reserved against ADRs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,500,000&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,500,000&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,000,000&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                          &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March 31, 2022, the outstanding shares purchased from secondary market are 468,471 shares for an aggregate consideration of Rs.1,601.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0.25in; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock option activity under the DRL 2018 Plan during the years ended March 31, 2022 and 2021 was as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31, 2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Market Value Options&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares arising out&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining useful&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life (months)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 40%; text-align: left; text-indent: 0px;"&gt;Outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;385,930&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00 to &lt;/div&gt;Rs.&#160;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,679.00&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;3,056.51&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;71&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8,856&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,662.70/ 5,301.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,289.76&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;90&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expired/forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(37,021&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00 to 5,310.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,157.39&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercised during the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(106,730&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00 to 3,679.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,938.55&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;Outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;251,035&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00 to &lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&#160;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,301.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,170.57&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;64&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;Exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;68,130&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00 to &lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&#160;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,679.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,859.13&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;47&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;               &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Market Value Options&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares arising out&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining useful&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life (months)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 40%; text-align: left; text-indent: 0px;"&gt;Outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;375,775&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00/ &lt;/div&gt;Rs.&#160;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,814.00&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;2,697.12&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;75&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;150,740&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,679.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,679.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;90&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expired/forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(55,335&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00 to 3,679.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,904.51&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercised during the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(85,250&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00/ 2,814.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,671.71&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;Outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;385,930&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,607.00 to &lt;/div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&#160;&lt;div style="font-weight:bold;display:inline;"&gt;3,679.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,056.51&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;71&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;Exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;71,225&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00/ &lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&#160;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,814.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,665.63&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;51&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                          &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0.25in; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average grant date fair value of options granted during the years ended March 31, 2022 and 2021 was Rs.1,848 and Rs.1,255 per option, respectively. The weighted average share price on the date of exercise of options during the years ended March 31, 2022 and 2021 was Rs.4,922 and Rs.4,609 per share, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aggregate intrinsic value of options exercised during the years ended March 31, 2022 and 2021 was Rs.212 and Rs.165, respectively. As of March 31, 2022, options outstanding had an aggregate intrinsic value of Rs.282 and options exercisable had an aggregate intrinsic value of Rs.77.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Valuation of stock options:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of services received in return for stock options granted to employees is measured by reference to the fair value of stock options granted. The fair value of stock options granted under the DRL 2002 Plan, DRL 2007 Plan and the DRL 2018 Plan has been measured using the Black&#x2013;Scholes-Merton model at the date of the grant.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Black-Scholes-Merton model includes assumptions regarding dividend yields, expected volatility, expected terms and risk free interest rates. In respect of par value options granted, the expected term of an option (or &#x201c;option life&#x201d;) is estimated based on the vesting term and contractual term, as well as the expected exercise behavior of the employees receiving the option. In respect of fair market value options granted, the option life is estimated based on the simplified method. Expected volatility of the option is based on historical volatility, during a period equivalent to the option life, of the observed market prices of the Company&#x2019;s publicly traded equity shares. Dividend yield of the options is based on recent dividend activity. Risk-free interest rates are based on the government securities yield in effect at the time of the grant. These assumptions reflect management&#x2019;s best estimates, but these assumptions involve inherent market uncertainties based on market conditions generally outside of the Company&#x2019;s control.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As a result, if other assumptions had been used in the current period, stock-based compensation expense could have been materially impacted. Further, if management uses different assumptions in future periods, stock based compensation expense could be materially impacted in future years.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The estimated fair value of stock options is recognized in the consolidated income statement on a straight-line basis over the requisite service period for each separately vesting portion of the award as if the award was, in substance, multiple awards.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average inputs used in computing the fair value of options granted were as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grants made on&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;January 17, 2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;October 28, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;October 28, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 55%; text-align: left;"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;28.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;29.20&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;28.53&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,663.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Option life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.5 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.0 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.5 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;6.52&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.94&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4.86&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.54&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.55&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.55&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Grant date share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,672.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,570.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,570.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grants made on&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;October 28, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;May 13, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;May 13, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 55%; text-align: left;"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;29.04&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;29.38&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;30.02&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,301.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Option life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.0 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.0 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.5 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.99&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.70&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4.64&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.54&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.47&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.47&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Grant date share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,570.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,301.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,301.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grants made on&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;October 27, 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;May 19, 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;May 19, 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 55%; text-align: left;"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;30.81&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;29.12&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;30.47&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,679.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Option life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.5 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.0 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.5 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4.36&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.67&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4.62&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.49&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.68&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.68&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Grant date share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,099.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,700.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,700.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                                 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-based payment expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 55%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity settled share-based payment expense&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;592&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;584&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;521&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash settled share-based payment expense&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;148&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;157&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;94&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;740&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;741&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;615&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0in;"/&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: bottom;"&gt;As of March 31, 2022 and 2021, there was Rs.701 and Rs.612, respectively, &lt;div style="display:inline;"&gt;of&lt;/div&gt; total unrecognized compensation cost related to unvested stock options. This cost is expected to be recognized over a weighted-average period of 1.93 years and 1.95 years, respectively.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; text-indent: -0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0in;"/&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Certain of the Company&#x2019;s employees are eligible for share-based payment awards that are settled in cash. These awards &lt;div style="display:inline;"&gt;entitl&lt;/div&gt;e the employees to a cash payment, on the exercise date, subject to vesting upon satisfaction of certain service conditions which range from 1 to 4 years. The amount of cash payment is determined based on the price of the Company&#x2019;s ADSs at the time of vesting. As of March 31, 2022 and 2021, there was Rs.101 and Rs.126, respectively of total unrecognized compensation cost related to unvested awards. This cost is expected to be recognized over a weighted-average period of 1.82 years and 1.88 years, respectively. This scheme does not involve dealing in or subscribing to or purchasing securities of the Company, directly or &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;indirectly.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <rdy:NumberOfInstrumentsInSharebasedPaymentArrangementAvailableForGrant
      contextRef="PAsOn03_31_2022_CategoriesAMemberRDYCategoryAxis_Drl2002PlanMemberRDYDrl2002PlanAxis"
      decimals="0"
      unitRef="Unit_shares">300000</rdy:NumberOfInstrumentsInSharebasedPaymentArrangementAvailableForGrant>
    <rdy:NumberOfInstrumentsInSharebasedPaymentArrangementAvailableForGrant
      contextRef="PAsOn03_31_2022_Drl2002PlanMemberRDYDrl2002PlanAxis"
      decimals="0"
      unitRef="Unit_shares">2295478</rdy:NumberOfInstrumentsInSharebasedPaymentArrangementAvailableForGrant>
    <rdy:NumberOfInstrumentsInSharebasedPaymentArrangementAvailableForGrant
      contextRef="PAsOn03_31_2022_CategoriesBMemberRDYCategoryAxis_Drl2002PlanMemberRDYDrl2002PlanAxis"
      decimals="0"
      unitRef="Unit_shares">1995478</rdy:NumberOfInstrumentsInSharebasedPaymentArrangementAvailableForGrant>
    <rdy:NumberOfInstrumentsInSharebasedPaymentArrangementAvailableForGrant
      contextRef="PAsOn03_31_2022_Drl2002PlanMemberRDYDrl2002PlanAxis"
      decimals="0"
      unitRef="Unit_shares">2295478</rdy:NumberOfInstrumentsInSharebasedPaymentArrangementAvailableForGrant>
    <rdy:DisclosureOfNumberOfOptionsReservedTableTextBlock contextRef="P04_01_2021To03_31_2022_Drl2002PlanMemberRDYDrl2002PlanAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;After the stock split effected in the form of a stock dividend issued by the Company in August 2006, the DRL 2002 Plan provides for stock option grants in the above two categories as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;options reserved&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;under category A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;options reserved&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;under category B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 55%; text-align: left;"&gt;Options reserved under original Plan&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;300,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;1,995,478&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;2,295,478&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Options exercised prior to stock dividend date (A)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;94,061&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;147,793&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;241,854&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Balance of shares that can be allotted on exercise of options (B)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;205,939&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,847,685&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,053,624&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Options arising from stock dividend (C)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;205,939&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,847,685&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,053,624&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Options reserved after stock dividend (A+B+C)&lt;/td&gt;&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;505,939&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,843,163&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4,349,102&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;            </rdy:DisclosureOfNumberOfOptionsReservedTableTextBlock>
    <rdy:OptionsReservedUnderStockPlan
      contextRef="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrlAxis"
      decimals="0"
      unitRef="Unit_shares">300000</rdy:OptionsReservedUnderStockPlan>
    <rdy:OptionsReservedUnderStockPlan
      contextRef="P04_01_2021To03_31_2022_CategoryBMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrlAxis"
      decimals="0"
      unitRef="Unit_shares">1995478</rdy:OptionsReservedUnderStockPlan>
    <rdy:OptionsReservedUnderStockPlan
      contextRef="P04_01_2021To03_31_2022_Drl2002PlanMemberRDYDrlAxis"
      decimals="0"
      unitRef="Unit_shares">2295478</rdy:OptionsReservedUnderStockPlan>
    <rdy:OptionsExercisedPriorToStockDividendDate
      contextRef="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrlAxis"
      decimals="0"
      unitRef="Unit_shares">94061</rdy:OptionsExercisedPriorToStockDividendDate>
    <rdy:OptionsExercisedPriorToStockDividendDate
      contextRef="P04_01_2021To03_31_2022_CategoryBMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrlAxis"
      decimals="0"
      unitRef="Unit_shares">147793</rdy:OptionsExercisedPriorToStockDividendDate>
    <rdy:OptionsExercisedPriorToStockDividendDate
      contextRef="P04_01_2021To03_31_2022_Drl2002PlanMemberRDYDrlAxis"
      decimals="0"
      unitRef="Unit_shares">241854</rdy:OptionsExercisedPriorToStockDividendDate>
    <rdy:BalanceOfSharesThatCanBeAllottedOnExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrlAxis"
      decimals="0"
      unitRef="Unit_shares">205939</rdy:BalanceOfSharesThatCanBeAllottedOnExerciseOfOptions>
    <rdy:BalanceOfSharesThatCanBeAllottedOnExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022_CategoryBMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrlAxis"
      decimals="0"
      unitRef="Unit_shares">1847685</rdy:BalanceOfSharesThatCanBeAllottedOnExerciseOfOptions>
    <rdy:BalanceOfSharesThatCanBeAllottedOnExerciseOfOptions
      contextRef="P04_01_2021To03_31_2022_Drl2002PlanMemberRDYDrlAxis"
      decimals="0"
      unitRef="Unit_shares">2053624</rdy:BalanceOfSharesThatCanBeAllottedOnExerciseOfOptions>
    <rdy:OptionsArisingFromStockDividend
      contextRef="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrlAxis"
      decimals="0"
      unitRef="Unit_shares">205939</rdy:OptionsArisingFromStockDividend>
    <rdy:OptionsArisingFromStockDividend
      contextRef="P04_01_2021To03_31_2022_CategoryBMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrlAxis"
      decimals="0"
      unitRef="Unit_shares">1847685</rdy:OptionsArisingFromStockDividend>
    <rdy:OptionsArisingFromStockDividend
      contextRef="P04_01_2021To03_31_2022_Drl2002PlanMemberRDYDrlAxis"
      decimals="0"
      unitRef="Unit_shares">2053624</rdy:OptionsArisingFromStockDividend>
    <rdy:OptionsReservedAfterStockDividend
      contextRef="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrlAxis"
      decimals="0"
      unitRef="Unit_shares">505939</rdy:OptionsReservedAfterStockDividend>
    <rdy:OptionsReservedAfterStockDividend
      contextRef="P04_01_2021To03_31_2022_CategoryBMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrlAxis"
      decimals="0"
      unitRef="Unit_shares">3843163</rdy:OptionsReservedAfterStockDividend>
    <rdy:OptionsReservedAfterStockDividend
      contextRef="P04_01_2021To03_31_2022_Drl2002PlanMemberRDYDrlAxis"
      decimals="0"
      unitRef="Unit_shares">4349102</rdy:OptionsReservedAfterStockDividend>
    <rdy:DisclosureOfNumberOfShareOptionsWeightedAverageExercisePriceRangeOfExercisePricesAndWeightedAverageRemainingContractualLifeTextBlock contextRef="P04_01_2021To03_31_2022_Drl2002PlanMemberRDYDrl2002PlanAxis">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0px; text-align: justify;"&gt;&#160;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category A &#x2014; Fair Market Value Options:&lt;/div&gt; There was no stock activity under this category during the years ended March 31, 2022 and 2021, and there were no stock options outstanding under this category as of March&#160;31, 2022 and 2021.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category B &#x2014; Par Value Options:&lt;/div&gt; Stock options activity under this category during the years ended March 31, 2022 and 2021 was as set forth in the below table.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 1em; margin-bottom: 1em"/&gt; &lt;div style="margin-top: 1em; margin-bottom: 1em"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31, 2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category B &#x2014; Par Value Options&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares arising out&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining useful&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life (months)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 40%; text-align: left;"&gt;Outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;217,253&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;69&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;106,870&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;91&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expired/forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(30,322&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercised during the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(86,626&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;207,175&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;74&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;21,235&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;43&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;           &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category B &#x2014; Par Value Options&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares arising out&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining useful&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life (months)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 40%; text-align: left;"&gt;Outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;232,837&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;69&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;92,092&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;93&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expired/forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(35,646&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercised during the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(72,030&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;217,253&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;69&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;46,130&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;44&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;         </rdy:DisclosureOfNumberOfShareOptionsWeightedAverageExercisePriceRangeOfExercisePricesAndWeightedAverageRemainingContractualLifeTextBlock>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">217253</ifrs-full:NumberOfOutstandingShareOptions>
    <rdy:RangesOfExercisePricesForOutstandingShareOptionsInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForOutstandingShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_M">69</rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">106870</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <rdy:RangesOfExercisePricesForShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOfGrantedShareOptions
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_M">91</rdy:WeightedAverageRemainingContractualLifeOfGrantedShareOptions>
    <rdy:NumberOfSharesOptionsExpiredForfeitedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">30322</rdy:NumberOfSharesOptionsExpiredForfeitedInSharebasedPaymentArrangement>
    <rdy:RangesOfExercisePricesForOptionsExpiredForfeitedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForOptionsExpiredForfeitedInSharebasedPaymentArrangement>
    <rdy:WeightedAverageExercisePriceOfShareOptionsExpiredForfeitedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</rdy:WeightedAverageExercisePriceOfShareOptionsExpiredForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">86626</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <rdy:RangesOfExercisePricesForShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">207175</ifrs-full:NumberOfOutstandingShareOptions>
    <rdy:RangesOfExercisePricesForOutstandingShareOptionsInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForOutstandingShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions
      contextRef="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_M">74</rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">21235</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <rdy:RangesOfExercisePricesForShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOfExercisableSharesOptionsAtEnd
      contextRef="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_M">43</rdy:WeightedAverageRemainingContractualLifeOfExercisableSharesOptionsAtEnd>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn03_31_2020_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">232837</ifrs-full:NumberOfOutstandingShareOptions>
    <rdy:RangesOfExercisePricesForOutstandingShareOptionsInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2020_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForOutstandingShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2020_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions
      contextRef="PAsOn03_31_2020_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_M">69</rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">92092</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <rdy:RangesOfExercisePricesForShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOfGrantedShareOptions
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_M">93</rdy:WeightedAverageRemainingContractualLifeOfGrantedShareOptions>
    <rdy:NumberOfSharesOptionsExpiredForfeitedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">35646</rdy:NumberOfSharesOptionsExpiredForfeitedInSharebasedPaymentArrangement>
    <rdy:RangesOfExercisePricesForOptionsExpiredForfeitedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForOptionsExpiredForfeitedInSharebasedPaymentArrangement>
    <rdy:WeightedAverageExercisePriceOfShareOptionsExpiredForfeitedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</rdy:WeightedAverageExercisePriceOfShareOptionsExpiredForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">72030</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <rdy:RangesOfExercisePricesForShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">217253</ifrs-full:NumberOfOutstandingShareOptions>
    <rdy:RangesOfExercisePricesForOutstandingShareOptionsInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForOutstandingShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_M">69</rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">46130</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <rdy:RangesOfExercisePricesForShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOfExercisableSharesOptionsAtEnd
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_Drl2002PlanMemberRDYDrl2002PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_M">44</rdy:WeightedAverageRemainingContractualLifeOfExercisableSharesOptionsAtEnd>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn03_31_2022_Drl2002PlanMemberRDYDrl2002PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">4985000000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn03_31_2021_Drl2002PlanMemberRDYDrl2002PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">3677000000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019
      contextRef="P04_01_2021To03_31_2022_Drl2002PlanMemberRDYDrl2002PlanAxis"
      decimals="0"
      unitRef="Unit_INR_per_Share">4948</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019
      contextRef="P04_01_2020To03_31_2021_Drl2002PlanMemberRDYDrl2002PlanAxis"
      decimals="0"
      unitRef="Unit_INR_per_Share">4565</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
    <rdy:IntrinsicValueOfOptionsExercised
      contextRef="PAsOn03_31_2022_Drl2002PlanMemberRDYDrl2002PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">428000000</rdy:IntrinsicValueOfOptionsExercised>
    <rdy:IntrinsicValueOfOptionsExercised
      contextRef="PAsOn03_31_2021_Drl2002PlanMemberRDYDrl2002PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">328000000</rdy:IntrinsicValueOfOptionsExercised>
    <rdy:IntrinsicValueOfOptionsOutstanding
      contextRef="PAsOn03_31_2022_Drl2002PlanMemberRDYDrl2002PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">889000000</rdy:IntrinsicValueOfOptionsOutstanding>
    <rdy:IntrinsicValueOfOptionsExercisable
      contextRef="PAsOn03_31_2021_Drl2002PlanMemberRDYDrl2002PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">91000000</rdy:IntrinsicValueOfOptionsExercisable>
    <rdy:NumberOfInstrumentsInSharebasedPaymentArrangementAvailableForGrant
      contextRef="PAsOn03_31_2022_CategoriesAMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_shares">382695</rdy:NumberOfInstrumentsInSharebasedPaymentArrangementAvailableForGrant>
    <rdy:NumberOfInstrumentsInSharebasedPaymentArrangementAvailableForGrant
      contextRef="PAsOn03_31_2022_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_shares">1530779</rdy:NumberOfInstrumentsInSharebasedPaymentArrangementAvailableForGrant>
    <rdy:NumberOfInstrumentsInSharebasedPaymentArrangementAvailableForGrant
      contextRef="PAsOn03_31_2022_CategoriesBMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_shares">1148084</rdy:NumberOfInstrumentsInSharebasedPaymentArrangementAvailableForGrant>
    <rdy:NumberOfInstrumentsInSharebasedPaymentArrangementAvailableForGrant
      contextRef="PAsOn03_31_2022_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_shares">1530779</rdy:NumberOfInstrumentsInSharebasedPaymentArrangementAvailableForGrant>
    <rdy:ParValueOfUnderlyingEquityShares
      contextRef="PAsOn03_31_2022_CategoriesBMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_INR_per_Share">5</rdy:ParValueOfUnderlyingEquityShares>
    <rdy:DisclosureOfNumberOfShareOptionsWeightedAverageExercisePriceRangeOfExercisePricesAndWeightedAverageRemainingContractualLifeTextBlock contextRef="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_Drl2007PlansMemberRDYDrl2007PlanAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options activity under the DRL 2007 Plan for the above two categories of options during the years ended March 31, 2022 and 2021 was as follows:&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31, 2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category A &#x2014; Fair Market Value Options&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares arising out&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining useful&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life (months)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 40%; text-align: left;"&gt;Outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;270,340&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,982.00 to Rs. 3,679.00&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;2,791.65&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;67&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,144&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,301.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,301.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;90&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expired/forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(3,150&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,679.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,679.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercised during the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(6,120&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00 to 3,679.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3,078.55&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;Outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;266,214&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,982.00 to &lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&#160;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,301.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,823.04&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;56&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;Exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;132,845&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,982.00 to &lt;/div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&#160;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,679.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,457.33&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;41&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;           &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category A &#x2014; Fair Market Value Options&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares arising out&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining useful&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life (months)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 40%; text-align: left; text-indent: 0px;"&gt;Outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;202,760&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;1,982.00 to Rs. 2,814.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;2,353.62&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;72&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;96,080&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,679.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,679.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;90&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expired/forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(13,348&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00/ 2,814.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,678.03&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercised during the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(15,152&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00/ 2,814.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,643.48&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;Outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;270,340&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,982.00 to &lt;/div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&#160;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,679.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,791.65&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;67&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;Exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;69,530&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,982.00 to &lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&#160;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,814.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,182.21&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;45&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </rdy:DisclosureOfNumberOfShareOptionsWeightedAverageExercisePriceRangeOfExercisePricesAndWeightedAverageRemainingContractualLifeTextBlock>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_shares">270340</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="PAsOn03_31_2021_BottomOfRangeMemberifrsfullRangeAxis_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">1982</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="PAsOn03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">3679</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">2791.65</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions
      contextRef="PAsOn03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_M">67</rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_Number">5144</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <rdy:ExercisePriceOfGrantedShareOptions
      contextRef="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">5301</rdy:ExercisePriceOfGrantedShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5301</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOfGrantedShareOptions
      contextRef="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_M">90</rdy:WeightedAverageRemainingContractualLifeOfGrantedShareOptions>
    <rdy:NumberOfSharesOptionsExpiredForfeitedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_Number">-3150</rdy:NumberOfSharesOptionsExpiredForfeitedInSharebasedPaymentArrangement>
    <rdy:RangeOfExercisePriceOfShareOptionsExpiredOrForfeitedShareBasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">3679</rdy:RangeOfExercisePriceOfShareOptionsExpiredOrForfeitedShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">3679</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_shares">6120</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <rdy:RangeOfExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">2607</rdy:RangeOfExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement>
    <rdy:RangeOfExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">3679</rdy:RangeOfExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2021To03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">3078.55</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_shares">266214</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="PAsOn03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">1982</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="PAsOn03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">5301</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">2823.04</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions
      contextRef="PAsOn03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_M">56</rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_Number">132845</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <rdy:ExercisePriceRangeOptionExercisableAtTheEndOfTheYears
      contextRef="PAsOn03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">1982</rdy:ExercisePriceRangeOptionExercisableAtTheEndOfTheYears>
    <rdy:ExercisePriceRangeOptionExercisableAtTheEndOfTheYears
      contextRef="PAsOn03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">3679</rdy:ExercisePriceRangeOptionExercisableAtTheEndOfTheYears>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">2457.33</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOfExercisableSharesOptionsAtEnd
      contextRef="PAsOn03_31_2022_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_M">41</rdy:WeightedAverageRemainingContractualLifeOfExercisableSharesOptionsAtEnd>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn03_31_2020_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_shares">202760</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="PAsOn03_31_2020_BottomOfRangeMemberifrsfullRangeAxis_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">1982</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="PAsOn03_31_2020_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">2814</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2020_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">2353.62</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions
      contextRef="PAsOn03_31_2020_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_M">72</rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_Number">96080</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <rdy:ExercisePriceOfGrantedShareOptions
      contextRef="P04_01_2020To03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">3679</rdy:ExercisePriceOfGrantedShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2020To03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">3679</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOfGrantedShareOptions
      contextRef="P04_01_2020To03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_M">90</rdy:WeightedAverageRemainingContractualLifeOfGrantedShareOptions>
    <rdy:NumberOfSharesOptionsExpiredForfeitedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_Number">-13348</rdy:NumberOfSharesOptionsExpiredForfeitedInSharebasedPaymentArrangement>
    <rdy:RangeOfExercisePriceOfShareOptionsExpiredOrForfeitedShareBasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_BottomOfRangeMemberifrsfullRangeAxis_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">2607</rdy:RangeOfExercisePriceOfShareOptionsExpiredOrForfeitedShareBasedPaymentArrangement>
    <rdy:RangeOfExercisePriceOfShareOptionsExpiredOrForfeitedShareBasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">2814</rdy:RangeOfExercisePriceOfShareOptionsExpiredOrForfeitedShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="P04_01_2020To03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">2678.03</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_shares">15152</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <rdy:RangeOfExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_BottomOfRangeMemberifrsfullRangeAxis_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">2607</rdy:RangeOfExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement>
    <rdy:RangeOfExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">2814</rdy:RangeOfExercisePriceOfShareOptionsExercisedInShareBasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2020To03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">2643.48</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_shares">270340</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="PAsOn03_31_2021_BottomOfRangeMemberifrsfullRangeAxis_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">1982</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="PAsOn03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">3679</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">2791.65</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions
      contextRef="PAsOn03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_M">67</rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_Number">69530</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <rdy:ExercisePriceRangeOptionExercisableAtTheEndOfTheYears
      contextRef="PAsOn03_31_2021_BottomOfRangeMemberifrsfullRangeAxis_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">1982</rdy:ExercisePriceRangeOptionExercisableAtTheEndOfTheYears>
    <rdy:ExercisePriceRangeOptionExercisableAtTheEndOfTheYears
      contextRef="PAsOn03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">2814</rdy:ExercisePriceRangeOptionExercisableAtTheEndOfTheYears>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">2182.21</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOfExercisableSharesOptionsAtEnd
      contextRef="PAsOn03_31_2021_CategoryMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_M">45</rdy:WeightedAverageRemainingContractualLifeOfExercisableSharesOptionsAtEnd>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn03_31_2022_CategoriesAMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">1841000000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn03_31_2021_CategoriesAMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">1255000000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019
      contextRef="P04_01_2021To03_31_2022_CategoriesAMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_INR_per_Share">4967</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019
      contextRef="P04_01_2020To03_31_2021_CategoriesAMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_INR_per_Share">4506</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
    <rdy:IntrinsicValueOfOptionsExercised
      contextRef="PAsOn03_31_2022_CategoriesAMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">12000000</rdy:IntrinsicValueOfOptionsExercised>
    <rdy:IntrinsicValueOfOptionsExercised
      contextRef="PAsOn03_31_2021_CategoriesAMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">28000000</rdy:IntrinsicValueOfOptionsExercised>
    <rdy:IntrinsicValueOfOptionsOutstanding
      contextRef="PAsOn03_31_2022_CategoriesAMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">392000000</rdy:IntrinsicValueOfOptionsOutstanding>
    <rdy:IntrinsicValueOfOptionsExercisable
      contextRef="PAsOn03_31_2022_CategoriesAMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">196000000</rdy:IntrinsicValueOfOptionsExercisable>
    <rdy:DisclosureOfNumberOfShareOptionsWeightedAverageExercisePriceRangeOfExercisePricesAndWeightedAverageRemainingContractualLifeTextBlock contextRef="P04_01_2021To03_31_2022_Drl2007PlansMemberRDYDrl2007PlanAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31, 2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category B &#x2014; Par Value Options&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares arising out&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining useful&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life (months)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 40%; text-align: left;"&gt;Outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;141,999&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;71&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;55,884&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;90&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expired/forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(18,996&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercised during the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(31,872&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;147,015&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;68&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;27,929&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;40&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category B &#x2014; Par Value Options&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares arising out&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining useful&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life (months)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 40%; text-align: left;"&gt;Outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;151,583&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;73&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;52,316&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;89&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expired/forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(19,933&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercised during the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(41,967&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;141,999&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;71&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15,393&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;41&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;      </rdy:DisclosureOfNumberOfShareOptionsWeightedAverageExercisePriceRangeOfExercisePricesAndWeightedAverageRemainingContractualLifeTextBlock>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">141999</ifrs-full:NumberOfOutstandingShareOptions>
    <rdy:RangesOfExercisePricesForOutstandingShareOptionsInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForOutstandingShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_M">71</rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">55884</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <rdy:RangesOfExercisePricesForShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOfGrantedShareOptions
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_M">90</rdy:WeightedAverageRemainingContractualLifeOfGrantedShareOptions>
    <rdy:NumberOfSharesOptionsExpiredForfeitedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">18996</rdy:NumberOfSharesOptionsExpiredForfeitedInSharebasedPaymentArrangement>
    <rdy:RangesOfExercisePricesForOptionsExpiredForfeitedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForOptionsExpiredForfeitedInSharebasedPaymentArrangement>
    <rdy:WeightedAverageExercisePriceOfShareOptionsExpiredForfeitedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</rdy:WeightedAverageExercisePriceOfShareOptionsExpiredForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">31872</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <rdy:RangesOfExercisePricesForShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2021To03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">147015</ifrs-full:NumberOfOutstandingShareOptions>
    <rdy:RangesOfExercisePricesForOutstandingShareOptionsInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForOutstandingShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions
      contextRef="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_M">68</rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">27929</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <rdy:RangesOfExercisePricesForShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOfExercisableSharesOptionsAtEnd
      contextRef="PAsOn03_31_2022_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_M">40</rdy:WeightedAverageRemainingContractualLifeOfExercisableSharesOptionsAtEnd>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn03_31_2020_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">151583</ifrs-full:NumberOfOutstandingShareOptions>
    <rdy:RangesOfExercisePricesForOutstandingShareOptionsInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2020_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForOutstandingShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2020_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions
      contextRef="PAsOn03_31_2020_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_M">73</rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">52316</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <rdy:RangesOfExercisePricesForShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOfGrantedShareOptions
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_M">89</rdy:WeightedAverageRemainingContractualLifeOfGrantedShareOptions>
    <rdy:NumberOfSharesOptionsExpiredForfeitedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">19933</rdy:NumberOfSharesOptionsExpiredForfeitedInSharebasedPaymentArrangement>
    <rdy:RangesOfExercisePricesForOptionsExpiredForfeitedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForOptionsExpiredForfeitedInSharebasedPaymentArrangement>
    <rdy:WeightedAverageExercisePriceOfShareOptionsExpiredForfeitedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</rdy:WeightedAverageExercisePriceOfShareOptionsExpiredForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_Number">41967</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <rdy:RangesOfExercisePricesForShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2020To03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_acre">141999</ifrs-full:NumberOfOutstandingShareOptions>
    <rdy:RangesOfExercisePricesForOutstandingShareOptionsInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_INR">5</rdy:RangesOfExercisePricesForOutstandingShareOptionsInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_acre">71</rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_acre">15393</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <rdy:RangesOfExercisePricesForShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="-4"
      unitRef="Unit_INR">5000000</rdy:RangesOfExercisePricesForShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOfExercisableSharesOptionsAtEnd
      contextRef="PAsOn03_31_2021_CategoryBParValueOptionsMemberifrsfullClassesOfOrdinarySharesAxis_DrlTwoThousandSevenPlanMemberRDYDrl2007PlanAxis_ExercisepricesRs5MemberifrsfullRangesOfExercisePricesForOutstandingShareOptionsAxis"
      decimals="0"
      unitRef="Unit_acre">41</rdy:WeightedAverageRemainingContractualLifeOfExercisableSharesOptionsAtEnd>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn03_31_2022_CategoriesBMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">5235000000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn03_31_2021_CategoriesBMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">3631000000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019
      contextRef="P04_01_2021To03_31_2022_CategoriesBMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_INR_per_Share">4975</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019
      contextRef="P04_01_2020To03_31_2021_CategoriesBMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="0"
      unitRef="Unit_INR_per_Share">4334</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
    <rdy:IntrinsicValueOfOptionsExercised
      contextRef="PAsOn03_31_2022_CategoriesBMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">158000000</rdy:IntrinsicValueOfOptionsExercised>
    <rdy:IntrinsicValueOfOptionsExercised
      contextRef="PAsOn03_31_2021_CategoriesBMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">182000000</rdy:IntrinsicValueOfOptionsExercised>
    <rdy:IntrinsicValueOfOptionsOutstanding
      contextRef="PAsOn03_31_2022_CategoriesBMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">631000000</rdy:IntrinsicValueOfOptionsOutstanding>
    <rdy:IntrinsicValueOfOptionsExercisable
      contextRef="PAsOn03_31_2022_CategoriesBMemberRDYCategoryAxis_Drl2007PlansMemberRDYDrl2007PlanAxis"
      decimals="-6"
      unitRef="Unit_INR">120000000</rdy:IntrinsicValueOfOptionsExercisable>
    <rdy:DisclosureAndDetailsAbout2018PlanTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The DRL 2018 Plan provides for option grants having an exercise price equal to the fair market value of the underlying equity shares on the date of grant as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;to be acquired from&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;secondary market&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;to be issued by the&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Company&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 55%; text-align: left;"&gt;Options reserved against equity shares&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;2,500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;1,500,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;4,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Options reserved against ADRs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,000,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,500,000&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,500,000&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5,000,000&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;            </rdy:DisclosureAndDetailsAbout2018PlanTableTextBlock>
    <rdy:OptionsReservedAgainstEquityShares
      contextRef="P04_01_2021To03_31_2022_DRL2018PlanMemberRDYPlanAxis_SecuritiesAcquiredFromSecondaryMarketMemberRDYSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">2500000</rdy:OptionsReservedAgainstEquityShares>
    <rdy:OptionsReservedAgainstEquityShares
      contextRef="P04_01_2021To03_31_2022_DRL2018PlanMemberRDYPlanAxis_SecuritiesIssuedByTheCompanyMemberRDYSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">1500000</rdy:OptionsReservedAgainstEquityShares>
    <rdy:OptionsReservedAgainstEquityShares
      contextRef="P04_01_2021To03_31_2022_DRL2018PlanMemberRDYPlanAxis"
      decimals="0"
      unitRef="Unit_shares">4000000</rdy:OptionsReservedAgainstEquityShares>
    <rdy:OptionsReservedAgainstADRS
      contextRef="P04_01_2021To03_31_2022_DRL2018PlanMemberRDYPlanAxis_SecuritiesAcquiredFromSecondaryMarketMemberRDYSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">0</rdy:OptionsReservedAgainstADRS>
    <rdy:OptionsReservedAgainstADRS
      contextRef="P04_01_2021To03_31_2022_DRL2018PlanMemberRDYPlanAxis_SecuritiesIssuedByTheCompanyMemberRDYSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">1000000</rdy:OptionsReservedAgainstADRS>
    <rdy:OptionsReservedAgainstADRS
      contextRef="P04_01_2021To03_31_2022_DRL2018PlanMemberRDYPlanAxis"
      decimals="0"
      unitRef="Unit_shares">1000000</rdy:OptionsReservedAgainstADRS>
    <rdy:OptionsReservedUnderStockPlan
      contextRef="P04_01_2021To03_31_2022_DRL2018PlanMemberRDYPlanAxis_SecuritiesAcquiredFromSecondaryMarketMemberRDYSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">2500000</rdy:OptionsReservedUnderStockPlan>
    <rdy:OptionsReservedUnderStockPlan
      contextRef="P04_01_2021To03_31_2022_DRL2018PlanMemberRDYPlanAxis_SecuritiesIssuedByTheCompanyMemberRDYSecuritiesAxis"
      decimals="0"
      unitRef="Unit_shares">2500000</rdy:OptionsReservedUnderStockPlan>
    <rdy:OptionsReservedUnderStockPlan
      contextRef="P04_01_2021To03_31_2022_DRL2018PlanMemberRDYPlanAxis"
      decimals="0"
      unitRef="Unit_shares">5000000</rdy:OptionsReservedUnderStockPlan>
    <rdy:EmployeeStockOptionTreasurySharesPurchased
      contextRef="PAsOn03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">468471</rdy:EmployeeStockOptionTreasurySharesPurchased>
    <rdy:ValueOfStockPurchased
      contextRef="PAsOn03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="-6"
      unitRef="Unit_INR">1601000000</rdy:ValueOfStockPurchased>
    <rdy:DisclosureOfNumberOfShareOptionsWeightedAverageExercisePriceRangeOfExercisePricesAndWeightedAverageRemainingContractualLifeTextBlock contextRef="P04_01_2021To03_31_2022_DRL2018PlanMemberRDYDRLPlanNameAxis">&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0.25in; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock option activity under the DRL 2018 Plan during the years ended March 31, 2022 and 2021 was as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31, 2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Market Value Options&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares arising out&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining useful&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life (months)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 40%; text-align: left; text-indent: 0px;"&gt;Outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;385,930&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00 to &lt;/div&gt;Rs.&#160;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,679.00&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;3,056.51&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;71&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8,856&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4,662.70/ 5,301.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,289.76&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;90&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expired/forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(37,021&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00 to 5,310.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,157.39&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercised during the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(106,730&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00 to 3,679.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,938.55&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;Outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;251,035&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00 to &lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&#160;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5,301.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,170.57&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;64&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;Exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;68,130&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00 to &lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&#160;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3,679.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,859.13&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;47&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;               &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair Market Value Options&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares arising out&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;of options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range of exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;prices&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;remaining useful&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: right; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;life (months)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 40%; text-align: left; text-indent: 0px;"&gt;Outstanding at the beginning of the year&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;375,775&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00/ &lt;/div&gt;Rs.&#160;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,814.00&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;2,697.12&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;75&lt;/td&gt;&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Granted during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;150,740&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,679.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,679.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;90&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expired/forfeited during the year&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(55,335&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00 to 3,679.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,904.51&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Exercised during the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(85,250&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00/ 2,814.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,671.71&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;Outstanding at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;385,930&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,607.00 to &lt;/div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&#160;&lt;div style="font-weight:bold;display:inline;"&gt;3,679.00&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,056.51&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;71&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;Exercisable at the end of the year&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;71,225&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,607.00/ &lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Rs.&lt;/div&gt;&#160;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,814.00&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,665.63&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0px; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;51&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;            </rdy:DisclosureOfNumberOfShareOptionsWeightedAverageExercisePriceRangeOfExercisePricesAndWeightedAverageRemainingContractualLifeTextBlock>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_Number">385930</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="PAsOn03_31_2021_BottomOfRangeMemberifrsfullRangeAxis_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">2607</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="PAsOn03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">3679</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">3056.51</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions
      contextRef="PAsOn03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_M">71</rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_Number">8856</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <rdy:ExercisePriceRangeOptionGranted
      contextRef="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">4662.7</rdy:ExercisePriceRangeOptionGranted>
    <rdy:ExercisePriceRangeOptionGranted
      contextRef="P04_01_2021To03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">5301</rdy:ExercisePriceRangeOptionGranted>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2021To03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5289.76</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOfGrantedShareOptions
      contextRef="P04_01_2021To03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_M">90</rdy:WeightedAverageRemainingContractualLifeOfGrantedShareOptions>
    <rdy:NumberOfSharesOptionsExpiredForfeitedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_Number">-37021</rdy:NumberOfSharesOptionsExpiredForfeitedInSharebasedPaymentArrangement>
    <rdy:RangeOfExercisePriceOfShareOptionsExpiredForfeitedInShareBasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">2607</rdy:RangeOfExercisePriceOfShareOptionsExpiredForfeitedInShareBasedPaymentArrangement>
    <rdy:RangeOfExercisePriceOfShareOptionsExpiredForfeitedInShareBasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">5310</rdy:RangeOfExercisePriceOfShareOptionsExpiredForfeitedInShareBasedPaymentArrangement>
    <rdy:WeightedAverageExercisePriceOfShareOptionsExpiredForfeitedInShareBasedPaymentArrangements
      contextRef="P04_01_2021To03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">3157.39</rdy:WeightedAverageExercisePriceOfShareOptionsExpiredForfeitedInShareBasedPaymentArrangements>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P04_01_2021To03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_Number">106730</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <rdy:ExercisePriceRangeOptionExercisedDuringTheYear
      contextRef="P04_01_2021To03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">2607</rdy:ExercisePriceRangeOptionExercisedDuringTheYear>
    <rdy:ExercisePriceRangeOptionExercisedDuringTheYear
      contextRef="P04_01_2021To03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">3679</rdy:ExercisePriceRangeOptionExercisedDuringTheYear>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2021To03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">2938.55</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_acre">251035</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="PAsOn03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2607</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="PAsOn03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5301</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3170.57</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions
      contextRef="PAsOn03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_acre">64</rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_acre">68130</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <rdy:ExercisePriceRangeOptionExercisableAtTheEndOfTheYear
      contextRef="PAsOn03_31_2022_BottomOfRangeMemberifrsfullRangeAxis_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2607</rdy:ExercisePriceRangeOptionExercisableAtTheEndOfTheYear>
    <rdy:ExercisePriceRangeOptionExercisableAtTheEndOfTheYear
      contextRef="PAsOn03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3679</rdy:ExercisePriceRangeOptionExercisableAtTheEndOfTheYear>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2859.13</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOfExercisableSharesOptionsAtEnd
      contextRef="PAsOn03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_acre">47</rdy:WeightedAverageRemainingContractualLifeOfExercisableSharesOptionsAtEnd>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn03_31_2020_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_Number">375775</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="PAsOn03_31_2020_BottomOfRangeMemberifrsfullRangeAxis_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">2607</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="PAsOn03_31_2020_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">2814</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2020_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">2697.12</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions
      contextRef="PAsOn03_31_2020_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_M">75</rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_Number">150740</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <rdy:ExercisePriceRangeOptionGranted
      contextRef="P04_01_2020To03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">3679</rdy:ExercisePriceRangeOptionGranted>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2020To03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">3679</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOfGrantedShareOptions
      contextRef="P04_01_2020To03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_M">90</rdy:WeightedAverageRemainingContractualLifeOfGrantedShareOptions>
    <rdy:NumberOfSharesOptionsExpiredForfeitedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_Number">-55335</rdy:NumberOfSharesOptionsExpiredForfeitedInSharebasedPaymentArrangement>
    <rdy:RangeOfExercisePriceOfShareOptionsExpiredForfeitedInShareBasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_BottomOfRangeMemberifrsfullRangeAxis_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">2607</rdy:RangeOfExercisePriceOfShareOptionsExpiredForfeitedInShareBasedPaymentArrangement>
    <rdy:RangeOfExercisePriceOfShareOptionsExpiredForfeitedInShareBasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">3679</rdy:RangeOfExercisePriceOfShareOptionsExpiredForfeitedInShareBasedPaymentArrangement>
    <rdy:WeightedAverageExercisePriceOfShareOptionsExpiredForfeitedInShareBasedPaymentArrangements
      contextRef="P04_01_2020To03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">2904.51</rdy:WeightedAverageExercisePriceOfShareOptionsExpiredForfeitedInShareBasedPaymentArrangements>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="P04_01_2020To03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_Number">85250</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <rdy:ExercisePriceRangeOptionExercisedDuringTheYear
      contextRef="P04_01_2020To03_31_2021_BottomOfRangeMemberifrsfullRangeAxis_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">2607</rdy:ExercisePriceRangeOptionExercisedDuringTheYear>
    <rdy:ExercisePriceRangeOptionExercisedDuringTheYear
      contextRef="P04_01_2020To03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">2814</rdy:ExercisePriceRangeOptionExercisedDuringTheYear>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="P04_01_2020To03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">2671.71</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="PAsOn03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_acre">385930</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="PAsOn03_31_2021_BottomOfRangeMemberifrsfullRangeAxis_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2607</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="PAsOn03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3679</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3056.51</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions
      contextRef="PAsOn03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_acre">71</rdy:WeightedAverageRemainingContractualLifeOutstandingShareOptions>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="PAsOn03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_acre">71225</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <rdy:ExercisePriceRangeOptionExercisableAtTheEndOfTheYear
      contextRef="PAsOn03_31_2021_BottomOfRangeMemberifrsfullRangeAxis_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2607</rdy:ExercisePriceRangeOptionExercisableAtTheEndOfTheYear>
    <rdy:ExercisePriceRangeOptionExercisableAtTheEndOfTheYear
      contextRef="PAsOn03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_TopOfRangeMemberifrsfullRangeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2814</rdy:ExercisePriceRangeOptionExercisableAtTheEndOfTheYear>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="PAsOn03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2665.63</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <rdy:WeightedAverageRemainingContractualLifeOfExercisableSharesOptionsAtEnd
      contextRef="PAsOn03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis"
      decimals="0"
      unitRef="Unit_acre">51</rdy:WeightedAverageRemainingContractualLifeOfExercisableSharesOptionsAtEnd>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis"
      decimals="-6"
      unitRef="Unit_INR">1848000000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted
      contextRef="PAsOn03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis"
      decimals="-6"
      unitRef="Unit_INR">1255000000</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019
      contextRef="P04_01_2021To03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis"
      decimals="0"
      unitRef="Unit_INR_per_Share">4922</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019
      contextRef="P04_01_2020To03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis"
      decimals="0"
      unitRef="Unit_INR_per_Share">4609</ifrs-full:WeightedAverageExercisePriceOfShareOptionsInSharebasedPaymentArrangementExercisedDuringPeriodAtDateOfExercise2019>
    <rdy:IntrinsicValueOfOptionsExercised
      contextRef="PAsOn03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis"
      decimals="-6"
      unitRef="Unit_INR">212000000</rdy:IntrinsicValueOfOptionsExercised>
    <rdy:IntrinsicValueOfOptionsExercised
      contextRef="PAsOn03_31_2021_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis"
      decimals="-6"
      unitRef="Unit_INR">165000000</rdy:IntrinsicValueOfOptionsExercised>
    <rdy:IntrinsicValueOfOptionsOutstanding
      contextRef="PAsOn03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis"
      decimals="-6"
      unitRef="Unit_INR">282000000</rdy:IntrinsicValueOfOptionsOutstanding>
    <rdy:IntrinsicValueOfOptionsExercisable
      contextRef="PAsOn03_31_2022_DrlTwoThousandEighteenPlanMemberRDYDrl2018PlanNameAxis_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis"
      decimals="-6"
      unitRef="Unit_INR">77000000</rdy:IntrinsicValueOfOptionsExercisable>
    <rdy:ScheduleOfWeightedAverageInputsOfFairValueOfOptionsGrantedTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average inputs used in computing the fair value of options granted were as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grants made on&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;January 17, 2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;October 28, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;October 28, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 55%; text-align: left;"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;28.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;29.20&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;28.53&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,663.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Option life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.5 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.0 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.5 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;6.52&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.94&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4.86&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.54&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.55&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.55&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Grant date share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,672.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,570.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,570.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grants made on&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;October 28, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;May 13, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;May 13, 2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 55%; text-align: left;"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;29.04&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;29.38&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;30.02&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,301.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Option life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.0 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.0 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.5 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.99&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.70&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4.64&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.54&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.47&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.47&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Grant date share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,570.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,301.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,301.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="text-align: center; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grants made on&lt;/div&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; border-top: 0.75pt solid black; border-bottom: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.375pt;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;October 27, 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;May 19, 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;May 19, 2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 55%; text-align: left;"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;30.81&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;29.12&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;30.47&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,679.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Option life&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.5 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5.0 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.5 Years&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4.36&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.67&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4.62&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left;"&gt;Expected dividends&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.49&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.68&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.68&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Grant date share price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,099.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,700.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,700.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;            </rdy:ScheduleOfWeightedAverageInputsOfFairValueOfOptionsGrantedTableTextBlock>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P01_17_2022To01_17_2022"
      decimals="4"
      unitRef="Unit_pure">0.286</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P10_28_2021To10_28_2021_OptionOneOnTwentyEightOctoberTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.292</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P10_28_2021To10_28_2021_OptionTwoOnTwentyEightOctoberTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.2853</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P01_17_2022To01_17_2022"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P10_28_2021To10_28_2021_OptionOneOnTwentyEightOctoberTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">4663</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P10_28_2021To10_28_2021_OptionTwoOnTwentyEightOctoberTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <rdy:DescriptionOfOptionLifeShareOptions contextRef="P01_17_2022To01_17_2022">P6Y6M</rdy:DescriptionOfOptionLifeShareOptions>
    <rdy:DescriptionOfOptionLifeShareOptions contextRef="P10_28_2021To10_28_2021_OptionOneOnTwentyEightOctoberTwoThousandTwentyOneMemberRDYAwardDateAxis">P5Y</rdy:DescriptionOfOptionLifeShareOptions>
    <rdy:DescriptionOfOptionLifeShareOptions contextRef="P10_28_2021To10_28_2021_OptionTwoOnTwentyEightOctoberTwoThousandTwentyOneMemberRDYAwardDateAxis">P2Y6M</rdy:DescriptionOfOptionLifeShareOptions>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P01_17_2022To01_17_2022"
      decimals="4"
      unitRef="Unit_pure">0.0652</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P10_28_2021To10_28_2021_OptionOneOnTwentyEightOctoberTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.0594</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P10_28_2021To10_28_2021_OptionTwoOnTwentyEightOctoberTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.0486</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="P01_17_2022To01_17_2022"
      decimals="4"
      unitRef="Unit_pure">0.0054</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="P10_28_2021To10_28_2021_OptionOneOnTwentyEightOctoberTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.0055</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="P10_28_2021To10_28_2021_OptionTwoOnTwentyEightOctoberTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.0055</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P01_17_2022To01_17_2022"
      decimals="2"
      unitRef="Unit_INR_per_Share">4672</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P10_28_2021To10_28_2021_OptionOneOnTwentyEightOctoberTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">4570</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P10_28_2021To10_28_2021_OptionTwoOnTwentyEightOctoberTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">4570</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P10_28_2021To10_28_2021"
      decimals="4"
      unitRef="Unit_pure">0.2904</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P05_13_2021To05_13_2021_OptionOneOnThirteenMayTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.2938</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P05_13_2021To05_13_2021_OptionTwoOnThirteenMayTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.3002</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P10_28_2021To10_28_2021"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P05_13_2021To05_13_2021_OptionOneOnThirteenMayTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5301</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P05_13_2021To05_13_2021_OptionTwoOnThirteenMayTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <rdy:DescriptionOfOptionLifeShareOptions contextRef="P10_28_2021To10_28_2021">P5Y</rdy:DescriptionOfOptionLifeShareOptions>
    <rdy:DescriptionOfOptionLifeShareOptions contextRef="P05_13_2021To05_13_2021_OptionOneOnThirteenMayTwoThousandTwentyOneMemberRDYAwardDateAxis">P5Y</rdy:DescriptionOfOptionLifeShareOptions>
    <rdy:DescriptionOfOptionLifeShareOptions contextRef="P05_13_2021To05_13_2021_OptionTwoOnThirteenMayTwoThousandTwentyOneMemberRDYAwardDateAxis">P2Y6M</rdy:DescriptionOfOptionLifeShareOptions>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P10_28_2021To10_28_2021"
      decimals="4"
      unitRef="Unit_pure">0.0599</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P05_13_2021To05_13_2021_OptionOneOnThirteenMayTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.057</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P05_13_2021To05_13_2021_OptionTwoOnThirteenMayTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.0464</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="P10_28_2021To10_28_2021"
      decimals="4"
      unitRef="Unit_pure">0.0054</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="P05_13_2021To05_13_2021_OptionOneOnThirteenMayTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.0047</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="P05_13_2021To05_13_2021_OptionTwoOnThirteenMayTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.0047</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P10_28_2021To10_28_2021"
      decimals="2"
      unitRef="Unit_INR_per_Share">4570</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P05_13_2021To05_13_2021_OptionOneOnThirteenMayTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5301</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P05_13_2021To05_13_2021_OptionTwoOnThirteenMayTwoThousandTwentyOneMemberRDYAwardDateAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5301</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P10_27_2020To10_27_2020"
      decimals="4"
      unitRef="Unit_pure">0.3081</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P05_19_2020To05_19_2020_OptionOneOnNineteenMayTwoThousandTwentyMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.2912</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted
      contextRef="P05_19_2020To05_19_2020_OptionTwoOnNineteenMayTwoThousandTwentyMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.3047</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P10_27_2020To10_27_2020"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P05_19_2020To05_19_2020_OptionOneOnNineteenMayTwoThousandTwentyMemberRDYAwardDateAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">3679</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P05_19_2020To05_19_2020_OptionTwoOnNineteenMayTwoThousandTwentyMemberRDYAwardDateAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">5</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <rdy:DescriptionOfOptionLifeShareOptions contextRef="P10_27_2020To10_27_2020">P2Y6M</rdy:DescriptionOfOptionLifeShareOptions>
    <rdy:DescriptionOfOptionLifeShareOptions contextRef="P05_19_2020To05_19_2020_OptionOneOnNineteenMayTwoThousandTwentyMemberRDYAwardDateAxis">P5Y</rdy:DescriptionOfOptionLifeShareOptions>
    <rdy:DescriptionOfOptionLifeShareOptions contextRef="P05_19_2020To05_19_2020_OptionTwoOnNineteenMayTwoThousandTwentyMemberRDYAwardDateAxis">P2Y6M</rdy:DescriptionOfOptionLifeShareOptions>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P10_27_2020To10_27_2020"
      decimals="4"
      unitRef="Unit_pure">0.0436</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P05_19_2020To05_19_2020_OptionOneOnNineteenMayTwoThousandTwentyMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.0567</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted
      contextRef="P05_19_2020To05_19_2020_OptionTwoOnNineteenMayTwoThousandTwentyMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.0462</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="P10_27_2020To10_27_2020"
      decimals="4"
      unitRef="Unit_pure">0.0049</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="P05_19_2020To05_19_2020_OptionOneOnNineteenMayTwoThousandTwentyMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.0068</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted
      contextRef="P05_19_2020To05_19_2020_OptionTwoOnNineteenMayTwoThousandTwentyMemberRDYAwardDateAxis"
      decimals="4"
      unitRef="Unit_pure">0.0068</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P10_27_2020To10_27_2020"
      decimals="2"
      unitRef="Unit_INR_per_Share">5099</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P05_19_2020To05_19_2020_OptionOneOnNineteenMayTwoThousandTwentyMemberRDYAwardDateAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">3700</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019
      contextRef="P05_19_2020To05_19_2020_OptionTwoOnNineteenMayTwoThousandTwentyMemberRDYAwardDateAxis"
      decimals="2"
      unitRef="Unit_INR_per_Share">3700</ifrs-full:WeightedAverageSharePriceShareOptionsGranted2019>
    <rdy:DisclosureOfDetailedInformationAboutShareBasedPaymentExpenseTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-based payment expense&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 55%; text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity settled share-based payment expense&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;592&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;584&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="width: 12%; text-align: right;"&gt;521&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash settled share-based payment expense&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;148&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;157&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;94&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;740&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;741&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;615&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0in;"/&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: bottom;"&gt;As of March 31, 2022 and 2021, there was Rs.701 and Rs.612, respectively, &lt;div style="display:inline;"&gt;of&lt;/div&gt; total unrecognized compensation cost related to unvested stock options. This cost is expected to be recognized over a weighted-average period of 1.93 years and 1.95 years, respectively.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; text-indent: -0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;"&gt;&lt;tr style="text-align: justify; vertical-align: top;"&gt;&lt;td style="width: 0in;"/&gt;&lt;td style="width: 0.25in; text-align: left;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify; vertical-align: bottom;"&gt;Certain of the Company&#x2019;s employees are eligible for share-based payment awards that are settled in cash. These awards &lt;div style="display:inline;"&gt;entitl&lt;/div&gt;e the employees to a cash payment, on the exercise date, subject to vesting upon satisfaction of certain service conditions which range from 1 to 4 years. The amount of cash payment is determined based on the price of the Company&#x2019;s ADSs at the time of vesting. As of March 31, 2022 and 2021, there was Rs.101 and Rs.126, respectively of total unrecognized compensation cost related to unvested awards. This cost is expected to be recognized over a weighted-average period of 1.82 years and 1.88 years, respectively. This scheme does not involve dealing in or subscribing to or purchasing securities of the Company, directly or &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;indirectly.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</rdy:DisclosureOfDetailedInformationAboutShareBasedPaymentExpenseTextBlock>
    <rdy:Equitypaymenttransactionswithemployees
      contextRef="P04_01_2021To03_31_2022_EquitySharedPaymentSettledMemberRDYAwardAxis"
      decimals="-6"
      unitRef="Unit_INR">592000000</rdy:Equitypaymenttransactionswithemployees>
    <rdy:Equitypaymenttransactionswithemployees
      contextRef="P04_01_2020To03_31_2021_EquitySharedPaymentSettledMemberRDYAwardAxis"
      decimals="-6"
      unitRef="Unit_INR">584000000</rdy:Equitypaymenttransactionswithemployees>
    <rdy:Equitypaymenttransactionswithemployees
      contextRef="P04_01_2019To03_31_2020_EquitySharedPaymentSettledMemberRDYAwardAxis"
      decimals="-6"
      unitRef="Unit_INR">521000000</rdy:Equitypaymenttransactionswithemployees>
    <ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="P04_01_2021To03_31_2022_CashSettledSharebasedPaymentMemberRDYAwardAxis"
      decimals="-6"
      unitRef="Unit_INR">148000000</ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="P04_01_2020To03_31_2021_CashSettledSharebasedPaymentMemberRDYAwardAxis"
      decimals="-6"
      unitRef="Unit_INR">157000000</ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="P04_01_2019To03_31_2020_CashSettledSharebasedPaymentMemberRDYAwardAxis"
      decimals="-6"
      unitRef="Unit_INR">94000000</ifrs-full:ExpenseFromCashsettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">740000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">741000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">615000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <rdy:EmployeesServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognized
      contextRef="PAsOn03_31_2022_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis"
      decimals="-6"
      unitRef="Unit_INR">701000000</rdy:EmployeesServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognized>
    <rdy:EmployeesServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognized
      contextRef="PAsOn03_31_2021_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis"
      decimals="-6"
      unitRef="Unit_INR">612000000</rdy:EmployeesServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognized>
    <rdy:RequisitePeriodForRecognitionOfExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="P04_01_2021To03_31_2022_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis">1.93 years</rdy:RequisitePeriodForRecognitionOfExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <rdy:RequisitePeriodForRecognitionOfExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="P04_01_2020To03_31_2021_EquitySettledShareBasedPaymentExpenseMemberRDYAwardAxis">1.95 years</rdy:RequisitePeriodForRecognitionOfExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <rdy:EmployeesServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognized
      contextRef="PAsOn03_31_2022_CashSettledSharebasedPaymentMemberRDYAwardAxis"
      decimals="-6"
      unitRef="Unit_INR">101000000</rdy:EmployeesServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognized>
    <rdy:EmployeesServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognized
      contextRef="PAsOn03_31_2021_CashSettledSharebasedPaymentMemberRDYAwardAxis"
      decimals="-6"
      unitRef="Unit_INR">126000000</rdy:EmployeesServiceSharebasedCompensationNonvestedAwardsCompensationCostNotYetRecognized>
    <rdy:RequisitePeriodForRecognitionOfExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="P04_01_2021To03_31_2022_CashSettledSharebasedPaymentMemberRDYAwardAxis">1.82 years</rdy:RequisitePeriodForRecognitionOfExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <rdy:RequisitePeriodForRecognitionOfExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="P04_01_2020To03_31_2021_CashSettledSharebasedPaymentMemberRDYAwardAxis">1.88 years</rdy:RequisitePeriodForRecognitionOfExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;29&lt;/div&gt;. Related parties&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has entered into transactions with the following related parties:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Green Park Hotel and Resorts Limited for hotel services;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Green Park Hospitality Services Private Limited for catering and other services;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Foundation towards contributions for social development;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kunshan Rotam Reddy Pharmaceuticals Company Limited for sales of goods and for research and development services;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pudami Educational Society towards contributions for social development;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Indus Projects Private Limited for engineering services relating to civil works;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CERG Advisory Private Limited for professional consulting services;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Institute of Life Sciences for research and development services;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AverQ Inc. for professional consulting services;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shravya Publications Private Limited for professional consulting services;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Samarjita Management Consultancy Private Limited for professional consulting services;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cancelled Plans LLP for the sale of scrap materials;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Araku Originals Private Limited for the purchase of coffee powder;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;DRES Energy Private Limited for the purchase of solar power; and&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"/&gt;&lt;td style="width: 0.2in;"&gt;&lt;div style="font-family: Symbol; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#xb7;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stamlo Industries Limited for hotel services.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These are enterprises over which key management personnel have control or significant influence. &#x201c;Key management personnel&#x201d; consists of the Company&#x2019;s Directors and members of the Company&#x2019;s Management Council.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has also entered into cancellable operating lease transactions with key management personnel and close members of their families.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Further, the Company contributes to the Dr. Reddy&#x2019;s Laboratories Gratuity Fund, which maintains the plan assets of the Company&#x2019;s Gratuity Plan for the benefit of its employees. See Note 2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;&#160;of these consolidated financial statements for information on transactions between the Company and the Gratuity Fund.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following is a summary of significant related party transactions:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%; text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Catering expenses paid&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;319&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;301&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;344&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contributions towards social development&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;230&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;232&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;233&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development services received&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;122&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;105&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;105&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Purchase of solar power&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;124&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;127&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;108&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional consultancy services paid&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;75&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;30&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;License fee&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;57&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;- &lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Civil works&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;52&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;55&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;101&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease rentals paid&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px;"&gt;39&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px;"&gt;37&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px;"&gt;35&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Facility management services paid&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;36&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;36&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;21&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;22&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hotel expenses paid&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px;"&gt;18&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px;"&gt;8&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px;"&gt;22&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Salaries to relatives of key management personnel&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;12&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;8&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease rentals received&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development services provided&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;93&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;58&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Others&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;*&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 5.65pt; text-indent: -19.15pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;* Rounded to the nearest million.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company had the following amounts due from related parties:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Key management personnel and close members of their families&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;8&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;8&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other related parties&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;72&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company had the following amounts due to related parties:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Due to related parties&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;10&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;93&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;














































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table describes the components of compensation paid or payable to key management personnel for the services rendered during the applicable year ended:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%; text-align: left;"&gt;Salaries and other benefits&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;627&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;803&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;684&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Contributions to defined contribution plans&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;30&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;34&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;34&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Commission to directors&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;305&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;301&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;298&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Share-based payments expense&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;214&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;259&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;165&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,176&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,397&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,181&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;














































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.7pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Some of the key management personnel of the Company are also covered under the Company&#x2019;s Gratuity Plan along with the other employees of the Company. Proportionate amounts of gratuity accrued under the Company&#x2019;s Gratuity Plan have not been separately computed or included in the above disclosure.&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following is a summary of significant related party transactions:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%; text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Catering expenses paid&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;319&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;301&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right; text-indent: 0px;"&gt;344&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contributions towards social development&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;230&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;232&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;233&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development services received&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;122&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;105&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;105&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Purchase of solar power&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;124&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;127&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;108&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional consultancy services paid&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;75&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;30&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;License fee&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;57&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;- &lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Civil works&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;52&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;55&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;101&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease rentals paid&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px;"&gt;39&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px;"&gt;37&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px;"&gt;35&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Facility management services paid&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;36&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;36&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sale of goods&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;21&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;22&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;14&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hotel expenses paid&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px;"&gt;18&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px;"&gt;8&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; text-indent: 0px;"&gt;22&lt;/td&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Salaries to relatives of key management personnel&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;12&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;8&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease rentals received&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development services provided&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;93&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;58&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;Others&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;*&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 5.65pt; text-indent: -19.15pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;* Rounded to the nearest million.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <rdy:CateringExpensesPaid
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">319000000</rdy:CateringExpensesPaid>
    <rdy:CateringExpensesPaid
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">301000000</rdy:CateringExpensesPaid>
    <rdy:CateringExpensesPaid
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">344000000</rdy:CateringExpensesPaid>
    <rdy:ContributionsTowardsSocialDevelopmentRelatedPartyTransactions
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">230000000</rdy:ContributionsTowardsSocialDevelopmentRelatedPartyTransactions>
    <rdy:ContributionsTowardsSocialDevelopmentRelatedPartyTransactions
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">232000000</rdy:ContributionsTowardsSocialDevelopmentRelatedPartyTransactions>
    <rdy:ContributionsTowardsSocialDevelopmentRelatedPartyTransactions
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">233000000</rdy:ContributionsTowardsSocialDevelopmentRelatedPartyTransactions>
    <rdy:ServicesReceived
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">122000000</rdy:ServicesReceived>
    <rdy:ServicesReceived
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">105000000</rdy:ServicesReceived>
    <rdy:ServicesReceived
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">105000000</rdy:ServicesReceived>
    <rdy:PurchaseOfSolarPower
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">124000000</rdy:PurchaseOfSolarPower>
    <rdy:PurchaseOfSolarPower
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">127000000</rdy:PurchaseOfSolarPower>
    <rdy:PurchaseOfSolarPower
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">108000000</rdy:PurchaseOfSolarPower>
    <rdy:ProfessionalConsultancyServicesPaidRelatedPartyTransactions
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">75000000</rdy:ProfessionalConsultancyServicesPaidRelatedPartyTransactions>
    <rdy:ProfessionalConsultancyServicesPaidRelatedPartyTransactions
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">30000000</rdy:ProfessionalConsultancyServicesPaidRelatedPartyTransactions>
    <rdy:ProfessionalConsultancyServicesPaidRelatedPartyTransactions
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">4000000</rdy:ProfessionalConsultancyServicesPaidRelatedPartyTransactions>
    <rdy:LicenseFee
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">57000000</rdy:LicenseFee>
    <rdy:CivilWorks
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">52000000</rdy:CivilWorks>
    <rdy:CivilWorks
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">55000000</rdy:CivilWorks>
    <rdy:CivilWorks
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">101000000</rdy:CivilWorks>
    <rdy:LeaseRentalsPaid
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">39000000</rdy:LeaseRentalsPaid>
    <rdy:LeaseRentalsPaid
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">37000000</rdy:LeaseRentalsPaid>
    <rdy:LeaseRentalsPaid
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">35000000</rdy:LeaseRentalsPaid>
    <rdy:FacilityManagementServicesPaid
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">36000000</rdy:FacilityManagementServicesPaid>
    <rdy:FacilityManagementServicesPaid
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">36000000</rdy:FacilityManagementServicesPaid>
    <rdy:FacilityManagementServicesPaid
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">24000000</rdy:FacilityManagementServicesPaid>
    <ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">21000000</ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions>
    <ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">22000000</ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions>
    <ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">14000000</ifrs-full:RevenueFromSaleOfGoodsRelatedPartyTransactions>
    <rdy:HotelExpensesPaid
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">18000000</rdy:HotelExpensesPaid>
    <rdy:HotelExpensesPaid
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">8000000</rdy:HotelExpensesPaid>
    <rdy:HotelExpensesPaid
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">22000000</rdy:HotelExpensesPaid>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">12000000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">8000000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">7000000</ifrs-full:KeyManagementPersonnelCompensation>
    <rdy:LeaseRentalsReceived
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1000000</rdy:LeaseRentalsReceived>
    <rdy:LeaseRentalsReceived
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1000000</rdy:LeaseRentalsReceived>
    <rdy:LeaseRentalsReceived
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">1000000</rdy:LeaseRentalsReceived>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">93000000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">58000000</ifrs-full:RevenueFromRenderingOfServicesRelatedPartyTransactions>
    <rdy:OtherPurchasessalesRelatedPartyTransactions
      contextRef="P04_01_2019To03_31_2020"
      id="Fact_50536904"
      unitRef="Unit_INR"
      xsi:nil="true"/>
    <rdy:ScheduleOfOutstandingBalancesForRelatedPartyTransactionsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company had the following amounts due from related parties:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Key management personnel and close members of their families&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;8&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;8&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other related parties&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;72&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company had the following amounts due to related parties:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Due to related parties&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;10&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;93&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































</rdy:ScheduleOfOutstandingBalancesForRelatedPartyTransactionsTableTextBlock>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions
      contextRef="PAsOn03_31_2022_KeyManagementPersonnelOfEntityOrParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">8000000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions
      contextRef="PAsOn03_31_2021_KeyManagementPersonnelOfEntityOrParentMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">8000000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions
      contextRef="PAsOn03_31_2022_OtherRelatedPartiesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">1000000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsReceivableRelatedPartyTransactions
      contextRef="PAsOn03_31_2021_OtherRelatedPartiesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">72000000</ifrs-full:AmountsReceivableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions
      contextRef="PAsOn03_31_2022_OtherRelatedPartiesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">10000000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <ifrs-full:AmountsPayableRelatedPartyTransactions
      contextRef="PAsOn03_31_2021_OtherRelatedPartiesMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">93000000</ifrs-full:AmountsPayableRelatedPartyTransactions>
    <rdy:DisclosureOfCompensationPaidOrPayableToKeyManagementPersonnelTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table describes the components of compensation paid or payable to key management personnel for the services rendered during the applicable year ended:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%; text-align: left;"&gt;Salaries and other benefits&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;627&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;803&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;684&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Contributions to defined contribution plans&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;30&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;34&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;34&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Commission to directors&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;305&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;301&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;298&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Share-based payments expense&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;214&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;259&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;165&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,176&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,397&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,181&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;












































</rdy:DisclosureOfCompensationPaidOrPayableToKeyManagementPersonnelTableTextBlock>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P04_01_2021To03_31_2022_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">627000000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P04_01_2020To03_31_2021_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">803000000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation
      contextRef="P04_01_2019To03_31_2020_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">684000000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="P04_01_2021To03_31_2022_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">30000000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="P04_01_2020To03_31_2021_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">34000000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits
      contextRef="P04_01_2019To03_31_2020_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">34000000</ifrs-full:KeyManagementPersonnelCompensationPostemploymentBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="P04_01_2021To03_31_2022_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">305000000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="P04_01_2020To03_31_2021_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">301000000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits
      contextRef="P04_01_2019To03_31_2020_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">298000000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="P04_01_2021To03_31_2022_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">214000000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="P04_01_2020To03_31_2021_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">259000000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment
      contextRef="P04_01_2019To03_31_2020_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">165000000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2021To03_31_2022_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">1176000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2020To03_31_2021_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">1397000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense
      contextRef="P04_01_2019To03_31_2020_KeyManagementPersonnelMemberifrsfullCategoriesOfRelatedPartiesAxis"
      decimals="-6"
      unitRef="Unit_INR">1181000000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0&lt;/div&gt;. Financial instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial instruments by category&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying value and fair value of financial instruments as of March 31, 2022 and 2021, respectively were as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total carrying&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total fair value&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total carrying&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total fair value&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 40%; text-align: left;"&gt;Cash and cash equivalents&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;14,852&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;14,852&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;14,829&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;14,829&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other investments&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;33,181&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;33,181&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24,702&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24,702&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other receivables&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;66,818&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;66,818&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;49,759&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;49,759&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Derivative financial instruments&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,906&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,906&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,218&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,218&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,347&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,347&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,626&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,626&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;119,104&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;119,104&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;93,134&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;93,134&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other payables&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;25,572&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;25,572&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;23,744&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;23,744&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Derivative financial instruments&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;479&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;479&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;326&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;326&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Long-term borrowings&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,763&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,763&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,163&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,163&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Short-term borrowings&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;27,082&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;27,082&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;23,136&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;23,136&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Bank overdraft&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;9&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;9&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities and provisions&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;26,238&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;26,238&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;23,233&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;23,233&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;86,134&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;86,134&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;77,611&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;77,611&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Other assets that are not financial assets (such as receivables from statutory authorities, export benefit receivables, prepaid expenses, advances paid and certain other receivables) of Rs.12,449 and Rs.12,717 as of March 31, 2022 and 2021, respectively, are not included.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table style="border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; width: 100%; table-layout: fixed;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="padding: 0pt; width: 0in;"/&gt;
			&lt;td style="white-space: nowrap; width: 0.25in; vertical-align: text-top; padding-left: 0px; padding-right: 0px; font-size: 10pt;"&gt;
			&lt;div style="font-size: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; color: black; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0pt 0px; vertical-align: text-top; font-size: 10pt;"&gt;
			&lt;div style="font-size: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; color: black; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities and provisions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;























&lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0.26in; text-indent: 0px;"&gt;Other liabilities and provisions that are not financial liabilities (such as statutory dues payable, deferred revenue, advances from customers and certain other accruals) of Rs. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,491 &lt;/div&gt;and Rs.13,091 as of March 31, 2022 and 2021, respectively, are not included.&lt;/div&gt;
&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;

&lt;div style="font-size: 10pt; margin: 3pt -7.6pt 0.0001pt 0.26in; text-align: justify; font-family: Calibri, sans-serif; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;Amounts as of March 31, 2021 includes contingent consideration of Rs.420 &lt;/div&gt;pursuant to the Business Transfer Agreement with Wockhardt Limited (Refer to Note 6 for details).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;




























&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Amounts as of March 31, 2022 includes consideration payable of Rs.84 pursuant to the Acquisition of Nimbus Health, GmbH (Refer to Note 6 for details).&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value hierarchy&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices).&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the fair value hierarchy of assets and liabilities measured at fair value on a recurring basis as of March&#160;31,&#160;2022:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 1&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 2&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 3&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 40%; text-align: left;"&gt;FVTPL - Financial asset - Investments in units of mutual funds&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;16,751&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;16,751&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;FVTPL - Financial asset - Investment in limited liability partnership firm&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;386&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;386&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;FVTPL - Financial asset - Investments in equity securities&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;200&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;201&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;FVTOCI - Financial asset - Investments in equity securities&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;999&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;999&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative financial instruments &#x2013; net gain/(loss) on outstanding foreign exchange forward, option and swap contracts and interest rate swap contracts&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,427&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,427&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the fair value hierarchy of assets and liabilities measured at fair value on a recurring basis as of March&#160;31,&#160;2021:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 1&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 2&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 3&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 40%; text-align: left;"&gt;FVTPL - Financial asset - Investments in units of mutual funds&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;13,263&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;13,263&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;FVTPL - Financial asset - Investment in limited liability partnership firm&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;400&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;400&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;FVTPL - Financial asset - Investments in equity securities&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;FVTOCI - Financial asset - Investments in equity securities&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,532&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,532&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative financial instruments &#x2013; net gain/(loss) on outstanding foreign exchange forward, option and swap contracts and interest rate swap contracts&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;892&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;892&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FVTPL- Contingent consideration pursuant to the Business Transfer Agreement with Wockhardt Limited &lt;div style="font-style:italic;display:inline;"&gt;(Refer to Note 6 for details)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;420&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;420&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;













































&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;The Company enters into derivative financial instruments with various counterparties, principally financial institutions and banks. Derivatives &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;wh&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ich are &lt;/div&gt;&lt;/div&gt;valued using valuation techniques with market observable inputs are mainly interest rate swaps, foreign exchange forward option and swap contracts. The most frequently applied valuation techniques include forward pricing, swap models and Black-Scholes-Merton models (for option valuation), using present value calculations. The models incorporate various inputs, including foreign exchange forward rates, interest rate curves and forward rate curves.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March 31, 2022 and 2021, the changes in counterparty credit risk had no material effect on the hedge effectiveness assessment for derivatives designated in hedge relationships and other financial instruments recognized at fair value.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivative financial instruments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company had a derivative financial asset and derivative financial liability of Rs.1,906 and Rs.479, respectively, as of March 31, 2022, as compared to derivative financial asset and derivative financial liability of Rs.1,218 and Rs.326, respectively, as of March 31, 2021, towards these derivative financial instruments.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Details of gain/(loss) recognized in respect of derivative contracts&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents details in respect of the gain/(loss) recognized in respect of derivative contracts during the applicable year ended:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%; text-align: left;"&gt;Net gain/(loss) recognized in finance costs in respect of foreign exchange derivative contracts and cross currency interest rate swaps contracts&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;(435&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;2,619&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;155&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Net gain/(loss) recognized in equity in respect of hedges of highly probable forecast transactions, net of amounts reclassified from equity and recognized as component of revenue&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;883&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,123&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(951&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Net gain/(loss) reclassified from equity and recognized as component of revenue occurrence of forecasted transaction&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;525&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;340&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(50&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The net carrying amount of the Company&#x2019;s &#x201c;hedging reserve&#x201d; as a component of equity before adjusting for tax impact was a gain of Rs.1,284 as of March 31, 2022, as compared to a gain of Rs.401 as of March 31, 2021.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Outstanding foreign exchange derivative contracts &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table gives details in respect of the notional amount of outstanding foreign exchange derivative contracts as of March&#160;31,&#160;2022.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr&gt;
			&lt;td style="width: 27%; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 15%; text-align: center; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Instrument&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: center; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Currency&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: center; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cross Currency&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: center; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amounts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: center; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Buy/Sell&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hedges of recognized assets and liabilities&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD 10&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP 9&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB 7,171&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 720&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;MXN&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 21&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ZAR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ZAR 31&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 1&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RON&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 12&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 4&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP 48&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR 47&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KZT&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 9&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CLP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 3&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 7&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BRL&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 3&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR 2&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;THB&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 2&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 60&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hedges of highly probable forecast transactions&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD 4&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB 9,600&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 68&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ZAR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ZAR 122&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 275&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






























&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table gives details in respect of the notional amount of outstanding foreign exchange derivative contracts as of March&#160;31,&#160;2021.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr&gt;
			&lt;td style="width: 27%; vertical-align: bottom; border-bottom: 1pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-top: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Instrument&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-top: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Currency&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-top: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cross Currency&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-top: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amounts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-top: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Buy/Sell&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hedges of recognized assets and liabilities&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD 7&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CHF&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CHF 200&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP 8&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB 2,799&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 353&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;MXN&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 10&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;UAH&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 14&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ZAR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ZAR 111&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 2&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RON&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 12&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 3&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP 48&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR 1&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR 16&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CHF&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CHF200&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KZT&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 4&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CLP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 3&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 4&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BRL&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 4&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KZT&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 9&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hedges of highly probable forecast transactions&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD 10&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB 6,850&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 645&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell - Risk Reversal&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ZAR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ZAR 148&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;&#x201c;INR&#x201d; means Indian rupees, &#x201c;U.S.$&#x201d; means United States dollars, &#x201c;RON&#x201d; means Romanian new leus, &#x201c;GBP&#x201d; means U.K. pounds sterling, &#x201c;AUD&#x201d; means Australian dollars, &#x201c;CHF&#x201d; means Swiss francs, &#x201c;ZAR&#x201d; means South African rands, &#x201c;EUR&#x201d; means Euros, &#x201c;BRL&#x201d; means Brazilian reals, &#x201c;CLP&#x201d; means Chilean pesos, &#x201c;COP&#x201d; means Colombian pesos, &#x201c;KZT&#x201d; means Kazakhstan tenges, &#x201c;MXN&#x201d; means Mexican pesos, &#x201c;UAH&#x201d; means Ukrainian hryvnias, &#x201c;RUB&#x201d; means Russian roubles and &#x201c;THB&#x201d; means Thai bahts.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






























 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The table below summarizes the periods when the cash flows associated with highly probable forecast transactions that are classified as cash flow hedges are expected to occur:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flows in U.S dollars&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Not later than one month&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;2,653&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,656&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Later than one month and not later than three months&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;5,305&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,311&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Later than three months and not later than six months&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,139&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;12,063&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Later than six months and not later than one year&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;11,824&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;24,126&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25,921&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;47,156&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flows in Russian roubles&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Not later than one month&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;460&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;437&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Later than one month and not later than three months&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,513&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;874&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Later than three months and not later than six months&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,528&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,748&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Later than six months and not later than one year&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3,331&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3,593&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,832&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,651&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flows in Australian dollars&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Not later than one month&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;10&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;46&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Later than one month and not later than three months&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;60&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;92&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Later than three months and not later than six months&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;48&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;139&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Later than six months and not later than one year&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;134&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;277&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;252&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;555&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flows in South African rands&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Not later than one month&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;41&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;61&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Later than one month and not later than three months&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;98&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;121&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Later than three months and not later than six months&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;146&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;182&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Later than six months and not later than one year&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;350&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;364&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;635&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;728&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Hedges of changes in the interest rates:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consistent with its risk management policy, the Company uses interest rate swaps (including cross currency interest rate swaps) to mitigate the risk of changes in interest rates. The Company does not use them for trading or speculative purposes.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A net gain/(loss) of Rs.Nil for each of the years ended March 31, 2022, 2021 and 2020, representing the changes in the fair value of interest rate swaps used as hedging instrument in a cash flow hedge is recognized in the statement of comprehensive income. For balance interest rate swaps, the changes in fair value (including cross currency interest rate swaps) are recognized as part of the finance costs. Accordingly the Company has recorded, as part of finance cost, a net gain of Rs.32,&#160;Rs.164 and&#160;Rs.33 for the years ended March 31, 2022, 2021 and 2020 respectively.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company had outstanding cross currency swap against INR borrowing of Rs.Nil and Rs.7,240 as of March 31, 2022 and 2021, respectively. The swap hedges the principal repayment of underlying INR liability and transforms it into U.S.$ principal repayment liability.&lt;/div&gt;&lt;/div&gt;
</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <rdy:CarryingValueAndFairValueOfFinancialInstrumentsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial instruments by category&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying value and fair value of financial instruments as of March 31, 2022 and 2021, respectively were as follows:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31, 2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31, 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total carrying&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total fair value&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total carrying&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total fair value&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 40%; text-align: left;"&gt;Cash and cash equivalents&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;14,852&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;14,852&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;14,829&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;14,829&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other investments&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;33,181&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;33,181&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24,702&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24,702&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other receivables&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;66,818&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;66,818&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;49,759&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;49,759&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Derivative financial instruments&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,906&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,906&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,218&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,218&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other assets&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,347&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,347&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,626&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;2,626&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;119,104&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;119,104&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;93,134&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;93,134&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other payables&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;25,572&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;25,572&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;23,744&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;23,744&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Derivative financial instruments&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;479&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;479&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;326&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;326&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Long-term borrowings&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,763&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,763&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,163&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,163&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Short-term borrowings&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;27,082&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;27,082&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;23,136&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;23,136&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Bank overdraft&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;9&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;9&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities and provisions&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;26,238&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;26,238&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;23,233&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;23,233&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;86,134&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;86,134&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;77,611&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;77,611&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Other assets that are not financial assets (such as receivables from statutory authorities, export benefit receivables, prepaid expenses, advances paid and certain other receivables) of Rs.12,449 and Rs.12,717 as of March 31, 2022 and 2021, respectively, are not included.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;table style="border-spacing: 0px; border-collapse: collapse; margin-bottom: 0.0001pt; width: 100%; table-layout: fixed;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="padding: 0pt; width: 0in;"/&gt;
			&lt;td style="white-space: nowrap; width: 0.25in; vertical-align: text-top; padding-left: 0px; padding-right: 0px; font-size: 10pt;"&gt;
			&lt;div style="font-size: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; color: black; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;)&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding: 0pt 0px; vertical-align: text-top; font-size: 10pt;"&gt;
			&lt;div style="font-size: 12pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; color: black; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other liabilities and provisions: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;























&lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0.26in; text-indent: 0px;"&gt;Other liabilities and provisions that are not financial liabilities (such as statutory dues payable, deferred revenue, advances from customers and certain other accruals) of Rs. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;14,491 &lt;/div&gt;and Rs.13,091 as of March 31, 2022 and 2021, respectively, are not included.&lt;/div&gt;
&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;

&lt;div style="font-size: 10pt; margin: 3pt -7.6pt 0.0001pt 0.26in; text-align: justify; font-family: Calibri, sans-serif; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;Amounts as of March 31, 2021 includes contingent consideration of Rs.420 &lt;/div&gt;pursuant to the Business Transfer Agreement with Wockhardt Limited (Refer to Note 6 for details).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;




























&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0.2in; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Amounts as of March 31, 2022 includes consideration payable of Rs.84 pursuant to the Acquisition of Nimbus Health, GmbH (Refer to Note 6 for details).&lt;/div&gt;&lt;/div&gt;</rdy:CarryingValueAndFairValueOfFinancialInstrumentsTableTextBlock>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2022_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">14852000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2022_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">14852000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2021_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">14829000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2021_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">14829000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">33181000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">33181000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">24702000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">24702000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:TradeReceivables
      contextRef="PAsOn03_31_2022_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">66818000000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="PAsOn03_31_2022_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">66818000000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="PAsOn03_31_2021_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">49759000000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="PAsOn03_31_2021_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">49759000000</ifrs-full:TradeReceivables>
    <ifrs-full:CurrentDerivativeFinancialAssets
      contextRef="PAsOn03_31_2022_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">1906000000</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentDerivativeFinancialAssets
      contextRef="PAsOn03_31_2022_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">1906000000</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentDerivativeFinancialAssets
      contextRef="PAsOn03_31_2021_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">1218000000</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentDerivativeFinancialAssets
      contextRef="PAsOn03_31_2021_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">1218000000</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:OtherFinancialAssets
      contextRef="PAsOn03_31_2022_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      id="Fact_50537228"
      unitRef="Unit_INR">2347000000</ifrs-full:OtherFinancialAssets>
    <ifrs-full:OtherFinancialAssets
      contextRef="PAsOn03_31_2022_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      id="Fact_50537227"
      unitRef="Unit_INR">2347000000</ifrs-full:OtherFinancialAssets>
    <ifrs-full:OtherFinancialAssets
      contextRef="PAsOn03_31_2021_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      id="Fact_50537226"
      unitRef="Unit_INR">2626000000</ifrs-full:OtherFinancialAssets>
    <ifrs-full:OtherFinancialAssets
      contextRef="PAsOn03_31_2021_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      id="Fact_50537225"
      unitRef="Unit_INR">2626000000</ifrs-full:OtherFinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn03_31_2022_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">119104000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn03_31_2022_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">119104000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn03_31_2021_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">93134000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="PAsOn03_31_2021_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">93134000000</ifrs-full:FinancialAssets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2022_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">25572000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2022_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">25572000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2021_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">23744000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2021_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">23744000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2022_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">479000000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2022_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">479000000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2021_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">326000000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2021_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">326000000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2022_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">6763000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2022_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">6763000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2021_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">7163000000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2021_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">7163000000</ifrs-full:Borrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2022_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">27082000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2022_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">27082000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2021_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">23136000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2021_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">23136000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
      contextRef="PAsOn03_31_2022_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
      contextRef="PAsOn03_31_2022_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
      contextRef="PAsOn03_31_2021_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">9000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:BankOverdraftsClassifiedAsCashEquivalents
      contextRef="PAsOn03_31_2021_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">9000000</ifrs-full:BankOverdraftsClassifiedAsCashEquivalents>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="PAsOn03_31_2022_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      id="Fact_50537200"
      unitRef="Unit_INR">26238000000</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="PAsOn03_31_2022_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      id="Fact_50537199"
      unitRef="Unit_INR">26238000000</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="PAsOn03_31_2021_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      id="Fact_50537198"
      unitRef="Unit_INR">23233000000</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="PAsOn03_31_2021_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      id="Fact_50537197"
      unitRef="Unit_INR">23233000000</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn03_31_2022_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">86134000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn03_31_2022_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">86134000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn03_31_2021_TotalCarryingValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">77611000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="PAsOn03_31_2021_TotalFairValueMemberRDYValueTypeOfFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_INR">77611000000</ifrs-full:FinancialLiabilities>
    <ifrs-full:OtherNonfinancialAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">12449000000</ifrs-full:OtherNonfinancialAssets>
    <ifrs-full:OtherNonfinancialAssets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">12717000000</ifrs-full:OtherNonfinancialAssets>
    <ifrs-full:OtherNonfinancialLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">14491000000</ifrs-full:OtherNonfinancialLiabilities>
    <ifrs-full:OtherNonfinancialLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">13091000000</ifrs-full:OtherNonfinancialLiabilities>
    <rdy:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn03_31_2021_WockhardtLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">420000000</rdy:BusinessCombinationContingentConsiderationLiability>
    <ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination
      contextRef="PAsOn03_31_2022_NimbusHealthGmbhMemberifrsfullBusinessCombinationsAxis"
      decimals="-6"
      unitRef="Unit_INR">84000000</ifrs-full:ContingentLiabilitiesRecognisedInBusinessCombination>
    <rdy:DisclosureOfDetailedInformationAboutFairValueMeasurementOfAssetsAndLiabilitiesTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the fair value hierarchy of assets and liabilities measured at fair value on a recurring basis as of March&#160;31,&#160;2022:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 1&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 2&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 3&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 40%; text-align: left;"&gt;FVTPL - Financial asset - Investments in units of mutual funds&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;16,751&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;16,751&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;FVTPL - Financial asset - Investment in limited liability partnership firm&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;386&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;386&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;FVTPL - Financial asset - Investments in equity securities&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;200&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;201&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;FVTOCI - Financial asset - Investments in equity securities&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;999&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;999&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative financial instruments &#x2013; net gain/(loss) on outstanding foreign exchange forward, option and swap contracts and interest rate swap contracts&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,427&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,427&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


















































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the fair value hierarchy of assets and liabilities measured at fair value on a recurring basis as of March&#160;31,&#160;2021:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 1&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 2&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level 3&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 40%; text-align: left;"&gt;FVTPL - Financial asset - Investments in units of mutual funds&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;13,263&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;13,263&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;FVTPL - Financial asset - Investment in limited liability partnership firm&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;400&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;400&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;FVTPL - Financial asset - Investments in equity securities&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;FVTOCI - Financial asset - Investments in equity securities&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,532&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,532&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative financial instruments &#x2013; net gain/(loss) on outstanding foreign exchange forward, option and swap contracts and interest rate swap contracts&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;892&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;892&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FVTPL- Contingent consideration pursuant to the Business Transfer Agreement with Wockhardt Limited &lt;div style="font-style:italic;display:inline;"&gt;(Refer to Note 6 for details)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;420&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;420&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;













































&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;The Company enters into derivative financial instruments with various counterparties, principally financial institutions and banks. Derivatives &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;wh&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ich are &lt;/div&gt;&lt;/div&gt;valued using valuation techniques with market observable inputs are mainly interest rate swaps, foreign exchange forward option and swap contracts. The most frequently applied valuation techniques include forward pricing, swap models and Black-Scholes-Merton models (for option valuation), using present value calculations. The models incorporate various inputs, including foreign exchange forward rates, interest rate curves and forward rate curves.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;
</rdy:DisclosureOfDetailedInformationAboutFairValueMeasurementOfAssetsAndLiabilitiesTableTextBlock>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2022_InvestmentInMfMemberRDYTransactionTypesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">16751000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2022_InvestmentInMfMemberRDYTransactionTypesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2022_InvestmentInMfMemberRDYTransactionTypesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2022_InvestmentInMfMemberRDYTransactionTypesAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">16751000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2022_InvestmentInLimitedLiabilityPartnershipFirmMemberRDYTransactionTypesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2022_InvestmentInLimitedLiabilityPartnershipFirmMemberRDYTransactionTypesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2022_InvestmentInLimitedLiabilityPartnershipFirmMemberRDYTransactionTypesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">386000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2022_InvestmentInLimitedLiabilityPartnershipFirmMemberRDYTransactionTypesAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">386000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2022_InvestmentInEquityMemberRDYTransactionTypesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">200000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2022_InvestmentInEquityMemberRDYTransactionTypesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2022_InvestmentInEquityMemberRDYTransactionTypesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">1000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2022_InvestmentInEquityMemberRDYTransactionTypesAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">201000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome
      contextRef="PAsOn03_31_2022_InvestmentInEquityMemberRDYTransactionTypesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">999000000</ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome
      contextRef="PAsOn03_31_2022_InvestmentInEquityMemberRDYTransactionTypesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome
      contextRef="PAsOn03_31_2022_InvestmentInEquityMemberRDYTransactionTypesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome
      contextRef="PAsOn03_31_2022_InvestmentInEquityMemberRDYTransactionTypesAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">999000000</ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <rdy:DerivativeFinanicialAssetsAndLiabilties
      contextRef="PAsOn03_31_2022_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      id="Fact_50537192"
      unitRef="Unit_INR">0</rdy:DerivativeFinanicialAssetsAndLiabilties>
    <rdy:DerivativeFinanicialAssetsAndLiabilties
      contextRef="PAsOn03_31_2022_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      id="Fact_50537191"
      unitRef="Unit_INR">1427000000</rdy:DerivativeFinanicialAssetsAndLiabilties>
    <rdy:DerivativeFinanicialAssetsAndLiabilties
      contextRef="PAsOn03_31_2022_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      id="Fact_50537190"
      unitRef="Unit_INR">0</rdy:DerivativeFinanicialAssetsAndLiabilties>
    <rdy:DerivativeFinanicialAssetsAndLiabilties
      contextRef="PAsOn03_31_2022_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      id="Fact_50537189"
      unitRef="Unit_INR">1427000000</rdy:DerivativeFinanicialAssetsAndLiabilties>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2021_InvestmentInMfMemberRDYTransactionTypesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">13263000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2021_InvestmentInMfMemberRDYTransactionTypesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2021_InvestmentInMfMemberRDYTransactionTypesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2021_InvestmentInMfMemberRDYTransactionTypesAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">13263000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2021_InvestmentInLimitedLiabilityPartnershipFirmMemberRDYTransactionTypesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2021_InvestmentInLimitedLiabilityPartnershipFirmMemberRDYTransactionTypesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2021_InvestmentInLimitedLiabilityPartnershipFirmMemberRDYTransactionTypesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">400000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2021_InvestmentInLimitedLiabilityPartnershipFirmMemberRDYTransactionTypesAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">400000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2021_InvestmentInEquityMemberRDYTransactionTypesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2021_InvestmentInEquityMemberRDYTransactionTypesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2021_InvestmentInEquityMemberRDYTransactionTypesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">1000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2021_InvestmentInEquityMemberRDYTransactionTypesAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">1000000</ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome
      contextRef="PAsOn03_31_2021_InvestmentInEquityMemberRDYTransactionTypesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">4532000000</ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome
      contextRef="PAsOn03_31_2021_InvestmentInEquityMemberRDYTransactionTypesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome
      contextRef="PAsOn03_31_2021_InvestmentInEquityMemberRDYTransactionTypesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome
      contextRef="PAsOn03_31_2021_InvestmentInEquityMemberRDYTransactionTypesAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">4532000000</ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncome>
    <rdy:DerivativeFinanicialAssetsAndLiabilties
      contextRef="PAsOn03_31_2021_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      id="Fact_50537188"
      unitRef="Unit_INR">0</rdy:DerivativeFinanicialAssetsAndLiabilties>
    <rdy:DerivativeFinanicialAssetsAndLiabilties
      contextRef="PAsOn03_31_2021_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      id="Fact_50537187"
      unitRef="Unit_INR">892000000</rdy:DerivativeFinanicialAssetsAndLiabilties>
    <rdy:DerivativeFinanicialAssetsAndLiabilties
      contextRef="PAsOn03_31_2021_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      id="Fact_50537186"
      unitRef="Unit_INR">0</rdy:DerivativeFinanicialAssetsAndLiabilties>
    <rdy:DerivativeFinanicialAssetsAndLiabilties
      contextRef="PAsOn03_31_2021_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      id="Fact_50537185"
      unitRef="Unit_INR">892000000</rdy:DerivativeFinanicialAssetsAndLiabilties>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2021_ContingentConsiderationpursuantToTheBusinessTransferAgreementMemberRDYTransactionTypesAxis_Level1OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2021_ContingentConsiderationpursuantToTheBusinessTransferAgreementMemberRDYTransactionTypesAxis_Level2OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2021_ContingentConsiderationpursuantToTheBusinessTransferAgreementMemberRDYTransactionTypesAxis_Level3OfFairValueHierarchyMemberifrsfullLevelsOfFairValueHierarchyAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">420000000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="PAsOn03_31_2021_ContingentConsiderationpursuantToTheBusinessTransferAgreementMemberRDYTransactionTypesAxis_RecurringFairValueMeasurementMemberifrsfullMeasurementAxis"
      decimals="-6"
      unitRef="Unit_INR">420000000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:DerivativeFinancialAssets
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1906000000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">479000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialAssets
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">1218000000</ifrs-full:DerivativeFinancialAssets>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">326000000</ifrs-full:DerivativeFinancialLiabilities>
    <rdy:DisclosureOfDetailedInformationAboutOfGainlossRecognizedInRespectOfDerivativeContractsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents details in respect of the gain/(loss) recognized in respect of derivative contracts during the applicable year ended:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Year Ended March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 55%; text-align: left;"&gt;Net gain/(loss) recognized in finance costs in respect of foreign exchange derivative contracts and cross currency interest rate swaps contracts&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;(435&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;)&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;2,619&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;155&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Net gain/(loss) recognized in equity in respect of hedges of highly probable forecast transactions, net of amounts reclassified from equity and recognized as component of revenue&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;883&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,123&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(951&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Net gain/(loss) reclassified from equity and recognized as component of revenue occurrence of forecasted transaction&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;525&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;340&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;(50&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





























</rdy:DisclosureOfDetailedInformationAboutOfGainlossRecognizedInRespectOfDerivativeContractsTableTextBlock>
    <rdy:NetGainsLossesOnForeignExchangeDerivativeAndInterestRateSwapsContracts
      contextRef="P04_01_2021To03_31_2022_DerivativesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-435000000</rdy:NetGainsLossesOnForeignExchangeDerivativeAndInterestRateSwapsContracts>
    <rdy:NetGainsLossesOnForeignExchangeDerivativeAndInterestRateSwapsContracts
      contextRef="P04_01_2020To03_31_2021_DerivativesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">2619000000</rdy:NetGainsLossesOnForeignExchangeDerivativeAndInterestRateSwapsContracts>
    <rdy:NetGainsLossesOnForeignExchangeDerivativeAndInterestRateSwapsContracts
      contextRef="P04_01_2019To03_31_2020_DerivativesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">155000000</rdy:NetGainsLossesOnForeignExchangeDerivativeAndInterestRateSwapsContracts>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P04_01_2021To03_31_2022_DerivativesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">883000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P04_01_2020To03_31_2021_DerivativesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">1123000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax
      contextRef="P04_01_2019To03_31_2020_DerivativesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-951000000</ifrs-full:GainsLossesOnCashFlowHedgesBeforeTax>
    <rdy:NetGainsLossesReclassifiedFromEquityAndRecordedInRevenueCashFlowHedges
      contextRef="P04_01_2021To03_31_2022_DerivativesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">525000000</rdy:NetGainsLossesReclassifiedFromEquityAndRecordedInRevenueCashFlowHedges>
    <rdy:NetGainsLossesReclassifiedFromEquityAndRecordedInRevenueCashFlowHedges
      contextRef="P04_01_2020To03_31_2021_DerivativesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">340000000</rdy:NetGainsLossesReclassifiedFromEquityAndRecordedInRevenueCashFlowHedges>
    <rdy:NetGainsLossesReclassifiedFromEquityAndRecordedInRevenueCashFlowHedges
      contextRef="P04_01_2019To03_31_2020_DerivativesMemberifrsfullClassesOfAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">-50000000</rdy:NetGainsLossesReclassifiedFromEquityAndRecordedInRevenueCashFlowHedges>
    <ifrs-full:ReserveOfCashFlowHedges
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">1284000000</ifrs-full:ReserveOfCashFlowHedges>
    <ifrs-full:ReserveOfCashFlowHedges
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">-401000000</ifrs-full:ReserveOfCashFlowHedges>
    <rdy:DisclosureOfNotionalAmountOfOutstandingForeignExchangeDerivativeContractsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table gives details in respect of the notional amount of outstanding foreign exchange derivative contracts as of March&#160;31,&#160;2022.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr&gt;
			&lt;td style="width: 27%; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 15%; text-align: center; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Instrument&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: center; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Currency&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: center; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cross Currency&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: center; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amounts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: center; vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Buy/Sell&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hedges of recognized assets and liabilities&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD 10&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP 9&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB 7,171&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 720&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;MXN&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 21&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ZAR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ZAR 31&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 1&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RON&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 12&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 4&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP 48&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR 47&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KZT&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 9&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CLP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 3&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 7&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BRL&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 3&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR 2&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;THB&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 2&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 60&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hedges of highly probable forecast transactions&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD 4&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB 9,600&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 68&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ZAR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ZAR 122&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 275&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






























&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table gives details in respect of the notional amount of outstanding foreign exchange derivative contracts as of March&#160;31,&#160;2021.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr&gt;
			&lt;td style="width: 27%; vertical-align: bottom; border-bottom: 1pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Category&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-top: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 15%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Instrument&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-top: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Currency&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-top: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cross Currency&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-top: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 13%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amounts&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: center; vertical-align: top; padding-bottom: 0.5pt; border-top: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 14%; text-align: center; vertical-align: bottom; border-bottom: 1pt solid black; border-top: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Buy/Sell&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hedges of recognized assets and liabilities&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD 7&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CHF&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CHF 200&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP 8&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB 2,799&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 353&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;MXN&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 10&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;UAH&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 14&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ZAR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ZAR 111&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 2&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RON&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 12&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 3&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP 48&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GBP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR 1&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EUR 16&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CHF&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CHF200&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KZT&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 4&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CLP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 3&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COP&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 4&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;BRL&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 4&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;KZT&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 9&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Buy&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Hedges of highly probable forecast transactions&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;AUD 10&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: bottom;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RUB 6,850&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Option contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.$ 645&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell - Risk Reversal&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forward contract&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ZAR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;INR&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ZAR 148&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: center; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sell&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; vertical-align: bottom;"&gt;&#x201c;INR&#x201d; means Indian rupees, &#x201c;U.S.$&#x201d; means United States dollars, &#x201c;RON&#x201d; means Romanian new leus, &#x201c;GBP&#x201d; means U.K. pounds sterling, &#x201c;AUD&#x201d; means Australian dollars, &#x201c;CHF&#x201d; means Swiss francs, &#x201c;ZAR&#x201d; means South African rands, &#x201c;EUR&#x201d; means Euros, &#x201c;BRL&#x201d; means Brazilian reals, &#x201c;CLP&#x201d; means Chilean pesos, &#x201c;COP&#x201d; means Colombian pesos, &#x201c;KZT&#x201d; means Kazakhstan tenges, &#x201c;MXN&#x201d; means Mexican pesos, &#x201c;UAH&#x201d; means Ukrainian hryvnias, &#x201c;RUB&#x201d; means Russian roubles and &#x201c;THB&#x201d; means Thai bahts.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






























</rdy:DisclosureOfNotionalAmountOfOutstandingForeignExchangeDerivativeContractsTableTextBlock>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractOneMemberifrsfullHedgingInstrumentsAxis_ForwardContractAudInrSellsMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_AUD">10000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractTwoMemberifrsfullHedgingInstrumentsAxis_ForwardContractGbpinrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">9000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractThreeMemberifrsfullHedgingInstrumentsAxis_ForwardContractRubInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_RUB">7171000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractFourMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">720000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractFiveMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsMxnBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">21000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractSixMemberifrsfullHedgingInstrumentsAxis_ForwardContractZarInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_ZAR">31000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractSevenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsRubBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractEightMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsRonBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">12000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractNineMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsAudBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">4000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractTenMemberifrsfullHedgingInstrumentsAxis_ForwardContractGbpUsBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">48000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractElevenMemberifrsfullHedgingInstrumentsAxis_ForwardContractEurUsBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_EUR">47000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractTwelveMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsKztBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">9000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractThirteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsClpBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractFourteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsCopBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">7000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractFifteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsBrlBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractSixteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractEurInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_EUR">2000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractSeventeenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsThbBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractEighteenMemberifrsfullHedgingInstrumentsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis_OptionContractUsInrSellMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_USD">60000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractNineteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractAudInrSellsMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_AUD">4000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractTwentyMemberifrsfullHedgingInstrumentsAxis_ForwardContractRubInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_RUB">9600000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractTwentyOneMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">68000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractTwentyTwoMemberifrsfullHedgingInstrumentsAxis_ForwardContractZarInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_ZAR">122000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2022_ContractTwentyThreeMemberifrsfullHedgingInstrumentsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis_OptionContractUsInrSellMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_USD">275000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractOneMemberifrsfullHedgingInstrumentsAxis_ForwardContractAudInrSellsMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_AUD">7000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractTwoMemberifrsfullHedgingInstrumentsAxis_ForwardContractChfInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_CHF">200000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractThreeMemberifrsfullHedgingInstrumentsAxis_ForwardContractGbpinrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">8000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractFourMemberifrsfullHedgingInstrumentsAxis_ForwardContractRubInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_RUB">2799000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractFiveMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">353000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractSixMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsMxnBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">10000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractSevenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsUahBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">14000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractEightMemberifrsfullHedgingInstrumentsAxis_ForwardContractZarInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_ZAR">111000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractNineMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsRubBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">2000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractTenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsRonBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">12000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractElevenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsAudBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractTwelveMemberifrsfullHedgingInstrumentsAxis_ForwardContractGbpUsBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_GBP">48000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractThirteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractEurGbpSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_EUR">1000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractFourteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractEurUsBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">16000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractFifteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractChfUsBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_CHF">200000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractSixteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsKztBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">4000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractSeventeenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsClpBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">3000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractEighteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsCopBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">4000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractNineteenMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsBrlBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">4000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractTwentyMemberifrsfullHedgingInstrumentsAxis_ForwardContractUsKztBuyMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfRecognisedAssetsAndLiabilitiesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_USD">9000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractTwentyOneMemberifrsfullHedgingInstrumentsAxis_ForwardContractAudInrSellsMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_AUD">10000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractTwentyTwoMemberifrsfullHedgingInstrumentsAxis_ForwardContractRubInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_RUB">6850000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractTwentyThreeMemberifrsfullHedgingInstrumentsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis_OptionContractUsInrSellRiskReversalMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_USD">645000000</ifrs-full:NotionalAmount>
    <ifrs-full:NotionalAmount
      contextRef="PAsOn03_31_2021_ContractTwentyFourMemberifrsfullHedgingInstrumentsAxis_ForwardContractZarInrSellMemberifrsfullClassesOfFinancialAssetsAxis_HedgesOfHighlyProbableForecastedTransactionsMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_ZAR">148000000</ifrs-full:NotionalAmount>
    <rdy:DisclosureOfDetailedInformationAboutHighlyProbableForecastTransactionsHedgedItemsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The table below summarizes the periods when the cash flows associated with highly probable forecast transactions that are classified as cash flow hedges are expected to occur:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flows in U.S dollars&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Not later than one month&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;2,653&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;3,656&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Later than one month and not later than three months&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;5,305&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,311&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Later than three months and not later than six months&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,139&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;12,063&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Later than six months and not later than one year&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;11,824&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;24,126&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;25,921&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;47,156&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flows in Russian roubles&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Not later than one month&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;460&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;437&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Later than one month and not later than three months&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,513&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;874&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Later than three months and not later than six months&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,528&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,748&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Later than six months and not later than one year&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3,331&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3,593&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8,832&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6,651&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flows in Australian dollars&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Not later than one month&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;10&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;46&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Later than one month and not later than three months&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;60&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;92&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Later than three months and not later than six months&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;48&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;139&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Later than six months and not later than one year&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;134&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;277&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;252&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;555&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash flows in South African rands&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Not later than one month&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;41&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;61&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Later than one month and not later than three months&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;98&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;121&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Later than three months and not later than six months&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;146&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;182&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Later than six months and not later than one year&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;350&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;364&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;635&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;728&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





























</rdy:DisclosureOfDetailedInformationAboutHighlyProbableForecastTransactionsHedgedItemsTableTextBlock>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_NotLaterThanOneMonthMemberifrsfullMaturityAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">2653000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_NotLaterThanOneMonthMemberifrsfullMaturityAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">3656000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_LaterThanOneMonthAndNotLaterThanThreeMonthsMemberifrsfullMaturityAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">5305000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_LaterThanOneMonthAndNotLaterThanThreeMonthsMemberifrsfullMaturityAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">7311000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrsfullMaturityAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">6139000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrsfullMaturityAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">12063000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_LaterThanSixMonthsAndNotLaterThanOneYearMemberifrsfullMaturityAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">11824000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_LaterThanSixMonthsAndNotLaterThanOneYearMemberifrsfullMaturityAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">24126000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">25921000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">47156000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_NotLaterThanOneMonthMemberifrsfullMaturityAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">460000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_NotLaterThanOneMonthMemberifrsfullMaturityAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">437000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_LaterThanOneMonthAndNotLaterThanThreeMonthsMemberifrsfullMaturityAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">1513000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_LaterThanOneMonthAndNotLaterThanThreeMonthsMemberifrsfullMaturityAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">874000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrsfullMaturityAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">3528000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrsfullMaturityAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">1748000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_LaterThanSixMonthsAndNotLaterThanOneYearMemberifrsfullMaturityAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">3331000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_LaterThanSixMonthsAndNotLaterThanOneYearMemberifrsfullMaturityAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">3593000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">8832000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">6651000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_AustralianDollarsMemberRDYTypeOfCurrencyAxis_NotLaterThanOneMonthMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">10000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_AustralianDollarsMemberRDYTypeOfCurrencyAxis_NotLaterThanOneMonthMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">46000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_AustralianDollarsMemberRDYTypeOfCurrencyAxis_LaterThanOneMonthAndNotLaterThanThreeMonthsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">60000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_AustralianDollarsMemberRDYTypeOfCurrencyAxis_LaterThanOneMonthAndNotLaterThanThreeMonthsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">92000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_AustralianDollarsMemberRDYTypeOfCurrencyAxis_LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">48000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_AustralianDollarsMemberRDYTypeOfCurrencyAxis_LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">139000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_AustralianDollarsMemberRDYTypeOfCurrencyAxis_LaterThanSixMonthsAndNotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">134000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_AustralianDollarsMemberRDYTypeOfCurrencyAxis_LaterThanSixMonthsAndNotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">277000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_AustralianDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">252000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_AustralianDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">555000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_NotLaterThanOneMonthMemberifrsfullMaturityAxis_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">41000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_NotLaterThanOneMonthMemberifrsfullMaturityAxis_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">61000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_LaterThanOneMonthAndNotLaterThanThreeMonthsMemberifrsfullMaturityAxis_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">98000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_LaterThanOneMonthAndNotLaterThanThreeMonthsMemberifrsfullMaturityAxis_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">121000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrsfullMaturityAxis_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">146000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_LaterThanThreeMonthsAndNotLaterThanSixMonthsMemberifrsfullMaturityAxis_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">182000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_LaterThanSixMonthsAndNotLaterThanOneYearMemberifrsfullMaturityAxis_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">350000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_LaterThanSixMonthsAndNotLaterThanOneYearMemberifrsfullMaturityAxis_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">364000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2021To03_31_2022_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">635000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <rdy:PeriodsWhenCashFlowsExpectedToOccur
      contextRef="P04_01_2020To03_31_2021_SouthAfricanRandsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">728000000</rdy:PeriodsWhenCashFlowsExpectedToOccur>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges
      contextRef="P04_01_2020To03_31_2021_InterestRateSwapContractMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges
      contextRef="P04_01_2019To03_31_2020_InterestRateSwapContractMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges
      contextRef="P04_01_2021To03_31_2022_InterestRateSwapContractMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxCashFlowHedges>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2021To03_31_2022_InterestRateSwapContractMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">32000000</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2020To03_31_2021_InterestRateSwapContractMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">164000000</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax
      contextRef="P04_01_2019To03_31_2020_InterestRateSwapContractMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">33000000</ifrs-full:GainsLossesOnCashFlowHedgesNetOfTax>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn03_31_2022_InterestRateSwapContractMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="0"
      unitRef="Unit_INRPerUSD">0</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:NominalAmountOfHedgingInstrument
      contextRef="PAsOn03_31_2021_InterestRateSwapContractMemberifrsfullClassesOfFinancialAssetsAxis"
      decimals="0"
      unitRef="Unit_INRPerUSD">7240</ifrs-full:NominalAmountOfHedgingInstrument>
    <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1&lt;/div&gt;. Financial risk management&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s activities expose it to a variety of financial risks, including market risk, credit risk and liquidity risk. The Company&#x2019;s primary risk management focus is to minimize potential adverse effects of market risk on its financial performance. The Company&#x2019;s risk management assessment and policies and processes are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor such risks and compliance with the same. Risk assessment and management policies and processes are reviewed regularly to reflect changes in market conditions and the Company&#x2019;s activities. The Board of Directors and the Audit Committee is responsible for overseeing the Company&#x2019;s risk assessment and management policies and processes.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 9pt; text-align: justify; text-indent: -9pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;a. Market risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Market risk is the risk of loss of future earnings, fair values or future cash flows that may result from adverse changes in market rates and prices (such as interest rates, foreign currency exchange rates and commodity prices) or in the price of market risk-sensitive instruments as a result of such adverse changes in market rates and prices. Market risk is attributable to all market risk-sensitive financial instruments, all foreign currency receivables and payables and all short-term and long-term debt. The Company is exposed to market risk primarily related to foreign exchange rate risk, interest rate risk and the market value of its investments. Thus, the Company&#x2019;s exposure to market risk is a function of investing and borrowing activities and revenue generating and operating activities in foreign currencies.&lt;/div&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Foreign exchange risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;The Company is exposed to exchange rate risk which arises from its foreign exchange revenues and expenses, primarily in U.S. dollars, U.K. pounds sterling, Russian roubles, Brazilian reals, Swiss francs, South African rands, Kazakhstan tenges, Romanian new leus, Australian dollars and Euros, and foreign currency debt in U.S. dollars, Russian roubles, Mexican pesos, Ukrainian hryvnias, Thai bahts, Chilean pesos, Colombian pesos and Brazilian reals. A significant portion of the Company&#x2019;s revenues are in these foreign currencies, while a significant portion of its costs are in Indian rupees. As a result, if the value of the Indian rupee appreciates relative to these foreign currencies, the Company&#x2019;s revenues measured in Indian rupees may decrease. The exchange rate between the Indian rupee and these foreign currencies has changed substantially in recent periods and may continue to fluctuate substantially in the future. Consequently, the Company uses both derivative and non-derivative financial instruments, such as foreign exchange forward contracts, option contracts, currency swap contracts and foreign currency financial liabilities, to mitigate the risk of changes in foreign currency exchange rates in respect of its highly probable forecast transactions and recognized assets and liabilities.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The details in respect of the outstanding foreign exchange forward and option contracts are given in Note 3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0&lt;/div&gt;&#160;to these consolidated financial statements.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In respect of the Company&#x2019;s forward and option contracts, a 10% decrease/increase in the respective exchange rates of each of the currencies underlying such contracts would have resulted in:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 9pt; text-align: justify; text-indent: -9pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;a Rs.3,169/(2,937) increase/(decrease) in the Company&#x2019;s hedging reserve and a Rs.5,378/(5,375) increase/(decrease) in the Company&#x2019;s profit from such contracts, as of March 31, 2022;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.45in; text-align: justify; text-indent: -0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;a Rs.4,824/(4,195) increase/(decrease) in the Company&#x2019;s hedging reserve and a Rs.2,658/(2,658) increase/(decrease) in the Company&#x2019;s profit from such contracts, as of March 31, 2021; and&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 0.45in; text-indent: -0.2in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0.25in;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;a Rs.1,203/(1,740) increase/(decrease) in the Company&#x2019;s hedging reserve and a Rs.2,070/(1,745) increase/(decrease) in the Company&#x2019;s profit from such contracts, as of March 31, 2020.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 4.5pt; text-align: justify; text-indent: -4.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table analyzes foreign currency risk from non-derivative financial instruments as of March 31, 2022:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;U.S. dollars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Euro&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Russian roubles&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;div style="text-decoration:underline;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 25%; text-align: left;"&gt;Cash and cash equivalents&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;11,468&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;205&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;80&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;87&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;11,840&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other investments&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;26&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;26&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other receivables&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;44,443&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;382&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;945&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;144&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;45,914&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Other assets&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;125&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;19&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;17&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;164&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;56,062&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;606&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,028&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;248&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;57,944&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other payables&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,742&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,019&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;455&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;284&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;9500&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Long-term borrowings&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,885&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;29&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;16&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;52&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,982&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Other liabilities and provisions&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;6,258&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;146&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;123&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;413&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;6,940&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,885&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,194&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;594&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;749&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18,422&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; text-align: justify; text-indent: -4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table analyzes foreign currency risk from non-derivative financial instruments as of March 31, 2021:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; text-align: justify; text-indent: -4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;U.S. dollars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Euro&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Russian roubles&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;div style="text-decoration:underline;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 25%; text-align: left;"&gt;Cash and cash equivalents&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;12,643&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;129&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;30&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;92&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;12,894&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Other investments&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other receivables&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;30,247&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;841&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;721&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;101&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;31,910&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Other assets&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;184&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;20&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;16&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;223&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;43,098&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;990&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;754&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;209&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;45,051&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other payables&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,207&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,270&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;*&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;210&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;5,687&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Long-term borrowings&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,216&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;52&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;18&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;43&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,329&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Short-term borrowings&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,657&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,717&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,374&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Other liabilities and provisions&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;4,665&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;65&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;81&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;292&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5,103&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,745&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,387&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,816&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;545&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20,493&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; text-align: justify; text-indent: -4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;* Rounded to the nearest million.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Others primarily consists of U.K. pounds sterling, Swiss francs, Romanian new leus, Chinese yuans (Renminbi), Canadian dollars and Ukrainian hryvnia.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the years ended March 31, 2022 and 2021, every 10% depreciation/appreciation in the exchange rate between the Indian rupee and the respective currencies for the above mentioned financial assets/liabilities would affect the Company&#x2019;s net profit by Rs.3,952 and Rs.2,456, respectively.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Interest rate risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March 31, 2022, &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the Company&lt;/div&gt; had loans with floating interest rates as follows: Rs.4,000 of loans carrying a floating interest rate of the 3 Months India Treasury Bill less 5 bps; Rs.13,800 of loans carrying a floating interest rate of the 3 Months India Treasury Bill; Rs.411 of loans carrying a floating interest rate of the 3 Months India Treasury Bill plus 25 bps; Rs. 1,137 of loans carrying a floating interest rate of 1 Month LIBOR + 80bps; Rs.800 of loans carrying a floating interest rate of CDI+1.79%&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;;&lt;/div&gt; and Rs.2,017 of loans carrying a floating interest rate of TIIE+1.15%.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March 31, 2021, the Company had loans with floating interest rates as follows: Rs.8,800 of loans carrying a floating interest rate of the 3 Months India Treasury Bill plus 30 bps and Rs.1,896 of loans carrying a floating interest rate of TIIE+1.20%.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For details of the Company&#x2019;s short-term and long-term loans and borrowings, including interest rate profiles, refer to Note 17 of these consolidated financial statements.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the years ended March 31, 2022, 2021 and 2020, every 10% increase or decrease in the floating interest rate component (i.e., Indian Treasury Bill, LIBOR, CDI, and TIIE) applicable to its loans and borrowings would affect the Company&#x2019;s net profit by Rs.89, Rs.37 and Rs.41, respectively.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying value of the Company&#x2019;s borrowings, interest component of which was designated in a cash flow hedge, was Rs.Nil as of March&#160;31,&#160;2022 and 2021.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s investments in term deposits (i.e., certificates of deposit) with banks and short-term liquid mutual funds are for short durations, and therefore do not expose the Company to significant interest rates risk.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note that &#x201c;CDI&#x201d; means Brazilian interbank deposit rate (Certificado de Dep&#xf3;sito Interbanc&#xe1;rio), &#x201c;TIIE&#x201d; means the Equilibrium Inter-banking Interest Rate (Tasa de Inter&#xe9;s Interbancaria de Equilibrio), and &#x201c;LIBOR&#x201d; means the London Inter-bank Offered Rate.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Commodity rate risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exposure to market risk with respect to commodity prices primarily arises from the Company&#x2019;s purchases and sales of active pharmaceutical ingredients, including the raw material components for such active pharmaceutical ingredients. These are commodity products, whose prices may fluctuate significantly over short periods of time. The prices of the Company&#x2019;s raw materials generally fluctuate in line with commodity cycles, although the prices of raw materials used in the Company&#x2019;s active pharmaceutical ingredients business are generally more volatile. Cost of raw materials forms the largest portion of the Company&#x2019;s cost of revenues. Commodity price risk exposure is evaluated and managed through operating procedures and sourcing policies. As of March 31, 2022, the Company had not entered into any material derivative contracts to hedge exposure to fluctuations in commodity prices.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;b. Credit risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company&#x2019;s receivables from customers and investment securities. The Company establishes an allowance for doubtful debts and impairment that represents its estimate of expected losses in respect of trade and other receivables and investments.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Trade and other receivables&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s exposure to credit risk is influenced mainly by the individual characteristics of each customer. The demographics of the customer, including the default risk of the industry and country in which the customer operates, also has an influence on credit risk assessment. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Company grants credit terms in the normal course of business.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Investments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Company does not expect any losses from non-performance by these counter-parties, and does not have any significant concentration of exposures to specific industry sectors or specific country risks.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Details of financial assets &#x2013; not due, past due and impaired&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;None of the Company&#x2019;s cash equivalents, including term deposits (i.e., certificates of deposit) with banks, were past due or impaired as of March 31, 2022. The Company&#x2019;s credit period for trade and other receivables payable by its customers generally ranges from 20 - 180 days.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aging of trade and other receivables is given below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Neither past due nor impaired&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;51,505&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;41,350&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Past due but not impaired&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&#160;Less than 365 days&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15,501&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;8,598&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;More than 365 days&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,006&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,107&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;68,012&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;51,055&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Less : &lt;/div&gt;Allowance for credit losses&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,194&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,296&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;66,818&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;49,759&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;































&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 13.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;See Note 9 of these consolidated financial statements for the activity in the allowance for credit losses on trade and other receivables.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other than trade and other receivables, the Company has no significant class of financial assets that is past due but not impaired.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 9pt; text-align: justify; text-indent: -9pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;c. Liquidity risk&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risk to the Company&#x2019;s reputation.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March 31, 2022 and 2021, the Company had uncommitted lines of credit from banks of Rs.39,989 and Rs. 38,766, respectively.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March 31, 2022, the Company had working capital of Rs.87,841, including cash and cash equivalents of Rs.14,852, investments in term deposits with banks&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&#160;bonds &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;and commercial papers,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;of Rs.12,562 and investments in units of mutual funds of Rs.16,751.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March 31, 2021, the Company had working capital of Rs.66,626 (excluding assets held for sale of Rs.151), including cash and cash equivalents of Rs.14,829, investments in term deposits with banks and bonds of Rs.6,481 and investments in units of mutual funds of Rs.13,263.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The table below provides details regarding the contractual maturities of significant financial liabilities (other than long-term borrowings and obligations under leases, which have been disclosed in Note 17 to these consolidated financial statements) as of March&#160;31, 2022:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2025&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2026&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%; text-align: left;"&gt;Trade and other payables&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;25,572&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;25,572&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Bank overdraft, short-term borrowings&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;27,082&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;27,082&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Derivative financial instruments&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;479&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;479&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other liabilities and provisions&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;25,485&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;753&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;26,238&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The table below provides details regarding the contractual maturities of significant financial liabilities (other than long-term borrowings and obligations under leases, which have been disclosed in Note 17 to these consolidated financial statements) as of March&#160;31, 2021:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2025&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%; text-align: left;"&gt;Trade and other payables&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;23,744&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;23,744&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Bank overdraft, short-term borrowings&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;23,145&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;23,145&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Derivative financial instruments&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;326&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;326&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other liabilities and provisions&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;22,507&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;726&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;23,233&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
    <rdy:PercentageDecreaseIncreaseExchangeRatesOfEachOfCurrenciesUnderlyingDerivativeContractsUsedForSensitivityAnalysis
      contextRef="P04_01_2021To03_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.10</rdy:PercentageDecreaseIncreaseExchangeRatesOfEachOfCurrenciesUnderlyingDerivativeContractsUsedForSensitivityAnalysis>
    <rdy:IncreaseInHedgingReserveSensitivityAnalysis
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">3169000000</rdy:IncreaseInHedgingReserveSensitivityAnalysis>
    <rdy:DecreaseInHedgingReserveSensitivityAnalysis
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">2937000000</rdy:DecreaseInHedgingReserveSensitivityAnalysis>
    <rdy:IncreaseInProfitFromContractsSensitivityAnalysis
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">5378000000</rdy:IncreaseInProfitFromContractsSensitivityAnalysis>
    <rdy:DecreaseInProfitFromContractsSensitivityAnalysis
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">5375000000</rdy:DecreaseInProfitFromContractsSensitivityAnalysis>
    <rdy:IncreaseInHedgingReserveSensitivityAnalysis
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">4824000000</rdy:IncreaseInHedgingReserveSensitivityAnalysis>
    <rdy:DecreaseInHedgingReserveSensitivityAnalysis
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">4195000000</rdy:DecreaseInHedgingReserveSensitivityAnalysis>
    <rdy:IncreaseInProfitFromContractsSensitivityAnalysis
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2658000000</rdy:IncreaseInProfitFromContractsSensitivityAnalysis>
    <rdy:DecreaseInProfitFromContractsSensitivityAnalysis
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2658000000</rdy:DecreaseInProfitFromContractsSensitivityAnalysis>
    <rdy:IncreaseInHedgingReserveSensitivityAnalysis
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">1203000000</rdy:IncreaseInHedgingReserveSensitivityAnalysis>
    <rdy:DecreaseInHedgingReserveSensitivityAnalysis
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">1740000000</rdy:DecreaseInHedgingReserveSensitivityAnalysis>
    <rdy:IncreaseInProfitFromContractsSensitivityAnalysis
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">2070000000</rdy:IncreaseInProfitFromContractsSensitivityAnalysis>
    <rdy:DecreaseInProfitFromContractsSensitivityAnalysis
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">1745000000</rdy:DecreaseInProfitFromContractsSensitivityAnalysis>
    <rdy:DisclosureOfForeignCurrencyRiskFromNonderivativeFinancialInstrumentsTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table analyzes foreign currency risk from non-derivative financial instruments as of March 31, 2022:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;U.S. dollars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Euro&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Russian roubles&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;div style="text-decoration:underline;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 25%; text-align: left;"&gt;Cash and cash equivalents&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;11,468&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;205&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;80&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;87&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;11,840&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other investments&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;26&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;26&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other receivables&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;44,443&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;382&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;945&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;144&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;45,914&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Other assets&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;125&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;19&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;17&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;164&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;56,062&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;606&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,028&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;248&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;57,944&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other payables&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;6,742&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,019&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;455&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;284&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;9500&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Long-term borrowings&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,885&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;29&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;16&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;52&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,982&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Other liabilities and provisions&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;6,258&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;146&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;123&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;413&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;6,940&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; font-weight: normal; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,885&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,194&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;594&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;749&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;18,422&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; text-align: justify; text-indent: -4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table analyzes foreign currency risk from non-derivative financial instruments as of March 31, 2021:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; text-align: justify; text-indent: -4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;U.S. dollars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Euro&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Russian roubles&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;div style="text-decoration:underline;display:inline;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="width: 25%; text-align: left;"&gt;Cash and cash equivalents&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;12,643&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;129&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;Rs.&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;30&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;92&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;12,894&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Other investments&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;24&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other receivables&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;30,247&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;841&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;721&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;101&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;31,910&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Other assets&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;184&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;20&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;3&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;16&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;223&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;43,098&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;990&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;754&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;209&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;45,051&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Trade and other payables&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;4,207&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;1,270&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;*&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;210&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;5,687&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Long-term borrowings&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,216&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;52&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;18&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;43&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;2,329&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Short-term borrowings&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,657&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;3,717&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;7,374&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;Other liabilities and provisions&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;4,665&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;65&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;81&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;292&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;5,103&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14,745&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,387&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3,816&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;545&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;20,493&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9pt; text-align: justify; text-indent: -4.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;* Rounded to the nearest million.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;</rdy:DisclosureOfForeignCurrencyRiskFromNonderivativeFinancialInstrumentsTableTextBlock>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">11468000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2022_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">205000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">80000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">87000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2022_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">11840000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">26000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">26000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">44443000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2022_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">382000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">945000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">144000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2022_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">45914000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:OtherAssets
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">125000000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="PAsOn03_31_2022_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">19000000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">3000000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">17000000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="PAsOn03_31_2022_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">164000000</ifrs-full:OtherAssets>
    <ifrs-full:Assets
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">56062000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn03_31_2022_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">606000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">1028000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">248000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn03_31_2022_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">57944000000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">6742000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2022_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2019000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">455000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">284000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2022_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">9500000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">1885000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn03_31_2022_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">29000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">16000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">52000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn03_31_2022_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">1982000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">6258000000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2022_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">146000000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">123000000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">413000000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2022_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">6940000000</ifrs-full:OtherLiabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">14885000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn03_31_2022_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2194000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">594000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn03_31_2022_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">749000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn03_31_2022_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">18422000000</ifrs-full:Liabilities>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">12643000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2021_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">129000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">30000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">92000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2021_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">12894000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">24000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">24000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">30247000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2021_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">841000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">721000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">101000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2021_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">31910000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:OtherAssets
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">184000000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="PAsOn03_31_2021_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">20000000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">3000000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">16000000</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets
      contextRef="PAsOn03_31_2021_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">223000000</ifrs-full:OtherAssets>
    <ifrs-full:Assets
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">43098000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn03_31_2021_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">990000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">754000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">209000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="PAsOn03_31_2021_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">45051000000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">4207000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2021_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">1270000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">210000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="PAsOn03_31_2021_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">5687000000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">2216000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn03_31_2021_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">52000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">18000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">43000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="PAsOn03_31_2021_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">2329000000</ifrs-full:LongtermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">3657000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2021_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">3717000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="PAsOn03_31_2021_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">7374000000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">4665000000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2021_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">65000000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">81000000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">292000000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2021_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">5103000000</ifrs-full:OtherLiabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_UsDollarsMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">14745000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn03_31_2021_EurosMemberRDYTypeOfCurrencyAxis_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">1387000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_RussianRoublesMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">3816000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn03_31_2021_NonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis_OtherCurrencyMemberRDYTypeOfCurrencyAxis"
      decimals="-6"
      unitRef="Unit_INR">545000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="PAsOn03_31_2021_ForeignCurrencyRiskFromNonderivativeFinancialInstrumentsMemberifrsfullClassesOfFinancialInstrumentsAxis"
      decimals="-6"
      unitRef="Unit_INR">20493000000</ifrs-full:Liabilities>
    <rdy:PercentageOfDepreciationOrAppreciationInExchangeRateUsedForSensitivityAnalysis
      contextRef="P04_01_2021To03_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.10</rdy:PercentageOfDepreciationOrAppreciationInExchangeRateUsedForSensitivityAnalysis>
    <rdy:PercentageOfDepreciationOrAppreciationInExchangeRateUsedForSensitivityAnalysis
      contextRef="P04_01_2020To03_31_2021"
      decimals="2"
      unitRef="Unit_pure">0.10</rdy:PercentageOfDepreciationOrAppreciationInExchangeRateUsedForSensitivityAnalysis>
    <rdy:ExpectedIncreaseOrDecreaseInNetProfitFromExchangeRate
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">3952000000</rdy:ExpectedIncreaseOrDecreaseInNetProfitFromExchangeRate>
    <rdy:ExpectedIncreaseOrDecreaseInNetProfitFromExchangeRate
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">2456000000</rdy:ExpectedIncreaseOrDecreaseInNetProfitFromExchangeRate>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanOneMemberRDYLoanAxis"
      decimals="-6"
      unitRef="Unit_INR">4000000000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRateBasis contextRef="P04_01_2021To03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanOneMemberRDYLoanAxis">3 Months India Treasury Bill less 5 bps</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanTwoMemberRDYLoanAxis"
      decimals="-6"
      unitRef="Unit_INR">13800000000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRateBasis contextRef="P04_01_2021To03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanTwoMemberRDYLoanAxis">3 Months India Treasury Bill</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanThreeMemberRDYLoanAxis"
      decimals="-6"
      unitRef="Unit_INR">411000000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRateBasis contextRef="P04_01_2021To03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanThreeMemberRDYLoanAxis">3 Months India Treasury Bill plus 25 bps</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanFourMemberRDYLoanAxis"
      decimals="-6"
      unitRef="Unit_INR">1137000000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRateBasis contextRef="P04_01_2021To03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanFourMemberRDYLoanAxis">1 Month LIBOR + 80bps</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanFiveMemberRDYLoanAxis"
      decimals="-6"
      unitRef="Unit_INR">800000000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRateBasis contextRef="P04_01_2021To03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanFiveMemberRDYLoanAxis">CDI+1.79%</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanSixMemberRDYLoanAxis"
      decimals="-6"
      unitRef="Unit_INR">2017000000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRateBasis contextRef="P04_01_2021To03_31_2022_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanSixMemberRDYLoanAxis">TIIE+1.15%</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanSevenMemberRDYLoanAxis"
      decimals="-6"
      unitRef="Unit_INR">8800000000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRateBasis contextRef="P04_01_2020To03_31_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanSevenMemberRDYLoanAxis">3 Months India Treasury Bill plus 30 bps</ifrs-full:BorrowingsInterestRateBasis>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanEightMemberRDYLoanAxis"
      decimals="-6"
      unitRef="Unit_INR">1896000000</ifrs-full:Borrowings>
    <ifrs-full:BorrowingsInterestRateBasis contextRef="P04_01_2020To03_31_2021_FloatingInterestRateMemberifrsfullTypesOfInterestRatesAxis_LoanEightMemberRDYLoanAxis">TIIE+1.20%</ifrs-full:BorrowingsInterestRateBasis>
    <rdy:PercentageOfIncreaseOrDecreaseInFloatingInterestRateUsedForSensitivityAnalysis
      contextRef="P04_01_2021To03_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.10</rdy:PercentageOfIncreaseOrDecreaseInFloatingInterestRateUsedForSensitivityAnalysis>
    <rdy:PercentageOfIncreaseOrDecreaseInFloatingInterestRateUsedForSensitivityAnalysis
      contextRef="P04_01_2020To03_31_2021"
      decimals="2"
      unitRef="Unit_pure">0.10</rdy:PercentageOfIncreaseOrDecreaseInFloatingInterestRateUsedForSensitivityAnalysis>
    <rdy:PercentageOfIncreaseOrDecreaseInFloatingInterestRateUsedForSensitivityAnalysis
      contextRef="P04_01_2019To03_31_2020"
      decimals="2"
      unitRef="Unit_pure">0.10</rdy:PercentageOfIncreaseOrDecreaseInFloatingInterestRateUsedForSensitivityAnalysis>
    <rdy:ExpectedIncreaseOrDecreaseInNetProfitFromFloatingInterestRate
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">89000000</rdy:ExpectedIncreaseOrDecreaseInNetProfitFromFloatingInterestRate>
    <rdy:ExpectedIncreaseOrDecreaseInNetProfitFromFloatingInterestRate
      contextRef="P04_01_2020To03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">37000000</rdy:ExpectedIncreaseOrDecreaseInNetProfitFromFloatingInterestRate>
    <rdy:ExpectedIncreaseOrDecreaseInNetProfitFromFloatingInterestRate
      contextRef="P04_01_2019To03_31_2020"
      decimals="-6"
      unitRef="Unit_INR">41000000</rdy:ExpectedIncreaseOrDecreaseInNetProfitFromFloatingInterestRate>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2022_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="PAsOn03_31_2021_CashFlowHedgesMemberifrsfullTypesOfHedgesAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:Borrowings>
    <rdy:AnalysisOfAgeOfTradeAndOtherReceivablesTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aging of trade and other receivables is given below:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="6" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31,&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 70%; text-align: left;"&gt;Neither past due nor impaired&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;51,505&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 12%; text-align: right;"&gt;41,350&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Past due but not impaired&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;&#160;Less than 365 days&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;15,501&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;8,598&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;More than 365 days&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,006&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;1,107&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;68,012&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;51,055&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt; font-style: normal;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Less : &lt;/div&gt;Allowance for credit losses&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,194&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;(1,296&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;66,818&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;49,759&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





























</rdy:AnalysisOfAgeOfTradeAndOtherReceivablesTableTextBlock>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2022_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis_NeitherPastDueNorImpairedMemberRDYImpairedAxis"
      decimals="-6"
      unitRef="Unit_INR">51505000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2021_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis_NeitherPastDueNorImpairedMemberRDYImpairedAxis"
      decimals="-6"
      unitRef="Unit_INR">41350000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2022_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">15501000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2021_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">8598000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2022_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis_LaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">1006000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2021_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis_LaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">1107000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2022_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">68012000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2021_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">51055000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets
      contextRef="PAsOn03_31_2022_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">1194000000</ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets
      contextRef="PAsOn03_31_2021_FinancialAssetsPastDueButNotImpairedMemberifrsfullImpairmentOfFinancialAssetsAxis"
      decimals="-6"
      unitRef="Unit_INR">1296000000</ifrs-full:AllowanceAccountForCreditLossesOfFinancialAssets>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">66818000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:TradeAndOtherReceivables
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">49759000000</ifrs-full:TradeAndOtherReceivables>
    <ifrs-full:UndrawnBorrowingFacilities
      contextRef="PAsOn03_31_2022_UnutilizedCreditLimitsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">39989000000</ifrs-full:UndrawnBorrowingFacilities>
    <ifrs-full:UndrawnBorrowingFacilities
      contextRef="PAsOn03_31_2021_UnutilizedCreditLimitsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">38766000000</ifrs-full:UndrawnBorrowingFacilities>
    <rdy:WorkingCapital
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">87841000000</rdy:WorkingCapital>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">14852000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2022_TermDepositsWithBanksAndBondsMemberRDYAssetCategoryAxis"
      decimals="-6"
      unitRef="Unit_INR">12562000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:FinancialAssetsAvailableforsale
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">16751000000</ifrs-full:FinancialAssetsAvailableforsale>
    <rdy:WorkingCapital
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">66626000000</rdy:WorkingCapital>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">151000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:CashAndCashEquivalents
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">14829000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="PAsOn03_31_2021_TermDepositsWithBanksAndBondsMemberRDYAssetCategoryAxis"
      decimals="-6"
      unitRef="Unit_INR">6481000000</ifrs-full:InvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:FinancialAssetsAvailableforsale
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">13263000000</ifrs-full:FinancialAssetsAvailableforsale>
    <rdy:MaturityAnalysisForFinancialLiabilitiesTableTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The table below provides details regarding the contractual maturities of significant financial liabilities (other than long-term borrowings and obligations under leases, which have been disclosed in Note 17 to these consolidated financial statements) as of March&#160;31, 2022:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2025&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2026&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%; text-align: left;"&gt;Trade and other payables&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;25,572&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;25,572&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Bank overdraft, short-term borrowings&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;27,082&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;27,082&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Derivative financial instruments&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;479&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;479&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other liabilities and provisions&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;25,485&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;753&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;26,238&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;






























































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The table below provides details regarding the contractual maturities of significant financial liabilities (other than long-term borrowings and obligations under leases, which have been disclosed in Note 17 to these consolidated financial statements) as of March&#160;31, 2021:&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Particulars&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2025&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
			&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/td&gt;
			&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="width: 34%; text-align: left;"&gt;Trade and other payables&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;23,744&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 8%; text-align: right;"&gt;23,744&lt;/td&gt;
			&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Bank overdraft, short-term borrowings&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;23,145&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;23,145&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="text-align: left;"&gt;Derivative financial instruments&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;326&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;326&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
			&lt;td style="text-align: left;"&gt;Other liabilities and provisions&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;22,507&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;726&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
			&lt;td style="text-align: right;"&gt;23,233&lt;/td&gt;
			&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





















































</rdy:MaturityAnalysisForFinancialLiabilitiesTableTextBlock>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn03_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">25572000000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn03_31_2022_LaterThanOneYearButNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn03_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn03_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn03_31_2022_LaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">25572000000</ifrs-full:TradeAndOtherPayables>
    <rdy:BankOverdraftAndShortTermBorrowings
      contextRef="PAsOn03_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">27082000000</rdy:BankOverdraftAndShortTermBorrowings>
    <rdy:BankOverdraftAndShortTermBorrowings
      contextRef="PAsOn03_31_2022_LaterThanOneYearButNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:BankOverdraftAndShortTermBorrowings>
    <rdy:BankOverdraftAndShortTermBorrowings
      contextRef="PAsOn03_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:BankOverdraftAndShortTermBorrowings>
    <rdy:BankOverdraftAndShortTermBorrowings
      contextRef="PAsOn03_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:BankOverdraftAndShortTermBorrowings>
    <rdy:BankOverdraftAndShortTermBorrowings
      contextRef="PAsOn03_31_2022_LaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:BankOverdraftAndShortTermBorrowings>
    <rdy:BankOverdraftAndShortTermBorrowings
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">27082000000</rdy:BankOverdraftAndShortTermBorrowings>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">479000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2022_LaterThanOneYearButNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2022_LaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">479000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2022_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">25485000000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2022_LaterThanOneYearButNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2022_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2022_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2022_LaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">753000000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">26238000000</ifrs-full:OtherLiabilities>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn03_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">23744000000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn03_31_2021_LaterThanOneYearButNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn03_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn03_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn03_31_2021_LaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">23744000000</ifrs-full:TradeAndOtherPayables>
    <rdy:BankOverdraftAndShortTermBorrowings
      contextRef="PAsOn03_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">23145000000</rdy:BankOverdraftAndShortTermBorrowings>
    <rdy:BankOverdraftAndShortTermBorrowings
      contextRef="PAsOn03_31_2021_LaterThanOneYearButNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:BankOverdraftAndShortTermBorrowings>
    <rdy:BankOverdraftAndShortTermBorrowings
      contextRef="PAsOn03_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:BankOverdraftAndShortTermBorrowings>
    <rdy:BankOverdraftAndShortTermBorrowings
      contextRef="PAsOn03_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:BankOverdraftAndShortTermBorrowings>
    <rdy:BankOverdraftAndShortTermBorrowings
      contextRef="PAsOn03_31_2021_LaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</rdy:BankOverdraftAndShortTermBorrowings>
    <rdy:BankOverdraftAndShortTermBorrowings
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">23145000000</rdy:BankOverdraftAndShortTermBorrowings>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">326000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2021_LaterThanOneYearButNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2021_LaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">326000000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2021_NotLaterThanOneYearMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">22507000000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2021_LaterThanOneYearButNotLaterThanTwoYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2021_LaterThanTwoYearsAndNotLaterThanThreeYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2021_LaterThanThreeYearsAndNotLaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">0</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2021_LaterThanFourYearsMemberifrsfullMaturityAxis"
      decimals="-6"
      unitRef="Unit_INR">726000000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_INR">23233000000</ifrs-full:OtherLiabilities>
    <ifrs-full:DisclosureOfContingentLiabilitiesExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2&lt;/div&gt;. Contingencies&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is involved in disputes, lawsuits, claims, governmental and/or regulatory inspections, inquiries, investigations and proceedings&#160; (collectively, &#x201c;Legal Proceedings&#x201d;), including patent and commercial matters that arise from time to time in the ordinary course of business. Most of the claims involve complex issues. Often, these issues are subject to uncertainties and therefore the probability of a loss, if any, being sustained and an estimate of the amount of any loss is difficult to ascertain. Consequently, for a majority of these claims, it is not possible to make a reasonable estimate of the expected financial effect, if any, that will result from ultimate resolution of the proceedings. This is due to a number of factors, including: the stage of the proceedings (in many cases trial dates have not been set) and the overall length and extent of pre-trial discovery; the entitlement of the parties to an action to appeal a decision; clarity as to theories of liability; damages and governing law; uncertainties in timing of litigation; and the possible need for further legal proceedings to establish the appropriate amount of damages, if any. In these cases, the Company based on internal and external legal advices discloses information with respect to the nature and facts of the case. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company also believes that disclosure of the amount sought by plaintiffs, if that is known, would not be meaningful with respect to those legal proceedings. &lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Although there can be no assurance regarding the outcome of any of the Legal Proceedings referred to in this Note, the Company does not expect them to have a materially adverse effect on its financial position, as it believes that the likelihood of loss in excess of amounts accrued (if any) is not probable. However, if one or more of such Legal Proceedings were to result in judgments against the Company, such judgments could be material to its results of operations in a given period.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product and patent related matters&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Launch of product &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June 14, 2018, the U.S. FDA granted the Company final approval for buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, a therapeutic equivalent generic version of Suboxone&#xae; sublingual film. The U.S. FDA approval came after the conclusion of litigation in the U.S. District Court for the District of Delaware (the &#x201c;Delaware District Court&#x201d;), where the Delaware District Court held that patents covering Suboxone&#xae; sublingual film would not be infringed by the Company&#x2019;s commercial launch of its generic sublingual film product. In light of the favorable decision from the Delaware District Court, the Company launched its generic sublingual film product in the United States immediately following the U.S. FDA approval on June 14, 2018. On July 12, 2019, the U.S. Court of Appeals for the Federal Circuit (&#x201c;the Court of Appeals&#x201d;) affirmed the Delaware District Court&#x2019;s ruling that the Company&#x2019;s generic version of Suboxone&#xae; sublingual films did not infringe the two remaining patents at issue in the Delaware District Court&#x2019;s case (U.S. patent numbers 8,603,514 and 8,015,150).&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;After the Delaware District Court&#x2019;s decision, Indivior filed a second lawsuit against the Company alleging infringement of three additional U.S. patents (numbers 9,687,454, 9,855,221 and 9,931,305) in the U.S. District Court for the District of New Jersey (the &#x201c;New Jersey District Court&#x201d;), styled Indivior Inc. et al. v. Dr. Reddy&#x2019;s Laboratories S.A., Civil Action No. 2:17-cv-07111 (D.N.J.). Following the launch, on June 15, 2018, Indivior filed an emergency application for a temporary restraining order and preliminary injunction against the Company in the New Jersey District Court. Indivior&#x2019;s motion alleged that the Company&#x2019;s generic sublingual film product infringed one of three U.S. patents (number 9,931,305) at issue in the New Jersey District Court. Pending a hearing and decision on the injunction application, the New Jersey District Court initially issued a temporary restraining order against the Company with respect to further sales, offer for sales, and imports of its generic sublingual film product in the United States. Subsequently, on July 14, 2018, the New Jersey District Court granted a preliminary injunction in favor of Indivior. Under the order, Indivior was required to and did post a bond of U.S.$72 to pay the costs and damages sustained by the Company if it was found to be wrongfully enjoined. The Company immediately appealed the decision, and the Court of Appeals agreed to expedite the appeal.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On November 20, 2018, the Court of Appeals issued a decision vacating the preliminary injunction. The Court of Appeals denied Indivior&#x2019;s petition for rehearing on February 4, 2019.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Indivior subsequently filed two emergency motions in the Court of Appeals to stay issuance of the mandate and to keep the preliminary injunction in place, which the Court of Appeals denied. Indivior then petitioned the U.S. Supreme Court to stay issuance of the mandate.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Indivior&#x2019;s petition was denied by the Chief Justice of the U.S. Supreme Court on February 19, 2019, and the mandate was issued on the same day. The Company resumed sales of its generic sublingual film product after the mandate was issued.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February 19, 2019, the New Jersey District Court entered a stipulated order of dismissal of Indivior&#x2019;s claims under U.S. patent number 9,855,221. On November 5, 2019, the New Jersey District Court issued its claim construction decision construing certain terms in U.S. patent numbers 9,931,305 and 9,687,454. After such claim construction decision, on January 8, 2020, the New Jersey District Court entered a stipulated order that the Company&#x2019;s generic sublingual film product does not infringe the asserted claims in U.S. patent number 9,931,305. In the stipulated order, Indivior reserved the ability to appeal the New Jersey District Court&#x2019;s claim construction order. The Company filed a motion requesting that the New Jersey District Court enter partial final judgment in the Company&#x2019;s favor relating to the allegations of infringement of U.S. patent number 9,931,305, which the District Court denied without prejudice on August 24, 2020, pending resolution of Indivior&#x2019;s allegations relating to U.S. patent number 9,687,454.&lt;/div&gt;&lt;/div&gt;
&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Launch of product (continued)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On November 11, 2019, a Magistrate Judge in the District of New Jersey granted the Company leave to file a counterclaim against Indivior that alleges that Indivior engaged in anticompetitive conduct by making false or misleading statements to the New Jersey District Court during the preliminary injunction proceedings in violation of federal antitrust laws. Indivior appealed the Magistrate Judge&#x2019;s ruling to the District Court Judge and, on August 24, 2020, the District Court Judge denied Indivior&#x2019;s appeal. The District Court did grant Indivior&#x2019;s motion to bifurcate the patent claims and the antitrust claims into two separate trials. Fact discovery closed on January 29, 2021&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;and&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;e&lt;/div&gt;xpert discovery closed on September 24, 2021. Indivior filed a motion for summary judgment that it is immune from antitrust liability under the Noerr-Pennington doctrine and that the Company is not entitled to seek damages in excess of the injunction bond. The Company filed a motion for summary judgment that Indivior&#x2019;s remaining claims for patent infringement are barred by the doctrines of issue preclusion, claim preclusion, and prosecution laches and that Indivior&#x2019;s damages claim should be limited to a reasonable royalty. Summary judgment briefing closed on January 12, 2022. No trial date ha&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt;&#160;been set.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition to the District Court proceeding, on November 13, 2018, the Company filed two petitions for inter-partes review challenging the validity of certain claims of U.S. patent number 9,687,454 before the Patent Trial and Appeal Board (&#x201c;PTAB&#x201d;). On June 13, 2019, the PTAB agreed to institute inter-partes review on one of the two petitions filed by the Company. The PTAB heard oral argument in the pending inter-partes review challenge on March 3, 2020.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June 2, 2020, the PTAB issued a final written decision in the Company&#x2019;s favor finding that the Company had demonstrated that claims 1&#x2013;5, 7, and 9&#x2013;14 of U.S. Patent No. 9,687,454 (&#x201c;the &#x2019;454 patent&#x201d;) were unpatentable. The PTAB upheld the validity of only one of the challenged claims, claim 8. Additionally, claim 6 was not at issue in the inter-partes review and therefore not subject to the final written decision. Claims 6 and 8 remain asserted against the Company in the New Jersey District Court litigation. Indivior filed a timely notice of appeal of the PTAB&#x2019;s Final Written Decision (&#x201c; FWD&#x201d;) for claims 1-5, 7, and 9-14, and the Company cross appealed the PTAB&#x2019;s FWD on claim 8&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt; On November 24, 2021, a panel of the Federal Circuit issued a decision affirming the PTAB&#x2019;s decision in all respects. On January 26, 2022, Indivior filed a petition with the Federal Circuit seeking rehearing of the panel&#x2019;s decision. On March 16, 2022, the Federal Circuit denied Indivior&#x2019;s petition for rehearing&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and&lt;/div&gt;&#160;the mandate&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;was&lt;/div&gt; issued on March 23, 2022. As a result of the Federal Circuit&#x2019;s decision, the only remaining valid claims of the &#x2019;454 patent to be litigated before the district court &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;were&lt;/div&gt;&#160;claims 6 and 8.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; text-indent: 0px; line-height: 10pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif;;display:inline;"&gt;On June 23, 2022, the Company entered into a settlement agreement with Indivior Inc. and Indivior UK Limited, and Aquestive Therapeutics, Inc.&#160; Pursuant to the agreement, the parties will file a stipulation of dismissal with prejudice in the underlying litigation.&#160; Under this settlement, the Company will receive payments totalling U.S.$72 by March 31, 2024.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;The agreement resolves all claims between the parties relating to the Company&#x2019;s generic buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, including Indivior&#x2019;s and Aquestive&#x2019;s patent infringement allegations and the Company&#x2019;s antitrust counterclaims.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; text-indent: 0.25in; line-height: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt; font-family: 'Times New Roman', Times, serif;;font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 17.85pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt;

&lt;div style="font-size: 10pt; margin: 0in -7.6pt 6pt 0in; text-align: justify; text-indent: 0in; font-family: &amp;quot;Univers 45 Light&amp;quot;, serif; color: black; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Matters relating to National Pharmaceutical Pricing Authority&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Norfloxacin, India litigation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company manufactures and distributes Norfloxacin, a formulations product, and in limited quantities, the active pharmaceutical ingredient norfloxacin. Under the Drugs (Prices Control) Order (the &#x201c;DPCO&#x201d;), the National Pharmaceutical Pricing Authority (the &#x201c;NPPA&#x201d;) established by the Government of India had the authority to designate a pharmaceutical product as a &#x201c;specified product&#x201d; and fix the maximum selling price for such product. In 1995, the NPPA issued a notification and designated Norfloxacin as a &#x201c;specified product&#x201d; and fixed the maximum selling price. In 1996, the Company filed a statutory Form III before the NPPA for the upward revision of the maximum selling price and a writ petition in the Andhra Pradesh High Court (the &#x201c;High Court&#x201d;) challenging the validity of the designation on the grounds that the applicable rules of the DPCO were not complied with while fixing the maximum selling price. The High Court had previously granted an interim order in favor of the Company; however it subsequently dismissed the case in April 2004.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company filed a review petition in the High Court in April 2004 which was also dismissed by the High Court in October 2004. Subsequently, the Company appealed to the Supreme Court of India, New Delhi (the &#x201c;Supreme Court&#x201d;) by filing a Special Leave Petition.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2006, the Company received a notice from the NPPA demanding the recovery of the price charged by the Company for sales of Norfloxacin in excess of the maximum selling price fixed by the NPPA, which was Rs.285 including interest.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company filed a writ petition in the High Court challenging this demand order. The High Court admitted the writ petition and granted an interim order, directing the Company to deposit 50% of the principal amount claimed by the NPPA, which was Rs.77. The Company deposited this amount with the NPPA in November 2005. In February&#160;2008, the High Court directed the Company to deposit an additional amount of Rs.30, which was deposited by the Company in March 2008. In November 2010, the High Court allowed the Company&#x2019;s application to include additional legal grounds that the Company believed strengthened its defense against the demand.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For example, the Company added as grounds that trade margins should not be included in the computation of amounts overcharged, and that it was necessary for the NPPA to set the active pharmaceutical ingredient price before the process of determining the ceiling on the formulation price. In October 2013, the Company filed an additional writ petition before the Supreme Court challenging the inclusion of Norfloxacin as a &#x201c;specified product&#x201d; under the DPCO. In January 2015, the NPPA filed a counter affidavit stating that the inclusion of Norfloxacin was based upon the recommendation of a committee consisting of experts in the field. On July&#160;20,&#160;2016, the Supreme Court remanded the matters concerning the inclusion of Norfloxacin as a &#x201c;specified product&#x201d; under the DPCO back to the High Court for further proceedings. During the three months ended September 30, 2016, the Supreme Court dismissed the Special Leave Petition pertaining to the fixing of prices for Norfloxacin formulations.&lt;/div&gt;&lt;/div&gt;

&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: Calibri, sans-serif; text-indent: 0px; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;Norfloxacin, India litigation&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt; (continued)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: Calibri, sans-serif; font-size: 10pt; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font-size: 10pt; margin: 0in -7.6pt 0.0001pt 0in; text-align: justify; text-indent: 0.26in; font-family: &amp;quot;Univers 45 Light&amp;quot;, serif; color: black;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="color: black; letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;During the three months ended December 31, 2016, a writ petition pertaining to Norfloxacin was filed by the Company with the Delhi High Court. &lt;/div&gt;In addition, the Company have filed writ petitions challenging the inclusion and designation of Theophylline/Doxofylline, Cloxacillin and Ciprofloxacin as &#x201c;specified product&#x201d; as per DPCO 1995&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt; and the related Demand Notices issued thereunder. The matters are tagged along with the Norfloxacin matter and have been adjourned to January 20, 2023&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt; for hearing.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font-size:10pt; margin:0in -7.6pt 0.0001pt 0in; text-align:justify; text-indent:0in; line-height:normal; font-family:'Univers 45 Light', serif; color:black"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font-size: 10pt; margin: 0in -7.6pt 0.0001pt 0in; text-align: justify; text-indent: 0.26in; font-family: &amp;quot;Univers 45 Light&amp;quot;, serif; color: black; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;Based on its best estimate, the Company has recorded a provision for potential liability for sale proceeds in excess of the notified selling prices, including the interest thereon, and believes that the likelihood of any further liability that may arise on account of penalties pursuant to this litigation is not probable.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Litigation relating to Cardiovascular and Anti-diabetic formulations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2014, the NPPA, pursuant to the guidelines issued in May 2014 and the powers granted by the Government of India under the Drugs (Price Control) Order, 2013, issued certain notifications regulating the prices for 108 formulations in the cardiovascular and antidiabetic therapeutic areas. The Indian Pharmaceutical Alliance (&#x201c;IPA&#x201d;), in which the Company is a member, filed a writ petition in the Bombay High Court challenging the notifications issued by the NPPA on the grounds that they were ultra vires, ex facie and ab initio void.&#160;The Bombay High Court issued an order to stay the writ in July 2014. On September 26, 2016, the Bombay High Court dismissed the writ petition filed by the IPA and upheld the validity of the notifications/orders passed by the NPPA in July 2014.&#160;Further, on October&#160;25,&#160;2016, the IPA filed a Special Leave Petition with the Supreme Court, which was dismissed by the Supreme Court.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the three months ended December 31, 2016, the NPPA issued show-cause notices relating to allegations that the Company exceeded the notified maximum prices for 11 of its products. The Company has responded to these notices.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March 20, 2017, the IPA filed an application before the Bombay High Court for the recall of the judgment of the Bombay High Court dated September 26, 2016. This recall application filed by the IPA was dismissed by the Bombay High Court on October 4, 2017. Further, on December 13, 2017, the IPA filed a Special Leave Petition with the Supreme Court for the recall of the judgment of the Bombay High Court dated October 4, 2017, which was dismissed by Supreme Court on January&#160;10, 2018.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the three months ended March 31, 2017, the NPPA issued notices to the Company demanding payments relating to the foregoing products for the allegedly overcharged amounts, along with interest. On July 13, 2017, in response to a writ petition which the Company had filed, the Delhi High Court set aside all the demand notices of the NPPA and directed the NPPA to provide a personal hearing to the Company and pass a speaking order. A personal hearing in this regard was held on July 21, 2017. On July 27, 2017, the NPPA passed a speaking order along with the demand notice directing the Company to pay an amount of Rs.776. On August 3, 2017, the Company filed a writ petition challenging the speaking order and the demand notice. Upon hearing the matter on August 8, 2017, the Delhi High Court stayed the operation of the demand order and directed the Company to deposit Rs.100 and furnish a bank guarantee for Rs.676. Pursuant to the order, the Company deposited Rs.100 on September 13, 2017 and submitted a bank guarantee of Rs.676 dated September 15, 2017 to the Registrar General, Delhi High Court. On November 22, 2017, the Delhi High Court directed the Union of India to file a final counter affidavit within six weeks, subsequent to which the Company could file a rejoinder. On May 10, 2018, the counter affidavit was filed by the Union of India. The Company subsequently filed a rejoinder and both were taken on record by the Delhi High Court. The matter has been adjourned to November 14, 2022 for hearing.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on its best estimate, the Company has recorded a provision of Rs.353 under &#x201c;Selling, general and administrative expenses&#x201d; as a potential liability for sale proceeds in excess of the notified selling prices, including the interest thereon, and believes that the likelihood of any further liability that may arise on account of penalties pursuant to this litigation is not probable.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;However, if the Company is unsuccessful in such litigation, it will be required to remit the sale proceeds in excess of the notified selling prices to the Government of India with interest and could potentially include penalties, which amounts are not readily ascertainable.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other product and patent related matters&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Child resistant packaging matter complaint under the False Claims Act (&#x201c;FCA&#x201d;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2012, the Consumer Product Safety Commission (the &#x201c;CPSC&#x201d;) requested that Dr. Reddy&#x2019;s Laboratories Inc., a wholly-owned subsidiary of the Company in the United States, provide certain information with respect to compliance with requirements of special packaging for child resistant blister packs for 6 products sold by the Company in the United States during the period commencing in 2002 through 2011. The Company provided the requested information. The CPSC subsequently alleged in a letter dated April 30, 2014 that the Company had violated the Consumer Product Safety Act (the &#x201c;CPSA&#x201d;) and the Poison Prevention Packaging Act (the &#x201c;PPPA&#x201d;) and that the CPSC intended to seek civil penalties. Specifically, the CPSC asserted, among other things, that from or about August 14, 2008 through June 1, 2012, the Company sold prescription drugs having unit dose packaging that failed to comply with the CPSC's special child resistant packaging regulations under the PPPA and failed to issue general certificates of conformance. In addition, the CPSC asserted that the Company violated the CPSA by failing to immediately advise the CPSC of the alleged violations. The Company disagrees with the CPSC&#x2019;s allegations.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other product and patent related matters (continued)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0.26in;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Simultaneously, the U.S. Department of Justice (the &#x201c;DOJ&#x201d;) began to investigate a sealed complaint which was filed in the United States District Court for the Eastern District of Pennsylvania under the Federal False Claims Act (&#x201c;FCA&#x201d;) related to these same issues (the &#x201c;FCA Complaint&#x201d;). The Company cooperated with the DOJ in its investigation. The DOJ and all States involved in the investigation declined to intervene in the FCA Complaint. On November 10, 2015, the FCA Complaint was unsealed and the plaintiff whistleblowers, who are two former employees of the Company, proceeded without the DOJ&#x2019;s and applicable States&#x2019; involvement. The unsealed FCA Complaint relates to the 6 blister pack products originally subject to the investigation and also 38 of the Company&#x2019;s generic prescription products sold in the U.S. in various bottle and cap packaging.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company filed its response to the FCA Complaint on February 23, 2016 in the form of a motion to dismiss for failure to state a claim upon which relief can be granted. On March 26, 2017, the Court granted the Company&#x2019;s motion to dismiss, dismissing the FCA Complaint and allowing the plaintiffs one more chance to refile this complaint in an attempt to plead sustainable allegations.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;29,&#160;2017, the plaintiffs filed their final amended FCA Complaint, which the Company opposed and during the three months ended March 31, 2018, the Company obtained dismissal of the FCA Complaint with prejudice. The plaintiffs filed a petition with the Court requesting that the Court reconsider its decision to dismiss the FCA Complaint with prejudice, and that request was denied.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The parallel investigation by the CPSC under the CPSA and the PPPA was referred by the CPSC to the DOJ&#x2019;s office in Washington, D.C. in April 2016, with the recommendation that the DOJ initiate a civil penalty action against the Company. The CPSC matter referred to the DOJ relates to five of the blister pack products.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January 18, 2018, the Company and the DOJ entered into a settlement of the action and agreed to a consent decree providing for a civil penalty of U.S.$5 (Rs.319), and injunctive relief. The settlement was without adjudication of any issue of fact or law, and the Company has not admitted any violations of law pursuant to this settlement.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the three months ended March 31, 2018, the Company obtained dismissal of the FCA Complaint with prejudice. The plaintiffs subsequently filed a petition with the Court requesting that the Court reconsider its decision to dismiss the FCA Complaint with prejudice, and that request was denied.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2018, the plaintiffs filed their Notice of Appeal to the Third Circuit Court of Appeals. During the three months ended September 2018, the plaintiffs and the DOJ settled and thus this appeal was dismissed. The plaintiffs then filed an application for recovery of attorneys' fees from the Company under the "alternative remedy doctrine." The Company made opposing filings to this and in response the plaintiffs withdrew their application.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company believes that the likelihood of any liability that may arise on account of the FCA Complaint is not probable. Accordingly, no provision has been made in these consolidated financial statements.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Namenda Litigation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2015, Sergeants Benevolent Assoc. Health &amp;amp; Welfare Fund (&#x201c;Sergeants&#x201d;) filed suit against the Company in the United States District Court for the Southern District of New York. Sergeants alleged that certain parties, including the Company, violated federal antitrust laws as a consequence of having settled patent litigation related to the Alzheimer&#x2019;s drug Namenda&#xae; (memantine) tablets during a period from about 2009 until 2010. Sergeants seeks to represent a class of &#x201c;end payor&#x201d; purchasers of Namenda&#xae; tablets (i.e., insurers, other third-party payors and consumers).&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sergeants seeks damages based upon an allegation made in the complaint that the defendants entered into patent settlements regarding Namenda&#xae; tablets for the purpose of delaying generic competition and facilitating the brand innovator&#x2019;s attempt to shift sales from the original immediate release product to the more recently introduced extended release product. &lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August 23, 2020, the Company and certain other defendants entered into a settlement agreement. The settlement agreement calls for the dismissal with prejudice of the claims brought by the plaintiff on behalf of the putative class, in exchange for the payment of U.S.$0.4. The Company paid that amount into escrow. The Court preliminarily approved the settlement on October 5, 2020. The settlement agreement is contingent upon final court approval. The settlement agreement explicitly disclaims any liability or wrongdoing.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Following the settlement agreement, the Company recognized such amount in the income statement for the three months ended September 30, 2020.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On November 5, 2019 plaintiffs MSP Recovery Claims, Series LLC and MSPA Claims 1, LLC filed suit against the Company and other drug manufacturers in the United States District Court for the Southern District of New York. The claims in this complaint were similar in nature to the claims in the Sergeants lawsuit, and those cases were coordinated for discovery purposes. On April 14, 2020, with the consent of the Company and the other defendants, plaintiffs MSP Recovery Claims, Series LLC and MSPA Claims 1, LLC voluntarily dismissed their claims without prejudice.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other class action complaints containing similar allegations to the Sergeants complaint have also been filed in the U.S. District Court for the Southern District of New York. However, apart from the Sergeants case described above, there are no such class actions that are pending and that name the Company as a defendant.&lt;/div&gt;&lt;/div&gt;

&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: Calibri, sans-serif; margin-left: 0in; text-indent: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other product and patent related matters&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="background: none;;font-style:italic;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(continued)&lt;/div&gt;&lt;/div&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font-size: 9pt; margin: 0in 0in 0.0001pt; text-align: justify; font-weight: bold; font-family: Arial, sans-serif; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-weight: normal; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font-size: 9pt; margin: 0in 0in 0.0001pt; text-align: justify; font-weight: bold; font-family: Arial, sans-serif; text-indent: 0.26in;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;In addition, the State of New York filed an antitrust case in the U.S. District Court for the Southern District of New York. The case brought by the State of New York contained some (but not all) of the allegations set forth in the class action complaints, but the Company was not named as a party. The case brought by the State of New York was dismissed by stipulation on November 30, 2015.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font-size: 9pt; margin: 0in 0in 0.0001pt; text-align: justify; font-family: Arial, sans-serif; text-indent: 0.26in;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; font-size: 9pt; text-indent: 0.26in; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font-size: 10pt; margin: 0in 0in 0.0001pt; text-align: justify; font-weight: bold; font-family: Arial, sans-serif; text-indent: 0.26in; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;The Company believes that the likelihood of any liability, apart from the settlement payment described above, that may arise on account of alleged violation of federal antitrust laws is not probable.&lt;/div&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt; Accordingly, no &lt;/div&gt;&lt;div style="color: black; font-weight: normal; letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;provision has been made in these consolidated financial statements.&lt;/div&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin-bottom: 0.0001pt; margin-top: 0px; font-family: Calibri, sans-serif; font-size: 10pt; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="margin-block: 0em; text-indent: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; line-height: 10pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ranitidine recall and litigation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="margin-block: 0em; text-indent: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; line-height: 10pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October 1, 2019, the Company initiated a voluntary nationwide retail (at the retail level for over-the-counter products and at the consumer level for prescription products) of its ranitidine medications sold in the United States due to the presence of N-Nitrosodimethylamine (&#x201c;NDMA&#x201d;) above levels established by the U.S. FDA. On November 1, 2019, the U.S. FDA issued a statement indicating that it had found levels of NDMA in ranitidine from its testing generally that were &#x201c;similar to the levels you would expect to be exposed to if you ate common foods like grilled or smoked meats.&#x201d; See https://www.fda.gov/news-events/press-announcements/statement-new-testing-results-including-low-levels-impurities-ranitidine-drugs. On April 1, 2020, the U.S. FDA issued a press release announcing that it was requesting manufacturers to withdraw all prescription and over-the-counter ranitidine drugs from the market immediately. See https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Individual federal court personal injury lawsuits, as well as various class actions, have been transferred to the In re Zantac (Ranitidine) Products Liability Litigation Multidistrict Litigation in the Southern District of Florida, MDL-2924 (&#x201c;MDL-2924&#x201d;). The Company and/or one or more of its U.S. subsidiaries have been named as a defendant in over 250 lawsuits pending in the MDL-2924. A census registry established in the MDL-2924 includes tens of thousands of claimants who have not filed complaints but are presenting claims for consideration in the MDL-2924 against the many pharmaceutical manufacturers, distributors and retailers which are defendants in the MDL-2924. The MDL-2924 also involves a proposed nationwide consumer class action and a proposed nationwide class action for medical monitoring. A third-party payor class action was dismissed without prejudice and has been appealed by plaintiffs to the U.S. Court of Appeals for the Eleventh Circuit.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December 31, 2020, the MDL-2924 Court ruled on multiple motions to dismiss in the MDL-2924 and granted the generic manufacturers&#x2019; (the Company is a generic manufacturer) motion to dismiss based on federal preemption. The plaintiffs&#x2019; failure-to-warn and design defect claims against the Company were dismissed with prejudice, but the Court permitted plaintiffs to attempt to replead several claims/theories. Plaintiffs filed their amended complaints and the defendants, including the Company, filed motions to dismiss seeking dismissal of all claims against them on March 24, 2021. On July 8, 2021, the Court dismissed the entirety of plaintiffs&#x2019; claims against the Company and other generic manufacturers with prejudice based on federal preemption.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;The MDL Court&#x2019;s dismissal decisions have been piecemeal appealed by plaintiffs to the U.S. Court of Appeals for the Eleventh Circuit, resulting in three rounds of appeals. Oral argument on the first round of appeals occurred on April 5, 2022.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There are several ranitidine-related actions currently pending against the Company in state courts. The New Mexico State Attorney General filed suit against the Company&#x2019;s U.S. subsidiary, and multiple other manufacturers and retailers. The State of New Mexico asserted claims of statutory and common law public nuisance and negligence claims against the Company. The Company joined in an effort to transfer the case from the Santa Fe County Court to the MDL-2924, but the case was remanded by the MDL-2924 Court to the Santa Fe County Court. Plaintiff filed an amended complaint on April 16, 2021&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&#160;The defendants&#x2019; motions to dismiss, including the Company&#x2019;s federal preemption motion to dismiss, were denied. The case is currently in the discovery stage. No trial date has been established.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;In November 2020, the City of Baltimore filed a similar action against the Company&#x2019;s U.S. subsidiary, and multiple other manufacturers and retailers. The City of Baltimore asserts public nuisance and negligence claims against the Company. The City of Baltimore action also was transferred to the MDL-2924 and subsequently was remanded to the Circuit Court of Maryland by the MDL-2924 Court. The City of Baltimore filed an amended complaint, which the defendants moved to dismiss. The Company&#x2019;s federal preemption motion to dismiss was granted in February 2022 and it is not currently a defendant in the case.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;In January 2021, the Company was served in a Proposition 65 case filed by the Center for Environmental Health&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;(&#x201c;CFEH&#x201d;) in the Superior Court of Alameda County, California. The plaintiff purports to bring the case on behalf of the people of California and alleges that the Company violated Proposition 65, a California law requiring manufacturers to disclose the presence of carcinogens in consumer products. The Company and other defendants have filed demurrers (motions to dismiss) in the case, and on May 7, 2021 the Court granted all such demurrers without leave to amend the pleadings. CFEH appealed that decision and appellate briefing is on-going.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There are now 10 plaintiffs who have filed actions against the Company and other brand and generic manufacturers and/or retailers in Illinois and Pennsylvania state courts. The Illinois cases have been filed in Madison, St. Clair and Cook counties. The Pennsylvania cases were filed in Philadelphia. Generally they allege, among other things, failure to warn, design defect and negligence. The defendants have moved, or intend to move, to dismiss these cases. In one case, Joseph Bayer, et al. v. Boehringer Ingelheim Pharmaceuticals, Inc., et al., Madison County Case No. 2021-L-000915, some of plaintiffs&#x2019; claims survived the Company&#x2019;s and other defendants&#x2019; motions to dismiss. The Bayer case involves two plaintiffs, Joseph Bayer and Gwendolyn Culverson. Their claims have been severed for trial, with his trial scheduled for August 2022 and her trial scheduled for February 6, 2023. Discovery is on-going, plaintiffs have disclosed their experts, and the defendants are scheduled to disclose experts shortly. No other cases have been set for trial.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Class Action and Other Civil Litigation on Pricing/Reimbursement Matters&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company believes that all of the aforesaid complaints and asserted claims are without merit and it denies any wrongdoing and intends to vigorously defend itself against the allegations. Any liability that may arise on account of these claims is unascertainable at this time. Accordingly, no provision was made in these consolidated financial statements of the Company.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December 30, 2015 and on February 4, 2016, respectively, a class action complaint (the &#x201c;First Pricing Complaint&#x201d;) and another complaint (not a class action) (the &#x201c;Second Pricing Complaint&#x201d;) were filed against the Company and eighteen other pharmaceutical defendants in State Court in the Commonwealth of Pennsylvania. In these actions, the class action plaintiffs allege that the Company and other defendants, individually or in some cases in concert with one another, have engaged in pricing and price reporting practices in violation of various Pennsylvania state laws. More specifically, the plaintiffs allege that: (1) the Company provided false and misleading pricing information to third party drug compendia companies for the Company&#x2019;s generic drugs, and such information was relied upon by private third party payers that reimbursed for drugs sold by the Company in the United States, and (2) the Company acted in concert with certain other defendants to unfairly raise the prices of generic divalproex sodium ER (bottle of 80, 500 mg tablets ER 24H) and generic pravastatin sodium (bottle of 500, 10&#160;mg&#160;tablets).&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The First Pricing Complaint was removed to the U.S. District Court for the Eastern District of Pennsylvania (the &#x201c;E.D.P.A. Federal Court&#x201d;) and, pending the outcome of the First Pricing Complaint, the Second Pricing Complaint was stayed. On September 25, 2017, the E.D.P.A. Federal Court dismissed all the claims of the plaintiffs in the First Pricing Complaint and denied leave to amend such complaint as futile. Subsequent to this decision, the plaintiffs&#x2019; right to appeal the dismissal of the First Pricing Complaint expired.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Further, on November 17, 2016, certain class action complaints were filed against the Company and a number of other pharmaceutical companies as defendants in the E.D.P.A. Federal Court. Subsequently, these complaints were consolidated into one amended complaint as part of a multi-district, multi-product litigation pending with the E.D.P.A. Federal Court. These complaints allege that the Company and the other named defendants have engaged in a conspiracy to fix prices and to allocate bids and customers in the sale of pravastatin sodium tablets and divalproex sodium extended-release tablets in the United States. &lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2017, plaintiffs agreed by stipulation to dismiss Dr. Reddy&#x2019;s Laboratories Inc. and Dr. Reddy&#x2019;s Laboratories Limited from the actions related to pravastatin sodium tablets without prejudice. The Company denies any wrongdoing and intends to vigorously defend against these allegations.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In response to the consolidated new complaint, the Company filed a motion to dismiss in October 2017. The plaintiffs filed opposition to the motion to dismiss in December 2017 and a reply was filed by the Company in January 2018. In October 2018, the Court denied the motion to dismiss on the grounds that the allegations pled leave open the possibility of conspiracy. Therefore, discovery will proceed to look into this possibility.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company believes that the asserted claims are without merit and intends to vigorously defend itself against the allegations. Also any liability that may arise on account of these claims is unascertainable. Accordingly, no provision was made in these consolidated financial statements.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;United States Antitrust Multi-District Litigations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following cases against the Company&#x2019;s U.S. subsidiary, Dr. Reddy&#x2019;s Laboratories, Inc., have been filed and are pending and consolidated in &lt;div style="font-style:italic;display:inline;"&gt;In re Generic Pharmaceutical Pricing Antitrust Litigation, MDL 2724, 14-MD-2724 (Eastern District of Pennsylvania)&lt;/div&gt;, Multi District Litigation (&#x201c;MDL&#x201d;) in the Eastern District of Pennsylvania (&#x201c;MDL-2724&#x201d;):&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 9pt; text-align: justify; text-indent: -9pt;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 9pt; text-align: justify; text-indent: -9pt;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;a) &lt;div style="text-decoration:underline;display:inline;"&gt;U.S. States Attorneys General Antitrust Complaints:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October 30, 2017, the Attorneys General of forty-nine U.S. States, the Commonwealth of Puerto Rico and the District of Columbia, filed an Amended Complaint in the United States District Court for the Eastern District of Pennsylvania, against eighteen generic pharmaceutical companies (including the Company&#x2019;s U.S. subsidiary) with respect to fifteen generic drugs, alleging that the Company&#x2019;s U.S. subsidiary and the other named defendants engaged in a conspiracy to fix prices and to allocate bids and customers in the United States in the sale of the fifteen named drugs. The Company&#x2019;s U.S. subsidiary is specifically named as a defendant with respect to two generic drugs (meprobamate and zoledronic acid), and is named as an alleged co-conspirator on an alleged &#x201c;overarching conspiracy&#x201d; with respect to the other thirteen generic drugs named. The Amended Complaint alleges violations of Section 1 of the Sherman Act, 15 U.S.C. &#xa7;1, and the consumer protection and antitrust laws of each of the jurisdictions that are plaintiffs. &lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Amended Complaint seeks injunctive relief, statutory penalties, punitive damages, and recovery of treble damages, plus attorney&#x2019;s fees and costs, against all named defendants on a joint and several basis, on behalf of the plaintiff jurisdictions and their citizens and inhabitants. The Company denies any wrongdoing and intends to vigorously defend against the claims asserted.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;United States Antitrust Multi-District Litigations (continued)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May 10, 2019, the Attorneys General of forty-nine U.S. States, the Commonwealth of Puerto Rico and the District of Columbia, filed a Complaint in the United States District Court for the District of Connecticut against twenty-one generic pharmaceutical companies (including the Company&#x2019;s U.S. subsidiary) and fifteen individual defendants, with respect to 116 generic drugs, alleging that the Company&#x2019;s U.S. subsidiary and the other named defendants engaged in a conspiracy to fix prices and to allocate bids and customers in the United States in the sale of the 116 named drugs. Under the MDL rules, this action will be designated a related &#x201c;tag along&#x201d; action and will be transferred to and become a part of the MDL-2724. The Company&#x2019;s U.S. subsidiary is specifically named as a defendant with respect to five generic drugs (ciprofloxacin HCL tablets, glimepiride tablets, oxaprozin tablets, paricalcitol and tizanidine), and is named as an alleged co-conspirator on an alleged &#x201c;overarching conspiracy&#x201d; with respect to the other thirteen generic drugs named. The Complaint alleges violations of Section 1 of the Sherman Act, 15 U.S.C. &#xa7;1, and the consumer protection and antitrust laws of each of the jurisdictions that are plaintiffs. The Complaint seeks injunctive relief, statutory penalties, punitive damages, and recovery of treble damages, plus attorney&#x2019;s fees and costs, against all named defendants on a joint and several basis, on behalf of the plaintiff jurisdictions and their citizens and inhabitants. The Company denies any wrongdoing and intends to vigorously defend against the claims asserted.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9.35pt; text-align: justify; text-indent: -9.35pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9.35pt; text-align: justify; text-indent: -9.35pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;b) &lt;div style="text-decoration:underline;display:inline;"&gt;Divalproex Antitrust Class Action Cases Filed by Direct Payor Plaintiffs, End Payor Plaintiffs and Indirect Reseller Plaintiffs Classes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Since November 17, 2016, certain class action complaints on behalf of Direct Purchaser Plaintiffs, Indirect Reseller Plaintiffs and End Payor Plaintiffs classes were filed against the Company&#x2019;s U.S. subsidiary, Dr. Reddy&#x2019;s Laboratories, Inc., and a number of other pharmaceutical defendants in the United States District Court for the District of Pennsylvania alleging that the Company&#x2019;s U.S. subsidiary and the other named defendants have engaged in a conspiracy to fix prices and to allocate bids and customers in the sale of divalproex ER tablets in the United States. &lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The actions allege violations of Section 1 of the Sherman Act, 15 U.S.C. &#xa7;1, and of state consumer protection and antitrust laws, and asserts claims of unjust enrichment, under a total of thirty-one States and the District of Columbia. The actions seek injunctive relief and recovery of treble damages, punitive damages, plus attorney&#x2019;s fees and costs, on a joint and several basis, on behalf of the plaintiff classes. The Company denies any wrongdoing and intends to vigorously defend against these class action claims.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9.35pt; text-align: justify; text-indent: -9.35pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;c) &lt;div style="text-decoration:underline;display:inline;"&gt;Pravastatin Antitrust Class Action Cases Filed by Direct Payor Plaintiffs, End Payor Plaintiffs and Indirect Reseller Plaintiffs Classes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Since November 17, 2016, certain class action complaints on behalf of Direct Purchaser Plaintiffs, Indirect Reseller Plaintiffs and End Payor Plaintiffs classes were filed against the Company and a number of other pharmaceutical defendants in the United States District Court for the District of Pennsylvania, alleging that the Company&#x2019;s U.S. subsidiary and the other named defendants engaged in a conspiracy to fix prices and to allocate bids and customers in the sale of pravastatin sodium tablets in the United States. The Company&#x2019;s U.S. subsidiary has been dismissed from these actions, without prejudice, in exchange for a tolling agreement with the plaintiffs suspending the statute of limitations as to the claims asserted. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;d) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust &#x201c;Overarching Conspiracy&#x201d; Cases Filed by Direct Payor Plaintiffs, End Payor Plaintiffs and Indirect Reseller Plaintiffs Classes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2018, three class action complaints were filed in the MDL-2724 by Direct Purchaser Plaintiffs, Indirect Resellers Plaintiffs and End Payor Plaintiffs classes. All three complaints allege conspiracies in restraint of trade in violation of Sections 1 of the Sherman Act, and violations of thirty-one State antitrust statutes and consumer protection statutes, and asserts claims of unjust enrichment seeking injunctive relief, recovery of treble damages, punitive damages, attorney's fees and costs against all named defendants on a joint and several basis. They allege an &#x201c;overarching conspiracy&#x201d; among the named defendants involving fifteen drugs and, with slight variations, name approximately twenty-five generic pharmaceutical manufacturers including the Company&#x2019;s U.S. subsidiary, Dr. Reddy&#x2019;s Laboratories, Inc. &lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The drug-specific allegations against the Company&#x2019;s U.S. subsidiary involve two of the fifteen drugs, meprobamate and zoledronic acid. Plaintiffs also allege that the Company&#x2019;s U.S. subsidiary (as well as all other manufacturers named) were part of a larger &#x201c;overarching conspiracy&#x201d; as to all of the drugs named in the complaints.&#160;The complaint alleges violations of Section 1 of the Sherman Act, 15 U.S.C. &#xa7;1, and violations of thirty-one States&#x2019; antitrust statutes and consumer protection statutes, and asserts claims of unjust enrichment.&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;The complaint seeks injunctive relief, recovery of treble damages, punitive damages, attorney's fees and costs against all named defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;e) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Case Filed by The Kroger Co., Albertsons Companies, LLC, and H.E. Butt Grocery Company, L.P.: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January 22, 2018, each of the Kroger Co., Albertsons Companies, LLC, and H.E. Butt Grocery Company, L.P., filed a complaint against the Company&#x2019;s U.S. subsidiary and thirty-one other companies alleging that they had engaged in a conspiracy to fix prices and to allocate bids and customers in the United States in the sale of the thirty named generic drugs. The Company&#x2019;s U.S. subsidiary is specifically named as a defendant with respect to three generic drugs (divalproex ER, meprobamate and zoledronic acid), and is named as an alleged co-conspirator on an alleged &#x201c;overarching conspiracy&#x201d; claim with respect to the other generic drugs named. &lt;/div&gt;&lt;/div&gt;


&lt;div style="font-style: normal; font-variant: normal; font-size: 10pt; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-stretch: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: bold 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;This action alleges violations of Section 1 of the Sherman Act, 15 U.S.C. &#xa7;1, and seeks injunctive relief and recovery of treble damages, punitive damages, plus attorney&#x2019;s fees and costs, against all named defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these class action claims.&lt;/div&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;United States Antitrust Multi-District Litigations (continued)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;f) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Case Filed by Humana Inc.: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August 3, 2018, Humana, Inc., filed a complaint against the Company&#x2019;s U.S. subsidiary and thirty-nine other companies alleging that they had engaged in a conspiracy to fix prices and to allocate bids and customers in the United States in the sale of twenty-nine named generic drugs. On December 15, 2020, Humana, Inc., filed an Amended Complaint encompassing fifty-one defendants and a total of one hundred forty nine drugs. In the Amended Complaint, the Company&#x2019;s U.S. subsidiary is specifically named as a defendant with respect to eighteen generic drugs: allopurinol, ciprofloxacin ER, eszopiclone, fluconazole, glimepiride, isotretinoin, lamotrigine ER, meprobamate, metroprolol succinate ER, montelukast, omeprazole sodium bicarbonate, oxaprozin, paricalcitol, ranitidine, sumatriptan, tizanidine, valganciclovir, and zoledronic acid. The Company&#x2019;s subsidiary is also named as a co-conspirator on an alleged &#x201c;overarching conspiracy&#x201d; claim with respect to the other generic drugs named. The complaint also alleges violations of Section 1 of the Sherman Act, 15 U.S.C. &#xa7;1, and violations of thirty-one States&#x2019; antitrust statutes and consumer protection statutes, and asserts claims of unjust enrichment. The complaint seeks injunctive relief, recovery of treble damages, punitive damages, attorney's fees and costs against all named defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;g) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Case Filed by Marion Diagnostic Center, LLC, and Marion Healthcare, LLC: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September 25, 2018, Marion Diagnostic Center, LLC, and Marion Healthcare, LLC, filed a complaint in the MDL-2724, on behalf of themselves and a class of all direct purchasers from distributors, against the Company&#x2019;s U.S. subsidiary and twenty-two other defendants, including a major distributor of pharmaceutical products, involving a total of sixteen generic drugs, alleging an &#x201c;overarching conspiracy&#x201d; to fix prices and to rig bids and allocate customers with respect to sixteen generic drugs. The Company&#x2019;s U.S. subsidiary is specifically named with respect to two drugs: meprobamate and zoledronic acid. Plaintiffs also allege that the Company&#x2019;s U.S. subsidiary (as well as all other manufacturers named) were part of a larger &#x201c;overarching conspiracy&#x201d; as to all of the drugs named in the complaints.&#160;The complaint alleges violations of Section 1 of the Sherman Act, 15 U.S.C. &#xa7;1, and violations of twenty-four States&#x2019; antitrust statutes and consumer protection statutes, and asserts claims of unjust enrichment. The complaint seeks injunctive relief, recovery of treble damages, punitive damages, attorney's fees and costs against all named defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;h) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Case Filed by United Healthcare Services, Inc.: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January 16, 2019, United Healthcare Services, Inc., filed a complaint against the Company&#x2019;s U.S. subsidiary and forty-two other defendants, involving a total of thirty generic drugs, alleging an &#x201c;overarching conspiracy&#x201d; to fix prices and to rig bids and allocate customers with respect to the thirty drugs. The Company&#x2019;s U.S. subsidiary is specifically named with respect to four drugs: divalproex ER, meprobamate, pravastatin and zoledronic acid. Plaintiffs also allege that the Company&#x2019;s U.S. subsidiary (as well as all other manufacturers named) were part of a larger &#x201c;overarching conspiracy&#x201d; as to all of the drugs named in the complaints.&#160;The complaint alleges violations of Section 1 of the Sherman Act, 15 U.S.C. &#xa7;1, and violations of the thirty States&#x2019; antitrust laws and consumer protection statutes, and asserts claims of unjust enrichment. The complaint seeks injunctive relief, recovery of treble damages, punitive damages, and attorney's fees and cost against all defendants on a joint and several basis. &lt;div style="background-color: white; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0px;"/&gt;&lt;td style="width: 0.15in;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;i)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Pennsylvania Court of Common Pleas Praecipe For a Writ of Summons Filed by 87 End Payor Entities consisting of Blue Cross Blue Shield entities and other health insurance companies and HMO entities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July 19, 2019, a Praecipe For a Writ of Summons for a tort action was filed in the Pennsylvania Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania, Civil Trial Division, by 87 Blue Cross Blue Shield entities, and other health insurance companies and HMO entities, against the Company&#x2019;s U.S. subsidiary and 69 other defendants (consisting of 51 other pharmaceutical companies and 17 individuals). These 87 plaintiffs had been previously encompassed by the End Payor Plaintiff class actions in the MDL-2724. Only a Praecipe &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;For&lt;/div&gt;&#160;Writ of Summons has been filed. No complaint has been filed and, therefore, the potential claims have not been asserted or delineated in any manner, including what drugs any such claims may relate to. A complaint may, at some point, be filed encompassing the claims asserted by the End Payor Plaintiffs in the MDL-2724 actions. On December 12, 2019, an Order of the Court of Common Pleas placed the matter &#x201c;in Deferred Status Pending Further Developments in Related Federal Multidistrict Litigation.&#x201d; Because no Complaint has been filed setting forth any claims, and because the action has been placed into Deferred Status, no response is required by the Company&#x2019;s subsidiary at this time.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;j) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Case Filed by United Healthcare Services, Inc.: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;On October &lt;div style="background-color: white; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11, 2019, United Healthcare Services, Inc. filed a second complaint (which substantially tracks the second complaint filed by the State Attorneys General on May 10, 2019) against the Company&#x2019;s U.S. subsidiary and twenty-four other defendants in the United States District Court for the District of Minnesota with respect to 116 generic drugs, alleging that the Company&#x2019;s U.S. subsidiary and the other named defendants engaged in a conspiracy to fix prices and to allocate bids and customers in the United States in the sale of the 116 &lt;/div&gt;named drugs. Under the MDL rules, this action will be designated a related &#x201c;tag along&#x201d; action and will be transferred to and become a part of the MDL-2724. The Company&#x2019;s U.S. subsidiary is specifically named as a defendant with respect to five generic drugs (ciprofloxacin HCL tablets, glimepiride tablets, oxaprozin tablets, paricalcitol and tizanidine), and is named as an alleged co-conspirator on an alleged &#x201c;overarching conspiracy&#x201d; with respect to the other generic drugs named. The complaint alleges violations of Section 1 of the Sherman Act, 15 U.S.C. &#xa7;1, and violations of the Minnesota antitrust laws and various other state antitrust and consumer protection laws, and asserts claims for unjust enrichment.&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;United States Antitrust Multi-District Litigations (continued)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="background-color: white; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The complaint seeks injunctive relief, statutory penalties, punitive damages, and recovery of treble damages, plus attorney&#x2019;s fees and costs, against all named defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;k) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust &#x201c;Overarching Conspiracy&#x201d; Cases Filed by Direct Payor Plaintiffs, End Payor Plaintiffs and Indirect Reseller Plaintiffs Classes: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December 19, 2019, a new class action complaint was filed by the End Payor Plaintiffs. The complaint alleges a conspiracy in restraint of trade in violation of Section 1 of the Sherman Act, 15 U.S.C. &#xa7;1, and violations of twenty-eight States&#x2019; antitrust statutes and twenty-nine States&#x2019; consumer protection statutes, and asserts claims of unjust enrichment. The complaint seeks injunctive relief, recovery of treble damages, punitive damages, attorney&#x2019;s fees and costs. The complaint alleges an &#x201c;overarching conspiracy&#x201d; among the named defendants involving one hundred and thirty-five drugs and, with slight variations, names approximately thirty-six generic pharmaceutical manufacturers, including the Company&#x2019;s U.S. subsidiary.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The drug-specific allegations against the Company&#x2019;s U.S. subsidiary involve eight of the one hundred thirty-five drugs, including allopurinol, ciprofloxacin HCL, fluconazone, glimepiride, oxaprozine, paricalcitol, ranitidine HCL and tizanidine. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December 19, 2019, a new class action complaint was filed by certain pharmacy and hospital indirect purchaser plaintiffs. The complaint alleges a conspiracy in restraint of trade in violation of Sections 1 and 3 of the Sherman Act, 15 U.S.C. &#xa7;1 and &#xa7;3, and violations of forty-three States&#x2019; antitrust statutes and consumer protection statutes, and asserts claims of unjust enrichment. The complaint seeks injunctive relief, recovery of treble damages, punitive damages, attorney&#x2019;s fees and costs against all named defendants on a joint and several basis. The complaint alleges an &#x201c;overarching conspiracy&#x201d; among the named defendants involving one hundred and sixty-two drugs and, with slight variations, names approximately twenty-eight generic pharmaceutical manufacturers, including the Company&#x2019;s U.S. subsidiary, as well as seven pharmaceutical distributor defendants and sixteen individual defendants. &lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The drug-specific allegations against the Company&#x2019;s U.S. subsidiary involve nineteen drugs: allopurinol, capecitabine, ciprofloxacin HCL, divalproex ER, eszopiclone, fenofibrate, glimepiride, isotretinoin, lamotrigine ER, meprobamate, metoprolol ER, montelukast granules, omeprazole sodium bicarbonate, oxaprozine, paricalcitol, sumatriptan, tizanidine HCL, valganciclovir and zoledronic acid. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-size: 10pt; margin: 0in 0in 6pt; text-align: justify; text-indent: 22.5pt; font-weight: bold; font-family: Arial, sans-serif; line-height: 10pt;"&gt;&lt;div style="font-size:10pt;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;The complaints seek injunctive relief, statutory penalties, punitive damages, and recovery of treble damages, plus attorney&#x2019;s fees and costs, against all named defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;l) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Case Filed by Fourteen New York State Counties:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On November 18, 2019, a&#160; class action complaint was filed in the Supreme Court of the State of New York, Nassau County, by fourteen New York State Counties (Nassau, Allegany, Clinton. Cortland, Franklin, Fulton, Greene, Herkimer, Lewis, Madison, Montgomery, Niagara, Schenectady and Steuben).&#160;&#160;&#160; The complaint alleging an &#x201c;overarching conspiracy&#x201d; to fix prices and to rig bids and allocate customers with respect to these drugs. The Company&#x2019;s U.S. subsidiary is specifically named with respect to five drugs: glimepiride, glyburide-metformin, meprobamate, tizanidine and zoledronic acid. Plaintiffs also allege that the Company&#x2019;s U.S. subsidiary was part of a larger &#x201c;overarching conspiracy&#x201d; with all other manufacturers named as to all of the drugs named in the complaint. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;div style="font-size: 1pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;m) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Case Filed by Health Care Services, Inc.:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December 11, 2019, Health Care Services, Inc. filed a complaint against the Company&#x2019;s U.S. subsidiary and thirty-eight other defendants, involving a total of one hundred twenty-eight generic drugs, alleging an &#x201c;overarching conspiracy&#x201d; to fix prices and to rig bids and allocate customers with respect to these drugs. On December 15, 2020, Health Care Services filed an Amended Complaint naming a total of one hundred seventy drugs. In the Amended Complaint, the&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Company&#x2019;s U.S. subsidiary is specifically named with respect to nineteen drugs: allopurinol, ciprofloxacin HCL, divalproex ER, eszopiclone, fluconazole, glimepiride, isotretinoin, lamotrigine ER, meprobamate, metroprolol succinate ER, montelukast, omeprazole sodium bicarbonate, oxaprozine, paricalcitol, ranitidine, sumatriptan, tizanidine, valganciclovir and zoledronic acid. Plaintiffs allege that the Company&#x2019;s U.S. subsidiary (as well as all other manufacturers named) were part of a larger &#x201c;overarching conspiracy&#x201d; as to all of the drugs named in the complaint. The complaint also alleges violations of Sections 1 and 2 of the Sherman Act, 15 U.S.C. &#xa7;1 and &#xa7;2, and violations of thirty-one States&#x2019; antitrust laws and twenty-seven States&#x2019; consumer protection statutes, and asserts claims of unjust enrichment. The complaint seeks injunctive relief, recovery of treble damages, punitive damages, and attorney&#x2019;s fees and costs against all defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0px;"/&gt;&lt;td style="width: 0.15in;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;n)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Case Filed by MSP Recovery Claims, Series LLC, MAO-MSO Recovery II, LLC, and MSPA Claims I, LLC (collectively &#x201c;MSP Recovery&#x201d;), as Assignees of certain Medicare Advantage Plans:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;              &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December 16, 2019, MSP Recovery filed a complaint against the Company&#x2019;s U.S. subsidiary and twenty-five other defendants, involving a total of sixteen generic drugs, alleging an &#x201c;overarching conspiracy&#x201d; to fix prices and to rig bids and allocate customers with respect to the sixteen drugs. The Company&#x2019;s U.S. subsidiary is specifically named with respect to one drug: Divalproex ER. Plaintiffs also allege that the Company&#x2019;s U.S. subsidiary (as well as all other manufacturers named) were part of a larger &#x201c;overarching conspiracy&#x201d; as to all of the drugs named in the complaint. &lt;/div&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;United States Antitrust Multi-District Litigations (continued)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The complaint alleges violations of Sections 1 and 3 of the Sherman Act, 15 U.S.C. &#xa7;1 and &#xa7;3, and violations of twenty-eight States&#x2019; antitrust laws and twenty-three States&#x2019; consumer protection statutes, and asserts claims of unjust enrichment. The complaint seeks injunctive relief, recovery of treble damages, punitive damages, and attorney&#x2019;s fees and costs against all defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;o) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Case Filed by Molina Healthcare Inc.:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December 27, 2019, Molina Healthcare Inc. filed a complaint against the Company&#x2019;s U.S. subsidiary and forty-one other defendants, involving a total of one hundred twenty-eight generic drugs, alleging an &#x201c;overarching conspiracy&#x201d; to fix prices and to rig bids and allocate customers with respect to these drugs. On December 15, 2020, Molina Healthcare filed an Amended Complaint against a total of fifty-eight defendants involving one hundred eighty four drugs. In the Amended Complaint, the Company&#x2019;s U.S. subsidiary is specifically named with respect to nineteen drugs: allopurinol, ciprofloxacin, divalproex ER, eszopiclone, fluconazole, glimepiride, isotretinoin, lamotrigine ER, meprobamate, metroprolol succinate ER, montelukast, omeprazole sodium bicarbonate, oxaprozine, paricalcitol, ranitidine, sumatriptan, tizanidine, valganciclovir and zoledronic acid. Plaintiffs allege that the Company&#x2019;s U.S. subsidiary (as well as all other manufacturers named) were part of a larger &#x201c;overarching conspiracy&#x201d; as to all of the drugs named in the complaint. The complaint also alleges violations of Sections 1 and 2 of the Sherman Act, 15 U.S.C. &#xa7;1 and &#xa7;2, and violations of eleven States&#x2019; antitrust laws and consumer protection statutes, and asserts claims of unjust enrichment. The complaint seeks injunctive relief, recovery of treble damages, punitive damages, and attorney&#x2019;s fees and costs against all defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;p) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Case Filed by Harris Count&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;y&lt;/div&gt;, Texas:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March 1, 2020, Harris County, Texas filed a Complaint against the Company's U.S. Subsidiary and forty-two other defendants, involving a total of one hundred twenty-eight generic drugs, alleging an "overarching conspiracy" to fix prices and to rig bids and allocate customers with respect to the one hundred eighty-seven drugs. The case is in the process of being transferred to the MDL-2724 proceeding. The Company's U.S. subsidiary is specifically named with respect to twenty drugs: &lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;allopurinol, amoxicillin, ciprofloxacin HCL, divalproex ER, famotidine, fenofibrate, fluconazole, fluoxetine, glimepiride, glycopyrrolate, levalbuterol, meprobamate, naproxen, ondansetron, oxaprozin, pravastatin sodium, raloxifene HCL, ranitidine, tizanidine and zoledronic acid. Plaintiffs also allege that the Company's U.S. subsidiary (as well as all other manufacturers named) were part of a larger "overarching conspiracy" as to all the drugs named in the complaints. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Complaint alleges violations of Sections 1 of the Sherman Act, 15 U.S.C. &#xa7;1, violations of twenty-eight State's antitrust laws, violations of the Texas Deceptive Trade Practices Act and Texas Free Enterprise and Antitrust Act and asserts claims of unjust enrichment and civil conspiracy. The Complaint seeks injunctive relief, recovery of treble damages, punitive damages, disgorgement, and attorney's fees and costs against all defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; font-stretch: normal; text-indent: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;q) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Complaint Filed by Westchester County, Illinois Public Risk Fund and the United Crafts Benefits Fund Insurance Companies&lt;div style="display:inline;"&gt;:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March 16, 2020, an Amended Complaint was filed by the County of Westchester, the Illinois Public Risk Fund and the United Crafts Benefits Fund against the Company and 35 other defendants. The Amended Complaint alleges an overarching conspiracy to fix prices and allocate markets for 294 generic drugs. Of the 294 drugs, DRL is specifically named with respect to 14 drugs: Allopurinol, Ciprofloxacin, Divalproex, Glimepiride, Glyburide-Metformin, Isotretinoin, Lamotrigine, Meprobamate, Metoprolol Succinate, Oxaprozin, Paricalcitol, Tizanidine, Valganciclovir and Zoledronic Acid. The Complaint alleges violations of Sections 4 and 16 of the Clayton Act, as well as violations of the Antitrust Statutes of Illinois and New York and Unjust Enrichment claims under the laws of Illinois and New York. The complaint seeks injunctive relief, recovery of treble damages, and attorney&#x2019;s fees and costs against all defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0px;"/&gt;&lt;td style="width: 0.15in;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;r)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Pennsylvania Court of Common Pleas Praecipe For a Writ of Summons Filed by 7 End Payor Entities consisting of Blue Cross Blue Shield entities and other health insurance companies:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May 6, 2020, a Praecipe For a Writ of Summons for a tort action was filed in the Pennsylvania Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania, Civil Trial Division, by 7 Blue Cross Blue Shield entities and other health insurance companies, against the Company&#x2019;s U.S. subsidiary and 69 other defendants (consisting of 51 other pharmaceutical companies and 17 individuals). These 7 plaintiffs had been previously encompassed by the End Payor Plaintiff class actions in the MDL-2724. Only a Praecipe &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;For&lt;/div&gt;&#160;Writ of Summons has been filed. No complaint has been filed and, therefore, the potential claims have not been asserted or delineated in any manner, including what drugs any such claims may relate to. A complaint may, at some point, be filed encompassing the claims asserted by the End Payor Plaintiff class actions in the MDL-2724 actions. It is anticipated that this action will be placed in Deferred Status Pending &lt;/div&gt;Further Developments in the related MDL&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;-2724 case. Because no Complaint has been filed setting forth any claims, and because it is expected that the action will be placed into Deferred Status, no response is required by the Company&#x2019;s subsidiary at this time.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;United States Antitrust Multi-District Litigations (continued)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt 9.35pt; text-align: justify; text-indent: -9.35pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;s) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Case Filed by Cigna Corp.:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June 9, 2020, Cigna Corp. filed a complaint against the Company&#x2019;s U.S. subsidiary and forty-one other defendants, involving a total of one hundred forty generic drugs, alleging an &#x201c;overarching conspiracy&#x201d; to fix prices and to rig bids and allocate customers with respect to these drugs. On December 15, 2020, Cigna Corp. filed an Amended Complaint against a total of forty-two defendants encompassing a total of two hundred and thirty-nine drugs. In the Amended Complaint, the Company&#x2019;s U.S. subsidiary is specifically named with respect to twelve drugs: allopurinol, ciprofloxacin HCL, divalproex ER, fluconazole, glimepiride, meprobamate, oxaprozine, paricalcitol, pravastatin, ranitidine, tizanidine and zoledronic acid. Plaintiffs allege that the Company&#x2019;s U.S. subsidiary (as well as all other manufacturers named) were part of a larger &#x201c;overarching conspiracy&#x201d; as to all of the drugs named in the complaint. The complaint also alleges violations of Sections 1 and 2 of the Sherman Act, 15 U.S.C. &#xa7;1 and &#xa7;2, and violations of thirty-one States&#x2019; antitrust laws and twenty-nine States&#x2019; consumer protection statutes, and asserts claims of unjust enrichment. The complaint seeks injunctive relief, recovery of treble damages, punitive damages, and attorney&#x2019;s fees and costs against all defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;t) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Case Filed by Rite Aid Corporation and Rite Aid Hdqtrs. Corp.:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July 9, 2020, Rite Aid Corporation and Rite Aid Hdqtrs Corp. filed a complaint on their own behalf, and as assignee of McKesson Corporation with regard to drugs sold by McKesson to Rite Aid, against the Company&#x2019;s U.S. subsidiary and forty-six other defendants, involving a total of one hundred thirty-five generic drugs, alleging an &#x201c;overarching conspiracy&#x201d; to fix prices and to rig bids and allocate customers with respect to these drugs. On December 15, 2020, Rite Aid filed an Amended Complaint against a total of fifty-five defendants involving a total of one hundred eighty eight drugs. In the Amended Complaint, the Company&#x2019;s U.S. subsidiary is specifically named with respect to eleven drugs: allopurinol, ciprofloxacin ER, divalproex ER, fluconazole, glimepiride, meprobamate, oxaprozine, paricalcitol, ranitidine, tizanidine and zoledronic acid. Plaintiff alleges that the Company&#x2019;s U.S. subsidiary was part of a larger &#x201c;overarching conspiracy&#x201d; with all other manufacturers named as to all of the drugs named in the complaint; and, alternatively, was part of an overarching conspiracy with eighteen of the defendants named with regard to forty-five of the drugs named. The complaint also alleges violations of Section 1 of the Sherman Act, 15 U.S.C. &#xa7;1. The complaint seeks injunctive relief, recovery of treble damages, and attorney&#x2019;s fees and costs against all defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims. &lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;u) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Complaint Filed by Suffolk County, New York:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August 27, 2020, Suffolk County, New York, filed a complaint against the Company&#x2019;s U.S. subsidiary and forty-six other defendants, involving a total of one hundred thirty generic drugs, alleging an &#x201c;overarching conspiracy&#x201d; to fix prices and to rig bids and allocate customers with respect to these drugs. The Company&#x2019;s U.S. subsidiary is specifically named with respect to twelve drugs: ciprofloxacin ER, divalproex ER, fenofibrate, fluconazole, glimepiride, glyburide, metformin, oxaprozin, pravastatin, ranitidine, tizanidine and zoledronic acid. Plaintiffs allege that the Company&#x2019;s U.S. subsidiary was part of a larger &#x201c;overarching conspiracy&#x201d; with all other manufacturers named as to all of the drugs named in the complaint. The complaint also alleges violations of Section 1 of the Sherman Act, 15 U.S.C. &#xa7;1. The complaint seeks injunctive relief, recovery of treble damages, and attorney&#x2019;s fees and costs against all defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;v) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Complaint Filed by J M Smith:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September 4, 2020, J M Smith Corporation, as assignee of Burlington Drug Company, filed a complaint against the Company&#x2019;s U.S. subsidiary and fifty other defendants, involving a total of one hundred thirty generic drugs, alleging an &#x201c;overarching conspiracy&#x201d; to fix prices and to rig bids and allocate customers with respect to these drugs. The Company&#x2019;s U.S. subsidiary is specifically named with respect to eleven drugs: allopurinol, ciprofloxacin ER, divalproex ER, fluconazole, glimepiride, meprobamate, oxaprozin, paricalcitol&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt; ranitidine, tizanidine and zoledronic acid. &lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plaintiffs allege that the Company&#x2019;s U.S. subsidiary was part of a larger &#x201c;overarching conspiracy&#x201d; with all other manufacturers named as to all of the drugs named in the complaint; The complaint also alleges violations of Section 1 of the Sherman Act, 15 U.S.C. &#xa7;1. The complaint seeks injunctive relief, recovery of treble damages, and attorney&#x2019;s fees and costs against all defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;w) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Complaint Filed by Walgreen Company:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December 11, 2020, Walgreen Company filed a complaint against the Company&#x2019;s U.S. subsidiary and fifty-four other defendants, involving a total of one hundred eighty-eight generic drugs, alleging an &#x201c;overarching conspiracy&#x201d; to fix prices and to rig bids and allocate customers with respect to these drugs. Walgreen asserts claims on its own behalf and as assignee of Amerisource Bergen for drugs that Amerisource Bergen sold to Walgreen. The Company&#x2019;s U.S. subsidiary is specifically named with respect to eleven drugs: allopurinol, &lt;/div&gt;ciprofloxacin ER, divalproex ER, fluconazole, glimepiride, meprobamate, oxaprozin, paricalcitol, ranitidine, tizanidine and zoledronic acid. Plaintiff alleges that the Company&#x2019;s U.S. subsidiary was part of a larger &#x201c;overarching conspiracy&#x201d; with all other manufacturers named as to all of the drugs named in the complaint. The complaint also alleges violations of Section 1 of the Sherman Act, 15 U.S.C. &#xa7;1. The complaint seeks injunctive relief, recovery of treble damages, and attorney&#x2019;s fees and costs against all defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;United States Antitrust Multi-District Litigations (continued)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;x) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Complaint Filed by CVS Pharmacy Inc.:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December 15, 2020, CVS Pharmacy, Inc., filed a complaint against the Company&#x2019;s U.S. subsidiary and fifty-seven other defendants, involving a total of four hundred four generic drugs, alleging an &#x201c;overarching conspiracy&#x201d; to fix prices and to rig bids and allocate customers with respect to these drugs. CVS Pharmacy asserts claims on its own behalf and as assignee of Cardinal Health and McKesson for drugs that Cardinal Health and McKesson sold to CVS Pharmacy, Inc. The Company&#x2019;s U.S. subsidiary is specifically named with respect to seven drugs: ciprofloxacin ER, glimepiride, meprobamate, oxaprozin, pravastatin, tizanidine and zoledronic acid. Plaintiff alleges that the Company&#x2019;s U.S. subsidiary was part of a larger &#x201c;overarching conspiracy&#x201d; with all other manufacturers named as to all of the drugs named in the complaint. The complaint also alleges violations of Section 1 of the Sherman Act, 15 U.S.C. &#xa7;1. The complaint seeks injunctive relief, recovery of treble damages, and attorney&#x2019;s fees and costs against all defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0in; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;y) &lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Complaint Filed by Various Counties, Cities and Insurance Companies:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0in; text-align: justify; text-indent: 0.13in;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0in; text-align: justify; text-indent: 0.26in;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December 15, 2020, a Complaint was filed in the Supreme Court of the State of New York, Suffolk County, by a group of 22 plaintiffs against the Company and &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;5 other defendants. Plaintiffs include 14 New York Counties (Albany, Cattaraugus, Chemung, Chenango, Columbia, Erie, Essex, Livingston, Monroe, Oneida, Onondaga, Otsego&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&#160;Schuyler&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and Yates&lt;/div&gt;), the Town of Amherst, New York, the City of Poughkeepsie, New York, the City of Mobile, Alabama, the Counties of Osceola, Florida, and Shelby, Tennessee, and three insurance companies (Magnacare Insurance, Mebco and WCA Group Health Trust). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 11pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The case has been transferred to, and consolidated with, the MDL litigation. The Complaint was amended on June 30, 2021. The Amended Complaint&lt;/div&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;alleges an overarching conspiracy to fix prices and allocate markets for 294 generic drugs. Of the 294 drugs, DRL is specifically named with respect to 14 drugs: Allopurinol, Ciprofloxacin, Divalproex, Glimepiride, Glyburide Metformin, Isotretinoin, Lamotrigine, Meprobamate, Metoprolol Succinate, Oxaprozin, Paricalcitol, Tizanidine, Valganciclovir and Zoledronic Acid. The Complaint alleges violations of Sections 1 and 2 of the Sherman Act, as well as violations of the Antitrust Statutes of Alabama, Florida, New York and Tennessee and Unjust Enrichment claims under the laws of Alabama, Florida, New York and Tennessee. The complaint seeks injunctive relief, recovery of treble damages, and attorney&#x2019;s fees and costs against all defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font-style: normal; font-variant: normal; font-size: 10pt; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-stretch: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: bold 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;z&lt;/div&gt;)&lt;/div&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Antitrust Complaint Filed by Westchester County, New York&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September 21, 2021, a Complaint was filed in the Supreme Court of the State of New York, Westchester County, by Westchester County against the Company and 57 other defendants. The case has been removed to the United States District Court for the Southern District of New York and is in the process of being transferred to, and consolidated with, the MDL-2724 litigation. The complaint alleges an overarching conspiracy to fix prices and allocate markets for approximately 294 generic drugs. Of the 294 drugs, the Company is specifically named with respect to 3 drugs: Divalproex, Meprobamate, and Zoledronic Acid. The complaint alleges violations of Sections 1 and 3 of the Sherman Act, Sections 4 and 16 of the Clayton Act, and the Antitrust Statutes of New York, as well as Unjust Enrichment claims under the laws of New York. The complaint seeks injunctive relief, recovery of treble damages, and attorney&#x2019;s fees and costs against all defendants on a joint and several basis. The Company denies any wrongdoing and intends to vigorously defend against these claims.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="text-indent: 0px;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;

&lt;div style="text-indent: 0px; margin-bottom: 1em; margin-top: 1em"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.15in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;aa)&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Pennsylvania Court of Common Pleas Praecipe For a Writ of Summons Filed by 21 End Payor Entities consisting of AmeriHealth entities and other health insurance companies&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;







































































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October 21, 2021, a Praecipe For a Writ of Summons for a tort action was filed in the Pennsylvania Court of Common Pleas of Philadelphia County, First Judicial District of Pennsylvania, Civil Trial Division, by 21 AmeriHealth entities and other health insurance companies, against the Company&#x2019;s U.S. subsidiary and 74 other defendants (consisting of 50 other pharmaceutical companies and 24 individuals). Only a Praecipe of Writ of Summons has been filed. No complaint has been filed and, therefore, the potential claims have not been asserted or delineated in any manner, including what drugs any such claims may relate to. A complaint may, at some point, be filed encompassing the claims asserted by the End Payor Plaintiff class actions in the MDL-2724 actions. It is anticipated that this action will be placed in Deferred Status Pending Further Developments in the related MDL-2724 case. Because no Complaint has been filed setting forth any claims, and because it is expected that the action will be placed into Deferred Status, no response is required by the Company&#x2019;s subsidiary at this time.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Note on Antitrust Complaints&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company believes that the aforesaid asserted claims in subsections a) though aa) above are without merit and intends to vigorously defend itself against the allegations. Also, any liability that may arise on account of these claims is unascertainable. Accordingly, no provision was made in these consolidated financial statements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Class Action under the Canadian Competition Act filed in Federal Court in Toronto, Canada&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 20.6pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June 3, 2020, a Class Action Statement of Claim was filed by an individual consumer in Federal Court in Toronto, Canada, against the Company&#x2019;s U.S. and Canadian subsidiaries and 52 other generic drug companies. The Statement of Claim alleges an industry-wide, overarching conspiracy to violate Section&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;36&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;of the Canadian Competition Act by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs in Canada. The action is brought on behalf of a class of all persons, from January 1, 2012 to the present, who purchased generic drugs in the private sector. The Statement of Claim states that it seeks damages against all defendants on a joint and several basis, attorney&#x2019;s fees and costs of investigation and prosecution. An Amended Statement of Claim was served on the Company&#x2019;s U.S. and Canadian subsidiaries on January 15, 2021 and adds an additional 20 generic drug companies. The Amended Statement of Claim also removes the identification of defendant companies with conspiracy allegations regarding specific generic drugs and alleges a conspiracy to allocate the North America Market as to all generic drugs in Canada.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company believes that the asserted claims are without merit and intends to vigorously defend itself against the allegations. Any liability that may arise on account of this claim is unascertainable. Accordingly, no provision was made in these consolidated financial statements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Civil litigation with Mezzion&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January 13, 2017, Mezzion Pharma Co. Ltd. and Mezzion International LLC (collectively, &#x201c;Mezzion&#x201d;) filed a complaint in the New Jersey Superior Court against the Company and its wholly owned subsidiary in the United States. The complaint pertains to the production and supply of the active pharmaceutical ingredient (&#x201c;API&#x201d;) for udenafil (a patented compound) and an udenafil finished dosage product during a period from calendar years 2007 to 2015. Mezzion alleges that the Company failed to comply with the U.S. FDA&#x2019;s current Good Manufacturing Practices (&#x201c;cGMP&#x201d;) at the time of manufacture of the API and finished dosage forms of udenafil and, consequently, that this resulted in a delay in the filing of a NDA for the product by Mezzion. The Company filed a motion to dismiss Mezzion&#x2019;s complaint on the technical grounds that the Court lacks jurisdiction over the Company. In January 2018, the Court denied the Company&#x2019;s motion to dismiss the complaint on the jurisdictional matter. The Company&#x2019;s interlocutory appeal of said denial was also denied. The case is continuing in pretrial discovery.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company denies any wrongdoing or liability in this regard, and intends to vigorously defend against the claims asserted in Mezzion&#x2019;s complaint. Any liability that may arise on account of this claim is unascertainable. Accordingly, no provision was made in these consolidated financial statements.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Civil Litigation and Arbitration with Hatchtech Pty Limited&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September 7, 2015, the Company&#x2019;s Swiss subsidiary, Dr. Reddy&#x2019;s Laboratories, S.A., entered into an Asset Purchase Agreement (&#x201c;APA&#x201d;) with Hatchtech Pty Limited (&#x201c;Hatchtech&#x201d;). Pursuant to the APA, the Company&#x2019;s subsidiary acquired from Hatchtech the patented product Xeglyze&#xae;, a topical lousicidal lotion for the treatment of head lice, and all rights in the product. The APA provides that the Company would seek to obtain New Drug Application (&#x201c;NDA&#x201d;) approval from the U.S. FDA, and would then commercialize the product in the United States. The APA specifies certain milestone payments to be paid by the Company&#x2019;s Swiss subsidiary to Hatchtech, including a U.S.$20 NDA approval milestone payment, a U.S.$25 ovicidal label approval milestone payment, and certain net sales milestone payments. &lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July 24, 2020, the Company received the NDA approval from the U.S. FDA for the Xeglyze&#xae; product. &lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September 25, 2020, the Company&#x2019;s Swiss subsidiary filed an action in Delaware Chancery Court against Hatchtech to rescind the APA based upon claims of fraud, negligent misrepresentations and mutual mistake in connection with the acquisition of the product Xeglyze&#xae;, which was dismissed as being untimely under the Delaware statute of limitations. &lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;
&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October 8, 2020, Hatchtech filed an arbitration demand against the Swiss subsidiary before the American Arbitration Association, International Center for Dispute Resolution (&#x201c;AAA-ICDR&#x201d;), in New York City, claiming that it was owed&lt;/div&gt; U.S.$20 for the NDA approval milestone and U.S.$25 for the ovicidal label approval milestone. &lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January 25, 2021, the Company&#x2019;s Swiss subsidiary filed a Writ of Summons and Statement of Claim in Victoria at Melbourne, Australia, against Hatchtech (as a nominal party), certain of its officers and a principal shareholder, alleging misrepresentations in connection with the acquisition of the Xeglyze&#xae; product and seeking damages and other relief.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Based on its best estimate, the Company had recorded a provision for potential liability of U.S.$20 relating to the AAA-ICDR arbitration filed by Hatchtech and believed that the likelihood of any further liability that may arise pursuant to that arbitration to be not probable. &lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June 14, 2021, the Company received the arbitration decision and an award was issued by the AAA-ICDR in favor of Hatchtech in an amount of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;U.S.$46.25 towards milestone payments, interest and fees.&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Of the total amount of U.S.$46.25 awarded to Hatchtech, the amount of U.S.$45 (Rs.3,291) was recognized in the consolidated income statement under the heading &#x201c;Impairment of non-current assets&#x201d; and the balance of U.S.$1.25 (Rs.91) was recognized under the heading, &#x201c;Selling, general and administrative expenses&#x201d;. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February 2, 2022, the Company and Hatchtech entered into a Global &#x201c;Settlement and Transfer Agreement&#x201d; dated February 2, 2022 pursuant to which the APA and all other agreements between the Company and Hatchtech were terminated, the pending litigation in Australia&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;was dismissed with prejudice, the Company and Hatchtech exchanged mutual general releases of all claims that they had or may have against each other, and the Company transferred the Xeglyze&#xae; product (and all patents and intellectual property relating to the Xeglyze&#xae; product) back to Hatchtech for the sum of US&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;$1 which Hatchtech paid and the Company received on February 15, 2022.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Securities Class Action Litigation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August 25, 2017, a securities class action lawsuit was filed against the Company, its Chief Executive Officer and its Chief Financial Officer in the United States District Court for the District of New Jersey. The Company&#x2019;s Co-Chairman, its Chief Operating Officer, and Dr. Reddy&#x2019;s Laboratories, Inc., were also subsequently named as defendants in the case. The operative complaint alleges that the Company made false or misleading statements or omissions in its public filings, in violation of U.S. federal securities laws, and that the Company&#x2019;s share price dropped and its investors were affected. On May 9, 2018, the Company and other defendants filed a motion to dismiss the complaint in the United States District Court for the District of New Jersey.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June 25, 2018, the plaintiffs filed an opposition to the motion to dismiss and, on July 25, 2018, a further reply in support of the motion to dismiss was filed by the Company. In August 2018, oral argument on the motion to dismiss was heard by the Court.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March 21, 2019, the District Court issued its decision granting in part and denying in part the motion to dismiss. Pursuant to that decision, the Court dismissed the plaintiffs claims with respect to seventeen out of the twenty two alleged misstatements and omissions. On May 15, 2020, Dr. Reddy&#x2019;s Laboratories Limited, Dr. Reddy&#x2019;s Laboratories, Inc., and certain of the Company&#x2019;s current or former directors and officers have entered into a Stipulation and Agreement of Settlement (the &#x201c;Stipulation&#x201d;) with lead plaintiff the Public Employees&#x2019; Retirement System of Mississippi in the putative securities class action filed against the defendants in the United States District Court for the District of New Jersey. As consideration for the settlement of the class action, the Company has agreed to pay U.S.$9.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The settlement is subject to the approval of the court and may be terminated prior to court approval pursuant to the grounds for termination set forth in the Stipulation. Subject to the terms of the Stipulation, in exchange for the settlement consideration, the lead plaintiff and members of the settlement class who do not opt-out of this settlement would release, among other things, the claims that were asserted, or that they could have asserted, in this class action. In entering into the settlement, the defendants do not admit, and explicitly deny, any liability or wrongdoing of any kind.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subject to the terms of the Stipulation, the settlement resolves the remainder of the litigation.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As the Company is adequately insured with respect to the aforesaid liability, the settlement did not have any impact on the Company&#x2019;s consolidated income statement for the year ended March 31, 2020.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The amount payable to the plaintiffs on account of the settlement and the corresponding receivable from the insurer have been presented under &#x201c;other current assets&#x201d; and &#x201c;other current liabilities&#x201d;, respectively, in the consolidated statement of financial position of the Company as of March 31, 2020.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December 23, 2020, the court issued a final order and judgment approving the settlement. Pursuant to the settlement/court order, the escrow was funded on January 4, 2021. The effective date of the settlement occurred on February 1, 2021, upon transfer of the settlement fund balance into the final escrow account. As the transfer of funds to the final escrow account constitutes settlement of liability, the amount of liability has been derecognized during the&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;year&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;ended March 31, 2021.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Veraring Litigation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;A Complaint was filed on November 15, 2021 in the Supreme Court of the State of New York, County of New York (trial court level) by Teva Pharmaceutical Industries Ltd. (&#x201c;Teva&#x201d;) against Dr. Reddy's Laboratories, S.A. (Case Index&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; No. 656499/2021).&#160; This Complaint was subsequently amended by Teva on January 26, 2022. &#160;In its Amended Complaint, Teva alleges that the Company breached the supply agreements between the parties relating to Veraring, failed to pay carrying costs, and breached the implied covenant of good faith and fair dealing, seeking monetary damages and all other remedies available under law.&#160; On January 6, 2022, the Company asserted counterclaims against Teva, asserting that Teva breached its contractual obligations to the Company by, among other things, failing to adhere to cGMP and producing product unfit for human use, seeking monetary damages and all other remedies available under law.&#160;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; line-height: 10pt; font-size: 10pt;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company believes that it is too early to speculate as to outcome, either with respect to liability or damages, and intends to vigorously defend against the claims made by Teva, while zealously prosecuting its affirmative counterclaims.&lt;/div&gt;&lt;/div&gt;

&lt;div style="text-align: justify; margin-bottom: 0.0001pt; margin-top: 0px; font-family: Calibri, sans-serif; font-size: 10pt; text-indent: 0px; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Other matters&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="text-align: justify; margin-bottom: 0.0001pt; margin-top: 0px; font-family: Calibri, sans-serif; font-size: 10pt; text-indent: 0px; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="text-align: justify; margin-bottom: 0.0001pt; margin-top: 0px; font-family: Calibri, sans-serif; font-size: 10pt; text-indent: 0px; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Internal Investigation&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt; font-family: Calibri, sans-serif; font-size: 10pt; text-indent: 0px; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"/&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt; font-family: Calibri, sans-serif; font-size: 10pt; text-indent: 0.25in; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0in; letter-spacing: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;The Company received an anonymous complaint in September 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0in; letter-spacing: 0px; line-height: 10pt; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;, alleging that healthcare professionals in Ukraine and potentially in other countries were provided with improper payments by or on behalf of the Company in violation of U.S. anti-corruption laws, specifically the U.S. Foreign Corrupt Practices Act. The Company disclosed the matter to the U.S. Department of Justice (&#x201c;DOJ&#x201d;), Securities and Exchange Commission (&#x201c;SEC&#x201d;) and Securities Exchange Board of India. The Company engaged a U.S. law firm to conduct the investigation at the instruction of a committee of the Company&#x2019;s Board of Directors. On July 6, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt; the Company received a subpoena from the SEC for the production of related documents, which were provided to the SEC.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt; font-family: Calibri, sans-serif; font-size: 10pt; text-indent: 0px; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt; font-family: Calibri, sans-serif; text-indent: 0.26in; font-size: 10pt; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company shared the report with respect to one&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt; country with the SEC and the DOJ during the three&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt; months ended September 30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;, and certain other countries in the three&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt; months ended March 31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;, and subsequent to the year end. The Company is complying with its listing obligations as it relates to updating the regulatory agencies. While the findings from the aforesaid investigations could result in government enforcement actions against the Company in the United States and/or foreign jurisdictions, which can lead to civil and criminal sanctions under relevant laws, the outcomes including liabilities are not reasonably ascertainable at this time.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt; font-family: Calibri, sans-serif; font-size: 10pt; text-indent: 0px; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="text-align: justify; margin-bottom: 0pt; margin-top: 0pt; font-family: Calibri, sans-serif; font-size: 10pt; text-indent: 0px; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Civil Investigative Demand from the Office of the Attorney General, State of Texas&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font-size: 11pt; text-align: justify; margin-bottom: 0pt; font-family: Calibri, sans-serif; text-indent: 0px; margin-top: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font-size: 11pt; text-align: justify; margin-bottom: 0pt; font-family: Calibri, sans-serif; text-indent: 0.26in; margin-top: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;;display:inline;"&gt;On or about November 10, 2014, Dr. Reddy&#x2019;s Laboratories, Inc., one of the Company&#x2019;s subsidiaries in the United States, received a Civil Investigative Demand (&#x201c;CID&#x201d;) from the Office of the Attorney General, State of Texas (the &#x201c;Texas AG&#x201d;) requesting certain information, documents and data regarding sales and price reporting practices in the U.S. marketplace for certain products (the &#x201c;Covered Conduct&#x201d;) for the time-period between January 1, 1995 and the date of the CID. On or about June 23, 2021, the Texas AG contacted the Company&#x2019;s counsel to request additional information related to the Texas AG&#x2019;s investigation and the Covered Conduct for the time-period of October 1, 2003 through February 29, 2012.&#160; The Company has continued to cooperate and respond to the Texas AG&#x2019;s requests for information related to the Covered Conduct.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font-size: 11pt; text-align: justify; margin-bottom: 0pt; font-family: Calibri, sans-serif; text-indent: 0.26in; margin-top: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font-size: 11pt; text-align: justify; margin-bottom: 0pt; font-family: Calibri, sans-serif; text-indent: 0.26in; margin-top: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif;;display:inline;"&gt;As on March 31, 2022, the Company based on its best estimate, was carrying a provision of Rs.983 in this regard.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font-size: 11pt; text-align: justify; margin-bottom: 0pt; font-family: Calibri, sans-serif; text-indent: 0.26in; margin-top: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font-size: 10pt; text-align: justify; margin-bottom: 0pt; font-family: Calibri, sans-serif; text-indent: 0.26in; margin-top: 0pt; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June 1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;, Dr. Reddy&#x2019;s Laboratories, Inc. entered into a Settlement Agreement and Release with the Texas AG and the Texas Health &amp;amp; Human Services Commission related to the Covered Conduct.&#160; Pursuant to the Settlement Agreement and Release, Dr. Reddy&#x2019;s Laboratories, Inc. will pay the total sum of U.S.$12.9&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt; to the State of Texas as a full and final settlement of any claims being investigated by the State of Texas in relation to the Covered Conduct.&#160; Neither Dr. Reddy&#x2019;s Laboratories, Inc. nor the Company has admitted to any facts or liability in connection with this settlement.&#160;The settlement is a compromise and settlement on disputed issues of fact and law.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font-size: 11pt; text-align: justify; margin-bottom: 0pt; font-family: Calibri, sans-serif; text-indent: 0.26in; margin-top: 0pt; line-height: 12pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subpoena duces tecum from the Office of the Attorney General, California&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On November 3, 2014, Dr. Reddy&#x2019;s Laboratories, Inc. received a subpoena duces tecum to appear before the Office of the Attorney General, California (the &#x201c;California AG&#x201d;) and produce records and documents relating to the pricing of certain products. A set of five interrogatories related to pricing practices was served as well. On July 18, 2016, the California AG sent a letter to inform Dr. Reddy&#x2019;s Laboratories, Inc. that, in light of the information which had been provided, no further information would be requested at such time in response to this subpoena.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subpoenas from the Antitrust Division of the U.S. Department of Justice (&#x201c;DOJ&#x201d;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July 6, 2016, Dr. Reddy&#x2019;s Laboratories, Inc. received &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;a &lt;/div&gt;subpoena&#160;from the DOJ (Anti-trust Division) seeking information relating to the marketing, pricing and sale of certain of our generic products and any communications with competitors about such products. On May 15, 2018, another subpoena was served on Dr. Reddy&#x2019;s Laboratories, Inc. by the DOJ (False Claims Division) seeking similar information. The Company has been cooperating, and intends to continue to fully cooperate, with these inquiries.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Civil Investigative Demand from Civil Division of the DOJ&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May 15, 2018, Dr. Reddy&#x2019;s Laboratories, Inc. received a Civil Investigative Demand from the Civil Division of the DOJ, enquiring whether there have been any violations of the U.S. False Claims Act. This query arose from allegations that generic pharmaceutical manufacturers, including us, have engaged in market allocation or price fixing agreements, or paid illegal remuneration, and caused false claims to be submitted in violation of the U.S. False Claims Act. The Company has been cooperating, and intends to continue to fully cooperate with the DOJ in responding to the demand.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0in; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Environmental matters&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Land pollution&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Indian Council for Environmental Legal Action filed a writ in 1989 under Article 32 of the Constitution of India against the Union of India and others in the Supreme Court of India for the safety of people living in the Patancheru and Bollaram areas of Medak district of the then existing undivided state of Andhra Pradesh. The Company has been named in the list of polluting industries. In 1996, the Andhra Pradesh District Judge proposed that the polluting industries compensate farmers in the Patancheru, Bollaram and Jeedimetla areas for discharging &lt;/div&gt;effluents which damaged the farmers&#x2019; agricultural land. The compensation was fixed at Rs.0.0013 per acre for dry land and Rs.0.0017 per acre for wet land. Accordingly, the Company has paid a total compensation of Rs.3. The Andhra Pradesh High Court disposed of the writ petition on February 12, 2013 and transferred the case to the National Green Tribunal (&#x201c;NGT&#x201d;), Chennai, India. The interim orders passed in the writ petitions will continue until the matter is decided by the NGT. The NGT has, through its order dated October 30, 2015, constituted a Fact Finding Committee.&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The NGT has also permitted the alleged polluting industries to appoint a person on their behalf in the Fact Finding Committee. However, the Company, along with the alleged polluting industries, has challenged the constitution and composition of the Fact Finding Committee. The NGT has directed that until all the applications challenging the constitution and composition of the Fact Finding Committee are disposed of, the Fact Finding Committee shall not commence its operation.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The NGT, Chennai in a judgment dated October 24, 2017, disposed of the matter. The Bulk Drug Manufacturers Association of India (&#x201c;BDMAI&#x201d;), in which the Company is a member, subsequently filed a review petition against the judgment on various aspects.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The NGT, Delhi, in a judgment dated November 16, 2017 in another case in which the Company is not a party, stated that the moratorium imposed in the Patancheru and Bollaram areas shall continue until the Ministry of Environment, Forest and Climate Change passes an order keeping in view the needs of the environment and public health. The Company filed an appeal challenging this judgment.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The High Court of Hyderabad heard the Company&#x2019;s appeal challenging this judgment in July 2018 and directed the respondents to file their response within a period of four weeks. During the three months ended September 30, 2018, the respondents filed counter affidavits and the matter has now been adjourned for final hearing.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The appeal came up for hearing before the High Court of Hyderabad on October 25, 2018 and has been adjourned for further hearing. The Hon&#x2019;ble High Court has closed the matter in June 2022, by granting liberty for the Company to take proper recourse for remedies available under the NGT Act, 2010 before the Hon&#x2019;ble Supreme Court of India.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On April 24, 2019, based upon the judgment of the NGT, Chennai dated October 24, 2017, the Government of Telangana has issued GO.Ms. No. 24 of 2019 that allows for expansion of production of all kinds of existing industrial units located within the stretch of Patancheru&#160;&#x2013; Bollaram upon depositing an amount equivalent to 1% of the annual turnover of the respective unit for the concluded fiscal year, i.e., March 31, 2019. Accordingly, the Company made a provision of Rs.29.4, representing the probable cost of expansion, during the year ended March 31, 2019. &lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the three months ended September, 2019, the Telangana State Pollution Control Board (&#x201c;TSPCB&#x201d;) has issued Operational Guidelines basis the NGT, Chennai Order dated October 24, 2017, G.O.Ms. No. 24 dated April 24, 2019 and G.O.Ms. No. 31 dated May 24, 2019 and sought to recover retrospectively an amount of 0.5% of the annual turnover from the fiscal years 2016-2017 to 2018-2019 for all the industrial units situated in Patancheru and Bollaram for the purposes of restoration of the said effected area. The Company has four industrial units situated in Patancheru and Bollaram. The Consent For Operation (&#x201c;CFO&#x201d;) for change of product mix application filed by one of the industrial unit of the Company has been recommended for issuance of CFO with change of product mix only upon payment of 0.5% of the annual turnover from the fiscal years 2016-2017 to 2018-2019 to the TSPCB. The Company intends to vigorously defend itself against the Operational Guidelines.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In November 2019, demand notices were issued by the TSPCB for collection of Corpus Fund of 0.5 % as remediation fee on the previous year turnover as per Operational Guidelines dated August 3, 2019 issued by TSPCB under the guise of G.O.Ms No. 24 dated April 24, 2019 and G.O.Ms No. 31 dated May 24, 2019 and basis the judgment of NGT, Chennai dated October 24, 2017 for the fiscal years 2015-2016 to 2018-2019 received by CTO-1, CTO-2&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;CTO-3 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;and CTO-5&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;of the Company. &lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On November 22, 2019, The Hon&#x2019;ble High Court of Judicature at Hyderabad issued an Interim Order which stayed the demand on the condition that the Company deposit Rs.60 as the remediation fee for the fiscal year 2018-2019 payable in the fiscal year 2019-2020. The deposit of Rs.60 was made and the Interim Order is continuing. The matter was adjourned to April 22, 2020 but has been delayed as a result of the closure of the Court due to the COVID-19 lockdown, and a new date has not yet been rescheduled.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Hon&#x2019;ble High Court has disposed the matter with a liberty to the Company to approach NGT, if necessary.&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;The Company believes that any additional liability that might arise in this regard is not probable. Accordingly, no provision relating to these claims has been made in the &lt;/div&gt;&lt;div style="font-size: 11pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;consolidated&lt;/div&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;financial statements.&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Water pollution and air pollution&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March 31, 2012, the Company, along with 14 other companies, received a notice from the Andhra Pradesh Pollution Control Board (the &#x201c;APP Control Board&#x201d;) to show cause as to why action should not be initiated against them for violations under the Indian Water Pollution Act and the Indian Air Pollution Act. Furthermore, the APP Control Board issued orders to the Company to (i)&#160;stop production of all new products at the Company&#x2019;s manufacturing facilities in Hyderabad, India without obtaining a &#x201c;Consent for Establishment&#x201d;, (ii) cease manufacturing products at such facilities in excess of certain quantities specified by the APP Control Board and (iii) furnish a bank guarantee to assure compliance with the APP Control Board&#x2019;s orders.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company appealed the APP Control Board orders to the Andhra Pradesh Pollution Appellate Board (the &#x201c;APP Appellate Board&#x201d;). The APP Appellate Board, on the basis of a report of a fact-finding advisory committee, recommended to the Andhra Pradesh Government to allow expansion of units fully equipped with Zero-Liquid Discharge (&#x201c;ZLD&#x201d;) facilities and otherwise found no fault with the Company (on certain conditions). The APP Appellate Board&#x2019;s decision was challenged by one of the petitioners that was pending in the National Green Tribunal, (the &#x201c;NGT&#x201d;), Delhi.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Separately, the Andhra Pradesh Government, following recommendations of the APP Appellate Board, published a notification in July 2013 that allowed expansion of production of all types of existing bulk drug and bulk drug intermediate manufacturing units subject to the installation of ZLD facilities and the outcome of cases pending in the NGT. Importantly, the notification directed pollution load of industrial units to be assessed at the point of discharge (if any) as opposed to the point of generation.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In September 2013, the Ministry of Environment and Forests, based on the revised Comprehensive Environment Pollution Index, issued a notification that re-imposed a moratorium on expansion of industries in certain areas where some of the Company&#x2019;s manufacturing facilities are located. This notification overrides the Andhra Pradesh Government&#x2019;s notification that conditionally permitted expansion.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The appeals filed by Mr. K. Chidambaram against the Orders of the Appellate Authority, Andhra Pradesh are disposed as the same do not survive for consideration as the G.O. based on which the then APPCB had passed its order which was subject matter of appeal before the Appellate Authority has itself been amended vide order July 25, 2013. However, the NGT, Delhi has passed a direction for the issue of pollution to be considered by the Joint Committee of Central Pollution Control Board, National Environmental Engineering Institute (&#x201c;NEERI&#x201d;), and the Telangana State Pollution Control Board to ascertain the present status of pollution issues in the Medak, Ranga Reddy, Mahaboobnagar and Nalagonda districts in the State of Telangana particularly in the Patancheru and Bollaram industrial clusters and file a report within three months before the NGT, Delhi.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fuel Surcharge Adjustments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Andhra Pradesh Electricity Regulatory Commission (the &#x201c;APERC&#x201d;) passed various orders approving the levy of Fuel Surcharge Adjustment (&#x201c;FSA&#x201d;) charges for the period from April 1, 2008 to March 31, 2013 by power distribution companies from all the consumers of electricity in the then existing undivided state of Andhra Pradesh, India where the Company&#x2019;s headquarters and principal manufacturing facilities are located. Separate writ petitions filed by the Company for various periods, challenging and questioning the validity and legality of this levy of FSA charges by the APERC, are pending before the High Court of Andhra Pradesh and the Supreme Court of India.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total amount approved by APERC for collection by the power distribution companies from the Company in respect of FSA charges for the period from April&#160;1,&#160;2008 to March 31, 2013 is Rs.482. After taking into account all of the available information and legal provisions, the Company has recorded Rs.219 as the potential liability towards FSA charges.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;However, the Company has paid, under protest, an amount of Rs.354 as demanded by the power distribution companies as part of monthly electricity bills. The Company remains exposed to additional financial liability should the orders passed by the APERC be upheld by the Courts.&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the three months ended June 30, 2016, the Supreme Court of India dismissed the Special Leave Petition filed by the Company in this regard for the period from April 1, 2012 to March 31, 2013. As a result, for the quarter ended June&#160;30,&#160;2016, the Company recognized an expenditure of Rs.55 (by de-recognizing the payments under protest) representing the FSA charges for the period from April&#160;1, 2012 to March&#160;31, 2013.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Indirect taxes related matters&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Value Added Tax (&#x201c;VAT&#x201d;) matter&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has received various demand notices from the Government of Telangana&#x2019;s Commercial Taxes Department objecting to the Company&#x2019;s methodology of calculation of VAT input credit. The below table shows the details of each of such demand notice, the amount demanded and the current status of the Company&#x2019;s responsive actions.&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr&gt;
			&lt;td style="width: 26%; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Period covered under the notice&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 32%; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount demanded&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 42%; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Status&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;April 2006 to March 2009&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.66 plus 10% penalty&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The State VAT Appellate Tribunal has remanded the matter to the assessing authority to re-compute the eligibility and penalty orders are set-aside. The Company filed appeal against the same with the High Court, Telangana. &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="width: 26%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;April 2009 to March 2011&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 32%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.59 plus 10% penalty&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 42%; text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has filed an appeal before the Sales Tax Appellate Tribunal. The matter was remanded to the original adjudicating authority with a direction to re-calculate the eligibility for the year ended March 31, 2010.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="vertical-align: bottom; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;April 2011 to March 2014&lt;/div&gt;&lt;/td&gt;
			&lt;td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.27 plus 10% penalty&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Appellate Deputy Commissioner issued an order partially in favor of the Company&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;























</ifrs-full:DisclosureOfContingentLiabilitiesExplanatory>
    <rdy:PaymentOfCostsAndDamages
      contextRef="P04_01_2021To03_31_2022"
      decimals="-6"
      unitRef="Unit_USD">72000000</rdy:PaymentOfCostsAndDamages>
    <rdy:PaymentsReceivablePursuantToLitigation
      contextRef="PAsOn06_23_2022"
      decimals="-6"
      unitRef="Unit_USD">72000000</rdy:PaymentsReceivablePursuantToLitigation>
    <rdy:IssuedNoticeDemandingPaymentByNppa
      contextRef="PAsOn03_31_2006_NorfloxacinIndiaLitigationMemberRDYLegalProceedingsContingentLiabilityAxis"
      decimals="-6"
      unitRef="Unit_INR">285000000</rdy:IssuedNoticeDemandingPaymentByNppa>
    <rdy:PercentageOfAmountDischargedAgainstPenalty
      contextRef="P04_01_2021To03_31_2022_NorfloxacinIndiaLitigationMemberRDYLegalProceedingsContingentLiabilityAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</rdy:PercentageOfAmountDischargedAgainstPenalty>
    <rdy:AmountDischargedAgainstPenalty
      contextRef="PAsOn03_31_2006_NorfloxacinIndiaLitigationMemberRDYLegalProceedingsContingentLiabilityAxis"
      decimals="-6"
      unitRef="Unit_INR">77000000</rdy:AmountDischargedAgainstPenalty>
    <rdy:AdditionalDepositAmountAgainstPenalty
      contextRef="PAsOn03_31_2008_NorfloxacinIndiaLitigationMemberRDYLegalProceedingsContingentLiabilityAxis"
      decimals="-6"
      unitRef="Unit_INR">30000000</rdy:AdditionalDepositAmountAgainstPenalty>
    <rdy:IssuedNoticeDemandingPaymentByNppa
      contextRef="PAsOn07_27_2017_CardiovascularMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">776000000</rdy:IssuedNoticeDemandingPaymentByNppa>
    <rdy:AmountDirectedToBeDepositedByCourt
      contextRef="PAsOn08_08_2017_CardiovascularMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">100000000</rdy:AmountDirectedToBeDepositedByCourt>
    <rdy:BankGuaranteeDirectedByDelhiHighCourtToBeFurnished
      contextRef="PAsOn09_15_2017_CardiovascularMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">676000000</rdy:BankGuaranteeDirectedByDelhiHighCourtToBeFurnished>
    <rdy:DepositMadeOnDemand
      contextRef="PAsOn09_13_2017_CardiovascularMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">100000000</rdy:DepositMadeOnDemand>
    <rdy:BankGuarantee
      contextRef="PAsOn09_15_2017_CardiovascularMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">676000000</rdy:BankGuarantee>
    <ifrs-full:OtherProvisions
      contextRef="PAsOn03_31_2022_CardiovascularMemberifrsfullSegmentsAxis"
      decimals="-6"
      unitRef="Unit_INR">353000000</ifrs-full:OtherProvisions>
    <rdy:SettlementCompensationPaid
      contextRef="PAsOn01_18_2018_ConsumerProductSafetyCommissionMemberRDYLegalProceedingsContingentLiabilityAxis"
      decimals="-6"
      unitRef="Unit_USD">5000000</rdy:SettlementCompensationPaid>
    <rdy:SettlementCompensationPaid
      contextRef="PAsOn01_18_2018_ConsumerProductSafetyCommissionMemberRDYLegalProceedingsContingentLiabilityAxis"
      decimals="-6"
      unitRef="Unit_INR">319000000</rdy:SettlementCompensationPaid>
    <rdy:SettlementCompensationHeldInEscrow
      contextRef="PAsOn08_23_2020_NamendaLitigationMemberRDYLegalProceedingsContingentLiabilityAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</rdy:SettlementCompensationHeldInEscrow>
    <rdy:MilestonePayment
      contextRef="P09_07_2015To09_07_2015_AssetPurchaseAgreementMemberRDYAgreementAxis_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis_HatchtechPtyLimitedMemberdeiLegalEntityAxis_NdaApprovedMemberRDYMilestoneAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</rdy:MilestonePayment>
    <rdy:MilestonePayment
      contextRef="P09_07_2015To09_07_2015_AssetPurchaseAgreementMemberRDYAgreementAxis_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis_HatchtechPtyLimitedMemberdeiLegalEntityAxis_OvicidalLabelApprovedMemberRDYMilestoneAxis"
      decimals="-6"
      unitRef="Unit_USD">25000000</rdy:MilestonePayment>
    <rdy:ArbitationDemandRecordedTowardsMilestonePayments
      contextRef="PAsOn10_08_2020_AssetPurchaseAgreementMemberRDYAgreementAxis_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis_HatchtechPtyLimitedMemberdeiLegalEntityAxis_NdaApprovedMemberRDYMilestoneAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</rdy:ArbitationDemandRecordedTowardsMilestonePayments>
    <rdy:ArbitationDemandRecordedTowardsMilestonePayments
      contextRef="PAsOn10_08_2020_AssetPurchaseAgreementMemberRDYAgreementAxis_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis_HatchtechPtyLimitedMemberdeiLegalEntityAxis_OvicidalLabelApprovedMemberRDYMilestoneAxis"
      decimals="-6"
      unitRef="Unit_USD">25000000</rdy:ArbitationDemandRecordedTowardsMilestonePayments>
    <ifrs-full:LegalProceedingsProvision
      contextRef="PAsOn01_25_2021_AaaicdrArbitrationMemberRDYAssociationAndDisputeResolutionAxis_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis"
      decimals="-6"
      unitRef="Unit_USD">20000000</ifrs-full:LegalProceedingsProvision>
    <rdy:SettlementCompensationTowardsMilestonePaymentsNetOfInterestAndFees
      contextRef="PAsOn06_14_2021_NonadjustingEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis"
      decimals="-4"
      unitRef="Unit_USD">46250000</rdy:SettlementCompensationTowardsMilestonePaymentsNetOfInterestAndFees>
    <rdy:AmountAwardedAgainstTheArbitrationLiability
      contextRef="P04_01_2021To03_31_2022_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis_HatchtechPtyLimitedMemberdeiLegalEntityAxis"
      decimals="-4"
      unitRef="Unit_USD">46250000</rdy:AmountAwardedAgainstTheArbitrationLiability>
    <rdy:LossContingencyAmountRecordedAsImpairmentOfNoncurrentAssets
      contextRef="P04_01_2021To03_31_2022_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis_HatchtechPtyLimitedMemberdeiLegalEntityAxis_ImpairmentOfNoncurrentAssetsMemberRDYIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_USD">45000000</rdy:LossContingencyAmountRecordedAsImpairmentOfNoncurrentAssets>
    <rdy:LossContingencyAmountRecordedAsImpairmentOfNoncurrentAssets
      contextRef="P04_01_2021To03_31_2022_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis_HatchtechPtyLimitedMemberdeiLegalEntityAxis_ImpairmentOfNoncurrentAssetsMemberRDYIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_INR">3291000000</rdy:LossContingencyAmountRecordedAsImpairmentOfNoncurrentAssets>
    <rdy:LossContingencyAmountRecordedAsExpense
      contextRef="P04_01_2021To03_31_2022_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis_HatchtechPtyLimitedMemberdeiLegalEntityAxis_SellingGeneralAndAdministrativeExpenseMemberRDYIncomeStatementLocationAxis"
      decimals="-4"
      unitRef="Unit_USD">1250000</rdy:LossContingencyAmountRecordedAsExpense>
    <rdy:LossContingencyAmountRecordedAsExpense
      contextRef="P04_01_2021To03_31_2022_CivilLitigationAndArbitrationWithHatchtechPtyLimitedMemberRDYLegalProceedingsContingentLiabilityAxis_HatchtechPtyLimitedMemberdeiLegalEntityAxis_SellingGeneralAndAdministrativeExpenseMemberRDYIncomeStatementLocationAxis"
      decimals="-6"
      unitRef="Unit_INR">91000000</rdy:LossContingencyAmountRecordedAsExpense>
    <rdy:ConsiderationReceivedForTransferOfXeglyzeProduct
      contextRef="P02_15_2022To02_15_2022_SettlementAndTransferAgreementDated2February2022MemberRDYAgreementAxis"
      decimals="-6"
      unitRef="Unit_USD">1000000</rdy:ConsiderationReceivedForTransferOfXeglyzeProduct>
    <rdy:SettlementCompensationPaid
      contextRef="PAsOn05_15_2020_SecuritiesClassActionLitigationMemberRDYLegalProceedingsContingentLiabilityAxis"
      decimals="-6"
      unitRef="Unit_USD">9000000</rdy:SettlementCompensationPaid>
    <rdy:PayableTowardsSettlement
      contextRef="PAsOn06_01_2022_NonadjustingEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_TexasAgAndTexasHealthAndHumanServicesCommissionMembersrtCounterpartyNameAxis"
      decimals="-5"
      unitRef="Unit_USD">12900000</rdy:PayableTowardsSettlement>
    <rdy:PollutionCompensationPerAcreFixedForDryLand
      contextRef="P04_01_2021To03_31_2022_LandPollutionMemberRDYLegalProceedingsContingentLiabilityAxis"
      decimals="4"
      unitRef="Unit_INR_acre">0.0013</rdy:PollutionCompensationPerAcreFixedForDryLand>
    <rdy:PollutionCompensationPerAcreFixedForWetLand
      contextRef="P04_01_2021To03_31_2022_LandPollutionMemberRDYLegalProceedingsContingentLiabilityAxis"
      decimals="4"
      unitRef="Unit_INR_acre">0.0017</rdy:PollutionCompensationPerAcreFixedForWetLand>
    <rdy:SecurityDepositForExpansionOnTurnover
      contextRef="P04_01_2021To03_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.01</rdy:SecurityDepositForExpansionOnTurnover>
    <rdy:ProvisionForCostOfExpansion
      contextRef="PAsOn03_31_2022"
      decimals="-5"
      unitRef="Unit_INR">29400000</rdy:ProvisionForCostOfExpansion>
    <rdy:DepositOnDemandForRemediationFee
      contextRef="PAsOn01_31_2020"
      decimals="-6"
      unitRef="Unit_INR">60000000</rdy:DepositOnDemandForRemediationFee>
    <rdy:TotalAmountApprovedByApercForCollectionRegardingFsaCharges
      contextRef="P04_01_2008To03_31_2013_FuelSurchargeAdjustmentsMemberRDYDisallowanceAxis"
      decimals="-6"
      unitRef="Unit_INR">482000000</rdy:TotalAmountApprovedByApercForCollectionRegardingFsaCharges>
    <rdy:PaymentsUnderProtest
      contextRef="P04_01_2008To03_31_2013_FuelSurchargeAdjustmentsMemberRDYDisallowanceAxis"
      decimals="-6"
      unitRef="Unit_INR">219000000</rdy:PaymentsUnderProtest>
    <rdy:PaymentsUnderProtest
      contextRef="P04_01_2012To03_31_2013_FuelSurchargeAdjustmentsMemberRDYDisallowanceAxis"
      decimals="-6"
      unitRef="Unit_INR">354000000</rdy:PaymentsUnderProtest>
    <ifrs-full:FuelAndEnergyExpense
      contextRef="P04_01_2016To06_30_2016_FuelSurchargeAdjustmentsMemberRDYDisallowanceAxis"
      decimals="-6"
      unitRef="Unit_INR">55000000</ifrs-full:FuelAndEnergyExpense>
    <rdy:DisclosureOfShowCauseNoticesIssuedByCommercialTaxesDepartmentRegardingVatInputCreditTableTextBlock contextRef="P04_01_2021To03_31_2022">The below table shows the details of each of such demand notice, the amount demanded and the current status of the Company&#x2019;s responsive actions.
&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; padding-top: 0pt; padding-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt; &lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr&gt;
			&lt;td style="width: 26%; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Period covered under the notice&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 32%; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount demanded&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 42%; text-align: center; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Status&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;April 2006 to March 2009&lt;/div&gt;&lt;/td&gt;
			&lt;td&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.66 plus 10% penalty&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The State VAT Appellate Tribunal has remanded the matter to the assessing authority to re-compute the eligibility and penalty orders are set-aside. The Company filed appeal against the same with the High Court, Telangana. &lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="width: 26%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;April 2009 to March 2011&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 32%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.59 plus 10% penalty&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 42%; text-align: justify;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has filed an appeal before the Sales Tax Appellate Tribunal. The matter was remanded to the original adjudicating authority with a direction to re-calculate the eligibility for the year ended March 31, 2010.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="vertical-align: bottom; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;April 2011 to March 2014&lt;/div&gt;&lt;/td&gt;
			&lt;td style="border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.27 plus 10% penalty&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Appellate Deputy Commissioner issued an order partially in favor of the Company&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;

























&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"/&gt;

































































&lt;div style="clear: both; max-height: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"/&gt;


&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has recorded a provision of Rs.51 as of March 31, 2022 and believes that the likelihood of any further liability that may arise on account of the ongoing litigation is not probable.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;
</rdy:DisclosureOfShowCauseNoticesIssuedByCommercialTaxesDepartmentRegardingVatInputCreditTableTextBlock>
    <rdy:DemandMadeByCommercialTaxesDepartmentToCompanyExcludingPenaltyAndInterest
      contextRef="P04_01_2006To03_31_2009"
      decimals="-6"
      unitRef="Unit_INR">66000000</rdy:DemandMadeByCommercialTaxesDepartmentToCompanyExcludingPenaltyAndInterest>
    <rdy:PercentageOfPenaltyChargedByCommercialTaxesDepartmentToCompany
      contextRef="P04_01_2006To03_31_2009"
      decimals="2"
      unitRef="Unit_pure">0.10</rdy:PercentageOfPenaltyChargedByCommercialTaxesDepartmentToCompany>
    <rdy:DemandMadeByCommercialTaxesDepartmentToCompanyExcludingPenaltyAndInterest
      contextRef="P04_01_2009To03_31_2011"
      decimals="-6"
      unitRef="Unit_INR">59000000</rdy:DemandMadeByCommercialTaxesDepartmentToCompanyExcludingPenaltyAndInterest>
    <rdy:PercentageOfPenaltyChargedByCommercialTaxesDepartmentToCompany
      contextRef="P04_01_2009To03_31_2011"
      decimals="2"
      unitRef="Unit_pure">0.10</rdy:PercentageOfPenaltyChargedByCommercialTaxesDepartmentToCompany>
    <rdy:DemandMadeByCommercialTaxesDepartmentToCompanyExcludingPenaltyAndInterest
      contextRef="P04_01_2011To03_31_2014"
      decimals="-6"
      unitRef="Unit_INR">27000000</rdy:DemandMadeByCommercialTaxesDepartmentToCompanyExcludingPenaltyAndInterest>
    <rdy:PercentageOfPenaltyChargedByCommercialTaxesDepartmentToCompany
      contextRef="P04_01_2011To03_31_2014"
      decimals="2"
      unitRef="Unit_pure">0.10</rdy:PercentageOfPenaltyChargedByCommercialTaxesDepartmentToCompany>
    <rdy:VatProvisionRecorded
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">51000000</rdy:VatProvisionRecorded>
    <rdy:NoticeReceivedFromCommissionerOfGoodsAndServicesTaxIndiaAllegingThatTheCompanyIrregularlyAvailedInputTaxCredit
      contextRef="P01_31_2020To01_31_2020"
      decimals="-6"
      unitRef="Unit_INR">307000000</rdy:NoticeReceivedFromCommissionerOfGoodsAndServicesTaxIndiaAllegingThatTheCompanyIrregularlyAvailedInputTaxCredit>
    <rdy:TaxDemandReceivedFromGstAuthorities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">31000000</rdy:TaxDemandReceivedFromGstAuthorities>
    <rdy:ProvisionForTaxDemandFromGstAuthorities
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">31000000</rdy:ProvisionForTaxDemandFromGstAuthorities>
    <rdy:PaymentsUnderProtest
      contextRef="P02_28_2022To02_28_2022"
      decimals="-6"
      unitRef="Unit_INR">123000000</rdy:PaymentsUnderProtest>
    <rdy:DemandMadeByIndianSalesTaxAuthoritiesToCompany
      contextRef="PAsOn03_31_2022"
      decimals="-6"
      unitRef="Unit_INR">463000000</rdy:DemandMadeByIndianSalesTaxAuthoritiesToCompany>
    <rdy:CollaborationLicenseAndOptionAgreementTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;. Collaboration, License and Option Agreement with Curis, Inc.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January 18, 2015, Aurigene Discovery Technologies Limited (&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;"&lt;/div&gt;ADTL&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;"&lt;/div&gt;), a wholly-owned subsidiary of the parent company, entered into a Collaboration, License and Option Agreement (as amended, the "Collaboration Agreement") with Curis, Inc. (&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;"&lt;/div&gt;Curis&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;"&lt;/div&gt;) to discover, develop and commercialize small molecule antagonists for immuno-oncology and precision oncology targets.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenues under the Collaboration Agreement consist of upfront consideration (including shares of Curis common stock) and the development and commercial milestone payments (including royalties) which are deferred and recognized as revenue over the period for which ADTL has continuing performance obligations.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As a partial consideration for the collaboration, the following shares of common stock of Curis were issued to ADTL:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of Curis&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;shares (pre-split)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 64%; text-align: left;"&gt;Pursuant to the collaboration agreement dated January 18, 2015&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;17.1 million&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.1,452 (U.S.$23.5)&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Pursuant to an amendment to collaboration agreement dated September 7, 2016 (Common stock in lieu of receiving up to U.S.$24.5 of milestone and other payments)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10.2 million&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.1,247 (U.S.$18.8)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                                                            &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has classified all of the shares of Curis common stock received, as a partial consideration for the collaboration, as an investment in equity instruments measured at FVTOCI.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-align: justify; text-indent: 0.25in; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2018, Curis completed a 1-for-5 reverse stock split of its common stock. After giving effect to such stock split, the total number of Curis equity shares held by the Company is 5.47 million.&lt;/div&gt;&lt;/div&gt;  &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table is a summary of the details of cost, fair value, and the amount recognized in OCI of the fair value changes:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31, 2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&#160;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Received on January 18, 2015&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs. &lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,452&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(834)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;618&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 61%; padding-bottom: 0.5pt;"&gt;Received on September 7, 2016&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; border-bottom: 1pt solid black;"&gt;1,247&lt;/td&gt;&lt;td style="width: 1%; text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; border-bottom: 1pt solid black;"&gt;(879&lt;/td&gt;&lt;td style="width: 1%; text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; border-bottom: 1pt solid black;"&gt;368&lt;/td&gt;&lt;td style="width: 1%; text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,699&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,713)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;986&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                                                 </rdy:CollaborationLicenseAndOptionAgreementTextBlock>
    <rdy:DisclosureOfDetailedInformationOfPartialConsiderationUnderCollaborationLicenseAndOptionAgreementTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As a partial consideration for the collaboration, the following shares of common stock of Curis were issued to ADTL:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 0.5pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of Curis&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;shares (pre-split)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt; white-space: nowrap;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 64%; text-align: left;"&gt;Pursuant to the collaboration agreement dated January 18, 2015&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;17.1 million&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.1,452 (U.S.$23.5)&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Pursuant to an amendment to collaboration agreement dated September 7, 2016 (Common stock in lieu of receiving up to U.S.$24.5 of milestone and other payments)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10.2 million&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.1,247 (U.S.$18.8)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                             </rdy:DisclosureOfDetailedInformationOfPartialConsiderationUnderCollaborationLicenseAndOptionAgreementTextBlock>
    <ifrs-full:NumberOfSharesIssued
      contextRef="PAsOn01_18_2015_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis"
      decimals="-5"
      unitRef="Unit_shares">17100000</ifrs-full:NumberOfSharesIssued>
    <rdy:FairValueOfInstrumentsOrInterests
      contextRef="PAsOn01_18_2015_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis"
      decimals="-6"
      unitRef="Unit_INR">1452000000</rdy:FairValueOfInstrumentsOrInterests>
    <rdy:FairValueOfInstrumentsOrInterests
      contextRef="PAsOn01_18_2015_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">23500000</rdy:FairValueOfInstrumentsOrInterests>
    <rdy:MilestoneAndOtherPaymentsToBeReceived
      contextRef="PAsOn09_07_2016_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">24500000</rdy:MilestoneAndOtherPaymentsToBeReceived>
    <rdy:NumberOfAdditionalSharesToBeIssuedUnderAmendmentOfCollaborationAgreement
      contextRef="PAsOn09_07_2016_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis"
      decimals="-5"
      unitRef="Unit_shares">10200000</rdy:NumberOfAdditionalSharesToBeIssuedUnderAmendmentOfCollaborationAgreement>
    <rdy:FairValueOfInstrumentsOrInterests
      contextRef="PAsOn09_07_2016_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis"
      decimals="-6"
      unitRef="Unit_INR">1247000000</rdy:FairValueOfInstrumentsOrInterests>
    <rdy:FairValueOfInstrumentsOrInterests
      contextRef="PAsOn09_07_2016_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">18800000</rdy:FairValueOfInstrumentsOrInterests>
    <rdy:ReverseStockSplit contextRef="P05_01_2018To05_31_2018_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis">1-for-5</rdy:ReverseStockSplit>
    <rdy:EquitySharesAfterStockSplit
      contextRef="PAsOn05_31_2019_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis"
      decimals="-4"
      unitRef="Unit_shares">5470000</rdy:EquitySharesAfterStockSplit>
    <ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory contextRef="P04_01_2021To03_31_2022_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table is a summary of the details of cost, fair value, and the amount recognized in OCI of the fair value changes:&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March 31, 2022&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cost&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&#160;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;Received on January 18, 2015&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs. &lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1,452&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Rs.&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(834)&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;618&lt;/td&gt;&lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 61%; padding-bottom: 0.5pt;"&gt;Received on September 7, 2016&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; border-bottom: 1pt solid black;"&gt;1,247&lt;/td&gt;&lt;td style="width: 1%; text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; border-bottom: 1pt solid black;"&gt;(879&lt;/td&gt;&lt;td style="width: 1%; text-align: left; padding-bottom: 0.5pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left; border-bottom: 1pt solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right; border-bottom: 1pt solid black;"&gt;368&lt;/td&gt;&lt;td style="width: 1%; text-align: left; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,699&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1,713)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Rs.&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: 1pt solid black;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;986&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 0.5pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;                        </ifrs-full:DisclosureOfFairValueOfEachInvestmentInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncomeExplanatory>
    <rdy:AmortisedCostOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="PAsOn03_31_2022_CollaborationAgreementMemberRDYAgreementAxis_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis"
      decimals="-6"
      unitRef="Unit_INR">1452000000</rdy:AmortisedCostOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <rdy:FairValueGainsLossesOnInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="PAsOn03_31_2022_CollaborationAgreementMemberRDYAgreementAxis_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis"
      decimals="-6"
      unitRef="Unit_INR">-834000000</rdy:FairValueGainsLossesOnInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="PAsOn03_31_2022_CollaborationAgreementMemberRDYAgreementAxis_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis"
      decimals="-6"
      unitRef="Unit_INR">618000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <rdy:AmortisedCostOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="PAsOn03_31_2022_AmendmentToCollaborationAgreementMemberRDYAgreementAxis_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis"
      decimals="-6"
      unitRef="Unit_INR">1247000000</rdy:AmortisedCostOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <rdy:FairValueGainsLossesOnInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="PAsOn03_31_2022_AmendmentToCollaborationAgreementMemberRDYAgreementAxis_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis"
      decimals="-6"
      unitRef="Unit_INR">-879000000</rdy:FairValueGainsLossesOnInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="PAsOn03_31_2022_AmendmentToCollaborationAgreementMemberRDYAgreementAxis_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis"
      decimals="-6"
      unitRef="Unit_INR">368000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <rdy:AmortisedCostOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="PAsOn03_31_2022_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis"
      decimals="-6"
      unitRef="Unit_INR">2699000000</rdy:AmortisedCostOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <rdy:FairValueGainsLossesOnInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="PAsOn03_31_2022_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis"
      decimals="-6"
      unitRef="Unit_INR">-1713000000</rdy:FairValueGainsLossesOnInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome
      contextRef="PAsOn03_31_2022_CurisIncMemberRDYNamePartyInvolvedInTransactionAxis"
      decimals="-6"
      unitRef="Unit_INR">986000000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
    <rdy:DisclosureOfMergerOfDrReddysHoldingsLimitedInToDrReddysLaboratoriesLimitedExplanatoryTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;. Merger of Dr. Reddy&#x2019;s Holdings Limited into Dr. Reddy&#x2019;s Laboratories Limited&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.4pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Board of Directors, at its meeting held on July 29, 2019, had approved the amalgamation of Dr. Reddy&#x2019;s Holdings Limited (&#x201c;DRHL&#x201d;), an entity held by the Promoter Group, which holds 24.83% of Dr. Reddy&#x2019;s Laboratories Limited (the &#x201c;Company&#x201d;) into the Company (the &#x201c;Scheme&#x201d;). This Scheme&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;is subject to the approval of shareholders, stock exchanges, the National Company Law Tribunal (&#x201c;NCLT&#x201d;) and other relevant regulators as per the provisions of Section 230 to 232 and any other applicable provisions of the Companies Act, 2013.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Scheme will lead to simplification of the shareholding structure and reduction of shareholding tiers. The Promoter Group cumulatively would continue to hold the same number of shares in the Company, pre and post the amalgamation. All costs, charges and expenses relating to the Scheme will be borne out of the surplus assets of DRHL. Further, any expense, if exceeding the surplus assets of DRHL, will be borne directly by the Promoters.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the fiscal year ended March 31, 2020, the Scheme was approved by the board of directors, members and unsecured creditors of the Company. The no-observation letters from the BSE Limited and National Stock Exchange of India Limited were received on the basis of no comments received from Securities and Exchange Board of India (&#x201c;SEBI&#x201d;). The petition for approval of the said Scheme was filed with the Hon&#x2019;ble NCLT, Hyderabad Bench.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0.26in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:normal;letter-spacing:0px;top:0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The aforementioned Scheme was approved by the NCLT, Hyderabad Bench vide its Order dated &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt; April 5, 2022. Subsequently, the Company filed the NCLT order, with the Ministry of Company Affairs on April 8, 2022 (&#x2018;Effective Date&#x2019;). Pursuant to the Scheme of Amalgamation and Arrangement as approved by the NCLT, an aggregate of&lt;/div&gt; 41,325,300 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;equity shares, face value of Rs.&lt;/div&gt; 5 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;each held by DRHL in the share capital of the Company has been cancelled and an equivalent&lt;/div&gt; 41,325,300 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;number of equity shares, face value of Rs.&lt;/div&gt;&#160;5 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;each were allotted to the shareholders of DRHL. There is no change in the total equity shareholding (Promoter/Public Shareholding) of the Company, on account of the allotment/ cancellation of equity shares pursuant to the approved Scheme.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Scheme also provides that the Promoters of the Company will jointly and severally indemnify, defend and hold harmless the Company, its directors, employees, officers, representatives, or any other person authorized by the Company (excluding the Promoters) for any liability, claim, or demand, which may devolve upon the Company on account of this amalgamation.&lt;/div&gt;&lt;/div&gt;</rdy:DisclosureOfMergerOfDrReddysHoldingsLimitedInToDrReddysLaboratoriesLimitedExplanatoryTextBlock>
    <ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests
      contextRef="P07_29_2019To07_29_2019_DrReddysHoldingsLimitedMemberifrsfullBusinessCombinationsAxis"
      decimals="4"
      unitRef="Unit_pure">0.2483</ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests>
    <rdy:NumberOfEquitySharesHeldCancelledAsPerSchemeOfAmalgamationAndArrangement
      contextRef="P04_08_2022To04_08_2022_EventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis"
      decimals="INF"
      unitRef="Unit_shares">41325300</rdy:NumberOfEquitySharesHeldCancelledAsPerSchemeOfAmalgamationAndArrangement>
    <ifrs-full:ParValuePerShare
      contextRef="PAsOn04_08_2022_EventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">5</ifrs-full:ParValuePerShare>
    <rdy:NumberOfEquitySharesAllottedToShareholdersAsPerSchemeOfAmalgamationAndArrangement
      contextRef="P04_08_2022To04_08_2022_EventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis"
      decimals="INF"
      unitRef="Unit_shares">41325300</rdy:NumberOfEquitySharesAllottedToShareholdersAsPerSchemeOfAmalgamationAndArrangement>
    <ifrs-full:ParValuePerShare
      contextRef="PAsOn04_08_2022_EventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis"
      decimals="INF"
      unitRef="Unit_INR_per_Share">5</ifrs-full:ParValuePerShare>
    <rdy:DisclosureOfImpactOfCovid19AndMilitaryConflictBetweenRussiaAndUkraineExplanatoryTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;&lt;/div&gt;. Impact of COVID-19 and military conflict between Russia and Ukraine&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0.26in; text-indent: 0px;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0.26in; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impact of COVID-19&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-align: justify; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;The Company considered the uncertainty relating to the COVID-19 pandemic&#160;in assessing the recoverability of receivables, goodwill, intangible assets, investments and other assets. For this purpose, the Company considered internal and external sources of information up to the date of approval of these consolidated financial statements. The Company based on its judgments, estimates and assumptions including sensitivity analysis, expects to fully recover the carrying amount of receivables, goodwill, intangible assets, investments and other assets.&#160;The Company will continue to closely monitor any material changes to future economic conditions.&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impact&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;of military conflict between Russia and Ukraine&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="background: white; margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considered the uncertainty relating to the military conflict between Russia and Ukraine in assessing the recoverability of receivables, goodwill, intangible assets, investments and other assets. The outcome of the war is difficult to predict, and it could have an adverse impact on the macroeconomic environment. Management has considered all potential impacts of the war including adherence of global sanctions and other restrictive measures against Russia and any retaliatory actions taken by Russia. For this purpose, the Company considered internal and external sources of information up to the date of approval of these consolidated financial statements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background: white; margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background: white; margin: 0in 0in 0.0001pt; text-align: justify; text-indent: 0.25in; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;The Company&#x2019;s supply chain has been impacted primarily in Russia and Ukraine, both in terms of higher freight costs and increase in the lead time by suppliers. However, the Company has been able to service its customers without any significant shortages or disruptions. The Company based on its judgments, estimates and assumptions including sensitivity analysis, expects to fully recover the carrying amount of receivables, inventory, goodwill, intangible assets, investments and other assets. Accordingly, during the year ended March 31, 2022, the impact of this conflict on the Company&#x2019;s operations and financial condition was not material. The Company will continue to closely monitor any material changes to future economic conditions.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;   &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt;  &lt;div style="clear: both; max-height: 0pt; text-indent: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt;</rdy:DisclosureOfImpactOfCovid19AndMilitaryConflictBetweenRussiaAndUkraineExplanatoryTextBlock>
    <rdy:DisclosureOfupdateOnCyberIncidentTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;. Update on Cyber Incident&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October 22, 2020, the Company experienced a cybersecurity incident related to ransom-ware. The &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;C&lt;/div&gt;ompany employed two leading cyber security incident response firms to assist with the investigation process. The incident was contained in a timely fashion and an enterprise-wide remediation was undertaken to ensure all traces of infection are completely removed from the network. Since then, the Company has strengthened a series of technical controls to augment the current cyber security posture and has also focused on implementing significant improvements to its cyber and data security systems to safeguard from such risks in the future.&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 45pt; text-indent: -45pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</rdy:DisclosureOfupdateOnCyberIncidentTextBlock>
    <rdy:DisclosureOfTheCodeOnSocialSecurity2020TextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;. The Code on Social Security, 2020 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 22.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&#x2019;s Code on Social Security, 2020, which aims to consolidate, &lt;div style="display:inline;"&gt;c&lt;/div&gt;odify and revise certain existing social security laws, received Presidential assent in September 2020 and has been published in the Gazette of India. However, the related final rules have not yet been issued and the date on which this Code will come into effect has not been announced. The Company will assess the impact of this Code and the rules thereunder when they come into effect.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;</rdy:DisclosureOfTheCodeOnSocialSecurity2020TextBlock>
    <rdy:DisclosureOfRegulatoryInspectionOfFacilitiesExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt 0px; text-align: center; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px;;font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="margin: 0in -7pt 3pt -13.5pt; text-align: justify; text-indent: 0.25in; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;8&lt;/div&gt;&lt;/div&gt;. Regulatory Inspection of facilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;br/&gt;&lt;/div&gt;

&lt;div style="margin: 0in -7pt 3pt -13.5pt; text-align: justify; text-indent: 0.25in; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="margin: 0in -7pt 3pt -13.5pt; text-align: justify; text-indent: 0.25in; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Tabulated below are the details of the U.S. FDA inspections carried out at other facilities of the Company:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="margin: 0in -7pt 3pt -13.5pt; text-align: justify; text-indent: 0.25in; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border: none; border-spacing: 0px; text-indent: 0px; margin: 6pt 0px;"&gt;

		&lt;tr&gt;
			&lt;td style="width: 20%; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt; vertical-align: top; border-bottom: 0.75pt solid black;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family:Times New Roman,Times,serif;;display:inline;"&gt;&lt;div style="color:#000000;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Month a&lt;div style="background-color:#ffffff;;display:inline;"/&gt;nd year&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in 0in 0.375pt; line-height: 10pt; font-size: 10pt; vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 20%; padding: 0in 5.4pt; font-size: 10pt; border-bottom: 0.75pt solid black; line-height: 10pt; vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in 0in 0.375pt; line-height: 10pt; font-size: 10pt; vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 56%; padding: 0in 5.4pt; font-size: 10pt; border-bottom: 0.75pt solid black; line-height: 10pt; vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Details of observations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 20%; padding: 0in 5.4pt; font-size: 9pt; background-color: rgb(204, 238, 255); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;January 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgb(204, 238, 255); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 20%;/* padding: 0in 5.4pt; */font-size: 9pt;background-color: rgb(204, 238, 255);vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Formulations Srikakulam Plant (SEZ) Unit I&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgb(204, 238, 255); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 56%;/* padding: 0in 5.4pt; */font-size: 9pt;background-color: rgb(204, 238, 255);vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Four observations were noted. The Company responded to the observations and an &lt;div style="color: black; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EIR indicating the closure of audit for this facility was issued by the U.S. FDA &lt;/div&gt;i&lt;div style="color: black; letter-spacing: 0px; top: 0px;;display:inline;"&gt;n April&#160;2019. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 20%; padding: 0in 5.4pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;January 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 20%;/* padding: 0in 5.4pt; */font-size: 9pt;background-color: rgba(255, 255, 255, 0);vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 9pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;API manufacturing Plant at Miryalaguda, &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nalgonda&#173;&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 56%;/* padding: 0in 5.4pt; */font-size: 9pt;background-color: rgba(255, 255, 255, 0);vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;One observation was noted. The Company responded to the observation.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2019, an EIR was issued by the U.S. FDA indicating the closure of audit and the inspection classification of the facility was determined as Voluntary Action Initiated (&#x201c;VAI&#x201d;).&#160; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 20%; padding: 0in 5.4pt; font-size: 9pt; background-color: rgb(204, 238, 255); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;January 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgb(204, 238, 255); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 20%;/* padding: 0in 5.4pt; */font-size: 9pt;background-color: rgb(204, 238, 255);vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Formulations manufacturing facility at Bachupally, Hyderabad&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgb(204, 238, 255); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 56%;/* padding: 0in 5.4pt; */font-size: 9pt;background-color: rgb(204, 238, 255);vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eleven observations were noted. The Company responded to the observations in January 2019.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In April 2019, an EIR was issued by the U.S. FDA indicating the closure of audit and the inspection classification of the facility was determined as VAI. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 20%; padding: 0in 5.4pt; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 20%;/* padding: 0in 5.4pt; */font-size: 9pt;background-color: rgba(255, 255, 255, 0);vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aurigene&#160;Discovery&#160;Technologies Limited, Hyderabad&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 56%;/* padding: 0in 5.4pt; */font-size: 9pt;background-color: rgba(255, 255, 255, 0);vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No observations noted. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2019, the Company received an EIR from the U.S. FDA &lt;div style="color: black; letter-spacing: 0px; top: 0px;;display:inline;"&gt;indicating the closure of audit for this facility.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 20%; padding: 0in 5.4pt; font-size: 9pt; background-color: rgb(204, 238, 255); vertical-align: top;"&gt;
			&lt;div style="margin: 0px 0in; text-align: justify; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-size: 9pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;June&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgb(204, 238, 255); vertical-align: top;"&gt;
			&lt;div style="margin: 0px 0in; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 20%;/* padding: 0in 5.4pt; */font-size: 9pt;background-color: rgb(204, 238, 255);vertical-align: top;"&gt;
			&lt;div style="margin: 0px 0in; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-size: 9pt; text-indent: 0px;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Formulations manufacturing plants, Duvvada {Vizag SEZ plant 1 (FTO VII) and Vizag SEZ plant 2(FTO IX)}&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgb(204, 238, 255); vertical-align: top;"&gt;
			&lt;div style="margin: 0px 0in; text-align: justify; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 56%;/* padding: 0in 5.4pt; */font-size: 9pt;background-color: rgb(204, 238, 255);vertical-align: top;"&gt;
			&lt;div style="margin: 0px 0in; text-align: justify; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-size: 9pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Two observations were noted. The Company responded to the observations.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="margin: 0px 0in; text-align: justify; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-size: 9pt; text-indent: 0px;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In September 2019, an EIR was issued by the U.S. FDA indicating the closure of audit of these facilities.&lt;/div&gt; &lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;



&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="margin: 0in -7pt 3pt -13.5pt; text-align: justify; text-indent: 0.25in; font-family: Calibri, 'sans-serif'; font-size: 9pt;"/&gt;


&lt;div style="font: 10pt 'Times New Roman', Times, serif; margin: 0pt 0px; text-align: center; text-indent: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; border: none; border-spacing: 0px; text-indent: 0px; margin: 6pt auto 6pt 0px;"&gt;

		&lt;tr&gt;
			&lt;td style="width: 20%; padding: 0in 5.4pt; font-size: 9pt; border-bottom: 0.75pt solid black; vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; text-align: center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 9pt; background: white; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; color: black; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Month and year&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in 0in 0.375pt; line-height: 10pt; font-size: 10pt; vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 20%; padding: 0in 5.4pt 0.5px; font-size: 10pt; line-height: 10pt; border-bottom: 0.75pt solid black; vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt; text-align: center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;"&gt;Unit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in 0in 0.375pt; line-height: 10pt; font-size: 10pt; vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: center; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 56%; padding: 0in 5.4pt; font-size: 10pt; line-height: 10pt; border-bottom: 0.75pt solid black; vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt; text-align: center;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="line-height: 10pt; font-size: 10pt;;font-weight:bold;display:inline;"&gt;Details of observations&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;





























































&lt;table style="width: 100%; border-collapse: collapse; border: none; border-spacing: 0px; text-indent: 0px; margin: 0in auto 0in 0px;"&gt;

		&lt;tr&gt;
			&lt;td style="width: 20%; padding: 0in 5.4pt; font-size: 10pt; background-color: rgb(204, 238, 255); line-height: 10pt; vertical-align: top;"&gt;
			&lt;div style="margin: 0px 0in; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-size: 10pt; text-indent: 0px; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt;;display:inline;"&gt;July&#160;&lt;/div&gt;&lt;/div&gt;2019 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgb(204, 238, 255); vertical-align: top;"&gt;
			&lt;div style="margin: 0px 0in; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 20%; font-size: 10pt; background-color: rgb(204, 238, 255); line-height: 10pt; vertical-align: top;"&gt;
			&lt;div style="margin: 0px 0in; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-size: 10pt; text-indent: 0in; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;API Hyderabad plant 2, Bollaram, Hyderabad&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgb(204, 238, 255); vertical-align: top;"&gt;
			&lt;div style="margin: 0px 0in; text-align: justify; line-height: normal; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-size: 9pt;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 56%;/* padding: 0in 5.4pt; */font-size: 10pt;background-color: rgb(204, 238, 255);line-height: 10pt;vertical-align: top;"&gt;
			&lt;div style="margin: 0px 0in; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-size: 10pt; text-indent: 0px; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Five observations were noted during U.S. FDA inspection. The Company responded to the observations in August 2019.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="margin: 0px 0in; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; font-size: 10pt; text-indent: 0px; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2019, an EIR was issued by the U.S. FDA indicating the closure of audit and the inspection classification of the facility was determined as VAI. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 20%; padding: 0in 5.4pt; font-size: 10pt; background-color: rgba(255, 255, 255, 0); line-height: 10pt; vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;August 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 20%;/* padding: 0in 5.4pt; */font-size: 10pt;background-color: rgba(255, 255, 255, 0);line-height: 10pt;vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Formulations manufacturing plants, (Vizag SEZ plant 1)&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;, Duvvada, Visakhapatnam &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="margin: 0in 0in 0.0001pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;(FTO VII) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 56%;/* padding: 0in 5.4pt; */font-size: 10pt;background-color: rgba(255, 255, 255, 0);line-height: 10pt;vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Eight&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt; observations were noted. The Company responded to the observations in September 2019&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;In February 2020&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;, an EIR was issued by the U.S. FDA indicating the closure of audit and the inspection classification of the facility was determined as VAI.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 20%; padding: 0in 5.4pt; font-size: 10pt; background-color: rgb(204, 238, 255); line-height: 10pt; vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;August 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgb(204, 238, 255); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 20%;/* padding: 0in 5.4pt; */font-size: 10pt;background-color: rgb(204, 238, 255);line-height: 10pt;vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Formulations manufacturing facility at Shreveport, Louisiana, U.S.A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgb(204, 238, 255); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 56%;/* padding: 0in 5.4pt; */font-size: 10pt;background-color: rgb(204, 238, 255);line-height: 10pt;vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;No&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt; observations were noted.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;In October 2019&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;, an EIR was issued by the U.S. FDA indicating the closure of the audit and the inspection classification of the facility was determined as No&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt; Action Initiated (&#x201c;NAI&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 20%; padding: 0in 5.4pt; font-size: 10pt; background-color: rgba(255, 255, 255, 0); line-height: 10pt; vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;October 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 20%;/* padding: 0in 5.4pt; */font-size: 10pt;background-color: rgba(255, 255, 255, 0);line-height: 10pt;vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;API Srikakulam plant (SEZ), Andhra Pradesh&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 56%;/* padding: 0in 5.4pt; */font-size: 10pt;background-color: rgba(255, 255, 255, 0);line-height: 10pt;vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Four&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt; observations were noted. The Company responded to the observations in November 2019&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;In May 2020&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;, an EIR was issued by the U.S. FDA indicating the closure of the audit.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 20%; padding: 0in 5.4pt; font-size: 10pt; background-color: rgb(204, 238, 255); line-height: 10pt; vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;February 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgb(204, 238, 255); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 20%;/* padding: 0in 5.4pt; */font-size: 10pt;background-color: rgb(204, 238, 255);line-height: 10pt;vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Formulations Srikakulam Plant (SEZ) Unit I&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgb(204, 238, 255); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 56%;/* padding: 0in 5.4pt; */font-size: 10pt;background-color: rgb(204, 238, 255);line-height: 10pt;vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;No&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt; observations were noted. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;In May 2020&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;, an EIR was issued by the U.S. FDA indicating the closure of the audit and the inspection classification of the facility was determined as NAI.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 20%; padding: 0in 5.4pt; font-size: 10pt; background-color: rgba(255, 255, 255, 0); line-height: 10pt; vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;February 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 20%;/* padding: 0in 5.4pt; */font-size: 10pt;background-color: rgba(255, 255, 255, 0);line-height: 10pt;vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Formulations manufacturing facility at Bachupally, Hyderabad (FTO Unit III)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 56%;/* padding: 0in 5.4pt; */font-size: 10pt;background-color: rgba(255, 255, 255, 0);line-height: 10pt;vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;One&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt; observation was noted. The Company responded to the observation in March 2020&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;. &lt;div style="color: black; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;In May 2020, an EIR was issued by the U.S. FDA indicating the closure of the audit and &lt;/div&gt;the inspection classification of the facility was determined as VAI.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 20%; padding: 0in 5.4pt; font-size: 10pt; background-color: rgb(204, 238, 255); line-height: 10pt; vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;February 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgb(204, 238, 255); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 20%;/* padding: 0in 5.4pt; */font-size: 10pt;background-color: rgb(204, 238, 255);line-height: 10pt;vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Integrated Product Development Organization (IPDO) at Bachupally, Hyderabad&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgb(204, 238, 255); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 56%;/* padding: 0in 5.4pt; */font-size: 10pt;background-color: rgb(204, 238, 255);line-height: 10pt;vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;No&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt; observation was noted. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;In May 2020&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;, an EIR was issued by the U.S. FDA indicating the closure of the audit and the inspection classification of the facility was determined as NAI.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="width: 20%; padding: 0in 5.4pt; font-size: 10pt; background-color: rgba(255, 255, 255, 0); line-height: 10pt; vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;March&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 20%;/* padding: 0in 5.4pt; */font-size: 10pt;background-color: rgba(255, 255, 255, 0);line-height: 10pt;vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: 10pt; text-indent: 0in;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;API manufacturing Plant at Miryalaguda, Nalgonda&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 2%; padding: 0in; font-size: 9pt; background-color: rgba(255, 255, 255, 0); vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; line-height: normal; font-family: Calibri, 'sans-serif'; font-size: 9pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, &amp;quot;serif&amp;quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;;white-space:pre-wrap;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 56%;/* padding: 0in 5.4pt; */font-size: 10pt;background-color: rgba(255, 255, 255, 0);line-height: 10pt;vertical-align: top;"&gt;
			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;Three&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt; observations were noted. The Company responded to the observations in March 2020&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="margin: 0in 0in 0.0001pt; text-align: justify; font-family: Calibri, &amp;quot;sans-serif&amp;quot;; font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;In April 2020&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;, an EIR was issued by the U.S. FDA indicating the closure of the audit and the inspection classification of the facility was determined as VAI.&#160; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;


		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="text-align: justify; background-color: rgb(204, 238, 255); width: 20%; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;March&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); width: 2%; vertical-align: top;"&gt;
			&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); width: 20%; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;API Middleburgh Plant, New York, United States&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; background-color: rgb(204, 238, 255); width: 2%; vertical-align: top;"&gt;
			&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; background-color: rgb(204, 238, 255); width: 56%; vertical-align: top;"&gt;
			&lt;div style="margin-left: 0in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Three observations were noted. In February 2022, an EIR was issued by the U.S. FDA indicating the closure of the audit.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="text-align: justify; background-color: rgba(255, 255, 255, 0); width: 20%; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;April&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); width: 2%; vertical-align: top;"&gt;
			&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); width: 20%; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Integrated Product Development Organization (IPDO), Bachupally, Hyderabad, India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); width: 2%; vertical-align: top;"&gt;
			&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0px;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgba(255, 255, 255, 0); width: 56%; vertical-align: top;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No observations noted.&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;EIR/Remote Record Review Summary was received on August 10, 2021 and the U.S. FDA concluded that this remote record review is closed.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="text-align: justify; background-color: rgb(204, 238, 255); width: 20%; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;October 2021&lt;/div&gt;&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); width: 2%; vertical-align: top;"&gt;
			&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="background-color: rgb(204, 238, 255); width: 20%; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Formulations manufacturing facilities {Vizag SEZ plant 1 (FTO VII) and Vizag SEZ plant 2 (FTO IX&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;} at Duvvada, Visakhapatnam, India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="text-align: justify; background-color: rgb(204, 238, 255); width: 2%; vertical-align: top;"&gt;
			&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="text-align: justify; background-color: rgb(204, 238, 255); width: 56%; vertical-align: top;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Eight observations were noted. In February 2022, an EIR was issued by the U.S. FDA indicating the closure of the audit.&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


</rdy:DisclosureOfRegulatoryInspectionOfFacilitiesExplanatory>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px 0pt -0.25in; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;39&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;. Subsequent events&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0in; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Please refer to Notes 20, 3&lt;div style="letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;"&gt;2&lt;/div&gt;&#160;and 34 of these consolidated financial statements for the details of subsequent events relating to the proposed dividend, contingencies and Merger of Dr. Reddy&#x2019;s Holdings Limited into Dr. Reddy&#x2019;s Laboratories Limited, respectively&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0in; text-align: justify; text-indent: 0.25in;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt / 12pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px 0pt 0in; text-align: justify; text-indent: 0.25in;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;On April 1, 2022, the Company has entered into an agreement with Novartis AG to acquire the cardiovascular brand Cidmus&#xae; in India. Under the agreement, the Company&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;completed the&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;acquisition of&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt; the Cidmus&#xae; trademark in India from Novartis AG for a consideration of &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;U.S.$&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;61&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-family: Calibri, sans-serif; font-size: 10pt; margin-left: 0.26in; text-indent: 0px; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-family: Calibri, sans-serif; font-size: 10pt; margin-left: 0in; text-indent: 0.25in; text-align: justify; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;On June 23, 2022, the Company allotted 15,169 equity shares to various employees (12,357 equity shares exercised at Rs.5 per share pursuant to the DRL 2002 Plan; 1,657 equity shares exercised at Rs.5 per share underlying &lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;1,657&lt;/div&gt; ADRs pursuant to the DRL 2007 plan; and 1,155 equity shares (575&lt;/div&gt;&lt;div style="font-family: Calibri, sans-serif; letter-spacing: 0px; top: 0px; line-height: 10pt; font-size: 10pt;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;equity shares exercised at Rs.2,814 per share and 580 equity shares exercised at Rs. 3,679 per share) underlying &lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;1,155&lt;/div&gt; ADRs pursuant to the DRL 2007 plan).&lt;/div&gt; &lt;br/&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-family: Calibri, sans-serif; font-size: 10pt; margin-left: 0.26in; text-indent: 0px; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-family: Calibri, sans-serif; font-size: 10pt; margin-left: 0in; text-indent: 0.25in; text-align: justify; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;On June 2&lt;div style="letter-spacing: 0px; top: 0px; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;3&lt;/div&gt;, 2022, the Company entered into a settlement agreement with Indivior Inc. and Indivior UK Limited, and Aquestive Therapeutics, Inc.&#160; Pursuant to the agreement the Company will receive payments totalling U.S.$72 by March 31, 2024. Please refer to Note 32 (&#x201c;Contingencies &#x2013; Product and patent related matters&#x201d;) of these consolidated financial statements.&lt;/div&gt; &lt;br/&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-family: Calibri, sans-serif; font-size: 10pt; margin-left: 0.26in; text-indent: 0px; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;

&lt;div style="margin-bottom: 0pt; margin-top: 0pt; font-family: Calibri, sans-serif; font-size: 9pt; margin-left: 0in; text-indent: 0.25in; text-align: justify; line-height: 12pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, serif; letter-spacing: 0px; top: 0px; line-height: 10pt; font-size: 10pt;;display:inline;"&gt;On June 24, 2022, the Company acquired a portfolio of branded and generic injectable products from Eton Pharmaceuticals, Inc., for an upfront payment of approximately U.S.$5 in cash, plus contingent payments of up to U.S.$45.&lt;/div&gt;&lt;/div&gt; &lt;br/&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <rdy:AssetAcquisitionConsiderationPayable
      contextRef="PAsOn04_01_2022_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_NovartisAGMemberRDYAcquireeAxis"
      decimals="-6"
      unitRef="Unit_USD">61000000</rdy:AssetAcquisitionConsiderationPayable>
    <ifrs-full:NumberOfSharesIssued
      contextRef="PAsOn06_23_2022_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis"
      decimals="0"
      unitRef="Unit_shares">15169</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="PAsOn06_23_2022_Drl2002PlanMemberRDYPlanNameAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis"
      decimals="0"
      unitRef="Unit_shares">12357</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P06_23_2022To06_23_2022_Drl2002PlanMemberRDYPlanNameAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">5</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfSharesIssued
      contextRef="PAsOn06_23_2022_Drl2007PlansMemberRDYPlanNameAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis"
      decimals="0"
      unitRef="Unit_shares">1657</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P06_23_2022To06_23_2022_Drl2007PlansMemberRDYPlanNameAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">5</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfSharesIssued
      contextRef="PAsOn06_23_2022_AdrMemberRDYClassOfStockAxis_Drl2007PlansMemberRDYPlanNameAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis"
      decimals="0"
      unitRef="Unit_shares">1155</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued
      contextRef="PAsOn06_23_2022_Drl2007PlansMemberRDYPlanNameAxis_ExercisePriceOfTwoEightOneFourPerShareMemberRDYExercisePriceAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis"
      decimals="0"
      unitRef="Unit_shares">575</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P06_23_2022To06_23_2022_Drl2007PlansMemberRDYPlanNameAxis_ExercisePriceOfTwoEightOneFourPerShareMemberRDYExercisePriceAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">2814</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:NumberOfSharesIssued
      contextRef="PAsOn06_23_2022_Drl2007PlansMemberRDYPlanNameAxis_ExercisePriceOfThreeSixSevenNinePerShareMemberRDYExercisePriceAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis"
      decimals="0"
      unitRef="Unit_shares">580</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ExercisePriceShareOptionsGranted2019
      contextRef="P06_23_2022To06_23_2022_Drl2007PlansMemberRDYPlanNameAxis_ExercisePriceOfThreeSixSevenNinePerShareMemberRDYExercisePriceAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">3679</ifrs-full:ExercisePriceShareOptionsGranted2019>
    <ifrs-full:Cash
      contextRef="PAsOn06_23_2022_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis_SettlementAgreementMemberRDYAgreementAxis"
      decimals="-6"
      unitRef="Unit_INR">72000000</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="PAsOn06_24_2022_BrandedAndGenericInjectableProductsMemberRDYProductOrServicesAxis_EtonPharmaceuticalsIncMemberRDYSupplierAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis"
      decimals="-6"
      unitRef="Unit_INR">5000000</ifrs-full:Cash>
    <rdy:ContingentPayments
      contextRef="PAsOn06_24_2022_BrandedAndGenericInjectableProductsMemberRDYProductOrServicesAxis_EtonPharmaceuticalsIncMemberRDYSupplierAxis_NonadjustongEventsAfterReportingPeriodMemberifrsfullNonadjustingEventsAfterReportingPeriodAxis"
      decimals="-6"
      unitRef="Unit_INR">45000000</rdy:ContingentPayments>
    <rdy:DisclosureOfSignificantInvestmentsInSubsidiariesAssociatesAndJointVenturesExplanatoryTextBlock contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;


&lt;div style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin: 0pt 0px; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;. Organizational structure&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
 &lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Limited is the parent company. Tabulated below is the list of subsidiaries and joint ventures as of March&#160;31,&#160;2022:&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 52%; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Name of the subsidiary/joint venture&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 15%; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Country of &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 31%; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Percentage of &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Direct/Indirect Ownership &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aurigene Discovery Technologies (Malaysia) Sdn. Bhd. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Malaysia&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aurigene Discovery Technologies Limited&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aurigene Pharmaceutical Services Limited (from September 16, 2019)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;beta Institut gemeinn&#xfc;tzige GmbH&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Germany&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(8)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;betapharm Arzneimittel GmbH &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Germany&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(8)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cheminor Investments Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cheminor Employees Welfare Trust&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Refer to below footnote&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(15)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chirotech Technology Limited&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United Kingdom&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)(5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Research Foundation&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Refer to below footnote&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(15)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy's Employees ESOS Trust &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Refer to below footnote&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(15)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Farmaceutica Do Brasil Ltda. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Brazil&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories (EU) Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United Kingdom&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories (Proprietary) Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;South Africa&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories (UK) Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United Kingdom&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Canada, Inc. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Canada&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy's Laboratories Chile SPA. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chile&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories, Inc.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.A.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Japan KK&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Japan&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Kazakhstan LLP &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kazakhstan&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Louisiana, LLC &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.A.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(6)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Malaysia Sdn. Bhd. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Malaysia&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories New York, LLC &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.A.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Philippines Inc.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Philippines&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Romania S.R.L. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Romania&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories SA&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Switzerland&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Taiwan Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Taiwan&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories (Thailand) Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Thailand&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories, LLC &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ukraine&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s New Zealand Limited&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;New Zealand&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s S.R.L.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Italy&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(11)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Bio-Sciences Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;India&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories (Australia) Pty. Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Australia&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories S.A.S. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Colombia&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Research and Development B.V. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Netherlands&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(12)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Venezuela, C.A. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Venezuela&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s (WUXI) Pharmaceutical Company Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;China&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s (Beijing) Pharmaceutical Co. Limited (from August 19, 2020)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;China&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;DRES Energy Private Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;26%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(14)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;DRL Impex Limited&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(13)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories B.V.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Netherlands&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(12)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Formulations Limited (from March 11, 2021)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Idea2Enterprises (India) Private Limited&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Imperial Credit Private Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Industrias Quimicas Falcon de Mexico, S.A. de CV&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mexico&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kunshan Rotam Reddy Pharmaceutical Co. Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;China&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;51.33%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(4)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lacock Holdings Limited&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cyprus&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nimbus Health, GmbH (from February 24, 2022)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Germany&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(8)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories LLC&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Russia&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;DRS LLC&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Russia&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(9)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;































































































































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="margin-top: 0px; margin-bottom: 0px; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 52%; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Name of the subsidiary/joint venture&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 15%; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Country of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 31%; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Percentage of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Direct/Indirect Ownership&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Promius Pharma, LLC&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;U.S.A.&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(6)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reddy Holding GmbH &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Germany&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reddy Netherlands B.V. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Netherlands&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reddy Pharma Iberia S.A.U.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Spain&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reddy Pharma Italia S.R.L. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Italy&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(7)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reddy Pharma SAS &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;France&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Svaas Wellness Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;India&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="white-space: nowrap;"&gt;
			&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aurigene Discovery Technologies, Inc.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;U.S.A.&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="white-space: nowrap; font-size: 8pt;"&gt;
			&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; line-height: 8pt;;display:inline;vertical-align: super;;font-size:8.9px"&gt;(3)(16)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;DRANU LLC&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;U.S.A.&lt;/td&gt;
			&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;50%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(17)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Dr. Reddy&#x2019;s Laboratories, Inc. (from October 29, 2020), formerly a subsidiary of Dr. Reddy&#x2019;s Laboratories SA. Also, conversion from corporation to limited liability company is effective October 30, 2020.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Entity under liquidation.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Aurigene Discovery Technologies Limited.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(4)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Kunshan Rotam Reddy Pharmaceutical Co. Limited is a subsidiary as per Indian Companies Act, 2013, as the Company holds a 51.33% stake. However, the Company accounts for this investment by the equity method and does not consolidate it in the Company&#x2019;s financial statements.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(5)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Dr. Reddy&#x2019;s Laboratories (EU) Limited.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(6)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Dr. Reddy&#x2019;s Laboratories Inc.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(7)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Lacock Holdings Limited.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(8)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Reddy Holding GmbH.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(9)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Dr. Reddy&#x2019;s Laboratories LLC, Russia.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Dr. Reddy&#x2019;s Laboratories SA.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(11)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Reddy Pharma Italia S.R.L.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(12)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Reddy Netherlands B.V.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(13)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Idea2Enterprises (India) Pvt. Limited.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(14)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Accounted in accordance with IFRS 11, &lt;div style="font-style:italic;display:inline;"&gt;&#x201c;Joint Arrangements&#x201d;&lt;/div&gt;.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(15)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;The Company does not have any equity interests in this entity, but has significant influence or control over it.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="padding: 0pt; width: 0in;"/&gt;
			&lt;td style="width: 0.25in; padding-left: 0px; padding-right: 0px;"&gt;
			&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(16)&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-left: 0px; padding-right: 0px; font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liquidated on March 23, 2022.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;























&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="padding: 0pt; width: 0in;"/&gt;
			&lt;td style="width: 0.25in; padding-left: 0px; padding-right: 0px;"&gt;
			&lt;div style="line-height: normal;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(17)&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-left: 0px; padding-right: 0px; font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="line-height: normal;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 8pt;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the sale of the membership interests in DRANU, LLC, it ceased to be a joint venture effective March 31, 2021.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;







































</rdy:DisclosureOfSignificantInvestmentsInSubsidiariesAssociatesAndJointVenturesExplanatoryTextBlock>
    <ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory contextRef="P04_01_2021To03_31_2022">&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Limited is the parent company. Tabulated below is the list of subsidiaries and joint ventures as of March&#160;31,&#160;2022:&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 52%; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Name of the subsidiary/joint venture&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 15%; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Country of &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 31%; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Percentage of &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Direct/Indirect Ownership &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aurigene Discovery Technologies (Malaysia) Sdn. Bhd. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Malaysia&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aurigene Discovery Technologies Limited&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aurigene Pharmaceutical Services Limited (from September 16, 2019)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;beta Institut gemeinn&#xfc;tzige GmbH&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Germany&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(8)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;betapharm Arzneimittel GmbH &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Germany&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(8)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cheminor Investments Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cheminor Employees Welfare Trust&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Refer to below footnote&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(15)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chirotech Technology Limited&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United Kingdom&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)(5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Research Foundation&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Refer to below footnote&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(15)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy's Employees ESOS Trust &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Refer to below footnote&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(15)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Farmaceutica Do Brasil Ltda. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Brazil&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories (EU) Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United Kingdom&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories (Proprietary) Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;South Africa&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories (UK) Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United Kingdom&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Canada, Inc. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Canada&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy's Laboratories Chile SPA. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Chile&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories, Inc.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.A.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Japan KK&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Japan&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Kazakhstan LLP &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kazakhstan&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Louisiana, LLC &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.A.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(6)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Malaysia Sdn. Bhd. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Malaysia&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories New York, LLC &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S.A.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Philippines Inc.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Philippines&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Romania S.R.L. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Romania&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories SA&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Switzerland&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories Taiwan Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Taiwan&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories (Thailand) Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Thailand&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories, LLC &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ukraine&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s New Zealand Limited&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;New Zealand&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s S.R.L.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Italy&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(11)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Bio-Sciences Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;India&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories (Australia) Pty. Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Australia&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories S.A.S. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Colombia&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Research and Development B.V. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Netherlands&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(12)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Venezuela, C.A. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Venezuela&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s (WUXI) Pharmaceutical Company Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;China&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s (Beijing) Pharmaceutical Co. Limited (from August 19, 2020)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;China&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;DRES Energy Private Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;26%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(14)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;DRL Impex Limited&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(13)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories B.V.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Netherlands&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(12)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Formulations Limited (from March 11, 2021)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Idea2Enterprises (India) Private Limited&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Imperial Credit Private Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;India&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Industrias Quimicas Falcon de Mexico, S.A. de CV&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mexico&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kunshan Rotam Reddy Pharmaceutical Co. Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;China&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;51.33%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(4)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lacock Holdings Limited&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cyprus&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nimbus Health, GmbH (from February 24, 2022)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Germany&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(8)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dr. Reddy&#x2019;s Laboratories LLC&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Russia&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;DRS LLC&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Russia&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(9)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;































































































































&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;


&lt;div style="margin-top: 0px; margin-bottom: 0px; text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;

		&lt;tr style="vertical-align: bottom;"&gt;
			&lt;td style="width: 52%; white-space: nowrap; border-bottom: 1pt solid black;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Name of the subsidiary/joint venture&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
			&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 15%; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Country of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="width: 1%; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
			&lt;td style="width: 31%; border-bottom: 1pt solid black;"&gt;
			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Percentage of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Direct/Indirect Ownership&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;

			&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Interest&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Promius Pharma, LLC&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;U.S.A.&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(6)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reddy Holding GmbH &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Germany&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reddy Netherlands B.V. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Netherlands&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reddy Pharma Iberia S.A.U.&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Spain&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reddy Pharma Italia S.R.L. &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;Italy&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(7)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: white;"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Reddy Pharma SAS &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;France&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr style="background-color: rgb(204, 238, 255);"&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Svaas Wellness Limited &lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;India&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;&#160;&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;/div&gt;&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="white-space: nowrap;"&gt;
			&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aurigene Discovery Technologies, Inc.&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="white-space: nowrap;"&gt;U.S.A.&lt;/td&gt;
			&lt;td style="vertical-align: top;"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="white-space: nowrap; font-size: 8pt;"&gt;
			&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;100%&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; line-height: 8pt;;display:inline;vertical-align: super;;font-size:8.9px"&gt;(3)(16)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;DRANU LLC&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;U.S.A.&lt;/td&gt;
			&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
			&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;50%&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(17)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;div style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0px; text-align: justify; text-indent: 0.25in; font-size-adjust: none; font-stretch: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Dr. Reddy&#x2019;s Laboratories, Inc. (from October 29, 2020), formerly a subsidiary of Dr. Reddy&#x2019;s Laboratories SA. Also, conversion from corporation to limited liability company is effective October 30, 2020.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(2)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Entity under liquidation.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(3)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Aurigene Discovery Technologies Limited.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(4)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Kunshan Rotam Reddy Pharmaceutical Co. Limited is a subsidiary as per Indian Companies Act, 2013, as the Company holds a 51.33% stake. However, the Company accounts for this investment by the equity method and does not consolidate it in the Company&#x2019;s financial statements.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(5)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Dr. Reddy&#x2019;s Laboratories (EU) Limited.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(6)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Dr. Reddy&#x2019;s Laboratories Inc.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(7)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Lacock Holdings Limited.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(8)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Reddy Holding GmbH.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(9)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Dr. Reddy&#x2019;s Laboratories LLC, Russia.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(10)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Dr. Reddy&#x2019;s Laboratories SA.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(11)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Reddy Pharma Italia S.R.L.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(12)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Reddy Netherlands B.V.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(13)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Indirectly owned through Idea2Enterprises (India) Pvt. Limited.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(14)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;Accounted in accordance with IFRS 11, &lt;div style="font-style:italic;display:inline;"&gt;&#x201c;Joint Arrangements&#x201d;&lt;/div&gt;.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;


































































































&lt;div style="clear: both; max-height: 0px;"/&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="width: 0px;"/&gt;
			&lt;td style="width: 0.2in;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(15)&lt;/div&gt;&lt;/td&gt;
			&lt;td style="vertical-align: bottom;"&gt;The Company does not have any equity interests in this entity, but has significant influence or control over it.&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;









































&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="padding: 0pt; width: 0in;"/&gt;
			&lt;td style="width: 0.25in; padding-left: 0px; padding-right: 0px;"&gt;
			&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(16)&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-left: 0px; padding-right: 0px; font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="font-size: 10pt; line-height: normal;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liquidated on March 23, 2022.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;























&lt;table cellpadding="0" cellspacing="0" style="font: 10pt &amp;quot;Times New Roman&amp;quot;, Times, serif; margin-top: 0pt; margin-bottom: 0pt; border-spacing: 0px;;width:100%;"&gt;

		&lt;tr style="vertical-align: top;"&gt;
			&lt;td style="padding: 0pt; width: 0in;"/&gt;
			&lt;td style="width: 0.25in; padding-left: 0px; padding-right: 0px;"&gt;
			&lt;div style="line-height: normal;"&gt;&lt;div style=";display:inline;vertical-align: super;;font-size:9.2px"&gt;(17)&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
			&lt;td style="padding-left: 0px; padding-right: 0px; font-size: 10pt; vertical-align: bottom;"&gt;
			&lt;div style="line-height: normal;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 8pt;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; line-height: 10pt; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the sale of the membership interests in DRANU, LLC, it ceased to be a joint venture effective March 31, 2021.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
			&lt;/td&gt;
		&lt;/tr&gt;

&lt;/table&gt;







































</ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_AurigeneDiscoveryTechnologiesMalaysiaSdnBhdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537781">Malaysia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_AurigeneDiscoveryTechnologiesMalaysiaSdnBhdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537874"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P04_01_2021To03_31_2022_AurigeneDiscoveryTechnologiesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_AurigeneDiscoveryTechnologiesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_AurigenePharmaceuticalServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537783">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_AurigenePharmaceuticalServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537876"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_BetaInstitutGemeinnutzigeGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537784">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_BetaInstitutGemeinnutzigeGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537877"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_BetapharmArzneimittelGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537785">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_BetapharmArzneimittelGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537878"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P04_01_2021To03_31_2022_CheminorInvestmentsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_CheminorInvestmentsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_CheminorEmployeesWelfareTrustsMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537787">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_ChirotechTechnologyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537788">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_ChirotechTechnologyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537880"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysResearchFoundationMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537789">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesEsosTrustMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537790">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P04_01_2021To03_31_2022_DrreddysFarmaceuticaDoBrasilLtdaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Brazil</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysFarmaceuticaDoBrasilLtdaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesEuLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537792">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesEuLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537882"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesProprietaryLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537793">South Africa</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesProprietaryLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537883"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537794">United Kingdom</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesUkLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537884"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesCanadaIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537795">Canada</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesCanadaIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537885"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesChileSpaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537796">Chile</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesChileSpaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537886"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537797">U.S.A.</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537887"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesJapanKkMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537798">Japan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesJapanKkMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537888"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesKazakhstanLlpMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537799">Kazakhstan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesKazakhstanLlpMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537889"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesLouisianaLlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537800">U.S.A.</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesLouisianaLlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537890"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesMalaysiaSdnBhdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537801">Malaysia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesMalaysiaSdnBhdMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537891"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesNewYorkIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537802">U.S.A.</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesNewYorkIncMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537892"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesPhilippinesMemberMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537920">Philippines</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesPhilippinesMemberMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537893"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesRomaniaSrlMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537803">Romania</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesRomaniaSrlMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537894"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesSaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Switzerland</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesSaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesTaiwanLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537921">Taiwan</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesTaiwanLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537896"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesThailandMemberMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537922">Thailand</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesThailandMemberMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537897"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesLlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537805">Ukraine</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesLlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537898"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysNewZealandLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537806">New Zealand</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysNewZealandLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537899"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysSrlMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537807">Italy</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysSrlMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537900"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P04_01_2021To03_31_2022_DrreddysBiosciencesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysBiosciencesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesAustraliaPtyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537924">Australia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysLaboratoriesAustraliaPtyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537902"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesSasMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537925">Colombia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesSasMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537903"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysResearchAndDevelopmentBvFormerlyOctoplusBvMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537926">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysResearchAndDevelopmentBvFormerlyOctoplusBvMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537904"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysVenezuelaCaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537927">Venezuela</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrreddysVenezuelaCaMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537905"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddyswuxiPharmaceuticalCompanyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537808">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddyswuxiPharmaceuticalCompanyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537906"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysBeijingPharmaceuticalCoLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537809">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysBeijingPharmaceuticalCoLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537907"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DresEnergyPrivateLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537810">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DresEnergyPrivateLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537908"
      unitRef="Unit_pure">0.26</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrlImpexLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537811">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrlImpexLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537909"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesBvFormerlyEuobridgeConsultingBvMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537932">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysLaboratoriesBvFormerlyEuobridgeConsultingBvMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537910"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P04_01_2021To03_31_2022_DrReddysFormulationsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrReddysFormulationsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P04_01_2021To03_31_2022_Idea2enterprisesIndiaPvtLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_Idea2enterprisesIndiaPvtLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P04_01_2021To03_31_2022_ImperialCreditPrivateLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_ImperialCreditPrivateLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoSaDeCvMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">Mexico</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_IndustriasQuimicasFalconDeMexicoSaDeCvMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_KunshanRotamReddyPharmaceuticalComanyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537816">China</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_KunshanRotamReddyPharmaceuticalComanyLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      id="Fact_50537915"
      unitRef="Unit_pure">0.5133</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_LacockHoldingsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537817">Cyprus</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_LacockHoldingsLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537916"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_NimbusHealthGmbhFromFebruary242022MemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537935">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_NimbusHealthGmbhFromFebruary242022MemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537917"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_Dr.ReddysLaboratoriesLlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537936">Russia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_Dr.ReddysLaboratoriesLlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537918"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrsLlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537937">Russia</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DrsLlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537919"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_PromiusPharmaLlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537938">U.S.A.</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_PromiusPharmaLlcMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537945"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_ReddyHoldingGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537939">Germany</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_ReddyHoldingGmbhMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537946"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_ReddyNetherlandsBvMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537940">Netherlands</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_ReddyNetherlandsBvMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537947"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_ReddyPharmaIberiaSauMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537941">Spain</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_ReddyPharmaIberiaSauMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537948"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_ReddyPharmaItaliaSrlMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537942">Italy</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_ReddyPharmaItaliaSrlMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537949"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_ReddyPharmasSasMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50537943">France</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_ReddyPharmasSasMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50537950"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary contextRef="P04_01_2021To03_31_2022_SvaasWellnessLimitedFormerlyRegkineticsServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis">India</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_SvaasWellnessLimitedFormerlyRegkineticsServicesLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_AurigeneDiscoveryTechnologiesInc.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50538613">U.S.A.</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_AurigeneDiscoveryTechnologiesInc.MemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50538615"
      unitRef="Unit_pure">1</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary
      contextRef="P04_01_2021To03_31_2022_DRANULLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      id="Fact_50538614">U.S.A.</ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_DRANULLCMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="2"
      id="Fact_50538616"
      unitRef="Unit_pure">0.50</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <ifrs-full:ProportionOfOwnershipInterestInSubsidiary
      contextRef="P04_01_2021To03_31_2022_KunshanRotamReddyPharmaceuticalsCoLimitedMemberifrsfullSignificantInvestmentsInSubsidiariesAxis"
      decimals="4"
      unitRef="Unit_pure">0.5133</ifrs-full:ProportionOfOwnershipInterestInSubsidiary>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_50535370"
          xlink:label="Fact_50535370"
          xlink:type="locator"/>
        <link:footnote id="FN_162308" xlink:label="FN_162308" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Revenues for the year ended March 31, 2022 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,255 (as compared to Rs. 6,905 and Rs. 5,910 for the years ended March 31, 2021 and 2020, respectively).

</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535370"
          xlink:to="FN_162308"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535371"
          xlink:label="Fact_50535371"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535371"
          xlink:to="FN_162308"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535372"
          xlink:label="Fact_50535372"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535372"
          xlink:to="FN_162308"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535373"
          xlink:label="Fact_50535373"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535373"
          xlink:to="FN_162308"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535374"
          xlink:label="Fact_50535374"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535374"
          xlink:to="FN_162308"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535375"
          xlink:label="Fact_50535375"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535375"
          xlink:to="FN_162308"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535376"
          xlink:label="Fact_50535376"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535376"
          xlink:to="FN_162308"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535377"
          xlink:label="Fact_50535377"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535377"
          xlink:to="FN_162308"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535378"
          xlink:label="Fact_50535378"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535378"
          xlink:to="FN_162308"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535385"
          xlink:label="Fact_50535385"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535385"
          xlink:to="FN_162308"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535386"
          xlink:label="Fact_50535386"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535386"
          xlink:to="FN_162308"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535387"
          xlink:label="Fact_50535387"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535387"
          xlink:to="FN_162308"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535388"
          xlink:label="Fact_50535388"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535388"
          xlink:to="FN_162308"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535389"
          xlink:label="Fact_50535389"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535389"
          xlink:to="FN_162308"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535390"
          xlink:label="Fact_50535390"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535390"
          xlink:to="FN_162308"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535436"
          xlink:label="Fact_50535436"
          xlink:type="locator"/>
        <link:footnote id="FN_162307" xlink:label="FN_162307" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Others include Germany, the United Kingdom, Ukraine, China, Canada and other countries across the world.

</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535436"
          xlink:to="FN_162307"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535437"
          xlink:label="Fact_50535437"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535437"
          xlink:to="FN_162307"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535438"
          xlink:label="Fact_50535438"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535438"
          xlink:to="FN_162307"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535685"
          xlink:label="Fact_50535685"
          xlink:type="locator"/>
        <link:footnote id="FN_162302" xlink:label="FN_162302" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During the year ended March 31, 2022, there was a significant decline in the expected cash flows of the Company&#x2019;s subsidiary, Dr. Reddy&#x2019;s Laboratories Louisiana, LLC (Shreveport Cash Generating Unit (&#x201c;CGU&#x201d;)). Consequently, the Company tested the carrying amount of the CGU, being the smallest identifiable group of assets that generate cash inflows that are largely independent of the cash inflows from other assets or group of assets. This resulted in the recoverable amount of the CGU being lower than its carrying amount. Accordingly, the Company recognized an impairment loss of the entire carrying value of Rs.2,570 for property, plant and equipment, Rs. 89 for capital-work-in-progress and Rs.392 for goodwill. This impairment loss pertains to the Company&#x2019;s Global Generics segment.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535685"
          xlink:to="FN_162302"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535686"
          xlink:label="Fact_50535686"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535686"
          xlink:to="FN_162302"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535687"
          xlink:label="Fact_50535687"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535687"
          xlink:to="FN_162302"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535714"
          xlink:label="Fact_50535714"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535714"
          xlink:to="FN_162302"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535715"
          xlink:label="Fact_50535715"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535715"
          xlink:to="FN_162302"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535716"
          xlink:label="Fact_50535716"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535716"
          xlink:to="FN_162302"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535770"
          xlink:label="Fact_50535770"
          xlink:type="locator"/>
        <link:footnote id="FN_162303" xlink:label="FN_162303" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Refer to Note 6 of these consolidated financial statements for further details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535770"
          xlink:to="FN_162303"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535771"
          xlink:label="Fact_50535771"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535771"
          xlink:to="FN_162303"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535905"
          xlink:label="Fact_50535905"
          xlink:type="locator"/>
        <link:footnote id="FN_162356" xlink:label="FN_162356" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily represents the shares of Curis, Inc. Refer to Note 33 of these consolidated financial statements for further details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535905"
          xlink:to="FN_162356"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535906"
          xlink:label="Fact_50535906"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535906"
          xlink:to="FN_162356"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535907"
          xlink:label="Fact_50535907"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535907"
          xlink:to="FN_162356"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535908"
          xlink:label="Fact_50535908"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535908"
          xlink:to="FN_162356"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535909"
          xlink:label="Fact_50535909"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535909"
          xlink:to="FN_162356"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535910"
          xlink:label="Fact_50535910"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535910"
          xlink:to="FN_162356"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535955"
          xlink:label="Fact_50535955"
          xlink:type="locator"/>
        <link:footnote id="FN_162295" xlink:label="FN_162295" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Balances and receivables from statutory authorities primarily consist of amounts recoverable towards the goods and service tax (&#x201c;GST&#x201d;), excise duty and value added tax, and from customs authorities of India.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535955"
          xlink:to="FN_162295"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535956"
          xlink:label="Fact_50535956"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535956"
          xlink:to="FN_162295"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535957"
          xlink:label="Fact_50535957"
          xlink:type="locator"/>
        <link:footnote id="FN_162338" xlink:label="FN_162338" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Export benefits receivables primarily consist of amounts receivable from various government authorities of India towards incentives on export sales made by the Company.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535957"
          xlink:to="FN_162338"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535958"
          xlink:label="Fact_50535958"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535958"
          xlink:to="FN_162338"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535961"
          xlink:label="Fact_50535961"
          xlink:type="locator"/>
        <link:footnote id="FN_162296" xlink:label="FN_162296" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Others primarily includes advances given to vendors and employees, security deposits, interest accrued but not due on investments, and claims receivable.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535961"
          xlink:to="FN_162296"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535962"
          xlink:label="Fact_50535962"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535962"
          xlink:to="FN_162296"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535995"
          xlink:label="Fact_50535995"
          xlink:type="locator"/>
        <link:footnote id="FN_162298" xlink:label="FN_162298" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">APSL subsidiary&#x201d; refers to Aurigene Pharmaceutical Services Limited.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535995"
          xlink:to="FN_162298"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535996"
          xlink:label="Fact_50535996"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535996"
          xlink:to="FN_162298"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535997"
          xlink:label="Fact_50535997"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535997"
          xlink:to="FN_162298"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50535998"
          xlink:label="Fact_50535998"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50535998"
          xlink:to="FN_162298"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536066"
          xlink:label="Fact_50536066"
          xlink:type="locator"/>
        <link:footnote id="FN_162289" xlink:label="FN_162289" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes Rs.181 representing the goodwill on acquisition of investment.

</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536066"
          xlink:to="FN_162289"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536067"
          xlink:label="Fact_50536067"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536067"
          xlink:to="FN_162289"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536068"
          xlink:label="Fact_50536068"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536068"
          xlink:to="FN_162289"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536101"
          xlink:label="Fact_50536101"
          xlink:type="locator"/>
        <link:footnote id="FN_162341" xlink:label="FN_162341" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes current portion.

</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536101"
          xlink:to="FN_162341"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536104"
          xlink:label="Fact_50536104"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536104"
          xlink:to="FN_162341"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536107"
          xlink:label="Fact_50536107"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536107"
          xlink:to="FN_162341"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536110"
          xlink:label="Fact_50536110"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536110"
          xlink:to="FN_162341"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536116"
          xlink:label="Fact_50536116"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536116"
          xlink:to="FN_162341"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536119"
          xlink:label="Fact_50536119"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536119"
          xlink:to="FN_162341"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536122"
          xlink:label="Fact_50536122"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536122"
          xlink:to="FN_162341"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536125"
          xlink:label="Fact_50536125"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536125"
          xlink:to="FN_162341"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536136"
          xlink:label="Fact_50536136"
          xlink:type="locator"/>
        <link:footnote id="FN_162310" xlink:label="FN_162310" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During the years ended March 31, 2022 and 2021, equity shares were issued as a result of the exercise of vested options granted to employees pursuant to the Dr. Reddy&#x2019;s Employees Stock Option Scheme, 2002 and the Dr. Reddy&#x2019;s Employees Stock Option Scheme, 2007. The options exercised had an exercise price of Rs.5, Rs.2,607, Rs.2,814 or Rs. 3,679 per share. Upon the exercise of such options, the amount of compensation cost (computed using the grant date fair value) previously recognized in the &#x201c;share based payment reserve&#x201d;  was transferred to &#x201c;share premium&#x201d; in the consolidated statements of changes in equity.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536136"
          xlink:to="FN_162310"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536137"
          xlink:label="Fact_50536137"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536137"
          xlink:to="FN_162310"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536166"
          xlink:label="Fact_50536166"
          xlink:type="locator"/>
        <link:footnote id="FN_162309" xlink:label="FN_162309" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As of March 31, 2022, 2021 and 2020, 13,284, 235,460 and 475,575 options, respectively, were excluded from the diluted weighted average number of equity shares calculation because their effect would have been anti-dilutive. The average market value of the Company&#x2019;s shares for the purpose of calculating the dilutive effect of stock options was based on quoted market prices for the year during which the options were outstanding.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536166"
          xlink:to="FN_162309"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536167"
          xlink:label="Fact_50536167"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536167"
          xlink:to="FN_162309"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536168"
          xlink:label="Fact_50536168"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536168"
          xlink:to="FN_162309"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536477"
          xlink:label="Fact_50536477"
          xlink:type="locator"/>
        <link:footnote id="FN_162290" xlink:label="FN_162290" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Refund liability is accounted for by recording a provision based on the Company&#x2019;s estimate of expected sales returns. See Note 3.m of these consolidated financial statements for the Company&#x2019;s accounting policy on refund liability.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536477"
          xlink:to="FN_162290"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536478"
          xlink:label="Fact_50536478"
          xlink:type="locator"/>
        <link:footnote id="FN_162343" xlink:label="FN_162343" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As a result of the acquisition of a unit of The Dow Chemical Company in April 2008, the Company assumed a liability for contamination of the Mirfield site acquired of Rs.39 (carrying value Rs.57). The seller is required to indemnify the Company for this liability. Accordingly, a corresponding asset has also been recorded in the consolidated statements of financial position.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536478"
          xlink:to="FN_162343"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536479"
          xlink:label="Fact_50536479"
          xlink:type="locator"/>
        <link:footnote id="FN_162353" xlink:label="FN_162353" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily consists of provision recorded towards the potential liability arising out of a litigation relating to cardiovascular and anti-diabetic formulations. Refer to Note 32 (Contingencies) of these consolidated financial statements under &#x201c;Product and patent related matters - Matters relating to National Pharmaceutical Pricing Authority and Litigation relating to Cardiovascular and Anti-diabetic formulations&#x201d; for further details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536479"
          xlink:to="FN_162353"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536481"
          xlink:label="Fact_50536481"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536481"
          xlink:to="FN_162290"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536482"
          xlink:label="Fact_50536482"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536482"
          xlink:to="FN_162343"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536483"
          xlink:label="Fact_50536483"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536483"
          xlink:to="FN_162353"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536485"
          xlink:label="Fact_50536485"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536485"
          xlink:to="FN_162290"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536486"
          xlink:label="Fact_50536486"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536486"
          xlink:to="FN_162343"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536487"
          xlink:label="Fact_50536487"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536487"
          xlink:to="FN_162353"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536489"
          xlink:label="Fact_50536489"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536489"
          xlink:to="FN_162290"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536490"
          xlink:label="Fact_50536490"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536490"
          xlink:to="FN_162343"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536491"
          xlink:label="Fact_50536491"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536491"
          xlink:to="FN_162353"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536493"
          xlink:label="Fact_50536493"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536493"
          xlink:to="FN_162290"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536494"
          xlink:label="Fact_50536494"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536494"
          xlink:to="FN_162343"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536495"
          xlink:label="Fact_50536495"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536495"
          xlink:to="FN_162353"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536497"
          xlink:label="Fact_50536497"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536497"
          xlink:to="FN_162290"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536498"
          xlink:label="Fact_50536498"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536498"
          xlink:to="FN_162343"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536499"
          xlink:label="Fact_50536499"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536499"
          xlink:to="FN_162353"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536501"
          xlink:label="Fact_50536501"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536501"
          xlink:to="FN_162290"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536502"
          xlink:label="Fact_50536502"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536502"
          xlink:to="FN_162343"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536503"
          xlink:label="Fact_50536503"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536503"
          xlink:to="FN_162353"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536511"
          xlink:label="Fact_50536511"
          xlink:type="locator"/>
        <link:footnote id="FN_162292" xlink:label="FN_162292" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Refer to Note 22 for details of deferred revenue.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536511"
          xlink:to="FN_162292"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536512"
          xlink:label="Fact_50536512"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536512"
          xlink:to="FN_162292"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536529"
          xlink:label="Fact_50536529"
          xlink:type="locator"/>
        <link:footnote id="FN_162316" xlink:label="FN_162316" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During the year ended March 31, 2022, the Company entered into the following agreements:
&#x2022;	An agreement with Alium JSC for the sale of the Company&#x2019;s territorial rights relating to two of its anti-bacterial brands (Ciprolet&#xae; and Levolet&#xae;) in Russia and certain countries of the former Soviet Union. The consideration for the arrangement is Rs.1,971 and the Company recognized revenue of Rs.1,774 for the performance obligations relating to the milestones met. This transaction pertains to the Company&#x2019;s Global Generics segment.

&#x2022;	An agreement with Mankind Pharma Limited towards the sale of two of the Company's brands (Daffy bar and Combihale) in India, which formed part of the Company&#x2019;s Global Generics segment. License fees includes an amount of  Rs.390 towards the aforesaid sales transaction.

&#x2022;	A definitive agreement with BioDelivery Sciences International, Inc. (&#x201c;BDSI&#x201d;), pursuant to which the Company sold its U.S. and Canada territory rights for ELYXYB (celecoxib oral solution) 25 mg/mL, to BDSI.  Under the terms of agreement, the Company was entitled to receive U.S.$6 up front at the closing, U.S.$9 one year from the closing, event based milestone payments upon achievement of certain regulatory approvals; sales-based milestone payments; and quarterly earn-out payments based on a percentage (which varies based on sales volumes) of net sales of the product in the territory. The Company recognized an amount of Rs.1,084 as a licensee fee from this transaction. This transaction pertains to the Company&#x2019;s Proprietary Products segment.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536529"
          xlink:to="FN_162316"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536530"
          xlink:label="Fact_50536530"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536530"
          xlink:to="FN_162316"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536531"
          xlink:label="Fact_50536531"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536531"
          xlink:to="FN_162316"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536536"
          xlink:label="Fact_50536536"
          xlink:type="locator"/>
        <link:footnote id="FN_162349" xlink:label="FN_162349" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During the year ended March 31, 2022, the Company entered into a definitive agreement with Citius Pharmaceuticals, Inc. ("Citius") for the sale of all of its rights relating to its anti-cancer agent E7777 (denileukin diftitox) to Citius. The Company received Rs. 2,951 (U.S.$40) as an up front amount upon the closing of the transaction. Further, the Company is entitled to additional payments on achievement of milestones of up to U.S.$40 upon the CTCL (cutaneous Tcell lymphoma) indication regulatory approval, up to U.S.$70 in milestone payments upon additional indication regulatory approvals, and certain sales-based milestones and tiered earn-out payments.  Consequently, an amount of Rs.1,064, representing the excess of sale consideration over the carrying cost, has been recognized as gain on sale of intangible assets. The transaction pertains to the Company&#x2019;'s Proprietary Products segment.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536536"
          xlink:to="FN_162349"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536537"
          xlink:label="Fact_50536537"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536537"
          xlink:to="FN_162349"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536904"
          xlink:label="Fact_50536904"
          xlink:type="locator"/>
        <link:footnote id="FN_162284" xlink:label="FN_162284" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Rounded to the nearest million.

</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536904"
          xlink:to="FN_162284"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536931"
          xlink:label="Fact_50536931"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536931"
          xlink:to="FN_162343"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536933"
          xlink:label="Fact_50536933"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536933"
          xlink:to="FN_162292"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536934"
          xlink:label="Fact_50536934"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536934"
          xlink:to="FN_162292"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536966"
          xlink:label="Fact_50536966"
          xlink:type="locator"/>
        <link:footnote id="FN_162357" xlink:label="FN_162357" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">During the years ended March 31, 2022, the Company recorded impairment loss of Rs.392 pertaining to Shreveport CGU.  Refer to Note 12 of these consolidated financial statements for further details. The said goodwill was included as part of &#x201c;Global Generics-North America Operations&#x201d;.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536966"
          xlink:to="FN_162357"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50536967"
          xlink:label="Fact_50536967"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50536967"
          xlink:to="FN_162357"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537014"
          xlink:label="Fact_50537014"
          xlink:type="locator"/>
        <link:footnote id="FN_162305" xlink:label="FN_162305" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">&#x201c;INR&#x201d; means Indian rupees, &#x201c;U.S.$&#x201d; means United States Dollars, &#x201c;RUB&#x201d; means Russian roubles, &#x201c;MXN&#x201d; means Mexican pesos, &#x201c;BRL&#x201d; means Brazilian reals and &#x201c;UAH&#x201d; means Ukrainian hryvnia.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537014"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537015"
          xlink:label="Fact_50537015"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537015"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537016"
          xlink:label="Fact_50537016"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537016"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537017"
          xlink:label="Fact_50537017"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537017"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537018"
          xlink:label="Fact_50537018"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537018"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537019"
          xlink:label="Fact_50537019"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537019"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537020"
          xlink:label="Fact_50537020"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537020"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537021"
          xlink:label="Fact_50537021"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537021"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537022"
          xlink:label="Fact_50537022"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537022"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537023"
          xlink:label="Fact_50537023"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537023"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537024"
          xlink:label="Fact_50537024"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537024"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537025"
          xlink:label="Fact_50537025"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537025"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537026"
          xlink:label="Fact_50537026"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537026"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537027"
          xlink:label="Fact_50537027"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537027"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537028"
          xlink:label="Fact_50537028"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537028"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537029"
          xlink:label="Fact_50537029"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537029"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537030"
          xlink:label="Fact_50537030"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537030"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537031"
          xlink:label="Fact_50537031"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537031"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537032"
          xlink:label="Fact_50537032"
          xlink:type="locator"/>
        <link:footnote id="FN_162306" xlink:label="FN_162306" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">&#x201c;LIBOR&#x201d; means the London Inter-bank Offered Rate, &#x201c;TIIE&#x201d; means the Equilibrium Inter-banking Interest Rate (Tasa de Inter&#xe9;s Interbancaria de Equilibrio), &#x201c;T-bill&#x201d; means India Treasury bill and &#x201c;CDI&#x201d; means Brazilian interbank deposit rate (Certificado de Dep&#xf3;sito Interbanc&#xe1;rio).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537032"
          xlink:to="FN_162306"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537033"
          xlink:label="Fact_50537033"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537033"
          xlink:to="FN_162306"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537034"
          xlink:label="Fact_50537034"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537034"
          xlink:to="FN_162306"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537036"
          xlink:label="Fact_50537036"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537036"
          xlink:to="FN_162306"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537037"
          xlink:label="Fact_50537037"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537037"
          xlink:to="FN_162306"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537038"
          xlink:label="Fact_50537038"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537038"
          xlink:to="FN_162306"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537039"
          xlink:label="Fact_50537039"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537039"
          xlink:to="FN_162306"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537041"
          xlink:label="Fact_50537041"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537041"
          xlink:to="FN_162306"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537042"
          xlink:label="Fact_50537042"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537042"
          xlink:to="FN_162306"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537043"
          xlink:label="Fact_50537043"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537043"
          xlink:to="FN_162306"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537046"
          xlink:label="Fact_50537046"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537046"
          xlink:to="FN_162306"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537185"
          xlink:label="Fact_50537185"
          xlink:type="locator"/>
        <link:footnote id="FN_162314" xlink:label="FN_162314" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company enters into derivative financial instruments with various counterparties, principally financial institutions and banks. Derivatives valued using valuation techniques with market observable inputs are mainly interest rate swaps, foreign exchange forward option and swap contracts. The most frequently applied valuation techniques include forward pricing, swap models and Black-Scholes-Merton models (for option valuation), using present value calculations. The models incorporate various inputs, including foreign exchange forward rates, interest rate curves and forward rate curves.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537185"
          xlink:to="FN_162314"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537186"
          xlink:label="Fact_50537186"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537186"
          xlink:to="FN_162314"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537187"
          xlink:label="Fact_50537187"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537187"
          xlink:to="FN_162314"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537188"
          xlink:label="Fact_50537188"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537188"
          xlink:to="FN_162314"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537189"
          xlink:label="Fact_50537189"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537189"
          xlink:to="FN_162314"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537190"
          xlink:label="Fact_50537190"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537190"
          xlink:to="FN_162314"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537191"
          xlink:label="Fact_50537191"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537191"
          xlink:to="FN_162314"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537192"
          xlink:label="Fact_50537192"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537192"
          xlink:to="FN_162314"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537197"
          xlink:label="Fact_50537197"
          xlink:type="locator"/>
        <link:footnote id="FN_162352" xlink:label="FN_162352" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other liabilities and provisions:
&#x2022;	Other liabilities and provisions that are not financial liabilities (such as statutory dues payable, deferred revenue, advances from customers and certain other accruals) of Rs.14,491 and Rs.13,091 as of March 31, 2022 and 2021, respectively, are not included.
&#x2022;	Amounts as of March 31, 2022 and 2021 includes contingent consideration of Rs.194 and Rs.420, respectively, pursuant to the Business Transfer Agreement with Wockhardt Limited (Refer to Note 6 for details).
&#x2022;	Amounts as of March 31, 2022 includes consideration payable of Rs.84 pursuant to the Acquisition of Nimbus Health, GmbH (Refer to Note 6 for details).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537197"
          xlink:to="FN_162352"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537198"
          xlink:label="Fact_50537198"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537198"
          xlink:to="FN_162352"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537199"
          xlink:label="Fact_50537199"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537199"
          xlink:to="FN_162352"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537200"
          xlink:label="Fact_50537200"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537200"
          xlink:to="FN_162352"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537225"
          xlink:label="Fact_50537225"
          xlink:type="locator"/>
        <link:footnote id="FN_162312" xlink:label="FN_162312" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Other assets that are not financial assets (such as receivables from statutory authorities, export benefit receivables, prepaid expenses, advances paid and certain other receivables) of Rs.12,449 and Rs.12,717 as of March 31, 2022 and 2021, respectively, are not included.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537225"
          xlink:to="FN_162312"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537226"
          xlink:label="Fact_50537226"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537226"
          xlink:to="FN_162312"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537227"
          xlink:label="Fact_50537227"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537227"
          xlink:to="FN_162312"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537228"
          xlink:label="Fact_50537228"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537228"
          xlink:to="FN_162312"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537704"
          xlink:label="Fact_50537704"
          xlink:type="locator"/>
        <link:footnote id="FN_162285" xlink:label="FN_162285" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents mark to market gain or loss on financial assets classified as fair value through other comprehensive income (&#x201c;FVTOCI&#x201d;).  Depending on the category and type of the financial asset, the mark to market gain or loss is either reclassified to the income statement or to retained earnings upon disposal of the investment. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537704"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537708"
          xlink:label="Fact_50537708"
          xlink:type="locator"/>
        <link:footnote id="FN_162286" xlink:label="FN_162286" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company has created a Special Economic Zone (&#x201c;SEZ&#x201d;) Reinvestment Reserve out of profits of its eligible SEZ Units in accordance with the terms of Section 10AA(1) of the Indian Income Tax Act, 1961. This reserve is to be utilized by the Company for acquiring Plant and Machinery in accordance with Section 10AA(2) of such Act.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537708"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537716"
          xlink:label="Fact_50537716"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537716"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537720"
          xlink:label="Fact_50537720"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537720"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537728"
          xlink:label="Fact_50537728"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537728"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537732"
          xlink:label="Fact_50537732"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537732"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537740"
          xlink:label="Fact_50537740"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537740"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537744"
          xlink:label="Fact_50537744"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537744"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537781"
          xlink:label="Fact_50537781"
          xlink:type="locator"/>
        <link:footnote id="FN_162319" xlink:label="FN_162319" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Indirectly owned through Aurigene Discovery Technologies Limited. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537781"
          xlink:to="FN_162319"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537783"
          xlink:label="Fact_50537783"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537783"
          xlink:to="FN_162319"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537784"
          xlink:label="Fact_50537784"
          xlink:type="locator"/>
        <link:footnote id="FN_162322" xlink:label="FN_162322" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Indirectly owned through Reddy Holding GmbH.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537784"
          xlink:to="FN_162322"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537785"
          xlink:label="Fact_50537785"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537785"
          xlink:to="FN_162322"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537787"
          xlink:label="Fact_50537787"
          xlink:type="locator"/>
        <link:footnote id="FN_162326" xlink:label="FN_162326" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company does not have any equity interests in this entity, but has significant influence or control over it. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537787"
          xlink:to="FN_162326"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537788"
          xlink:label="Fact_50537788"
          xlink:type="locator"/>
        <link:footnote id="FN_162317" xlink:label="FN_162317" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Entity under liquidation.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537788"
          xlink:to="FN_162317"
          xlink:type="arc"/>
        <link:footnote id="FN_162318" xlink:label="FN_162318" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Indirectly owned through Dr. Reddy&#x2019;s Laboratories (EU) Limited.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537788"
          xlink:to="FN_162318"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537789"
          xlink:label="Fact_50537789"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537789"
          xlink:to="FN_162326"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537790"
          xlink:label="Fact_50537790"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537790"
          xlink:to="FN_162326"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537792"
          xlink:label="Fact_50537792"
          xlink:type="locator"/>
        <link:footnote id="FN_162315" xlink:label="FN_162315" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Indirectly owned through Dr. Reddy&#x2019;s Laboratories SA.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537792"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537793"
          xlink:label="Fact_50537793"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537793"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537794"
          xlink:label="Fact_50537794"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537794"
          xlink:to="FN_162318"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537795"
          xlink:label="Fact_50537795"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537795"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537796"
          xlink:label="Fact_50537796"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537796"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537797"
          xlink:label="Fact_50537797"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537797"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537798"
          xlink:label="Fact_50537798"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537798"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537799"
          xlink:label="Fact_50537799"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537799"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537800"
          xlink:label="Fact_50537800"
          xlink:type="locator"/>
        <link:footnote id="FN_162327" xlink:label="FN_162327" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Indirectly owned through Dr. Reddy&#x2019;s Laboratories Inc.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537800"
          xlink:to="FN_162327"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537801"
          xlink:label="Fact_50537801"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537801"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537802"
          xlink:label="Fact_50537802"
          xlink:type="locator"/>
        <link:footnote id="FN_162329" xlink:label="FN_162329" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Indirectly owned through Dr. Reddy&#x2019;s Laboratories, Inc. (from October 29, 2020), formerly a subsidiary of Dr. Reddy&#x2019;s Laboratories SA. Also, conversion from corporation to limited liability company is effective October 30, 2020.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537802"
          xlink:to="FN_162329"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537803"
          xlink:label="Fact_50537803"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537803"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537805"
          xlink:label="Fact_50537805"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537805"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537806"
          xlink:label="Fact_50537806"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537806"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537807"
          xlink:label="Fact_50537807"
          xlink:type="locator"/>
        <link:footnote id="FN_162330" xlink:label="FN_162330" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Indirectly owned through Reddy Pharma Italia S.R.L.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537807"
          xlink:to="FN_162330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537808"
          xlink:label="Fact_50537808"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537808"
          xlink:to="FN_162317"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537808"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537809"
          xlink:label="Fact_50537809"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537809"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537810"
          xlink:label="Fact_50537810"
          xlink:type="locator"/>
        <link:footnote id="FN_162332" xlink:label="FN_162332" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Accounted in accordance with IFRS 11, &#x201c;Joint Arrangements&#x201d;. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537810"
          xlink:to="FN_162332"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537811"
          xlink:label="Fact_50537811"
          xlink:type="locator"/>
        <link:footnote id="FN_162333" xlink:label="FN_162333" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Indirectly owned through Idea2Enterprises (India) Pvt. Limited.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537811"
          xlink:to="FN_162333"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537816"
          xlink:label="Fact_50537816"
          xlink:type="locator"/>
        <link:footnote id="FN_162334" xlink:label="FN_162334" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Kunshan Rotam Reddy Pharmaceutical Co. Limited is a subsidiary as per Indian Companies Act, 2013, as the Company holds a 51.33% stake. However, the Company accounts for this investment by the equity method and does not consolidate it in the Company&#x2019;s financial statements.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537816"
          xlink:to="FN_162334"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537817"
          xlink:label="Fact_50537817"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537817"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537818"
          xlink:label="Fact_50537818"
          xlink:type="locator"/>
        <link:footnote id="FN_162287" xlink:label="FN_162287" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company has created a Debenture Redemption Reserve out of profits of its subsidiary Aurigene Pharmaceutical Services Limited that issued  debentures  in accordance with the terms of Section 18(7)(iv) &amp; 18(7)(v) AA(1) of the of Companies (Share Capital and Debentures) Rules, 2014. This reserve is to be utilized by the Company for payment of dividend and redemption of debentures.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537818"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537819"
          xlink:label="Fact_50537819"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537819"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537820"
          xlink:label="Fact_50537820"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537820"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537824"
          xlink:label="Fact_50537824"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537824"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537832"
          xlink:label="Fact_50537832"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537832"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537836"
          xlink:label="Fact_50537836"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537836"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537837"
          xlink:label="Fact_50537837"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537837"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537845"
          xlink:label="Fact_50537845"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537845"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537849"
          xlink:label="Fact_50537849"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537849"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537874"
          xlink:label="Fact_50537874"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537874"
          xlink:to="FN_162319"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537876"
          xlink:label="Fact_50537876"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537876"
          xlink:to="FN_162319"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537877"
          xlink:label="Fact_50537877"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537877"
          xlink:to="FN_162322"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537878"
          xlink:label="Fact_50537878"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537878"
          xlink:to="FN_162322"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537880"
          xlink:label="Fact_50537880"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537880"
          xlink:to="FN_162317"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537880"
          xlink:to="FN_162318"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537882"
          xlink:label="Fact_50537882"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537882"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537883"
          xlink:label="Fact_50537883"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537883"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537884"
          xlink:label="Fact_50537884"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537884"
          xlink:to="FN_162318"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537885"
          xlink:label="Fact_50537885"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537885"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537886"
          xlink:label="Fact_50537886"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537886"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537887"
          xlink:label="Fact_50537887"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537887"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537888"
          xlink:label="Fact_50537888"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537888"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537889"
          xlink:label="Fact_50537889"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537889"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537890"
          xlink:label="Fact_50537890"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537890"
          xlink:to="FN_162327"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537891"
          xlink:label="Fact_50537891"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537891"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537892"
          xlink:label="Fact_50537892"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537892"
          xlink:to="FN_162329"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537893"
          xlink:label="Fact_50537893"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537893"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537894"
          xlink:label="Fact_50537894"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537894"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537896"
          xlink:label="Fact_50537896"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537896"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537897"
          xlink:label="Fact_50537897"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537897"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537898"
          xlink:label="Fact_50537898"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537898"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537899"
          xlink:label="Fact_50537899"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537899"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537900"
          xlink:label="Fact_50537900"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537900"
          xlink:to="FN_162330"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537902"
          xlink:label="Fact_50537902"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537902"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537903"
          xlink:label="Fact_50537903"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537903"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537904"
          xlink:label="Fact_50537904"
          xlink:type="locator"/>
        <link:footnote id="FN_162331" xlink:label="FN_162331" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Indirectly owned through Reddy Netherlands B.V.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537904"
          xlink:to="FN_162331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537905"
          xlink:label="Fact_50537905"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537905"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537906"
          xlink:label="Fact_50537906"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537906"
          xlink:to="FN_162317"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537906"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537907"
          xlink:label="Fact_50537907"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537907"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537908"
          xlink:label="Fact_50537908"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537908"
          xlink:to="FN_162332"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537909"
          xlink:label="Fact_50537909"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537909"
          xlink:to="FN_162333"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537910"
          xlink:label="Fact_50537910"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537910"
          xlink:to="FN_162331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537915"
          xlink:label="Fact_50537915"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537915"
          xlink:to="FN_162334"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537916"
          xlink:label="Fact_50537916"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537916"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537917"
          xlink:label="Fact_50537917"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537917"
          xlink:to="FN_162322"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537918"
          xlink:label="Fact_50537918"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537918"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537919"
          xlink:label="Fact_50537919"
          xlink:type="locator"/>
        <link:footnote id="FN_162335" xlink:label="FN_162335" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Indirectly owned through Dr. Reddy&#x2019;s Laboratories LLC, Russia.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537919"
          xlink:to="FN_162335"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537920"
          xlink:label="Fact_50537920"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537920"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537921"
          xlink:label="Fact_50537921"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537921"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537922"
          xlink:label="Fact_50537922"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537922"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537924"
          xlink:label="Fact_50537924"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537924"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537925"
          xlink:label="Fact_50537925"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537925"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537926"
          xlink:label="Fact_50537926"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537926"
          xlink:to="FN_162331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537927"
          xlink:label="Fact_50537927"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537927"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537932"
          xlink:label="Fact_50537932"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537932"
          xlink:to="FN_162331"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537935"
          xlink:label="Fact_50537935"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537935"
          xlink:to="FN_162322"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537936"
          xlink:label="Fact_50537936"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537936"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537937"
          xlink:label="Fact_50537937"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537937"
          xlink:to="FN_162335"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537938"
          xlink:label="Fact_50537938"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537938"
          xlink:to="FN_162327"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537939"
          xlink:label="Fact_50537939"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537939"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537940"
          xlink:label="Fact_50537940"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537940"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537941"
          xlink:label="Fact_50537941"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537941"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537942"
          xlink:label="Fact_50537942"
          xlink:type="locator"/>
        <link:footnote id="FN_162328" xlink:label="FN_162328" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Indirectly owned through Lacock Holdings Limited.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537942"
          xlink:to="FN_162328"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537943"
          xlink:label="Fact_50537943"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537943"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537945"
          xlink:label="Fact_50537945"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537945"
          xlink:to="FN_162327"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537946"
          xlink:label="Fact_50537946"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537946"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537947"
          xlink:label="Fact_50537947"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537947"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537948"
          xlink:label="Fact_50537948"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537948"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537949"
          xlink:label="Fact_50537949"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537949"
          xlink:to="FN_162328"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537950"
          xlink:label="Fact_50537950"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537950"
          xlink:to="FN_162315"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50537954"
          xlink:label="Fact_50537954"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50537954"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538047"
          xlink:label="Fact_50538047"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538047"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538051"
          xlink:label="Fact_50538051"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538051"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538059"
          xlink:label="Fact_50538059"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538059"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538063"
          xlink:label="Fact_50538063"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538063"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538071"
          xlink:label="Fact_50538071"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538071"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538075"
          xlink:label="Fact_50538075"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538075"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538083"
          xlink:label="Fact_50538083"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538083"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538087"
          xlink:label="Fact_50538087"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538087"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538095"
          xlink:label="Fact_50538095"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538095"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538099"
          xlink:label="Fact_50538099"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538099"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538107"
          xlink:label="Fact_50538107"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538107"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538111"
          xlink:label="Fact_50538111"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538111"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538119"
          xlink:label="Fact_50538119"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538119"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538123"
          xlink:label="Fact_50538123"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538123"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538131"
          xlink:label="Fact_50538131"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538131"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538135"
          xlink:label="Fact_50538135"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538135"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538143"
          xlink:label="Fact_50538143"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538143"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538147"
          xlink:label="Fact_50538147"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538147"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538155"
          xlink:label="Fact_50538155"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538155"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538159"
          xlink:label="Fact_50538159"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538159"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538167"
          xlink:label="Fact_50538167"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538167"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538171"
          xlink:label="Fact_50538171"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538171"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538179"
          xlink:label="Fact_50538179"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538179"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538183"
          xlink:label="Fact_50538183"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538183"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538191"
          xlink:label="Fact_50538191"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538191"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538195"
          xlink:label="Fact_50538195"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538195"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538203"
          xlink:label="Fact_50538203"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538203"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538207"
          xlink:label="Fact_50538207"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538207"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538211"
          xlink:label="Fact_50538211"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538211"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538212"
          xlink:label="Fact_50538212"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538212"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538213"
          xlink:label="Fact_50538213"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538213"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538214"
          xlink:label="Fact_50538214"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538214"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538215"
          xlink:label="Fact_50538215"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538215"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538216"
          xlink:label="Fact_50538216"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538216"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538217"
          xlink:label="Fact_50538217"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538217"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538218"
          xlink:label="Fact_50538218"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538218"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538222"
          xlink:label="Fact_50538222"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538222"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538226"
          xlink:label="Fact_50538226"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538226"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538230"
          xlink:label="Fact_50538230"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538230"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538234"
          xlink:label="Fact_50538234"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538234"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538238"
          xlink:label="Fact_50538238"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538238"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538242"
          xlink:label="Fact_50538242"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538242"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538252"
          xlink:label="Fact_50538252"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538252"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538256"
          xlink:label="Fact_50538256"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538256"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538257"
          xlink:label="Fact_50538257"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538257"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538265"
          xlink:label="Fact_50538265"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538265"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538269"
          xlink:label="Fact_50538269"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538269"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538270"
          xlink:label="Fact_50538270"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538270"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538278"
          xlink:label="Fact_50538278"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538278"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538282"
          xlink:label="Fact_50538282"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538282"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538283"
          xlink:label="Fact_50538283"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538283"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538291"
          xlink:label="Fact_50538291"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538291"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538295"
          xlink:label="Fact_50538295"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538295"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538296"
          xlink:label="Fact_50538296"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538296"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538300"
          xlink:label="Fact_50538300"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538300"
          xlink:to="FN_162284"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538304"
          xlink:label="Fact_50538304"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538304"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538308"
          xlink:label="Fact_50538308"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538308"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538309"
          xlink:label="Fact_50538309"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538309"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538317"
          xlink:label="Fact_50538317"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538317"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538321"
          xlink:label="Fact_50538321"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538321"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538322"
          xlink:label="Fact_50538322"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538322"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538330"
          xlink:label="Fact_50538330"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538330"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538334"
          xlink:label="Fact_50538334"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538334"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538335"
          xlink:label="Fact_50538335"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538335"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538365"
          xlink:label="Fact_50538365"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538365"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538369"
          xlink:label="Fact_50538369"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538369"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538377"
          xlink:label="Fact_50538377"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538377"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538381"
          xlink:label="Fact_50538381"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538381"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538389"
          xlink:label="Fact_50538389"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538389"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538393"
          xlink:label="Fact_50538393"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538393"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538409"
          xlink:label="Fact_50538409"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538409"
          xlink:to="FN_162284"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538422"
          xlink:label="Fact_50538422"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538422"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538426"
          xlink:label="Fact_50538426"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538426"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538499"
          xlink:label="Fact_50538499"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538499"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538500"
          xlink:label="Fact_50538500"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538500"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538501"
          xlink:label="Fact_50538501"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538501"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538505"
          xlink:label="Fact_50538505"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538505"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538509"
          xlink:label="Fact_50538509"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538509"
          xlink:to="FN_162284"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538513"
          xlink:label="Fact_50538513"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538513"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538517"
          xlink:label="Fact_50538517"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538517"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538518"
          xlink:label="Fact_50538518"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538518"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538559"
          xlink:label="Fact_50538559"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538559"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538560"
          xlink:label="Fact_50538560"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538560"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538564"
          xlink:label="Fact_50538564"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538564"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538613"
          xlink:label="Fact_50538613"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538613"
          xlink:to="FN_162319"
          xlink:type="arc"/>
        <link:footnote id="FN_162354" xlink:label="FN_162354" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Liquidated on March 23, 2022.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538613"
          xlink:to="FN_162354"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538614"
          xlink:label="Fact_50538614"
          xlink:type="locator"/>
        <link:footnote id="FN_162355" xlink:label="FN_162355" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Pursuant to the sale of the membership interests in DRANU, LLC, it ceased to be a joint venture effective March 31, 2021</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538614"
          xlink:to="FN_162355"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538615"
          xlink:label="Fact_50538615"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538615"
          xlink:to="FN_162319"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538615"
          xlink:to="FN_162354"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538616"
          xlink:label="Fact_50538616"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538616"
          xlink:to="FN_162355"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538671"
          xlink:label="Fact_50538671"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538671"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538675"
          xlink:label="Fact_50538675"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538675"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538689"
          xlink:label="Fact_50538689"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538689"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538693"
          xlink:label="Fact_50538693"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538693"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538804"
          xlink:label="Fact_50538804"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538804"
          xlink:to="FN_162284"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538835"
          xlink:label="Fact_50538835"
          xlink:type="locator"/>
        <link:footnote id="FN_162300" xlink:label="FN_162300" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Additions for the year ended March 31, 2021 include recognition of a right-of-use asset of Rs.1,852 relating to a warehousing services agreement in the United States.

</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538835"
          xlink:to="FN_162300"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538836"
          xlink:label="Fact_50538836"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538836"
          xlink:to="FN_162300"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538837"
          xlink:label="Fact_50538837"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538837"
          xlink:to="FN_162300"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538838"
          xlink:label="Fact_50538838"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538838"
          xlink:to="FN_162300"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538839"
          xlink:label="Fact_50538839"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538839"
          xlink:to="FN_162300"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538840"
          xlink:label="Fact_50538840"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538840"
          xlink:to="FN_162300"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538940"
          xlink:label="Fact_50538940"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538940"
          xlink:to="FN_162341"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538943"
          xlink:label="Fact_50538943"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538943"
          xlink:to="FN_162341"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538946"
          xlink:label="Fact_50538946"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538946"
          xlink:to="FN_162341"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538949"
          xlink:label="Fact_50538949"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538949"
          xlink:to="FN_162341"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538954"
          xlink:label="Fact_50538954"
          xlink:type="locator"/>
        <link:footnote id="FN_162347" xlink:label="FN_162347" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Pursuant to the special resolution approved by the shareholders in the Annual General Meeting held on July 27, 2018, the Dr. Reddy&#x2019;s Employees ESOS Trust (the &#x201c;ESOS Trust&#x201d;) was formed to support the Dr. Reddy&#x2019;s Employees Stock Option Scheme, 2018 by acquiring, from the Company or through secondary market acquisitions, equity shares which are used for issuance to eligible employees (as defined therein) upon exercise of stock options thereunder. During the years ended March 31, 2022 and 2021, an aggregate of 106,730 and 85,250 equity shares, respectively were issued as a result of the exercise of vested options granted to employees pursuant to the Dr. Reddy&#x2019;s Employees Stock Option Scheme, 2018. The options exercised had an exercise price of Rs.2,607, Rs.2,814 or Rs. 3,679 per share. Upon the exercise of such options, the amount of compensation cost (computed using the grant date fair value) previously recognized in the &#x201c;share based payment reserve&#x201d; was transferred to &#x201c;share premium&#x201d; in the consolidated statements of changes in equity. In addition, any difference between the carrying amount of treasury shares and the consideration received was recognized in the &#x201c;share premium&#x201d;. As of March 31, 2022 and 2021, the ESOS Trust had outstanding 468,471 and 575,201 shares, respectively, which it purchased from the secondary market for an aggregate consideration of Rs.1,601 and Rs.1,967, respectively. Refer to Note 28 of these consolidated financial statements for further details on the Dr. Reddy&#x2019;s Employees Stock Option Scheme, 2018.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538954"
          xlink:to="FN_162347"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538955"
          xlink:label="Fact_50538955"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538955"
          xlink:to="FN_162347"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538956"
          xlink:label="Fact_50538956"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538956"
          xlink:to="FN_162347"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50538957"
          xlink:label="Fact_50538957"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50538957"
          xlink:to="FN_162347"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539037"
          xlink:label="Fact_50539037"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539037"
          xlink:to="FN_162307"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539038"
          xlink:label="Fact_50539038"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539038"
          xlink:to="FN_162307"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539039"
          xlink:label="Fact_50539039"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539039"
          xlink:to="FN_162307"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539067"
          xlink:label="Fact_50539067"
          xlink:type="locator"/>
        <link:footnote id="FN_162359" xlink:label="FN_162359" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company&#x2019;s overall refund liability as of March 31, 2022 relating to the Company North America Generics business was U.S.$24 million, as compared to a liability of U.S.$19 million as of March 31, 2021. This increase in liability was primarily attributable to certain product mix changes and recent trends in actual sales returns for the year ended March 31, 2022, as compared to the year ended March 31, 2021.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539067"
          xlink:to="FN_162359"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539071"
          xlink:label="Fact_50539071"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539071"
          xlink:to="FN_162359"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539072"
          xlink:label="Fact_50539072"
          xlink:type="locator"/>
        <link:footnote id="FN_162320" xlink:label="FN_162320" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Currently, the Company does not separately track provisions and adjustments, in each case to the extent relating to prior years for chargebacks. However, the adjustments are expected to be non-material. The volumes used to calculate the closing balance of chargebacks represent approximately 1.1 to 1.4 months equivalent of sales, which corresponds to the pending chargeback claims yet to be processed.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539072"
          xlink:to="FN_162320"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539075"
          xlink:label="Fact_50539075"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539075"
          xlink:to="FN_162359"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539076"
          xlink:label="Fact_50539076"
          xlink:type="locator"/>
        <link:footnote id="FN_162321" xlink:label="FN_162321" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Currently, the Company does not separately track the credits and payments, in each case to the extent relating to prior years for chargebacks, rebates, medicaid payments or refund liability.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539076"
          xlink:to="FN_162321"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539077"
          xlink:label="Fact_50539077"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539077"
          xlink:to="FN_162321"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539078"
          xlink:label="Fact_50539078"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539078"
          xlink:to="FN_162321"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539079"
          xlink:label="Fact_50539079"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539079"
          xlink:to="FN_162321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539079"
          xlink:to="FN_162359"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539083"
          xlink:label="Fact_50539083"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539083"
          xlink:to="FN_162359"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539087"
          xlink:label="Fact_50539087"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539087"
          xlink:to="FN_162359"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539088"
          xlink:label="Fact_50539088"
          xlink:type="locator"/>
        <link:footnote id="FN_162360" xlink:label="FN_162360" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Chargebacks provisions and payments for the year ended March 31, 2021 were each higher as compared to the year ended March 31, 2020, primarily as a result of higher sales volumes and also due to higher pricing rates per unit for chargebacks, due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company&#x2019;s products. The rebates provisions and payments for the year ended March 31, 2021 were each lower as compared to the year ended March 31, 2020, primarily as a result of lower pricing rates per unit for rebates, due to a reduction in the invoice price to wholesalers for certain of the Company&#x2019;s products and also due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company&#x2019;s products, which were partially off-set by higher sales volumes during the year ended March 31, 2021 as compared to the year ended March 31, 2020.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539088"
          xlink:to="FN_162360"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539089"
          xlink:label="Fact_50539089"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539089"
          xlink:to="FN_162360"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539090"
          xlink:label="Fact_50539090"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539090"
          xlink:to="FN_162360"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539091"
          xlink:label="Fact_50539091"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539091"
          xlink:to="FN_162359"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539091"
          xlink:to="FN_162360"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539092"
          xlink:label="Fact_50539092"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539092"
          xlink:to="FN_162320"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539095"
          xlink:label="Fact_50539095"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539095"
          xlink:to="FN_162359"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539096"
          xlink:label="Fact_50539096"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539096"
          xlink:to="FN_162321"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539097"
          xlink:label="Fact_50539097"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539097"
          xlink:to="FN_162321"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539098"
          xlink:label="Fact_50539098"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539098"
          xlink:to="FN_162321"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539099"
          xlink:label="Fact_50539099"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539099"
          xlink:to="FN_162321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539099"
          xlink:to="FN_162359"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539103"
          xlink:label="Fact_50539103"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539103"
          xlink:to="FN_162359"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539107"
          xlink:label="Fact_50539107"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539107"
          xlink:to="FN_162359"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539108"
          xlink:label="Fact_50539108"
          xlink:type="locator"/>
        <link:footnote id="FN_162361" xlink:label="FN_162361" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Chargebacks provisions and payments for the year ended March 31, 2022 were each higher as compared to the year ended March 31, 2021, primarily as a result of higher sales volumes and also due to higher pricing rates per unit for chargebacks, due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company products, which were partially off-set due to a lower pricing rates per unit for chargebacks. Such lower pricing rates were primarily on account of a reduction in the invoice price to wholesalers for certain of the Company products The rebates provisions and payments for the year ended March 31, 2022 were each lower as compared to the year ended March 31, 2021, primarily as a result of lower pricing rates per unit for rebates, due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company products.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539108"
          xlink:to="FN_162361"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539109"
          xlink:label="Fact_50539109"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539109"
          xlink:to="FN_162361"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539110"
          xlink:label="Fact_50539110"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539110"
          xlink:to="FN_162361"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539114"
          xlink:label="Fact_50539114"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539114"
          xlink:to="FN_162359"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539115"
          xlink:label="Fact_50539115"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539115"
          xlink:to="FN_162361"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539115"
          xlink:to="FN_162359"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539116"
          xlink:label="Fact_50539116"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539116"
          xlink:to="FN_162320"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539119"
          xlink:label="Fact_50539119"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539119"
          xlink:to="FN_162359"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539120"
          xlink:label="Fact_50539120"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539120"
          xlink:to="FN_162321"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539121"
          xlink:label="Fact_50539121"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539121"
          xlink:to="FN_162321"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539122"
          xlink:label="Fact_50539122"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539122"
          xlink:to="FN_162321"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539123"
          xlink:label="Fact_50539123"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539123"
          xlink:to="FN_162321"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539123"
          xlink:to="FN_162359"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539145"
          xlink:label="Fact_50539145"
          xlink:type="locator"/>
        <link:footnote id="FN_162350" xlink:label="FN_162350" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Rounded to the nearest million.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539145"
          xlink:to="FN_162350"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539328"
          xlink:label="Fact_50539328"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539328"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539329"
          xlink:label="Fact_50539329"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539329"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539347"
          xlink:label="Fact_50539347"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539347"
          xlink:to="FN_162353"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539348"
          xlink:label="Fact_50539348"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539348"
          xlink:to="FN_162343"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539349"
          xlink:label="Fact_50539349"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539349"
          xlink:to="FN_162290"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539367"
          xlink:label="Fact_50539367"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539367"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539368"
          xlink:label="Fact_50539368"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539368"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539371"
          xlink:label="Fact_50539371"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539371"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539553"
          xlink:label="Fact_50539553"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539553"
          xlink:to="FN_162302"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539624"
          xlink:label="Fact_50539624"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539624"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539628"
          xlink:label="Fact_50539628"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539628"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539636"
          xlink:label="Fact_50539636"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539636"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539640"
          xlink:label="Fact_50539640"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539640"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539642"
          xlink:label="Fact_50539642"
          xlink:type="locator"/>
        <link:footnote id="FN_162288" xlink:label="FN_162288" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents gain on disposal of financial instruments classified as FVTOCI instruments re-classified to retained earnings.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539642"
          xlink:to="FN_162288"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539649"
          xlink:label="Fact_50539649"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539649"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539653"
          xlink:label="Fact_50539653"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539653"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539661"
          xlink:label="Fact_50539661"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539661"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539665"
          xlink:label="Fact_50539665"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539665"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539673"
          xlink:label="Fact_50539673"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539673"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539677"
          xlink:label="Fact_50539677"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539677"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539688"
          xlink:label="Fact_50539688"
          xlink:type="locator"/>
        <link:footnote id="FN_162301" xlink:label="FN_162301" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Refer to Note 6 of these consolidated financial statements for further details.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539688"
          xlink:to="FN_162301"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539689"
          xlink:label="Fact_50539689"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539689"
          xlink:to="FN_162301"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539690"
          xlink:label="Fact_50539690"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539690"
          xlink:to="FN_162301"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539691"
          xlink:label="Fact_50539691"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539691"
          xlink:to="FN_162301"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539692"
          xlink:label="Fact_50539692"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539692"
          xlink:to="FN_162301"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539693"
          xlink:label="Fact_50539693"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539693"
          xlink:to="FN_162301"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539700"
          xlink:label="Fact_50539700"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539700"
          xlink:to="FN_162301"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539701"
          xlink:label="Fact_50539701"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539701"
          xlink:to="FN_162301"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539702"
          xlink:label="Fact_50539702"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539702"
          xlink:to="FN_162301"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539703"
          xlink:label="Fact_50539703"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539703"
          xlink:to="FN_162301"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539704"
          xlink:label="Fact_50539704"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539704"
          xlink:to="FN_162301"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539705"
          xlink:label="Fact_50539705"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539705"
          xlink:to="FN_162301"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539711"
          xlink:label="Fact_50539711"
          xlink:type="locator"/>
        <link:footnote id="FN_162293" xlink:label="FN_162293" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents amounts receivable pursuant to an out-licensing arrangement with a customer. As these amounts are not expected to be realized within twelve months from the end of the reporting date, they are disclosed as non-current.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539711"
          xlink:to="FN_162293"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539712"
          xlink:label="Fact_50539712"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539712"
          xlink:to="FN_162293"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539776"
          xlink:label="Fact_50539776"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539776"
          xlink:to="FN_162357"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539777"
          xlink:label="Fact_50539777"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539777"
          xlink:to="FN_162357"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539785"
          xlink:label="Fact_50539785"
          xlink:type="locator"/>
        <link:footnote id="FN_162297" xlink:label="FN_162297" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">&#x201c;INR&#x201d; means Indian rupees. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539785"
          xlink:to="FN_162297"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539786"
          xlink:label="Fact_50539786"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539786"
          xlink:to="FN_162310"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539786"
          xlink:to="FN_162284"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539787"
          xlink:label="Fact_50539787"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539787"
          xlink:to="FN_162310"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539791"
          xlink:label="Fact_50539791"
          xlink:type="locator"/>
        <link:footnote id="FN_162358" xlink:label="FN_162358" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Miscellaneous income, net for the year ended March 31, 2020 includes Rs.3,457 received from Celgene pursuant to a settlement agreement entered into in April 2019. The agreement effectively settles any claim the Company or its affiliates may have had for damages under section 8 of the Canadian Patented Medicines (Notice of Compliance) Regulations in regard to the Company&#x2019;s ANDS for a generic version of REVLIMID&#xae; brand capsules (Lenalidomide) pending before Health Canada.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539791"
          xlink:to="FN_162358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539792"
          xlink:label="Fact_50539792"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539792"
          xlink:to="FN_162358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539793"
          xlink:label="Fact_50539793"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539793"
          xlink:to="FN_162358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539951"
          xlink:label="Fact_50539951"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539951"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539952"
          xlink:label="Fact_50539952"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539952"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539953"
          xlink:label="Fact_50539953"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539953"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539954"
          xlink:label="Fact_50539954"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539954"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539955"
          xlink:label="Fact_50539955"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539955"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539957"
          xlink:label="Fact_50539957"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539957"
          xlink:to="FN_162288"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539963"
          xlink:label="Fact_50539963"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539963"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539967"
          xlink:label="Fact_50539967"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539967"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539968"
          xlink:label="Fact_50539968"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539968"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539976"
          xlink:label="Fact_50539976"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539976"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539980"
          xlink:label="Fact_50539980"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539980"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539981"
          xlink:label="Fact_50539981"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539981"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539989"
          xlink:label="Fact_50539989"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539989"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539993"
          xlink:label="Fact_50539993"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539993"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50539994"
          xlink:label="Fact_50539994"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50539994"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50540092"
          xlink:label="Fact_50540092"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50540092"
          xlink:to="FN_162287"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50540093"
          xlink:label="Fact_50540093"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50540093"
          xlink:to="FN_162286"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50540097"
          xlink:label="Fact_50540097"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50540097"
          xlink:to="FN_162285"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50540129"
          xlink:label="Fact_50540129"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50540129"
          xlink:to="FN_162297"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50540722"
          xlink:label="Fact_50540722"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50540722"
          xlink:to="FN_162349"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50540737"
          xlink:label="Fact_50540737"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50540737"
          xlink:to="FN_162306"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50540738"
          xlink:label="Fact_50540738"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50540738"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50540739"
          xlink:label="Fact_50540739"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50540739"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50540740"
          xlink:label="Fact_50540740"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50540740"
          xlink:to="FN_162306"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50540741"
          xlink:label="Fact_50540741"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50540741"
          xlink:to="FN_162306"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50540742"
          xlink:label="Fact_50540742"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50540742"
          xlink:to="FN_162305"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_50540743"
          xlink:label="Fact_50540743"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_50540743"
          xlink:to="FN_162306"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
